<SEC-DOCUMENT>0001280776-21-000009.txt : 20210226
<SEC-HEADER>0001280776-21-000009.hdr.sgml : 20210226
<ACCEPTANCE-DATETIME>20210226072021
ACCESSION NUMBER:		0001280776-21-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210226
DATE AS OF CHANGE:		20210226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		21683765

	BUSINESS ADDRESS:	
		STREET 1:		AM KLOPFERSPITZ 19
		CITY:			MARTINSRIED
		STATE:			2M
		ZIP:			82152
		BUSINESS PHONE:		49 89 250079460

	MAIL ADDRESS:	
		STREET 1:		AM KLOPFERSPITZ 19
		CITY:			MARTINSRIED
		STATE:			2M
		ZIP:			82152

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>imux-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:5279c717-4640-48e4-aa74-73546e28db9a,g:602f65cf-bbe8-45d8-a039-a1d02730d21d,d:0d8d624238c9468ba14749fb49b7ca69--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:imux="http://imux.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>imux-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV80L2ZyYWc6OTY1NTI2M2I2MWE0NDliM2IwZTA0ZTcxMTNhYTU2YzEvdGFibGU6OGM1ZGRmZjBjMGM3NDAxOGI2MDgxMDRkMTY2MWYwZmYvdGFibGVyYW5nZTo4YzVkZGZmMGMwYzc0MDE4YjYwODEwNGQxNjYxZjBmZl8zLTEtMS0xLTA_1f78d415-fcfc-4937-8d69-d5b8b9846bad">0001280776</ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV80L2ZyYWc6OTY1NTI2M2I2MWE0NDliM2IwZTA0ZTcxMTNhYTU2YzEvdGFibGU6OGM1ZGRmZjBjMGM3NDAxOGI2MDgxMDRkMTY2MWYwZmYvdGFibGVyYW5nZTo4YzVkZGZmMGMwYzc0MDE4YjYwODEwNGQxNjYxZjBmZl80LTEtMS0xLTA_9d8fcc5b-4212-40c2-a04b-301c6b240280">2020</ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV80L2ZyYWc6OTY1NTI2M2I2MWE0NDliM2IwZTA0ZTcxMTNhYTU2YzEvdGFibGU6OGM1ZGRmZjBjMGM3NDAxOGI2MDgxMDRkMTY2MWYwZmYvdGFibGVyYW5nZTo4YzVkZGZmMGMwYzc0MDE4YjYwODEwNGQxNjYxZjBmZl81LTEtMS0xLTA_b10d5060-2517-440a-95f3-7dd8cff77471">FY</ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV80L2ZyYWc6OTY1NTI2M2I2MWE0NDliM2IwZTA0ZTcxMTNhYTU2YzEvdGFibGU6OGM1ZGRmZjBjMGM3NDAxOGI2MDgxMDRkMTY2MWYwZmYvdGFibGVyYW5nZTo4YzVkZGZmMGMwYzc0MDE4YjYwODEwNGQxNjYxZjBmZl82LTEtMS0xLTA_bb172b63-3e33-40f3-bbc8-a43d965244c0">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ia8b8f818b75b45b29b714b36192e1bd5_D20190412-20190412" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzYvZnJhZzo5ODdmNDc2ZTRmMTc0ZmYzODI0ZWM0NmFiNTA0ZjZmNC90ZXh0cmVnaW9uOjk4N2Y0NzZlNGYxNzRmZjM4MjRlYzQ2YWI1MDRmNmY0XzI5_f5453273-e5ef-4111-a9b3-49bce8f1c983">0.025</ix:nonFraction><ix:nonNumeric contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE2NDkyNjc0NDgzOTA_02686f89-0de8-4c0b-a81a-71f470466ead">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i9edfadac1b9748399350f656eaeb7769_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE3Mjg_67b7eb76-947a-407e-81f5-65bf99e5e7da">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="imux-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i4062cfe935644e299fdecc0eb484705d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i113e2604b2a24be8a887c8a8b2cea29b_I20210219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec7edf46a34f43399671610813b08a6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifedde0176e664cb6aff9c43204468770_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b37649abfa476e8663e7096706f97e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6865d74fb3c44e108442faced8021edf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7671da9018c545b3817f9563d19e0261_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if37994c8a1974311901413ff52b1e230_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440b26b7a65b40cba6e77e9d545181b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if188cbbb4056418e817200cb3a88ab28_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4298d26d7d8640bb99d1f84822b95179_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9a7fc5636d462982c27ea109928534_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ec86347b48487488f1c2b7053d37cc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if52f51af4dd14483aa5dd285b20cb6c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreClosingFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11abdac7c3c743d3a599ef1d1fe7969d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreClosingFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fc3a70ddcc2416da33598ca112c4ec6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreClosingFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic942c4f9cf4f4506ac6fc6619d7741a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:ExecutiveBonusAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be2e94565534b38a1b810c6d9c76e40_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:ExecutiveBonusAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id653ff8493bb4f28b484c985e561ac7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:ExecutiveBonusAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2df4d80998e4e6fbb1105df3cc50d87_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCSettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie42c6f1afb234a33ac5df351a682ac65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCSettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f2bc238cf84494f92f2d022a107611a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCSettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482400df09b44e2ba6f90598101aea5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6691293a863540519bd390ff32edae71_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee2b8da709d477caa8f18d809bc9f32_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce55168c27842fcba430142ef8577a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78983d83235a444bb1184ca248359fe6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41cf71437d1148fd87ec313c6ab59abc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378b311e84c3477d87b10194049b52c6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a2646a9310481db842eb9736d24b75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22d73ebb34f94a97a65d4cc981b33181_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide45a6f10a8143968b9977470c96fcf0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26eab55dd1c4325a2bf6fcd5b7880f5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b2a4218e23645fe8a43795e53bd917d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90db4b0e7fa9494cb6a2c2d5438fde97_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd95d995b8c1481499d8fe54a95ec8a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i263afee333724006aaeff1f3dcee49a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45563a45c561425c82c1d8ae4a882b06_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb99b20fe3f4285812691db62887373_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i714a7516a3074b3b819b97a2f9753718_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d89043cac44e13a241896366e02310_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic64924c0859a41d59136ed99d077e63b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc4d7683bd124ea18385d5d19135a5c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e16527720b5489a87c3709cb393b31c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9c5353dcba14224be159080140a4539_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c794d23984e413d94b0ee6303307fe7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6174bd787b0d4b3e9f91e9b34de11988_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e803724dcf84ceba79eba0078a118c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreClosingFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f2a878d5224327b9c3906b7957b0e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ef75f825ff45d4ba01031c2df25949_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic948d92ac1714503a6fd146abfa629ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3268a88a2d6d4e30b39a112e210ac828_D20190412-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-12</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9ea2ecf153a24b4f9905b7b614e7adf6_I20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b85b15cda004eb0acf9c15243874440_D20190412-20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-12</xbrli:startDate><xbrli:endDate>2019-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72933fde204541c88561a57e1bfee92c_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dbfed922e6b4c3db53e3607146b69ef_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8389cccd92494f9385f182bf002a92_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025ac79fc8a04af682b83198235a9390_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af0ec8f1a5c4c69afa77ae4992a4b27_D20190411-20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ia8b8f818b75b45b29b714b36192e1bd5_D20190412-20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-12</xbrli:startDate><xbrli:endDate>2019-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee3e91a49e343c1a30694c684b021f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c360cf3166a497fb3d4cf65ac71195d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74aac56ff24b4f3ca37eebd86a9d4423_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcfc4dd48ac4131bacce1f46671b617_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>imux:lease</xbrli:measure></xbrli:unit><xbrli:context id="ie37f05a546ec4332b17b507cececa315_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a4868f4553f43c3bcb215ef4452c84d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143eb8d6d87d45839179cc8aefbf2bd9_D20190412-20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-12</xbrli:startDate><xbrli:endDate>2019-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7215f1ac4e44d195ec898605132171_D20190412-20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-12</xbrli:startDate><xbrli:endDate>2019-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a3ae5995884982bf7fb0499c7d2af8_I20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291065e6920c4b3690091eb4f57fd587_D20190412-20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-12</xbrli:startDate><xbrli:endDate>2019-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id235fedbb81d4e0c9ede860eafed7c3d_I20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie48d0609d585480ab6c4bfe322a0961d_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19a1cf43d9744216bb5785e547d4a706_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61d4640357d4308b1168153fff8bcd2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1424157daa84861a0f78d13c01de311_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a9132f0eeb46a4b87b6f6be10c44a4_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib628ae02a7aa42c28a8f9aec169f0c34_D20190528-20190528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb39dad72584b63ab750036af27e280_I20190528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f08f68c8dad42d6bad9ef5236f6e645_D20190528-20190528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd46d22b09cb441787f0d5370dea6303_I20190528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib70b7b4cf5694c7a8586dce401819182_D20190528-20190528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6683c08bed64561b5b0505930b9950c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imux:ClinicalDevelopmentEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5901cce52944f6baa8aaf2af6e02ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imux:SuppliesAndWorkingCellBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780e082104054e5f93c97de39af38fdf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5086e5f37b694c38bf5cab8772addc83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib203b4c845154f8f8ad1c43f6b7e19c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67800579096d4497ad722732c4249a21_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f881980aec452681faf1a0f7dd4395_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie337d38b905741b0be8509a5988751e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f631b15ff24c389fa32b2b1b7ee96e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6873df0f6d9c43829d62758343daf989_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8dd00728074e99b84c1dca45194253_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a0a829483c0417eba5fa667a551ed28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e15b766485e4b65beeb7634f309978f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b12db73e4fa4be7ae419856ea963c2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i222effbc88ad4922acfd743d8d31835e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie581a8ba756a444ba46878adb72aeb7f_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42baf0370ea48d7a0e0cc425578b84c_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8556577d1b4e5f865b603839247770_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2019EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if19cb443fde445938a82a57f80350118_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2019EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e80fc4dc65422fb46f2324ebab4469_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9121799d001479e948d946e83f048f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d04edecca964096b86caf4fc622d519_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieddd58f3d1014eb8926a60bb85a16000_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-23</xbrli:startDate><xbrli:endDate>2020-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed6b68efee3460089ffa2c5e40b8094_I20200423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-10</xbrli:startDate><xbrli:endDate>2020-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ade7fa5ecd45d28246214c1fb60452_I20200610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f483edcdbf4d8bbd4fcfedfede902b_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf950f67a01b415ab0151c454064f1cb_I20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib39d17f19add4e67851d0c580a248614_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c150f722064296929dd00a3a6f971d_I20190327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5a7d12cd12ee4917abc990f2310687c0_I20190327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3fe40add06a4c1e9d53068bac00bb0f_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b71f1d3cd7c4b9b9c8ee7ebac91ffec_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f592217ac8841e7a80512fd12ad30e0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c982f0f472740879b53dcb38a14a979_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9c91096020641aa94b1d1135b433890_I20190925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2c83765c344137b31b8874c897fac3_I20190925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87a8c7a070d48d7a85d8cbb57c3b164_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fe3c6f83fe24a859c84ef448153d453_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca14bfd5d1a46d6abbbe154703eaed5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde26f9196c647299fc79cdab514e92c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d1d01b5e1504c569debfc0effaa9d69_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPSBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id98ccd8847d942049dcebd55acab88b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884fec6fb3674d73b8111a30c60f263f_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d10718e641e49e498dc108252d3c28e_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf1e238f2761438b9315ac40fda6d259_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90330a9e562f4e60896ceea327263918_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia083d8fbd94c4989a08ae4001339a6f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9edfadac1b9748399350f656eaeb7769_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26faf7d6c8d4e9d8a5282e0a5e8930d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e3be07c1751461587012f74b2b0f7a0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf95cecb7c14be781cbd9b72385544b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsImmunicAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic83994845a8140129953443b3610acec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9fcfd27c68040008f2db78d30da709f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82708f17c53b4c37b78d4fe97415cb49_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8030a5507c8490583fc32147238685d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf66576a68e1467aaeb276eb0a1d220d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i630a7b979f974930b0bba2578eadd634_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd8ece903fa44ea2a909aa615b1a5ba0_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:ExecutiveBonusAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b19f4b3636941f2900ae6ec1f44f9d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf29fd89a5442609bee7357c0b527ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fd0b65f75d4e63a2e869c2631bf0ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58388d7d9c6a4379884d6768a332b251_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic803cd5d0c184b89902cb243dfeb5916_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7cdba0abab7408cbfbfdb0c19a562a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9010bd0189fc4f5baf921a2f5f4333bd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4812e273894e708953a3a86ae37e95_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib314b2e7a1bb4652a04c736a3427cd77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6283c69a3a9a4598bf3bc29177b58dd2_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0f6cb2694343c6b174f7126d1b497c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibabb7926e0324b259339a9246df9291b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i831a36d6192c47e5b5bf54b78aaeba94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2528cb0a73b4870ae39bb50b3b9d6d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc75b1a787fb4655b51ea8fab14201f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice52c31a25f74dc481dd7ac060b4aa62_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2658237935944ab880c53895d440839_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">imux:ForeignExcludingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadfaa4f5c09647ca9cde1fa1c8cd3403_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">imux:ForeignExcludingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7147fc86cd64277aadeebf96a225804_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25a9ed10cb1c434e881185327a3fab3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">imux:TaxYearsPriorTo2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d3b597607a4a96ad990267323ffb6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">imux:TaxYearsPost2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c7b6124efd40999803947e39ba5996_I20201019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imux:EuropeanInvestmentBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>imux:tranche</xbrli:measure></xbrli:unit><xbrli:context id="id3797128a5a3499face40e421c2bb72f_I20201019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56a7a2ec7a864425ad54d86b2456da61_D20201019-20201019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-19</xbrli:startDate><xbrli:endDate>2020-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d94aba3d11445ea650849b72cf2899_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd92710d99b48ba8db45f94ef6715f4_D20201015-20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-15</xbrli:startDate><xbrli:endDate>2020-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ede6cd330124ec6a00d9b69f6869d26_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe8c1c50bbcc47cd82232e72f9c1d366_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35dad35cf93d448a8881d824be1e6f81_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb99bde8e3a84965bc53a2495c5be965_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49383c3200664df28115e65f5e1bf1a7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ccd299d58334dac9edfb2ac321eecfe_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7188adef1744a990c1f5be2b5baaec_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0d8d624238c9468ba14749fb49b7ca69_1"></div><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:18.785%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDky_4e82e96f-b3aa-4369-9b63-3350736b28e2"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDk5_4a156479-675d-4ec6-9823-9785199c7456">10-K</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:18.785%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6NDU4MzNlMGQ2ODFjNGRiMzk3OWYzMzkxN2I1ZTY0NTYvdGFibGVyYW5nZTo0NTgzM2UwZDY4MWM0ZGIzOTc5ZjMzOTE3YjVlNjQ1Nl8wLTAtMS0xLTA_07436ec9-dd64-470f-806f-929abac4ceab">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8xMzE_4bfdfbe1-b2e9-4e85-8a6a-a3fba69a64c3"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8xMzE_343e85b5-71c9-4bd6-9160-3bc054c83ddd">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.468%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6MzNlZWY5NGVjM2U5NDFiZjgyOGJlNWVjOWZmYTIxOGQvdGFibGVyYW5nZTozM2VlZjk0ZWMzZTk0MWJmODI4YmU1ZWM5ZmZhMjE4ZF8wLTAtMS0xLTA_13e580a5-51aa-4e4d-8307-06c6ed13a2b2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDkz_5f07ce3f-57b3-4707-a488-472993a5b060">001-36201</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDgz_d59194f6-d6f2-48e7-a5c1-8a0677f6bdf3">Immunic, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:18.785%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.497%"><tr><td style="width:1.0%"></td><td style="width:43.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8wLTAtMS0xLTA_dbb12f50-c492-4ca3-a40d-e0086915cd84">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8wLTItMS0xLTA_9df8d266-66c8-40d0-8977-924cf581ea2d">56-2358443</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8yLTAtMS0xLTA_350b5f24-95b2-4e50-9528-2228a71d5064">1200 Avenue of the Americas,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8yLTEtMS0xLTA_3ba40da7-41f4-47d6-9e78-a92286f90068">Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8zLTAtMS0xLTA_c37009ef-6a3a-4d8d-bdc7-32f50d892770">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8zLTEtMS0xLTA_e4e07ac4-4774-4db7-b3cf-12624e22b079">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8zLTItMS0xLTA_096a9a1d-1c3f-4e1a-a4b3-bcd5d6fbceb4">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDg4_5cac90cb-fb37-4e8e-8216-3b1cd241207f">332</ix:nonNumeric>) <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNzQ4Nzc5MDcyMDA5_7337440f-1598-4630-a8d5-14838cc49c88">255-9818</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.468%"><tr><td style="width:1.0%"></td><td style="width:35.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6ZDAwMDEwNjg2ZjI2NDZlOTg5MmI3MGFiYjEyZDAzOTcvdGFibGVyYW5nZTpkMDAwMTA2ODZmMjY0NmU5ODkyYjcwYWJiMTJkMDM5N18xLTAtMS0xLTA_5ba74b32-2d2e-440e-8ea1-89124014fc21">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6ZDAwMDEwNjg2ZjI2NDZlOTg5MmI3MGFiYjEyZDAzOTcvdGFibGVyYW5nZTpkMDAwMTA2ODZmMjY0NmU5ODkyYjcwYWJiMTJkMDM5N18xLTEtMS0xLTA_beb8392f-1637-4b29-a756-09ea5a237fa6">IMUX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:83%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6ZDAwMDEwNjg2ZjI2NDZlOTg5MmI3MGFiYjEyZDAzOTcvdGFibGVyYW5nZTpkMDAwMTA2ODZmMjY0NmU5ODkyYjcwYWJiMTJkMDM5N18xLTItMS0xLTA_351effa7-44f0-4fbf-9630-e453072413ec">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDg0_b8a37541-44ec-44f6-bcf2-2bde0eaec06e">No</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes  <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDg5_f1bdb3ad-33d4-4c68-bb6c-b3f2ff651369">No</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8xMTMy_9e711402-34c0-4fba-bb06-8d9d7ba6cf51">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8xNDY5_61719b75-c2fe-4495-ad23-87fd09edcb3b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.949%"><tr><td style="width:1.0%"></td><td style="width:18.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6NGVhMzU4Yzg0NmZhNDIzYzk5ZjBlMjk0MWMxOTBiNDQvdGFibGVyYW5nZTo0ZWEzNThjODQ2ZmE0MjNjOTlmMGUyOTQxYzE5MGI0NF8wLTItMS0xLTA_71f0820d-1f2d-4e2b-9b72-e31bae01789a">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6NGVhMzU4Yzg0NmZhNDIzYzk5ZjBlMjk0MWMxOTBiNDQvdGFibGVyYW5nZTo0ZWEzNThjODQ2ZmE0MjNjOTlmMGUyOTQxYzE5MGI0NF8xLTMtMS0xLTA_2209576b-692d-41bb-baf3-327a214e0c92">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6NGVhMzU4Yzg0NmZhNDIzYzk5ZjBlMjk0MWMxOTBiNDQvdGFibGVyYW5nZTo0ZWEzNThjODQ2ZmE0MjNjOTlmMGUyOTQxYzE5MGI0NF8yLTMtMS0xLTA_ed51f1dc-f4b2-4a72-99ad-18ecc7dc1267">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNzQ4Nzc5MDcyODk2_2a7d1cc6-6161-4436-8e8c-735b7ae5c113">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDk4_2e02da71-2da0-4908-92b7-03e073536d6b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the common equity held by non-affiliates of the Registrant, based on the closing price of the common stock on The Nasdaq Stock Market on June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i4062cfe935644e299fdecc0eb484705d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yMzk0_7f692c26-96cd-4746-af41-3acfb0d553fa">181.4</ix:nonFraction>&#160;million.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 19, 2021, <ix:nonFraction unitRef="shares" contextRef="i113e2604b2a24be8a887c8a8b2cea29b_I20210219" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNzQ4Nzc5MDcyMDEx_95851384-9d19-4be8-b065-f826510b9059">21,168,240</ix:nonFraction> shares of common stock, $0.0001 par value, were outstanding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Documents Incorporated by Reference: <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNzQ4Nzc5MDcyODk3_b2f6d4bf-fcba-4490-b76d-954f55d8c9ba" escape="true">Certain portions of the registrant&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunic, Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Fiscal Year Ended December&#160;31, 2020 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_16">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_19">Business.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_22">Risk Factors.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_22">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_25">Unresolved Staff Comments.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_25">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_28">Properties.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_28">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_31">Legal Proceedings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_31">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_34">Mine Safety Disclosures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_34">70</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_37">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_37">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_40">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_43">Selected Financial Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_43">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_46">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_64">Quantitative and Qualitative Disclosures About Market Risk.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_64">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_67">Financial Statements and Supplementary Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_67">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_70">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_70">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_73">Controls and Procedures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_73">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_76">Other Information.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_76">85</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_79">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_79">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_82">Directors, Executive Officers and Corporate Governance.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_82">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_85">Executive Compensation.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_85">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_88">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_88">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_91">Certain Relationships and Related Transactions, and Director Independence.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_91">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_94">Principal Accountant Fees and Services.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_94">86</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_97">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_97">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_100">Exhibits and Financial Statement Schedules.&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_100">87</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_175">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic, Inc. is a clinical-stage biopharmaceutical company focused on the development of selective oral therapies in immunology with the goal of becoming a leader in treatments for chronic inflammatory and autoimmune diseases. On April 12, 2019, Vital Therapeutics, Inc. (&#8220;Vital&#8221;) completed its Transaction with Immunic AG in accordance with the terms of an agreement, dated as of January 6, 2019 (the &#8220;Agreement&#8221;). Pursuant to the terms of the Agreement, the holders of Immunic AG ordinary shares exchanged all of their outstanding shares for shares of Vital common stock (the &#8220;Transaction&#8221;), resulting in Immunic AG becoming a wholly-owned subsidiary of Vital. Immediately prior to the Transaction, Vital effected a 40-for-1 reverse split of its common stock (the &#8220;Reverse Stock Split&#8221;). Immediately after the Transaction, Vital changed its name to Immunic, Inc. and adopted the business priorities of Immunic AG. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise noted, all references to common stock share amounts and per share amounts in this Annual Report on Form 10-K have been retroactively adjusted to reflect the Reverse Stock Split. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used herein, the words &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to, for periods following the Exchange, Immunic, Inc. (formerly Vital Therapies, Inc.) and its direct and indirect subsidiaries, and for periods prior to the Exchange, Immunic AG and its direct and indirect subsidiaries, as applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management, and are contained principally in the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;might,&#8221; &#8220;can,&#8221; &#8220;continue&#8221; or similar expressions and the negatives of those terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements include, among other things, statements about:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">the strategies, prospects, plans, expectations and objectives of management;</span></div><div style="padding-left:40.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to regain or maintain compliance with Nasdaq listing standards;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">strategies with respect to our development programs;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our estimates regrading expenses, capital requirements, projected cash requirements and needs for additional financing;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">possible sources of funding for future operations;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to protect intellectual property rights and our intellectual property position;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">future economic conditions or performance;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">proposed products or product candidates;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to retain key personnel;</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">our ability to maintain effective internal control over financial reporting; and</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">beliefs and assumptions underlying any of the foregoing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements including those described in &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Annual Report. You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the Securities and Exchange Commission ("SEC") as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;Business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis ("RRMS"), ulcerative colitis ("UC"), Crohn&#8217;s disease ("CD") and psoriasis. Immunic is headquartered in New York with its main operations in Gr&#228;felfing, Germany. Immunic currently has 28 employees.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Acquisition</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2019, pursuant to the terms of the Agreement, dated as of January 6, 2019, between Vital Therapies, Inc., a Delaware corporation (&#8220;Vital&#8221;), Immunic AG, and the shareholders of Immunic AG party thereto, the holders of Immunic AG ordinary shares exchanged all of their outstanding shares for shares of Vital common stock, resulting in Immunic AG becoming a wholly-owned subsidiary of Vital. Immediately following the Transaction, Vital Therapies, Inc. changed its name to &#8220;Immunic, Inc.&#8221; and its ticker symbol to &#8220;IMUX&#8221;.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transaction has been accounted for as a reverse acquisition under the acquisition method of accounting. Because Immunic AG&#8217;s pre-transaction owners held an 88.25% economic and voting interest in the combined company immediately following the closing of the Transaction, Immunic AG is considered to be the acquirer of Vital for accounting purposes. Additionally, Immunic AG is considered to be the predecessor for reporting purposes and the financial results of Immunic AG are reported in the historical comparable periods.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2019, immediately following the closing of the Transaction, the Company effected the Reverse Stock Split. Accordingly, all references to share and per share amounts in the accompanying audited consolidated financial statements and notes have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. No fractional shares were issued in connection with the Reverse Stock Split. Unless otherwise noted, all references to common stock share and per share amounts have also been adjusted to reflect the exchange ratio of 17.17.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $103.9&#160;million as of December&#160;31, 2020 and approximately $59.9&#160;million as of December&#160;31, 2019. Substantially all of Immunic&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2020, Immunic has raised net cash of approximately $216.8 million from private and public offerings of preferred and common stock. As of December&#160;31, 2020, Immunic had cash and cash equivalents of approximately $127.5&#160;million. With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying audited consolidated financial statements. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategy</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic is currently pursuing three development programs, all orally available small molecule inhibitors in the clinical development phase. These include the IMU-838 program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of ROR&#947;t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (&#8220;ROR&#947;&#8221;), and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function. These product candidates are being developed to address diseases such as RRMS, UC, CD, and psoriasis. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), and Guillain-Barr&#233; syndrome (&#8220;GBS&#8221;). Immunic is also investigating IMU-838 as a potential treatment option for coronavirus disease 2019 (&#8220;COVID-19&#8221;).</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential indications, clinical targets and clinical development status of Immunic&#8217;s three product candidates:</span></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><img src="imux-20201231_g1.jpg" alt="imux-20201231_g1.jpg" style="height:359px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic expects to continue to lead most of its research and development activities from its Gr&#228;felfing, Germany location, where its dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, Immunic anticipates that this will result in timely, cost-effective execution of Immunic&#8217;s development programs. In addition, Immunic is using its subsidiary in Melbourne, Australia to expedite the early clinical trials for IMU-935 and IMU-856. Immunic's subsidiary also conducts preclinical work in Halle/Saale, through a collaboration with the Fraunhofer Institute.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Key Status Updates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">IMU-838</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Trial of IMU-838 in RRMS (EMPhASIS Trial)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2020, Immunic announced positive top-line data from its Phase 2 EMPhASIS trial of IMU-838 in patients with RRMS. The trial achieved statistical significance on all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the study met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active ("CUA") magnetic resonance imaging ("MRI") lesions up to week 24 in patients receiving 45 mg of IMU-838 once daily, by 62% (p=0.0002), as compared to placebo. The study also met its key secondary endpoint, showing a statistically significant reduction in the cumulative number of CUA MRI lesions for the 30 mg once daily dose by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70% (p&lt;0.0001), as compared to placebo.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2020, the Company published the full unblinded clinical data set from its Phase 2 EMPhASIS trial of IMU-838 in patients with RRMS. The data confirmed and expanded on the previously announced top-line results.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the relative equal performance of the two doses tested and to allow for pharmacodynamic modeling of the dose-response relationship, data from a lower dose in the effective dose range would be beneficial to complete a dose-effect assessment of IMU-838 in RRMS. For this reason, Immunic has started an additional, small Cohort 2 sub-trial to obtain exploratory data on the expanded dose response of IMU&#8209;838, as previously announced. This additional, double-blind assessment includes a cohort of approximately 60 patients who receive 10 mg/day of IMU-838 or placebo for 24 weeks. An unblinded interim analysis of selected MRI data is planned after all Cohort 2 patients have completed week 12 MRI assessments. This additional study cohort is already fully enrolled and the Company expects the 12-week data to be available at the end of March or in early April 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic intends to submit formal end-of-Phase 2 meeting requests to discuss the proposed Phase 3 program with major regulatory authorities around the end of the first quarter of 2021. The outcome of the end-of-Phase 2 meetings are expected to be available in or about May 2021. Based on the Phase 2 results in RRMS and if approved for commercial use by regulatory agencies, Immunic believes that IMU-838 has the potential to be a best-in-class oral drug with a unique balance between robust efficacy and favorable safety profile for patients with early Multiple Sclerosis (&#8220;MS&#8221;). The mechanism of action of IMU-838 (inhibition of the enzyme DHODH) represents a proven target for drug development, with other DHODH inhibitors (e.g., Aubagio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sanofi) available commercially for the treatment of conditions such as RRMS.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Envisaged Phase 3 Program of IMU-838 in RRMS</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously announced, in parallel to the preparation and execution of the regulatory discussions, Immunic is currently performing formal feasibility activities for a Phase 3 program of IMU-838 in RRMS, including country and site selection, as well as other preparatory activities. For this purpose and after a comprehensive selection process, a global contract research organization ("CRO") focused on regions of particular interest and with broad experience in MS trials was formally engaged. This will help ensure that a potential Phase 3 program can be executed efficiently following regulatory advice. The Company also believes that this feasibility assessment will help ensure an expeditious execution of the development strategy for IMU-838.  Immunic intends to maintain a competitive selection process for a clinical CRO to conduct the potential Phase 3 program.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic plans to announce details on the design of the envisaged Phase 3 program in RRMS after its end-of-Phase 2 meetings with the regulatory authorities. The Phase 3 program is currently expected to start in the second half of 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:102%">Phase 2 Trial of IMU-838 in UC (CALDOSE-1 Trial)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trial is ongoing and enrolling patients. Recruitment is expected to be completed in the second half of 2021 and top-line data of the induction phase is expected to be available in the first half of 2022, as previously announced.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Phase 2 Trial of IMU-838 in Moderate COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(CALVID-1 Trial) </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 17, 2021, Immunic announced that IMU-838 has shown evidence of clinical activity in hospitalized patients with moderate COVID-19. This planned main analysis of the Company&#8217;s Phase 2 CALVID-1 trial was based on data from 204 randomized patients and included top-line clinical efficacy, safety, disease marker, and virology data. Although no formal statistical analysis was pre-specified for this main analysis, endpoints were analyzed descriptively. A final analysis of the complete randomized patient population of 223, which will comprise data on all endpoints, including subgroup and sensitivity analyses, is expected to be available in the second quarter of 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While primary and key secondary endpoints of the trial were not evaluable due to the very low rates of serious complications in the population of hospitalized patients with moderate COVID-19, the data did show clinical activity of IMU-838 based on multiple secondary endpoints, including clinically meaningful improvements in time to clinical recovery and time to clinical improvement. In addition, high-risk patients and patients over 65 years of age experienced a more substantial treatment effect of IMU-838. An anti-viral effect of IMU-838 on SARS-CoV-2 was observed by viral titers at the end of the treatment period (day 14) and at the end of the study (day 28). A robust anti-inflammatory effect was also observed, based on a more effective reduction of C-reactive protein (&#8220;CRP&#8221;) in IMU-838 treated patients, as compared to placebo. A more effective reduction of D-dimer, a well-known prognostic disease marker for COVID-19, was observed in IMU-838 treated patients, as compared to placebo. Initial data from a post hoc analysis of &#8220;Long COVID&#8221; symptoms, the frequently remaining symptoms of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19 after elimination of the virus, indicated that IMU-838 may have the potential to contribute to the prevention of long-term fatigue. Finally, IMU-838 was found to be safe and well-tolerated in hospitalized patients with moderate COVID-19.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:102%">Phase 2 Trial of IMU-838 in Primary Sclerosing Cholangitis (&#8220;PSC&#8221;) </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 18, 2021, Immunic announced positive top-line data from its investigator-sponsored proof-of-concept clinical trial of IMU-838 in PSC, which was conducted at Mayo Clinic in Arizona and Minnesota, both of which are tertiary referral centers for PSC patients. As previously announced, due to the COVID-19 pandemic, only 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, &#8220;ITT&#8221;), of whom only 11 patients completed the full IMU-838 treatment course and were evaluable over the 24-week treatment period (per-protocol population, &#8220;PP&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The PP population experienced a statistically significant decrease in serum alkaline phosphatase (&#8220;ALP&#8221;) levels (p=0.041) after 24 weeks of treatment using 30 mg IMU-838 once daily, as compared to baseline. A consistent individual pattern of a stable decrease in ALP values was observed in the PP population between baseline and week 24, without any single patient showing an increase of more than 20% of ALP. As per definition of the primary objective of the study, 27.3% of the patients in the PP population had a clinically relevant reduction of serum ALP higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline. Regarding the secondary objectives of the study, no changes in aspartate aminotransferase (&#8220;AST&#8221;), alanine aminotransferase (&#8220;ALT&#8221;), or total, direct or indirect bilirubin were observed in the ITT or PP populations, as compared to baseline. In addition, despite the limited scope of the data, encouraging results were observed regarding symptoms of inflammatory bowel disease (&#8220;IBD&#8221;), a common comorbidity for PSC patients, and patient assessments of health-related quality of life. The study also found that IMU-838 is a safe and well-tolerated oral drug for PSC patients and treatment-emergent adverse events were rare and generally mild.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the COVID-19 pandemic, recruitment for this study was hampered, as patients with PSC are at a high risk of COVID-19 infections and were advised to avoid travel and unnecessary social contacts such as those required to participate in a clinical trial. Together with the investigators, Immunic determined to readout data of the 18 patients who were enrolled prior to the COVID-19 pandemic. The ongoing pandemic situation also triggered the principal investigator&#8217;s decision to terminate the study in late 2020, before the intended recruitment goal of 30 patients was reached.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">IMU-935</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic&#8217;s second drug candidate, IMU-935, has the potential to be a highly potent and selective inverse agonist of a transcription factor called ROR&#947;t with additional activity on DHODH. Immunic believes that the nuclear receptor ROR&#947;t is the main driver for the differentiation of T helper 17 (&#8220;Th17&#8221;) cells and the expression of various cytokines involved in various inflammatory and autoimmune diseases. Immunic believes this target is an attractive alternative to approved antibodies for targets such as interleukin-23 ("IL-23"), IL-17 receptor and IL-17A as well as IL-17F cytokine directly. Immunic has observed strong cytokine inhibition targeting both Th1 and Th17 responses in preclinical testing, as well as indications of activity in animal models for psoriasis and IBD. Preclinical experiments indicated that, while leading to a potent inhibition of Th17 differentiation and cytokine secretion, IMU-935 did not affect thymocyte maturation, one of the physiological functions of ROR&#947;t, and therefore reduces the risk for thymoma development in patients. Based on these preclinical data, Immunic believes that IMU-935 has potential to be a best-in-class therapy for various autoimmune diseases and beyond.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A clinical Phase 1 trial exploring safety, pharmacodynamics and pharmacokinetics of IMU-935 is currently ongoing and progressing. Subsequent to the ongoing single and multiple ascending dose parts of the trial in healthy volunteers, Immunic plans to extend this trial to assess safety and exploratory disease endpoints in patients with psoriasis. Upon completion of at least the first two cohorts of the multiple ascending dose portion in healthy volunteers, the Company anticipates that it may also begin a Phase 2a proof-of-concept clinical trial of IMU-935 in an orphan autoimmune indication. After a thorough review of suitable autoimmune conditions, Immunic has prioritized GBS as additional indication for IMU-935, as previously announced.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">IMU-856</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic&#8217;s third program, IMU-856, which Immunic believes to be novel and highly innovative, is an orally available, small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function. Immunic has not yet disclosed the molecular target for IMU-856. Based on preclinical data, Immunic believes this compound represents a new and potentially disruptive treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function in patients suffering from diseases like IBD, diarrhea-predominant irritable bowel syndrome (&#8220;IBS-D&#8221;), immune checkpoint inhibitor (&#8220;ICI&#8221;)-induced colitis, and other intestinal barrier function associated diseases. Immunic believes that because IMU-856 avoids suppression of the immune functions, it should therefore maintain immune surveillance for patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 20, 2020, Immunic announced dosing of the first healthy volunteer in a clinical Phase 1 trial of IMU-856. Immunic Australia Pty Ltd. received clearance from the Bellberry Human Research Ethics Committee in Australia to begin a Phase 1 trial of IMU-856 under the Clinical Trial Notification scheme of the Australian Therapeutic Goods Administration. The clinical Phase 1 trial is ongoing and progressing. The trial includes single and multiple ascending dose parts in healthy volunteers to assess safety, pharmacodynamics and pharmacokinetics of IMU-856. Subsequently, Immunic plans to extend this trial to assess biomarkers, disease symptoms, safety and drug trough levels in patients with several conditions involving an impaired bowel barrier function.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Acquisition History</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic&#8217;s wholly-owned subsidiary Immunic AG acquired IMU-838 and IMU-935 in September 2016 from 4SC AG (hereinafter, 4SC), a publicly traded company based in Planegg-Martinsried, Germany, through asset acquisitions. As part of the transaction, 4SC is entitled to receive a royalty on net sales if products originating from these acquisitions achieve market approval. Immunic&#8217;s rights to IMU-856 are secured pursuant to an option and license agreement (the &#8220;Daiichi Sankyo Option&#8221;) with Daiichi Sankyo Co., Ltd. (hereinafter, "Daiichi Sankyo") in Tokyo, Japan. On January 5, 2020, Immunic AG exercised its option under the Daiichi Sankyo Option and acquired the exclusive global rights to commercialize IMU-856. The license also grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. Going forward, Daiichi Sankyo is eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. Financial terms of the agreement have not been disclosed.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leadership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic is led by a team of dedicated and committed experienced professionals with an entrepreneurial spirit and track record of successful licensing transactions in the healthcare industry worldwide (EU, the United States and Asia). The team brings together several decades of leadership experience in the pharmaceutical industry with a strong scientific background and sound knowledge in drug discovery, product development, chemistry, manufacturing and controls processes, intellectual property, clinical trial design, health economics and market access, merger and acquisitions, capital markets, corporate finance, business development, regulatory affairs and project valuation. Immunic&#8217;s team members are inventors on project-related patents and have successfully published project-related scientific publications.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMU-838</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IMU-838 is a small molecule investigational drug (vidofludimus calcium) under development as an oral tablet formulation for the treatment of RRMS, IBD and other chronic inflammatory and autoimmune diseases. By inhibiting DHODH, a key enzyme of pyrimidine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">de novo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">biosynthesis, highly metabolically activated T and B immune cells experience metabolic stress, which leads to a modulation of their activity and function. Thereby, pro-inflammatory cytokines such as interferon gamma (&#8220;IFN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#947;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), tumor necrosis factor alpha (&#8220;TNF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), IL-17A and IL-17F, produced by activated Th1 and Th17 cells, which represent subtypes of so-called T helper cells, are repressed and thereby reduce the inflammation associated with IBD, MS and other chronic inflammatory diseases. In preclinical studies of vidofludimus, the active ingredient of IMU-838, apoptosis (or programmed cell death) was induced in activated T cells, which Immunic believes may also play a crucial role in the activity of the drug in IBD by further dampening the inflammatory response. Immunic believes that a key advantage of DHODH inhibition, in general, is that the sensitivity of specific immune cells to DHODH inhibition correlates with their intracellular metabolic activation state, and therefore may not negatively impact &#8220;normal&#8221; immune and bone marrow cells. In animal studies of IMU-838, animals treated with large doses of the active moiety of IMU-838 were shown to lack detrimental effects on bone marrow, supporting the lack of an unspecific anti-proliferative effect regularly seen with many traditional immunomodulators.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the selectivity toward metabolically activated cells (with a high need for ribonucleic acid and deoxyribonucleic acid production), DHODH inhibition also leads to a direct antiviral effect, which has been observed in various virus infected cells, such as hepatitis C virus infections, cytomegalovirus infections and even hemorrhagic fever-causing viruses, such as Arena virus infections. Treatment with IMU-838 may avoid virus reactivation, one of the major drawbacks of the long-term use of traditional immunomodulators in IBD patients.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efficacy of vidofludimus, the active moiety and free acid form of IMU-838, has been observed in several animal disease models for IBD, as well as systemic lupus erythematosus and transplant rejection. Previous filings by Immunic with the SEC have summarized the development history of vidofludimus and the previous amorphous formulation of the free acid form of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vidofludimus. After the consummation of the asset acquisition from 4SC, Immunic developed and filed a patent application for a new specific polymorph of the calcium salt formulation of vidofludimus, IMU-838, which Immunic believes exhibits improved physicochemical and pharmacokinetic properties. In 2017, Immunic completed two Phase 1 studies of single or repeated once-daily doses of IMU-838 in healthy volunteers, where Immunic observed results supporting tolerability of repeated daily dosing of up to 50 mg of IMU-838.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indication: Multiple Sclerosis</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MS is an autoimmune disease that affects the brain, spinal cord and optic nerve. In MS, myelin, the coating that protects the nerves, is attacked and damaged by the immune system. Thus, MS is considered an immune-mediated demyelinating disease of the central nervous system ("CNS"). MS is a progressive disease which, without effective treatment, leads to severe disability. Immunic is developing IMU-838 for the treatment of RRMS, the most common form of MS. Approximately 85% of patients with MS are expected to develop RRMS, with some of these patients later developing more progressive forms of the disease. RRMS is characterized by clearly defined attacks of new or increasing neurologic symptoms. These relapses are followed by periods of remissions, or partial or complete recovery. During remissions, all symptoms may disappear, or some symptoms may continue and become permanent.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MS is a disease with unpredictable symptoms that can vary widely. Common early signs of MS include vision problems, tingling and numbness or other unspecific neurological symptoms. Diagnosis of MS is confirmed via blood tests and a spinal tap, in which a small sample of fluid is removed from the spinal cord. However, most important for diagnosis are characteristic CNS lesions found using magnetic resonance imaging ("MRI").</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to Wallin et al. (2019), MS affects more than 700,000 people in the United States, and more than 2.2 million people worldwide. The disease has a large economic impact as it affects mainly young adults in the prime working age, peaking around 30 years old, although MS can occur in children and in adults. MS is at least two to three times more common in women than in men. MS affects twice as many women and men in certain age cohorts and is more common in areas inhabited by people of northern European ancestry, such as Europe, the United States, Canada, New Zealand and parts of Australia.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently two main treatment types available for RRMS. Some therapies, such as short-term corticosteroid medications, are used for treating relapses of MS symptoms. Other approaches are used as long-term treatments to reduce the number of relapses and prevent disability progression. The latter are referred to as disease-modifying therapies. Immunic intends to develop IMU-838 as a disease-modifying therapy for RRMS.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main first-line treatment options for RRMS patients are beta interferons (either as interferon beta-1a or interferon beta-1b) or glatiramer acetate, all of which are given by injection. For patients requiring more advanced treatment options, there are several oral medications, such as dimethyl fumarate, fingolimod, siponimod, teriflunomide, ozanimod or cladribine, and biologics, such as natalizumab, ocrelizumab, ofatumumab or alemtuzumab, approved for commercial use in MS in various countries. In addition, some of these drugs, such as fingolimod, already have generic versions available in some countries and other drugs will become generic in the next years.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no specific guidance on which therapies or medications are used in which sequence of the MS disease course. Typically, treatments are escalated over time, considering:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Persistent high MS disease activity under treatment with base medications (relapse(s), disability worsening, MRI lesions),</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Risks of long-term immunosuppression,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Patient preferences or risks perceptions, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Safety/tolerability aspects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite many therapies approved and nearing approval for relapsing forms of MS, many opportunities remain for a safe, oral, well-tolerated, robust anti-inflammatory, with neuroprotective properties beyond what would be expected by reducing inflammation. DHODH inhibitors have already shown a particular advantage in the inhibition of disability worsening.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Competition</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currently, only a few new oral treatment options for RRMS patients are in advanced clinical development, the most advanced being a Bruton's tyrosine kinase (&#8220;BTK&#8221;) inhibitor developed by Sanofi. This BTK inhibitor (SAR442168) is an oral, brain-penetrant, selective small molecule that met both the primary and secondary endpoints in a Phase 2b trial evaluating efficacy and safety in participants with relapsing forms of MS. It significantly reduced disease activity associated with MS, as measured by MRI. Sanofi has now initiated a global, randomized, double-blind efficacy and safety trial comparing SAR442168 to teriflunomide in 900 participants with relapsing forms of MS. The trial will assess efficacy of daily SAR442168 treatment, as compared to a daily dose of 14 mg teriflunomide measured by annualized adjudicated relapse rate (&#8220;ARR&#8221;) in participants with relapsing forms of MS. Secondary objectives will assess efficacy of SAR442168, as compared to teriflunomide, on disability progression, MRI lesions, cognitive performance and quality of life. Evobrutinib, a BTK inhibitor developed by EMD Serono, and BIIB091, a BTK inhibitor developed by Biogen, are currently in phase 2 clinical development.  In addition, Roche is developing fenebrutinib in a phase 3 program for  RRMS and primary progressive MS in clinical Phase 3. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many drugs approved for patients with RRMS have reported a rare and often lethal viral disease of the brain called progressive multifocal leukoencephalopathy ("PML"). Many disease-modifying therapies alter how the immune system functions, including its ability to effectively fight viral infections. As a result, people who take these therapies are at higher risk for John Cunningham virus infection or re-activation, which is believed to be the cause of PML. To date, occurrences of PML have been reported in individuals with RRMS treated with natalizumab, dimethyl fumarate and fingolimod. No case of PML has yet been reported for the DHODH inhibitor teriflunomide, which has been one of the key differentiators of teriflunomide from other disease-modifying therapies in RRMS. The active moiety of IMU-838 has also shown direct antiviral effects in several models of virus-infected cells, which Immunic believes is caused by DHODH inhibition. Subject to further clinical trials, Immunic believes that this could be a &#8220;class effect&#8221; of the DHODH inhibitors and if shown, could be an important potential differentiator against other drug classes in RRMS.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the results of future clinical trials, Immunic believes that IMU-838 has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RRMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties. IMU-838 could provide RRMS patients with a distinctive combination of robust efficacy and favorable safety and tolerability including the following properties:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">A robust MRI lesion suppression of IMU-838 compares favorably to other first-line and oral base medications commercially available in RRMS.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">A very low discontinuation rate for IMU-838-treated RRMS patients, substantially below placebo, indicates an encouraging combination of tolerability and efficacy.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">The absence of hepatotoxicity signals and other relevant adverse events leading to discontinuations distinguishes IMU-838 well from other oral RRMS treatments.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">A robust decrease in serum neurofilament light chain, a biomarker for axonal damage, was observed for IMU-838 and provides evidence of IMU-838&#8217;s potential neuroprotective activity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Development Plan and Ongoing Studies</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Trial of IMU-838 in RRMS (EMPhASIS Trial)</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic is developing IMU-838 for use in RRMS. The clinical Phase 2 trial design in RRMS is based on well-established MRI endpoints (i.e., the difference between the two dose groups of 30 mg/day and 45 mg/day of IMU-838 and placebo in the cumulative number of combined unique active MRI lesions up to week 24). Immunic has not obtained formal regulatory advice for the Phase 2 study of IMU-838 in RRMS. Further information regarding Immunic&#8217;s RRMS study can be found on ClinicalTrials.gov under the identifier NCT03846219.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2020, Immunic announced positive top-line data from its Phase 2 EMPhASIS trial of IMU-838 in patients with RRMS. The study achieved statistical significance on all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the study met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of CUA MRI lesions up to week 24 in patients receiving 45 mg of IMU-838 once daily, by 62% (p=0.0002), as compared to placebo. The study also met its key secondary endpoint, showing a statistically significant reduction in the cumulative number of CUA MRI lesions for the 30 mg once daily dose by 70% (p&lt;0.0001), as compared to placebo.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 11, 2020, the Company published the full unblinded clinical data set from its Phase 2 EMPhASIS trial of IMU-838 in patients with RRMS. The data confirmed and expanded on the previously announced top-line results.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Activities Relating to the Preparation of a Phase 3 Program of IMU-838 in RRMS</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 Trial of IMU-838 in RRMS (EMPhASIS Trial) and Related Activities</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the Phase 2 trial of IMU-838 in RRMS were publicized on August 2, 2020 and September 11, 2020. Based on these results, 30 and 45 mg/day doses of IMU-838 appear to be equally safe and efficacious in patients with RRMS. Based on established regulatory guidance that the lowest effective dose should be considered for future clinical trials, Immunic may propose the dose of 30 mg/day of IMU-838 for investigation in a Phase 3 program. Currently, the Company considers this to be the most likely conclusion based on the Phase 2 data of IMU-838 in RRMS.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the relative equal performance of the two doses tested and to allow for pharmacodynamic modeling of the dose-response relationship, data from a lower dose in the effective dose range would be beneficial to complete a dose-effect assessment of IMU-838 in RRMS. For this reason, Immunic has started an additional, small Cohort 2 sub-trial to obtain exploratory data on the expanded dose response of IMU&#8209;838, as previously announced. This additional, double-blind assessment includes a cohort of approximately 60 patients who receive 10 mg/day of IMU-838 or placebo for 24 weeks. The still-active sites of the Phase 2 trial of IMU-838 in RRMS continue to be used and, as a result, Immunic currently expects that this assessment can be executed in an accelerated fashion.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of this additional, small patient cohort are not expected to change any conclusions for dosing of IMU-838 in a future Phase 3 program. Rather, they are expected to provide additional data to address any potential regulatory requests for pharmacodynamic modeling of the dose-response relationship in the context of the design of a Phase 3 program. An unblinded interim analysis of selected MRI data is planned after all Cohort 2 patients have completed week 12 MRI assessments. In the main analysis done for this trial in August and September 2020, a recognizable reduction of the number of CUA and gadolinium-enhancing lesions by IMU-838, as compared to placebo, was already observed at week 12. This additional interim analysis will, therefore, provide a beneficial assessment of the dose-response of the 10 mg/day of IMU-838 dose and may facilitate expeditious regulatory review for the execution of a Phase 3 program. This additional study cohort is already fully enrolled and the Company expects the 12-week data to be available at the end of March or in early April 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic believes that the foregoing strategy for IMU-838 in RRMS will enable risk reduction for end-of-Phase 2 discussions with regulatory agencies. The Company currently does not expect any significant delays for the start of a Phase 3 program.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preparation for End-of-Phase 2 Discussions with Regulatory Agencies</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to providing data from Phase 2 trials, Immunic must also conduct end-of-Phase 2 discussions with regulatory agencies and provide the opportunity to discuss the necessary aspects of a Phase 3 program.  Immunic intends to submit formal end-of-Phase 2 meeting requests to discuss the proposed Phase 3 program with major regulatory authorities around the end of the first quarter of 2021. The outcome of the end-of-Phase 2 meetings are expected to be available in or about May 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The execution of clinical Phase 3 trials usually requires the use of a commercial formulation of the investigational drug manufactured at commercially usable quantities. Immunic has developed and manufactured a roller compactor formulation of IMU-838 which would allow commercially usable production batches. An experimental Phase 1 bioequivalence study between the previous wet granulation and the new roller compactor version of IMU-838 has completed the experimental phase and the evaluation of the results is currently ongoing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a confirmatory relative bioavailability and food effect study is currently being prepared. The results will further characterize the roller compactor formulation of IMU-838 in preparation for a Phase 3 program. Additional investigations regarding metabolite characterization, metabolic modeling and potential drug-drug interactions, as well as other activities relating to clinical pharmacology are also being finalized at this time in anticipation for presentation to regulatory authorities.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic is currently working with clinical advisors to propose a pediatric development plan for IMU-838 in RRMS in the near future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Envisaged Phase 3 Program of IMU-838 in RRMS</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously announced, in parallel to the preparation and execution of the regulatory discussions, Immunic is currently performing formal feasibility activities for a Phase 3 program of IMU-838 in RRMS, including country and site selection, as well as other preparatory activities. For this purpose and after a comprehensive selection process, a global CRO focused on regions of particular interest and with broad experience in multiple sclerosis trials was formally engaged. This will help ensure that a potential Phase 3 program can be executed efficiently following regulatory advice.  The Company also believes that this feasibility assessment will help ensure an expeditious execution of the development strategy for IMU-838.  Immunic intends to maintain a competitive selection process for a clinical CRO to conduct the potential Phase 3 program.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic plans to announce details on the design of the envisaged Phase 3 program in RRMS after its end-of-Phase 2 meetings with the regulatory authorities. The Company currently expects the Phase 3 program to start in the second half of 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indication: Ulcerative Colitis</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UC is a chronic inflammatory disease characterized by diffuse inflammation of the mucosa of the colon and rectum. The hallmark clinical symptoms of UC are diarrhea and bloody stool, and its clinical course is marked by exacerbations and remissions, which may occur spontaneously or in response to treatment changes or intercurrent illnesses.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UC is most commonly diagnosed in late adolescence or early adulthood, but it can occur at any age. The occurrence of UC worldwide has increased over the past few years, particularly in Latin America, Asia and Eastern Europe (Burisch et al. 2015). Recent estimates note that there are more than 700,000 patients affected by UC in the United States, as well as 1.5 million in Europe (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Understanding Ulcerative Colitis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, available at https://www.crohnsandcolitis.com/ulcerative-colitis (last accessed July 16, 2019); Burisch et al. 2013) and more than 100,000 in Canada (Rocchi et al. 2012). UC is almost equally distributed between genders (Kappelman et al. 2007).</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The severity and extent of UC are characterized based on clinical and endoscopic findings. The treatment approach often depends on disease severity and typically follows a stepwise treatment regimen. Patients with mild disease may initially receive aminosalicylates or non-systemic steroids such as budesonide. Patients with moderate to severe disease activity may receive traditional immunomodulators (such as azathioprine or 6-mercaptopurine), steroids (such as prednisone) or selective immunomodulators (such as tofacitinib). If patients fail to respond to these therapies, treatment may be escalated to the use of biologics. The most common category of biologics used to treat UC includes TNF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> antibody drugs, such as infliximab or adalimumab. New biologic options are alpha-4-beta-7 (&#945;4&#223;7) integrin-specific antibodies, such as vedolizumab and anti-IL-12/IL-23 antibodies, such as ustekinumab. All biologics currently used to treat UC are injectables. Biologics are usually the most expensive treatment option and reserved for patients who have failed other therapies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment of UC is differentiated between induction treatment (during periods of disease symptoms or following relapse) and maintenance treatment (often a long-term treatment to keep a patient relapse-free). Since many UC patients fail to respond to treatments, cease to respond to their treatments or develop unacceptable side effects, there is a need for safe and effective treatments for UC with novel mechanisms. Additionally, patients prefer the convenience of oral treatments over injections. For some of the currently available oral immunomodulators or those in clinical testing, a higher rate of infections (particularly virus re-activations) have been reported versus placebo control, which can be a medically significant event for patients.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMU-838 is being developed to be a new treatment option for patients with moderate to severe UC who have failed current therapies and are now candidates for therapy with biologics.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Competition</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there are several new oral treatment options for UC patients in advanced clinical development or in regulatory review. Most of them fall into one of the following two categories: S1P agonists, such as ozanimod or etrasimod, or JAK inhibitors, such as upadacitinib or filgotinib. Some of these drug candidates may be approved by regulatory authorities for commercial use before IMU-838 may receive approval. However, depending on the results of future clinical trials, Immunic believes that IMU-838 has the potential to demonstrate medically important advantages compared with other treatments, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particularly for long-term therapy in UC patients, due to the selectivity of DHODH targeting of metabolically activated lymphocytes, the absence of general detrimental effects on bone marrow and the direct antiviral activity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tofacitinib, marketed as Xeljanz by Pfizer, is a first-in-class inhibitor of kinases called JAK kinases. Tofacitinib is particularly active on the isoform JAK3. Based on two Phase 3 trials, tofacitinib was approved in 2018 in the United States and Europe for the treatment of UC.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since IBD is still a substantially underserved market, several innovative late-stage projects are currently in Phase 2 and Phase 3 testing in patients with UC and/or CD.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Filgotinib: A JAK1 inhibitor developed by Gilead and Galapagos which delivered promising Phase 2 data in a clinical trial in UC. However, filgotinib led to a substantial number of herpes zoster virus reactivations in patients, which may have a negative impact on the number of patients treated with this drug, if it is approved in the future.  Additional side effects are reported to have occurred during preclinical development. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Ozanimod: A S1P1 receptor agonist which was developed by Receptos and acquired by Celgene in a $7.2 billion acquisition. Ozanimod is approved for use in RRMS and is currently being tested for UC and CD.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Upadacitinib: A JAK1 kinase inhibitor developed by AbbVie which delivered promising clinical Phase 2 data in patients with UC. In February of 2019, AbbVie initiated a Phase 3 study and is currently actively recruiting patients. As was the case with filgotinib, upadacitinib has also demonstrated reactivation of viruses such as herpes zoster in clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further relevant immuno-modulators are in late-stage development for UC and CD. These include S1P targeting drugs and JAK/TYK2 inhibitors. Immunic is not aware of other DHODH inhibitors currently in development for IBD. Immunic believes that the only approved DHODH inhibitor, Aubagio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and its predecessor molecule Arava</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are unlikely to be successful for IBD due to its side effect profile, which includes diarrhea.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Development Plan and Ongoing/Planned Clinical Studies</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared a clinical development plan for IBD, including UC, in collaboration with a group of well-known and experienced physicians from North America and Europe. Immunic also sought regulatory advice on its development program from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), and the Bundesinstitut f&#252;r Arzneimittel und Medizinprodukte (&#8220;BfArM&#8221;), before commencing its development program.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Trial of IMU-838 in UC (CALDOSE-1 Trial)</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CALDOSE-1 trial is a Phase 2b, dose-finding, multicenter, double-blind, placebo-controlled study including a blinded induction and maintenance phase, with double randomization (initial randomization for induction and second randomization for maintenance). The study also includes an option for an open-label treatment extension for patients discontinuing from or completing blinded treatment. The primary endpoint of the study consists of a patient-reported outcome and an endoscopy-assessed outcome, both to be evaluated following ten weeks of induction treatment comparing IMU-838 to placebo. Immunic has an active Investigational New Drug (&#8220;IND&#8221;) application for IMU-838 in UC with the FDA. Further information regarding Immunic&#8217;s UC study can be found on ClinicalTrials.gov under the identifier NCT03341962.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CALDOSE-1 is being conducted in more than 100 study centers throughout 14 countries, including the United States and countries in Western, Central and Eastern Europe. Enrollment in the study includes a central, blinded and independent assessment of endoscopy at screening to confirm patient eligibility. Immunic believes that it has taken prudent steps to ensure that the study is conducted in a manner that is consistent with the study protocol in all countries in which the study is being conducted, even though such countries have varying healthcare systems and practices.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A total of approximately 240 patients are planned to be randomized in CALDOSE-1. The first patient was enrolled in April 2018. Although the recruitment of this trial has continued during the COVID-19 pandemic, the pandemic has affected, among other things, access to endoscopy sites or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">hospitals in some countries, which has interfered with recruitment speed, new site activations and clinical site access. As a result, recruitment is expected to be completed in the second half of 2021 and top-line data of the induction phase is expected to be available in the first half of 2022, as previously announced.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under an agreement between Immunic and the FDA, reached during the company&#8217;s pre-IND meeting in 2017, the UC Phase 2b trial was designed to begin enrollment with three active dosing arms of 10 mg, 30 mg and 45 mg, respectively, in addition to a placebo arm. At the end of August 2019, an interim dosing analysis was performed by an unblinded and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent data review committee, which has concluded that the lowest dose of 10 mg appeared not to be likely ineffective, the highest dose of 45 mg was not intolerable, and no safety signal was identified for any of the trial&#8217;s three doses of IMU-838. The data review committee has not shared with the company any of the unblinded data underlying these conclusions, and the study remains blinded to the company, the investigators and the enrolled patients. The interim dosing analysis was not designed to be a futility analysis nor was the primary endpoint or any other endpoint of the study tested statistically. As a result of these findings, the trial&#8217;s steering committee has recommended continuation of all three dosing arms, which recommendation was implemented by Immunic. Expansion of IMU-838&#8217;s potentially effective dose range required continuation of all three dose groups and increased the overall number of patients expected to be included in the ongoing trial from a previously anticipated 195 patients, to a total of approximately 240 anticipated patients.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indication: Crohn&#8217;s Disease</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CD is an idiopathic chronic inflammatory disease of unknown etiology with genetic, immunologic and environmental influences. Like UC, it is one of the major diseases that are generally characterized as IBD. Both UC and CD are caused by chronic inflammation in the gastrointestinal ("GI") tract, but CD can involve the entire GI tract, from the mouth to the anus (but it most commonly involves both the large and small intestines), whereas UC is restricted to the colon and rectum. Distinguishing CD from UC can be challenging when inflammation is confined to the colon. CD typically involves all layers of the bowel wall, thereby causing complications such as abscesses, strictures and fistulas that regularly require surgical intervention.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hallmark clinical symptoms of CD are chronic diarrhea and abdominal pain. However, the diagnosing physician needs to evaluate laboratory tests, endoscopy results, pathology findings and radiographic tests to arrive at a clinical diagnosis of CD. In general, it is the presence of chronic intestinal inflammation that leads to a diagnosis of CD.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CD is most commonly diagnosed in late adolescence or early adulthood, but it can manifest at any age. According to recent data and literature reviews on the incidence of CD (Kappelman 2007; Burisch 2013; Rocchi 2012; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Understanding Crohn&#8217;s Disease,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> available at https://www.crohnsandcolitis.com/crohns (last accessed July 16, 2019), there are more than 600,000 patients affected by CD in the United States as well as 1.1 million in Europe and more than 125,000 in Canada. CD is slightly more prevalent in women than in men.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment of CD is similar to treatment of UC. However, some of the therapies available for UC (such as tofacitinib) have shown varying levels of activity in CD. Conversely, and based on the treatment needs of patients with CD, some drugs have been primarily developed for CD. One such example is the biologic ustekinumab, an antibody directed against IL-12 and IL-23. There are now some approved treatments, such as alofisel, that target the specific structural complications of CD, including fistulas.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Competition</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leflunomide is used off-label in patients with CD and has shown an initial suggestion of the value of DHODH inhibition in this patient population (Holtmann, et al 2008, Prajapati, et al 2003). In two small investigator trials of leflunomide in CD patients, investigators observed DHODH inhibitor activity in the treatment of moderate to severe CD in patients who have failed or are intolerant to traditional immunomodulator therapy. However, the side effect profile of leflunomide included diarrhea. The prescribing information for teriflunomide, leflunomide&#8217;s active metabolite, lists a 15-18% rate of diarrhea, which makes it one of the most prevalent side effects of this DHODH inhibitor. Immunic believes that despite the findings of efficacy for leflunomide in the investigator trials in CD patients, the side effect profile makes it unlikely that this type of DHODH inhibitor can be developed in the indication of IBD, and particularly in CD.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Development Plan and Ongoing Studies</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic is considering its development strategy for IMU-838 for the treatment of CD. During the previously noted discussions with the FDA regarding the Company&#8217;s UC trial, Immunic and the FDA reached agreement that a clinical trial of IMU-838 in CD could commence when the interim dosing analysis for the Phase 2b CALDOSE-1 trial in UC has been completed. This would allow Immunic to execute its development of IMU-838 in CD with the remaining active dose groups from CALDOSE-1 and placebo, thereby potentially allowing more efficient recruitment into this trial. Immunic had also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received additional written advice from the FDA regarding patient-reported outcomes to be used in this trial, called CALDOSE-2. Given the outcome of the interim dosing analysis of the CALDOSE-1 trial, Immunic is currently re-evaluating the study design in CD and also considering an evaluation of the upcoming CALDOSE-1 results prior to the start of a potential CALDOSE-2 clinical trial. In addition, Immunic is evaluating the optimal time for efficiently executing such study following the COVID-19 pandemic.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indication: COVID-19</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The World Health Organization (&#8220;WHO&#8221;) declared SARS-CoV-2 infections causing COVID-19 a pandemic on March 11, 2020. At present, the total number of cases is difficult to accurately quantify but continues to rise and, according to Johns Hopkins University &amp; Medicine (2020), has grown to more than 100,000,000 cases globally.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Main clinical symptoms include fever, cough, myalgia or fatigue, expectoration, and dyspnea, but a range of other symptoms have been connected to COVID-19 as well. While a majority of patients do not experience severe symptoms, one meta-analysis found that approximately 18 % of cases were severe (Sun et al. 2020). The symptoms of COVID-19 typically appear within 3 to 14 days after initial exposure to SARS-CoV-2. If any patient develops characteristic symptoms of COVID-19 or was exposed to a person with COVID-19, infection with SARS-CoV-2 leading to COVID-19 has to be considered. As there are no specific clinical features that can reliably distinguish COVID-19 from other viral respiratory infections, the patient will then need to undergo specific testing for SARS-CoV-2. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although several testing methods have been developed, polymerase chain reaction testing remains the primary and most reliable COVID-19 diagnostic testing method in the United States and in most developed countries. Generally, a sample from the nose (nasopharyngeal swab) or throat (throat swab) is taken and then sent to a laboratory for testing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 2021, at least two vaccines have been authorized and recommended by the FDA for preventing COVID-19:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Pfizer-BioNTech's COVID-19 vaccine (BNT162b2)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">Moderna&#8217;s COVID-19 vaccine (mRNA-1273)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, many questions still remain open on the efficacy of these and other COVID-19 vaccines. It will still take a substantial amount of time to produce, distribute and administer the vaccines worldwide and, as a result, to protect a broad basis of the global population. It is also still unclear if the vaccines will enable a 100% protection; some vaccinated individuals may still become ill or transmit the virus. In addition, there are people who do not want to be vaccinated or who cannot be vaccinated, such as those with pre-existing conditions, cancer therapy patients, or individuals undergoing long-term immunosuppressive therapies for autoimmune diseases. It is also still unclear how long the vaccine protection will last which may have a significant effect on the practicalities and logistics of immunization. Finally, it is unclear whether SARS-CoV-2 will disappear completely or whether genetic changes to the virus may occur in the future which could have an impact on the efficacy of available vaccines.  On February 7, 2021, the government of South Africa halted rollout of AZD1222 vaccine given that the protection in patients with an emerging mutant form B.1.351 was found not to prevent mild or moderate cases of COVID-19.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current approaches to COVID-19 therapies generally fall into two categories: antivirals, which prevent the virus from multiplying, and immune modulators, which help the immune system to fight the virus or stop it from overreacting dangerously. Some potential therapies act in a different way or via multiple mechanisms.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the FDA issued an Emergency Use Authorization (&#8220;EUA&#8221;) for emergency use of remdesivir (Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of hospitalized patients with severe COVID-19. Remdesivir is a direct acting antiviral drug that inhibits viral RNA synthesis. On November 20, 2020, the WHO issued a conditional recommendation against the use of remdesivir in hospitalized COVID-19 patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Eli Lilly's neutralizing antibody bamlanivimab (LY-CoV555) received EUA from the FDA for the treatment of recently diagnosed COVID-19 patients. Bamlanivimab is authorized for the treatment of recently diagnosed, mild </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to moderate COVID-19 in high-risk patients. However, the ACTIV-3 trial, which is evaluating multiple investigational agents in hospitalized patients with COVID-19, stopped randomizing patients to treatment with LY-CoV555 based on an analysis suggesting that the antibody was not beneficial in this population.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although numerous pharmacological interventions have obtained an EUA and several are still under clinical investigation, clear efficacy has not yet been determined for any of the COVID-19 drugs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Competition</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of Pfizer/BioNTech and Moderna have estimated that they will be able to produce up to 1 billion does of their respective vaccines in 2021. However, many millions of people at high risk of the disease will not be immunized any time soon, necessitating the continued research and development of efficacious drug therapies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the first clinical trials for COVID-19 therapies started in early 2020, only about 7% of the trials testing therapies for the disease have read out so far, according to the BioCentury COVID-19 Resource Center. Of the over 1,300 ongoing trials, 37% are due to complete by the end of the first half of 2021. As of January 2021, there are around 55 classes of therapies currently in clinical trials with immunosuppressants being the class with the highest number of ongoing trials. Studies have shown that it is vital to combine antiviral therapy with immune suppressants because using molecules that control only cytokine storms may make viral clearance difficult.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A recent publication from scientists in Wuhan, China (Xiong et al. 2020) shows promising activity of DHODH inhibitors against SARS-CoV-2 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cellular studies. New DHODH inhibitors (PTC299 and PP001) are currently being tested in addition to established DHODH inhibitors, such as leflunomide and Brequinar. However, due to unfavorable pharmacokinetic profiles (leflunomide) and toxicity (Brequinar), these drugs are not perceived as suitable acute antiviral treatments. In addition, although the new DHODH inhibitors seem promising, so far, no animal safety data and no human safety data are available. Therefore, developing new DHODH inhibitors may take significant time, even if accelerated by support of regulatory authorities. Regarding IMU-838, currently in phase 2 for COVID-19, more than 800 individuals have been dosed to date and a placebo like safety profile has been observed across the entire IMU-838 development program.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Development Plan and Ongoing Studies </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2020, Immunic announced that IMU-838 had successfully demonstrated preclinical activity against SARS-CoV-2. Specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with COVID-19. In cellular assays, IMU-838 demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with IMU-838 dosing regimens studied in ongoing and previous clinical trials. These positive, broad </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antiviral results of IMU-838 had encouraged the Company to start a clinical Phase 2 trial to explore IMU-838 as a potential treatment option for hospitalized patients with moderate COVID-19.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 Trial of IMU-838 in Moderate COVID-19 (CALVID-1 Trial)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, Immunic announced the first patients had been dosed in its Phase 2, CALVID-1 clinical trial of IMU-838 in COVID-19. This was a prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial in hospitalized patients with moderate COVID-19, designed to evaluate efficacy, safety and tolerability of IMU-838. CALVID-1 received regulatory allowance from the BfArM, from the FDA and from regulatory authorities in other European countries involved in the study. The trial was conducted under an IND application accepted by the FDA using a single global protocol with clinical sites in the United States, Germany and a range of other European countries. On November 2, 2020, Immunic announced that the enrollment goal of 200 patients was reached, pre-specified in the protocol as sufficient to perform the main efficacy analysis of the Phase 2 part of the CALVID-1 trial. Enrollment benefited from country selection for this trial, which included additional countries outside of the United States and Western Europe with a less competitive trial environment but increasing infection numbers in fall 2020. Immunic believes that this country selection strongly contributed to the ability to timely execute the recruitment of this trial. Further information regarding the COVID-19 study can be found on ClinicalTrials.gov under the identifier NCT04379271.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aim of the CALVID-1 trial was to investigate IMU-838 as an oral treatment option for COVID-19 and to support</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential use of IMU-838 as a treatment for current and potential future viral pandemic threats. The prospective, multicenter,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">randomized, placebo-controlled, double-blind Phase 2 trial was designed to evaluate efficacy, safety and tolerability of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMU-838 in patients with moderate COVID-19. Patients were enrolled at 20 sites in eleven countries, including the United</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States, Germany, and a range of other European countries. Patients were randomized to receive either 22.5 mg of IMU-838</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">twice daily (45 mg/day), or placebo twice daily, for 14 consecutive days. Patients in both arms were also eligible to receive</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigator&#8217;s choice of standard-of-care therapy throughout the duration of the study. Inclusion criteria called for hospitalized</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adult patients with a confirmed SARS-CoV-2 infection fulfilling clinical status category 3 or 4, as assessed with the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine-category ordinal scale proposed by the World Health Organization (WHO) COVID-19 Therapeutic Trial Synopsis, as well</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as certain additional clinical and laboratory criteria.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 17, 2021, Immunic announced that IMU-838 has shown evidence of clinical activity in hospitalized patients with moderate COVID-19. This planned main analysis of the Company&#8217;s Phase 2 CALVID-1 trial was based on data from 204 randomized patients and included top-line clinical efficacy, safety, disease marker, and virology data. Although no formal statistical analysis was pre-specified for this main analysis, endpoints were analyzed descriptively. A final analysis of the complete randomized patient population of 223, which will comprise data on all endpoints, including subgroup and sensitivity analyses, is expected to be available in the second quarter of 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary endpoint of the randomized, placebo-controlled, double-blind trial was defined as the proportion of patients without any need for invasive ventilation through day 28. In contrast to the relatively high rates of ventilation reported in the first COVID-19 wave in early 2020, the CALVID-1 trial found an actual rate of less than 1% of invasive ventilation for hospitalized patients with moderate COVID-19. This very low event rate, consistent with the findings of many recent third-party trials in COVID-19, prevented the primary endpoint from being evaluable.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regarding the key secondary endpoints, the trial was designed to investigate IMU-838's ability to reduce the probability of major complications for COVID-19 patients, such as 28-day mortality, survival without respiratory failure, and probability of use of intensive care unit ("ICU") treatment. Similar to the low ventilation rates discussed above, the trial found a rate of less than 2% for 28-day mortality, balanced between the two arms, and less than 4.5% of patients required an ICU stay. Based on the very low complication rates in this trial and due to the known variability of the disease course, Immunic believes that the evaluation of these key secondary endpoints is also not feasible.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Despite the low mortality and invasive ventilation rates observed in this trial, clinical activity of IMU-838 was confirmed based on the assessment of multiple secondary clinical endpoints, including clinically meaningful improvements in time to clinical recovery and time to clinical improvement. In addition, high-risk patients and patients aged over 65 years experienced a more substantial treatment effect of IMU-838. An anti-viral effect of IMU-838 on SARS-CoV-2 was observed by viral titers at the end of the treatment period (day 14) and at the end of the study (day 28). A robust anti-inflammatory effect was also observed, based on a more effective reduction of CRP in IMU-838 treated patients, as compared to placebo. A more effective reduction of D-dimer, a well-known prognostic disease marker for COVID-19, was observed in IMU-838 treated patients, as compared to placebo. Initial data from a post hoc analysis of &#8220;Long COVID&#8221; symptoms, the frequently remaining symptoms of COVID-19 after elimination of the virus, indicated that IMU-838 may have the potential to contribute to the prevention of long-term fatigue.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IMU-838 was found to be safe and well-tolerated in hospitalized patients with moderate COVID-19. No general safety signals regarding new or more severe adverse events were observed for IMU-838 in this patient population, as compared to placebo. In addition, IMU-838&#8217;s rate of serious adverse events and adverse events leading to treatment discontinuation was not increased, as compared to placebo. The trial also found fewer COVID-19 related adverse events with increased intensity in IMU-838 treated patients (7.1%), as compared to placebo (12.6%) and IMU-838 did not intensify any hematological effects of COVID-19. In addition, IMU-838 did not increase the rate of infections and infestations as well as the rate of liver events in patients with COVID-19, as compared to placebo.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 204 patients were included in the main analysis of the CALVID-1 trial, as per the protocol requirement of approximately 200 patients. 202 patients received at least one dose of study drug, of whom 99 patients received 45 mg/day of IMU-838 and 103 patients received placebo. The main analysis contains top-line data for the treatment period until day 14 and the follow-up period until day 28 as well as the full safety data until day 28. Additional data will be reported after the full analysis of all 223 randomized patients, which is expected to be available in the second quarter of 2021. This supplemental data set will contain full efficacy, virology, and drug trough level data, as well as the safety follow-up until day 60.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investigator-Sponsored Clinical Phase 2 Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19 (IONIC Trial)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, Immunic announced enrollment of the first patients in an investigator-sponsored clinical Phase 2 IONIC trial of IMU-838 for the treatment of patients with COVID-19. This trial is run by sponsor and lead site, University Hospitals Coventry and Warwickshire NHS Trust, and is a prospective, randomized, parallel-group, open-label Phase 2b trial, designed to evaluate efficacy and safety of IMU-838 in combination with the neuraminidase inhibitor, Oseltamivir (Tamiflu</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#9415;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 120 adult patients with moderate-to-severe COVID-19. On February 5, 2021, the investigators informed the Company that 30 patients have been enrolled in the trial, pre-specified in the protocol as sufficient to perform a first interim analysis.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indication: Primary Sclerosing Cholangitis</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic is also exploring the use of IMU-838 in orphan diseases that may allow for an accelerated path to commercialization. Immunic is exploring such orphan diseases in conjunction with interested investigators.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSC is a rare liver disease in which the bile ducts in the liver become inflamed, narrow and prevent bile from flowing properly. According to Toy et al. (2011), PSC has a prevalence of approximately 4.15 per 100,000 in the United States. The exact cause and disease mechanism of PSC are still unknown, but an autoimmune mechanism may play a role. According to Singh et al. (2013), there is an association with IBD, most often with UC and less commonly with CD. Progressive biliary and hepatic damage results in portal hypertension and hepatic failure in a significant majority of patients over a 10-15 year period from initial diagnosis.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment of PSC is supportive, with a focus on monitoring the disease progression and treating symptoms and complications as they arise. The only substantial treatment is liver transplantation, which may be an option when the disease progresses to cirrhosis and liver function is significantly affected. When some of the larger bile ducts become blocked in patients with PSC, one potential is to open them with endoscopy-based methods, balloon dilatation or stent placement. No medication is currently approved to treat PSC, but medications may be used to control symptoms. Although many trials have failed to meet their endpoints in PSC, there are now a few studies for medications (such as obeticholic acid) that have shown limited activity in PSC.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Development Plan and Ongoing Studies</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic has entered into a collaboration with investigators at the Mayo Clinic to explore the use of IMU-838 in PSC. An investigator-sponsored proof-of-concept clinical trial of IMU-838 in PSC, for which Immunic provided the study medication, was conducted at the Mayo Clinic in Arizona and Minnesota, both of which are tertiary referral centers for PSC patients. The study was led by Elizabeth Carey, M.D., Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, who had received Investigator IND approval from the FDA and had been granted Institutional Review Board ("IRB") approval to conduct the study. The study was supported by a grant from the National Institutes of Health (&#8220;NIH&#8221;). Further information regarding the PSC study can be found on ClinicalTrials.gov under the identifier NCT03722576.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 18, 2021, Immunic announced positive top-line data from the study which was designed to investigate IMU-838's potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation randomized PSC trials. As previously announced, due to the COVID-19 pandemic, only 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, &#8220;ITT&#8221;), of whom only 11 patients completed the full IMU-838 treatment course and were evaluable over the 24-week treatment period (per-protocol population, &#8220;PP&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary objective of this study was to determine whether IMU-838 reduces serum alkaline phosphatase (&#8220;ALP&#8221;) in adult patients diagnosed with PSC. The main analysis for the primary objective was whether patients could achieve a reduction of ALP at week 24 which is greater or equal to 25%, as compared to baseline, with an AST increase at week 24 of no more than 33%, as compared to baseline. This positive primary outcome was achieved by 3 of 11 patients in the PP population (27.3%, 95% CI: 6-61%). By virtue of inclusion criteria, patients at baseline had to have an elevated ALP value of at least 1.5 times the upper limit of normal. In addition, time from baseline was calculated as a continuous variable and treated as the primary predictor using a random intercept model which was adjusted for age at baseline and gender. For this longitudinal analysis of ALP from baseline to week 24 in the PP population, the ALP value statistically significantly (p=0.041) decreased by an average of 5.76 IU/L every 30 days (95% CI: -11.29, -0.23; statistical model). The time trend was not statistically significant in the ITT analysis (p=0.578) due to missing data following the high rate of treatment discontinuations during the COVID-19 pandemic. A consistent individual pattern of a stable decrease in ALP values was observed in the PP population between baseline and week 24, without any single patient showing an increase of more than 20% of ALP.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Secondary objectives were to investigate the liver biochemistry parameters, AST, ALT, and total/direct/indirect bilirubin, as well as the concentrations of proinflammatory cytokines, as compared to baseline. The longitudinal analysis of both AST and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ALT as well as total, direct and indirect bilirubin values showed a stable pattern in the PP population with no statistically significant change over time and the confidence interval to include the no-change scenario (AST: average 30 day change 1.22 IU/L, 95% CI: -0.53, 2.97, p=0.170; ALT: average 30 day change 0.85 IU/L, 95% CI -1.46, 3.15, p=0.467, total bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.02, p=0.561, direct bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.861, indirect bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.556). Similar results were found in the ITT population. In addition, a decrease in the Ulcerative Colitis Clinical Score was observed in evaluated patients, although the number of assessed patients was limited. The study also found that IMU-838 is a safe and well-tolerated oral drug for PSC patients and treatment-emergent adverse events were rare and generally mild.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study, for which Immunic provided the study medication, planned to enroll 30 patients with PSC, aged 18 to 75 years, who received 30 mg of IMU-838 once daily for a period of 24 weeks. Enrollment for the study took place between July 2019 and September 2020, but almost all enrollment occurred in 2019 and early 2020. During the COVID-19 pandemic, recruitment for this study was hampered, as patients with PSC are at a high risk of COVID-19 infections and were advised to avoid travel and unnecessary social contacts such as those required to participate in a clinical trial. Together with the investigators, Immunic determined to readout data of the 18 patients who were enrolled prior to the COVID-19 pandemic. The ongoing pandemic situation also triggered the principal investigator&#8217;s decision to terminate the study in late 2020, before the intended recruitment goal of 30 patients was reached.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Plan</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of Immunic&#8217;s drug development candidates require approval from the FDA and corresponding agencies in other countries before they can be marketed for sale. The activities required before drugs or biologics may be marketed in the United States include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">preclinical laboratory tests, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> preclinical studies and formulation and stability studies;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">the submission to the FDA of an application for human clinical testing, which is known as an IND;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">adequate and well-controlled human clinical trials to demonstrate the safety and effectiveness of the drug;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">the submission of an NDA for a drug; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;padding-left:13.8pt">the approval by the FDA of an NDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews all available data relating to safety, efficacy and quality and assesses the risk/benefit profile of a product candidate before granting approval. The data assessed by the FDA in reviewing an NDA includes animal or preclinical testing data, chemistry, drug-drug interaction data, manufacturing controls data and clinical safety and efficacy data.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future human clinical testing and marketing outside the United States will be subject to foreign regulatory requirements. These requirements vary by jurisdiction, differ from those in the United States and may require Immunic to perform additional preclinical or clinical testing regardless of whether FDA approval has been obtained. The amount of time required to obtain necessary approvals from foreign regulatory agencies may be longer or shorter than that required for FDA approval. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic announced positive top-line data from its Phase 2 EMPhASIS trial of IMU-838 in patients with RRMS on August 2, 2020 and expects to have end-of-Phase 2 discussions with regulatory agencies in May of 2021 to discuss the necessary aspects of a Phase 3 program. Immunic also has ongoing Phase 2b trials for IMU-838 in UC and COVID-19, and one investigator-sponsored proof-of-concept clinical trial in PSC.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also considering whether to conduct another clinical trial in CD. If any of these studies meet their primary endpoint and demonstrate general safety and efficacy of IMU-838, Immunic intends to conduct pivotal trials to be initiated either by Immunic itself or by Immunic in collaboration with a potential partner. For our lead indications RRMS and IBD, marketing approval would require completion of two successful, well-controlled Phase 3 studies. Completing such studies would require substantial financial and resource investments and may take several years to complete. In parallel, additional preclinical and clinical investigations need to be conducted in preparation for filing applications for regulatory approval, including additional pharmacological studies in special populations or drug-drug interaction studies. There are also additional steps required to develop and validate large-scale manufacturing capabilities as well as manufacturing controls.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant accelerated approval for drugs that address life-threatening diseases without effective therapies, based on findings from surrogate endpoints reasonably expected to predict clinical outcomes. Additionally, the FDA may grant orphan status for drugs that address high unmet medical needs in rare diseases. Accordingly, due to its relatively low prevalence, PSC may have the potential for an accelerated path toward commercial approval. Based on the rarity of PSC, the life-threatening nature of the disease and the lack of effective therapies, the FDA and other regulatory agencies may agree to an abbreviated development plan, including the possibility of only one single open-label pivotal trial. However, any such development path needs to be discussed with regulatory agencies once proof-of-concept data in PSC are available for IMU-838. This approval may require Immunic to study dosing of IMU-838 in a liver impaired patient population.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Manufacturing and Formulation</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMU-838 is provided as a white, uncoated immediate release tablet. Dose strengths for clinical trials are 5 mg, 15 mg, 22.5 mg, 30 mg and 45 mg, compared with placebo. The tablets are packaged in polyethylene bottles. Vidofludimus calcium, the active ingredient of IMU-838, has been synthesized in batches up to 250 kg of active pharmaceutical ingredient (&#8220;API&#8221;) and a drug product batch size of 500,000 tablets has been produced.  The Company has the capacity for batch sizes of up to several million units.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization Strategy</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic&#8217;s products are being developed with the aim of delivering proof-of-efficacy in state-of-the-art clinical trials with multiple compounds in multiple indications. Subsequent pivotal trials may be conducted by Immunic alone or with a potential partner.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A recent unpublished report by the National Multiple Sclerosis Society suggests that the prevalence of MS in the United States is about 1 million. Even though the prevalence of MS in the United States is potentially higher, Wallin et al. (2019) state that the number of diagnosed patients remains at about 700,000 patients. Of the approximately 700,000 patients diagnosed with MS, about 85% are diagnosed with RRMS. MS affects twice as many women and men in certain age cohorts and is more common in areas inhabited by people of northern European ancestry, such as Europe, the United States, Canada, New Zealand and parts of Australia. MS symptoms typically appear during young adulthood, peaking around 30 years old.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to a recent market study, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Multiple Sclerosis Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Players, Competitive Strategies and Forecasts, 2017 to 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. the global MS market is expected to be worth $27.4 billion by 2025. The United States holds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the largest portion of the global market share for MS treatments, which is expected to continue to grow rapidly due to the increasing incidence of MS, technological advances, and rising drug costs in the United States. Unmet medical need remains high and is a main driver for new pipeline entrances. Oral, small molecule therapeutics are seeing the fastest growth in the MS market due to their increased patient convenience.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UC and CD are prevalent in the Western population, and according to recent literature reviews on the incidence of IBD (Kappelman 2007; Burisch 2013; Rocchi 2012), almost 4.1 million patients suffer from IBD in the United States, Europe and Canada. Worldwide, according to GBD 2015 Lancet (2016), around 11.2 million patients are affected by IBD. In total, the global market for IBD is estimated to be $7.6 billion in 2023, according to Global IBD Market Forecast 2018.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic believes that IMU-838 has the potential to be differentiated from current treatment options as it is being developed to potentially (i) provide a convenient, oral delivery and (ii) avoid viral reactivation.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property, Licenses and Royalties</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMU-838 is covered by several layers of patents and applications, all either granted or filed in the United States, the European Union and other territories.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, IMU-838 is protected by a granted patent claiming the composition of matter of IMU-838&#8217;s active moiety, vidofludimus, the free acid form of IMU-838. This patent is granted in most major markets and expires in 2022 in most of these jurisdictions. Additionally, a second layer of applications was filed to cover IMU-838&#8217;s active ingredient, the calcium salt of vidofludimus. These applications are granted in some jurisdictions and cover IMU-838 until 2031, and U.S. Patent Term Extension and/or European Supplementary Protection Certificates could provide prolonged protection from generic entry up to 2036, depending on NDA submission time and IND filing in the United States and analogous filings in the European Union. Another layer consists of patent applications filed in early 2018 and directed to composition of matter of a newly-identified, specific polymorph of IMU-838 and a related method of production of the clinical material for IMU-838, which is now the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">active ingredient of the currently used IMU-838 formulation. In addition, a patent application covering a dosing scheme currently used with IMU-838 was filed in 2017, based on unexpected findings from Phase 1 and preclinical investigations. If issued, this patent could extend patent protection for IMU-838 to 2038.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMU-838 and IMU-935 were acquired in a transaction with the originator 4SC in September 2016. As part of the transaction, 4SC is entitled to receive a royalty on net sales if products originating from these acquisitions achieve market approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has subsequently submitted additional patent applications for independently developed intellectual property relating to each of IMU-838 and IMU-935.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMU-935 &#8211; Targeting ROR&#947;t and Th17</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mechanism of Action and Key Mechanistic Data</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The target ROR&#947; (RORC) has three known main functions: (i) is a key regulator of Th17 cell differentiation, (ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">is the crucial transcription factor for the genes encoding IL-17A and IL-17F, and (iii) drives normal thymocyte maturation. Preclinical results confirm that IMU-935 is a highly potent and selective inverse agonist of ROR&#947;t with an IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:1.69pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (the concentration of drug that inhibits 50% of the activity of the target) of around 24 nM with additional activity on DHODH (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:1.69pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of 240 nM). The resulting effect of IMU-935 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on IL-17A, IL-17F, IFN&#947; and TNF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> cytokine release from stimulated human lymphocytes is in the low single-digit nanomolar range. The dual target activity of IMU-935 may offer the opportunity to increase the therapeutic window of IMU-935 compared with pure RORC inhibitors. Furthermore, IMU-935 potently inhibits Th17 differentiation and has demonstrated dose dependent activity in several cellular test systems and in psoriasis/IL-17F and IBD animal models.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">One of the potential risks of drugs targeting ROR&#947;t was identified in prior research suggesting that ROR&#947;t knockout or inhibition impacts Th17 differentiation, IL-17 transcription and thymocyte maturation to the same extent. More recent research published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Nature Immunology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (2017) suggests that these functions are differentially mediated by small structural changes of the ROR&#947;t protein impacting the interaction with co-factors and other proteins. In preclinical testing, IMU-935 was found to fully maintain the T cell maturation function. Immunic believes that this may potentially be an important differential feature to other ROR&#947;t inhibitors, and may provide a better safety profile, however this needs to be confirmed in future clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preclinical effect of targeting ROR&#947;t has been demonstrated in several preclinical experiments of competing ROR&#947;t modulators. Some molecules progressed to clinical stage. However, to date, only a limited number of products have reached clinical Phase 2 studies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indication: Psoriasis</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriasis is a chronic inflammatory disease of the skin with unknown etiology that leads to hyperproliferation of keratinocytes and endothelial cells. Most mechanistic data support the hypothesis that psoriasis is an autoimmune disease driven by activated T-lymphocytes which then release cytokines, chemokines and pro-inflammatory molecules into the dermis and epidermis.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriasis is characterized clinically by development of red, scaly, itchy, symmetrical, dry plaques typically located on skin overlying the elbows, knees, lumbar area and scalp. Plaques vary from a few millimeters in diameter to several centimeters and can be localized to a specific area or extend over most of the body surface.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriasis is one of the most common chronic inflammatory skin diseases (Di Meglio et al. 2014). The disease prevalence varies between geographic regions. Studies of psoriasis suggest an overall prevalence of 2% to 3% of the world&#8217;s population, with a higher prevalence in U.S. and Canadian populations (4.6% and 4.7%, respectively). Psoriasis is considered equally prevalent between genders and can occur at any age. However, there seems to be a bimodal distribution of the age of disease onset, with a first peak between 15 and 30 years, and a second peak between 50 and 60 years of age.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current treatments for patients with psoriasis include topical therapies, oral therapies and biologics. Topical therapies, such as corticosteroids and vitamin D3 analogues, reduce inflammation, which slows the proliferation of keratinocytes and reduces itching. Oral therapies such as methotrexate, cyclosporine, apremilast and tofacitinib target anti-inflammatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">processes. Biologics block proteins produced by keratinocytes, dendritic cells, Th17 lymphocytes or other immune cells. Examples of biologics include anti-TNF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> biologics such as infliximab, etanercept and adalimumab. More recently approved monoclonal antibodies, such as secukinumab, ixekizumab and brodalumab, have been developed to target the pro-inflammatory cytokine IL-17. IL-17 antibodies have largely revolutionized the treatment of patients with moderate to severe psoriasis as they have achieved highly successful skin clearance rates.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic intends to develop IMU-935 as an oral and more convenient treatment option for patients with moderate to severe psoriasis with a mechanism of action and efficacy that approximates those of IL-17 antibodies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Competitors</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, several ROR&#947;t inverse agonists are in preclinical development for the treatment of psoriasis, but only a few are in clinical development. To Immunic&#8217;s knowledge, these are:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">JTE-451 Phase 2 completed (Japan Tobacco)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">AUR-101 in Phase 2 (Aurigene Discovery)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">BI 730357 in Phase 2 (Boehringer Ingelheim)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ESR-114 Phase 1/2 completed (Escalier Biosciences)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">BOS172767 / ARN-6039 Phase 1 completed (Boston Pharmaceuticals, licensed from Arrien Pharmaceuticals)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">RTA-1701 Phase 1 completed (Reata Pharmaceuticals)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ABBV-157 in Phase 1 (AbbVie)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">SAR-441169 in Phase 1 (Lead Pharma/Sanofi)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indication: Guillain-Barr&#233; Syndrome</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diagnosis and Prevalence</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, GBS was considered a single disease entity. It is now known to be a heterogeneous syndrome with several variant forms. Acute inflammatory demyelinating polyradiculopathy is the most common form in North America, Europe and most of the developed world, where it accounts for approximately 90% of cases. GBS is thought to result from an immune response to a preceding infection that cross-reacts with peripheral nerve components. The exact mechanisms are unknown. However, cellular and humoral immune responses are of relevance in the pathogenesis of GBS.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical manifestation of GBS is characterized by an acute or subacute onset of a progressive, symmetric weakness in limbs or cranial nerve-innervated muscles, accompanied by absent or depressed deep tendon reflexes, and a characteristic profile in the cerebrospinal fluid and electrodiagnostic studies (Hughes et al. 2005). Patients usually present a few days to a week after onset of symptoms. The weakness can vary from mild difficulty with walking to nearly complete paralysis of all extremity, facial, respiratory, and bulbar muscles.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GBS occurs worldwide with an overall incidence of 0.16 to 3.0 per 100,000 person-years (McGrogan et al. 2009). Thus, it is considered a rare disease. The incidence increases by approximately 20% with every 10-year increase in age beyond the first decade of life (Sejvar et al. 2011). In addition, the incidence is slightly greater in males than in females.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Treatment Options</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current treatments for patients with GBS include plasma exchange (also called plasmapheresis) and administration of intravenous immune globulin (&#8220;IVIg&#8221;). Over the past three decades, no other therapies have been found to be effective for GBS.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Competitors</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To Immunic&#8217;s knowledge, there are currently no other ROR&#947;t inverse agonists in clinical development for the treatment of GBS. According to ClinicalTrials.gov (last assessed January 18, 2021), the following new treatments are being evaluated in clinical trials:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ANX005 in Phase 1 (Annexon Biosciences, monoclonal antibody inhibiting complement factor C1q)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">CK0801 in Phase 1 (Cellenkos, allogeneic cord blood derived T-reg cells)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Imlifidase in Phase 2 (Hansa Biopharma, bacterial endopeptidase cleaving human immunoglobulin)</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Development Plan and Ongoing/Planned Clinical Studies</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic believes that IMU-935 is a unique modulator of ROR&#947;t, as compared to previous and current competitors. IMU-935 is an inverse agonist (and not an antagonist) and is unable to completely block ROR&#947;t activity, thereby allowing a basal remaining ROR&#947;t activity to support normal T cell maturation. Immunic believes this mechanism of action may avoid unwanted side effects. In addition, because IMU-935 blocks two separate pathways relevant to the function of Th17 cells (ROR&#947;t and DHODH), it was shown in preclinical studies to have single nanomolar activity of inhibition of cytokine release in human peripheral blood mononuclear cells. Given these properties, Immunic believes that IMU-935 may provide a reasonable therapeutic window between an effective dose and an intolerable dose.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic&#8217;s current development plan for IMU-935 focuses on two initial goals: (i) to rapidly obtain human safety and pharmacokinetic data for IMU-935 in order to evaluate the safety profile of this development candidate, and (ii) to obtain preliminary clinical activity data using safe doses.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic is currently performing early clinical trials with IMU-935, including single and multiple ascending dose trials, through its Australian subsidiary. Immunic believes that this development approach allows it to accelerate the program due to certain unique regulatory requirements and processes in Australia. In the third quarter of 2019, Immunic&#8217;s Australian subsidiary received clearance from the Bellberry Human Research Ethics Committee in Australia to begin Phase 1 trials of IMU-935 under the Clinical Trial Notification scheme of the Australian Therapeutic Goods Administration. The first healthy volunteer in the clinical Phase 1 trial of IMU-935 was dosed in September 2019. The trial is currently ongoing and recruiting trial subjects. Several single ascending dose cohorts have successfully been completed. Data from this ongoing Phase 1 trial of IMU-935 are still blinded, however at this time no safety signals have been identified that would, in the assessment of the safety monitoring group of the trial, preclude from potential evaluation in a first multiple ascending dose cohort. In February 2021, Immunic received clearance from the Bellberry Human Research Ethics Committee in Australia to commence multiple ascending dose cohorts, which are expected to start in the first quarter of 2021. Unblinded safety data from the single and multiple ascending dose parts in healthy volunteers is expected to be available in the second half of 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical Phase 1 trial of IMU-935 is comprised of three parts:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part A: Single Ascending Dose Part</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first part of the Phase 1 trial is a single ascending dose, double-blind, placebo-controlled study of IMU-935 in healthy volunteers. This part is designed to evaluate the drug&#8217;s safety and pharmacokinetic profile and will also include the evaluation of food effects.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part B: Multiple Ascending Dose Part</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the single ascending dose part, Immunic plans to initiate a second portion of the Phase 1 trial which will be a multiple ascending dose, double-blind, placebo-controlled study in healthy volunteers with IMU-935 given daily for 14 consecutive days. This part will assess the safety and pharmacokinetic properties of IMU-935.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part C: Psoriasis Patients</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to extend these multiple ascending dose studies around mid-2021 by including mild-to-moderate psoriasis patients given IMU-935 daily over 28 consecutive days, in order to assess safety and exploratory disease endpoints in patients with psoriasis.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential Phase 2 Trial in GBS</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic believes that the mechanism of action of IMU-935 may also support its evaluation for the treatment of potential orphan indications. Upon completion of the single and multiple ascending dose portions of the ongoing Phase 1 trial, Immunic anticipates that it may also begin a Phase 2a proof-of-concept clinical trial of IMU-935 in an orphan autoimmune indication. This orphan approach may allow for an accelerated path to approval, in parallel to IMU-935&#8217;s previously planned development in psoriasis. After a thorough review of suitable autoimmune conditions, Immunic has targeted GBS as additional indication for IMU-935, as previously announced. GBS is an acute neurological disorder in which the body's immune system attacks its peripheral nervous system, and for which very few therapies exist. The Company plans to announce additional details as soon as design and timing of the envisaged trial are further defined.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Manufacturing and Formulation</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IM105935, the API of the IMU-935 drug product, is a small molecule compound and is currently synthesized at up to 20 to 30kg scale. Single and multiple ascending dose studies are supplied with a spray dried dispersed formulation dosed in gastro-resistant capsules. However, Immunic may also switch to a potentially updated dosage form, such as tablets, for future usage.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commercialization Strategy</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the WHO, psoriasis affects 2-3% of the world&#8217;s population and according to the National Psoriasis Foundation over 8 million people in the United States have psoriasis. GBS occurs worldwide with an overall incidence of 0.16 to 3.0 per 100,000 person-years.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic believes that ROR&#947;t is an attractive target in the field of autoimmune diseases since it is the key transcription factor and nuclear receptor for regulation of Th17 cell differentiation and production of the IL-17 family of cytokines. The imbalance between regulatory T cells and Th17 cells is a hallmark of autoimmune diseases, and by preventing differentiation towards Th17 cells and impairing their function, IMU-935 targets this imbalance in a beneficial manner. Therefore, Immunic believes that IMU-935 has the potential to provide a safe and cost-effective oral treatment in psoriasis and other autoimmune disorders.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property ("IP"), Licenses and Royalties</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic filed a patent application covering composition of matter for IMU-935 and related molecules with the European Patent Office in September 2017, and this application entered the international phase in September 2018. Assuming this patent issues with sufficient claim coverage, IMU-935 is expected to be under patent protection until 2037, with further extension possible.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IP related to IMU-838 and IMU-935 was acquired in a transaction with the originator 4SC in September 2016. As part of the transaction, 4SC is entitled to receive a royalty on net sales if products originating from these acquisitions achieve market approval. Immunic has subsequently submitted additional patent applications for independently developed intellectual property relating to each of IMU-838 and IMU-935.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMU-856 &#8211; Targeting Intestinal Barrier Function</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mechanism of Action and Key Mechanistic Data</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMU-856, which Immunic believes to have paradigm-changing potential for multiple diseases, is an orally available, small molecule modulator that targets a protein which serves as a transcriptional regulator of the intestinal barrier function. Immunic has not yet disclosed the molecular target for IMU-856. Based on preclinical data, this compound appears to represent a new and potentially disruptive treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function in patients suffering from diseases like IBD, IBS-D, ICI-induced colitis and other barrier function associated diseases. Immunic believes that because IMU-856 has not been shown to cause suppression of the immune functions, it should therefore maintain immune surveillance for patients.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Importance of Targeting Bowel Permeability in Multiple Diseases</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bowel permeability is suspected to be involved in the initiation of many chronic inflammatory or autoimmune conditions, as the impaired intestinal barrier function may be one of the preconditions for antigens of the microbiome to be recognized by the body&#8217;s immune system. This is not only true for diseases of the bowel; the interaction of the immune system with components of the microbiome is suspected for many diseases throughout the body. To date, there are no good treatment strategies to ameliorate impaired bowel permeability.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBD is a chronic, inflammatory disorder characterized by transmural inflammation of a part of the GI tract (UC) or the entire GI tract (CD). IBD is defined by relapsing and remitting episodes with progression over time to complications, including intestinal ulcers and bleeding. The current hypothesis regarding the onset of IBD involves an impaired bowel wall barrier function as the central element of the pathophysiology. In healthy bowel walls, bacteria cannot pass from the lumen to the lamina propria because tightness is maintained between the epithelial cells in what resembles an intact barrier function of the bowel wall. However, in response to environmental or genetic factors, bowel wall barrier function may be weakened, allowing bacteria to pass through and enter the bowel wall, where immune cells recognize the bacteria. This would trigger an initial inflammation event. It is hypothesized that in IBD patients, the initial inflammatory response is abnormally sustained from lack </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of efficient apoptosis of immune cells, but this mechanism is not yet fully understood. Ultimately, patients develop a chronic and systemic immune response. The presence of certain &#8220;bad bacteria&#8221;, which may contain certain epitopes in the microbiota, or the overall makeup of the microbiome, which lack &#8220;good bacteria&#8221;, are also known to contribute to the sustained and overshooting inflammation in IBD. Additionally, it was shown that IBD patients in endoscopic remission still display IBD symptoms if bowel tightness is not normalized. Episodes of impaired bowel wall barrier function are also correlated with relapse weeks later.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irritable bowel syndrome is a common GI disorder in which the underlying pathophysiology is poorly understood. However, increased intestinal permeability in IBS-D patients has been reported. Studies have shown that IBS-D patients have increased intestinal membrane permeability. This increased intestinal permeability may be due to a number of factors, including low-grade inflammation, which has been reported in mucosal biopsies of some diarrhea-predominant and post-infectious patients, but not constipation-predominant patients. It has been established that patients with inflammatory conditions such as celiac sprue and acute alcoholic gastroenteritis also have increased gut permeability. Acute symptoms usually coincide with the acute inflammation that leads to chronic abdominal pain, diarrhea and bloating.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ICIs have been one of the major advances of cancer care in recent years. ICIs are monoclonal antibodies that inactivate repressors of the anti-cancer immune response. However, immune-related adverse events affecting various organs, including the GI tract, causing diarrhea and colitis, might occur due to the fact that the immune system becomes less suppressed. The median time to onset of diarrhea is within the first weeks or months of treatment. The exact mechanism of these immune-mediated side effects is currently unknown; however, one hypothesis is that impaired bowel barrier function due to ICI treatment may play a role in this condition.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Targeting the Disease-Causing and Sustaining Processes</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current treatments of many conditions of the bowel are aimed at inhibiting inflammation, but they do not target the impaired bowel wall barrier function. IMU-856 is designed to target pathways impacting the bowel wall barrier function and is aimed to normalize such function. Immunic believes that normalized bowel wall barrier function may avoid bacterial triggers, which may lead to the achievement and maintenance of remission without significantly influencing the immune competency of the patient.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Development Plan and Planned Studies</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic is performing early clinical trials of IMU-856, including Phase 1 single and multiple ascending dose trials, through its Australian subsidiary. Immunic believes that this development approach will allow it to accelerate the studies due to certain unique regulatory requirements and processes in Australia. The development activities for IMU-856 are intended to largely follow established processes and service provider relationships established for the IMU-935 development program. This may lead to operational and financial synergies in study preparation and execution.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the third quarter of 2020, Immunic&#8217;s Australian subsidiary received clearance from the Bellberry Human Research Ethics Committee in Australia to begin Phase 1 trials of IMU-856 under the Clinical Trial Notification scheme of the Australian Therapeutic Goods Administration. The first healthy volunteer in the clinical Phase 1 trial of IMU-856 was dosed in August 2020. The trial is currently ongoing and active.  Unblinded safety data from the single and multiple ascending dose parts in healthy volunteers is expected to be available in the second half of 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical Phase 1 trial of IMU-856 is comprised of three parts:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part A: Single Ascending Dose Part</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first part of the Phase 1 trial is a single ascending dose, double-blind, placebo-controlled study in healthy volunteers with up to five ascending dose levels of IMU-856. This part is designed to assess safety, pharmacodynamic and pharmacokinetic properties of IMU-856. One dose level evaluates intra-individual differences between fasted and fed conditions.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part B: Multiple Ascending Dose Part</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the single ascending dose part, Immunic plans to initiate a second portion of the Phase 1 trial which will be a multiple ascending dose, double-blind, placebo-controlled study in healthy volunteers with two ascending dose levels of IMU-856 and the study drug given daily for 14 consecutive days. This part is designed to assess safety, pharmacodynamic and pharmacokinetic properties of IMU-856 and is expected to start in the first quarter of 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part C: Patients with Conditions Involving Impaired Bowel Barrier Function</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company plans to extend these single and multiple ascending dose studies in the second half of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to include patients with several diseases involving bowel barrier dysfunction. This would be a double-blind, placebo-controlled study with partial parallel group design. The study drug would be given daily over 28 consecutive days in patients with several conditions with impaired bowel barrier function that were screened for increased bowel permeability using oral marker tests. The change in bowel permeability would be evaluated as change from baseline and comparing one or two active dose groups to placebo. Additionally, biomarkers, disease symptoms, safety and drug trough levels would be assessed. Immunic expects that this would provide an early indication of pharmacodynamic feasibility of IMU-856 by measuring barrier function surrogate markers in IBS-D, UC and CD patients.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Manufacturing and Formulation</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SPIM-15, the API of the IMU-856 drug product, is a small molecule compound and is currently synthesized at up to 6 kg scale. It is formulated as an immediate release tablet.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commercialization Strategy</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic believes that IMU-856 has the potential to be part of a new category of GI treatments focusing on normalizing bowel wall barrier function. The likely focus of product differentiation will be on safe long-term treatment to avoid disease relapse. Additionally, IMU-856 is designed to target the intestinal barrier function rather than directly targeting immune regulation, which may lead to a different safety profile from current immunomodulatory therapies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property, Licenses and Royalties</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 5, 2018, Daiichi Sankyo and Immunic AG entered into an option and license agreement that grants Immunic AG an exclusive global option to exclusively license a group of compounds, designated by Immunic as IMU-856. Under this agreement, Immunic has the exclusive rights to commercialization of IMU-856 in all countries, including the United States, Europe and Japan. The option also includes exclusivity on a patent application filed by Daiichi Sankyo in early 2018, covering IMU-856&#8217;s composition of matter. Immunic exercised the option on January 5, 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the option exercise, Immunic paid to Daiichi Sankyo a one-time upfront licensing fee. Going forward, Daiichi Sankyo is eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), and its implementing regulations. All of Immunic&#8217;s drug development candidates require approval from the FDA and corresponding agencies in other countries before they can be marketed for sale. The activities required before drugs or biologics may be marketed in the United States include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical laboratory tests, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical studies and formulation and stability studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the submission to the FDA of an application for human clinical testing, which is known as an IND application;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adequate and well-controlled human clinical trials to demonstrate the safety and effectiveness of the drug;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the submission to the FDA of an NDA for a drug; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current GMP (&#8220;cGMP&#8221;), requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the approval by the FDA of an NDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews all available data relating to safety, efficacy and quality and assesses the risk/benefit profile of a product candidate before granting approval. The data assessed by the FDA in reviewing an NDA includes animal or preclinical testing data, chemistry, drug-drug interaction data, manufacturing controls data and clinical safety and efficacy data.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. Preclinical trials must also be conducted in accordance with FDA and comparable foreign authorities&#8217; legal requirements, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations or guidelines, including Good Laboratory Practice (&#8220;GLP&#8221;), an international standard meant to harmonize the conduct and quality of non-clinical studies and the archiving and reporting of findings. Before human clinical testing can begin, a sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND, a request for authorization from the FDA to administer an IND product to humans. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may impose a clinical hold at any time before or during clinical trials due to safety concerns about proposed or ongoing clinical trials or non-compliance with FDA requirements, and the trials may not commence or continue until the FDA notifies the sponsor that the hold has been lifted.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials must be conducted under the supervision of one or more qualified investigators pursuant to protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection, inclusion/exclusion criteria and the safety and effectiveness criteria to be evaluated. The trial sponsor submits the protocol, as well as any subsequent protocol amendments, to the FDA as part of the IND. Sponsors must also provide all participating investigators and FDA safety reports of any serious and unexpected adverse events and any findings from laboratory tests in animals that suggests a significant risk for human subjects. For each institution where a clinical trial will be conducted, an IRB must review and approve the clinical trial protocol and informed consent form required to be provided to each trial subject or his or her legal representative prior to a clinical trial commencing, and conduct on-going monitoring of the study until completed or termination to assure that appropriate steps are taken to protect the human subjects participating in the research.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase 1: In Phase 1 studies, the product candidate is initially introduced into healthy human volunteers and tested for safety, dosage and tolerability, absorption, distribution, metabolism, excretion, and effect on the body.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase 2: Phase 2 studies are conducted in a limited patient population. These studies continue to evaluate safety while gathering preliminary data on effectiveness in patients with the targeted disease or condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase 3: Phase 3 trials further evaluate efficacy and safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval studies, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These studies are used to gather additional information about a product&#8217;s safety and/or efficacy in patients affected by the therapeutic indication. The FDA may require Phase 4 studies as a condition of approval of an NDA.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must also be conducted in accordance with legal requirements, regulations or guidelines of the FDA and comparable foreign authorities, including human subject protection requirements and current good clinical practice (&#8220;cGCP&#8221; or &#8220;GCP&#8221;). In addition, clinical trials must be conducted product candidates produced under cGMP requirements. The FDA or the sponsor may suspend a clinical trial at any time for various reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB may suspend or terminate approval of a clinical trial at an institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts, known as a data safety monitoring board or committee, which monitors data from the trial to ensure patient safety and data integrity and may also make recommendations to alter or terminate a trial based on concerns for patient safety.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval for the commercial sale of any drug product, a sponsor must demonstrate in preclinical studies and well-controlled clinical trials that the product is safe and effective for its intended use and that the manufacturing facilities, processes and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity. The results of these preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">($2,875,842 for 2021)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; under certain limited circumstances, a waiver of such fees may be obtained. After the submission of an NDA, but before approval of the NDA, the manufacturing facilities used to manufacture a product candidate must be inspected by the FDA to ensure compliance with the applicable cGMP requirements. The FDA may also inspect clinical trial sites and audit clinical study data to ensure that the sponsor&#8217;s studies were properly conducted in accordance with the IND regulations, human subject protection regulations, and cGCP.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the current Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines, FDA goal for acting on the submission of an NDA for a new molecular entity is ten months from the date of &#8220;filing.&#8221; The FDA conducts a preliminary review of an NDA within 60 days after submission to determine whether it is sufficiently complete to permit substantive review, before accepting the NDA for filing. This two month preliminary review effectively extends the typical NDA review period to twelve months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the FDA&#8217;s evaluation of an NDA, it will issue an approval letter or a complete response letter (&#8220;CRL&#8221;). An approval letter authorizes the sponsor to begin commercial marketing of the drug for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL describes the specific deficiencies in the NDA identified by the FDA. When possible, a CRL will recommend actions that the applicant might take, including providing additional clinical data, such as an additional Phase 3 trial or other significant and time consuming requirements related to clinical trials, nonclinical studies or manufacturing, to place the application in condition for approval. If a CRL is issued, the sponsor must resubmit the NDA addressing all of the deficiencies identified in the letter, or withdraw the application. Even if the sponsor submits the recommended data and information, the FDA may decide that the NDA does not satisfy the criteria for approval.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As condition to a product&#8217;s regulatory approval, the FDA may require a sponsor to conduct Phase 4 studies designed to further assess the drug&#8217;s safety and effectiveness after NDA approval, or may require other testing and surveillance programs to monitor the safety of the approved product. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to assure the safe use of the drug. A REMS could include medication guides, communication plans to healthcare professionals or other activities to assure safe use, such as provider certification or training, restricted distribution methods, and patient registries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic recognized $38.6 million and $22.5 million in research and development expenses in the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of Immunic&#8217;s long-lived assets were located within both the United States and Germany in 2020 and 2019.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2021, Immunic had 28 employees, three of whom held M.D. degrees. Of the employees, 18 were engaged in research and development and 10 in administration. The Company considers its employee relations to be good.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information and Website</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic maintains a website at www.imux.com. The information contained on, or that can be accessed through, the website is not a part of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page of the internet website as soon as reasonably practicable after the Company electronically files such material with, or furnish it to, the SEC.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Before deciding to invest in our company or deciding to maintain or increase your investment, you should consider carefully the risks and uncertainties described below. The risks and uncertainties described below and in our other filings with the SEC are not the only risks we face. If one or more of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the market price for our common stock could decline, and you may lose your entire investment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Risk Factor Summary</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of certain important factors that may make an investment in our Company speculative or risky. You should carefully consider the fuller risk factor disclosure set forth in this Annual Report, in addition to the other information herein, including the section of this report titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our pursuit of a COVID-19 drug candidate is at an early stage. We may be unable to produce a drug that successfully treats the virus in a timely manner, if at all. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">The coronavirus pandemic has caused interruptions or delays of our business plan and may have a significant adverse effect on our business. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic has a limited operating history with its current business plan, has incurred significant losses since 2016, anticipates that it will continue to incur significant and increasing losses for the foreseeable future and may never achieve or maintain profitability. The absence of any commercial sales and Immunic&#8217;s limited operating history make it difficult to assess its future viability.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic currently has no source of product sales revenue and may never be profitable. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic will require substantial additional funding, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force Immunic to delay, limit, reduce or terminate its product development, other operations or future commercialization efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Raising additional capital may cause dilution to Immunic&#8217;s existing stockholders, restrict its operations or require Immunic to relinquish rights to its technologies or product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">The marketing approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if Immunic is ultimately unable to obtain marketing approval for its product candidates, its business will be substantially harmed. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate Immunic advances through clinical trials may not have favorable results in later clinical trials or receive marketing approval. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic&#8217;s product candidates may cause undesirable adverse effects or have other properties that could delay or prevent their marketing approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if obtained. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic is heavily dependent on the success of its product candidates, which are in the early stages of clinical development. Immunic cannot give any assurance that it will generate data for any of its product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">candidates sufficient to receive regulatory approval in its planned indications, which will be required before they can be commercialized. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Due to Immunic&#8217;s limited resources and access to capital, it must decide to prioritize development of its current product candidates for certain indications and at certain doses. These decisions may prove to have been wrong and may materially adversely affect Immunic&#8217;s business, financial condition, results of operations and prospects. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">If Immunic fails to attract and retain key management and scientific personnel, it may be unable to successfully develop or commercialize its product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Even if Immunic obtains the required regulatory approvals in the United States and other territories, the commercial success of its product candidates will depend on market awareness and acceptance of its product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic currently has limited marketing and sales experience. If Immunic is unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell its product candidates, Immunic may be unable to generate any revenue. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">If Immunic fails to enter into strategic relationships or collaborations, its business, financial condition, commercialization prospects and results of operations may be materially adversely affected. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic faces substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than Immunic does. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic may be unable to realize the potential benefits of any collaboration. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic&#8217;s proprietary rights may not adequately protect its technologies and product candidates. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic may not be able to protect its intellectual property rights throughout the world. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Intellectual property rights do not protect against all potential threats to Immunic&#8217;s competitive advantage. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic incurs significant costs and demands upon management as a result of complying with the laws and regulations affecting public companies. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">The market price of Immunic&#8217;s common stock is volatile.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Immunic does not anticipate that it will pay any cash dividends in the foreseeable future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Risks Related to COVID-19</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Our pursuit of a COVID-19 drug candidate is at an early stage. We may be unable to produce a drug that successfully treats the virus in a timely manner, if at all.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In response to the global coronavirus pandemic and based on preclinical data, we have started and are in the process of conducting an antiviral clinical trial for IMU-838, our lead product candidate and a selective oral DHODH inhibitor. Our clinical development program for IMU-838 as a potential treatment option for patients with COVID-19 is in early stages, we may be unable to recruit enough patients based on limited disease prevalence in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">countries in which we are recruiting trial participants, we may not be able to show any activity of IMU-838 in COVID-19, our COVID-19 drug candidate may not prove to be safe for the treatment of COVID-19, and we may be unable to produce a drug that successfully treats COVID-19 in a timely manner, if at all. We are also committing financial resources and personnel to the development of a drug to target COVID-19, which may cause delays in or otherwise negatively impact our other development programs. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable and could rapidly dissipate or against which, our drug, if developed, may not be effective or safe. Furthermore, there are a number of preventative vaccines in development with two having received an Emergency Use Authorization approval and others potentially nearing regulatory approval. Additionally, the United States and other countries throughout the world have recently begun to approve and commence distributing COVID-19 vaccines in their jurisdictions. The broad distribution of COVID-19 vaccines may limit the availability of governmental and quasi-governmental funding and limit the commercial viability of any approved product candidate for the treatment of COVID-19.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">The coronavirus pandemic has caused interruptions or delays of our business plan and may have a significant adverse effect on our business. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In an effort to contain and mitigate the spread of COVID-19, many countries, including the United States, Canada, the European Union and China, have imposed unprecedented restrictions on travel, quarantines and other public health safety measures. The extent to which the pandemic may continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted, but the development of clinical supply materials could be delayed and enrollment of patients in our ongoing studies may be delayed or suspended, as hospitals and clinics in areas where we are conducting trials have shifted resources to cope with the COVID-19 pandemic and may limit access or close clinical facilities due to the COVID-19 pandemic. Additionally, if our trial participants are unable to travel to our clinical study sites as a result of quarantines or other restrictions resulting from the COVID-19 pandemic, we may experience higher discontinuation rates or delays in our clinical studies, as occurred in our investigator-sponsored trial of IMU-838 in PSC being conducted at the Mayo Clinic. Government-imposed quarantines and restrictions may also require us to temporarily terminate our clinical sites. Furthermore, if we determine that our trial participants may suffer from exposure to COVID-19 as a result of their participation in our clinical trials, we may voluntarily terminate certain clinical sites as a safety measure until we reasonably believe that the likelihood of exposure has subsided. As a result, our expected development timelines for our product candidates may be negatively impacted. In addition, the COVID-19 pandemic has affected and may continue to affect the operations of the U.S. Food and Drug Administration and other regulatory authorities, which could result in delays of reviews and approvals with respect to our product candidates. We cannot predict the continuing impact of the COVID-19 pandemic, as consequences of such an event are highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts that have affected and may continue to affect our business, or our clinical studies in general; however, the COVID-19 pandemic may materially disrupt or delay our business operations, further divert the attention and efforts of the medical community to coping with COVID-19, disrupt the marketplace in which we operate, and/or have a material adverse effect on our operations. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, Phase 1 trials are ongoing for drug candidates IMU-935 and IMU-856 in Australia. Such Phase 1 trials are customarily conducted in healthy volunteers who have no potential benefits from participation in such trials. Hence, Phase 1 trials usually are subject to more strict evaluation and assessments during pandemic periods. Such Phase 1 trials may for that reason be interrupted or delayed.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, the various precautionary measures taken by many governmental authorities throughout the world in order to limit the spread of COVID-19 has had and may continue to have an adverse effect on the global markets and global economy generally, including on the availability and pricing of employees, resources, materials, manufacturing and delivery efforts and other aspects of the global economy. There have been business closures and a substantial global reduction in economic activity as a result of COVID-19. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on the global economy. We cannot currently predict the duration of the pandemic or its impact on global or regional economic activity. The COVID-19 pandemic could materially disrupt our business and operations, interrupt our sources of supply, hamper our ability to raise additional funds or sell our securities, continue to slow down the overall economy or curtail consumer spending.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Immunic&#8217;s Business and Financial Condition </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic has a limited operating history with its current business plan, has incurred significant losses since 2016, anticipates that it will continue to incur significant and increasing losses for the foreseeable future and may never achieve or maintain profitability. The absence of any commercial sales and Immunic&#8217;s limited operating history make it difficult to assess its future viability.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic is a development-stage pharmaceutical company with a limited operating history with its current business plan. Immunic&#8217;s net losses were $44.0 million and $34.9 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, Immunic had an accumulated deficit of $103.9 million to date and has not generated any revenue from its current product candidates. Moreover, Immunic AG, the company&#8217;s operating subsidiary, has only a limited operating history upon which stockholders can evaluate its business and prospects, is not profitable and has incurred losses in each year since its inception in 2016. In addition, Immunic has limited experience and has not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic has devoted substantially all of its financial resources to identify, acquire and develop its product candidates, including providing general and administrative support for its operations. Immunic expects its losses to increase as it conducts clinical trials and continues to develop its lead product candidates. Immunic expects to invest significant funds into the research and development of its current product candidates to determine the potential to advance these product candidates to regulatory approval. To date, Immunic has financed its operations primarily through the sale of equity securities. The amount of its future net losses will depend, in part, on the rate of its future expenditures and its ability to obtain funding through equity or debt financings, strategic collaborations or grants. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic does not expect to generate significant revenue unless and until it is able to obtain marketing approval for, and successfully commercialize, any current or future product candidate. However pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. In addition, if Immunic obtains regulatory approval to market a product candidate, its future revenue will depend upon the size of any markets in which its product candidates may receive regulatory approval, and its ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for its product candidates. Even if Immunic eventually obtains adequate market share for its product candidates, to the extent they receive regulatory and market approval, the potential markets for its product candidates are may not be large enough for Immunic to become profitable.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic expects to continue to incur significant expenses and increasing operating losses for the foreseeable future, and its expenses will increase substantially if and as Immunic: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">continues the clinical development of its product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">continues efforts to discover, develop and/or acquire new product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">undertakes the manufacturing of its product candidates for clinical development and, potentially, commercialization, or increases volumes manufactured by third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">advances its programs into larger, more expensive clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">initiates additional preclinical, clinical, or other trials or studies for its product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">seeks regulatory and marketing approvals and reimbursement for its product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">experiences any delays or encounters issues with the development and process for regulatory approval of its product candidates such as safety issues, clinical trial accrual delays, longer follow-up for planned studies, additional major studies or supportive studies necessary to support marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">establishes a sales, marketing and distribution infrastructure to commercialize any products for which Immunic may obtain marketing approval and market for itself;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">makes milestone, royalty or other payments under any third-party license agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">seeks to maintain, protect and expand its intellectual property portfolio;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">seeks to retain current skilled personnel and attract additional personnel; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">adds operational, financial and management, and information systems personnel, including personnel to support our product development and commercialization efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, the net losses Immunic incurs may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of its results of operations may not be a good indication of its future performance. Failure to become and remain profitable would decrease the value of the company and could impair its ability to raise capital, expand its business, maintain its development efforts, expand its pipeline of product candidates or continue its operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic currently has no source of product sales revenue and may never be profitable. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic has not generated any revenues from commercial sales of any of its current product candidates. Immunic&#8217;s ability to generate product revenue depends upon its ability to successfully commercialize these product candidates or other product candidates that it may develop, in-license or acquire in the future. Immunic does not anticipate generating revenue from the sale of products for the foreseeable future. Immunic&#8217;s ability to generate revenue from its current or future product candidates also depends on a number of additional factors, including its ability to: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">successfully complete research and clinical development of current and future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtain regulatory approval from relevant regulatory authorities in jurisdictions where Immunic intends to market its product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">launch and commercialize any product candidates for which Immunic obtains marketing approval, and if launched independently, successfully establish a sales force and marketing and distribution infrastructure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtain coverage and adequate product reimbursement from third-party payors, including government payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">achieve market acceptance for any approved products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish, maintain and protect its intellectual property rights; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">attract, hire and retain qualified personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, because of the numerous risks and uncertainties associated with clinical product development, including that Immunic&#8217;s product candidates may not advance through development or achieve regulatory approval, Immunic is unable to predict the timing or amount of any potential future product sale revenues. Immunic&#8217;s expenses also could increase beyond expectations if Immunic decides to or is required by the FDA or comparable foreign regulatory authorities, to perform studies or trials in addition to those that Immunic currently anticipates. Even if Immunic completes the development and regulatory processes described above, Immunic anticipates incurring significant costs associated with launching and commercializing any product candidates that may be approved. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic will require substantial additional funding, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force Immunic to delay, limit, reduce or terminate its product development, other operations or future commercialization efforts.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since the inception of Immunic AG, substantially all of its resources have been dedicated to the clinical development of its product candidates. Developing pharmaceutical products, including conducting preclinical and non-clinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We have consumed substantial amounts of cash since our inception. For example, in the years ended December 31, 2020 and December 31, 2019, we used net cash of $46.1 million and $28.5 million, respectively, in our operating activities, substantially all of which related to development of our current product candidates. Immunic believes that it will continue to expend substantial resources for the foreseeable future on the completion of clinical development and regulatory preparedness of its product candidates, preparations for a commercial launch </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of any approved product candidates, and development of any other current or future product candidates it may choose to further develop. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, obtaining marketing approvals, and manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any drug development process is highly uncertain, Immunic cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any approved current or future product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic&#8217;s operating plan may change as a result of factors currently unknown to Immunic, and it may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to Immunic&#8217;s stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect its business. In addition, Immunic may seek additional capital due to favorable market conditions or strategic considerations even if Immunic believes it has sufficient funds for its current or future operating plans. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2022. Our estimate as to how long we expect our existing cash and cash equivalents to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume cash and cash equivalents significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Immunic&#8217;s future capital requirements depend on many factors, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the scope, progress, results and costs of researching and developing Immunic&#8217;s current product candidates, future product candidates and related preclinical and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost of commercialization activities if Immunic&#8217;s current product candidates and future product candidates are approved for sale, including marketing, sales and distribution costs and preparedness of its corporate infrastructure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost of manufacturing current product candidates and future product candidates that Immunic may obtain approval for and successfully commercialize;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic&#8217;s ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number and characteristics of any additional product candidates Immunic may develop or acquire;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">any product liability or other lawsuits related to Immunic&#8217;s products or otherwise commenced against Immunic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the expenses needed to attract and retain skilled personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs associated with being a public company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing Immunic&#8217;s intellectual property rights, including litigation costs and the outcome of any such litigation; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing, receipt and amount of sales of, or royalties on, any future approved products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional funds may not be available when Immunic needs them, on terms that are acceptable to Immunic, or at all. If adequate funds are not available to Immunic on a timely basis, Immunic may be required to delay, limit, reduce or terminate: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical studies, clinical trials or other development activities for Immunic&#8217;s current product candidates or any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">its research and development activities; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">its establishment of sales and marketing capabilities or other activities that may be necessary to commercialize its future product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to Immunic&#8217;s existing stockholders, restrict its operations or require Immunic to relinquish rights to its technologies or product candidates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic may seek additional capital through a combination of public and private equity offerings, debt financings, strategic collaborations and alliances and licensing arrangements. To the extent that Immunic raises additional capital through the sale of equity or convertible debt securities, the ownership interest of Immunic&#8217;s stockholders will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that adversely affect the rights of Immunic&#8217;s stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on Immunic&#8217;s ability to incur additional debt, acquire or license intellectual property rights, redeem stock or declare dividends, and other operating restrictions that could adversely impact Immunic&#8217;s ability to conduct its business. If Immunic raises additional funds through strategic collaborations and alliances and licensing arrangements with third parties, Immunic may have to relinquish valuable rights to its technologies or product candidates, or grant licenses on terms unfavorable to Immunic. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Our finance contract (the &#8220;Loan Agreement&#8221;) with the European Investment Bank (&#8220;EIB&#8221;) contains various covenants which, if not complied with, could accelerate repayment under the facility, thereby materially and adversely affecting our liquidity, financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For so long as any amount is outstanding under the Loan Agreement with EIB, we are subject to covenants that restrict our ability to incur additional indebtedness, create liens, sell assets, and consolidate or merge. Failure to comply with certain covenants could result in an event of default which, if we were unable to obtain a waiver from EIB, could result in an acceleration of repayment under the facility and have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, the restrictive covenants contained in the Loan Agreement could affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to the Clinical Development and Marketing Approval of Immunic&#8217;s Product Candidates </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The marketing approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if Immunic is ultimately unable to obtain marketing approval for its product candidates, its business will be substantially harmed. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">None of Immunic&#8217;s current product candidates have gained marketing approval for sale in the United States or any other country, and Immunic cannot guarantee that it will ever have marketable products. Immunic&#8217;s business is substantially dependent on its ability to complete the development of, obtain marketing approval for, and successfully commercialize its product candidates in a timely manner. Immunic cannot commercialize its product candidates in the United States without first obtaining approval from the FDA to market each product candidate. Similarly, Immunic cannot commercialize its product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Immunic&#8217;s product candidates could fail to receive marketing approval for many reasons, including the following: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Immunic&#8217;s clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may find the human subject protections for Immunic&#8217;s clinical trials inadequate and place a clinical hold on (i) an IND application at the time of its submission, precluding commencement of any trials, or (ii) one or more clinical trials at any time during the conduct of such trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may disagree with Immunic&#8217;s interpretation of data from preclinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the data collected from clinical trials of Immunic&#8217;s product candidates may not be sufficient to support the submission of an application to obtain marketing approval in the United States or elsewhere;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities may find inadequate the manufacturing processes or facilities of third-party manufacturers with which Immunic contracts for clinical and commercial supplies of its product candidates; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner that would delay marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before obtaining marketing approval for the commercial sale of any drug product for a target indication, Immunic must demonstrate in preclinical studies and well-controlled clinical trials and, with respect to approval in the United States, to the satisfaction of the FDA, that the product is safe and effective for its intended use and that the manufacturing facilities, processes and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity. In the United States, it is necessary to submit and obtain approval of a new drug application (&#8220;NDA&#8221;) from the FDA. The submission of an NDA is subject to the payment of substantial user fees ($2,875,842 for 2021); under certain limited circumstances, a waiver of such fees may be obtained. An NDA must include extensive preclinical and clinical data and supporting information to establish the product safety and efficacy for each desired indication. The NDA must also include significant information regarding the chemistry, manufacturing and controls for the product. After the submission of an NDA, but before approval of the NDA, the manufacturing facilities used to manufacture a product candidate must be inspected by the FDA to ensure compliance with the applicable current good manufacturing practice (&#8220;cGMP&#8221;) requirements. The FDA, the competent authorities of the member states of the European Economic Area, and comparable foreign regulatory authorities may also inspect Immunic&#8217;s clinical trial sites and audit clinical study data to ensure that its studies are properly conducted in accordance with the IND regulations, human subject protection regulations, and current good clinical practice (&#8220;cGCP&#8221;). </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Under the current Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines, FDA goal for acting on the submission of an NDA for a new molecular entity is ten months from the date of &#8220;filing.&#8221; The FDA conducts a preliminary review of an NDA within 60 days after submission to determine whether it is sufficiently complete to permit substantive review, before accepting the NDA for filing. This two month preliminary review effectively extends the typical NDA review period to twelve months. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. Immunic cannot be certain that any submissions will be accepted for filing and reviewed by the FDA, or ultimately be approved. If an application is not accepted for review, the FDA may require that Immunic conduct additional clinical studies or preclinical testing, or take other actions before it will reconsider Immunic&#8217;s application. If the FDA requires additional studies or data, Immunic would incur increased costs and delays in the marketing approval process, which may require Immunic to expend more resources than Immunic has available. In addition, the FDA may not consider any additional information to be complete or sufficient to support the filing or approval of the NDA. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regulatory authorities outside of the United States, such as in Europe and Japan and in emerging markets, also have requirements for approval of drugs for commercial sale with which Immunic must comply prior to marketing in those jurisdictions. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of Immunic&#8217;s product candidates into the relevant markets. Clinical trials conducted in one country may not be accepted or the results may not be found adequate by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. However, the failure to obtain regulatory approval in one jurisdiction could have a negative impact on Immunic&#8217;s ability to obtain approval in a different jurisdiction. Approval processes vary among countries and can involve additional product candidate testing and validation and additional administrative review periods. Seeking foreign regulatory approval could require additional non-clinical studies or clinical trials, which could be costly and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">time-consuming. Foreign regulatory approval may be subject to all of the risks associated with obtaining FDA approval. For all of these reasons, Immunic may not obtain foreign regulatory approvals on a timely basis, if at all. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The process to develop, obtain marketing approval for, and commercialize product candidates both inside and outside of the United States is long, complex and costly, and approval is never guaranteed. The time required to obtain approval by the FDA and comparable regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary between jurisdictions. Even if Immunic&#8217;s product candidates were to successfully obtain approval from regulatory authorities, any such approval might significantly limit the approved indications for use, including conditioning approval on the requirement of (i) more limited patient populations, (ii) precautions, warnings or contraindications on the product labeling, including &#8220;black box&#8221; warnings, (iii) expensive and time-consuming post-approval clinical studies, risk evaluation and mitigation strategies ("REMS"), or surveillance, or (iv) limiting the claims that the product label may make, any of which may impede the successful commercialization of Immunic&#8217;s product candidates. Following any approval for commercial sale of Immunic&#8217;s product candidates, certain changes to the product, such as changes in manufacturing processes and additional labeling claims, as well as new safety information, may require new studies and will be subject to additional FDA notification, or review and approval. Also, marketing approval for any of Immunic&#8217;s product candidates may be withdrawn. If Immunic is unable to obtain and maintain marketing approval for its product candidates in one or more jurisdictions, or any approval contains significant limitations, Immunic&#8217;s ability to market its product candidates to its full target market will be reduced and its ability to realize the full market potential of its product candidates will be impaired. Furthermore, Immunic may not be able to obtain sufficient funding or generate sufficient revenue and cash flows to continue or complete the development of any of its current or future product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. The FDA and comparable foreign regulatory authorities have substantial discretion when and if to grant approval to Immunic&#8217;s product candidates. Even if Immunic believes the data collected from clinical trials of its current product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">authorities. Immunic&#8217;s future clinical trial results also may not be successful. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is impossible to predict the extent to which the clinical trial process may be affected by existing or prospective legislative and regulatory developments. Due to these and other factors, Immunic&#8217;s current or future product candidates could take a significantly longer than expected to gain marketing approval, if at all. This could delay or eliminate any potential product revenue by delaying or terminating the potential commercialization of Immunic&#8217;s current product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Preclinical trials must also be conducted in accordance with FDA and comparable foreign regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">authorities&#8217; legal requirements, regulations or guidelines, including Good Laboratory Practice ("GLP"), an international standard meant to harmonize the conduct and quality of non-clinical studies and the archiving and reporting of findings. Preclinical studies, including long-term toxicity studies and carcinogenicity studies in experimental animals, may require further evaluation, which could affect the risk-benefit evaluation of clinical development, or which may even lead the regulatory agencies to delay, prohibit the initiation of or halt clinical trials or delay or deny marketing authorization applications. Failure to adhere to the applicable GLP standards or misconduct during the course of preclinical trials may invalidate the data and require repeating one or more studies or conducting additional testing. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical trials must also be conducted in accordance with legal requirements, regulations or guidelines of the FDA and comparable foreign regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">authorities, including human subject protection requirements and GCP. Clinical trials are subject to further oversight by these governmental agencies and IRBs at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of Immunic&#8217;s </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">current product candidates produced under cGMP and other requirements. Immunic&#8217;s clinical trials are conducted at multiple sites, including some sites in countries outside the United States and the European Union, which may subject Immunic to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of foreign and non-European Union contract research organizations ("CROs"), as well as expose Immunic to risks associated with clinical investigators who are unknown to the FDA or European regulatory authorities, and with different standards of diagnosis, screening and medical care. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To date, Immunic has not completed all clinical trials required for the approval of its current product candidates. The commencement and completion of clinical trials for Immunic&#8217;s current product candidates may be delayed, suspended or terminated as a result of many factors, including but not limited to: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the delay or refusal of regulators or IRBs to authorize Immunic to commence a clinical trial at a prospective trial site;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in regulatory requirements, policies and guidelines;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of Immunic&#8217;s clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to reach agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in patient enrollment and variability in the number and types of patients available for clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to enroll a sufficient number of patients in trials to ensure adequate statistical power to detect statistically significant treatment effects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">lower than anticipated retention rates of patients and volunteers in clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">clinical sites deviating from trial protocols or dropping out of a trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">adding new clinical trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">negative or inconclusive results, which may require Immunic to conduct additional preclinical or clinical trials or to abandon projects that Immunic expects to be promising;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">safety or tolerability concerns, which could cause Immunic to suspend or terminate a trial if it finds that participants are exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulators or IRBs requiring that Immunic or its investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic&#8217;s third-party research and manufacturing contractors failing to comply with regulatory requirements or meet their contractual obligations to Immunic in a timely manner, or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">third-party researchers becoming debarred or otherwise penalized by FDA or other regulatory authorities for violations of regulatory requirements, which could call into question data collected by such researcher and potentially affecting Immunic&#8217;s ability rely on some or all of the data in support of our marketing applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulty in maintaining contact with patients after treatment, resulting in incomplete data;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in establishing the appropriate dosage levels;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the quality or stability of Immunic&#8217;s current product candidates falling below acceptable standards;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to produce or obtain sufficient quantities of Immunic&#8217;s current product candidates to complete clinical trials; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">exceeding budgeted costs due to difficulty in accurately predicting the costs associated with clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, and competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications Immunic is investigating. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are significant requirements imposed on Immunic and on clinical investigators who conduct clinical trials that Immunic sponsors. Although Immunic is responsible for selecting qualified clinical investigators, providing them with the information they need to conduct the clinical trial properly, ensuring proper monitoring of the clinical trial, and ensuring that the clinical trial is conducted in accordance with the general investigational plan and protocols contained in the IND, Immunic cannot ensure that clinical investigators will maintain compliance with all regulatory requirements at all times. The pharmaceutical industry has experienced cases where clinical investigators have been found to incorrectly record, omit, or even falsify data. Immunic cannot ensure that the clinical investigators in its trials will not make mistakes or otherwise compromise the integrity or validity of data, any of which would have a significant negative effect on Immunic&#8217;s ability to obtain marketing approval, Immunic&#8217;s business, and Immunic&#8217;s financial condition. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic could encounter delays if a clinical trial is suspended or terminated by Immunic, the IRBs or ethics committees of the institutions in which such trial is being conducted, the independent steering committee, the data safety monitoring board ("DSMB"), for such trial, or the FDA or comparable foreign regulatory authorities. Immunic or such authorities may impose a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Immunic&#8217;s clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using the drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Delay or termination of clinical trials of Immunic&#8217;s current product candidates will harm their commercial prospects and impair Immunic&#8217;s ability to generate revenues from such product candidates. In addition, any delays in completion of Immunic&#8217;s clinical trials will increase its costs, slow its development and approval process and jeopardize its ability to commence product sales and generate revenues. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, clinical investigators for Immunic&#8217;s clinical trials may serve as scientific advisors or consultants to Immunic from time to time and receive compensation in connection with such services. Immunic is required to report certain financial relationships with clinical investigators to the FDA and, where applicable, take steps to minimize the potential for bias resulting from such financial relationships. The FDA may evaluate the reported information and conclude that a financial relationship between Immunic and a clinical investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. The FDA may refuse to accept Immunic&#8217;s marketing applications, and other delays or even denial of marketing approval could result.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Preclinical testing or clinical trials of any development candidate may also show new and unexpected findings regarding safety and tolerability. Such findings may harm the ability to conduct further development of product candidates, delay such development, require additional expensive tests, harm the ability of Immunic to partner these development candidates, or delay or prevent marketing approval by regulatory agencies. Such findings may also harm the ability to compete in the market with other products or to achieve certain pricing thresholds. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any of these occurrences could materially adversely affect Immunic&#8217;s business, financial condition, results of operations, and prospects. In addition, many of the factors that could cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of Immunic&#8217;s current product candidates. Significant clinical trial delays could also allow Immunic&#8217;s competitors to bring products to market before Immunic, shorten any periods during which Immunic may have the exclusive right to commercialize any approved current product candidates, and impair its ability to commercialize any approved current product candidates, which may harm Immunic&#8217;s business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of patient-reported outcomes in Immunic&#8217;s clinical trials may delay the development of its product candidates or increase development costs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Due to the difficulty of objectively measuring the efficacy of IMU-838, patient-reported outcomes ("PROs"), may have an important role in the development and regulatory approval of Immunic&#8217;s IMU-838. PROs involve </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">patients&#8217; subjective assessments of efficacy, and this subjectivity increases the uncertainty in determining clinical endpoints. Such assessments can be influenced by factors outside of Immunic&#8217;s control, and can vary widely from day-to-day for a particular patient, and from patient-to-patient and site-to-site within a clinical trial. Use of PROs may make the outcome of trials more uncertain and may increase Immunic&#8217;s costs and time to finish regulatory approval trials.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate Immunic advances through clinical trials may not have favorable results in later clinical trials or receive marketing approval. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of Immunic&#8217;s clinical development. The results of preclinical studies and early clinical trials of Immunic&#8217;s product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of pharmaceutical companies have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Clinical trials may produce negative or inconclusive results, and Immunic may decide, or regulators may require Immunic, to conduct additional clinical or preclinical testing. Data obtained from trials are susceptible to varying interpretations, and regulators may not interpret Immunic&#8217;s data as favorably as Immunic does, which may delay, limit or prevent marketing approval of Immunic&#8217;s product candidates. In addition, the design of a clinical trial can determine whether its results will support approval of a product, or approval of a product for desired indications, and flaws or shortcomings in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Immunic has limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval for Immunic&#8217;s desired indications. Further, clinical trials of product candidates often reveal that it is not practical or feasible to continue development efforts. If one of Immunic&#8217;s product candidates is found to be unsafe or lack efficacy, Immunic will not be able to obtain marketing approval for such product candidate and Immunic&#8217;s business would be harmed. For example, if the results of Immunic&#8217;s clinical trials of its product candidates do not achieve pre-specified endpoints, Immunic is unable to provide primary or secondary endpoint measurements deemed acceptable by the FDA or comparable foreign regulators or Immunic is unable to demonstrate an acceptable level of safety relative to the efficacy associated with its proposed indications, the prospects for approval of Immunic&#8217;s product candidates would be materially and adversely affected. A number of companies in the pharmaceutical industry, including those with greater resources and experience than Immunic, have suffered significant setbacks in Phase 2 and Phase 3 clinical trials, even after seeing promising results in earlier clinical trials. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including differences in trial protocols and design, the size and type of the patient population, adherence to the dosing regimen and the rate of dropout among clinical trial participants. Immunic does not know whether any clinical trials it may conduct will demonstrate consistent and/or adequate efficacy and safety to obtain marketing approval for Immunic&#8217;s product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Marketing approval may be substantially delayed or may not be obtained for one or all of Immunic&#8217;s product candidates if regulatory authorities require additional or more time-consuming studies to assess the safety and efficacy of its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic may be unable to initiate or complete development of its product candidates on schedule, if at all. The completion of the studies for Immunic&#8217;s product candidates will require additional funding. In addition, if regulatory authorities require additional or more time-consuming studies to assess the safety or efficacy of Immunic&#8217;s product candidates, Immunic may not have or be able to obtain adequate funding to complete the necessary steps for approval for any or all of its product candidates. Additional delays may result if the FDA, an FDA advisory committee (if one is convened to review Immunic&#8217;s NDA) or other regulatory authority indicates that the product candidate should not be approved or there should be restrictions on approval, such as the requirement for a REMS, to ensure safe use of the drug. Delays in marketing approval or rejections of applications for marketing approval in the United States or other markets may result from many factors, including: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable foreign regulatory authorities disagreeing with the design or implementation of Immunic&#8217;s clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory requests for additional analyses, reports, data, non-clinical and preclinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDA or comparable regulatory authorities questioning or disagreeing with interpretations of data and results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the emergence of new information regarding Immunic&#8217;s current or future product candidates or the field of research;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">unfavorable or inconclusive results of clinical trials and supportive non-clinical studies, including unfavorable results regarding safety or efficacy of Immunic&#8217;s product candidates during clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to meet the level of statistical significance required for approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">lack of adequate funding to commence or continue Immunic&#8217;s clinical trials due to unforeseen costs or other business decisions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may find inadequate the manufacturing processes or facilities of the third-party manufacturers with which Immunic contracts for clinical and commercial supplies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic may have insufficient funds to pay the significant user fees required by the FDA upon the filing of an NDA; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner that would delay marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The lengthy and unpredictable approval process, as well as the unpredictability of future clinical trial results, may result in Immunic&#8217;s failure to obtain marketing approval to market its product candidates, which would significantly harm Immunic&#8217;s business, results of operations and prospects. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic&#8217;s product candidates may cause undesirable adverse effects or have other properties that could delay or prevent their marketing approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if obtained. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Undesirable side effects caused by Immunic&#8217;s product candidates could cause Immunic or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or other comparable foreign regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">authorities. If any of Immunic&#8217;s current or future product candidates is associated with serious adverse, undesirable or unacceptable side effects, Immunic may need to abandon such candidate&#8217;s development or limit development to certain uses or sub-populations in which such side effects are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many drug candidates that initially showed promise in early-stage or clinical testing have later been found to cause side effects that prevented their further development. Results of Immunic&#8217;s trials could reveal a high and unacceptable prevalence of these or other side effects. In such an event, Immunic&#8217;s trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order Immunic to cease further development of or deny approval of its product candidates for any or all targeted indications. Drug-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Immunic&#8217;s product candidates receive marketing approval, and Immunic or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may withdraw approvals of such products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic may be required to recall a product or change the way such product is administered to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing process for the product or any component thereof;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may require the addition of labeling statements, such as a precaution, &#8220;black box&#8221; warning or other warnings or a contraindication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic or its collaborators may be required to implement a REMS or create a medication guide outlining the risks of such side effect for distribution to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic or its collaborators could be sued and held liable for harm caused to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the product may become less competitive; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic&#8217;s reputation may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any of these events could prevent Immunic from achieving or maintaining market acceptance of any approved product candidates, and could materially adversely affect Immunic&#8217;s business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic is heavily dependent on the success of its product candidates, which are in the early stages of clinical development. Immunic cannot give any assurance that it will generate data for any of its product candidates sufficient to receive regulatory approval in its planned indications, which will be required before they can be commercialized. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic has invested substantially all of its efforts and financial resources to identify, acquire and develop its portfolio of product candidates. Its future success is dependent on its ability to successfully further develop, obtain regulatory approval for, and commercialize one or more product candidates. Immunic currently generates no revenue from sales of any products, and Immunic may never be able to develop or commercialize a product candidate. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The first of Immunic&#8217;s product candidates, IMU-838, is being advanced into a Phase 3 program for RRMS, and pivotal trials are expected to start later in 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Immunic is not permitted to market or promote any of its product candidates before it receives regulatory approval from the FDA or comparable foreign regulatory authorities, and Immunic may never receive such regulatory approval for any of its product candidates. Immunic cannot be certain that any of its product candidates will be successful in clinical trials or receive regulatory approval. Further, its product candidates may not receive regulatory approval even if they are successful in clinical trials. If Immunic does not receive regulatory approvals for its product candidates, Immunic may not be able to continue its operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may use its financial and operational resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because Immunic has limited financial and operational</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">resources, it may forego or delay pursuit of opportunities in some programs, product candidates or indications that later prove to have greater commercial potential. Immunic&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or more profitable market opportunities. Immunic&#8217;s spending on current and future research and development programs and future product candidates for specific indications may not yield any commercially viable products. Immunic may also enter into additional strategic collaboration agreements to develop and commercialize some of its programs and potential product candidates in indications with potentially large commercial markets. If Immunic does not accurately evaluate the commercial potential or target market for a particular product candidate, it may (i) relinquish valuable rights to that product candidate through strategic collaborations, licensing or other royalty arrangements when it would have been more advantageous to retain sole development and commercialization rights to such product candidate, or (ii) allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaborative arrangement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may find it difficult to enroll patients in its clinical trials given the limited number of patients who have the diseases for which its product candidates are being studied. Difficulty in enrolling patients could delay or prevent clinical trials of its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of Immunic&#8217;s product candidates is essential to its success. The timing of Immunic&#8217;s clinical trials depends in part on the rate at which Immunic can recruit patients to participate in clinical trials of its product candidates, and Immunic may experience delays in its clinical trials if Immunic encounters difficulties in enrollment. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The specific eligibility criteria of Immunic&#8217;s planned clinical trials may further limit the available eligible trial participants. Immunic may not be able to identify, recruit, and enroll a sufficient number of patients to initiate or complete its clinical trials in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, and the willingness of physicians to participate in its planned clinical trials. If patients are unwilling to participate in Immunic&#8217;s clinical trials for any reason, the timeline for conducting trials and obtaining regulatory approval of its product candidates may be delayed. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Immunic experiences delays in the completion of, or experiences termination of, any clinical trials of its product candidates, the commercial prospects of its product candidates could be harmed, and its ability to generate product revenue from product candidates could be delayed or impaired. In addition, any delays in initiating or completing clinical trials would likely increase Immunic&#8217;s overall costs, impair product candidate development and impair Immunic&#8217;s ability to obtain regulatory approval. Any of these occurrences may harm its business, financial condition, and prospects significantly. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Even if Immunic receives marketing approval for its product candidates, such approved products will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, any approved product candidates could be subject to labeling and other restrictions, and Immunic may be subject to penalties and legal sanctions if it fails to comply with regulatory requirements or experience unanticipated problems with its approved products. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority approves any of Immunic&#8217;s product candidates, the manufacturing processes, packaging, distribution, adverse event reporting, storage, labeling, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP regulations and GCP for any clinical trials that Immunic conducts post-approval. Any marketing approvals that Immunic receives for its product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for potentially costly post-approval studies, including Phase 4 clinical trials, and surveillance to monitor safety and efficacy. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with an approved product, including adverse events of unanticipated severity or frequency, or with manufacturing operations or processes, or failure to comply with regulatory requirements, or evidence of acts that raise questions about the integrity of data supporting the product approval, may result in, among other things: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">fines, warning letters, untitled letters, or holds on clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by Immunic, or suspension or revocation of product approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval, manufacturing or commercialization of Immunic&#8217;s product candidates. Immunic cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other jurisdictions. If Immunic is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or not able to maintain regulatory compliance, it may lose any marketing approval that may have been obtained and it may not achieve or sustain profitability, which would adversely affect Immunic&#8217;s business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The occurrence of any event described above may limit Immunic&#8217;s ability to commercialize any approved product candidates and harm its business, financial condition, and prospects significantly.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If Immunic fails to obtain regulatory approval in jurisdictions outside the United States, it will not be able to market its products in those jurisdictions. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic intends to market any approved product candidates in international markets, or in conjunction with collaborators. Such marketing will require separate regulatory approvals in each market and compliance with numerous and varying regulatory requirements. The approval procedures vary from country to country and may require testing in addition to what is required for a marketing application in the United States. Moreover, the time required to obtain approval in other countries may be different than in the United States. In addition, in many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact Immunic&#8217;s ability to obtain approval in another jurisdiction. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and additional or different risks. Immunic may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize its products in any market, which would significantly harm Immunic&#8217;s business, results of operations and prospects.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agencies like the FDA and national competition regulators in European countries strictly regulate the promotion of drugs. If Immunic is found to have improperly promoted its current product candidates for uses beyond those that are approved, Immunic may become subject to significant liability. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regulatory authorities like the FDA and national competition laws in Europe strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or comparable foreign regulatory authorities as reflected in the product&#8217;s approved labeling, known as &#8220;off-label&#8221; use, nor may it be promoted prior to marketing approval. If Immunic receives marketing approval for its product candidates for Immunic&#8217;s proposed indications, physicians may nevertheless prescribe Immunic&#8217;s products for their patients in a manner that is inconsistent with the approved label if the physicians personally believe in their professional medical judgment it could be used in such manner. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the FDA requires that promotional claims not be &#8220;false or misleading&#8221; as such terms are interpreted by the FDA. For example, the FDA requires substantial evidence, which generally consists of two adequate and well-controlled head-to-head clinical trials, for a company to make a claim that its product is superior to another product in terms of safety or effectiveness. Generally, unless Immunic performs clinical trials meeting that standard comparing its product candidates to competing products and these claims are approved for Immunic&#8217;s </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">product labeling, Immunic will not be able promote its current product candidates as superior to competing products. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States, regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses. If Immunic is found to have improperly promoted its product, including for an off-label use, it may become subject to significant liability. Numerous drug manufacturers have been the subject of investigations related to off-label promotion resulting in multi-billion dollar settlements, consent decrees, and on-going monitoring under corporate integrity agreements or deferred prosecution agreements. In addition, the FDA could also seek permanent injunctions under which specified promotional conduct is monitored, changed or curtailed. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic&#8217;s current and future relationships with healthcare professionals, investigators, consultants, collaborators, actual customers, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose Immunic to sanctions. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which Immunic may obtain marketing approval. Immunic&#8217;s current and future arrangements with healthcare professionals, investigators, consultants, collaborators, actual customers, potential customers and third-party payors may expose Immunic to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act ("FCA"), that may constrain the business or financial arrangements and relationships through which Immunic sells, markets and distributes any drug candidates for which it obtains marketing approval. In addition, Immunic may be subject to physician payment transparency laws and patient privacy and security regulation by the federal government and by the U.S. states and foreign jurisdictions in which Immunic conducts its business. The applicable federal, state and foreign healthcare laws that may affect Immunic&#8217;s ability to operate include the following: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">The federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. Remuneration has been interpreted broadly to include anything of value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor. A conviction for violation of the Anti-Kickback Statute results in mandatory exclusion from participation in federal healthcare programs. This statute has been applied to arrangements between pharmaceutical manufacturers and those in a position to purchase products or refer others including prescribers, patients, purchasers and formulary managers. In addition, the Affordable Care Act amended the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act penalties for which are described below. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">Federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $11,665 to $23,331 per false claim or statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">The federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") imposes criminal and civil penalties for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations impose obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">The federal Open Payments program, created under the Physician Payment Sunshine Act, also known as Section 6002 of the Patient Protection and Affordable Care Act (the &#8220;Affordable Care Act&#8221;), and its implementing regulations, impose annual reporting requirements for certain manufacturers of drugs, devices, biologicals and medical supplies for payments and &#8220;transfers of value&#8221; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The SUPPORT for Patients and Communities Act expanded the scope of reporting such that companies must also report payments and transfers of value provided to other types of healthcare professionals. Failure to submit timely, accurately and completely the required information for all covered payments, transfers of value and ownership or investment interests may result in civil monetary penalties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">There are many analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Efforts to ensure that Immunic&#8217;s future business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that Immunic&#8217;s business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If Immunic&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, Immunic may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of Immunic&#8217;s operations, which could significantly harm its business. If any of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">physicians or other healthcare providers or entities with whom Immunic expects to do business, including current and any future collaborators are found not to be in compliance with applicable laws, those persons or entities may be subject to criminal, civil or administrative sanctions, including exclusion from participation in government healthcare programs, which could also affect Immunic&#8217;s business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties and other remedial measures, and incur legal expenses, which could adversely affect our business, financial condition, results of operations, stock price and prospects. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act ("FCPA"), and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We also may participate in collaborations and relationships with third parties whose actions, if non-compliant, could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and authorities in the European Union, including applicable import and export control regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as trade control laws. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and incur legal expenses, which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. Likewise, any investigation of any potential violations of these anti-corruption laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, business, financial condition, results of operations, stock price and prospects. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The impact of recent and future healthcare reform legislation and other changes in the healthcare industry and healthcare spending on Immunic is currently unknown, and may adversely affect its business model. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, legislative and regulatory changes and proposed changes regarding the healthcare system could prevent or delay marketing approval of Immunic&#8217;s drug candidates, restrict or regulate post-approval activities and affect its ability to profitably sell any drug candidates for which Immunic obtains marketing approval. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Immunic&#8217;s revenue prospects could be affected by changes in healthcare spending and policy in the United States and other jurisdictions. Immunic operates in a highly regulated industry and new laws, regulations, judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact Immunic&#8217;s business, financial condition, results of operations and prospects. There is significant interest in promoting healthcare reform, as evidenced by the enactment in the United States of the Affordable Care Act. Among other things, the Affordable Care Act contains provisions that may reduce the profitability of drug products, including, for example, revising the methodology by which rebates owed by manufacturers for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, extending Medicaid rebates to individuals enrolled in Medicaid managed care plans, imposing mandatory discounts for certain Medicare Part D beneficiaries who fall into a coverage gap, and subjecting drug manufacturers to payment of an annual fee based on its market share of prior year total sales of branded programs to certain federal healthcare programs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">There have been judicial and congressional challenges to the Affordable Care Act, as well as efforts to repeal or replace certain aspects of the Affordable Care Act. In 2019, the United States Court of Appeals for the Fifth Circuit upheld a lower court decision finding the Affordable Care Act unconstitutional and eliminating the individual mandate. The U.S. Supreme Court declined to expedite this appeal, and thus will not issue a decision until early 2021. If a new law is enacted, or if the Affordable Care Act is overturned by the Supreme Court, many if not all of the provisions of the Affordable Care Act may no longer apply to prescription drugs. While we are unable to predict what changes may ultimately be enacted, to the extent that future changes affect how any future products are paid for and reimbursed by government and private payors, our business could be adversely impacted. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of 2% per fiscal year, which started in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, also reduced Medicare payments to several categories of healthcare providers. The Biden administration and Congress may announce initiatives intended to result in lower drug prices. We are not in a position to know at this time whether such initiatives will become law or what impact they would have on our business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic expects that additional healthcare reform measures and drug pricing regulations that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the revenue that it receives for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent Immunic from being able to generate revenue or commercialize Immunic&#8217;s drugs. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing healthcare legislation. Immunic cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the demand for any drug products for which Immunic may obtain marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic&#8217;s ability to set a price for its products that Immunic believes is fair;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic&#8217;s ability to obtain coverage and reimbursement approval for a product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic&#8217;s ability to generate revenues and achieve or maintain profitability; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the level of taxes that Immunic is required to pay.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If Immunic fails to comply with environmental, health and safety laws and regulations, Immunic could become subject to fines or penalties or incur costs that could have a material adverse effect on its business, financial condition or results of operations. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic&#8217;s research and development activities and the activities of its third-party manufacturers and suppliers involve the controlled storage, use, and disposal of hazardous materials, including the components of its product candidates and other hazardous compounds. Immunic and its manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at facilities of Immunic and its manufacturers pending their use and disposal. Immunic cannot eliminate the risk of contamination, which could cause an interruption of its commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although Immunic believes that the safety procedures utilized by it and its third-party manufacturers and suppliers for handling and disposing of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">these materials generally comply with the standards prescribed by applicable laws and regulations, Immunic cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In the event of contamination of injury, Immunic may be held liable for any resulting damages, which could exceed its resources or result in government-imposed restrictions on Immunic&#8217;s use of specified materials or interruptions of its business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent over time. Immunic cannot predict the impact of such changes and cannot be certain of its future compliance. Immunic does not currently carry biological or hazardous waste insurance coverage. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Risks Related to Immunic&#8217;s Business </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Due to Immunic&#8217;s limited resources and access to capital, it must decide to prioritize development of its current product candidates for certain indications and at certain doses. These decisions may prove to have been wrong and may materially adversely affect Immunic&#8217;s business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because Immunic has limited resources and access to capital to fund its operations, it must decide which dosages and indications to pursue for the clinical development of its current product candidates and the amount of resources to allocate to each. Immunic&#8217;s decisions concerning the allocation of research, collaboration, management and financial resources toward dosages or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. If Immunic makes incorrect determinations regarding the market potential of its current product candidates or misreads trends in the pharmaceutical industry, Immunic&#8217;s business, financial condition, results of operations and prospects could be materially adversely affected.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may not be able to win contracts or grants from governments, academic institutions or non-profits. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, Immunic may apply for contracts or grants from government agencies, non-profit entities and academic institutions. Such contracts or grants can be highly attractive because they provide capital to fund the ongoing development of Immunic&#8217;s product candidates without diluting its stockholders. However, there is often significant competition for these contracts or grants. Entities offering contracts or grants may have requirements to apply for or to otherwise be eligible for certain contracts or grants that Immunic&#8217;s competitors may be able to satisfy that Immunic cannot. In addition, such entities may make arbitrary decisions as to whether to offer contracts or make grants, to whom the contracts or grants may or will be awarded and the size of the contracts or grants to each awardee. Even if Immunic is able to satisfy the award requirements, there is no guarantee that Immunic will be a successful awardee. Therefore, Immunic may not be able to win any contracts or grants in a timely manner, if at all. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, even if successfully Immunic enters into contracts with or receives grants from government agencies, non-profit entities or academic institutions, it may lose such contracts or grants due to failure to comply with applicable terms, limitations, or government regulations. As a result, our business, results of operations, financial condition and prospects could be harmed.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If Immunic fails to attract and retain key management and scientific personnel, it may be unable to successfully develop or commercialize its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic&#8217;s success as a biotechnology company depends on its continued ability to attract, retain and motivate highly qualified management and scientific and clinical personnel. The loss of the services of any of Immunic&#8217;s management could delay or prevent obtaining marketing approval or commercialization of its product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Immunic may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a limited number of qualified personnel among biotechnology, pharmaceutical and other companies. Immunic&#8217;s failure to attract, hire, integrate and retain qualified personnel could impair its ability to achieve its business objectives. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If a successful product liability claim or series of claims is brought against Immunic for uninsured liabilities or in excess of insured liabilities, Immunic could be forced to pay substantial damage awards. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The use of any of Immunic&#8217;s product candidates in clinical trials and the sale of any approved products may expose Immunic to product liability claims. Immunic currently maintains product liability insurance. Immunic intends to monitor the amount of coverage it maintains as the size and design of its clinical trials evolve and adjust the amount of coverage it maintains accordingly. However, there is no assurance that such insurance coverage will fully protect Immunic against some or all of the claims to which it might become subject. Immunic might not be able to maintain adequate insurance coverage at a reasonable cost or in sufficient amounts or scope to protect it against potential losses. In the event a claim is brought against Immunic, it might be required to pay legal and other expenses to defend the claim, as well as uncovered damages awards resulting from a claim brought successfully against Immunic. Furthermore, whether or not Immunic is ultimately successful in defending any such claims, Immunic might be required to direct financial and managerial resources to such defense and adverse publicity could result, all of which could harm Immunic&#8217;s business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic&#8217;s employees, independent contractors, investigators, CROs, consultants, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic is exposed to the risk that its employees and other third parties may engage in fraudulent conduct or other illegal activity. Misconduct by employees and other third parties could include intentional, reckless and/or negligent conduct or violation of FDA regulations and laws that require requiring reporting true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare fraud and abuse laws and regulations, or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to Immunic&#8217;s reputation. It is not always possible to identify and deter employee and other third-party misconduct, and the precautions Immunic takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Immunic from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against Immunic, and Immunic is not successful in defending itself or asserting its rights, those actions could have a significant impact on Immunic&#8217;s business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of Immunic&#8217;s operations, any of which could adversely affect Immunic&#8217;s ability to operate. Even if Immunic is ultimately successful in defending any such actions, Immunic could be required to divert financial and managerial resources to such action and adverse publicity could result, all of which could harm Immunic&#8217;s business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic will need to expand its organization and Immunic may experience difficulties in managing this growth, which could disrupt its operations. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of February 26, 2021, Immunic had 28 employees. As Immunic&#8217;s development and commercialization plans and strategies develop, Immunic may need additional managerial, operational, sales, marketing, financial, legal and other resources. Its management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing its growth. As Immunic advances its product candidates through clinical trials, it will need to expand its development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities. As Immunic&#8217;s operations expand, Immunic expects that it will need to manage additional relationships with such third parties, as well as additional collaborators and suppliers. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic may not be able to effectively manage the expansion of its operations, which may result in weaknesses in its infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Immunic&#8217;s expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If Immunic&#8217;s management is unable to effectively manage its growth, its expenses may increase more than expected, its ability to generate and/or grow revenue could be reduced and Immunic may not be able to implement its business strategy. Immunic&#8217;s future financial performance and its ability to commercialize product candidates and compete effectively will depend, in part, on its ability to effectively manage any future growth. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic&#8217;s internal computer systems, or those of its development collaborators, third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of Immunic&#8217;s product development programs. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our internal computer systems and those of our current and any future strategic collaborators, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, cybersecurity threats, war and telecommunication and electrical failures. We may experience cyber-attacks on our information technology systems by threat actors of all types (including but not limited to nation states, organized crime, other criminal enterprises, individual actors and/or advanced persistent threat groups). In addition, we may experience intrusions on our physical premises by any of these threat actors. If any such cyber-attack or physical intrusion were to cause interruptions in our operations, such as a material disruption of our development programs or our manufacturing operations, whether due to a loss of our trade secrets or other proprietary information, it would have a material and adverse effect on us. For example, the loss of clinical trial data from one or more ongoing or completed or future clinical trials could result in delays in our regulatory approval efforts, significantly increase our costs to recover or reproduce the data and expose us to liability. In addition, any breach of our computer systems or physical premises could result in a loss of data or compromised data integrity across more than one of our programs in different stages of development. Any such breach, loss, or compromise of clinical trial participant personal data may also subject us to civil fines and penalties or claims for damages, either under the General Data Protection Regulation and relevant member state law in the European Union, other foreign laws, and HIPAA, and other relevant state and federal privacy laws in the United States including the California Consumer Privacy Act. On May 13, 2020, the Federal Bureau of Investigation (&#8220;FBI&#8221;) and Cybersecurity and Infrastructure Security Agency announced that the FBI is investigating the targeting and compromise of U.S. organizations conducting COVID-19-related research by People&#8217;s Republic of China-affiliated cyber actors. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, including but not limited to information related to our IMU-838 product candidate, we could incur liability, our competitive and reputational position could be harmed, and the further development and commercialization of our investigational medicines could be delayed. On July 31, 2020 we discovered that an email account at the Company was subject to attempted unauthorized access for a period of up to 24 hours and we have hired an investigator to ascertain what, if any, Company or patient information was impacted. We do not currently believe any confidential or proprietary information was compromised and have taken steps to prevent unauthorized action in the future such as implementing two factor authentication for our email accounts. While we believe that our insurance policies include liability coverage for security breaches, we could be subject to indemnity claims or other damages that exceed our insurance coverage. As a result, the ramifications of a potential security breach could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as cause a decline in the trading price of our common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Immunic&#8217;s Product Candidates </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Even if Immunic obtains the required regulatory approvals in the United States and other territories, the commercial success of its product candidates will depend on market awareness and acceptance of its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if Immunic obtains marketing approval for its current product candidates or any other product candidates that it may develop or acquire in the future, the products may not gain market acceptance among physicians, key </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">opinion leaders, healthcare payors, patients and the medical community. Market acceptance of any approved products depends on a number of factors, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing of market introduction;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the efficacy and safety of the product, as demonstrated in clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the clinical indications for which the product is approved and the label approved by regulatory authorities for use with the product, including any precautions, warnings or contraindications that may be required on the label;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">acceptance by physicians, key opinion leaders and patients of the product as a safe and effective treatment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost, safety and efficacy of treatment in relation to alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number and clinical profile of competing products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the growth of drug markets in Immunic&#8217;s various indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">relative convenience and ease of administration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">marketing and distribution support;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the prevalence and severity of adverse side effects; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the effectiveness of Immunic&#8217;s sales and marketing efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Market acceptance is critical to Immunic&#8217;s ability to generate revenue. Any approved and commercialized product candidate may be accepted in only limited capacities or not at all. If any approved products are not accepted by the market to the extent that Immunic expects, Immunic may not be able to generate revenue and its business would suffer. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic currently has limited marketing and sales experience. If Immunic is unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell its product candidates, Immunic may be unable to generate any revenue. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic has never commercialized a product candidate, and Immunic currently has no marketing and sales organization. To the extent Immunic&#8217;s product candidates are approved for marketing, if Immunic is unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell its product candidates, Immunic may not be able to effectively market and sell its product candidates or generate product revenue. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, Immunic currently does not have marketing, sales or distribution capabilities for its product candidates. In order to commercialize any of Immunic&#8217;s products that receive marketing approval, it would have to build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and Immunic may not be successful in doing so. In the event of successful development of Immunic&#8217;s product candidates, if Immunic elects to build a targeted specialty sales force, such an effort would be expensive and time consuming. Any failure or delay in the development of Immunic&#8217;s internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. Immunic may choose to collaborate with third parties that have their own sales forces and established distribution systems, in lieu of or to augment any sales force and distribution systems Immunic may create. If Immunic is unable to enter into collaborations with third parties for the commercialization of any approved products on acceptable terms or at all, or if any such collaborator does not devote sufficient resources to the commercialization of Immunic&#8217;s product or otherwise fails in commercialization efforts, Immunic may not be able to successfully commercialize its product candidates if it receives marketing approval. If Immunic is not successful in commercializing its product candidates, either on its own or through collaborations with one or more third parties, its future revenue will be materially and adversely impacted. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If Immunic fails to enter into strategic relationships or collaborations, its business, financial condition, commercialization prospects and results of operations may be materially adversely affected. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic&#8217;s product development programs and the potential commercialization of its current product candidates will require substantial additional cash to fund expenses. Therefore, in addition to financing the development of Immunic&#8217;s product candidates through additional equity financings or through debt financings, Immunic may decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic faces significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. Immunic may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. Immunic may not be able to negotiate collaborations on acceptable terms, or at all. Any of these contingencies may require Immunic to curtail the development of a particular product, reduce or delay its development program or one or more of its other development programs, delay its potential commercialization or reduce the scope of its sales or marketing activities, or increase its expenditures and undertake development or commercialization activities at its own expense. If Immunic elects to increase its expenditures to fund development or commercialization activities on its own, Immunic may need to obtain additional capital, which may not be available to Immunic on acceptable terms or at all. If Immunic does not have sufficient funds, Immunic will not be able to bring its product candidates to market and generate product revenue. If Immunic does enter into a new collaboration agreement, it could be subject to the following risks, each of which may materially harm Immunic&#8217;s business, commercialization prospects and financial condition: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic may not be able to control the amount or timing of resources that the collaborator devotes to the product development program;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the collaborator may experience financial difficulties and thus not commit sufficient financial resources to the product development program;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic may be required to relinquish important rights such as marketing, distribution and intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including Immunic&#8217;s competitors; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect Immunic&#8217;s willingness to complete its obligations under any arrangement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for Immunic&#8217;s product candidates, which could make it difficult for Immunic to sell its products profitably. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The pricing, coverage, and reimbursement of any of Immunic&#8217;s approved products must be sufficient to support its commercial efforts and other development programs, and the availability and adequacy of coverage and reimbursement by third-party payors, including governmental and private insurers, are essential for most patients to be able to afford expensive treatments. Sales of any of Immunic&#8217;s approved product candidates will depend substantially, both domestically in other jurisdictions, on the extent to which the costs of any of its approved products will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government payors and private payors. If coverage and reimbursement are not available, or are available only in limited amounts, Immunic may have to subsidize or provide products for free or Immunic may not be able to successfully commercialize its products. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services ("CMS"), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for Immunic&#8217;s novel product candidates and what reimbursement codes its product candidates may receive if approved. There also may be delays in obtaining coverage for newly-approved drugs. Obtaining coverage and reimbursement approval is time-consuming and costly, requiring us to provide payors with scientific, clinical, and cost-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">effectiveness data. Further, eligibility for coverage does not necessarily signify that a drug will be reimbursed in all cases or at a rate that covers our costs. Thus, even if we succeed in bringing a product to market, it may not be considered medically necessary or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and Immunic believes the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that Immunic is able to charge for any of its products. Accordingly, the potential revenue and profits from markets outside the United States may be commercially inadequate. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and private payors in the United States and other jurisdictions to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for Immunic&#8217;s products. Immunic expects to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs in particular, has and is expected to continue to increase in the future. For instance, government and private payors who reimburse patients or healthcare providers are increasingly seeking greater upfront discounts, additional rebates and other concessions to reduce prices for pharmaceutical products. As a result, it may be difficult for any of Immunic&#8217;s products to achieve profitability, even if they receive regulatory approval. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic faces substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than Immunic does. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. Immunic faces competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities and other research institutions worldwide with respect to its product candidates that it may seek to develop or commercialize in the future. Many of Immunic&#8217;s competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than it does. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in its competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with Immunic&#8217;s competitors. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In particular, the field of IBD, including UC, and CD are highly competitive. Immunic&#8217;s competitors in the United States and elsewhere include major pharmaceutical, biotechnology and biosimilar manufacturers. Some of these competitors may have more extensive research and development, regulatory compliance, manufacturing, marketing and sales capabilities than Immunic. Many competitors also have significantly greater financial resources. These companies may succeed in developing products that are more effective or more economical than any of Immunic&#8217;s product candidates and may also be more successful than Immunic in manufacturing, developing and registering products. In addition, technological advances or different approaches developed by one or more of Immunic&#8217;s competitors may render Immunic&#8217;s products obsolete, less effective or uneconomical.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Immunic&#8217;s competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than Immunic does, they could establish a strong market position before Immunic is able to enter the market. Third-party payors, including governmental and private insurers, also may encourage the use of generic products. Failure of any approved product candidates to effectively compete against established treatment options or in the future with new products currently in development would harm Immunic&#8217;s business, financial condition, results of operations and prospects. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The potential market opportunities for our product candidates are difficult to estimate and will depend on a number of factors beyond our control. Our estimates of potential market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys. Although we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Negative developments in the field of oral therapies for chronic inflammatory and autoimmune diseases could damage public perception of our product candidates and negatively affect our business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The commercial success of our product candidates will depend in part on public acceptance of the use of oral therapies for the treatment of chronic inflammatory and autoimmune diseases. Adverse events in clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for our product candidates. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. Our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials. As a result, we may not be able to continue or may be delayed in conducting our development programs. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Price controls may be imposed in foreign markets, which may adversely affect Immunic&#8217;s future profitability. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, Immunic may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of its product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of Immunic&#8217;s products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Immunic&#8217;s business could be adversely affected. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Third Parties </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic relies on third-party suppliers and other third parties for production of its product candidates, and Immunic&#8217;s dependence on these third parties may impair the advancement of its research and development programs and the development of its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic does not currently own or operate manufacturing facilities for clinical or commercial production of its product candidates. Immunic lacks the resources and the capability to manufacture any of its product candidates on a clinical or commercial scale. Instead, Immunic relies on, and expects to continue to rely on, third parties for the supply of raw materials and manufacture of drug supplies necessary to conduct its preclinical studies and clinical trials. Immunic&#8217;s reliance on third parties for manufacturing exposes Immunic to additional risks. Delays in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">production by third parties could delay Immunic&#8217;s clinical trials or have an adverse impact on any commercial activities. In addition, Immunic&#8217;s dependence on third parties for the manufacture of and formulation of its product candidates subjects it to the risk that such products may have manufacturing defects that Immunic has limited ability to prevent or control. Although Immunic oversees these activities to ensure compliance with its quality standards, budgets and timelines, Immunic has, and will continue to have, less control over the manufacturing of its product candidates than if it was to manufacture its product candidates. Further, the third parties Immunic contracts with could have staffing difficulties, might undergo changes in priorities or may become financially distressed, any of which would adversely affect the manufacturing and production of Immunic&#8217;s product candidates. In addition, a third party could be acquired by, or enter into an exclusive arrangement with, one of Immunic&#8217;s competitors, which would adversely affect Immunic&#8217;s ability to access the formulations it requires for the manufacturing of its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The facilities used by Immunic&#8217;s current contract manufacturers and any future manufacturers to manufacture Immunic&#8217;s product candidates must be inspected by the FDA after Immunic submits its NDA. Immunic does not control the manufacturing process of, and is completely dependent on, its contract manufacturers for compliance with the regulatory requirements, known as cGMPs, for manufacture of both active drug substances and finished drug products. If Immunic&#8217;s contract manufacturers cannot successfully manufacture material that conforms to Immunic&#8217;s specifications and the strict regulatory requirements of the FDA, the FDA may refuse to approve Immunic&#8217;s NDA. If the FDA does not approve Immunic&#8217;s NDA because of concerns about the manufacture of its product candidates or if significant manufacturing issues arise in the future, Immunic may need to find alternative manufacturing facilities, which would significantly impact its ability to develop its product candidates, obtain marketing approval of its NDA or to continue to market any approved product candidates. Although Immunic is ultimately responsible for ensuring compliance with these regulatory requirements, Immunic does not have day-to-day control over a contract manufacturing organization ("CMO"), or other third-party manufacturer&#8217;s compliance with applicable laws and regulations, including cGMPs and other laws and regulations, such as those related to environmental health and safety matters. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject Immunic to the risk that Immunic may have to suspend the manufacturing of its product candidates or that obtained approvals could be revoked, which would adversely affect Immunic&#8217;s business and reputation. In addition, third-party contractors, such as Immunic&#8217;s CMOs, may elect not to continue to work with Immunic due to factors beyond Immunic&#8217;s control. They may also refuse to work with Immunic because of their own financial difficulties, business priorities or other reasons, at a time that is costly or otherwise inconvenient for Immunic. If Immunic was unable to find adequate replacement or another acceptable solution in time, Immunic&#8217;s clinical trials could be delayed or its commercial activities could be harmed. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Problems with the quality of the work performed by third parties may lead Immunic to seek to terminate its working relationships and use alternative service providers. However, making this change may be costly and may delay clinical trials. In addition, it may be very challenging, and in some cases impossible, to find replacement service providers that can develop and manufacture Immunic&#8217;s drug candidates in an acceptable manner and at an acceptable cost and on a timely basis. The sale of products containing any defects or any delays in the supply of necessary services could adversely affect Immunic&#8217;s business, financial condition, results of operations, and prospects. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Growth in the costs and expenses of components or raw materials may also adversely affect Immunic&#8217;s business, financial condition, results of operations, and prospects. Supply sources could be interrupted from time to time and, if interrupted, supplies may not be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic plans to rely on third parties to conduct clinical trials for its product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, it may cause delays in commencing and completing clinical trials of Immunic&#8217;s product candidates or Immunic may be unable to obtain marketing approval for or commercialize its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical trials must meet applicable FDA and foreign regulatory requirements. Immunic does not have the ability to independently conduct clinical trials for any of its product candidates. Immunic relies and expects to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">continue relying on third parties, such as CROs, medical institutions, clinical investigators and contract laboratories, to conduct all of its clinical trials of its product candidates; however, Immunic remains responsible for ensuring that each of its clinical trials is conducted in accordance with its investigational plan and protocol. Moreover, the FDA and other foreign regulatory authorities require Immunic to comply with IND and human subject protection regulations and cGCPs for conducting, monitoring, recording, and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. Immunic&#8217;s reliance on third parties does not relieve Immunic of these responsibilities and requirements. Regulatory authorities enforce eGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If Immunic or any of its third-party contractors fail to comply with applicable eGCPs, the clinical data generated in Immunic&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Immunic to perform additional clinical trials before approving its marketing applications. There is no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Immunic&#8217;s clinical trials comply with eGCPs. Immunic&#8217;s failure to comply with these regulations may require Immunic to repeat clinical trials, which would delay the marketing approval process. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are significant requirements imposed on Immunic and on clinical investigators who conduct clinical trials that Immunic sponsors. Although Immunic is responsible for selecting qualified CROs or clinical investigators, providing them with the information they need to conduct the clinical trials properly, ensuring proper monitoring of the clinical trials, and ensuring that the clinical trials are conducted in accordance with the general investigational plan and protocols contained in the IND, Immunic cannot ensure that the CROs or clinical investigators will maintain compliance with all regulatory requirements at all times. The pharmaceutical industry has experienced cases where clinical investigators have been found to incorrectly record data, omit data, or even falsify data. Immunic cannot ensure that the CROs or clinical investigators in Immunic&#8217;s trials will not make mistakes or otherwise compromise the integrity or validity of data, any of which would have a significant negative effect on Immunic&#8217;s ability to obtain marketing approval, its business, and its financial condition. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic or the third parties it relies on may encounter problems in clinical trials that may cause Immunic or the FDA or foreign regulatory agencies to delay, suspend or terminate Immunic&#8217;s clinical trials at any phase. These problems could include the possibility that Immunic may not be able to manufacture sufficient quantities of materials for use in its clinical trials, conduct clinical trials at its preferred sites, enroll a sufficient number of patients for its clinical trials at one or more sites, or begin or successfully complete clinical trials in a timely fashion, if at all. Furthermore, Immunic, the FDA or foreign regulatory agencies may suspend clinical trials of Immunic&#8217;s product candidates at any time if Immunic or they believe the subjects participating in the trials are being exposed to unacceptable health risks, whether as a result of adverse events occurring in Immunic&#8217;s trials or otherwise, or if Immunic or they find deficiencies in the clinical trial process or conduct of the investigation. The FDA or foreign regulatory agencies could also require additional clinical trials before or after granting marketing approval for any products, which would result in increased costs and significant delays in the development and commercialization of such products and could result in the withdrawal of such products from the market even if marketing approval has already been obtained. Immunic&#8217;s failure to adequately demonstrate the safety and efficacy of a product candidate in clinical development could delay or prevent marketing approval of the product candidate. Even if market approval has already been obtained, adverse data from post-approval studies could result in the product being withdrawn from the market. These contingencies would likely have a material adverse effect on Immunic&#8217;s business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may be unable to realize the potential benefits of any collaboration. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if Immunic is successful in entering into a collaboration with respect to the development and/or commercialization of one or more product candidates, there is no guarantee that the collaboration will be successful. Collaborations may pose a number of risks, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators often have significant discretion in determining the efforts and resources that they will apply to the collaboration, and may not commit sufficient resources to the development, marketing or commercialization of the product or products that are subject to the collaboration;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may not perform their obligations as expected;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">any such collaboration may significantly limit Immunic&#8217;s share of potential future profits from the associated program, and may require it to relinquish potentially valuable rights to its current product candidates, potential product candidates or proprietary technologies or grant licenses on terms that are not favorable to Immunic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may cease to devote resources to the development or commercialization of Immunic&#8217;s product candidates if the collaborators view its product candidates as competitive with their own products or product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the course of development, might cause delays or termination of the development or commercialization of product candidates, and might result in legal proceedings, which would be time-consuming, distracting and expensive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may be impacted by changes in their strategic focus or available funding, or business combinations involving them, which could cause them to divert resources away from the collaboration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may infringe the intellectual property rights of third parties, which may expose Immunic to litigation and potential liability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the collaborations may not result in Immunic achieving revenues to justify such transactions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborations may be terminated, which may require Immunic to raise additional capital to pursue further development or commercialization of the applicable product candidate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, a collaboration may not result in the successful development or commercialization of Immunic&#8217;s product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic enters into various contracts in the normal course of its business in which Immunic indemnifies the other party to the contract. In the event Immunic has to perform under these indemnification provisions, it could have a material adverse effect on its business, financial condition and results of operations. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the normal course of business, Immunic periodically enters into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to Immunic&#8217;s academic and other research agreements, Immunic typically indemnifies the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which Immunic has secured licenses, and from claims arising from Immunic&#8217;s or its sublicensees&#8217; exercise of rights under the agreements. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Should Immunic&#8217;s obligation under an indemnification provision exceed applicable insurance coverage or if Immunic were denied insurance coverage, Immunic&#8217;s business, financial condition and results of operations could be adversely affected. Similarly, if Immunic is relying on a collaborator to indemnify Immunic and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify Immunic, Immunic&#8217;s business, financial condition and results of operations could be adversely affected. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If Immunic&#8217;s contract manufacturers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">fail to comply with continuing regulations, resulting enforcement action could adversely affect Immunic. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If any of Immunic&#8217;s contract manufacturers fails to comply with regulatory requirements or if previously unknown problems with products, such manufacturers or manufacturing processes are discovered, Immunic or the manufacturer could be subject to administrative or judicially imposed sanctions, including restrictions on the products or the manufacturers or manufacturing processes Immunic uses, warning letters, untitled letters, civil or criminal penalties, fines, injunctions, product seizures or detentions, import bans, voluntary or mandatory product recalls and publicity requirements, suspension or withdrawal of regulatory approvals, total or partial suspension of production, and refusal to approve pending applications for marketing approval of new products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Immunic&#8217;s Intellectual Property </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic&#8217;s proprietary rights may not adequately protect its technologies and product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Immunic&#8217;s commercial success will depend in part on its ability to obtain additional patents and protect its existing patent position as well as its ability to maintain adequate protection of other intellectual property for its technologies, product candidates, and any future products in the United States and other countries. If Immunic does not adequately protect its intellectual property, competitors may be able to use Immunic&#8217;s technologies and erode or negate any competitive advantage Immunic may have, which could harm Immunic&#8217;s business and ability to achieve profitability. The laws of some foreign countries, in particular China and India, do not protect Immunic&#8217;s proprietary rights to the same extent or in the same manner as U.S. laws, and Immunic may encounter significant problems in protecting and defending its proprietary rights in these countries. Immunic will be able to protect its proprietary rights from unauthorized use by third parties only to the extent that Immunic&#8217;s proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic applies for patents covering both its technologies and product candidates as it deems appropriate. However, Immunic may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all. Immunic&#8217;s existing patents and any future patents it obtains may not be sufficiently broad to prevent others from using its technologies or developing competing products and technologies. Immunic cannot be certain that its patent applications will be approved or that any patents issued will adequately protect Immunic&#8217;s intellectual property. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, the patent positions of pharmaceutical companies are highly uncertain and involve complex legal and factual questions for which important legal principles are evolving and remain unresolved. As a result, the validity and enforceability of patents cannot be predicted with certainty. In addition, Immunic does not know whether: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic or its licensors were the first to make the inventions covered by each of Immunic&#8217;s issued patents and pending patent applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic or its licensors were the first to file patent applications for these inventions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">any of the patents that cover Immunic&#8217;s product candidates will be eligible to be listed in the FDA&#8217;s compendium of &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; sometimes referred to as the FDA&#8217;s Orange Book;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">others will independently develop similar or alternative technologies or duplicate any of Immunic&#8217;s technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">any of Immunic&#8217;s or its licensors&#8217; pending patent applications will result in issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">any of Immunic&#8217;s or its licensors&#8217; patents will be valid or enforceable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">any patents issued to Immunic or its licensors and collaborators will provide Immunic with any competitive advantages, or will be challenged by third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic will develop additional proprietary technologies that are patentable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">governmental authorities will exercise any of its statutory rights to Immunic&#8217;s intellectual property that was developed with government funding; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic&#8217;s business may infringe the patents or other proprietary rights of others.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The actual protection afforded by a patent varies based on products or processes, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country, the validity and enforceability of the patents and Immunic&#8217;s financial ability to enforce its patents and other intellectual property. Immunic&#8217;s ability to maintain and solidify its proprietary rights to its product candidates and future products will depend on its success in obtaining effective claims and enforcing those claims once granted. Immunic&#8217;s issued patents and those that may issue in the future, or those licensed to Immunic, may be challenged, narrowed, invalidated or circumvented, and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rights granted under any issued patents may not provide Immunic with proprietary protection or competitive advantages against competitors with similar products. Due to the extensive amount of time required for the development, testing and regulatory review of a product candidate, it is possible that, before any of Immunic&#8217;s product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic may also rely on trade secrets to protect some of its technology, especially where Immunic does not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to maintain. While Immunic uses reasonable efforts to protect its trade secrets, Immunic&#8217;s or any of its collaborators&#8217; employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose Immunic&#8217;s proprietary information to competitors and Immunic may not have adequate remedies in respect of such disclosure. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain. In addition, foreign courts are sometimes less willing than U.S. courts to protect trade secrets. If Immunic&#8217;s competitors independently develop equivalent knowledge, methods or know-how, Immunic would not be able to assert its rights to trade secrets and Immunic&#8217;s business could be harmed. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic is a party to license agreements under which Immunic licenses intellectual property and receives commercialization rights relating to certain of its product candidates. If Immunic fails to comply with obligations in such agreements or otherwise experience disruptions to its business relationships with its licensors, Immunic could lose license rights that are important to its business; any termination of such agreements would adversely affect Immunic&#8217;s business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic is a party to license agreements that give Immunic various commercialization rights, the loss of which (whether due to Immunic&#8217;s actions or those of the respective counterparties) may adversely affect Immunic&#8217;s business. For instance, in November 2018, Immunic and Daiichi Sankyo entered into a license and option agreement that grants Immunic an exclusive global option to license IMU-856 and related molecules. In January 2020, Immunic exercised this option and acquired the rights to commercialization of IMU-856 in all countries including the U.S., Europe and Japan. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The loss of (i) the licenses granted to Immunic under its agreements with Daiichi Sankyo and other licensors, or (ii) the rights provided under such agreements, would prevent Immunic from developing, manufacturing or marketing products covered by the license or subject to supply commitments, and could materially harm Immunic&#8217;s business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may not be able to protect its intellectual property rights throughout the world. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and Immunic&#8217;s intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, Immunic may not be able to prevent third parties from practicing Immunic&#8217;s technologies in all countries outside the United States, or from selling or importing products made using Immunic&#8217;s technologies in and into the United States or other jurisdictions. Competitors may use Immunic&#8217;s technologies in jurisdictions where Immunic has not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where Immunic has patent protection but enforcement rights are weaker than in the United States. These products may compete with Immunic&#8217;s product candidates in jurisdictions where Immunic does not have any issued patents and Immunic&#8217;s patent claims or other intellectual rights may not be effective or sufficient to prevent such competition.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries do not favor the enforcement of patents and other intellectual property rights, which could make it difficult for Immunic to stop the infringement of its patents </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">generally. Proceedings to enforce Immunic&#8217;s patent rights in foreign jurisdictions could result in substantial costs and divert Immunic&#8217;s efforts and attention from other aspects of its business, could put its patents at risk of being invalidated or interpreted narrowly and its patent applications at risk of not issuing and could provoke third parties to assert claims against Immunic. Immunic may not prevail in any lawsuits that it initiates and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, Immunic&#8217;s efforts to enforce its intellectual property rights throughout the world may be inadequate to obtain a significant commercial advantage from the intellectual property that it develops or licenses. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If Immunic does not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, it may be unable to extend the term of marketing exclusivity for its product candidates and its business may be materially harmed. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depending on the timing, duration and specifics of any FDA marketing approval of Immunic&#8217;s product candidates, one of the U.S. patents covering each of such approved product or the use thereof may be eligible for up to five years of patent term restoration under the Hatch-Waxman Act. The Hatch-Waxman Act allows extension of a maximum of one patent per FDA-approved product. Patent term extension or special protection certificates also may be available in certain foreign countries upon regulatory approval of Immunic&#8217;s product candidates. Nevertheless, Immunic may not be granted patent term extension either in the United States or in any foreign country because of, among other things, failing to apply prior to applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension afforded as well as the scope of patent protection during any such extension could be less than Immunic requests. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Immunic is unable to obtain patent term extension or restoration, or the term of any such extension is less than Immunic or its collaborators request, the period during which Immunic will have the right to exclusively market its product will be shortened and Immunic&#8217;s competitors may obtain approval of competing products following Immunic&#8217;s patent expiration, and Immunic&#8217;s revenue could be materially reduced. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent, which may adversely affect Immunic&#8217;s ability to develop and market its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic cannot guarantee that any of its patent searches or analyses (including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents) are complete or thorough, nor can Immunic be certain that Immunic has identified each and every patent and pending application in the United States and other jurisdictions that is relevant to or necessary for the commercialization of its product candidates in any jurisdiction. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The scope of a patent claim is determined by legal interpretation, the written disclosure in a patent and the patent&#8217;s prosecution history. Immunic&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact its ability to market its product candidates. Immunic may incorrectly determine that its product candidates are not covered by a third-party patent. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many patents may cover a marketed product, including but not limited to patents covering the composition, methods of use, formulations, production processes and purification processes of or for the product. The identification of all patents and their expiration dates relevant to the production and sale of a therapeutic product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. Immunic&#8217;s determination of the expiration date of any patent in the United States or other jurisdictions that it considers relevant may be incorrect, which may negatively impact its ability to develop and market its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining Immunic&#8217;s patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and Immunic&#8217;s patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The United States Patent and Trademark Office ("USPTO"), and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. Immunic employs an outside firm and relies on its outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If Immunic fails to maintain the patents and patent applications covering its product candidates, Immunic&#8217;s competitors might be able to enter the market sooner, which would have a material adverse effect on Immunic&#8217;s business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The patent protection for Immunic&#8217;s product candidates may expire before Immunic is able to maximize their commercial value, which may subject Immunic to increased competition and reduce or eliminate its opportunity to generate product revenue. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The patents for Immunic&#8217;s product candidates have varying expiration dates and, if these patents expire, Immunic may be subject to increased competition and Immunic may not be able to recover its development costs or market any of its approved products profitably. In some of the larger potential markets, such as the United States and Europe, patent term extension or restoration may be available to compensate for time taken during aspects of the product&#8217;s development and regulatory review. However, Immunic cannot be certain that such an extension will be granted, or if granted, what the applicable time period or the scope of patent protection afforded during any extension period will be. In addition, even though some regulatory authorities may provide some other exclusivity for a product under their own laws and regulations, Immunic may not be able to qualify the product or obtain exclusivity. If Immunic is unable to obtain patent term extension, restoration or some other exclusivity, Immunic could be subject to increased competition and its opportunity to establish or maintain product revenue could be substantially reduced or eliminated. Furthermore, Immunic may not have sufficient time to recover its development costs prior to the expiration of its U.S. and foreign patents. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may become involved in lawsuits to protect its patents or other intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Competitors may infringe Immunic&#8217;s patents or other intellectual property rights. To counter infringement or unauthorized use, Immunic may be required to file infringement claims, directly or through its licensors, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of Immunic&#8217;s licensor is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that Immunic&#8217;s patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of the patents Immunic licenses at risk of being invalidated or interpreted narrowly and could put Immunic&#8217;s licensors&#8217; patent applications at risk of not issuing. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to patents of Immunic&#8217;s licensors and patent applications or those of Immunic&#8217;s current or future collaborators. An unfavorable outcome could require Immunic to cease using the technology or to attempt to license rights to it from the prevailing party. Immunic&#8217;s business could be harmed if a prevailing party does not offer Immunic a license on terms that are acceptable to Immunic. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of Immunic&#8217;s management and other employees. Immunic may not be able to prevent, alone or with its collaborators, misappropriation of its proprietary rights, particularly in countries whose laws do not grant the same protections to intellectual property as fully as the United States. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Immunic&#8217;s confidential and proprietary information could be compromised by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Immunic&#8217;s common stock. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement or misappropriation may adversely affect Immunic&#8217;s business and could prevent Immunic from developing or commercializing its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic&#8217;s commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex-parte review, inter party review and post-grant review proceedings before the USPTO and foreign patent offices. Numerous U.S. and foreign patents and patent applications exist in the fields in which Immunic is developing and may develop its product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that Immunic&#8217;s product candidates may be subject to third-party claims of patent infringement. Third-party claims that Immunic infringes on their products or technology could present a number of issues, including: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">infringement and other intellectual property claims, whether with or without merit, can be expensive and time-consuming to litigate and can divert management&#8217;s attention from Immunic&#8217;s core business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the risk of substantial court-imposed damages for past infringement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">a court prohibiting Immunic from selling or licensing its product unless the patent holder licenses the patent to Immunic, which it would not be required to do;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">even if a license is available from the patent holder, Immunic may have to pay substantial royalties or grant cross licenses to Immunic&#8217;s patents; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic may need to redesign its processes to avoid further infringement, which may not be possible or could require expenditure of substantial funds and time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third parties may assert that Immunic is employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of Immunic&#8217;s product candidates, that Immunic failed to identify. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until issued as patents. Except for the preceding exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of approximately 18 months after the earliest filing. Therefore, patent applications covering Immunic&#8217;s product candidates may have been filed by others without the knowledge of Immunic or its licensors. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover Immunic&#8217;s product candidates or the use or manufacture of its product candidates. Immunic may also face misappropriation claims if a third party believes that Immunic inappropriately obtained and used its trade secrets. If the third-party prevails on such claims, Immunic may be prevented from further using such trade secrets, limiting its ability to develop its product candidates, and may be required to pay damages. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a court of competent jurisdiction held that any third-party patents cover aspects of Immunic&#8217;s materials, formulations, methods of manufacture or methods for treatment, the holders of any such patents would be able to block Immunic&#8217;s ability to develop and commercialize the applicable product candidate until such patent expired or unless Immunic obtains a license. A license may not be available on acceptable terms, if at all. Even if Immunic was able to obtain a license, the rights could be nonexclusive, which could result in Immunic&#8217;s competitors having access to its licensed intellectual property. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ultimately, Immunic could be prevented from commercializing a product, or be forced to cease some aspect of its business operations, if, as a result of actual or threatened patent infringement claims, Immunic is unable to enter into licenses on acceptable terms or at all. In addition, during the course of any patent or other intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">perceived value of Immunic&#8217;s product candidates, programs, or intellectual property could be diminished. Accordingly, the market price of Immunic&#8217;s common stock may decline. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Parties making claims against Immunic may obtain injunctive or other equitable relief, which could effectively block Immunic&#8217;s ability to further develop and commercialize one or more of its product candidates. Defending against claims of patent infringement or misappropriation of trade secrets could be costly and time-consuming, regardless of the outcome. Thus, even if Immunic was to ultimately prevail, or to settle at an early stage, such litigation could burden Immunic with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of Immunic&#8217;s management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against Immunic, Immunic may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign its infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial expenditure of time and money. In addition, the uncertainties associated with litigation could have a material adverse effect on Immunic&#8217;s ability to raise the funds necessary to continue its clinical trials, continue its research programs, license necessary technology from third parties, or enter into collaborative arrangements that would help Immunic bring its product candidates to market. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing Immunic&#8217;s ability to protect its product candidates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As is the case with other pharmaceutical companies, Immunic&#8217;s success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents and patent rights. Obtaining and enforcing patents and patent rights in the biotechnology industry involves both technological and legal complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Further, several recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to Immunic&#8217;s ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents and patent rights, once obtained. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For Immunic&#8217;s U.S. patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act ("the AIA"), was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and reviewed after issuance, and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA and many of the substantive changes to patent law associated with the AIA. It is not clear what other, if any, impact the AIA will have on the operation of Immunic&#8217;s business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of patent rights, all of which could have a material adverse effect on Immunic&#8217;s business and financial condition. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-inventor-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but Immunic or Immunic&#8217;s licensor could therefore be awarded a patent covering an invention of Immunic&#8217;s even if Immunic or its licensor had made the invention before the third party. This will require Immunic to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, Immunic&#8217;s ability to obtain and maintain valid and enforceable patent rights depends on whether the differences between the licensor&#8217;s or Immunic&#8217;s technology and the prior art allow Immunic&#8217;s technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, Immunic cannot be certain that a licensor or it was the first to either (i) file any patent application related to Immunic&#8217;s product candidates or (ii) invent any of the inventions claimed in Immunic&#8217;s patents or patent applications. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Among other changes, the AIA limits where a patentee may file a patent infringement suit and provides opportunities for third parties to challenge any issued patent in the USPTO. This applies to all U.S. patents, even those issued before March 16, 2013. Because the evidentiary standard to invalidate a patent claim in USPTO proceedings is lower than for a procedure in U.S. federal court, a third party may attempt to use the USPTO procedures to invalidate patent rights that would not have been invalidated in federal court. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken Immunic&#8217;s ability to obtain new patents or to enforce its existing patents and patents that Immunic might obtain in the future. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Because of the expense and uncertainty of litigation, Immunic may not be in a position to enforce its intellectual property rights against third parties. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because of the expense and uncertainty of litigation, Immunic may conclude that even if a third party is infringing the patents of Immunic&#8217;s licensors or Immunic or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of Immunic or its stockholders. In such cases, Immunic may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not protect against all potential threats to Immunic&#8217;s competitive advantage. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The degree of future protection afforded by Immunic&#8217;s intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect Immunic&#8217;s business, or permit Immunic to maintain its competitive advantage. The following examples are illustrative: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Others may be able to make products that are similar to Immunic&#8217;s product candidates but that are not covered by the claims of the patents that Immunic licenses from others or may license or own in the future.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Others may independently develop similar or alternative technologies or otherwise circumvent any of Immunic&#8217;s technologies without infringing its intellectual property rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any of Immunic&#8217;s collaborators might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that Immunic licenses or will, in the future, own or license.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any of Immunic&#8217;s collaborators might not have been the first to file patent applications covering certain of the patents or patent applications that Immunic licenses or will, in the future, license.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Issued patents that have been licensed to Immunic may not provide Immunic with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by Immunic&#8217;s competitors.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Immunic&#8217;s competitors might conduct research and development activities in countries where Immunic does not have license rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in Immunic&#8217;s major commercial markets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Ownership of patents or patent applications licensed to Immunic may be challenged by third parties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">The patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on Immunic&#8217;s business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees, consultants and others may not adequately prevent disclosure of trade secrets and protect other proprietary information. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade secrets and/or confidential know-how can be difficult to maintain as confidential. To protect this type of information against disclosure or appropriation by competitors, Immunic requires its employees, consultants, contractors and advisors to enter into confidentiality agreements with Immunic. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose Immunic&#8217;s confidential </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time-consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Failure to obtain or maintain trade secrets and/or trade protection of confidential know-how could adversely affect Immunic&#8217;s competitive position. Moreover, Immunic&#8217;s competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, Immunic&#8217;s competitors could limit Immunic&#8217;s use of its trade secrets and/or confidential know-how. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of Immunic&#8217;s product candidates. It may be necessary for Immunic to use the patented or proprietary technology of third parties to commercialize its product candidates, in which case Immunic would be required to obtain a license from such third parties. Such a license may not be available on commercially reasonable terms or at all, which could materially harm Immunic&#8217;s business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic has received confidential and proprietary information from third parties. In addition, Immunic employs individuals who were previously employed at other biotechnology or pharmaceutical companies. Immunic may be subject to claims that Immunic or its employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of third parties or the former employers of Immunic&#8217;s employees, consultants or independent contractors. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, Immunic may be subject to ownership disputes in the future arising from, among other things, consultants or third-parties who are involved in developing Immunic&#8217;s product candidates. Immunic may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in Immunic&#8217;s patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging Immunic&#8217;s right to and use of confidential and proprietary information. If Immunic fails in defending any such claims, in addition to paying monetary damages, Immunic may lose its rights to certain intellectual property. Such an outcome could have a material adverse effect on Immunic&#8217;s business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if Immunic is successful in defending against these claims, litigation could result in substantial cost and be a distraction to Immunic&#8217;s management and employees. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in its patents and other intellectual property. Immunic may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing Immunic&#8217;s product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If Immunic fails in defending any such claims, in addition to paying monetary damages, Immunic may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Immunic&#8217;s business. Even if Immunic is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic&#8217;s reliance on third parties requires Immunic to share its trade secrets, which increases the possibility that a competitor will discover them or that Immunic&#8217;s trade secrets will be misappropriated or disclosed. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because Immunic relies on third parties to assist with research and development and to manufacture its product candidates, Immunic must, at times, share trade secrets with them. Immunic seeks to protect its proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with its advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use, disclose or publish Immunic&#8217;s confidential information, including its trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets will become known to Immunic&#8217;s competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that Immunic&#8217;s proprietary position is based, in part, on its know-how and trade secrets, a competitor&#8217;s discovery of Immunic&#8217;s trade secrets or other unauthorized use or disclosure would impair Immunic&#8217;s competitive position and may have a material adverse effect on its business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the future Immunic may also conduct joint research and development programs that may require it to share trade secrets under the terms of its research and development or similar agreements. Despite Immunic&#8217;s efforts to protect its trade secrets, Immunic&#8217;s competitors may discover its trade secrets, either through breach of Immunic&#8217;s agreements with third parties, independent development or publication of information by any of Immunic&#8217;s third-party collaborators. A competitor&#8217;s discovery of Immunic&#8217;s trade secrets would impair Immunic&#8217;s competitive position and have an adverse impact on its business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If Immunic&#8217;s trademarks and trade names are not adequately protected, then Immunic may not be able to build name recognition in its markets of interest and its business may be adversely affected. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Immunic&#8217;s trademarks and trade names are not adequately protected, then Immunic may not be able to build name recognition in its markets of interest and its business may be adversely affected. Immunic&#8217;s unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. Immunic may not be able to protect its rights to these trademarks and trade names, which Immunic needs to build name recognition among potential collaborators or customers in its markets of interest. At times, competitors may adopt trade names or trademarks similar to Immunic&#8217;s, thereby impeding Immunic&#8217;s ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of Immunic&#8217;s unregistered trademarks or trade names. Over the long term, if Immunic is unable to successfully register its trademarks and trade names and establish name recognition based on its trademarks and trade names, then Immunic may not be able to compete effectively and its business may be adversely affected. Immunic&#8217;s efforts to enforce or protect its proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact Immunic&#8217;s financial condition or results of operations. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Being a Public Company </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic incurs significant costs and demands upon management as a result of complying with the laws and regulations affecting public companies. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic incurs significant legal, accounting and other expenses that it would not incur as a private company, including costs associated with public company reporting requirements. Immunic also incurs costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), as well as new rules implemented by the SEC and The Nasdaq Stock Market ("Nasdaq"). These rules and regulations increase the company&#8217;s legal and financial compliance costs and make some activities more time-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">consuming and costly. Not all members of Immunic&#8217;s management have previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. These rules and regulations may also make it difficult and expensive for the company to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for Immunic to attract and retain qualified individuals to serve on its board of directors or as executive officers of the company, which may adversely affect investor confidence in Immunic and could cause Immunic&#8217;s business or stock price to suffer. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective December 31, 2019, Immunic is no longer an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to &#8220;emerging growth companies&#8221; no longer apply, which will increase Immunic&#8217;s costs as a public company and increase the demands on management.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective December 31, 2019, the fiscal year-end following the fifth anniversary of the completion of its initial public offering, Immunic is no longer an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act. As a result, Immunic will incur significant additional expenses in complying with certain provisions of the Sarbanes-Oxley Act and rules implemented by the SEC. Moreover, if Immunic or its independent registered public accounting firm identifies deficiencies in Immunic&#8217;s internal control over financial reporting that are deemed to be material weaknesses, the market price of Immunic&#8217;s stock could decline, and Immunic could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. Furthermore, investor perceptions of Immunic may suffer if, in the future, material weaknesses are found, and this could cause a decline in the market price of Immunic&#8217;s stock. Any failure of Immunic&#8217;s internal control over financial reporting could have a material adverse effect on the company&#8217;s stated operating results and harm its reputation. If Immunic is unable to implement these changes effectively or efficiently, it could harm Immunic&#8217;s operations, financial reporting or financial results and could result in an adverse opinion on internal control from its independent registered public accounting firm.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, Immunic is no longer eligible for reduced disclosure requirements and exemptions requirements applicable to emerging growth companies regarding executive compensation and exemptions from the requirements of holding advisory say-on-pay votes on executive compensation and as such, Immunic will hold a say-on-pay vote and a say-on-frequency vote at its 2021 annual meeting of stockholders. Immunic expects that the increased disclosure requirements will require additional attention from management and will result in increased costs to the company, which could include higher legal fees, accounting fees and fees associated with investor relations activities, among others.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Immunic&#8217;s Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The market price of Immunic&#8217;s common stock is volatile.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The market price of Immunic&#8217;s common stock can be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of Immunic&#8217;s common stock to fluctuate include: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">reports on or the perception of clinical progress, or the lack thereof;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the ability of Immunic to obtain regulatory approvals for its product candidates, and delays or failures to obtain such approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure of any of Immunic&#8217;s approved product candidates to achieve commercial success;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to maintain its existing third-party license and supply agreements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure by Immunic or its licensors to prosecute, maintain, or enforce its intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in laws or regulations applicable to its product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">any inability to obtain adequate supply of its product candidates or the inability to do so at acceptable prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">adverse regulatory authority decisions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">introduction of new products, services, or technologies by its competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to meet or exceed financial and development projections that Immunic may provide to the public;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to meet or exceed the financial and development projections of the investment community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by Immunic or its competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and its ability to obtain patent protection for its technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">additions or departures of key personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">if securities or industry analysts do not publish research or reports about its business, or if they issue adverse or misleading opinions regarding its business and stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the market valuations of similar companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">general market or macroeconomic conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales of common stock by the company or its stockholders in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">trading volume of its common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">adverse publicity relating to the markets in which Immunic operates, including with respect to other products and product candidates in such markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the introduction of technological innovations or new therapies that compete with product candidates of Immunic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the structure of healthcare payment systems; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">period-to-period fluctuations in Immunic&#8217;s financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Immunic&#8217;s common stock. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm Immunic&#8217;s profitability and reputation. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, a decrease in the stock price of Immunic may cause the company&#8217;s common stock to no longer satisfy the continued listing standards of The Nasdaq Global Select Market. If the company is not able to maintain the requirements for listing on The Nasdaq Global Select Market, it could be delisted, which could have a materially adverse effect on its ability to raise additional funds as well as the price and liquidity of its common stock. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in Immunic&#8217;s organizational documents and Delaware law might discourage or delay acquisition attempts for the company that stockholders might consider favorable. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic&#8217;s Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), and Amended and Restated Bylaws (the "Bylaws"), contain provisions that may delay or prevent an acquisition or change in control of the company. Immunic&#8217;s certificate of incorporation and bylaws include provisions that: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">authorize Immunic&#8217;s board of directors to issue without further action by the stockholders, up to 20,000,000 shares of undesignated preferred stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">require that any action to be taken by Immunic&#8217;s stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of Immunic&#8217;s stockholders, including proposed nominations of persons for election to Immunic&#8217;s board of directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">provide that vacancies on Immunic&#8217;s board of directors may be filled only by a majority of directors then in office, even though less than a quorum; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish that Immunic&#8217;s board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, as a Delaware corporation, Immunic is subject to provisions of Delaware law, which may impair a takeover attempt that Immunic&#8217;s stockholders may find beneficial. These anti-takeover provisions and other provisions under Delaware law could discourage, delay or prevent a transaction involving a change in control of Immunic, including actions that its stockholders may deem advantageous, or negatively affect the trading price of its common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and to cause Immunic to take other corporate actions they desire. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic may experience adverse consequences because of required indemnification of officers and directors. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Provisions of Immunic&#8217;s Certificate of Incorporation and Bylaws provide that it will indemnify any director and officer as to liabilities incurred in their capacity as a director or officer and on those terms and conditions set forth therein to the fullest extent of Delaware law. Further, Immunic may purchase and maintain insurance on behalf of any such persons whether or not Immunic would have the power to indemnify such person against the liability insured against. The foregoing could result in substantial expenditures by Immunic and prevent any recovery from its officers, directors, agents and employees for losses incurred by the company as a result of their actions. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic does not anticipate that it will pay any cash dividends in the foreseeable future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The current expectation is that Immunic will retain any future earnings to fund the development and growth of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">its business. As a result, any capital appreciation of the common stock of the company will be stockholders&#8217; sole source of any gain for the foreseeable future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The ownership of Immunic&#8217;s common stock is highly concentrated, which may prevent stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause Immunic&#8217;s stock price to decline. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive officers and directors of Immunic and their affiliates and entities that are related to such officers and directors beneficially own or control approximately 31% of the outstanding shares of common stock of the company. Accordingly, these executive officers, directors and their affiliates, acting as a group, have substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of Immunic&#8217;s assets or any other significant corporate transactions. These stockholders may also delay or prevent a change of control of Immunic, even if such a change of control would benefit the other stockholders of the company. The significant concentration of stock ownership may adversely affect the trading price of Immunic&#8217;s common stock due to investors&#8217; perception that conflicts of interest may exist or arise, and may adversely affect the liquidity of Immunic&#8217;s common stock. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If Immunic fails to maintain proper and effective internal controls, its ability to produce accurate financial</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">statements on a timely basis could be impaired.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunic is subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and Nasdaq rules and regulations. The Sarbanes-Oxley Act requires, among other things, that Immunic maintain effective disclosure controls and procedures and internal control over financial reporting. Effective internal control over </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">financial reporting is necessary for Immunic to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Immunic must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form 10-K for each year, as required by Section 404 of the Sarbanes-Oxley Act ("Section 404").  This requires significant management efforts and requires Immunic to incur substantial professional fees and internal costs to expand its accounting and finance functions. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause the company to fail to meet its reporting obligations. In addition, any testing by Immunic, as and when required, conducted in connection with Section 404, or any subsequent testing by the company&#8217;s independent registered public accounting firm, as and when required, may reveal deficiencies in the company&#8217;s internal control over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to its financial statements or identify other areas for further attention or improvement. Furthermore, Immunic cannot be certain that its efforts will be sufficient to remediate or prevent future material weaknesses or significant deficiencies from occurring.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Immunic is not able to comply with the requirements of Section 404, or if it is unable to maintain proper and effective internal controls, it may not be able to produce timely and accurate financial statements. If that were to happen, the market price of Immunic&#8217;s common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Immunic&#8217;s business and stock price could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of its securities. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on Immunic&#8217;s board of directors and management. Activist campaigns that contest or conflict with Immunic&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on Immunic&#8217;s operating results and financial condition. A proxy contest would require Immunic to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by Immunic&#8217;s board of directors and management, diverting their attention from the pursuit of Immunic&#8217;s business strategy. Any perceived uncertainties as to Immunic&#8217;s future direction and control, its ability to execute on its strategy, or changes to the composition of its board of directors or management team arising from a proxy contest could lead to the perception of a change in the direction of its business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue strategic initiatives, or limit its ability to attract and retain qualified personnel and business partners, any of which could adversely affect its business and operating results. If individuals are ultimately elected to Immunic&#8217;s board of directors with a specific agenda, Immunic&#8217;s ability to effectively implement its business strategy and create additional value for its stockholders may adversely effected. Immunic may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to its board of directors and management and would require it to incur significant additional costs. In addition, actions such as those described above could cause significant negative or other fluctuations in Immunic&#8217;s stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of Immunic&#8217;s business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for Immunic&#8217;s common stock may not be sustained and its stockholders may not be able to resell their shares of common stock for a profit, if at all. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">An active trading market for Immunic&#8217;s shares of common stock may not be sustained. If an active market for Immunic&#8217;s common stock is not sustained, it may be difficult for stockholders to sell their shares at an attractive price or at all. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Future sales of shares by existing stockholders could cause</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Immunic&#8217;s stock price to decline. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If existing stockholders of Immunic sell, or indicate an intention to sell, substantial amounts of the company&#8217;s common stock in the public market after legal restrictions on resale lapse, the trading price of the common stock of the company could decline. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about Immunic, its business or its market, its stock price and trading volume could decline. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The trading market for Immunic&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect not to provide research coverage of Immunic&#8217;s common stock, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, Immunic will not have any control over the analysts or the content and opinions included in their reports. The price of Immunic&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of Immunic or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;Unresolved Staff Comments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Properties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we lease approximately 5,700 square feet in Germany in Halle and Gr&#228;felfing, in two different facilities, and approximately 3,300 of office space in the U.S. in New York City. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The New York City lease, which we entered into in November 2019, expires in April 2023 and provides the principal location for our U.S. operations. The Halle, Germany lease is month to month and the Gr&#228;felfing, Germany lease, which was effective July 1, 2020, expires in June 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may look to expand the space available to us in our German facilities. </span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;Legal Proceedings. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the symbol "IMUX".</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;12, 2021, there were 34 holders of record of our common stock, which excludes stockholders whose shares were held in nominee or street name by brokers. The actual number of common stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to Item&#160;12 of Part&#160;III of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;Selected Financial Data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in &#8220;Risk Factors&#8221; included elsewhere in this Annual Report. As used in this report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; our&#8221; or &#8220;the Company&#8221; refer to Immunic, Inc. and its subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis ("RRMS"), ulcerative colitis ("UC"), Crohn&#8217;s disease ("CD") and psoriasis. We are headquartered in New York with our main operations in Gr&#228;felfing, Germany. We currently have 28 employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently pursuing three development programs, all orally available small molecule inhibitors in the clinical development phase. These include the IMU-838 program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of ROR&#947;t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (&#8220;ROR&#947;&#8221;), and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function. These product candidates are being developed to address diseases such as RRMS, UC, CD, and psoriasis. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), and Guillain-Barr&#233; syndrome (&#8220;GBS&#8221;). We are also investigating IMU-838 as a potential treatment option for coronavirus disease 2019 (&#8220;COVID-19&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception of $103.9 million through December&#160;31, 2020. We anticipate that we will continue to incur losses for at least the next several years. Due to the uncertainties involved with therapeutic product development and the clinical trial process, we cannot predict the timing or level of future expenses with certainty, when product approval might occur, if ever, or when profitability may be achieved or sustained.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. $50M At-the-Market Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an additional at-the-market sales agreement with SVB Leerink LLC (&#8220;SVB Leerink&#8221;) as agent (the "December 2020 ATM"). We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $50.0 million in capacity remains under the December 2020 ATM. The prior at-the-market sales agreement between the Company and SVB Leerink, dated as of July 17, 2019, which provides for the offer and sale of common stock from time to time having an aggregate offering price of up to $40.0 million (the &#8220;July 2019 ATM&#8221;), remains in effect. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3 (the &#8220;2020 Shelf Registration Statement&#8221;), which became effective in November 2020. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. Loan Agreement with The European Investment Bank</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2020, we and Immunic AG entered into a Finance Contract with the European Investment Bank (&#8220;EIB&#8221;), pursuant to which EIB agreed to provide Immunic AG with a term loan in an aggregate amount of up to &#8364;24.5 million to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">support the development of our lead asset, IMU-838, in moderate COVID-19, to be made available to be drawn in three tranches, with the second and third tranches subject to the completion of certain pre-defined milestones. We have the right to defer payment of principal and interest on the first and second tranches until five years after the respective borrowing dates, at which point such tranches must be repaid in full. The third tranche is repayable in annual installments commencing one year after its respective borrowing date and must be repaid in full no later than five years after such date. Any outstanding borrowings under the Loan Agreement will accrue interest as provided in the Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2021 until December 31, 2030, we and Immunic AG are also obligated to pay EIB a very low single digit percentage of our revenue, as set forth in the Loan Agreement, subject to certain conditions and limitations tied to the total amount drawn under the Loan Agreement and subject to a cap of &#8364;8.6 million if only the first tranche is drawn and subject to a cap of &#8364;30 million if the full loan amount is drawn. The Loan Agreement also includes certain prepayment penalties that may be triggered by certain prepayments prior to the maturity date. We will guarantee Immunic AG&#8217;s obligations to EIB pursuant to a Guarantee Agreement to be executed by us, Immunic AG and EIB. As of December 31, 2020, no funds have been drawn down under the Loan Agreement.</span></div><div style="margin-top:12pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. Equity Financings</span></div><div style="margin-top:12pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">August 2020 Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with SVB Leerink, as representative of the several underwriters, relating to our public offering of 5,000,000 shares of our common stock, at a public offering price of $18.00 per share. Under the terms of the Underwriting Agreement, we granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 750,000 shares of common stock (the &#8220;Option Shares&#8221;) at the public offering price, less underwriting discounts and commissions, which was exercised in full on August 6, 2020. On August 7, 2020, we closed the offering. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to us from this offering, after giving effect to the exercise in full by the underwriters of their option to purchase the Option Shares, was approximately $96.5 million, after deducting underwriting discounts and commissions and offering expenses payable by us.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">June 2020 Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2020, we entered into a placement agency agreement with ROTH Capital Partners, LLC ("RCP") and Ladenburg Thalmann &amp; Co. Inc. relating to our public offering of 2,175,000 shares of our common stock. Pursuant to this agreement, we agreed to pay the placement agents a cash fee of 6.5% of the gross proceeds from the offering raised from investors and to reimburse the placement agents for certain costs incurred in connection therewith.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, on June 10, 2020, we and certain institutional investors entered into securities purchase agreements relating to the issuance and sale of an aggregate of 2,175,000 shares of our common stock. The purchase price per share in this offering was $11.40 for aggregate gross proceeds of approximately $25.0 million. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The net proceeds to us from this offering, after deducting our offering expenses, were approximately $23.0 million.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">April 2020 Registered Direct Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, we entered into an engagement letter with RCP relating to our registered direct offering of common stock to select institutional investors. Pursuant to this agreement, we agreed to pay RCP a cash fee of 6.5% of the gross proceeds from the offering raised from investors and to reimburse RCP for certain costs incurred in connection therewith.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 23, 2020, we and the investors entered into a securities purchase agreement relating to the issuance and sale of an aggregate of 1,764,706 shares of our common stock. The purchase price per share was $8.50 for aggregate gross proceeds to us of approximately $15.0&#160;million.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The net proceeds to us from this offering, after deducting our offering expenses, were  approximately $13.9&#160;million. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ATM Issuances</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, we raised gross proceeds of $11.3&#160;million pursuant to the July 2019 ATM through the sale of 733,728 shares of common stock at a weighted average price of $15.42 per share. The net proceeds from the July </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 ATM were  $11.0&#160;million after deducting underwriter commissions of $339,356. As of December&#160;31, 2020, there was $23.3&#160;million available under the July 2019 ATM and $50.0 million available under the December 2020 ATM.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Other</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Immunic Joins the NASDAQ Biotech Index</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We were selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on December 21, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#9415;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index must be listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Immunic Joins the Nasdaq Global Select Market</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective October 7, 2020, we transferred the listing of our common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. The Global Select Market is the most selective of Nasdaq&#8217;s three market tiers.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mmunic Joins the Russell 3000 Index</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the conclusion of the 2020 Russell indexes annual reconstitution effective June 29, 2020, we joined the Russell 3000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#9415;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Index.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes to Executive Team</span></div><div style="margin-top:12pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation Agreement with Sanjay S. Patel</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, our former Chief Financial Officer, Sanjay S. Patel, resigned and entered into a Confidential Severance Agreement and Full and General Release with the Company (the &#8220;Separation Agreement&#8221;). Pursuant to the terms of the Separation Agreement, Mr. Patel&#8217;s employment terminated on April 17, 2020. </span></div><div style="margin-top:12pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of our Board independently reviewed and approved entering into an employment agreement with our current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, we and Mr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Mr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020. On October 15, 2020, we and Mr. Nash entered into an addendum to the Executive Chairman Agreement, pursuant to which the term of the agreement was extended to April 15, 2021. In connection therewith, we agreed to make a one-time award of 120,000 stock options to Mr. Nash, which began to vest monthly starting on November 15, 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms of the employment agreement remain the same.</span></div><div style="margin-top:12pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promotion of Glenn Whaley</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, Glenn Whaley, the Company&#8217;s Principal Accounting Officer and Controller, was promoted to the position of Vice President Finance, Principal Financial and Accounting Officer. Mr. Whaley has assumed day-to-day financial management responsibilities, and reports directly to Daniel Vitt, Ph.D., Chief Executive Officer and President of the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Option Exercise</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, Immunic AG, under the terms of the Daiichi Sankyo Agreement, exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, we paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States ("US"), or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, management makes its best estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are typically recognized in the period when new information regarding estimates becomes available to management. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 2, "Summary of Significant Accounting Policies," in the notes to the consolidated financial statements. See below for what we believe are our Critical Accounting Policies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is US dollars. During the twelve months ended December&#160;31, 2020 and 2019, Immunic AG&#8217;s operations were located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the US dollar are translated into US dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into US dollars are recorded in stockholders&#8217; equity net of the anticipated income tax effects as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses  related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income. The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform a quantitative test that compares the fair value to its carrying value to determine the amount of any impairment. Impairment testing for goodwill is done at the reporting unit level. The Company has determined that it operates in a single operating segment and has a single reporting unit. The Company has determined there was no goodwill impairment as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with CROs to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for diseases such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement is recorded as other income. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is estimated (i) at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model, which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2020, and December&#160;31, 2019, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal personnel expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in March 2016, we have spent a total of approximately $82.4 million in research and development expenses through December 31, 2020. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, IMU-838, IMU-935 and IMU-856. We have spent the majority of our research and development resources on IMU-838, our lead development program for clinical trials in RRMS, UC, COVID-19 and PSC.   IMU-935 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in September 2019. IMU-856 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in August 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Immunic AG received a grant of up to approximately $730,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project.  The grant funds will be used to fund a three-year research project relating to autoimmune diseases by us and our three project partners.  Since the inception of the grant, we have received $101,000 which was recorded in other income in the accompanying consolidated statement of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase for the foreseeable future as we continue to conduct ongoing regulatory and development activities, initiate new preclinical and clinical trials and build our pipeline. The process of commercialization, conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has not been significant due to low interest rates earned on invested balances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists primarily of reimbursement of research and development expenses in connection with our option and licensing agreement with Daiichi Sankyo Co., Ltd.,  the gain on the settlement of a note receivable in connection with the sale of ELAD Assets (See Note 4), a research and development tax incentive related to clinical trials performed in Australia and foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Fiscal Years Ended December&#160;31, 2020 and 2019 </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the years ended December&#160;31, 2020 and 2019 (dollars in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,971)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,933)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,084)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Research and development expenses increased by $16.1 million during the twelve months ended December 31, 2020, as compared to the twelve months ended December 31, 2019. The increase reflects (i) a $9.6 million increase in external development costs for IMU-838 related to the Phase 2 clinical trial in patients with COVID-19 since the trial was started in 2020, (ii) a $5.0 million increase in license fees, drug supply and Phase 1 costs related to IMU-856 since these trials have ramped up in 2020, (iii) a $2.1 million increase in drug supply, Phase 1 and preclinical costs related to IMU-935 since these trials have ramped up in 2020, (iv) a $1.5 million increase in personnel expenses, (v) a $0.7 million increase in drug supply costs related to IMU-838, and (vi) a $0.7 million increase for a bioequivalence study related to IMU-838. The increases were partially offset by (i) a $2.0 million decrease related to the Phase 2 clinical trial of IMU-838 in patients with RRMS as the clinical trial came to an end in 2020, and (ii) a $1.5 million decrease in costs related to a Phase 2 clinical trial in patients with Crohn&#8217;s disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:99%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">General and administrative expenses decreased by $4.2 million during the twelve months ended December 31, 2020, as compared to the twelve months ended December 31, 2019. The decrease is primarily due to (i) $5.1 million lower stock compensation expense as a result of non-recurring costs recorded in 2019 related to the Transaction, (ii) $0.9 million of decreased legal, accounting and consultancy costs, and (iii) a $0.7 million decrease in travel costs due to worldwide travel </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:99%">restrictions in connection with the COVID-19 pandemic. The decrease was partially offset by (i) a $2.2 million increase in personnel expenses, and (ii) $0.3 million of increased costs across numerous categories.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Total other income increased by $2.9 million during the twelve months ended December 31, 2020, as compared to the twelve months ended December 31, 2019. The increase is primarily attributable to (i) a $2.5 million foreign exchange gain on a $68.0 million intercompany loan between Immunic, Inc. and Immunic AG, and (ii) a $0.9 million increase in research and development tax incentives for clinical trials in Australia as a result of increased spending on clinical trials in Australia.  This increase was partially offset by (i) the $0.4 million difference between the face value and fair value of the promissory note collected in full in September 2019 in connection with the sale of ELAD Assets, offset by the $0.1 million write-off of the investment in VTL China included in the ELAD Assets sale, and (ii) a $0.2 million decrease of recognized income attributable to reimbursements of research and development expenses in connection with the Daiichi Sankyo Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. Our net losses were approximately $44.0&#160;million  and $34.9&#160;million for the year ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of approximately $103.9&#160;million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the pre-clinical and clinical development of our product candidates and add personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2020, we have raised net cash of approximately $216.8 million from private and public offerings of preferred and common stock. As of December&#160;31, 2020, we had cash and cash equivalents of approximately $127.5&#160;million. With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have an effective shelf registration statement on Form S-3 on file with the SEC which expires in June 2021. The shelf registration statement currently permits the offering, issuance and sale by us of up to an aggregate offering price of $200.0 million of common stock, preferred stock, warrants, debt securities or units in one or more offerings and in any combination, of which $40.0 million may be offered, issued and sold under an at-the-market sales agreement with SVB Leerink. We may use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. In the year ended December&#160;31, 2020, we raised gross proceeds of $11.3&#160;million pursuant to the July 2019 ATM through the sale of 733,728 shares of common stock at a weighted average price of $15.42 per share. The net proceeds from the July 2019 ATM were  $11.0&#160;million after deducting underwriter commissions of $339,356. As of December&#160;31, 2020, there was $23.3&#160;million available under the July 2019 ATM.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3.   The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an additional at-the-market sales agreement with SVB Leerink as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $50.0 million in capacity remains under the December 2020 ATM.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Financing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2020, Immunic, Inc. and Immunic AG entered into the Loan Agreement with EIB, pursuant to which EIB agreed to provide Immunic AG with a term loan in an aggregate amount of up to &#8364;24.5 million to support the development of our lead asset, IMU-838, in moderate COVID-19, to be made available to be drawn in three tranches, with the second and third tranches subject to the completion of certain pre-defined milestones. We have the right to defer payment of principal and interest on the first and second tranches until five years after the respective borrowing dates, at which point such tranches must be repaid in full. The third tranche is repayable in annual installments commencing one year after its respective borrowing date and must be repaid in full no later than five years after such date. Any outstanding borrowings under the Loan Agreement will accrue interest as provided in the Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2021 until December 31, 2030, we and Immunic AG are also obligated to pay EIB a very low single digit percentage of our revenue, as set forth in the Loan Agreement, subject to certain conditions and limitations tied to the total amount drawn under the Loan Agreement and subject to a cap of &#8364;8.6 million if only the first tranche is drawn and subject to a cap of &#8364;30 million if the full loan amount is drawn. The Loan Agreement also includes certain prepayment penalties that may be triggered by certain prepayments prior to the maturity date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. will guarantee Immunic AG&#8217;s obligations to EIB pursuant to a Guarantee Agreement to be executed by Immunic, Inc., Immunic AG and EIB.  As of December 31, 2020, no funds have been drawn down under the Loan Agreement.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Public Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%;text-decoration:underline">August 2020 Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, we entered into an Underwriting Agreement with SVB Leerink, as representative of the several underwriters, relating to our public offering of 5,000,000 shares of our common stock, at a public offering price of $18.00 per share. Under the terms of the Underwriting Agreement, we granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions, which option was exercised in full on August 6, 2020. On August 7, 2020, we closed the offering. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to us from this offering, after giving effect to the exercise in full by the underwriters of their option to purchase the Option Shares, was approximately $96.5 million, after deducting underwriting discounts and commissions and offering expenses payable by us.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">June 2020 Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2020, we entered into a placement agency agreement with RCP and Ladenburg Thalmann &amp; Co. Inc. relating to our public offering of 2,175,000 shares of our common stock. Pursuant to this agreement, we agreed to pay the placement agents a cash fee of 6.5% of the gross proceeds from the offering raised from investors and to reimburse the placement agents for certain costs incurred in connection therewith.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, on June 10, 2020, we and certain institutional investors entered into securities purchase agreements relating to the issuance and sale of an aggregate of 2,175,000 shares of our common stock. The purchase price per share in this offering was $11.40 for aggregate gross proceeds of approximately $25.0 million. The net proceeds to us from this offering, after deducting our offering expenses, were approximately $23.0 million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">April 2020 Registered Direct Offering</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, we entered into an engagement letter with RCP relating to our registered direct offering of common stock to select institutional investors. Pursuant to this agreement, we agreed to pay RCP a cash fee of 6.5% of the gross proceeds from the offering raised from investors and to reimburse RCP for certain costs incurred in connection therewith.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 23, 2020, we and certain institutional investors entered into a securities purchase agreement relating to the issuance and sale of an aggregate of 1,764,706 shares of our common stock. The purchase price per share was $8.50 for aggregate gross proceeds to us of approximately $15.0 million.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to us from this offering, after deducting our offering expenses, were  approximately $13.9 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the years ended December&#160;31 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, operating activities used $46.1 million of cash. The use of cash related to our net loss of $44.0 million adjusted for non-cash charges of $2.7 million related to stock-based compensation and was partially offset by a $2.5 million unrealized foreign currency gain as well as a $2.4 million net change in our operating assets and liabilities. Changes in our operating assets and liabilities during the year ended December 31, 2019 consisted primarily of an increase of $2.8 million in prepaid expenses and other current assets partially offset by $0.4 million increase in other current liabilities, accrued expenses and accounts payable.  The increase in prepaid expenses and other current assets is primarily due to higher prepaid clinical costs, increased receivable for the Australian research and development credit and other miscellaneous items.  The increase in liabilities is primarily due to an increase in clinical costs as a result of more Phase 2 clinical studies than in the prior year, the timing of year-end 2020 bonus payments partially offset by lower deferred income related to Daiichi Sankyo at year-end 2020. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, net investing activities used $0.1 million of cash, primarily due to purchase of equipment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, financing activities provided $144.4&#160;million of cash of consisting of net cash proceeds from the sale of common stock under the July 2019 ATM and the April 2020, June 2020, and August 2020 equity offerings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forecast of the period of time through which our financial resources will support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Our future capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options and transactions, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of any future litigation costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of research and development and any future clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of future regulatory submissions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing and validating the manufacturing processes for any potential product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we pursue, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with being a public company;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount from the sales of, or royalties on any future product candidates, if any.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. We do not expect to achieve revenue from product sales prior to the use of the net proceeds from our public and private offerings to date. We do not have any committed external source of funds other than the Loan Agreement with the EIB. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, we may relinquish all control over the organization and could experience detrimental tax effects.  If we are unable to raise adequate funds, we may have to liquidate some or all of our assets. Any of these factors could harm our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2020, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction was accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#8217;s common stock, immediately following the Transaction, to 4SC while keeping the obligation to pay Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. No royalties are payable as of December&#160;31, 2020 or December 31, 2019 as sales have not commenced.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 regarding the Company&#8217;s obligations under the option agreement with Daiichi Sankyo, which includes the potential payment of future development, regulatory and sales milestone payments, as well as royalties related to IMU-856</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations as of December&#160;31, 2020 and the effect such obligations are expected to have on our cash flows in future periods:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase obligations above represent non-cancelable contractual obligations under certain agreements related to our development programs IMU-838, IMU-935 and IMU-856.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_61"></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU 2017-04, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." This guidance eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit&#8217;s fair value. The Company adopted this ASU, as required, in the quarter ended March 31, 2020 on a prospective basis. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement - Disclosure Framework&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-13.") ASU 2018-13 modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty, and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments must be applied retrospectively to all periods presented upon their effective date. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-18"). ASU 2018-18, clarifies that elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The Company does not have any agreements that meet the definition of a collaboration arrangement at this time.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_64"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents of $127.5 million as of December&#160;31, 2020, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $2.9 million of these funds are held in German bank accounts that were earning negative interest of 0.5% as of December 31, 2020.  There was also $79.1 million held in German banks that are U.S. dollar denominated bank accounts and $44.0 million in U.S. bank accounts that are earning nominal interest. Declines or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development operations are conducted in our facilities in Germany. We have entered and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders&#8217; equity. Our German subsidiaries are currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on their financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our consolidated balance sheets. As of December&#160;31, 2020, our German subsidiaries had net current assets (defined as current assets less current liabilities), subject to foreign currency translation risk, of $82.0 million. The potential decrease in net current assets as of December&#160;31, 2020, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, due primarily to the euro, would be approximately $8.2 million. In addition, a 10% change in the foreign currency exchange rates for the year ended December&#160;31, 2020, would have impacted our net loss by approximately $3.5 million due primarily to the euro.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;Financial Statements and Supplementary Data.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements required pursuant to this item are included in Part IV, Item&#160;15 of this Annual Report, and are presented beginning on page&#160;F-1.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, with the participation of its Chief Executive Officer and Principal Financial and Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rule 13a-15(e) of the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2020, our Chief Executive Officer and Principal Financial and Accounting Officer have concluded that, as of December&#160;31, 2020, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance (a) transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, (b) our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (c) regarding the prevention or timely detection of the unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our management conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013). Based on this evaluation, our management concluded that, as of December&#160;31, 2020, our internal control over financial reporting was effective.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;Other Information.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our definitive proxy statement (the &#8220;Definitive Proxy Statement&#8221;), to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2020, under the headings &#8220;Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Section 16(a) Beneficial Ownership Reporting Compliance,&#8221; and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a written Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer and our principal accounting officer and every other director, officer and employee of Immunic. The Code of Business Conduct and Ethics is available on our Internet website at www.imux.com. A copy of the Code of Business Conduct and Ethics will be provided free of charge by making a written request and mailing it to our corporate headquarters offices to the attention of the Investor Relations Department. If any amendment to, or a waiver from, a provision of the Code of Business Conduct and Ethics that applies to the principal executive officer, principal financial officer and principal accounting officer is made, such information will be posted on our Internet website within four business days at www.imux.com.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;Executive Compensation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be found in our Definitive Proxy Statement under the heading "Executive Compensation" and is incorporated herein by reference.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be found in our Definitive Proxy Statement under the headings "Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authorized for Issuance Under Equity Compensation Plans," "Security Ownership of Certain Beneficial Owners" and "Security Ownership of Directors and Executive Officers" and is incorporated herein by reference.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be found in our Definitive Proxy Statement under the headings "The Board of Directors and Board Committees" and "Certain Relationships and Related-Party Transactions" and is incorporated herein by reference.</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;Principal Accounting Fees and Services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be found in our Definitive Proxy Statement under the heading "Proposal to Ratify the Appointment of Independent Registered Public Accounting Firm" and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;Exhibits, Financial Statement Schedules.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:11.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1. Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#160;We have filed the following documents as part of this Annual Report:</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Baker Tilly U.S,  LLP, Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_109">F-2</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_112">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_112">4</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_118">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_118">5</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_121">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_121">6</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_124">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_124">7</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_127">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_127">8</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_130">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0d8d624238c9468ba14749fb49b7ca69_130">9</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2. Financial Statement Schedules.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> None.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3. Exhibits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The following exhibits are filed herewith or are incorporated by reference to exhibits previously </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">filed with the U.S. Securities and Exchange Commission.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Amended and Restated Articles of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm">Third Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm">2019 Omnibus Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 20, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit42.htm">Description of Registrant's Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-1.htm">Sales Agreement, dated July 17, 2019, between Immunic, Inc. and SVB Leerink LLC.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-2.htm">Option and License Agreement, dated September 27, 2018, between Immunic AG and Daiichi Sankyo Company, Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-3.htm">Asset Purchase Agreement, dated May 13, 2016, between Immunic AG and 4SC AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-4.htm">Form of Indemnification Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-5.htm">Employment Agreement between Dr. Daniel Vitt and Immunic AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex10-1.htm">Addendum to Service Agreement between Immunic AG and Dr. Daniel Vitt.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-6.htm">Employment Agreement between Dr. Manfred Groeppel and Immunic AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex10-2.htm">Addendum to Service Agreement between Immunic AG and Dr. Manfred Groeppel.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000499/e619564_ex10-2.htm">Employment Agreement dated April 17, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000128077620000035/addendtoemplagre-1012.htm">Addendum to Employment Agreement dated October 15, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 6, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/e619576_ex10-1.htm">Placement Agency Agreement, dated April 23, 2020, between Immunic, Inc. and Roth Capital Partners, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/e619576_ex10-2.htm">Form of Securities Purchase Agreement, dated April 23, 2020, between Immunic, Inc. and the investors party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/e619697_ex10-1.htm">Placement Agency Agreement, dated June 10, 2020, between Immunic, Inc.  and the Roth Partners, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/e619697_ex10-2.htm">Form of Securities Purchase Agreement, dated June 10, 2020, between Immunic, Inc. and the investors party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000975/e619841_ex1-1.htm">Underwriting Agreement, dated August 4, 2020, by and between Immunic, Inc. and SVB Leerink LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/e620006_ex10-1.htm">Finance Contract, dated October 19, 2020, between Immunic, Inc., Immunic AG and European Investment Bank</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/e620006_ex10-2.htm">Form of Guarantee Agreement between Immunic, Inc., Immunic AG and European Investment Bank.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-1.htm">Sales Agreement, dated December 29, 2020 between Immunic, Inc. and SVB Leerink LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001425/e620080_ex10-1.htm">Amendment Letter, dated November 11, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123120xexhibit211.htm">List of subsidiaries of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231.htm">Consent of Baker Tilly </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231.htm">U.S.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231.htm"> LLP, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_175">Power of Attorney (included on the signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123120xexhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123120xexhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123120xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-123120xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-3.htm">Employment Agreement, dated September 4, 2019, between Immunic, Inc. and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-2.htm">Addendum, dated September 4, 2019, to Service Agreement between Immunic AG and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-4.htm">Addendum, dated September 4, 2019, to Service Agreement between Immunic AG and Dr. Hella Kohlhof.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Database.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item&#160;601(b)(32)(ii) of Regulation S-K and SEC Release No.&#160;33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_109">Report of Baker Tilly </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_109">U.S. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_109">LLP, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_112">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_118">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_121">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_124">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_127">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0d8d624238c9468ba14749fb49b7ca69_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-9</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 1</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To the shareholders and the board of directors of Immunic, Inc.:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have audited the accompanying consolidated balance sheets of Immunic, Inc. (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Assessment of accrual for research and development costs related to clinical trial activities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Critical Audit Matter Description</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described in Notes 2 and 5 to the consolidated financial statements, the Company records expenses and accruals for estimated costs of research and development activities, including third party contract services costs for clinical research. Clinical trial activities performed by third parties are expensed based upon estimates of work completed in accordance with agreements with the respective Clinical Research Organization (&#8220;CRO&#8221;). Billing terms and payments are reviewed by management to ensure estimates of outstanding obligations are appropriate as of period end. Tracking the progress of completion for clinical trial activities performed by third parties allows the Company to record the appropriate expense and accruals under the terms of the agreements. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Auditing the accounting for accrued clinical trial expenses is complex because of the high volume of data used in management&#8217;s estimates, the assumptions used by management to develop their estimates and the procedures necessary to verify the cost and extent of unbilled work performed during the reporting period.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">How We Addressed the Matter in Our Audit</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We obtained an understanding of the Company&#8217;s process and evaluated the design and implementation of internal controls related to the completeness and valuation of accrued clinical trial expenses.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To test the clinical trial accrual, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating and testing the significant assumptions used by management to estimate the accruals. To test the significant assumptions, we corroborated the progress of clinical trials and other research and development projects with the Company&#8217;s research and development personnel that oversee the clinical trials, and obtained information received directly from third parties, which included the third parties&#8217; estimate of costs incurred to date. We also tested subsequent invoicing received from third parties.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Baker Tilly US, LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company's auditor since 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Minneapolis, MN</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">February 26, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 3</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzQtMS0xLTEtMA_73b21b38-a776-4786-8b76-b7d61949a02b">127,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzQtMy0xLTEtMA_a9df473e-83e9-425e-b2c8-cd1e04b50f88">29,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzUtMS0xLTEtMA_f1e18d5f-f096-4bf8-8b70-7b4ed3a69a53">6,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzUtMy0xLTEtMA_d56660c4-5459-4096-80f1-95baa2f6da1b">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzYtMS0xLTEtMA_988642d6-84d0-45da-98cb-4557057ce597">133,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzYtMy0xLTEtMA_cddcf713-4d66-4978-8eb6-65074c78e020">32,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzctMS0xLTEtMA_d59e86d4-da93-4b40-92d8-72714605dec1">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzctMy0xLTEtMA_089ae93f-2ff0-4813-b509-997a63dcf717">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzgtMS0xLTEtMA_f89b1d37-0627-41ce-9aab-4e89ec797641">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzgtMy0xLTEtMA_b0c18cdd-326a-4c9f-b5b5-64c49d99f13f">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzktMS0xLTEtMA_0d31503e-8afb-445b-9368-c6d58cecc9a8">901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzktMy0xLTEtMA_840ec890-b9d0-4114-808d-13513a0e1715">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzEwLTEtMS0xLTA_540219ad-4809-4fa1-86a3-9428d484ab3c">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzEwLTMtMS0xLTA_d1bf6a6b-e276-4984-ae4d-492a18a9c772">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzExLTEtMS0xLTA_38aa25f4-d633-4454-b0ba-f3536b8a79bc">167,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzExLTMtMS0xLTA_1fdf1a6d-44ac-43a9-a48b-0828be809a4f">65,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities  and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE0LTEtMS0xLTA_752321ff-45af-4c02-84de-19453377e3c9">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE0LTMtMS0xLTA_de601750-74d6-49af-8300-f26cab06ce31">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE1LTEtMS0xLTA_e6820193-6c66-4378-a1c2-9a0c81697e39">4,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE1LTMtMS0xLTA_144c6d31-4f03-47d5-8ae7-3f483c366d93">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE2LTEtMS0xLTA_e9d99ef6-0e2f-4b50-aaaf-570d2fff03b5">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE2LTMtMS0xLTA_47b231ec-007f-426a-8c39-48af69835ec3">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE3LTEtMS0xLTA_a809978a-75e9-44a3-9c9e-9515bbf15998">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE3LTMtMS0xLTA_d7e55b17-6fb2-4bf7-ad10-36d3a2c24d6f">7,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE5LTEtMS0xLTA_462eaf49-718a-4f81-822b-5243f9cf13f7">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE5LTMtMS0xLTA_3d937533-a10a-4cbb-9805-d409f4a6e883">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIwLTEtMS0xLTA_a533ab2d-e140-48dc-862a-51a04af895e3">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIwLTMtMS0xLTA_fc1d546c-052b-4180-8d7e-e005038fcf9c">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIxLTEtMS0xLTA_ead94357-8477-40d6-8f6c-b7345dc40eeb">9,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIxLTMtMS0xLTA_70a41245-67cc-423e-ac22-615f89c12dde">7,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (note 6)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIyLTEtMS0xLTA_fd981853-334a-4c55-aec5-6879cd30a16e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIyLTMtMS0xLTA_d7bb33b3-834e-47ac-a226-3c57323e09d7"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTc0_13780025-c183-403e-b14e-5faeb24196e7"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTc0_6e38d85a-2399-467d-b48b-7d2e21f73736">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTg3_11b9bded-c495-4352-9f65-9f47a42d90f5"><ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTg3_fda3ea2d-9702-485f-a69d-ac2390ea47c2">20,000,000</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTky_1981cd51-9569-473e-878c-78d475d74482"><ix:nonFraction unitRef="shares" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTky_69668e5d-73e2-4dc4-94f5-474d2c987616"><ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTky_a85b4112-828b-40d2-a7b2-5e54dd3859b5"><ix:nonFraction unitRef="shares" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTky_eeb3322f-059a-40e0-98c5-b2dd79be1ca7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December&#160;31, 2020 and 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTEtMS0xLTA_41d49051-6f4a-4e78-b57b-5a3ee0371a33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTMtMS0xLTA_a2c042a1-ae31-486c-ac12-f2cbd3c86e06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjE3_3fc69153-3fa9-4f1b-9288-02874750ed58"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjE3_bebbb066-f6f3-46f5-b94a-6e672f379d85">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjMx_838a8073-05ba-4541-96d5-b114a47cea93"><ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjMx_bbde9585-0eee-4d60-b4a7-650409a4ca81">130,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjQ0_5727a808-d86c-48fe-b87a-7080f393d0e9"><ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjQ0_8db82f7f-62d4-4487-ac2d-f507ed674044">21,168,240</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjU3_4250f5a8-6137-4310-a5be-45d23ed089a8"><ix:nonFraction unitRef="shares" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjU3_8f1abaa6-5228-424d-a3f0-7593cb445843">10,744,806</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTEtMS0xLTA_91c7c521-4fed-46a9-ad9a-b0f7c226e35e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTMtMS0xLTA_e40b5c62-955c-463c-84d6-d1922684687c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI4LTEtMS0xLTA_6d7ae77b-54d8-4494-b0f1-fe07f1333eef">266,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI4LTMtMS0xLTA_7dc23769-f06a-4b36-98d1-4e7317efeb2a">119,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI5LTEtMS0xLTA_8244193a-2601-450d-a3c8-278662ccd4d0">4,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI5LTMtMS0xLTA_94f25fe4-3519-4591-a13e-fd980a8c5dc8">1,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMwLTEtMS0xLTA_f709d97d-48f6-466f-b771-33df672ff2c8">103,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMwLTMtMS0xLTA_ceaa2b0b-c2cc-49d9-b85d-eb25b9ab9eb1">59,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMxLTEtMS0xLTA_edcc58f1-ee66-4cbd-9754-37469dbde14e">158,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMxLTMtMS0xLTA_08776007-5cf4-4296-a0e5-9a9f2f72f068">58,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMyLTEtMS0xLTA_2f75d91f-a47c-47a1-b11b-6e825d647357">167,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMyLTMtMS0xLTA_84203928-353f-4ea5-9abb-e6ad28a87010">65,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 4</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.403%"><tr><td style="width:1.0%"></td><td style="width:68.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzMtMS0xLTEtMA_52718cb0-7c2d-4ad3-9aa5-9ebce23f638c">38,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzMtMy0xLTEtMA_1f81636e-adb8-451b-afb8-168b35b53c94">22,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzQtMS0xLTEtMA_22d6722c-95b3-4bcc-9dc8-8d808085f583">10,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzQtMy0xLTEtMA_666c1376-4a5f-4b03-bd35-8e437bd3d01e">14,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzUtMS0xLTEtMA_978ac801-2b8f-4142-9a9b-c52462eda8d1">48,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzUtMy0xLTEtMA_2c3d51fa-c6de-4d5f-994b-465eb485ef6f">37,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzYtMS0xLTEtMA_65ab3678-2e5b-4a3c-895e-e99f92227dff">48,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzYtMy0xLTEtMA_d04472de-5bc6-4d1f-8a78-e982443e0fac">37,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzgtMS0xLTEtMA_212fa854-92a9-4df2-bef5-c62887df79c6">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzgtMy0xLTEtMA_c87a3ca9-0af8-4ab5-a0c0-d591cc7f2aed">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzktMS0xLTEtMA_2ebaab90-9080-4444-89e1-ce2be9446108">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzktMy0xLTEtMA_191bda6c-1fd3-41d7-8cf7-3ba2f468d5d0">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzEwLTEtMS0xLTA_2ef26e3b-d313-4af5-adf8-c14742c3d186">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzEwLTMtMS0xLTA_22bfc9e3-98f0-4442-9939-33d9e4c92576">2,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzExLTEtMS0xLTA_c09e80fb-5410-4f81-860a-2695511d5324">44,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzExLTMtMS0xLTA_7d35542d-9344-499d-81ff-0aef4523ba8b">34,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzEzLTEtMS0xLTA_1b0eba70-5999-4e99-b22e-ebb755663a17">2.81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzEzLTMtMS0xLTA_8f821b5e-d0e3-4d98-a311-865d0c3b1b64">4.52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzE1LTEtMS0xLTA_cd9e9291-34f9-43c0-84b9-b66d382f8b9a">15,663,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzE1LTMtMS0xLTA_d7abdafe-6cba-4a3b-b2d8-51c51ae557ce">7,722,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 5</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.403%"><tr><td style="width:1.0%"></td><td style="width:68.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzItMS0xLTEtMA_c09e80fb-5410-4f81-860a-2695511d5324">44,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzItMy0xLTEtMA_7d35542d-9344-499d-81ff-0aef4523ba8b">34,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzQtMS0xLTEtMA_2f9fb478-4bee-43ca-8ea5-86d55e57d90e">2,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzQtMy0xLTEtMA_c35990bc-7347-4b05-96ed-87d236d29f39">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzUtMS0xLTEtMA_9decc73f-e29c-44a0-bd44-d32d0a45ecd9">46,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzUtMy0xLTEtMA_201db8c8-b72a-4801-92d9-43980b24175f">35,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 6</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_124"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;shares)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:13.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.915%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.383%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A-2 Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A-1 Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifedde0176e664cb6aff9c43204468770_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMS0xLTEtMA_69da2ff9-59d4-459e-b1aa-af97c20541a1">299,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedde0176e664cb6aff9c43204468770_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMy0xLTEtMA_61ffbb30-3adc-48d2-ad9a-073361560787">34,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98b37649abfa476e8663e7096706f97e_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtNS0xLTEtMA_1eebe7c6-1331-4f27-b57b-3f07b4ec8ff6">13,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b37649abfa476e8663e7096706f97e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtNy0xLTEtMA_bae38239-9711-4a2c-9987-fc2128d926af">2,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6865d74fb3c44e108442faced8021edf_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTAtMS0xLTA_d4d5440f-825d-44a5-9e01-b44cdb333dc5">846,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6865d74fb3c44e108442faced8021edf_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTItMS0xLTA_786ad5e1-cc94-4782-82c5-1310ffc31534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7671da9018c545b3817f9563d19e0261_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTQtMS0xLTA_84af03ee-84cf-44a6-ac31-93c2dca4d5b9">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37994c8a1974311901413ff52b1e230_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTYtMS0xLTA_371185b5-8f18-4ef1-b107-7068e8c9a968">819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i440b26b7a65b40cba6e77e9d545181b2_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTgtMS0xLTA_ca90c895-cd1e-4221-aaa8-2d49371c6f55">24,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMjAtMS0xLTA_68edeac7-b252-41fa-8d4e-a2abdd81c75a">25,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if188cbbb4056418e817200cb3a88ab28_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzctMTgtMS0xLTA_125121db-d970-4560-a17f-ee6043efc40b">34,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzctMjAtMS0xLTA_a87137ed-01c1-4ded-9882-d1fc9bcb0a50">34,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4298d26d7d8640bb99d1f84822b95179_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzgtMTYtMS0xLTA_4ec1742a-9f70-4a2d-a3be-b141a1ecae03">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzgtMjAtMS0xLTA_043a4552-ac88-42c2-9c50-b954ce05b367">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9a7fc5636d462982c27ea109928534_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzktMTQtMS0xLTA_88ec25a2-403e-4117-8b46-82deb443c789">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzktMjAtMS0xLTA_7ddf1075-0f6e-41a5-b9c2-bfc203725365">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of Series A Preferred Stock to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i24ec86347b48487488f1c2b7053d37cc_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTEtMS0xLTA_aa3cc6b4-4d26-42c7-93ee-58f374650ff7">299,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24ec86347b48487488f1c2b7053d37cc_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTMtMS0xLTA_3f61ce7a-325a-4460-bd1f-926b0a68232b">34,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if52f51af4dd14483aa5dd285b20cb6c6_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTUtMS0xLTA_c968b49d-767c-484f-af91-5295ecab441e">13,541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if52f51af4dd14483aa5dd285b20cb6c6_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTctMS0xLTA_9fbacb22-d8c3-4357-8935-1ab510f6e2a8">2,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTEwLTEtMS0w_0bf924c5-108e-4567-87b2-765a7d0bfd85">5,302,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTEyLTEtMS0w_704d983f-fef8-4ddb-8701-245d54a3e2e5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9a7fc5636d462982c27ea109928534_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTE0LTEtMS0w_9d56f3db-c376-4de8-933d-9564de98d9a0">37,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTIwLTEtMS0w_6263251a-2020-4f87-b693-140750ff2508">37,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock in pre-closing financing for cash, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjoyNmY4MTcxNzg0YzI0MmFkOTU3ZjdiMzk3YTBjNmQxMF84OQ_0aedd507-a0b4-4f05-9a1e-fac5d429df1f">61</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11abdac7c3c743d3a599ef1d1fe7969d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzExLTEwLTEtMS0w_7247186d-0a0b-4304-b2dd-aa7c279fa58a">2,197,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc3a70ddcc2416da33598ca112c4ec6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzExLTE0LTEtMS0w_0d4e455b-02c0-48fd-946b-6f091171058d">29,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzExLTIwLTEtMS0w_2b8103d9-7e78-4001-9f19-e107b46acbf8">29,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock - Bonus share agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic942c4f9cf4f4506ac6fc6619d7741a1_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEyLTEwLTEtMS0w_e3036ed0-2d11-4044-a7f1-1b9cc549c994">460,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be2e94565534b38a1b810c6d9c76e40_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEyLTE0LTEtMS0w_0ba794bb-3db7-4c0c-991c-e4d7f7eca093">6,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id653ff8493bb4f28b484c985e561ac7d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEyLTIwLTEtMS0w_776c4ec0-e739-44a0-a398-8426806fb155">6,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock - settlement of contingent payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2df4d80998e4e6fbb1105df3cc50d87_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEzLTEwLTEtMS0w_e846c858-426f-4086-80b0-5f94901f4bcc">120,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42c6f1afb234a33ac5df351a682ac65_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEzLTE0LTEtMS0w_5a4c6ca4-b66a-4b09-9a79-e7a632be03da">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2bc238cf84494f92f2d022a107611a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEzLTIwLTEtMS0w_1d8072a4-3250-42fd-8885-203a04cfb4b2">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exchange of common stock in connection with Transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE0LTEwLTEtMS0w_9fc4b55d-b488-4f2f-9c9c-db8d990908e5">1,059,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9a7fc5636d462982c27ea109928534_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE0LTE0LTEtMS0w_8d6071d5-aa64-4458-9ce3-cff1a6c70621">39,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE0LTIwLTEtMS0w_92174abc-3bd2-481a-b47b-c76f88d20d9f">39,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock under restricted stock unit agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE1LTEwLTEtMS0w_56604cb7-250c-4a1e-9f5b-f88ece7782b6">127,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE1LTIwLTEtMS0w_cfc1abcf-8527-466f-bb8a-ae73a4fb176a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public offering of common stock - net of issuance costs $<ix:nonFraction unitRef="usd" contextRef="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpiNzVmZGEzYTM0ZDY0NTU5YTExZjE1MDMxNjQ5ZjE1YV82MA_c1bc88fb-5008-4cf7-9a4f-7377832af64c">377</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i482400df09b44e2ba6f90598101aea5d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE2LTEwLTEtMS0w_b2423402-1342-4285-a7e1-f5a6c032ac6c">630,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691293a863540519bd390ff32edae71_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE2LTE0LTEtMS0w_f76424c0-aaa8-4c29-8f3a-43125ce0e973">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE2LTIwLTEtMS0w_f30c93a6-79f0-40af-ae02-3bcc343054b7">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibee2b8da709d477caa8f18d809bc9f32_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTEtMS0xLTA_3ccf3be9-fee7-4b16-b8da-722883f5e9f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee2b8da709d477caa8f18d809bc9f32_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTMtMS0xLTA_5fb31133-d144-4736-b41c-73e85b2ad62e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ce55168c27842fcba430142ef8577a2_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTUtMS0xLTA_f66a9b57-0de6-406f-9b78-c4dbb3f6f666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce55168c27842fcba430142ef8577a2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTctMS0xLTA_de57bac0-fa47-4317-94c6-946d2c8dd55d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78983d83235a444bb1184ca248359fe6_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTEwLTEtMS0w_9443e043-113b-439d-bb18-9d204e103279">10,744,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78983d83235a444bb1184ca248359fe6_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTEyLTEtMS0w_5db69043-74e5-4b7f-b051-b5de5e7498e3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cf71437d1148fd87ec313c6ab59abc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTE0LTEtMS0w_774320e2-08df-4be9-a39e-66bbaa5485cd">119,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i378b311e84c3477d87b10194049b52c6_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTE2LTEtMS0w_15bbc1b1-46d6-4018-8485-af6150cc8e7b">1,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5a2646a9310481db842eb9736d24b75_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTE4LTEtMS0w_075961d2-4afe-4f7e-a84f-a0d5440dfcb8">59,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTIwLTEtMS0w_1b6f7088-e060-40a4-a3dc-808a34d1e8f4">58,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22d73ebb34f94a97a65d4cc981b33181_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE4LTE4LTEtMS0yMDg0_4bc8874b-724c-49e6-a237-60cbf4f8c0a6">44,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE4LTIwLTEtMS02Mjc_2207dcd9-b1ce-4e3f-a510-71d6a7999ed5">44,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide45a6f10a8143968b9977470c96fcf0_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE5LTE2LTEtMS0yMDgw_26c44488-f418-4303-b309-8fb1997a6c2d">2,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE5LTIwLTEtMS02Mjc_4930ce83-578e-47c3-9996-06cff2288ff7">2,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26eab55dd1c4325a2bf6fcd5b7880f5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIwLTE0LTEtMS02MTU_e55bc043-9916-4557-8bd4-814fb0409c8e">2,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIwLTIwLTEtMS02Mjc_dd46bc1d-5dad-4d58-9c6c-997ff2c7ca26">2,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock - At The Market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIxLTAtMS0xLTUyOC90ZXh0cmVnaW9uOjFiOTI5MjMyNWY4NjRjMzhhNWQzYTFlMGJlMTk5MTQ1XzI3NDg3NzkwNjk1MzQ_5889432e-8326-4808-a59e-34ff322a11b8">339</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b2a4218e23645fe8a43795e53bd917d_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIxLTEwLTEtMS02MDc_9a2f4edb-b957-4408-b1c2-cc6b5817aa64">733,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90db4b0e7fa9494cb6a2c2d5438fde97_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIxLTE0LTEtMS02MTU_63c7c57d-426c-47f9-9fc0-fde4a407af54">10,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIxLTIwLTEtMS02Mjc_85785846-78c8-450f-927d-6bcf2b3bbdc6">10,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock - April registered direct equity offering net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIyLTAtMS0xLTUyOC90ZXh0cmVnaW9uOmRlZTA4OWFkMjRkMTRiNDZhOWFmYzdlM2I4Njg1MDAzXzI3NDg3NzkwNjk1NDg_26c231e2-4c3a-4735-977e-c4e727247c90">1,082</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd95d995b8c1481499d8fe54a95ec8a4_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIyLTEwLTEtMS02MDc_90d8fce6-65f6-47d8-8bc6-ffdd91badc98">1,764,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263afee333724006aaeff1f3dcee49a5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIyLTE0LTEtMS02MTU_fbc6103b-21d4-452b-bed6-eaa962b052ec">13,918</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIyLTIwLTEtMS02Mjc_1216f58b-2da2-4c88-ac22-e355782002cb">13,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock - June public equity offering net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIzLTAtMS0xLTUyOC90ZXh0cmVnaW9uOjZkM2FkOWVhNjhmODQ3M2VhNDRkZDI0NjgxNzIyOWI3XzI3NDg3NzkwNjk1MzY_2bd8e781-90d3-4b69-854e-ad72e0c5b681">1,752</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45563a45c561425c82c1d8ae4a882b06_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIzLTEwLTEtMS02MDc_d0984180-be8c-48f4-97a4-9a91b4a7a259">2,175,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacb99b20fe3f4285812691db62887373_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIzLTE0LTEtMS02MTU_001cbc19-125d-45e2-8daa-b585bf4d935d">23,048</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIzLTIwLTEtMS02Mjc_8ed37efb-3a81-4aad-8ea5-64934d2e2379">23,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock - August public equity offering net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTAtMS0xLTUyOC90ZXh0cmVnaW9uOmQwYjE4MDdjOGYyMzRkMTM4YzcxYTc0YjE4MTU3N2M1XzI3NDg3NzkwNjk1Mzg_e72b1050-e9e0-420b-bd2d-3c596f5d8b2a">6,960</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i714a7516a3074b3b819b97a2f9753718_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTEwLTEtMS02MDc_f0f53175-5126-4560-8675-4ee454ebec57">5,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714a7516a3074b3b819b97a2f9753718_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTEyLTEtMS02MTE_5857bbcb-f2c1-4f85-9042-158c0135b6df">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d89043cac44e13a241896366e02310_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTE0LTEtMS02MTU_fc252cb6-7fc2-40ae-97ef-94c4594bedfa">96,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTIwLTEtMS02Mjc_d9e9e8ed-6609-4f9c-b07b-f38f03faeb79">96,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic64924c0859a41d59136ed99d077e63b_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTEtMS0xLTU5MQ_0588d962-634a-4a66-95d1-972049c30e21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64924c0859a41d59136ed99d077e63b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTMtMS0xLTU5NQ_5e824d77-5723-4b6f-9403-e9f4cdc9f36c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc4d7683bd124ea18385d5d19135a5c7_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTUtMS0xLTU5OQ_f7b581fc-68de-41ba-890e-84421efb961f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4d7683bd124ea18385d5d19135a5c7_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTctMS0xLTYwMw_133245cd-fed7-4087-9683-0152c4acf6f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e16527720b5489a87c3709cb393b31c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTEwLTEtMS02MDc_93797e34-1f48-4b8e-892c-2eaf70b0be94">21,168,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e16527720b5489a87c3709cb393b31c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTEyLTEtMS02MTE_4141d337-f0fe-4846-adba-a92270a8d02d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9c5353dcba14224be159080140a4539_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTE0LTEtMS02MTU_a085378a-509f-4ad1-b691-b4986f911c56">266,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c794d23984e413d94b0ee6303307fe7_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTE2LTEtMS02MTk_89b48484-f5c9-47f0-ae32-a85302bb2982">4,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6174bd787b0d4b3e9f91e9b34de11988_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTE4LTEtMS02MjM_a3518b35-ca75-4220-b803-07031b3a1baf">103,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTIwLTEtMS02Mjc_4c9e2614-a701-42bd-9930-431d93ff36bc">158,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 7</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.988%"><tr><td style="width:1.0%"></td><td style="width:70.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.851%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMtMS0xLTEtMA_3cd67c10-9b06-4d63-b395-62a68f02be4e">44,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMtMy0xLTEtMA_318e7ba0-d57e-4c9c-8147-d515a519d18b">34,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzUtMS0xLTEtMA_a2c82722-22a0-46be-acf3-3e707ae35d3a">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzUtMy0xLTEtMA_96a21022-dde7-484a-9e32-ba6083d223f9">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of ELAD Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzYtMS0xLTEtMA_51db75ae-a901-40ea-97a2-7cc71a40b83a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzYtMy0xLTEtMA_bd800e20-997a-43fd-9975-d5a96599c670">329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzctMS0xLTEtMA_432c399b-5a94-4aa1-8843-ea17ac9c894b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzctMy0xLTEtMA_e7cb8485-03d9-44ae-a1be-b48c11349f67">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzgtMS0xLTEtMA_607a4518-0985-4740-bef2-2a903b51d12d">2,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzgtMy0xLTEtMA_7058c91b-7447-460c-822f-42a71e685d03">6,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized  foreign currency gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzktMS0xLTEtMjg2NA_937609f0-35f0-49b2-9338-46fa430c60f9">2,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzktMy0xLTEtMjg2OA_12e70c57-f142-4861-9af8-503c46f6682a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent payment settled in common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzktMS0xLTEtMA_89581fc3-7525-4a76-844e-cc6e42784e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzktMy0xLTEtMA_16b57026-e8cf-4b93-a6b8-925e58b94cde">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzExLTEtMS0xLTA_3ef430f8-47b7-41cc-bd1b-8f5eaf2a8925">2,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzExLTMtMS0xLTA_dfe2abaa-0596-4442-9836-793486c21d54">2,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzEyLTEtMS0xLTA_ac9205b6-f073-4714-b72f-d3d21b390066">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzEyLTMtMS0xLTA_245ef039-53d1-4f56-9a20-b6a35cf17985">462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzEzLTEtMS0xLTA_4d57a3cb-7d02-456c-a9fe-d6f838de604f">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzEzLTMtMS0xLTA_d7c9b84b-2ed2-4e71-9b64-6e597ccafd25">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE0LTEtMS0xLTA_25534838-4a8b-4026-b62f-e0fc547ec303">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE0LTMtMS0xLTA_f40bfabf-0204-4e8c-87bd-73b3f0aa8653">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE1LTEtMS0xLTA_50c466a4-9255-47d5-be7b-f84e1e8f66ad">46,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE1LTMtMS0xLTA_9824a416-76ea-4716-a3cd-e7552ae73ccf">28,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE3LTEtMS0xLTA_e4be72b3-d0f7-47ab-88e7-6f3f386b56a8">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE3LTMtMS0xLTA_a47becb0-7fea-43cc-8323-46746e0caf25">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash distribution in connection with ELAD Assets sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE4LTEtMS0xLTA_299cb8d8-02fd-453a-a128-0dd99ceb43a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE4LTMtMS0xLTA_a9be0787-b449-4bd9-9929-15c1b3a8e7d2">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of ELAD assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE5LTEtMS0xLTA_f4065e57-31b7-4c06-9e39-0b708c6c2c46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE5LTMtMS0xLTA_c40bd62a-529d-4114-a53c-4f91b0e99408">2,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash acquired in connection with the Transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="imux:CashAcquiredInConnectionWithReverseAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIwLTEtMS0xLTA_352e7371-94f5-4023-8be7-a94b29a91384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="imux:CashAcquiredInConnectionWithReverseAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIwLTMtMS0xLTA_5faf936e-fcae-42c7-9a88-a239f8725738">8,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIxLTEtMS0xLTA_742d886a-c23f-4d88-b647-51057f71c9b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIxLTMtMS0xLTA_fcb796ab-899c-48c5-8cbf-c559ab726eff">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by  investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIyLTEtMS0xLTA_4a87c24c-b0c2-4a03-bed0-c8ca7fb441a4">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIyLTMtMS0xLTA_aa69b739-e82f-4053-9017-4a217f1948e1">10,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI0LTEtMS0xLTA_a394522d-81e7-49e4-8efb-60cca011ed80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" xsi:nil="true" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI0LTMtMS0xLTA_80cc7ef3-9d62-4001-b78b-b2ab380dbd21"></ix:nonFraction></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in pre-closing financing, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i3e803724dcf84ceba79eba0078a118c9_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjoxODZmYjc5MTg4ZGQ0MmZjYjM4ZTZlZjczNjEwN2Q2OF85NA_af9fe9b0-e4fc-4e34-80c6-ec2436500de5">61</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e803724dcf84ceba79eba0078a118c9_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI1LTEtMS0xLTA_e588be7f-601d-40f5-9dd8-501086dbcd04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI1LTMtMS0xLTA_b014d04a-25c0-4c41-9500-2e8785db57c0">29,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock through At The Market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkNmMxOWEwZTVlZTg0M2UxYjY1YjQzNDE0MjE3NTg3Nl8yNzQ4Nzc5MDY5NTc4_30e1fa0f-1d4f-4da4-9b0c-a2a1452fcafb">339</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkNmMxOWEwZTVlZTg0M2UxYjY1YjQzNDE0MjE3NTg3Nl8yNzQ4Nzc5MDY5NTg1_49b2eb5a-8cec-4446-8b68-b233b13f5657">161</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI2LTEtMS0xLTA_51493e9e-0fea-45a3-b9d1-8fb7d12b21c9">10,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI2LTMtMS0xLTA_06d1c64d-403e-4ee3-9266-e46d27015c59">5,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from April 2020 registered direct equity offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTAtMS0xLTIzOTYvdGV4dHJlZ2lvbjpmMmQ1MWIyOTA0YmU0ODM3OTQ1ZDk1ZDY3OGU3N2E4NV8yNzQ4Nzc5MDY5NTQx_2b6bf0fb-b18a-4e57-a660-0b5f7afc1b20">1,082</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTEtMS0xLTI0MTI_7e6422d0-e7ac-4649-af8b-59aa75cfbf37">13,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f2a878d5224327b9c3906b7957b0e5_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTMtMS0xLTI0MTY_d8133f8f-1b6a-4052-82c3-fd651f60ed06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from June 2020 public equity offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTAtMS0xLTI0MDIvdGV4dHJlZ2lvbjphNzI2NmRmZmFhOTM0NTRlOTBlZDY0NzcwN2M4YmI1MV8yNzQ4Nzc5MDY5NTI5_42f50fda-599c-45cc-9699-d001c847783d">1,752</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTEtMS0xLTI0MTI_d8e8fb6a-c7eb-4a0c-b7a4-e0e926ee15d6">23,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ef75f825ff45d4ba01031c2df25949_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTMtMS0xLTI0MTY_9e5d419f-e3c8-429c-9cd4-4ebc95dae5e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from August 2020 public equity offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTAtMS0xLTI0MDcvdGV4dHJlZ2lvbjoxOTMxN2M3ODRjODM0ODQyOTExYzE0Nzg2MjRlOTQwMV8yNzQ4Nzc5MDY5NTMx_f618e98b-ae7e-4e08-82cc-f4acb874ff8d">6,960</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTEtMS0xLTI0MTI_172fb251-f5ca-4042-8e57-9be396182138">96,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic948d92ac1714503a6fd146abfa629ce_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTMtMS0xLTI0MTY_275afa87-76ef-47f2-a908-dc4ffc24db89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTEtMS0xLTA_106a828e-4966-4b4d-b50b-945559f4f959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTMtMS0xLTA_a456cd65-5d8a-4fd3-8b0f-81649e4ea22d">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTEtMS0xLTA_b027b8ff-7bb6-46a0-bf28-155a0571cf1f">144,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTMtMS0xLTA_4e0de02e-360a-476f-9924-5f6d9617021b">34,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTEtMS0xLTA_b29f8624-23ec-4856-904a-c557beb41fed">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTMtMS0xLTA_f96ed6d3-27bd-4400-bfbf-1262464a2880">589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMwLTEtMS0xLTA_d0c6ceca-e072-45fb-a01d-3fd0147055c0">98,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMwLTMtMS0xLTA_363571f2-a7eb-44c6-a4ac-538f2a3ce6dd">16,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMxLTEtMS0xLTA_4cef5a82-9a97-4025-a7d2-d2630aee5bea">29,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMxLTMtMS0xLTA_f1bc8f39-8375-45d5-8f0e-d7c5f4dc0336">13,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMyLTEtMS0xLTA_73f974ee-194d-4db6-aab1-f9ea875752e9">127,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMyLTMtMS0xLTA_d095757c-a458-4e65-981b-7582705307c0">29,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock issuance and deferred financing costs included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="imux:DeferredStockIssuanceCostsIncludedInLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM2LTEtMS0xLTA_f001b553-f62f-4b10-a475-f301944a2bf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="imux:DeferredStockIssuanceCostsIncludedInLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM2LTMtMS0xLTA_947cca7e-cd90-481c-adc9-4d40a307ebdd">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of convertible preferred stock to common stock</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM3LTEtMS0xLTA_d7677a7a-8327-4e34-a0df-8610c94d8adb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM3LTMtMS0xLTA_2e66ce03-7356-4ebe-9b80-4c16bcd5490f">37,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired in the Transaction</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM4LTEtMS0xLTA_e12b8e05-f034-44f7-9653-e77166508cc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM4LTMtMS0xLTA_bd11c628-3d05-4e64-821c-aa89038160e2">39,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offering costs in accrued expenses</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" name="imux:OfferingCostsIncludedInAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzQzLTEtMS0xLTI4ODg_f36d7ea8-a73c-4a16-9867-d449ce4588fb">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="imux:OfferingCostsIncludedInAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzQzLTMtMS0xLTI4ODQ_3a658296-42ac-40ac-8e34-b4828d39eb39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="imux:PropertyPlantAndEquipmentIncludedInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM5LTEtMS0xLTA_da378363-584c-4e84-a5fb-65e141618b60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" name="imux:PropertyPlantAndEquipmentIncludedInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM5LTMtMS0xLTA_8b2415d4-dd9c-4139-93ce-047b39355246">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 8</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzg0MjY_ca7c2554-4644-4254-8df4-37653b12fa46" continuedAt="i23ed7684bb124ec29f568032b2916eeb" escape="true">Description of Business and Basis of Financial Statements</ix:nonNumeric></span></div><ix:continuation id="i23ed7684bb124ec29f568032b2916eeb" continuedAt="ie3d0a2eb8acc4f9f863d3c8bc9a4e4ac"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic, Inc. ("Immunic" or the "Company") a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis ("RRMS"), ulcerative colitis ("UC"), Crohn&#8217;s disease ("CD") and psoriasis. Immunic is headquartered in New York with its main operations in Gr&#228;felfing, Germany. Immunic currently has 28 employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic is currently pursuing three development programs, all orally available small molecule inhibitors in the clinical development phase. These include the IMU-838 program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of ROR&#947;t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (&#8220;ROR&#947;&#8221;), and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function. These product candidates are being developed to address diseases such as RRMS, UC, CD, and psoriasis. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), and Guillain-Barr&#233; syndrome (&#8220;GBS&#8221;). Immunic is also investigating IMU-838 as a potential treatment option for coronavirus disease 2019 (&#8220;COVID-19&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzE4NTY_5b732074-5ec9-4be5-bbe2-c874d6a5d86c">103.9</ix:nonFraction>&#160;million as of December&#160;31, 2020 and approximately $<ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzE4ODY_2e517015-ac3b-466c-ab01-b90d5160948d">59.9</ix:nonFraction>&#160;million as of December&#160;31, 2019. Substantially all of Immunic&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2020, Immunic has raised net cash of approximately $<ix:nonFraction unitRef="usd" contextRef="i3268a88a2d6d4e30b39a112e210ac828_D20190412-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzEwOTk1MTE2NDcwMDI_0958fbc8-5a83-41cf-a0fa-799b12f7158e">216.8</ix:nonFraction> million from private and public offerings of preferred and common stock. As of December&#160;31, 2020, Immunic had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzMwNDE_dc4c063c-3064-427a-a76a-3384a7b21d98">127.5</ix:nonFraction>&#160;million. With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying audited consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Acquisition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2019, pursuant to the terms of the Agreement, dated as of January 6, 2019, between Vital Therapies, Inc., a Delaware corporation (&#8220;Vital&#8221;), Immunic AG, and the shareholders of Immunic AG party thereto (the &#8220;Agreement&#8221;), the holders of Immunic AG ordinary shares exchanged all of their outstanding shares for shares of Vital common stock, resulting in Immunic AG becoming a wholly-owned subsidiary of Vital (the &#8220;Transaction&#8221;). Immediately following the Transaction, Vital Therapies, Inc. changed its name to &#8220;Immunic, Inc.&#8221; and its ticker symbol to &#8220;IMUX&#8221;.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Transaction, (i) each Immunic AG preferred share was converted into one Immunic AG ordinary share, and (ii) each Immunic AG ordinary share was converted into the right to receive <ix:nonFraction unitRef="number" contextRef="i9ea2ecf153a24b4f9905b7b614e7adf6_I20190411" decimals="INF" name="imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzQ4NzU_2e668d8c-f258-421a-b6a6-dbc1b0d1a147">17.17</ix:nonFraction> shares of Vital&#8217;s common stock, after giving effect to the Reverse Stock Split (as defined below). The exchange ratio was determined through arm&#8217;s-length negotiations between Vital and Immunic AG. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration issuable in the Transaction, after giving effect to the Reverse Stock Split, was <ix:nonFraction unitRef="shares" contextRef="i6b85b15cda004eb0acf9c15243874440_D20190412-20190412" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzUxODU_bf5b4275-0dbf-4482-adab-0a8db869d82e">8,927,130</ix:nonFraction> shares of Vital&#8217;s common stock. Following the Transaction and after giving effect to the Reverse Stock Split, the former shareholders of Immunic AG owned approximately <ix:nonFraction unitRef="number" contextRef="i72933fde204541c88561a57e1bfee92c_I20190412" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzUzNTY_b6809656-d6a4-4101-abf1-8894ae0c0a30">88.25</ix:nonFraction>% of the fully diluted common stock of the Company, and the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie3d0a2eb8acc4f9f863d3c8bc9a4e4ac"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders of Vital immediately prior to the Transaction owned <ix:nonFraction unitRef="shares" contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412" decimals="INF" format="ixt:numdotdecimal" name="imux:BusinessCombinationSharesOwnedPriorToTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzU0ODI_485e5cda-0c93-4256-b699-f533bab1d2e7">1,059,269</ix:nonFraction> shares (plus <ix:nonFraction unitRef="shares" contextRef="i2d8389cccd92494f9385f182bf002a92_I20190412" decimals="INF" format="ixt:numdotdecimal" name="imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzU0OTg_672dc242-0a91-4551-a16f-701a98ef4b50">127,500</ix:nonFraction> restricted stock units (&#8220;RSUs&#8221;) all of which have been issued to date to former Vital officers) of the common stock of the Company or approximately <ix:nonFraction unitRef="number" contextRef="i025ac79fc8a04af682b83198235a9390_I20190412" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzU2NDk_f6561678-918d-4341-954a-f97cd2244302">11.75</ix:nonFraction>%. The issuance of shares of Vital&#8217;s common stock in the Transaction was registered with the Securities and Exchange Commission (&#8220;SEC&#8221;) on a Registration Statement on Form S-4 (Registration No. 333-229510).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Transaction, Immunic AG issued, in a private placement transaction (the &#8220;Financing&#8221;), an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6af0ec8f1a5c4c69afa77ae4992a4b27_D20190411-20190411" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzU5OTk_7c0fa65c-07b6-459f-8ffe-c0fe1005b7e3">2,197,742</ix:nonFraction> ordinary shares to certain of its shareholders for aggregate consideration of &#8364;<ix:nonFraction unitRef="eur" contextRef="i6af0ec8f1a5c4c69afa77ae4992a4b27_D20190411-20190411" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzYwODA_3618f571-d05a-42ae-a717-5591b5ac2ca7">26.7</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="usd" contextRef="i6af0ec8f1a5c4c69afa77ae4992a4b27_D20190411-20190411" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzYwOTg_e37b83ff-df68-413f-8cdf-c31beabc646f">29.9</ix:nonFraction> million), pursuant to the terms of the Investment and Subscription Agreement, dated as of January 6, 2019, between Immunic and the shareholders and investors party thereto (the &#8220;Subscription Agreement&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transaction has been accounted for as a reverse acquisition under the acquisition method of accounting. Because Immunic AG&#8217;s pre-Transaction owners held an <ix:nonFraction unitRef="number" contextRef="i72933fde204541c88561a57e1bfee92c_I20190412" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzY0NTg_35680399-1b17-4141-83ba-0eeceee55f85">88.25</ix:nonFraction>% economic and voting interest in the combined company immediately following the closing of the Transaction, Immunic AG is considered to be the acquirer of Vital for accounting purposes. Additionally, Immunic AG is considered to be the predecessor for reporting purposes and the financial results of Immunic AG are reported in the historical comparable periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2019, immediately following the closing of the Transaction, the Company effected a 40-for-1 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;). Accordingly, all references to share and per share amounts in the accompanying audited consolidated financial statements and notes have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. No fractional shares were issued in connection with the Reverse Stock Split. Unless otherwise noted, all references to common stock share and per share amounts have also been adjusted to reflect the exchange ratio of <ix:nonFraction unitRef="number" contextRef="i9ea2ecf153a24b4f9905b7b614e7adf6_I20190411" decimals="INF" name="imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzc0NTg_d11dfdc6-f9a7-4bc6-b4d5-ec64e5f8d749">17.17</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Research GmbH (which both began operations in 2016), Immunic Australia Pty Ltd. (which began operations in 2018) and Vital Therapies (Beijing) Company Limited (&#8220;VTL China&#8221;), acquired through the Transaction (which began operations in 2005). VTL China was sold in September 2019 in connection with the sale of certain of Vital's clinical development-related intellectual property rights (the "ELAD Assets"). All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. Certain prior period amounts have been reclassified to conform to the current basis of presentation.</span></div></ix:continuation><div id="i0d8d624238c9468ba14749fb49b7ca69_139"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDk4_62fdd44e-136c-473a-a3db-b1bad4b955f9" continuedAt="i0f35ebefc8b043e1afa063744a6d7a89" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i0f35ebefc8b043e1afa063744a6d7a89" continuedAt="ib0bf594eb6ac485198f52f5546380568"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDk3_1f981e37-c8be-4ebb-9959-af8642b367c4" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, clinical trial expenses, share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDkz_bcc313a0-e3e4-402f-9e44-cf6aa5e1fbe4" continuedAt="i850c9d93e02f464a8cc0bc688808d79f" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. During the twelve months ended December&#160;31, 2020 and 2019, Immunic AG and Immunic Research GmbH&#8217;s operations were located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib0bf594eb6ac485198f52f5546380568" continuedAt="i88d65afefb4a47458ebaf9399fade6b8"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i850c9d93e02f464a8cc0bc688808d79f">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income. The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</ix:continuation></span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDY3_ce9e5ac2-f3fb-4af7-9586-de9e91828342" continuedAt="i06adf4946c7e4fea989fc152dc09ba77" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:durwordsen" name="imux:CashEquivalentsInvestmentsMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIyODE_1647820e-6637-4781-91a8-5af03278be97">three months</ix:nonNumeric> or less to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i06adf4946c7e4fea989fc152dc09ba77">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.</ix:continuation>  </span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDcy_e94b52cd-911b-4378-968f-1fd4c32741b6" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDk1_b0d071b4-486f-4efa-adec-24aab148c0e5" continuedAt="i829ef45475f247c1bf2402d98e64d99f" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i829ef45475f247c1bf2402d98e64d99f">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from <ix:nonNumeric contextRef="idee3e91a49e343c1a30694c684b021f4_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ1MDg_8cf3c298-9e1c-4824-82de-b811012e5690">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="i7c360cf3166a497fb3d4cf65ac71195d_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ1MTQ_55781c58-9487-4ced-8cd1-7f5b3a00b022">thirteen years</ix:nonNumeric>.</ix:continuation> Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ1NjA_904637a6-8cd4-4e3a-be8f-8f67cc9a85e0">39,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ1Njc_d451bf94-989e-42a4-b351-1d76b843e30a">50,000</ix:nonFraction> for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNTA1_6a33e798-cbb5-4356-85ea-c13f9842a0a5" continuedAt="icc2dcf3d31b1475e878a0aed271d0c68" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icc2dcf3d31b1475e878a0aed271d0c68">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ5NjE_7f5ce372-9daf-4642-98af-0fedd151d0e6"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ5NjE_ab78d2a8-0c3d-442b-9a22-e5cc92109b85">no</ix:nonFraction></ix:nonFraction> impairment losses during the years ended December&#160;31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDcz_669436bb-f971-49b4-b498-2bd4c4878e28" continuedAt="iaeb2cc50f94c4af8b13b24b7903bca68" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i88d65afefb4a47458ebaf9399fade6b8" continuedAt="i8cd73d9462224c2a960c840878244f6b"><ix:continuation id="iaeb2cc50f94c4af8b13b24b7903bca68" continuedAt="i0ab7dde2ff1941daa6802c0f5295cefe"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0ab7dde2ff1941daa6802c0f5295cefe">The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform a quantitative test that compares the fair value to its carrying value to determine the amount of any impairment. Impairment testing for goodwill is done at the reporting unit level. The Company has determined that it operates in a single operating segment and has a single reporting unit.</ix:continuation> The Company has determined there was <ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzcwNDQ_54ec11b0-b4fb-4772-9fc0-ad3623eaa2b3">no</ix:nonFraction> goodwill impairment as of December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDc5_4273b38b-94c3-45f9-b38e-3ad79abfcbd8" escape="true"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNTAx_47fde00a-86dc-4e76-b64c-d7e3b229b796" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, IMU-838, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on IMU-838, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  IMU-935 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in September 2019. IMU-856 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in August 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNTA3_67992f57-c68a-4bd0-b579-6945c32a31e5" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for diseases such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no more research and development reimbursements expected under this agreement.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNTA4_9bcba400-35db-4a85-939e-8522347aae4e" continuedAt="ie562720a69024f99809d05de65b10fd3" escape="true">General and Administrative Expenses</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8cd73d9462224c2a960c840878244f6b" continuedAt="i42489ef1f04d4b8790b7aa6689ef8d13"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie562720a69024f99809d05de65b10fd3">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</ix:continuation></span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDg2_ed881c74-e4ac-4af5-9e95-2a9a091c9d0d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDky_54830713-8033-4b47-94b5-7c143f4f664d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than <ix:nonNumeric contextRef="i74aac56ff24b4f3ca37eebd86a9d4423_I20201231" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzEwOTk1MTE2NzAyOTE_0abb61ab-0a9d-4383-a1ef-7a0c6528dce1">12</ix:nonNumeric> months and up to <ix:nonNumeric contextRef="iedcfc4dd48ac4131bacce1f46671b617_I20201231" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzEwOTk1MTE2NzAzMDU_e2885a39-d8a4-449e-a3ec-3033813e5e0b">60</ix:nonNumeric> months. The short-term leases are deemed immaterial and have not been included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="imux:LesseeOperatingLeasesNumberOfExistingLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzEwOTk1MTE2NzA0NzA_b2e1734a-324e-494a-8160-53ac843c17f8">two</ix:nonFraction> existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's <ix:nonFraction unitRef="lease" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="imux:LesseeOperatingLeasesNumberOfExistingLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzEwOTk1MTE2NzA3MzA_b2e1734a-324e-494a-8160-53ac843c17f8">two</ix:nonFraction> leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDgw_0bb1417c-6071-4513-b958-96a2e650c91a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDgx_ec55027b-c94a-4644-b271-58c8705cf4c6" continuedAt="ia0beac6125274b8f82aaa21e4344524c" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i42489ef1f04d4b8790b7aa6689ef8d13"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia0beac6125274b8f82aaa21e4344524c" continuedAt="i93d1ce8a7a8c44b0b066f039e61506e6">differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2020, and December&#160;31, 2019, the Company maintained a full valuation allowance against the balance of deferred tax assets.</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i93d1ce8a7a8c44b0b066f039e61506e6">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</ix:continuation>  </span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDY1_dca4f7c5-6cfb-4dfa-a0f2-e3bb58b59617" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDY2_c77e4c17-fb85-4375-a71d-48683373ffcb" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie37f05a546ec4332b17b507cececa315_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90YWJsZToyYzEzMzliM2FiNmE0YTg0YWU2M2FhMmRlNWE2YWQ4OC90YWJsZXJhbmdlOjJjMTMzOWIzYWI2YTRhODRhZTYzYWEyZGU1YTZhZDg4XzItMS0xLTEtMA_8ffa09ba-9dfc-4089-a7ed-49ac49516eee">1,117,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a4868f4553f43c3bcb215ef4452c84d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90YWJsZToyYzEzMzliM2FiNmE0YTg0YWU2M2FhMmRlNWE2YWQ4OC90YWJsZXJhbmdlOjJjMTMzOWIzYWI2YTRhODRhZTYzYWEyZGU1YTZhZDg4XzItMy0xLTEtMA_9cba8668-8f55-412b-b02b-7c4d5e3ab02d">471,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDg3_735e98f6-4d89-43fe-8ac7-34835f3f8a59" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU 2017-04, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." This guidance eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit&#8217;s fair value. The Company adopted this ASU, as required, in the quarter ended March 31, 2020 on a prospective basis. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement - Disclosure Framework&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-13.") ASU 2018-13 modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty, and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments must be applied retrospectively to all periods presented upon their effective date. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-18"). ASU 2018-18, clarifies that elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The Company does not have any agreements that meet the definition of a collaboration arrangement at this time.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 14</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzM4MTM_da8fcd24-4e60-4e3a-adbe-fd0c0fc06b03" continuedAt="id936bf4031c24bbaa9393c14018ed0bf" escape="true">Accounting for the Transaction </ix:nonNumeric></span></div><ix:continuation id="id936bf4031c24bbaa9393c14018ed0bf" continuedAt="ia3c85f3c021c4ef894bd3864ff0a63a1"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the exchange ratio of <ix:nonFraction unitRef="number" contextRef="i9ea2ecf153a24b4f9905b7b614e7adf6_I20190411" decimals="INF" name="imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3Xzcx_f724044a-9e68-4ab2-b893-21b5ef4220e0">17.17</ix:nonFraction> shares of Vital common stock for each share of Immunic AG, immediately following the Transaction, former Vital stockholders owned approximately <ix:nonFraction unitRef="number" contextRef="i025ac79fc8a04af682b83198235a9390_I20190412" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzIxOA_e2780f79-9b2e-47d5-abdf-16d1bb1caf16">11.75</ix:nonFraction>% of the capital stock of the combined organization on a fully diluted basis, and former Immunic AG stockholders owned approximately <ix:nonFraction unitRef="number" contextRef="i72933fde204541c88561a57e1bfee92c_I20190412" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzM1Mg_ae65d6e0-2fe1-484a-bfd0-ab3fb1182af5">88.25</ix:nonFraction>% of the capital stock of the combined organization on a fully diluted basis. At the closing of the Transaction, all shares of Immunic AG common stock then outstanding were exchanged for Vital common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the terms of the Agreement, the Company, for accounting purposes, assumed all outstanding stock options to purchase <ix:nonFraction unitRef="shares" contextRef="i143eb8d6d87d45839179cc8aefbf2bd9_D20190412-20190412" decimals="INF" format="ixt:numdotdecimal" name="imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzcwMQ_06f73416-41ae-4e16-b212-5132d0013f32">16,987</ix:nonFraction> shares of Vital common stock and <ix:nonFraction unitRef="shares" contextRef="iaa7215f1ac4e44d195ec898605132171_D20190412-20190412" decimals="INF" format="ixt:numdotdecimal" name="imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzI3NDg3NzkwNzMyNjU_b34a5a34-6b81-4105-9e1b-0727f83515f7">127,500</ix:nonFraction> RSUs at the closing of the Transaction, after giving effect to the Reverse Stock Split. Since the exercise prices of the outstanding options to purchase common stock were less than the trading price on the day of the consummation of the Transaction, they were not included in the formula below in calculating the purchase price.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tangible and intangible assets and liabilities of Vital acquired in the Transaction are recorded based on their fair values as of the completion of the Transaction, with the excess of the purchase consideration over the fair value of net assets assigned to and recorded as goodwill. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzM4MTQ_312f9693-26ed-4494-9797-e34c00e7c6bc" continuedAt="ief4611a84c3a47d8ba76fc1bbb014907" escape="true">The following summarizes the purchase price paid in the Transaction (amounts in thousands except share and per share amounts):</ix:nonNumeric></span></div><ix:continuation id="ief4611a84c3a47d8ba76fc1bbb014907"><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares owned by Vital stockholders (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzAtMS0xLTEtMA_e53392b7-4661-4fb7-9b1e-54240123bbb7">1,059,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d8389cccd92494f9385f182bf002a92_I20190412" decimals="INF" format="ixt:numdotdecimal" name="imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzEtMS0xLTEtMA_f43a82a7-325a-4a3f-a859-203458ba1801">127,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fully-diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412" decimals="INF" format="ixt:numdotdecimal" name="imux:BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzItMS0xLTEtMA_35ca1288-ef0d-4225-8bd0-d320a9f973f1">1,186,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Vital common stock (3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzMtMS0xLTEtMA_b378313b-6f8a-4024-a520-8349573756bd">33.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b85b15cda004eb0acf9c15243874440_D20190412-20190412" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzQtMS0xLTEtMA_e7c36adf-772a-4416-8f9a-76f9e4279955">39,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The number of shares of <ix:nonFraction unitRef="shares" contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzE1MTI_91c750fc-da56-49b1-979a-5e72ce0ba746">1,059,269</ix:nonFraction> represents the historical <ix:nonFraction unitRef="shares" contextRef="i25a3ae5995884982bf7fb0499c7d2af8_I20190411" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzE1NDE_0cca16c7-f52a-49aa-962e-7f43eb7cc9ea">42,369,694</ix:nonFraction> shares of Vital common stock outstanding immediately prior to the closing of the Transaction, adjusted for the Reverse Stock Split.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The number of RSUs of <ix:nonFraction unitRef="shares" contextRef="i291065e6920c4b3690091eb4f57fd587_D20190412-20190412" decimals="INF" format="ixt:numdotdecimal" name="imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzE2OTg_911f7209-4a01-4794-a3e4-41f50addd8a0">127,500</ix:nonFraction> represents the historical <ix:nonFraction unitRef="shares" contextRef="id235fedbb81d4e0c9ede860eafed7c3d_I20190411" decimals="INF" format="ixt:numdotdecimal" name="imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzE3Mjc_87b85f88-c37e-4743-b7fd-62952dace76f">5,100,000</ix:nonFraction> Vital RSUs of which all have been issued to date to Vital former officers in 2019.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on the last reported sale price of Vital common stock on the Nasdaq Global Market on April 12, 2019, the closing of the Transaction, adjusted for the Reverse Stock Split.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzEtMS0xLTEtMA_d7491ee3-a880-4dda-851f-b87c40ae8c7f">8,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzItMS0xLTEtMA_c9cecf58-c44d-4ba5-8cc6-d940ec1dea67">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and working cell banks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" format="ixt:numdotdecimal" name="imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzMtMS0xLTEtMA_fbbf42f0-e1c4-42ea-bb50-3996f06c519a">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzQtMS0xLTEtMA_70d395f2-0483-4383-b126-e710e1b20657">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" name="imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzUtMS0xLTEtMA_a3518dfc-ce76-4ebf-a4bf-966fd51e5c68">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (&#8220;IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzYtMS0xLTEtMA_7942d1e5-52a7-484a-8a26-78a1563faae6">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" format="ixt:numdotdecimal" name="imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzctMS0xLTEtMA_f094bdcc-7273-4d33-bce6-1cdfdc793c77">4,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzgtMS0xLTEtMA_bdfb6cca-403c-46d1-997d-7cb9dc08498b">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzktMS0xLTEtMA_b5d4e105-5db5-42fc-afa1-36ec15ceac13">39,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia3c85f3c021c4ef894bd3864ff0a63a1" continuedAt="i9fc8fde710a845b89bc8a386316d04fa">The fair value of IPR&amp;D was estimated based on the sales price of the ELAD Assets (including the present value of the promissory note issued by the ELAD buyer) less the fair value of the ELAD Assets. See Note 4 below for a description of the ELAD Assets transaction.</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9fc8fde710a845b89bc8a386316d04fa">The goodwill of $<ix:nonFraction unitRef="usd" contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzIzNDE_febd44c7-aa1b-46aa-a510-96186d37d05e">32.97</ix:nonFraction> million is not tax deductible. Goodwill is mainly attributable to the enhanced value of the combined company, as reflected in the increase in market value of the Vital common shares following the announcement of the Transaction with Immunic AG. The Company incurred costs directly related to the Transaction of approximately $<ix:nonFraction unitRef="usd" contextRef="i19a1cf43d9744216bb5785e547d4a706_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzI2NjE_4d48e3d3-0f5b-43f6-a2bd-67bd9dc0a641">10.0</ix:nonFraction> million for the year ended December 31, 2019, which were expensed as incurred ($<ix:nonFraction unitRef="usd" contextRef="ic61d4640357d4308b1168153fff8bcd2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="imux:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzI3NDg3NzkwNzQ0ODU_8a8f4ae5-3a63-416e-80bc-b1da4c7f28fe">7.5</ix:nonFraction>&#160;million of such costs were non-cash charges related to the 4SC settlement share issuances and the Immunic exit bonus shares as described below in Note 6 and Note 9, respectively).</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzIwMDM_fedc6122-8c3d-4e60-8ceb-b1c91fe394a5" continuedAt="i52533f0d426f40fa959ca76041cca248" escape="true">ELAD Sales Agreement</ix:nonNumeric></span></div><ix:continuation id="i52533f0d426f40fa959ca76041cca248"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Vital entered into an asset purchase agreement (the &#8220;Vital APA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to sell certain of Vital&#8217;s clinical development-related assets and related intellectual property rights to RH Cell Therapeutics (the &#8220;Purchaser&#8221;) for approximately $<ix:nonFraction unitRef="usd" contextRef="ib1424157daa84861a0f78d13c01de311_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzI3Mw_73278212-b4d8-44d4-9aec-df983d68d595">2.5</ix:nonFraction> million. The assets sold were clinical development equipment, supplies, intellectual property and working cell banks in addition to the equity interest in VTL China (collectively the &#8220;ELAD Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Purchaser deposited $<ix:nonFraction unitRef="usd" contextRef="i16a9132f0eeb46a4b87b6f6be10c44a4_D20190301-20190331" decimals="-5" format="ixt:numdotdecimal" name="imux:DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzQ5MQ_91f5de94-9c16-47c9-b2ae-877a7c009d22">1.1</ix:nonFraction> million into escrow and paid the Company $<ix:nonFraction unitRef="usd" contextRef="i16a9132f0eeb46a4b87b6f6be10c44a4_D20190301-20190331" decimals="-3" format="ixt:numdotdecimal" name="imux:DisposalGroupIncludingDiscontinuedOperationCashConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzUyNw_a884450c-9e1e-44cb-ba48-2ff2be99fe35">50,000</ix:nonFraction> prior to the Transaction. The Vital APA was amended and restated on May 28, 2019, to allow for two closings. In the first closing which occurred on May 28, 2019, the $<ix:nonFraction unitRef="usd" contextRef="ib628ae02a7aa42c28a8f9aec169f0c34_D20190528-20190528" decimals="-5" format="ixt:numdotdecimal" name="imux:DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzY5Ng_613c851a-e0d2-41ec-87cf-8352fcbcbe52">1.1</ix:nonFraction> million was released from escrow to the Company. In addition, the Purchaser executed a promissory note with a face amount of $<ix:nonFraction unitRef="usd" contextRef="iaeb39dad72584b63ab750036af27e280_I20190528" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivableWithImputedInterestFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzgxNg_6a18b95d-9c4c-4640-8fc7-3eb3b59eb5e2">1.325</ix:nonFraction> million, which accrues simple interest of <ix:nonFraction unitRef="number" contextRef="i3f08f68c8dad42d6bad9ef5236f6e645_D20190528-20190528" decimals="2" name="us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5Xzg1Mw_199614cb-d7de-4de8-9c4f-a20b5b44b237">10</ix:nonFraction>% per annum. The fair value of the promissory note was estimated to be $<ix:nonFraction unitRef="usd" contextRef="ifd46d22b09cb441787f0d5370dea6303_I20190528" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzkyNQ_c88cc33d-b4b3-4e05-8ede-f80f035e2910">920,000</ix:nonFraction>. Therefore, the fair value of the ELAD Assets was based on the cash in escrow, the $<ix:nonFraction unitRef="usd" contextRef="ib70b7b4cf5694c7a8586dce401819182_D20190528-20190528" decimals="-3" format="ixt:numdotdecimal" name="imux:DisposalGroupIncludingDiscontinuedOperationCashConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzI3NDg3NzkwNzE1OTU_c8c76553-7e7c-4cac-8d18-9c5cdf9cd31d">50,000</ix:nonFraction> deposit and the fair value of the promissory note. </span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzIwMDQ_c50065a2-37da-4b9c-8bf0-58f37b383d49" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the ELAD Assets was included in the purchase accounting allocation as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:87.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.648%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6683c08bed64561b5b0505930b9950c_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90YWJsZTo3ZWQ0MTRkMDRhOTk0ZWQ0YWI5ZTZhOGVlM2U4MDE1My90YWJsZXJhbmdlOjdlZDQxNGQwNGE5OTRlZDRhYjllNmE4ZWUzZTgwMTUzXzAtMS0xLTEtMA_f4e23951-5891-4ee8-8ecc-52a9761e0e58">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and working cell banks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b5901cce52944f6baa8aaf2af6e02ce_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90YWJsZTo3ZWQ0MTRkMDRhOTk0ZWQ0YWI5ZTZhOGVlM2U4MDE1My90YWJsZXJhbmdlOjdlZDQxNGQwNGE5OTRlZDRhYjllNmE4ZWUzZTgwMTUzXzEtMS0xLTEtMA_28a04b38-e272-4d1a-82fc-a5ded5c703e6">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In process research &amp; development (&#8220;IPR&amp;D&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780e082104054e5f93c97de39af38fdf_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90YWJsZTo3ZWQ0MTRkMDRhOTk0ZWQ0YWI5ZTZhOGVlM2U4MDE1My90YWJsZXJhbmdlOjdlZDQxNGQwNGE5OTRlZDRhYjllNmE4ZWUzZTgwMTUzXzItMS0xLTEtMA_8a1ad30f-5208-4411-b801-ef7c1539a7d7">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5086e5f37b694c38bf5cab8772addc83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90YWJsZTo3ZWQ0MTRkMDRhOTk0ZWQ0YWI5ZTZhOGVlM2U4MDE1My90YWJsZXJhbmdlOjdlZDQxNGQwNGE5OTRlZDRhYjllNmE4ZWUzZTgwMTUzXzMtMS0xLTEtMA_4cc7145c-163d-4f25-b93d-19d4de0dc48e">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first closing, the Company transferred title of the clinical development equipment and supplies to the Purchaser. Also, the fair value of the promissory note was recorded as a note receivable and the fair value of the IPR&amp;D and working cell banks assets were removed from the Company&#8217;s audited consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promissory note was paid in full upon the second closing on September 4, 2019, at which time the Company transferred title to the intellectual property and working cell banks as well as its equity interest in VTL China. The difference of $<ix:nonFraction unitRef="usd" contextRef="ib203b4c845154f8f8ad1c43f6b7e19c2_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzE3NjI_98433325-4497-4bce-a5eb-06227a6dea49">405,000</ix:nonFraction> between the $<ix:nonFraction unitRef="usd" contextRef="iaeb39dad72584b63ab750036af27e280_I20190528" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivableWithImputedInterestFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzE4MjI_6a18b95d-9c4c-4640-8fc7-3eb3b59eb5e2">1.325</ix:nonFraction> million face value of the promissory note collected and the fair value of $<ix:nonFraction unitRef="usd" contextRef="ifd46d22b09cb441787f0d5370dea6303_I20190528" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzE4NDg_c88cc33d-b4b3-4e05-8ede-f80f035e2910">920,000</ix:nonFraction> was recorded as other income in the accompanying consolidated statements of operations for the year ended December 31, 2019.  The Purchaser is not a related party.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 16</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90ZXh0cmVnaW9uOjYwZjg4OGI5ZjM3MjQ5YzE4ODQzYTNiYTA2ZTA2MzM3XzQ5OA_1114635b-2fdc-4143-8c6c-67f712d0ef37" continuedAt="idc12b0d63862453498e7e4d6d4cc4744" escape="true">Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="idc12b0d63862453498e7e4d6d4cc4744" continuedAt="i1defd7a6a83e4c98811e49099b8cdd9f"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90ZXh0cmVnaW9uOjYwZjg4OGI5ZjM3MjQ5YzE4ODQzYTNiYTA2ZTA2MzM3XzUwNw_f40e4f22-32ce-40bf-b51a-13c01eef1355" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid Expense and Other Current Assets consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="imux:PrepaidClinicalAndRelatedCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzItMS0xLTEtMA_d3976518-dcee-4867-8fd7-726787220206">3,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="imux:PrepaidClinicalAndRelatedCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzItMy0xLTEtMA_5f6e01e7-1250-4542-a40f-4f1ee30154e1">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzMtMS0xLTEtMA_ac4aa80f-ebe2-4e85-a78b-55f9581b62cb">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzMtMy0xLTEtMA_ee460591-3c52-493c-8165-32ed8a5ab3c2">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="imux:ResearchAndDevelopmentTaxIncentiveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzQtMS0xLTEtMA_1ca972a4-aa1b-4753-a1fd-baea43a543ec">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="imux:ResearchAndDevelopmentTaxIncentiveCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzQtMy0xLTEtMA_2976115d-97f1-4f43-bdda-b14d1603e98e">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzUtMS0xLTEtMA_00153ec2-c78b-4ccc-9f28-0bc5666e4eba">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzUtMy0xLTEtMA_83289fb6-5e55-47a6-9b3f-4eba2bc28e06">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzYtMS0xLTEtMA_377c16df-0322-4c4e-ad2d-7d285815ad20">6,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzYtMy0xLTEtMA_f729bdb2-f94c-4b61-b1d6-39db6eba1764">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90ZXh0cmVnaW9uOjYwZjg4OGI5ZjM3MjQ5YzE4ODQzYTNiYTA2ZTA2MzM3XzUwOA_e318a316-e877-461a-973a-2502ff696ccf" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="imux:ClinicalCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzItMS0xLTEtMA_6e753a80-2dc1-412c-bee8-c4f437ced3d0">3,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="imux:ClinicalCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzItMy0xLTEtMA_dd00d4e6-b462-4173-a3b2-5f4eccec0477">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="imux:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzMtMS0xLTEtMA_59307645-cbd7-4603-8166-bf5318fd665b">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="imux:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzMtMy0xLTEtMA_6e4baed8-98db-4972-b725-de419d4f1c5e">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzQtMS0xLTEtMA_5e910613-3264-45c1-9e6b-ce4a0866026d">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzQtMy0xLTEtMA_ac07b33d-d400-42ef-9b41-984adf6f557b">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzUtMS0xLTEtMA_8c655f5d-6832-4e1d-8bfe-152ad950c991">3,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzUtMy0xLTEtMA_194e8e6c-e1da-45aa-a122-623273724d56">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="imux:AccruedClinicalCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzItMS0xLTEtMA_a50fb894-ba8e-4402-b090-371b39f1c55b">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="imux:AccruedClinicalCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzItMy0xLTEtMA_b384c841-b9f3-45b2-88d6-ced989eed2bd">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="imux:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzMtMS0xLTEtMA_595252b4-7ec8-42d9-a844-9533f7842a0e">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="imux:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzMtMy0xLTEtMA_c258deba-eb4c-4c7f-b17e-ce30350fabd8">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="imux:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzQtMS0xLTEtMTEwMw_6ec303c3-e904-46bb-ac62-fb144166245c">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:zerodash" name="imux:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzQtMy0xLTEtMTEwMw_760f1cc2-c231-4c5c-8fdf-47e69c96582c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzQtMS0xLTEtMA_5fb83e0c-4685-4261-9485-b5049061fc35">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzQtMy0xLTEtMA_b3b7703c-a510-41a5-87fe-5583edf19573">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzUtMS0xLTEtMA_bb47997d-5658-4ce2-b991-975057692eb6">4,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzUtMy0xLTEtMA_cfec01da-c1ca-4abf-a6e1-215d752b2746">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90ZXh0cmVnaW9uOjYwZjg4OGI5ZjM3MjQ5YzE4ODQzYTNiYTA2ZTA2MzM3XzUwOQ_98f72048-4137-43da-bc6b-dd544f0bc596" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist  of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzItMS0xLTEtMA_67473a33-bb39-4fde-aa03-6ac0ce7ee307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzItMy0xLTEtMA_0ed316e4-dbc3-4971-95ac-e44d28d29753">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzMtMS0xLTEtMA_f7665167-1aa5-4a78-ad6f-0a1517a4b46a">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzMtMy0xLTEtMA_bf8d1794-ddd4-4bf6-b4a8-3209c3a53e13">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzQtMS0xLTEtMA_3d07ec29-0ccd-4e58-8931-741ad32d27f6">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzQtMy0xLTEtMA_b388e7a1-33c1-4cc8-acf0-d548892fa18c">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1defd7a6a83e4c98811e49099b8cdd9f">Deferred income represents cash reimbursement on invoices received from third party billings, prior to the related services being performed.</ix:continuation>  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 17</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzQxMDk_87fe52b5-05a1-4b17-92fd-73fd7803c8a8" continuedAt="ia91e3f816dc04a9bb5449b1ddd45987b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ia91e3f816dc04a9bb5449b1ddd45987b" continuedAt="i84b37cc8dcc1452da5c8c10c66af8443"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and June 30, 2025 for the Gr&#228;felfing, Germany office.  The Company formerly leased office space in Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE2NDkyNjc0NDgzOTA_02686f89-0de8-4c0b-a81a-71f470466ead">five</span> year lease for its new facility in Gr&#228;felfing, Germany. Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease.  There were net additions to right of use assets of $<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE2NDkyNjc0NDg4NjE_873f4cd0-a656-438c-a832-8c0cb7f8cafc">427,000</ix:nonFraction> as a result of signing the Gr&#228;felfing lease and shortening the term of the Martinsried lease during the year ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="imux:OperatingAndVariableLeasesCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE4OTM_3622af73-fd27-4db5-8450-d65fe53982fb">354,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="imux:OperatingAndVariableLeasesCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE5MDA_5b4851fc-a649-4fed-9670-0f1f8a0da9a8">135,000</ix:nonFraction> for the years ended December&#160;31, 2020 and 2019, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzQxMDY_41b76e1d-6c1e-451c-b4b0-d9209e668edc" continuedAt="i2143dc04e00d479c8a4fce2f93359146" escape="true">Maturities of the operating lease obligation are as follows as of December&#160;31, 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><ix:continuation id="i2143dc04e00d479c8a4fce2f93359146"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzAtMi0xLTEtMA_9f702d87-4f26-49bc-898c-1f188b3cb8a3">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzEtMi0xLTEtMA_01bcb31e-d129-4dd9-aaea-122ec57b9cbc">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzItMi0xLTEtMA_4adc301d-034b-491d-bbee-a4a7a307551c">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzMtMi0xLTEtMA_b7bb4acd-fecf-45eb-8c45-bd92e085dc7a">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzQtMi0xLTEtMA_2e6a70f0-34b2-4a4b-9c90-104d53dcba3e">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzUtMi0xLTEtMA_21dcb49b-712c-4fdd-af95-ca6c9693f6e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzYtMi0xLTEtMA_e8013c16-5bf0-43ef-81ae-17b75bffd7a1">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzctMi0xLTEtMA_b7bf23ab-2870-4899-a55d-30395effa06c">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzgtMi0xLTEtMA_31c69a73-35e0-437d-9d57-766fc27427e0">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has non-cancelable contractual obligations under certain agreements related to its development programs IMU-838, IMU-935 and IMU-856 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzIzOTQ_c299ac5c-0677-4f9a-a21d-0fa650b2da3b">1.2</ix:nonFraction> million, all of which is expected to be paid in 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016 the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC AG whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to <ix:nonFraction unitRef="number" contextRef="i67800579096d4497ad722732c4249a21_D20160501-20160531" decimals="3" name="imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzMwNDE_6c71296c-ad56-4313-b7e7-b219f5fa8315">4.4</ix:nonFraction>% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing <ix:nonFraction unitRef="shares" contextRef="i79f881980aec452681faf1a0f7dd4395_I20190412" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzMyNTk_06e7dba4-041c-491a-ac89-60fe16a3f467">120,070</ix:nonFraction> shares of the Company&#8217;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $<ix:nonFraction unitRef="usd" contextRef="i79f881980aec452681faf1a0f7dd4395_I20190412" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzM0MDA_4a8004ae-607a-492e-84f8-7ef9bc2c6ae5">1.5</ix:nonFraction> million of expense was recorded as a result of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i84b37cc8dcc1452da5c8c10c66af8443"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the issuance of these shares on April 12, 2019. No royalties are payable as of December&#160;31, 2020 or 2019 as sales have not commenced.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div></ix:continuation><div id="i0d8d624238c9468ba14749fb49b7ca69_157"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90ZXh0cmVnaW9uOjVhZTcyYzczMGI5MTRkMDI4ZTViNjliMGMzNTc2ZTI4XzExMDA_342978c9-6a0b-4207-a0be-dc19ab2e7ccb" continuedAt="id4cc91b7dc184c318d2fb26f02e54a7b" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="id4cc91b7dc184c318d2fb26f02e54a7b" continuedAt="i3bc4a248ada240189066d0af71163dd7"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90ZXh0cmVnaW9uOjVhZTcyYzczMGI5MTRkMDI4ZTViNjliMGMzNTc2ZTI4XzEwOTY_d1fa381d-09b4-4803-a2c1-088b10930867" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie337d38b905741b0be8509a5988751e0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzQtMS0xLTEtMTkxNw_686c2eb3-3835-4e92-aa1a-4409c69bc66b">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f631b15ff24c389fa32b2b1b7ee96e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzQtMy0xLTEtMTkxNw_ae3a7ecd-3235-4f91-b3fe-d04ab3c503ad">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6873df0f6d9c43829d62758343daf989_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzQtNS0xLTEtMTkxNw_0c02e81e-9d89-4ec7-8754-152806595bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8dd00728074e99b84c1dca45194253_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzQtNy0xLTEtMTkxNw_a0c536c5-1b07-4df5-91ba-ec8e42b4bbfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a0a829483c0417eba5fa667a551ed28_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzgtMS0xLTEtMTExNQ_eecf93fe-ec29-4c8d-8318-41f03840c521">4,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e15b766485e4b65beeb7634f309978f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzgtMy0xLTEtMTExNQ_c8858f99-e294-451a-b89b-67dcc201f42e">4,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b12db73e4fa4be7ae419856ea963c2c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzgtNS0xLTEtMTExNQ_bcb77002-6854-48e1-bea9-f8756a7867de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i222effbc88ad4922acfd743d8d31835e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzgtNy0xLTEtMTExNQ_5235382f-c6a1-4953-b32c-2ac2e4002023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3bc4a248ada240189066d0af71163dd7">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</ix:continuation>  </span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzQxNDA_3db58fc9-2877-4f78-b153-d664131ebd0e" continuedAt="i3d43b2622a0946589f24df20635fa116" escape="true">Common Stock and Preferred Stock (Converted into Common Stock)</ix:nonNumeric></span></div><ix:continuation id="i3d43b2622a0946589f24df20635fa116" continuedAt="i88498dd06053426fac0300941168d5b5"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, Vital filed a shelf registration statement on Form S-3, (the &#8220;2018 Shelf Registration Statement&#8221;), which became effective in June 2018. The 2018 Shelf Registration Statement permits the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="ie581a8ba756a444ba46878adb72aeb7f_I20180531" decimals="-5" format="ixt:numdotdecimal" name="imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2Mjg_2f45debf-eaba-480f-a196-248790c4ca93">200.0</ix:nonFraction>&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i88498dd06053426fac0300941168d5b5" continuedAt="i3f792cf52c564110a14b2f6744b818a4"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $<ix:nonFraction unitRef="shares" contextRef="ib42baf0370ea48d7a0e0cc425578b84c_I20201130" decimals="INF" format="ixt:numdotdecimal" name="imux:MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2NDQ_99a7e8df-ebd3-4481-adee-931752811cee">250.0</ix:nonFraction>&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i1c8556577d1b4e5f865b603839247770_I20190731" decimals="-5" format="ixt:numdotdecimal" name="imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2NjA_84fb6949-819d-4414-925d-3b5e8e226dfa">40.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("July 2019 ATM") with SVB Leerink LLC (&#8220;SVB Leerink&#8221;) as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The July 2019 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the July 2019 ATM or (ii) termination of the July 2019 ATM as otherwise permitted thereby. The July 2019 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="if19cb443fde445938a82a57f80350118_I20201231" decimals="-5" format="ixt:numdotdecimal" name="imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2NzU_e4dcac59-c2f8-4cb7-88e4-f02c7d9cbfb5">23.3</ix:nonFraction>&#160;million in capacity remains under the July 2019 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed another Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i21e80fc4dc65422fb46f2324ebab4469_I20201231" decimals="-5" format="ixt:numdotdecimal" name="imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2OTA_5458f762-b284-417f-b1c1-71df3c179455">50.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i21e80fc4dc65422fb46f2324ebab4469_I20201231" decimals="-5" format="ixt:numdotdecimal" name="imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg3MDU_ffe7c219-63a8-4a22-a198-872060e9c1ab">50.0</ix:nonFraction>&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has agreed to pay SVB Leerink a commission equal to <ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="3" name="imux:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzE4NTQ_3c2daa60-2373-40d2-a99e-817ecc8004a8">3.0</ix:nonFraction>% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzIwODU_5cf6d048-0ff1-4e0d-9b53-146ab45a88c5">11.3</ix:nonFraction>&#160;million pursuant to the July 2019 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzIxMjg_1f7abadc-4164-4dc2-8f67-e0eea60d40c1">733,728</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9121799d001479e948d946e83f048f8_I20201231" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzE2NDkyNjc0NTM0NDI_bbe72db1-961f-4877-8ad6-120156fdbecd">15.42</ix:nonFraction> per share. The net proceeds from the July 2019 ATM were  $<ix:nonFraction unitRef="usd" contextRef="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzE2NDkyNjc0NTM0NDc_fe249615-a7c6-4fce-aab5-69a485fcd8f8">11.0</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzIyODE_0003d5a5-5583-4067-b726-43c64ec54ebe">339,356</ix:nonFraction>. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzMzNjA_075306be-c9cb-4f34-86da-22a401a7704e">5.4</ix:nonFraction>&#160;million pursuant to the July 2019 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM0MDQ_c2b77475-63a7-428a-99db-3d4ac82738b2">630,907</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ieddd58f3d1014eb8926a60bb85a16000_I20191231" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM0NjI_0a92f482-c6e2-40ad-870c-ffd8a6b9df73">8.49</ix:nonFraction> per share. The net proceeds from the July 2019 ATM were  $<ix:nonFraction unitRef="usd" contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM1MTM_fdc5d2b3-6b8e-4c81-b1ac-fa32e9050632">4.9</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM1NjA_e161fa78-bae1-41b8-a4b4-7881f92698fb">161,000</ix:nonFraction> and estimated offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM1OTk_11b4c4b8-321e-4ff8-8fef-c8b75d61476b">305,000</ix:nonFraction>. As of December&#160;31, 2019, there was $<ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM2MjI_aff990be-9d5c-4e9f-bc6a-1bfb9c2926b4">34.6</ix:nonFraction> million available under the July 2019 ATM.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3f792cf52c564110a14b2f6744b818a4" continuedAt="i777842fd4ab8425cbdc7a5ded53c8bcc"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">April 2020 Registered Direct Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, the Company entered into an engagement letter with ROTH Capital Partners, LLC ("RCP") relating to the Company&#8217;s registered direct offering of common stock to select institutional investors. Pursuant to this agreement, the Company agreed to pay RCP a cash fee of <ix:nonFraction unitRef="number" contextRef="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423" decimals="INF" name="imux:EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQwMTA_70762fe7-900b-4e22-84d1-cf1828d17cac">6.5</ix:nonFraction>% of the gross proceeds from the offering raised from investors and to reimburse RCP for certain costs incurred in connection therewith.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 23, 2020, the Company and the investors entered into a securities purchase agreement relating to the issuance and sale of an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQzMDk_e7b062d1-2e4a-4b93-b38d-917fadb38771">1,764,706</ix:nonFraction> shares of common stock. The purchase price per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="iaed6b68efee3460089ffa2c5e40b8094_I20200423" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQzNzA_19c2fa0b-c532-48c1-8a08-90457f17d1dd">8.50</ix:nonFraction> for aggregate gross proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423" decimals="-5" format="ixt:numdotdecimal" name="imux:ProceedsFromIssuanceOfCommonStockGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQ0MzU_e2ac4771-6d51-4e30-b27f-06ee43a58ab3">15.0</ix:nonFraction>&#160;million.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to the Company from this offering, after deducting the Company&#8217;s offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQ1NjM_759cab3d-88f5-4a0f-adac-6d22488f71e0">13.9</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">June 2020 Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2020, the Company entered into a placement agency agreement with RCP and Ladenburg Thalmann &amp; Co. Inc. relating to the Company&#8217;s public offering of <ix:nonFraction unitRef="shares" contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQ3NzI_c0a1cbf7-e706-4e17-bb77-79be9e8ee197">2,175,000</ix:nonFraction> shares of common stock. Pursuant to this agreement, the Company agreed to pay the placement agents a cash fee of <ix:nonFraction unitRef="number" contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610" decimals="3" name="imux:PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQ4ODk_e82fd4bf-a90d-490e-b65a-8f4f80c2b5c4">6.5</ix:nonFraction>% of the gross proceeds from the offering raised from investors and to reimburse the placement agents for certain costs incurred in connection therewith.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, on June 10, 2020, the Company and certain institutional investors entered into securities purchase agreements relating to the issuance and sale of an aggregate of <ix:nonFraction unitRef="shares" contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzUyMjI_d45c8e3a-9de0-49cc-b8cb-bec526dd4ffe">2,175,000</ix:nonFraction> shares of the Company&#8217;s common stock. The purchase price per share in the Offering was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic7ade7fa5ecd45d28246214c1fb60452_I20200610" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzUzMTM_1de6a95b-e1e7-41e2-a41f-40d4d9d95b2a">11.40</ix:nonFraction> for aggregate gross proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610" decimals="-5" format="ixt:numdotdecimal" name="imux:ProceedsFromIssuanceOfCommonStockGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzUzNzg_aba46557-3586-4806-8cc1-cade98da69a2">25.0</ix:nonFraction>&#160;million. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The net proceeds to the Company from this offering, after deducting the Company&#8217;s offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU1MDU_23ad8ed2-6eec-4dd3-b22f-aa8b0143f1a9">23.0</ix:nonFraction>&#160;million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%;text-decoration:underline">August 2020 Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into an underwriting agreement with SVB Leerink LLC, as representative of the several underwriters in connection with the Company&#8217;s public offering of <ix:nonFraction unitRef="shares" contextRef="i61f483edcdbf4d8bbd4fcfedfede902b_D20200804-20200804" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU3MjI_2e460511-bb93-40b1-bc36-690ce90fa35d">5,000,000</ix:nonFraction> shares of common stock, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaf950f67a01b415ab0151c454064f1cb_I20200804" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU3ODA_420cc360-4f6d-4abf-9daa-ce222f4342e2">18.00</ix:nonFraction> per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for <ix:nonNumeric contextRef="i61f483edcdbf4d8bbd4fcfedfede902b_D20200804-20200804" format="ixt-sec:durday" name="imux:SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU5MDY_48e44b57-b9b4-4622-aea9-9973df5c3147">30</ix:nonNumeric> days, to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="i61f483edcdbf4d8bbd4fcfedfede902b_D20200804-20200804" decimals="INF" format="ixt:numdotdecimal" name="imux:SaleOfStockNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU5NDM_979a4df4-29ac-4c74-a59e-a2ef01eda132">750,000</ix:nonFraction> shares of Common Stock at the public offering price, less underwriting discounts and commissions, which was exercised in full on August 6, 2020.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company closed the Offering. The net proceeds to the Company from the Offering, after giving effect to the exercise in full by the Underwriters of their option to purchase the Option Shares, was approximately $<ix:nonFraction unitRef="usd" contextRef="ib39d17f19add4e67851d0c580a248614_D20200807-20200807" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzYzMjY_ab4f142c-6d23-4871-9b4f-a6abfedf6937">96.5</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.  </span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Subscription Not Yet Issued</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">On March 27, 2019, stockholders of the Company resolved to increase the Company&#8217;s share capital by an additional <ix:nonFraction unitRef="shares" contextRef="i15c150f722064296929dd00a3a6f971d_I20190327" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzY1OTk_222409c1-86e2-41aa-a3e1-c6f544fb3403">156,920</ix:nonFraction> ordinary shares, par value &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i15c150f722064296929dd00a3a6f971d_I20190327" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzY2MzA_279dd9da-9a5a-4ae4-a326-292271d30ebb">1.00</ix:nonFraction> per share, of which <ix:nonFraction unitRef="shares" contextRef="i5a7d12cd12ee4917abc990f2310687c0_I20190327" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzY2NTQ_595b0b7a-7db1-42a0-929e-b490c180b5d7">27,176</ix:nonFraction> shares related to bonuses for executive officers of the Company. Under German law a capital increase is valid as soon as the consummation of the capital increase has been officially registered with the commercial register, which occurred on April 3, 2019. Therefore, the capital increase became effective subsequent to March 31, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic AG, a non-public company as of December 31, 2018, had authorized <ix:nonFraction unitRef="shares" contextRef="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI0NTQ_4337dac7-24b8-4e1f-a68f-8b8f06131fe8">846,953</ix:nonFraction> shares of common stock, par value &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI0OTE_702cb439-e04e-4cc8-8615-c891420b41f2">1.00</ix:nonFraction> per share, which were issued in March 2016 for approximately $<ix:nonFraction unitRef="usd" contextRef="ib3fe40add06a4c1e9d53068bac00bb0f_I20160331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI1NTU_aea53c0c-696d-4134-adec-4d38dc77ad34">56,000</ix:nonFraction>. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI2ODY_9e8e1441-91eb-4dac-a0af-4ed46e48178f">130,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3MjY_a0c218ed-78ed-4c0d-89d5-df7110bfe48e">0.0001</ix:nonFraction>. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i777842fd4ab8425cbdc7a5ded53c8bcc"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December&#160;31, 2020, <ix:nonFraction unitRef="usdPerShare" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI5ODY_1a2633ad-5544-4684-9f01-588e32e8b144"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI5ODY_746e9aa3-08ce-4939-9619-ac838bde1235">no</ix:nonFraction></ix:nonFraction> cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception (2016) through 2018, Immunic AG issued <ix:nonFraction unitRef="shares" contextRef="i5b71f1d3cd7c4b9b9c8ee7ebac91ffec_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMwNjU_6855d3fa-4673-4226-b300-5222401cc73b">13,541</ix:nonFraction> Series A-1 Convertible and <ix:nonFraction unitRef="shares" contextRef="i8f592217ac8841e7a80512fd12ad30e0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMwOTU_b2e3fdba-85b7-4713-9228-65d7da3441c2">299,456</ix:nonFraction> Series A-2 Convertible preferred shares, par value &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i5b71f1d3cd7c4b9b9c8ee7ebac91ffec_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMxNDk_06f922e8-e998-4aad-bc7a-91d2f2122d3e">1.00</ix:nonFraction> per share, to investors as part of its growth financing plan in the total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="i4c982f0f472740879b53dcb38a14a979_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMyMzY_e6385e99-9e42-4063-b3dd-97a14cc8eee6">31.7</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="usd" contextRef="i4c982f0f472740879b53dcb38a14a979_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMyNTQ_f3e737be-d465-46c6-9a53-e17e51af5775">37.2</ix:nonFraction> million). Series A-1 Convertible and Series A-2 Convertible preferred shares were converted into Immunic AG&#8217;s ordinary shares immediately prior to the Transaction and were then exchanged for Immunic (former Vital) common shares at the consummation of the Transaction.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzM2NTM_bc490dd0-f548-4600-aec0-040ad3218671">20,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzM2NjY_661a5172-46f1-48cf-b013-1457e05b831b">0.0001</ix:nonFraction> par value preferred stock, rights and preferences to be set by the board of directors. <ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzM3NTY_c02acf8b-a935-433d-8b26-a4024315db0f">No</ix:nonFraction> preferred shares were outstanding as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued warrants to purchase common stock in connection with financing activities and for consulting services in 2011. Warrants for <ix:nonFraction unitRef="shares" contextRef="ib9c91096020641aa94b1d1135b433890_I20190925" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzM5NjE_a50b6e1a-521d-4f69-ad73-73caf73e2933">6,015</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8a2c83765c344137b31b8874c897fac3_I20190925" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzQwMTE_d0e64b2a-0eb2-4ab6-9a7e-62ab0b724dd8">3,719.60</ix:nonFraction> expired on September 25, 2019.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzQxNDE_5c280000-67e1-4f42-87a5-63d065e1f4eb" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance as of December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87a8c7a070d48d7a85d8cbb57c3b164_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzItMS0xLTEtMA_8120d617-564c-4e0e-be49-1d471191a4d7">1,117,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fe3c6f83fe24a859c84ef448153d453_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzQtMS0xLTEtMA_2051c334-c0bb-4873-bd1d-867c4a2cdc28">43,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ca14bfd5d1a46d6abbbe154703eaed5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzUtMS0xLTEtMA_3407918e-11f2-4f97-bf02-a84c7c83c1f6">46,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idde26f9196c647299fc79cdab514e92c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzYtMS0xLTEtMA_06ad3cbc-52b5-4da3-b429-51b15f577336">831,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzctMS0xLTEtMA_e1d8994d-5283-4e58-a53d-561cf68a315f">2,038,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzQ0_617f0aae-7829-437e-8198-4974dd7d2272" continuedAt="i9cd3debea906453587e93e1097ea6daa" escape="true">Stock Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="i9cd3debea906453587e93e1097ea6daa" continuedAt="ia9811a01eb214de4847e8914d9be5709"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, (i) a company&#8217;s management board consists of employee members and is responsible for overseeing its daily business, and (ii) a company&#8217;s supervisory board supervises the management board and serves a role equivalent to the board of directors of an American corporation. Under two stock option programs, the Company granted stock options to the members of the Immunic AG supervisory board (the &#8220;Supervisory Board&#8221;) and to key employees in 2018 and in 2019 prior to the Transaction. The programs were intended to incentivize the beneficiaries to dedicate their working capabilities in the best manner possible to the benefit of the Company. The stock options vest if and when an exit event occurs. An exit event is defined as a direct initial public offering has taken place, or an indirect initial public offering has taken place, or a trade sale has been consummated, or a disposal of the Company&#8217;s assets has been consummated, or another financially equivalent realization event has occurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the stock option program for the members of the Supervisory Board (the &#8220;VSOP SB&#8221;), the Company granted stock options of the Company to members of the Company&#8217;s Supervisory Board for the time period of their service as members of the Supervisory Board. The shareholders&#8217; approved the VSOP SB with a total of <ix:nonFraction unitRef="shares" contextRef="i6d1d01b5e1504c569debfc0effaa9d69_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="imux:ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEzODI_a7467c20-8ede-4363-88a2-5eebbe9b95f1">31,593</ix:nonFraction> stock options, corresponding to approximately <ix:nonFraction unitRef="number" contextRef="i6d1d01b5e1504c569debfc0effaa9d69_D20200101-20201231" decimals="3" name="imux:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzE0MzE_bc0f7a3b-3892-45da-912d-e2e8e1adae61">0.5</ix:nonFraction>% of the Company&#8217;s issued share capital at the time of the decision. Under the stock option program for key employees (the &#8220;VSOP&#8221;), the Company granted stock options of the Company to certain key employees. With the approval of the Supervisory Board, Immunic AG&#8217;s management board determined how many stock options were granted and how they were allocated to the respective beneficiaries up to a total of <ix:nonFraction unitRef="shares" contextRef="i6d1d01b5e1504c569debfc0effaa9d69_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="imux:ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzE4NTI_a7467c20-8ede-4363-88a2-5eebbe9b95f1">31,593</ix:nonFraction>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia9811a01eb214de4847e8914d9be5709" continuedAt="i4bbd582d51e6419e91566666b645c662"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further terms and conditions of both programs, the VSOP SB and the VSOP, were substantially similar. The following information is therefore shown aggregated for both programs. The Company accounts for both programs as cash-settled options and classifies their fair value as a liability upon vesting. Vesting of options granted under the VSOP SB and VSOP was contingent upon an exit event. Upon consummation of the Transaction, which occurred on April 12, 2019, all of the awards vested and were settled for cash of $<ix:nonFraction unitRef="usd" contextRef="id98ccd8847d942049dcebd55acab88b9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzIzNzA_37f3ee51-d583-43ec-b271-6d13a34f654f">508,000</ix:nonFraction> based on their fair value. As a result, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="id98ccd8847d942049dcebd55acab88b9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzI0MzQ_37f3ee51-d583-43ec-b271-6d13a34f654f">508,000</ix:nonFraction> in compensation expense related to these stock options in the twelve months ended December 31, 2019.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of <ix:nonFraction unitRef="shares" contextRef="i884fec6fb3674d73b8111a30c60f263f_I20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDA2NDc_283a2c4a-07e3-4875-a0c2-7d7a7f1a3a63">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock are available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to <ix:nonFraction unitRef="number" contextRef="i3d10718e641e49e498dc108252d3c28e_D20190701-20190731" decimals="INF" name="imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDA4MjQ_1045c287-bba5-4be7-9681-ce65f4b23aac">4</ix:nonFraction>% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of <ix:nonFraction unitRef="shares" contextRef="i3d10718e641e49e498dc108252d3c28e_D20190701-20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDA5MTU_e479b580-157c-49b3-9810-6d12595b7856">4,900,000</ix:nonFraction> shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased by <ix:nonFraction unitRef="shares" contextRef="icf1e238f2761438b9315ac40fda6d259_D20200701-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDEwNTY_0bc650af-dc32-44a5-9ebe-9a03ebaa6775">448,634</ix:nonFraction> shares effective April 1, 2020. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than <ix:nonNumeric contextRef="i90330a9e562f4e60896ceea327263918_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE1MTY_13ac078d-fc9b-46c6-8117-af76952e4664">ten years</ix:nonNumeric>. Incentive stock options granted to employees typically vest over <ix:nonNumeric contextRef="ia083d8fbd94c4989a08ae4001339a6f9_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE1ODY_0f80f497-d7fa-4de6-8e5c-77b027430b55">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE3Mjg_67b7eb76-947a-407e-81f5-65bf99e5e7da">three</span> or <ix:nonNumeric contextRef="ia26faf7d6c8d4e9d8a5282e0a5e8930d_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE3MzU_5d89fd47-affd-4d89-8ee5-21463dbd8122">four years</ix:nonNumeric>. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year</span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzQ2_511db112-1e17-4a2c-9df0-a0ef4e59b614" continuedAt="i47ed110f4f5e4b52818f34d1875e8eda" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the number and weighted average exercise prices of, and movements in, stock options for the VSOP SB and VSOP during the year ended December 31, 2019.  There were no awards granted or outstanding after the awards settled in 2019:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:75.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unvested Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e3be07c1751461587012f74b2b0f7a0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzItNS0xLTEtMA_e85d2524-c1e4-4c67-b48f-d0e92c8a2da6">6,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e3be07c1751461587012f74b2b0f7a0_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzItNy0xLTEtMA_9f78cc31-2cbe-4aac-ad40-8ed7f851f733">12.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzMtNS0xLTEtMA_7b8fcb61-9779-410a-8f3c-361ecb096f68">32,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzMtNy0xLTEtMA_697da609-3d6c-4cb9-892a-987a5d02d6b2">12.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzQtNS0xLTEtMA_f28c60c9-5c30-4854-a4ac-a68f0c415276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzQtNy0xLTEtNzk1_9b167b08-4f9a-4b58-a1f6-1e10f920053d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled in cash during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="imux:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzUtNS0xLTEtMA_a1858cab-d4f7-4f70-a83d-a80fe9e65fe3">39,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231" decimals="2" name="imux:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzUtNy0xLTEtNzg1_2454e32c-2535-4a4c-81e2-75a8b3e8b03a">12.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired during the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzYtNS0xLTEtMA_6a5033f9-417d-497c-aa73-f87c7534ab91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdf95cecb7c14be781cbd9b72385544b_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzctNS0xLTEtMA_3c581c30-142e-4c27-a241-352af7a43e92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifdf95cecb7c14be781cbd9b72385544b_I20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzctNy0xLTEtMA_0b9ebafb-d983-4ee2-8acd-83463bd4cd49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdf95cecb7c14be781cbd9b72385544b_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzgtNS0xLTEtMA_45dfe409-3f97-4f11-a1c0-3f385d3b8d97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic83994845a8140129953443b3610acec_D20200101-20201231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzQxMDQ_9be46de6-3d86-4433-ab93-dcf447ab51cb">No</ix:nonFraction> expense was recognized during the year ended December 31, 2020. There was $<ix:nonFraction unitRef="usd" contextRef="id98ccd8847d942049dcebd55acab88b9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzQxODE_125cf697-8f74-4498-92fb-af9974d87457">508,000</ix:nonFraction> of expense recognized in 2019 upon the vesting of the awards as a result of closing the Transaction.  There were no cancellations or modifications to the awards in 2019. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4bbd582d51e6419e91566666b645c662" continuedAt="ifeda6e6bb27e4b71b71260c356349b25"><ix:continuation id="i47ed110f4f5e4b52818f34d1875e8eda"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity since January 1, 2019 under the 2019 Plan:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9fcfd27c68040008f2db78d30da709f_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEtMS0xLTEtMA_733c7d8f-c54d-438b-9dd2-7e63da32f117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9fcfd27c68040008f2db78d30da709f_I20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEtMy0xLTEtMA_61ab822a-5f24-4f20-a9d4-8942be651a05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzItMS0xLTEtMA_e39ceb4a-a6ae-4aff-b8d9-b5189c28c0a1">456,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzItMy0xLTEtMA_8b12cb48-8f7a-4b60-a1ae-aa430fb10ccb">12.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzMtMS0xLTEtMA_dc8e7b84-acad-42d0-84cd-10665bfbe592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzMtMy0xLTEtMA_9bab5622-d4cf-4bbd-86fa-7582d932d3d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzQtMS0xLTEtMA_4bd40755-afb3-4d38-b54c-c37a36dbbf55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzQtMy0xLTEtMA_0f4c403d-667b-424a-abe7-806e9e8ad54c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzUtMS0xLTEtMA_b689e5e9-0253-4cd2-b12f-9cd903421531">456,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzUtMy0xLTEtMA_5c029a30-38a2-4587-807d-51e5b6c3f7dd">12.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzUtNS0xLTEtMA_6df0d855-1968-4a88-934f-5e63682dc0b3">9.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzUtNy0xLTEtMA_a472f0ff-cc85-4df6-b071-552779198298">114,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzYtMS0xLTEtMA_7dfc8dba-5969-4971-b6eb-501eab6b73d7">456,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzYtMy0xLTEtMA_e3f66665-2980-4751-895a-857c3429d4ff">12.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzYtNS0xLTEtMA_c694b3de-c9ee-433f-8224-8195ec290b01">9.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzYtNy0xLTEtMA_63a19f90-11dd-48bd-a1cb-4cf513f064e1">114,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzctMS0xLTEtMA_f4ec42e1-c139-48bb-9f08-fee6f68408cd">31,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzctMy0xLTEtMA_5e86d28c-a92e-4473-b77e-e6f9b9063dda">13.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzctNS0xLTEtMA_53f70c5d-550f-466d-ae4a-762f871759d2">9.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzctNy0xLTEtMA_d3d9e656-575c-47ea-aa95-39aa9dee253b">3,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEwLTEtMS0xLTgwMw_28e4b498-e2cc-4352-9f7c-3af72dec40c5">456,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEwLTMtMS0xLTgwMw_c9ff209f-28af-4750-a302-fb263d9406a4">12.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzExLTEtMS0xLTgwMw_62ba576e-6dae-446e-8c0a-7347a872c79a">744,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzExLTMtMS0xLTgwMw_5399d1c2-bc28-4a1b-886f-b3570315f81f">13.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEyLTEtMS0xLTgwMw_e5b26402-1991-46b1-954c-8e9b862a786c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEyLTMtMS0xLTgwMw_87dc5483-f5fc-48e2-945a-507c64994443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEzLTEtMS0xLTgwMw_abcd9c0b-9c70-49d2-8115-c21307519473">83,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEzLTMtMS0xLTgwMw_4198394f-bbd7-467c-ba62-66ece2dac5f7">13.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE0LTEtMS0xLTgwMw_4ad16b47-8498-4b36-8d4a-fa4a3868f131">1,117,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE0LTMtMS0xLTgwMw_c716afff-e5b5-4335-8502-4a3eecd3bca5">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE0LTUtMS0xLTgwMw_2bb3cfca-86d2-4aff-abaf-dbbee37cdec7">9.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE0LTctMS0xLTgwMw_515c5b41-bb2d-4f80-81cf-8566cf0eb0b4">2,894,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE1LTEtMS0xLTgwMw_225102e6-977a-4a28-a44e-63b5ae3be19c">1,117,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE1LTMtMS0xLTgwMw_165b112e-4654-4955-9ccf-bcdd611f464c">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE1LTUtMS0xLTgwMw_8f3954da-7aea-41dd-865e-0ca75f27238d">9.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE1LTctMS0xLTgwMw_d5a79631-15a2-4c80-bd0b-011f278e0378">2,894,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE2LTEtMS0xLTgwMw_dc47e691-4eab-4f14-ad94-1c9d41724c23">263,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE2LTMtMS0xLTgwMw_0d8f87c9-5ac7-4ee0-8603-7440a86a2bb7">13.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE2LTUtMS0xLTgwMw_9ba77602-c128-4842-bb6e-386561ff1a81">8.92</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE2LTctMS0xLTgwMw_96108346-0e32-4524-a0f1-5f34e06dc8b3">661,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s stock for purposes of determining the exercise price of options granted under the VSOP for the year ended December 31, 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib8030a5507c8490583fc32147238685d_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzQ1MTY_555e2f8a-ceca-43f2-a609-9c3f36d6d5d2"><ix:nonFraction unitRef="usdPerShare" contextRef="idf66576a68e1467aaeb276eb0a1d220d_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzQ1MTY_7dec6908-2f1d-418c-a1a5-ef8caee9713e">12.87</ix:nonFraction></ix:nonFraction>, which was determined based on prices negotiated with investors participating in the Financing as noted above. The fair value of the zero-cost VSOP SB and the VSOP options was equal to the fair value of the underlying stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of comparable companies that are publicly </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifeda6e6bb27e4b71b71260c356349b25" continuedAt="i54d13927931e4cafbfd52d7aaa890b13"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected  term of options is estimated considering the vesting period at the grant date, the life of the  option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzYxNDc_8a53dfc4-23e8-4cdf-a47e-5b5019c3277f">9.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE5Mjg_9b3b00ed-98c7-4704-859c-831bdef7c9b6">8.28</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzUw_18659ced-e64f-4ec9-a32f-b4bd411a7160" continuedAt="i0100a5d329fe4f09b241d81830a5dc08" escape="true">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><ix:continuation id="i0100a5d329fe4f09b241d81830a5dc08"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.526%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzEtMS0xLTEtMA_68b79f75-3a6a-46e6-b706-ce5db54e88d3">0.42</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzEtMi0xLTEtODUw_4f8daa87-216f-4f29-a1d3-b62d0a12c74f">1.71</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzItMS0xLTEtMA_e4125276-aa71-4aff-a1de-49a4ab159606">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzItMi0xLTEtODUw_83a2e17f-d68e-433c-bbf6-4fb8ef732415">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzMtMS0xLTEtMA_69bd7abf-6680-413e-8850-ddef89eff016">88.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzMtMi0xLTEtODUw_9395a5d9-6b4c-4e2f-8ff7-704ab49c20e8">75.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzQtMS0xLTEtMA_6ab0ae58-aae2-4278-af2e-30469c7c4b5b">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzQtMi0xLTEtODUw_fa9eaaaa-6c60-4e84-b65c-edd685af30d8">5.9</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exit Bonus Share Agreement (Anti-Dilution Adjustment) </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with an Early Exit Bonus Share Agreement (Anti-Dilution Adjustment) between the shareholders of Immunic AG dated August 2017, each of the four members of the Management Board of Immunic AG, through a limited liability company controlled by the respective board member, received new shares in Immunic AG as a form of anti-dilution protection. The AG shares were subscribed by the Management Board members at a price corresponding to their nominal value in the course of the Additional Financing of Immunic AG, which was carried out in March 2019. As part of the closing of the share exchange with Vital, Therapies, Inc., now Immunic, Inc., in April 2019, the AG shares were exchanged for <ix:nonFraction unitRef="shares" contextRef="icd8ece903fa44ea2a909aa615b1a5ba0_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzcxMjU_772ef6df-10db-4fc0-8e2a-ae5f95e39f68">460,336</ix:nonFraction> restricted shares in with Vital, Therapies, Inc., now Immunic, Inc., which were issued to the members of the management Board. Upon consummation of the Transaction, compensation cost of &#8364;<ix:nonFraction unitRef="eur" contextRef="icd8ece903fa44ea2a909aa615b1a5ba0_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzczMTQ_7e0bf5ac-a310-4d34-9e70-e0aeebc7ba64">5.3</ix:nonFraction>&#160;million (approximately $<ix:nonFraction unitRef="usd" contextRef="icd8ece903fa44ea2a909aa615b1a5ba0_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzczMzI_015b718f-4633-4adf-8a0b-d554d89c9812">6.0</ix:nonFraction> million) was recognized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzQ3_cc01d212-1ba6-4265-bc8c-874e3f46a681" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/> Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b19f4b3636941f2900ae6ec1f44f9d8_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzItMS0xLTEtMA_4945cec5-ca18-4432-812c-5a0f53eb8d77">731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf29fd89a5442609bee7357c0b527ac_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzItMy0xLTEtMA_c3e62991-9196-48e4-879d-f744d92b14cb">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fd0b65f75d4e63a2e869c2631bf0ab_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzMtMS0xLTEtMA_69540739-89b5-4460-949d-e35573d3d11a">2,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58388d7d9c6a4379884d6768a332b251_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzMtMy0xLTEtMA_f202cbd0-f19a-45bd-8afa-81ed54520cbe">6,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic803cd5d0c184b89902cb243dfeb5916_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzQtMS0xLTEtMA_a330ef44-5a61-461d-9bb5-6811d8912bd5">2,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7cdba0abab7408cbfbfdb0c19a562a0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzQtMy0xLTEtMA_8925d09c-3a19-4beb-9f79-8b929e26156c">8,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 there was $<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0Xzc1ODQ_8199e45f-4566-4ea4-9b34-098a7d7c8ec8">7.0</ix:nonFraction>&#160;million  in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDIwMjY_3568ed2c-95a8-4ece-a18c-a16e3ed0b6ef">2.72</ix:nonNumeric> years.  General and administrative expenses for the year ended December 31, 2019 include $<ix:nonFraction unitRef="usd" contextRef="i9010bd0189fc4f5baf921a2f5f4333bd_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDIxMjk_e282d593-9a73-4aa2-af72-ec6202c48d5c">6.0</ix:nonFraction>&#160;million of stock compensation expense related to the  Early Exit Bonus Share Agreement disclosed above.  Research and development expense for the year ended December 31, 2019 includes $<ix:nonFraction unitRef="usd" contextRef="i0d4812e273894e708953a3a86ae37e95_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDIzMDM_3211fbf1-b34d-4160-b8a4-3aa23e9e9bad">1.5</ix:nonFraction> million of stock compensation expense as a result of the settlement of Tranche IV with 4SC AG as explained in Note 6.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i54d13927931e4cafbfd52d7aaa890b13" continuedAt="i31ce71881f124d6a92355bfb5430e6f8"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain <ix:nonFraction unitRef="shares" contextRef="ib314b2e7a1bb4652a04c736a3427cd77_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDU3MzY_cda2ba46-879f-4f5f-8ca7-d8ede9ff4ea7">43,311</ix:nonFraction> shares available for grant under the 2014 Plan as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan <ix:nonFraction unitRef="shares" contextRef="i6283c69a3a9a4598bf3bc29177b58dd2_I20170930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDU5NDk_879aebb5-cf54-4b19-a9f9-5a40be7f85e4">46,250</ix:nonFraction> shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the years ended December 31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzQ4_9e1982a5-0b67-41fc-9358-38dead0fd030" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity since January 1, 2019 under the plans assumed from Vital:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d0f6cb2694343c6b174f7126d1b497c_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEtMS0xLTEtMA_b301732a-9e0d-4980-935e-b7a6c35c464f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d0f6cb2694343c6b174f7126d1b497c_I20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEtMy0xLTEtMA_deb47b96-dd96-4125-86db-59cf42a52168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed in the Transaction with Vital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzItMS0xLTEtMA_497eb85a-1278-4088-a6b2-4d01bf3779c3">17,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzItMy0xLTEtMA_91f59286-2634-40b1-9315-15731990d711">306.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzMtMS0xLTEtMA_8b13365d-18fc-4318-a8da-2e79c46aba32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzMtMy0xLTEtMA_05cb218a-8f2f-44c4-a846-b8b24511aff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzQtMS0xLTEtMA_92b34536-8d7a-4b22-b56b-87b01804ed49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzQtMy0xLTEtMA_354d346d-de73-496f-b2b7-14e69a8dd14c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzUtMS0xLTEtMA_3376b65d-1d86-431a-8bed-d4a45362e78a">2,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzUtMy0xLTEtMA_34edcb4d-4141-49a5-b54b-e66f1f5986a6">312.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzYtMS0xLTEtMA_0a932752-d28f-4075-bbcf-d3511c6e4abb">14,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzYtMy0xLTEtMA_c709fee9-627e-4bf6-ba43-0780a3a2d1ac">306.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzYtNS0xLTEtMA_7f36b8d1-8ec7-4b71-bf51-aaf5f3c75294">2.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzYtNy0xLTEtMA_dbc3d2cc-f979-4b15-a720-1d4b1dfae9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzctMS0xLTEtMA_e9dee496-2299-490c-85f4-5610b09a19e3">14,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzctMy0xLTEtMA_6ba7340d-b8a1-4f48-acce-8f985d1b6d9f">306.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzctNS0xLTEtMA_0757d9f1-d7d5-4da8-ba8e-8b73fcda40da">2.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzctNy0xLTEtMA_4f380eed-11ab-4eb8-9b00-f87102b3e24c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzgtMS0xLTEtMA_83e4ca95-eba0-4728-99e3-75f239c692a7">14,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzgtMy0xLTEtMA_bee4c968-3fad-46fd-8e42-960b9392800f">306.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzgtNS0xLTEtMA_620986e7-4a71-49c0-9716-54de7682f5d4">2.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzgtNy0xLTEtMA_65c8adf4-dbff-4d64-900c-3f2ff4b0e05e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzExLTEtMS0xLTEwNjA_da0f69cd-47ce-4c1e-ad92-dd7201d82186">14,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzExLTMtMS0xLTEwNjA_d95eba32-8708-4f6c-90ec-ab57a3c1c73e">306.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEyLTEtMS0xLTEwNjA_27681a7d-2591-423f-b518-f18c45461103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEyLTMtMS0xLTEwNjA_ca1c5f11-e2db-4fe7-b4f5-52ffac98b5e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEzLTEtMS0xLTEwNjA_874be2b2-dc93-44e8-ad3e-5cbce8e0a079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEzLTMtMS0xLTEwNjA_6c62a045-7a15-4cf9-9046-23b0205db797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE0LTEtMS0xLTEwNjA_e90ec0ef-5199-4ea2-9365-d666134d437f">14,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE0LTMtMS0xLTEwNjA_45b8b483-1a28-43a5-aa7b-9b61a7077974">306.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE1LTEtMS0xLTEwNjA_9de6882a-471f-4526-9da6-1d0c6a3ec753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE1LTMtMS0xLTEwNjA_ddb13fb7-6791-407d-ac73-32b28b18c53c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE2LTEtMS0xLTEwNjA_73a45a9b-d67d-49ef-84c8-b4ff9853af1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE2LTMtMS0xLTEwNjA_bd534f73-ef64-4d4c-96ef-4e6df5406dfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE2LTUtMS0xLTEwNjA_5ee03de5-817f-4084-8a36-f8d676bfbd15">0.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE2LTctMS0xLTEwNjA_b6d1eff1-a5ee-47ce-945b-44c14f950730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE3LTEtMS0xLTEwNjA_82185629-046e-4b6b-8290-e7213e350823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE3LTMtMS0xLTEwNjA_b13c3ff2-507f-4af2-9c7a-37cc8724b203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE3LTUtMS0xLTEwNjA_5e50bb4d-4806-474d-a2bf-89aaa773cd60">0.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE3LTctMS0xLTEwNjA_6b734c8e-f4be-4af0-92c7-51a52ff97d13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE4LTEtMS0xLTEwNjA_ddb44e3b-742c-44d2-a5c8-cfce071b23f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE4LTMtMS0xLTEwNjA_141fa570-70dd-49a6-ac0c-dea2ec117ffe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE4LTUtMS0xLTEwNjA_7bff2f71-ddcf-4b1a-8cc7-ba0d4b7d13f5">0.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE4LTctMS0xLTEwNjA_3969eeee-7b43-4e45-93d0-6b83cd9cd8bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to maximize the cash on Vital&#8217;s balance sheet for the Transaction, Vital restructured existing change of control and severance agreements with certain of its executive officers in January 2019. At the same time, Vital canceled options granted to such officers and granted them a total of <ix:nonFraction unitRef="shares" contextRef="ibabb7926e0324b259339a9246df9291b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMTEz_d5ca433a-c323-4705-a8c1-06578dbc0391">127,500</ix:nonFraction> RSUs. The primary effect of the amendments and the RSU grants was to substitute stock awards for cash payments owed upon a change of control. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i31ce71881f124d6a92355bfb5430e6f8">The RSUs vested in full upon consummation of the Transaction. As of December 31, 2019, all RSUs were settled.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 26</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzUwNjY_c78f42ba-f2d9-4169-a6a8-5b50eb062e16" continuedAt="i456361689c7e459ba75721d1d740fa4c" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i456361689c7e459ba75721d1d740fa4c" continuedAt="i6549d456b84a4bd186b75cf25ad6d4bd"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzUwNjc_4166ddda-f9ca-45d0-a6b0-c64fe0415952" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" xsi:nil="true" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzEtMC0xLTEtMzkwOA_2802cc48-aa7e-4e00-9a3e-b16ca4e64a66" escape="true"></ix:nonNumeric>&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i831a36d6192c47e5b5bf54b78aaeba94_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzItMS0xLTEtMA_9d26fec6-f4b2-4a95-8e04-98b9072a3cc0">8,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2528cb0a73b4870ae39bb50b3b9d6d1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzItMy0xLTEtMA_17e34d88-3439-4e32-b1e7-265ad57aa806">20,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc75b1a787fb4655b51ea8fab14201f2_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzMtMS0xLTEtMA_5448698c-ebc0-44a6-a2b1-5c5ff3d3729b">33,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice52c31a25f74dc481dd7ac060b4aa62_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzMtMy0xLTEtMA_750c0cba-5c36-4fb5-8af7-3d841877d520">23,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2658237935944ab880c53895d440839_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzQtMS0xLTEtMA_2f776c26-927b-4c54-ab33-44cf8ebbda48">1,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadfaa4f5c09647ca9cde1fa1c8cd3403_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzQtMy0xLTEtMA_a8a4502a-a679-4d53-845b-9fbad991ea04">827</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzUtMS0xLTEtMA_7f0cb02e-9ea9-49a8-a2e3-07549b63d23c">44,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzUtMy0xLTEtMA_d8d6ae69-5571-4fd3-a00a-741fc163d31c">44,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzUwNTc_236a216c-6b20-49ed-8178-aab3291cfa15" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate reconciliation consists of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzItMS0xLTEtMA_ba7a9e76-f987-49d0-b150-fd2d3e64c810">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzItMy0xLTEtMA_c53bff78-66fa-4f00-9251-e8ed60d58c7f">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzMtMS0xLTEtMA_c8e60a8d-d44b-417a-ae06-ff60d33e44be">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzMtMy0xLTEtMA_010f0085-4f51-4810-868f-78e205ddfc7f">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzQtMS0xLTEtMA_147ccd23-5a6e-40af-8fbc-cee617319abd">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzQtMy0xLTEtMA_0f4eacfa-6498-41a6-84a7-8613669841a2">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzUtMS0xLTEtMA_29700a15-8f5c-4616-8d59-35ea58eeee71">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzUtMy0xLTEtMA_efc5f2b9-114d-4703-b601-66fb15093333">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzctMS0xLTEtMzAxOQ_d34fac34-65b2-4ffd-a81a-8a2af3419ea4">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzctMy0xLTEtMzAxOQ_6ddb92cd-0054-4a81-a090-761c81654598">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzYtMS0xLTEtMA_69437007-1d02-42b8-a1a5-72e0ee691e65">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzYtMy0xLTEtMA_e11ebd0e-b1dd-4788-ab63-097a0f8fe950">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzctMS0xLTEtMA_5c92df99-2167-42ac-bf85-0f7bcf68a381">20.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzctMy0xLTEtMA_bb475357-cfe0-4e10-b9e0-4d9129e3c2c6">20.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzgtMS0xLTEtMA_a0019133-a6d2-4980-aba5-f134e8909ba7">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzgtMy0xLTEtMA_9a507dea-a2a9-4dbb-9260-9afc56109846">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is no current or deferred income tax expense in the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.</span></div></ix:continuation><ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzUwNzY_8ed332c5-b701-4c59-b0e5-c967f44bdd1c" continuedAt="i4ee670c7529648f4a1349b4d38e9d9fb" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6549d456b84a4bd186b75cf25ad6d4bd" continuedAt="ic7682517b5b44a4a9b1f182ee8946c80"><div style="margin-bottom:6pt"><ix:continuation id="i4ee670c7529648f4a1349b4d38e9d9fb"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzQtMS0xLTEtMA_d7e37754-63ea-4f59-8df8-c34fd4241462">17,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzQtMy0xLTEtMA_fc292f21-f7cc-40fe-a000-c8cc88a2e1eb">16,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzUtMS0xLTEtMA_9f5cf20c-37cd-4f18-8b11-40efe1484dcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzUtMy0xLTEtMA_addcf0b2-a4bb-4f38-bd02-21d74f7016d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzYtMS0xLTEtMA_ed6c82a9-b7e4-4c0f-a116-ceb94f70bb28">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzYtMy0xLTEtMA_917dbfd3-af72-4f41-ba1d-bfbbf5d85a64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzctMS0xLTEtMA_b5f215e4-9386-4285-8ecc-7bb32cf4641d">18,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzctMy0xLTEtMA_871f6fd1-bf89-4f11-a16e-8c161a669a2c">12,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzgtMS0xLTEtMA_f0ddfc71-8252-4ffb-a2bd-d0523abc0cc0">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzgtMy0xLTEtMA_79a3230c-ef83-4ace-aba5-daee90f8512a">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzktMS0xLTEtMA_07ae1cf0-0e71-4bda-ba40-0e4326dcd9fe">36,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzktMy0xLTEtMA_6bd7504c-86b1-4522-a46f-12972543f907">28,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzExLTEtMS0xLTMwMzU_f56adb2b-96eb-40dd-aff1-14a5fa97a193">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzExLTMtMS0xLTMwMzU_7dfd4daa-f1b6-401b-9235-67c838de9ef2">311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEyLTEtMS0xLTMwMzU_ae5563f2-5561-4b00-8d87-4112453f3b0d">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEyLTMtMS0xLTMwMzU_c0127cb6-e8ad-4e5d-8eed-78172df66751">311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="imux:DeferredTaxAssetsAndLiabilitiesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEzLTEtMS0xLTMwMzU_8d470286-41c9-4e71-9b0a-97b5d00692e1">36,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="imux:DeferredTaxAssetsAndLiabilitiesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEzLTMtMS0xLTMwMzU_8e4d0282-0af7-438a-9acc-722775445489">28,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEwLTEtMS0xLTA_2ed45efe-1254-46c4-be04-0c9e01d59b50">36,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEwLTMtMS0xLTA_d173f0e7-137c-4e14-9ca4-ab80044da8d4">28,355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7edf46a34f43399671610813b08a6d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzExLTEtMS0xLTA_932b7620-922c-4fba-9c39-580f59f86025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzExLTMtMS0xLTA_c391d16f-1106-4628-b32e-8fe2b59e7753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODM5ODk_2f509739-5956-42aa-b7cd-a2d84bc601fb">6.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODQwMDM_a18c714a-2163-4efb-a2ed-1bba652a78b2">23.7</ix:nonFraction>&#160;million for the years ended December 31, 2020 and 2019, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, Immunic had available NOLs of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7147fc86cd64277aadeebf96a225804_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODQwMTg_097e6f4f-d064-4ecc-9329-1d590a7f6523">75.7</ix:nonFraction>&#160;million in Germany and Australia. These NOLs do not expire.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i25a9ed10cb1c434e881185327a3fab3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODQwNjM_dc3a6127-bcd8-4f15-80f5-a53066af949c">15.6</ix:nonFraction>&#160;million were generated prior to 2018 and expire over 20 years beginning in 2023. The $<ix:nonFraction unitRef="usd" contextRef="i42d3b597607a4a96ad990267323ffb6b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODQwNDc_e67dfbdb-8ce7-4c0a-95e6-065ad43ca357">67.1</ix:nonFraction>&#160;million of post 2017 federal NOL carryforwards do not expire. Section 382 of the Internal Revenue Code of 1986, as amended, subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined thereunder. The Company may have undergone such an ownership change and therefore may be limited in the amount of net operating losses available for utilization in the future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any uncertain tax positions for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are no uncertain tax positions that would impact the effective tax rate if recognized.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2019 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7682517b5b44a4a9b1f182ee8946c80">Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_1634"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8zMjk4NTM0ODg1NDI1_a48e7879-c3bf-46ef-897c-7ddbfd28023e" continuedAt="i3fcec7b0519640309514ddeb38d091d0" escape="true">EIB Loan</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3fcec7b0519640309514ddeb38d091d0" continuedAt="if2bd95802b2347d0b71433c00211a635">On October 19, 2020, Immunic, Inc. (the &#8220;Company&#8221;) and Immunic AG, its wholly-owned subsidiary, entered into a Finance Contract (the &#8220;Loan Agreement&#8221;) with the European Investment Bank (&#8220;EIB&#8221;), pursuant to which EIB agreed to provide Immunic AG with a term loan in an aggregate amount of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="ic5c7b6124efd40999803947e39ba5996_I20201019" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNDU1_9fe62b42-3c0a-4048-9196-fb3de515f9d6">24.5</ix:nonFraction>&#160;million to support the development of Immunic&#8217;s lead asset, IMU-838, in moderate coronavirus disease 2019 (&#8220;COVID-19&#8221;), to be made available to be drawn in <ix:nonFraction unitRef="tranche" contextRef="id3797128a5a3499face40e421c2bb72f_I20201019" decimals="INF" format="ixt-sec:numwordsen" name="imux:LineOfCreditFacilityNumberOfTranches" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNDY5_112b916d-5a16-4791-b6cc-e1b6861ae7fa">three</ix:nonFraction> tranches, </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if2bd95802b2347d0b71433c00211a635"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the second and third tranches subject to the completion of certain pre-defined milestones. The Company has the right to defer payment of principal and interest on the first and second tranches until <ix:nonNumeric contextRef="i56a7a2ec7a864425ad54d86b2456da61_D20201019-20201019" format="ixt-sec:durwordsen" name="imux:LineOfCreditFacilityTranchePaymentDeferralTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNDc5_7d926b30-7565-4d1c-8e10-c6c51c977926">five years</ix:nonNumeric> after the respective borrowing dates, at which point such tranches must be repaid in full. The third tranche is repayable in annual installments commencing one year after its respective borrowing date and must be repaid in full no later than <ix:nonNumeric contextRef="i56a7a2ec7a864425ad54d86b2456da61_D20201019-20201019" format="ixt-sec:durwordsen" name="imux:LineOfCreditFacilityTranchePaymentDeferralTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNDk0_f975c074-691d-4d9b-a984-01abcfe12fcd">five years</ix:nonNumeric> after such date. Any outstanding borrowings under the Loan Agreement will accrue interest as provided in the Loan Agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2021 until December 31, 2030, the Company and Immunic AG are also obligated to pay EIB a very low single digit percentage of their revenue, as set forth in the Loan Agreement, subject to certain conditions and limitations tied to the total amount drawn under the Loan Agreement and subject to a cap of &#8364;<ix:nonFraction unitRef="eur" contextRef="ic5c7b6124efd40999803947e39ba5996_I20201019" decimals="INF" format="ixt:numdotdecimal" name="imux:LineOfCreditFacilityRevenueShareCapFirstTranche" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNTEw_966e65b9-3b47-47e2-884b-921c171ea0c8">8.6</ix:nonFraction>&#160;million if only the first tranche is drawn and subject to a cap of &#8364;<ix:nonFraction unitRef="eur" contextRef="ic5c7b6124efd40999803947e39ba5996_I20201019" decimals="INF" format="ixt:numdotdecimal" name="imux:LineOfCreditFacilityRevenueShareCapFullyDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNTI0_386e6fae-2538-440e-aed4-56c44728f07e">30</ix:nonFraction>&#160;million if the full loan amount is drawn. The Loan Agreement also includes certain prepayment penalties that may be triggered by certain prepayments prior to the maturity date.  As of December 31, 2020, nothing was drawn down under this loan agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will guarantee Immunic AG&#8217;s obligations to EIB pursuant to a Guarantee Agreement to be executed by the Company, Immunic AG and EIB (the &#8220;Guarantee Agreement&#8221;, and together with the Loan Agreement, the &#8220;Agreements&#8221;).</span></div></ix:continuation><div id="i0d8d624238c9468ba14749fb49b7ca69_1642"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjQyL2ZyYWc6ODg5OGFiYTU3MDUyNDhhM2FhMGEyMGM4ZWU5ZmNiYmEvdGV4dHJlZ2lvbjo4ODk4YWJhNTcwNTI0OGEzYWEwYTIwYzhlZTlmY2JiYV8yNzQ4Nzc5MDcxNTA2_7a0410b0-2c26-4f7b-b810-07e2d1b8efc8" continuedAt="i04d2057e2bf44dbc98ededccac0b7ad0" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i04d2057e2bf44dbc98ededccac0b7ad0"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on April 15, 2020, the compensation committee of the Company&#8217;s Board independently reviewed and approved entering into an employment agreement with the Company&#8217;s current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Mr. Nash entered into the Executive Chairman Agreement.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Executive Chairman Agreement, Mr. Nash serves as the Executive Chairman of the Board as long as he is a member of the Board, or until termination of the Executive Chairman Agreement (as described below) or upon his earlier death, incapacity, removal, or resignation. Pursuant to the Executive Chairman Agreement, Mr. Nash is entitled to receive: (i) a monthly base salary of $<ix:nonFraction unitRef="usd" contextRef="i04d94aba3d11445ea650849b72cf2899_D20200417-20200417" decimals="0" format="ixt:numdotdecimal" name="imux:SalaryCostsMonthlyBaseSalary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjQyL2ZyYWc6ODg5OGFiYTU3MDUyNDhhM2FhMGEyMGM4ZWU5ZmNiYmEvdGV4dHJlZ2lvbjo4ODk4YWJhNTcwNTI0OGEzYWEwYTIwYzhlZTlmY2JiYV8xNjQ5MjY3NDQyNTMy_509ed528-cb26-4186-9904-cadd370109de">25,417</ix:nonFraction> (it being agreed that such fee is inclusive of any fees associated with Mr. Nash&#8217;s services as both a director of the Company and in the capacity of Executive Chairman), (ii) employee benefits including, health insurance, dental insurance, basic life and accidental death and dismemberment insurance, long and short term disability insurance and participation in the Company&#8217;s 401(k) Plan, and (iii) reimbursements for pre-approved reasonable business-related expenses incurred in good faith in the performance of the Mr. Nash&#8217;s duties for the Company. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Mr. Nash serves as Executive Chairman. The Executive Chairman Agreement contemplated a term that ended on October 15, 2020 and was subsequently extend.  On October 15, 2020, the Company and Mr. Nash entered into an addendum to the Executive Chairman Agreement, pursuant to which the term of the agreement was extended to April 15, 2021. The Company made a one-time award to Mr. Nash of <ix:nonFraction unitRef="shares" contextRef="i7dd92710d99b48ba8db45f94ef6715f4_D20201015-20201015" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjQyL2ZyYWc6ODg5OGFiYTU3MDUyNDhhM2FhMGEyMGM4ZWU5ZmNiYmEvdGV4dHJlZ2lvbjo4ODk4YWJhNTcwNTI0OGEzYWEwYTIwYzhlZTlmY2JiYV8xNjQ5MjY3NDQzNTkx_41df52cb-d5bc-4097-ae6f-af7fd2161358">120,000</ix:nonFraction> stock options, which vest monthly starting on November 15, 2020. All other terms of the employment agreement remained the same.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 29</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90ZXh0cmVnaW9uOmU0Mzc4MTJhYmVkOTQ0ZWFiOGFkYTA2NDliN2FmMmUwXzUzOA_93ef7ee3-1bcf-4601-b9bb-e0af3fb84169" continuedAt="i9958e85affa344b6ae768d5c8fde79ef" escape="true">Selected Quarterly Data (unaudited)</ix:nonNumeric></span></div><ix:continuation id="i9958e85affa344b6ae768d5c8fde79ef"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. <ix:nonNumeric contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90ZXh0cmVnaW9uOmU0Mzc4MTJhYmVkOTQ0ZWFiOGFkYTA2NDliN2FmMmUwXzU0NA_a274dd7c-8497-48bc-bd1d-40d81e7a8430" continuedAt="ica10a057b00d455e9e55f7702b5e41b4" escape="true">Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share data):</ix:nonNumeric></span></div><ix:continuation id="ica10a057b00d455e9e55f7702b5e41b4"><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Quarters Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ede6cd330124ec6a00d9b69f6869d26_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtMS0xLTEtMA_1e9d019f-4569-4e5c-91df-028e8fd7dcd2">9,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8c1c50bbcc47cd82232e72f9c1d366_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtMy0xLTEtMA_f8e47176-b0de-401f-aaef-d380bf4dfbd4">12,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35dad35cf93d448a8881d824be1e6f81_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtNS0xLTEtMA_baa38431-5e33-4b51-85d3-2909bb2cdf15">13,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtNy0xLTEtMA_89f56309-8503-48da-95ed-6ec9c4cbb41c">14,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtOS0xLTEtMA_4d3f3e9f-3924-4cf2-9ad8-c981a1302673">48,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ede6cd330124ec6a00d9b69f6869d26_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtMS0xLTEtMA_900032d9-a462-45c6-8890-ee80f2c4895a">8,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe8c1c50bbcc47cd82232e72f9c1d366_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtMy0xLTEtMA_bf4b6cb3-4857-4b1d-b315-aa731e57fce3">11,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35dad35cf93d448a8881d824be1e6f81_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtNS0xLTEtMA_b8814354-0e45-44a0-9adf-b6de5f161cc4">12,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtNy0xLTEtMA_da445772-8b62-4a95-895d-217e8fae21a2">11,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtOS0xLTEtMA_431f1474-0a2b-4934-afba-57a8612d03e1">44,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9ede6cd330124ec6a00d9b69f6869d26_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtMS0xLTEtMA_387ce40c-ecfc-433e-b2bc-7778590dcb1c">0.79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibe8c1c50bbcc47cd82232e72f9c1d366_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtMy0xLTEtMA_be13ebe6-36dd-4768-82e2-a3ca326e3950">0.90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i35dad35cf93d448a8881d824be1e6f81_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtNS0xLTEtMA_b33c447e-445b-4af1-bb56-0def56dc0c51">0.70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtNy0xLTEtMA_e1d6daa3-d381-4dc2-9308-44321b99e3f1">0.53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtOS0xLTEtMA_1b0eba70-5999-4e99-b22e-ebb755663a17">2.81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb99bde8e3a84965bc53a2495c5be965_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctMS0xLTEtMA_bc77bade-ac72-421f-b7cb-c116144ae676">4,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49383c3200664df28115e65f5e1bf1a7_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctMy0xLTEtMA_f154c766-7f6b-4052-a1ea-d7f5cc72a672">15,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ccd299d58334dac9edfb2ac321eecfe_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctNS0xLTEtMA_bbbf22da-3908-4abb-96d6-b8c45cbe06a9">9,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7188adef1744a990c1f5be2b5baaec_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctNy0xLTEtMA_c0e9d057-c7d2-4167-8f18-09b1b69adb8d">8,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctOS0xLTEtMA_e2872fea-4dd9-4563-9dc6-c91065aad531">37,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb99bde8e3a84965bc53a2495c5be965_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtMS0xLTEtMA_10d679a5-bdc4-4094-9361-1158d2ff586a">4,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49383c3200664df28115e65f5e1bf1a7_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtMy0xLTEtMA_de3ce41a-7e40-4428-8bf2-0f594a1be326">14,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ccd299d58334dac9edfb2ac321eecfe_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtNS0xLTEtMA_f773acfa-aaf6-46e3-bfe9-5f58b56242a0">8,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a7188adef1744a990c1f5be2b5baaec_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtNy0xLTEtMA_664e3366-3359-4c8b-b71b-24a2f5fb2a17">7,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtOS0xLTEtMA_14bb91ae-24e0-4dd3-b970-33128f273971">34,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibb99bde8e3a84965bc53a2495c5be965_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktMS0xLTEtMA_53216505-bcd2-466a-88da-e9f7ab10de23">5.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i49383c3200664df28115e65f5e1bf1a7_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktMy0xLTEtMA_1de111ee-5d92-48ca-a6bb-54be9046af8c">1.52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0ccd299d58334dac9edfb2ac321eecfe_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktNS0xLTEtMA_1757fd92-5227-43d5-83da-d04107b8ff8e">0.82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6a7188adef1744a990c1f5be2b5baaec_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktNy0xLTEtMA_21b294aa-2ad8-43e6-8d52-eb33aad1731d">0.75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktOS0xLTEtMA_8f821b5e-d0e3-4d98-a311-865d0c3b1b64">4.52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share calculations will not necessarily equal the annual per share calculation.</span></div></ix:continuation></ix:continuation><div id="i0d8d624238c9468ba14749fb49b7ca69_172"></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:18pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 30</span></div></div></div><div id="i0d8d624238c9468ba14749fb49b7ca69_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form&#160;10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunic,&#160;Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 26, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL VITT</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and President</span></td></tr></table></div><div><span><br/></span></div><div id="i0d8d624238c9468ba14749fb49b7ca69_178"></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel Vitt and Glenn Whaley, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form&#160;10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form&#160;10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL VITT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Chief Executive Officer and President</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ GLENN WHALEY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Financial and Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DUANE D. NASH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duane D. Nash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ TAMAR HOWSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tamar Howson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JOERG NEERMANN</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joerg Neermann</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ VINCENT OSSIPOW</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vincent Ossipow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ BARCLAY A. PHILLIPS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barclay A. Phillips</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JAN VAN DEN BOSSCHE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jan Van den Bossche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exhibit42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib36d45d892ac41bc95f186294d297241_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF CAPITAL STOCK </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer to our certificate of incorporation and our bylaws that are incorporated by reference into the Annual Report on Form 10-K of which this exhibit is a part.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, there were 21,168,240 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stockholders will not be able to elect directors on the basis of their votes alone.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to preferences that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of us, holders of the common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any of our outstanding preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Listing</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;IMUX.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Transfer Agent and Registrar</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC (&#8220;AST&#8221;). The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not declared any cash dividends on our common stock since inception and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Possible Anti-Takeover Effects of Delaware Law and our Charter Documents</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult&#58; an acquisition of us by means of a tender offer, an acquisition of us by means of a proxy contest or otherwise, or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the market price for our shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delaware Anti-Takeover Statute</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation&#8217;s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Undesignated Preferred Stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ability of our board of directors, without action by the stockholders, to issue up to 20,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Requirements for Advance Notification of Stockholder Nominations and Proposals.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Elimination of Stockholder Action by Written Consent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Staggered Board.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Removal of Directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stockholders Not Entitled to Cumulative Voting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Authorized but Unissued Shares</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the future. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Director Liability</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our bylaws limit the extent to which our directors are personally liable to us and our stockholders, to the fullest extent permitted by the DGCL. The inclusion of this provision in our bylaws may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders or management from bringing a lawsuit against directors for breach of their duty of care.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>imux-123120xexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id618cc50f6cd44ac89936a9c1415cb65_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of the Registrant</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a list of subsidiaries of the Registrant. All of the subsidiaries listed below are wholly-owned subsidiaries of Immunic, Inc. and are owned directly by Immunic, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:77.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.642%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction&#160;of<br>Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunic AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i13ee79883d504977b80aa2a13ad42468_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the Registration Statements on Form S&#8209;3 (File No. 333&#8209;225230 and 333-250083), Form S&#8209;4 (File No. 333&#8209;229510), and Form S-8 (File No. 333&#8209;233864) of Immunic, Inc. of our report dated February 26, 2021, relating to the consolidated financial statements of Immunic, Inc., which appears in this annual report on Form 10-K for the year ended December 31, 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Baker Tilly US, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Minneapolis, Minnesota </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">February 26, 2021</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>imux-123120xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia174cb6f3238453d8e74c0ba329d8378_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Vitt, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2020 of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 26, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>imux-123120xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id93b77d1dfa04a4bba6bbc65f0da4a3b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glenn Whaley, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2020 of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 26, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Financial and Accounting Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer and Duly Authorized Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>imux-123120xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ica5c3ddfc13d45c9ac9b60b18288e87d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Vitt, as Chief Executive Officer and President of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 26, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>imux-123120xexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8977da9610224620ad91964c72cb1a4f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned,Glenn Whaley as Principal Financial and Accounting Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 26, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Financial and Accounting Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer and Duly Authorized Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>imux-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5279c717-4640-48e4-aa74-73546e28db9a,g:602f65cf-bbe8-45d8-a039-a1d02730d21d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:imux="http://imux.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://imux.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imux-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imux-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imux-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imux-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://imux.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://imux.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://imux.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>1008009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatements" roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements">
        <link:definition>2101101 - Disclosure - Description of Business and Basis of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail" roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail">
        <link:definition>2402401 - Disclosure - Description of Business and Basis of Financial Statements - Additional Details (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://imux.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail" roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingfortheTransaction" roleURI="http://imux.com/role/AccountingfortheTransaction">
        <link:definition>2108103 - Disclosure - Accounting for the Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingfortheTransactionTables" roleURI="http://imux.com/role/AccountingfortheTransactionTables">
        <link:definition>2309302 - Disclosure - Accounting for the Transaction (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingfortheTransactionAdditionalInformationDetail" roleURI="http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail">
        <link:definition>2410404 - Disclosure - Accounting for the Transaction - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail" roleURI="http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail">
        <link:definition>2411405 - Disclosure - Accounting for the Transaction - Preliminary Estimate of Purchase Price (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail" roleURI="http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail">
        <link:definition>2412406 - Disclosure - Accounting for the Transaction - Assets Acquired and Liabilities Assumed (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ELADSalesAgreement" roleURI="http://imux.com/role/ELADSalesAgreement">
        <link:definition>2113104 - Disclosure - ELAD Sales Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ELADSalesAgreementTables" roleURI="http://imux.com/role/ELADSalesAgreementTables">
        <link:definition>2314303 - Disclosure - ELAD Sales Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ELADSalesAgreementAdditionalInformationDetail" roleURI="http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail">
        <link:definition>2415407 - Disclosure - ELAD Sales Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ELADSalesAgreementEstimatedFairValueofELADAssetsDetail" roleURI="http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail">
        <link:definition>2416408 - Disclosure - ELAD Sales Agreement - Estimated Fair Value of ELAD Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetails" roleURI="http://imux.com/role/BalanceSheetDetails">
        <link:definition>2117105 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://imux.com/role/BalanceSheetDetailsTables">
        <link:definition>2318304 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail">
        <link:definition>2419409 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccountsPayableDetail" roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail">
        <link:definition>2420410 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccruedExpensesDetail" roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail">
        <link:definition>2421411 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail">
        <link:definition>2422412 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://imux.com/role/CommitmentsandContingencies">
        <link:definition>2123106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://imux.com/role/CommitmentsandContingenciesTables">
        <link:definition>2324305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2425413 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail" roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail">
        <link:definition>2426414 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1" roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1">
        <link:definition>2426414 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://imux.com/role/FairValue">
        <link:definition>2127107 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://imux.com/role/FairValueTables">
        <link:definition>2328306 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" roleURI="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>2429415 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStock" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock">
        <link:definition>2130108 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockTables" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables">
        <link:definition>2331307 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail">
        <link:definition>2432416 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Shelf Registration Statement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails">
        <link:definition>2433417 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Registered Direct Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails">
        <link:definition>2434418 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Public Equity Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails">
        <link:definition>2435419 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Stock Subscription Not Yet Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail">
        <link:definition>2436420 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail">
        <link:definition>2437421 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Preferred Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail">
        <link:definition>2438422 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Stock Warrants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail" roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail">
        <link:definition>2439423 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Shares Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPlans" roleURI="http://imux.com/role/StockCompensationPlans">
        <link:definition>2140109 - Disclosure - Stock Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPlansTables" roleURI="http://imux.com/role/StockCompensationPlansTables">
        <link:definition>2341308 - Disclosure - Stock Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPlansAdditionalInformationDetail" roleURI="http://imux.com/role/StockCompensationPlansAdditionalInformationDetail">
        <link:definition>2442424 - Disclosure - Stock Compensation Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPlansSummaryofStockOptionActivityDetail" roleURI="http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail">
        <link:definition>2443425 - Disclosure - Stock Compensation Plans - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" roleURI="http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
        <link:definition>2444426 - Disclosure - Stock Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail" roleURI="http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail">
        <link:definition>2445427 - Disclosure - Stock Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://imux.com/role/IncomeTaxes">
        <link:definition>2146110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://imux.com/role/IncomeTaxesTables">
        <link:definition>2347309 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail" roleURI="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail">
        <link:definition>2448428 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxRateReconciliationDetail" roleURI="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail">
        <link:definition>2449429 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail" roleURI="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail">
        <link:definition>2450430 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://imux.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2451431 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EIBLoan" roleURI="http://imux.com/role/EIBLoan">
        <link:definition>2152111 - Disclosure - EIB Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EIBLoanDetails" roleURI="http://imux.com/role/EIBLoanDetails">
        <link:definition>2453432 - Disclosure - EIB Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://imux.com/role/RelatedPartyTransactions">
        <link:definition>2154112 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2455433 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyDataunaudited" roleURI="http://imux.com/role/SelectedQuarterlyDataunaudited">
        <link:definition>2156113 - Disclosure - Selected Quarterly Data (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyDataunauditedTables" roleURI="http://imux.com/role/SelectedQuarterlyDataunauditedTables">
        <link:definition>2357310 - Disclosure - Selected Quarterly Data (unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail" roleURI="http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail">
        <link:definition>2458434 - Disclosure - Selected Quarterly Data (unaudited) - Summarized Quarterly Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="imux_ImmunicInc.Member" abstract="true" name="ImmunicInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_DeferredTaxAssetsAndLiabilitiesGross" abstract="false" name="DeferredTaxAssetsAndLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_SaleOfStockNumberOfAdditionalSharesAuthorized" abstract="false" name="SaleOfStockNumberOfAdditionalSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="imux_TaxYearsPriorTo2018Member" abstract="true" name="TaxYearsPriorTo2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_VSOPSBMember" abstract="true" name="VSOPSBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="imux_PreClosingFinancingMember" abstract="true" name="PreClosingFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="imux_LineOfCreditFacilityNumberOfTranches" abstract="false" name="LineOfCreditFacilityNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="imux_ProceedsFromIssuanceOfCommonStockGross" abstract="false" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" abstract="false" name="MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="imux_VSOPAndVSOPSBMember" abstract="true" name="VSOPAndVSOPSBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" abstract="false" name="BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="imux_SuppliesAndWorkingCellBanksMember" abstract="true" name="SuppliesAndWorkingCellBanksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_LineOfCreditFacilityRevenueShareCapFirstTranche" abstract="false" name="LineOfCreditFacilityRevenueShareCapFirstTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" abstract="false" name="SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_PrepaidClinicalAndRelatedCostsCurrent" abstract="false" name="PrepaidClinicalAndRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_BusinessCombinationSharesOwnedPriorToTransaction" abstract="false" name="BusinessCombinationSharesOwnedPriorToTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="imux_OfferingCostsIncludedInAccruedExpenses" abstract="false" name="OfferingCostsIncludedInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationCashConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" abstract="false" name="AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" abstract="false" name="BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="imux_ClinicalCostsPayableCurrent" abstract="false" name="ClinicalCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_EmployeeStockOptionsImmunicAGMember" abstract="true" name="EmployeeStockOptionsImmunicAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="imux_August2020EquityIssuancesMember" abstract="true" name="August2020EquityIssuancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_VitalTherapiesInc.Member" abstract="true" name="VitalTherapiesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_LesseeOperatingLeasesNumberOfExistingLeases" abstract="false" name="LesseeOperatingLeasesNumberOfExistingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_SeriesA2ConvertiblePreferredStockMember" abstract="true" name="SeriesA2ConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_OperatingAndVariableLeasesCost" abstract="false" name="OperatingAndVariableLeasesCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_SalaryCostsMonthlyBaseSalary" abstract="false" name="SalaryCostsMonthlyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_SeriesA1ConvertiblePreferredStockMember" abstract="true" name="SeriesA1ConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_April2020EquityIssuancesMember" abstract="true" name="April2020EquityIssuancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_June2020EquityIssuancesMember" abstract="true" name="June2020EquityIssuancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_A2017InducementEquityIncentivePlanMember" abstract="true" name="A2017InducementEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" abstract="false" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="imux_LineOfCreditFacilityRevenueShareCapFullyDrawn" abstract="false" name="LineOfCreditFacilityRevenueShareCapFullyDrawn" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_ImmunicAGMember" abstract="true" name="ImmunicAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_ClinicalDevelopmentEquipmentMember" abstract="true" name="ClinicalDevelopmentEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_TwoThousandFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="imux_DeferredStockIssuanceCostsIncludedInLiabilities" abstract="false" name="DeferredStockIssuanceCostsIncludedInLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_NonStatutoryEmployeeStockOptionMember" abstract="true" name="NonStatutoryEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" abstract="false" name="ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" abstract="false" name="MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="imux_EmployeeStockOptionsVitalTherapiesInc.Member" abstract="true" name="EmployeeStockOptionsVitalTherapiesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_A2019OmnibusEquityIncentivePlanMember" abstract="true" name="A2019OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_AccruedLegalAndAuditCostsCurrent" abstract="false" name="AccruedLegalAndAuditCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_TaxYearsPost2017Member" abstract="true" name="TaxYearsPost2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_ELADRelatedAssetsMember" abstract="true" name="ELADRelatedAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" abstract="false" name="MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_ExecutiveBonusAgreementMember" abstract="true" name="ExecutiveBonusAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_CashAcquiredInConnectionWithReverseAcquisition" abstract="false" name="CashAcquiredInConnectionWithReverseAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_December2020EquityIssuancesMember" abstract="true" name="December2020EquityIssuancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="imux_ResearchAndDevelopmentTaxIncentiveCurrent" abstract="false" name="ResearchAndDevelopmentTaxIncentiveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_A4SCSettlementAgreementMember" abstract="true" name="A4SCSettlementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_CashEquivalentsInvestmentsMaturityPeriod" abstract="false" name="CashEquivalentsInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="imux_EuropeanInvestmentBankLoanMember" abstract="true" name="EuropeanInvestmentBankLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_AccruedCompensationCurrent" abstract="false" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" abstract="false" name="BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_AtTheMarketSalesAgreementMember" abstract="true" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_PropertyPlantAndEquipmentIncludedInAccountsPayable" abstract="false" name="PropertyPlantAndEquipmentIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_IncentiveEmployeeStockOptionMember" abstract="true" name="IncentiveEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_ForeignExcludingGermanyMember" abstract="true" name="ForeignExcludingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_July2019EquityIssuancesMember" abstract="true" name="July2019EquityIssuancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_EmployeeStockOptionsforFutureGrantMember" abstract="true" name="EmployeeStockOptionsforFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="imux_LineOfCreditFacilityTranchePaymentDeferralTerm" abstract="false" name="LineOfCreditFacilityTranchePaymentDeferralTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="imux_LegalAndAuditCostsPayableCurrent" abstract="false" name="LegalAndAuditCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>imux-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5279c717-4640-48e4-aa74-73546e28db9a,g:602f65cf-bbe8-45d8-a039-a1d02730d21d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imux.com/role/CoverPage" xlink:type="simple" xlink:href="imux-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://imux.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_617f7b61-c64a-428d-8c99-d97a484ad21c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fe4e5466-7076-4da6-8922-5b0d3f7db5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_617f7b61-c64a-428d-8c99-d97a484ad21c" xlink:to="loc_us-gaap_AccountsPayableCurrent_fe4e5466-7076-4da6-8922-5b0d3f7db5d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_de29916f-1bc9-4e29-a1a8-6ef104abd4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_617f7b61-c64a-428d-8c99-d97a484ad21c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_de29916f-1bc9-4e29-a1a8-6ef104abd4f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1fa525ba-58ea-41d0-b1ac-ddde6b70d939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_617f7b61-c64a-428d-8c99-d97a484ad21c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1fa525ba-58ea-41d0-b1ac-ddde6b70d939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_040cf25e-f2dc-4894-b762-eb9f72e3ff17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_70b83828-e8ba-4775-95c7-58261506b579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_040cf25e-f2dc-4894-b762-eb9f72e3ff17" xlink:to="loc_us-gaap_PreferredStockValue_70b83828-e8ba-4775-95c7-58261506b579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2747fdef-1477-4815-b725-0c87b1377ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_040cf25e-f2dc-4894-b762-eb9f72e3ff17" xlink:to="loc_us-gaap_CommonStockValue_2747fdef-1477-4815-b725-0c87b1377ba8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_30459baa-169a-4f36-9037-d8a27b3b844b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_040cf25e-f2dc-4894-b762-eb9f72e3ff17" xlink:to="loc_us-gaap_AdditionalPaidInCapital_30459baa-169a-4f36-9037-d8a27b3b844b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ca926936-4f02-44b0-b111-1b01ad113c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_040cf25e-f2dc-4894-b762-eb9f72e3ff17" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ca926936-4f02-44b0-b111-1b01ad113c32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a19afb64-58de-4ab7-82e0-62edf670718e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_040cf25e-f2dc-4894-b762-eb9f72e3ff17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a19afb64-58de-4ab7-82e0-62edf670718e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6fe2ee84-4235-47c7-a2f8-d6909e31342d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8426020c-3ed0-4c45-b153-d40c4afe9082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6fe2ee84-4235-47c7-a2f8-d6909e31342d" xlink:to="loc_us-gaap_LiabilitiesCurrent_8426020c-3ed0-4c45-b153-d40c4afe9082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9a0b3032-03ac-4b6c-9e30-ad98b1277eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6fe2ee84-4235-47c7-a2f8-d6909e31342d" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9a0b3032-03ac-4b6c-9e30-ad98b1277eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_db1fa697-191c-47b1-8e84-452bff93ec1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5cac5501-fc06-4c25-a1eb-27fbcaa9649b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_db1fa697-191c-47b1-8e84-452bff93ec1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_5cac5501-fc06-4c25-a1eb-27fbcaa9649b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e0c8e9f3-f3e8-4f94-81fe-98c7eeee510c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_db1fa697-191c-47b1-8e84-452bff93ec1c" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_e0c8e9f3-f3e8-4f94-81fe-98c7eeee510c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_16362263-16e1-43f4-a7a8-15fca71d592b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_db1fa697-191c-47b1-8e84-452bff93ec1c" xlink:to="loc_us-gaap_StockholdersEquity_16362263-16e1-43f4-a7a8-15fca71d592b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4512bfe6-b231-48f1-b28f-d9e2e57f8684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_db1fa697-191c-47b1-8e84-452bff93ec1c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4512bfe6-b231-48f1-b28f-d9e2e57f8684" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0bd97c76-9cf0-40fd-a1fd-54bab451f371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_02d4bc5c-063b-48d6-8480-e2348059343c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bd97c76-9cf0-40fd-a1fd-54bab451f371" xlink:to="loc_us-gaap_AssetsCurrent_02d4bc5c-063b-48d6-8480-e2348059343c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b8a50cec-70b9-4b70-a2b9-040dc748ca59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bd97c76-9cf0-40fd-a1fd-54bab451f371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b8a50cec-70b9-4b70-a2b9-040dc748ca59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_87a62bf6-6134-4c6c-8d25-5bca42fba95e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bd97c76-9cf0-40fd-a1fd-54bab451f371" xlink:to="loc_us-gaap_Goodwill_87a62bf6-6134-4c6c-8d25-5bca42fba95e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8a35ddba-daa7-4c22-a23d-592226b01732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bd97c76-9cf0-40fd-a1fd-54bab451f371" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8a35ddba-daa7-4c22-a23d-592226b01732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6848d07d-1e99-43b9-a9e7-c09f4d5995f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bd97c76-9cf0-40fd-a1fd-54bab451f371" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6848d07d-1e99-43b9-a9e7-c09f4d5995f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_da02377a-2edf-4213-a95a-af57a2a5f5cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_35755167-3e63-458d-83b7-6848e1092d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_da02377a-2edf-4213-a95a-af57a2a5f5cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_35755167-3e63-458d-83b7-6848e1092d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5c92a952-1c23-4500-a7b6-6cc2c2dcdde1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_da02377a-2edf-4213-a95a-af57a2a5f5cc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5c92a952-1c23-4500-a7b6-6cc2c2dcdde1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_24281a95-846c-49c8-98f4-2320afabd0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d185d328-8a35-4c61-bf0c-1fa6a6d7db44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_24281a95-846c-49c8-98f4-2320afabd0f7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d185d328-8a35-4c61-bf0c-1fa6a6d7db44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_57475dbd-82d7-47ad-ad86-6a067dea7452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9fe06b2b-27a0-4f24-aecc-4a2c702f36d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_57475dbd-82d7-47ad-ad86-6a067dea7452" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9fe06b2b-27a0-4f24-aecc-4a2c702f36d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b4ed5188-09d5-4f5a-b9c2-30e869bbd034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_57475dbd-82d7-47ad-ad86-6a067dea7452" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b4ed5188-09d5-4f5a-b9c2-30e869bbd034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_784945c6-d2e8-48f3-8858-b834c209bc82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eb8f4ceb-3fa3-4436-8233-5b194a6b958f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_784945c6-d2e8-48f3-8858-b834c209bc82" xlink:to="loc_us-gaap_OperatingIncomeLoss_eb8f4ceb-3fa3-4436-8233-5b194a6b958f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_60c36c0f-d057-414f-b06a-dd08042ea087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_784945c6-d2e8-48f3-8858-b834c209bc82" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_60c36c0f-d057-414f-b06a-dd08042ea087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_89687acb-e37a-4772-b7bf-60fa795510d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ae392d6b-55a1-4322-b00d-f8e382046c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89687acb-e37a-4772-b7bf-60fa795510d7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ae392d6b-55a1-4322-b00d-f8e382046c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6e56af6b-41ce-4e1c-b67b-f3de7f94e882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89687acb-e37a-4772-b7bf-60fa795510d7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6e56af6b-41ce-4e1c-b67b-f3de7f94e882" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6d9c49c-4af5-47b3-a1b9-15bab7a7002b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e185e468-3829-4d9c-ac06-b7af6a7ceee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6d9c49c-4af5-47b3-a1b9-15bab7a7002b" xlink:to="loc_us-gaap_NetIncomeLoss_e185e468-3829-4d9c-ac06-b7af6a7ceee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e9f0ac18-77da-42c9-bcce-569dcad32538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6d9c49c-4af5-47b3-a1b9-15bab7a7002b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e9f0ac18-77da-42c9-bcce-569dcad32538" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79ef83b1-fe0a-49f1-a478-5597247430c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_NetIncomeLoss_79ef83b1-fe0a-49f1-a478-5597247430c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f443bb2d-555f-42fc-a236-e7d8dd1ce94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f443bb2d-555f-42fc-a236-e7d8dd1ce94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_90357259-a4bd-41b9-a1c9-424e64cc5e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_90357259-a4bd-41b9-a1c9-424e64cc5e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5111e747-a30f-4689-b7cc-2693aa657d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_ShareBasedCompensation_5111e747-a30f-4689-b7cc-2693aa657d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8d7e950f-605d-4978-913e-216b8e04402e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8d7e950f-605d-4978-913e-216b8e04402e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8d9126ee-0a95-48eb-9b90-4de151620755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8d9126ee-0a95-48eb-9b90-4de151620755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c01a2e4-8604-447a-98f2-32b242165035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c01a2e4-8604-447a-98f2-32b242165035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_aa074455-08bd-4953-9920-f16a8eed41a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_aa074455-08bd-4953-9920-f16a8eed41a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3a31d8e6-ba90-4e88-9860-b9a9c89e6b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3a31d8e6-ba90-4e88-9860-b9a9c89e6b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a1cd4cde-bc9f-47cb-8ca0-c057b9bc3d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a1cd4cde-bc9f-47cb-8ca0-c057b9bc3d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_daece071-5b2a-4cad-bdfe-fd2892253626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_087c8db2-b051-466f-a782-849497aa4f38" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_daece071-5b2a-4cad-bdfe-fd2892253626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b2efd0f-1d34-49eb-84de-b1f1e459434a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_be80d96f-170e-40a5-b2d3-054ab5b6ec30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b2efd0f-1d34-49eb-84de-b1f1e459434a" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_be80d96f-170e-40a5-b2d3-054ab5b6ec30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_ffa063ab-71cf-4e5b-9e4f-94ddd3ebd2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b2efd0f-1d34-49eb-84de-b1f1e459434a" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_ffa063ab-71cf-4e5b-9e4f-94ddd3ebd2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashAcquiredInConnectionWithReverseAcquisition_322a4606-4ccb-4c38-9301-5a4259a51d5e" xlink:href="imux-20201231.xsd#imux_CashAcquiredInConnectionWithReverseAcquisition"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b2efd0f-1d34-49eb-84de-b1f1e459434a" xlink:to="loc_imux_CashAcquiredInConnectionWithReverseAcquisition_322a4606-4ccb-4c38-9301-5a4259a51d5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_47acd3c1-8f60-4b6a-9b13-a5423a87d86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b2efd0f-1d34-49eb-84de-b1f1e459434a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_47acd3c1-8f60-4b6a-9b13-a5423a87d86a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a2d745e7-b3cf-4a63-b3db-89a1c2e17e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b2efd0f-1d34-49eb-84de-b1f1e459434a" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a2d745e7-b3cf-4a63-b3db-89a1c2e17e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2c0ccf9-35f8-4504-98a6-08ba638abf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07ea6e6e-0552-4d85-89b7-3dbbc2e2906d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2c0ccf9-35f8-4504-98a6-08ba638abf7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07ea6e6e-0552-4d85-89b7-3dbbc2e2906d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b1e56eba-c9f7-4f4f-87e9-65d8c3832530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2c0ccf9-35f8-4504-98a6-08ba638abf7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b1e56eba-c9f7-4f4f-87e9-65d8c3832530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27b7ce99-7584-4f7e-b27b-ce818b838895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2c0ccf9-35f8-4504-98a6-08ba638abf7a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27b7ce99-7584-4f7e-b27b-ce818b838895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c916a5be-f18c-4f0a-ae1c-ec06e71e7488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2c0ccf9-35f8-4504-98a6-08ba638abf7a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c916a5be-f18c-4f0a-ae1c-ec06e71e7488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0da3852a-f57a-4d4e-a044-6bb31f40ecb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f75e0f8-aa5b-44ab-89d7-05a8faad0afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0da3852a-f57a-4d4e-a044-6bb31f40ecb5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f75e0f8-aa5b-44ab-89d7-05a8faad0afc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5771eeba-8af4-4d6e-bbd7-a2c222abedd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0da3852a-f57a-4d4e-a044-6bb31f40ecb5" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5771eeba-8af4-4d6e-bbd7-a2c222abedd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_dc82c664-991b-4467-84d7-9f67ea99043f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0da3852a-f57a-4d4e-a044-6bb31f40ecb5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_dc82c664-991b-4467-84d7-9f67ea99043f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:calculationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="imux-20201231.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:calculationLink xlink:role="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransaction" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransaction"/>
  <link:calculationLink xlink:role="http://imux.com/role/AccountingfortheTransaction" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionTables" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/AccountingfortheTransactionTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_aa4a4b11-e492-46b5-9adb-2d2a04adaf1e" xlink:href="imux-20201231.xsd#imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11510681-ec3e-44ba-a95e-4a9810faf5a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_aa4a4b11-e492-46b5-9adb-2d2a04adaf1e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11510681-ec3e-44ba-a95e-4a9810faf5a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_dd7c1537-578f-4169-8043-ce57b57f6201" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_aa4a4b11-e492-46b5-9adb-2d2a04adaf1e" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_dd7c1537-578f-4169-8043-ce57b57f6201" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bcf8db2c-4930-4827-8ca6-7d88c05fd1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bcf8db2c-4930-4827-8ca6-7d88c05fd1b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9441e691-1ede-4485-9bfa-1564c7acbce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_9441e691-1ede-4485-9bfa-1564c7acbce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9acb4ae4-4e05-4727-8857-0879e0bc4253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_9acb4ae4-4e05-4727-8857-0879e0bc4253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_09b21937-1564-42d1-bf98-c5c94230066e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_09b21937-1564-42d1-bf98-c5c94230066e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_b850d834-7aed-4852-9841-4666d94b1b89" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_b850d834-7aed-4852-9841-4666d94b1b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_11127284-348c-4f1b-953a-935cce6fadb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:to="loc_us-gaap_Goodwill_11127284-348c-4f1b-953a-935cce6fadb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_21c85235-3f4b-44dc-9aed-f0e0b7b5c31a" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_21c85235-3f4b-44dc-9aed-f0e0b7b5c31a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_9d08f8ba-abed-460a-9c5e-dcc72a74c6aa" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_21caa124-e76d-41e9-9343-9dffe7ad1840" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_9d08f8ba-abed-460a-9c5e-dcc72a74c6aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreement" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreement"/>
  <link:calculationLink xlink:role="http://imux.com/role/ELADSalesAgreement" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementTables" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/ELADSalesAgreementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf3c2115-c97a-424a-bb89-74e2354b87b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PrepaidClinicalAndRelatedCostsCurrent_20e3a6e6-66b5-42fd-8df9-015396252112" xlink:href="imux-20201231.xsd#imux_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf3c2115-c97a-424a-bb89-74e2354b87b9" xlink:to="loc_imux_PrepaidClinicalAndRelatedCostsCurrent_20e3a6e6-66b5-42fd-8df9-015396252112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent_6824f0a1-3bb9-4ff1-b948-21528d6efd78" xlink:href="imux-20201231.xsd#imux_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf3c2115-c97a-424a-bb89-74e2354b87b9" xlink:to="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent_6824f0a1-3bb9-4ff1-b948-21528d6efd78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d018c850-1666-4133-9d6c-117976d3262e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf3c2115-c97a-424a-bb89-74e2354b87b9" xlink:to="loc_us-gaap_OtherAssetsCurrent_d018c850-1666-4133-9d6c-117976d3262e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_5299a359-1bbb-419d-b35e-c28503f149d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf3c2115-c97a-424a-bb89-74e2354b87b9" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_5299a359-1bbb-419d-b35e-c28503f149d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_48a938f0-c58b-4c16-9c03-28298ce42d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalCostsPayableCurrent_1a6bb545-e090-4599-88ed-ced05a1538a0" xlink:href="imux-20201231.xsd#imux_ClinicalCostsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_48a938f0-c58b-4c16-9c03-28298ce42d6f" xlink:to="loc_imux_ClinicalCostsPayableCurrent_1a6bb545-e090-4599-88ed-ced05a1538a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LegalAndAuditCostsPayableCurrent_ae4212d3-9473-4e88-a20a-ad6146143e14" xlink:href="imux-20201231.xsd#imux_LegalAndAuditCostsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_48a938f0-c58b-4c16-9c03-28298ce42d6f" xlink:to="loc_imux_LegalAndAuditCostsPayableCurrent_ae4212d3-9473-4e88-a20a-ad6146143e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_012110a0-8588-497c-8fd2-26b07823e169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_48a938f0-c58b-4c16-9c03-28298ce42d6f" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_012110a0-8588-497c-8fd2-26b07823e169" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14ee0d1e-e0ce-421a-b63b-33988c034e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1db677dc-155b-44f0-9ffc-951db9c1f0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_14ee0d1e-e0ce-421a-b63b-33988c034e60" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1db677dc-155b-44f0-9ffc-951db9c1f0c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedClinicalCostsCurrent_dc5d671c-805a-408e-be7f-72153b086d95" xlink:href="imux-20201231.xsd#imux_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_14ee0d1e-e0ce-421a-b63b-33988c034e60" xlink:to="loc_imux_AccruedClinicalCostsCurrent_dc5d671c-805a-408e-be7f-72153b086d95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedLegalAndAuditCostsCurrent_cb33189f-d9de-46c3-8a79-fe13f90b746d" xlink:href="imux-20201231.xsd#imux_AccruedLegalAndAuditCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_14ee0d1e-e0ce-421a-b63b-33988c034e60" xlink:to="loc_imux_AccruedLegalAndAuditCostsCurrent_cb33189f-d9de-46c3-8a79-fe13f90b746d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedCompensationCurrent_01be602a-661e-4aca-9ee5-25b59fd38f64" xlink:href="imux-20201231.xsd#imux_AccruedCompensationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_14ee0d1e-e0ce-421a-b63b-33988c034e60" xlink:to="loc_imux_AccruedCompensationCurrent_01be602a-661e-4aca-9ee5-25b59fd38f64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_69f641a6-b884-409a-bdb8-d6673aec44fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_7cb4866e-75f8-4806-a144-1aa3eff0ba03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_69f641a6-b884-409a-bdb8-d6673aec44fe" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_7cb4866e-75f8-4806-a144-1aa3eff0ba03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_128f0a4a-b141-4053-a963-99b296907547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_69f641a6-b884-409a-bdb8-d6673aec44fe" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_128f0a4a-b141-4053-a963-99b296907547" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce8bd8f2-6714-47cf-8df7-11ec84821cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ae1d6558-9e9d-4e7a-9a99-11a7838551e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce8bd8f2-6714-47cf-8df7-11ec84821cc1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ae1d6558-9e9d-4e7a-9a99-11a7838551e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_def48d47-c485-4f97-a4b8-d02b7cddb33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce8bd8f2-6714-47cf-8df7-11ec84821cc1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_def48d47-c485-4f97-a4b8-d02b7cddb33c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e4bbbd12-7c48-46a8-ba53-9d983f861f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce8bd8f2-6714-47cf-8df7-11ec84821cc1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e4bbbd12-7c48-46a8-ba53-9d983f861f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7e5ff3ce-03ec-424a-ac36-f5e377fbe8f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce8bd8f2-6714-47cf-8df7-11ec84821cc1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7e5ff3ce-03ec-424a-ac36-f5e377fbe8f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e8db02b7-7c64-4a8d-a50e-7ebde3351180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce8bd8f2-6714-47cf-8df7-11ec84821cc1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e8db02b7-7c64-4a8d-a50e-7ebde3351180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_90ef657a-b91d-43a4-9e8e-b1adf8518e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce8bd8f2-6714-47cf-8df7-11ec84821cc1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_90ef657a-b91d-43a4-9e8e-b1adf8518e30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ba547da-d277-43b0-948a-fae1afb45be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2805e731-8d78-4484-b86c-59ad4c06d0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ba547da-d277-43b0-948a-fae1afb45be5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2805e731-8d78-4484-b86c-59ad4c06d0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_90cb8ebc-41f6-4b2d-b1fb-f81c8356c41a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ba547da-d277-43b0-948a-fae1afb45be5" xlink:to="loc_us-gaap_OperatingLeaseLiability_90cb8ebc-41f6-4b2d-b1fb-f81c8356c41a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/FairValue" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValue"/>
  <link:calculationLink xlink:role="http://imux.com/role/FairValue" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/FairValueTables" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValueTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/FairValueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStock"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlans" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlans"/>
  <link:calculationLink xlink:role="http://imux.com/role/StockCompensationPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansTables" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/StockCompensationPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/StockCompensationPlansAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansSummaryofStockOptionActivityDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxes" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://imux.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesIncomeTaxRateReconciliationDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8fb55-47e6-4f6b-969a-eee092a1794a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_abe6f3af-a639-4453-84e8-d34894fa3793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8fb55-47e6-4f6b-969a-eee092a1794a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_abe6f3af-a639-4453-84e8-d34894fa3793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1f176df0-5f56-42df-b3af-36f0d69d4992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8fb55-47e6-4f6b-969a-eee092a1794a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1f176df0-5f56-42df-b3af-36f0d69d4992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_10812a85-b836-4bd6-af23-94702c79fa46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8fb55-47e6-4f6b-969a-eee092a1794a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_10812a85-b836-4bd6-af23-94702c79fa46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_3e84fbcc-ccf3-49bb-81d4-f7ea3cc83d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8fb55-47e6-4f6b-969a-eee092a1794a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_3e84fbcc-ccf3-49bb-81d4-f7ea3cc83d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f73964a8-439e-4599-9c21-0d72934d68c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8fb55-47e6-4f6b-969a-eee092a1794a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f73964a8-439e-4599-9c21-0d72934d68c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7f210eec-7db9-44a7-bc4e-3f3a09747c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8fb55-47e6-4f6b-969a-eee092a1794a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7f210eec-7db9-44a7-bc4e-3f3a09747c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_b21031ae-aa47-4714-a752-daec3f267579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d8d8fb55-47e6-4f6b-969a-eee092a1794a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_b21031ae-aa47-4714-a752-daec3f267579" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_7b852f4c-b1b2-4c14-aea9-bc62a8e24b33" xlink:href="imux-20201231.xsd#imux_DeferredTaxAssetsAndLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_235388f4-cbfc-4b78-8ecf-fcfec3825190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_7b852f4c-b1b2-4c14-aea9-bc62a8e24b33" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_235388f4-cbfc-4b78-8ecf-fcfec3825190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ec7d5432-7710-4bef-acfe-df67a4a97154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_7b852f4c-b1b2-4c14-aea9-bc62a8e24b33" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ec7d5432-7710-4bef-acfe-df67a4a97154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e634b8a1-ff58-480f-aa4f-4d87ba32faa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_82e615f1-f56f-4f38-bb48-9481e3ea6e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e634b8a1-ff58-480f-aa4f-4d87ba32faa0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_82e615f1-f56f-4f38-bb48-9481e3ea6e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c04b6eec-0246-4ecb-a98a-32422d2a45cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d864ccc1-e79d-4542-aa94-5714a466cad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c04b6eec-0246-4ecb-a98a-32422d2a45cc" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d864ccc1-e79d-4542-aa94-5714a466cad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_663df02e-1664-4511-b2ec-3875343bb188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c04b6eec-0246-4ecb-a98a-32422d2a45cc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_663df02e-1664-4511-b2ec-3875343bb188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1b8d60eb-109d-4b60-9f44-30e644b4ab94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c04b6eec-0246-4ecb-a98a-32422d2a45cc" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1b8d60eb-109d-4b60-9f44-30e644b4ab94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_27e15466-4b89-463f-953a-f43c2c74f80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c04b6eec-0246-4ecb-a98a-32422d2a45cc" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_27e15466-4b89-463f-953a-f43c2c74f80f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8d97aac3-be9d-4363-aee0-91eaeeac20c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c04b6eec-0246-4ecb-a98a-32422d2a45cc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8d97aac3-be9d-4363-aee0-91eaeeac20c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8764ec59-2494-4335-8dff-ec9d7e7a1f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21c8b0c5-1292-4329-bc23-246ef2f3cc78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8764ec59-2494-4335-8dff-ec9d7e7a1f27" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21c8b0c5-1292-4329-bc23-246ef2f3cc78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_26ac5a1d-7b54-4a24-a112-def49ac029f6" xlink:href="imux-20201231.xsd#imux_DeferredTaxAssetsAndLiabilitiesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8764ec59-2494-4335-8dff-ec9d7e7a1f27" xlink:to="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_26ac5a1d-7b54-4a24-a112-def49ac029f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/EIBLoan" xlink:type="simple" xlink:href="imux-20201231.xsd#EIBLoan"/>
  <link:calculationLink xlink:role="http://imux.com/role/EIBLoan" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/EIBLoanDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#EIBLoanDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/EIBLoanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="imux-20201231.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://imux.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunaudited" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunaudited"/>
  <link:calculationLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunauditedTables" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunauditedTables"/>
  <link:calculationLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail"/>
  <link:calculationLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>imux-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5279c717-4640-48e4-aa74-73546e28db9a,g:602f65cf-bbe8-45d8-a039-a1d02730d21d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://imux.com/role/CoverPage" xlink:type="simple" xlink:href="imux-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://imux.com/role/CoverPage" xlink:type="extended" id="id4f34cc28f4f488dafb2cb100e61fb84_CoverPage"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i5ca2a42b8c0844529330fc7d4a36e13f_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i651de8cc28ae4b92a4035c0186f255d5_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="ib49adb34bdc649a4b6d20236b84d443e_ConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i3682c0ada460497aaed897be7ac56017_ConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2dbb4446e8554a6b963eeab74e62f12f_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ce8d2429-660e-4f14-ae63-cc3e509de725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ce8d2429-660e-4f14-ae63-cc3e509de725" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c6db8865-8f74-4333-b8cd-a9727353463b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_SharesOutstanding_c6db8865-8f74-4333-b8cd-a9727353463b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3253f9e6-1e24-4856-a2ba-6ff98f2bc762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockholdersEquity_3253f9e6-1e24-4856-a2ba-6ff98f2bc762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3f6be30-a9a6-4306-b1da-2e615095116e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_NetIncomeLoss_a3f6be30-a9a6-4306-b1da-2e615095116e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18a45ad9-5e23-4b58-9bee-d7dc61e1d56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18a45ad9-5e23-4b58-9bee-d7dc61e1d56e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e37ee718-5542-4bfa-a7d9-4ecc90760159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e37ee718-5542-4bfa-a7d9-4ecc90760159" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8fc017e7-a21a-45bc-9146-04d24ba6d2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8fc017e7-a21a-45bc-9146-04d24ba6d2c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69fd2ae4-936d-42dd-a8a7-2f8b3a4392d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69fd2ae4-936d-42dd-a8a7-2f8b3a4392d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_94dd3467-4a64-468c-85d1-7a65c7368a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_94dd3467-4a64-468c-85d1-7a65c7368a20" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4622e06c-1b49-47bb-bf04-fbe7350a3b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4622e06c-1b49-47bb-bf04-fbe7350a3b91" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2c8f05c2-384f-46a1-91fc-70a585aecdb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2c8f05c2-384f-46a1-91fc-70a585aecdb3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fb858184-46cb-4354-9778-9382d7af18e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fb858184-46cb-4354-9778-9382d7af18e3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f911fc89-b4e6-426b-9071-d9758fa77ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_34c0f59e-d65c-40ae-bd49-0ce12f0e38b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ce8d2429-660e-4f14-ae63-cc3e509de725" xlink:to="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_587f6d3d-f2c6-4faf-982b-22246a1171ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_PlanNameAxis_587f6d3d-f2c6-4faf-982b-22246a1171ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_587f6d3d-f2c6-4faf-982b-22246a1171ed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_587f6d3d-f2c6-4faf-982b-22246a1171ed" xlink:to="loc_us-gaap_PlanNameDomain_587f6d3d-f2c6-4faf-982b-22246a1171ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7ef1950a-930f-43ac-aae5-aa21a6420fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_587f6d3d-f2c6-4faf-982b-22246a1171ed" xlink:to="loc_us-gaap_PlanNameDomain_7ef1950a-930f-43ac-aae5-aa21a6420fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ExecutiveBonusAgreementMember_28563487-61d1-4200-976f-95a83da5c9e9" xlink:href="imux-20201231.xsd#imux_ExecutiveBonusAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7ef1950a-930f-43ac-aae5-aa21a6420fe6" xlink:to="loc_imux_ExecutiveBonusAgreementMember_28563487-61d1-4200-976f-95a83da5c9e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fc975f40-eadc-4948-bce8-3f010eaeb429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fc975f40-eadc-4948-bce8-3f010eaeb429" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc975f40-eadc-4948-bce8-3f010eaeb429_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc975f40-eadc-4948-bce8-3f010eaeb429" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc975f40-eadc-4948-bce8-3f010eaeb429_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc975f40-eadc-4948-bce8-3f010eaeb429" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember_d248e71b-4d11-4cfc-9966-37953acfdaff" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_PreClosingFinancingMember_d248e71b-4d11-4cfc-9966-37953acfdaff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A4SCSettlementAgreementMember_5805d7e1-194e-4114-bfbc-89bfca3085ef" xlink:href="imux-20201231.xsd#imux_A4SCSettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_A4SCSettlementAgreementMember_5805d7e1-194e-4114-bfbc-89bfca3085ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_ced8162d-cd21-4d04-82c1-ef9f3212fbc6" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_PublicOfferingMember_ced8162d-cd21-4d04-82c1-ef9f3212fbc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_90865ec3-7126-4cb3-848f-a1bcaaeebf99" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_April2020EquityIssuancesMember_90865ec3-7126-4cb3-848f-a1bcaaeebf99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_380e999f-9397-49d5-8929-5b92f30955d7" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_June2020EquityIssuancesMember_380e999f-9397-49d5-8929-5b92f30955d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_7355881f-03ae-4dfc-adfd-48f4fe5b1d94" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_August2020EquityIssuancesMember_7355881f-03ae-4dfc-adfd-48f4fe5b1d94" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_59eef9cf-46a9-40f2-9a31-0874a4482431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_StatementClassOfStockAxis_59eef9cf-46a9-40f2-9a31-0874a4482431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_59eef9cf-46a9-40f2-9a31-0874a4482431_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59eef9cf-46a9-40f2-9a31-0874a4482431" xlink:to="loc_us-gaap_ClassOfStockDomain_59eef9cf-46a9-40f2-9a31-0874a4482431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6846945d-44db-42eb-8126-432f8afa7175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59eef9cf-46a9-40f2-9a31-0874a4482431" xlink:to="loc_us-gaap_ClassOfStockDomain_6846945d-44db-42eb-8126-432f8afa7175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA2ConvertiblePreferredStockMember_3507984c-db37-4be7-ab0e-412c5bf34386" xlink:href="imux-20201231.xsd#imux_SeriesA2ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6846945d-44db-42eb-8126-432f8afa7175" xlink:to="loc_imux_SeriesA2ConvertiblePreferredStockMember_3507984c-db37-4be7-ab0e-412c5bf34386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA1ConvertiblePreferredStockMember_1b4452e3-8610-4b1c-9bbc-9dd54eed9743" xlink:href="imux-20201231.xsd#imux_SeriesA1ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6846945d-44db-42eb-8126-432f8afa7175" xlink:to="loc_imux_SeriesA1ConvertiblePreferredStockMember_1b4452e3-8610-4b1c-9bbc-9dd54eed9743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_03a3b989-1071-4843-9c22-9077cff1d277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_03a3b989-1071-4843-9c22-9077cff1d277" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_03a3b989-1071-4843-9c22-9077cff1d277_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03a3b989-1071-4843-9c22-9077cff1d277" xlink:to="loc_us-gaap_EquityComponentDomain_03a3b989-1071-4843-9c22-9077cff1d277_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03a3b989-1071-4843-9c22-9077cff1d277" xlink:to="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_7c754bf7-72f3-4bf6-bc0d-ad08a699ba0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_PreferredStockMember_7c754bf7-72f3-4bf6-bc0d-ad08a699ba0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4e7bd003-196b-4e3b-a658-1217eb791d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_CommonStockMember_4e7bd003-196b-4e3b-a658-1217eb791d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4b297d16-1d2c-4fcc-adac-ffb8dcfea1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4b297d16-1d2c-4fcc-adac-ffb8dcfea1b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4a1eca88-9177-4e62-a426-2cfe8760fc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4a1eca88-9177-4e62-a426-2cfe8760fc1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_40512782-6925-4f85-a1dd-58b29d8325a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_RetainedEarningsMember_40512782-6925-4f85-a1dd-58b29d8325a5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i932e992eacfe4bc8b8fef1cf4dfa0804_ConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2b2a7a03-af0a-4a33-a99d-3fa2fd1e79ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51e7555d-ec1e-485d-a629-33595f7eba81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2b2a7a03-af0a-4a33-a99d-3fa2fd1e79ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51e7555d-ec1e-485d-a629-33595f7eba81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f62f8a45-3fc3-4a62-93df-3b5129c405e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2b2a7a03-af0a-4a33-a99d-3fa2fd1e79ad" xlink:to="loc_us-gaap_StatementTable_f62f8a45-3fc3-4a62-93df-3b5129c405e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_040778d9-6d56-4377-b82c-6508c4bf75fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f62f8a45-3fc3-4a62-93df-3b5129c405e4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_040778d9-6d56-4377-b82c-6508c4bf75fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_040778d9-6d56-4377-b82c-6508c4bf75fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_040778d9-6d56-4377-b82c-6508c4bf75fd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_040778d9-6d56-4377-b82c-6508c4bf75fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_040778d9-6d56-4377-b82c-6508c4bf75fd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember_26a7a90e-e9e9-4880-b8df-1fe49930606f" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_PreClosingFinancingMember_26a7a90e-e9e9-4880-b8df-1fe49930606f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_673fdff7-049c-45a1-bb1a-dfbb76db4d90" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_PublicOfferingMember_673fdff7-049c-45a1-bb1a-dfbb76db4d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_9819868e-cc4b-4d48-88f4-68fe98d4eb50" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_April2020EquityIssuancesMember_9819868e-cc4b-4d48-88f4-68fe98d4eb50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_00aeba5d-0a77-46f9-8c54-43e6dd344810" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_June2020EquityIssuancesMember_00aeba5d-0a77-46f9-8c54-43e6dd344810" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_6496185c-9f0a-4d01-a256-68ecdc681d40" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_August2020EquityIssuancesMember_6496185c-9f0a-4d01-a256-68ecdc681d40" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i1b9088c397b0415eb51aa454d418e55c_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_097ca399-aeee-4489-8562-8b211eac3f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:to="loc_us-gaap_NetIncomeLoss_097ca399-aeee-4489-8562-8b211eac3f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c79eb954-19c0-4c14-b42f-2ab11d9870e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c79eb954-19c0-4c14-b42f-2ab11d9870e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_bd8f2fa4-0703-4ba4-afea-cad3c4ce55c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_bd8f2fa4-0703-4ba4-afea-cad3c4ce55c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_90756140-2c52-4bf8-855f-6c8c1a07152f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_90756140-2c52-4bf8-855f-6c8c1a07152f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2602abf4-879f-417a-8c59-7a3a58631856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_ShareBasedCompensation_2602abf4-879f-417a-8c59-7a3a58631856" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d513e7fa-1b8b-4a6a-a995-2fbbf4dac34e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d513e7fa-1b8b-4a6a-a995-2fbbf4dac34e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_0768b9ad-bba7-404f-a3f5-60bfc1fa6e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_0768b9ad-bba7-404f-a3f5-60bfc1fa6e5c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6b1fe643-0f75-488f-aa25-c30a524848f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6b1fe643-0f75-488f-aa25-c30a524848f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c228bde8-f2fc-4a0e-aeda-09aa0803860c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c228bde8-f2fc-4a0e-aeda-09aa0803860c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_af08b854-07a3-4e5d-9a3c-50702a0a6f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_af08b854-07a3-4e5d-9a3c-50702a0a6f75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5eed7c32-a068-47d8-a45c-823430140410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5eed7c32-a068-47d8-a45c-823430140410" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f111dc95-764d-476c-acb1-3080addf0144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f111dc95-764d-476c-acb1-3080addf0144" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6f9bad1d-eac4-4144-8d0d-795020da07fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6f9bad1d-eac4-4144-8d0d-795020da07fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_23c19aef-7de0-46b8-964d-a1d264ffd270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_23c19aef-7de0-46b8-964d-a1d264ffd270" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_b435c956-707a-4b7a-8b78-3b4db6e3338e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_b435c956-707a-4b7a-8b78-3b4db6e3338e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashAcquiredInConnectionWithReverseAcquisition_7a1bf159-8209-45f3-bebd-8f9a377b3b59" xlink:href="imux-20201231.xsd#imux_CashAcquiredInConnectionWithReverseAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_imux_CashAcquiredInConnectionWithReverseAcquisition_7a1bf159-8209-45f3-bebd-8f9a377b3b59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_b073dc19-428d-4fa8-8766-828f4e8fc802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_b073dc19-428d-4fa8-8766-828f4e8fc802" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_efe35d5b-cdc8-48ad-a560-f3b3320e3281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_efe35d5b-cdc8-48ad-a560-f3b3320e3281" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_a3d351fd-732c-4a05-84d7-9a0c1596eebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_a3d351fd-732c-4a05-84d7-9a0c1596eebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fe739b33-3c16-4938-95d2-dab1eb96db55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fe739b33-3c16-4938-95d2-dab1eb96db55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f3d3c6db-d6df-4b47-9c0d-66fcb100ee67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f3d3c6db-d6df-4b47-9c0d-66fcb100ee67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c314946c-8a64-4751-9f53-1646eb463c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c314946c-8a64-4751-9f53-1646eb463c7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_733421d2-60de-4388-8543-c2b84d0d1362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_733421d2-60de-4388-8543-c2b84d0d1362" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_57393539-3916-49fc-9e1f-34cffc98cfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_57393539-3916-49fc-9e1f-34cffc98cfdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d55206e-6533-446c-b46f-a774767c260b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d55206e-6533-446c-b46f-a774767c260b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ddce115-1c5b-4384-a8fa-0910d523d013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredStockIssuanceCostsIncludedInLiabilities_e5521ff1-be6e-4d29-91ad-847424c34d83" xlink:href="imux-20201231.xsd#imux_DeferredStockIssuanceCostsIncludedInLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_imux_DeferredStockIssuanceCostsIncludedInLiabilities_e5521ff1-be6e-4d29-91ad-847424c34d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_d21909c1-82f6-4ef2-a443-34e1c2510caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_d21909c1-82f6-4ef2-a443-34e1c2510caa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_7637a985-5ad7-4717-b225-71d78d34c49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_7637a985-5ad7-4717-b225-71d78d34c49b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OfferingCostsIncludedInAccruedExpenses_549b998c-ffcc-4aac-a23a-06e47342305f" xlink:href="imux-20201231.xsd#imux_OfferingCostsIncludedInAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_imux_OfferingCostsIncludedInAccruedExpenses_549b998c-ffcc-4aac-a23a-06e47342305f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable_94f5ff1b-9a4a-49a5-9773-637cc514c8c2" xlink:href="imux-20201231.xsd#imux_PropertyPlantAndEquipmentIncludedInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable_94f5ff1b-9a4a-49a5-9773-637cc514c8c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9dce4da0-1294-4074-8b85-59a10c351575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_StatementTable_9dce4da0-1294-4074-8b85-59a10c351575" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3f99e116-82b2-4402-a79f-f53f22b339ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9dce4da0-1294-4074-8b85-59a10c351575" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3f99e116-82b2-4402-a79f-f53f22b339ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3f99e116-82b2-4402-a79f-f53f22b339ae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3f99e116-82b2-4402-a79f-f53f22b339ae" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3f99e116-82b2-4402-a79f-f53f22b339ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3f99e116-82b2-4402-a79f-f53f22b339ae" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember_1d466561-eeef-47be-baa8-309cfe5c582d" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_PreClosingFinancingMember_1d466561-eeef-47be-baa8-309cfe5c582d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_0929da6b-045e-45b4-9552-688bff3c2565" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_PublicOfferingMember_0929da6b-045e-45b4-9552-688bff3c2565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_0e9d2a3d-f66c-4f48-9b14-10a3886c3c8a" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_April2020EquityIssuancesMember_0e9d2a3d-f66c-4f48-9b14-10a3886c3c8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_a42efb1a-a5e2-4be4-bcf8-2cff91989028" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_June2020EquityIssuancesMember_a42efb1a-a5e2-4be4-bcf8-2cff91989028" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_44e52620-c48c-4e54-a954-752cd732ed31" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_August2020EquityIssuancesMember_44e52620-c48c-4e54-a954-752cd732ed31" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="id6d553c027124a8e8a19e3494f375ab3_ConsolidatedStatementsofCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_26e3babf-e733-41c4-bcce-b8d6aa9f57b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_42391861-39d4-4a41-9db1-4c50d5ce211e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26e3babf-e733-41c4-bcce-b8d6aa9f57b0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_42391861-39d4-4a41-9db1-4c50d5ce211e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_34b5b7c6-58ac-44ee-9abc-07801ba2e024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_26e3babf-e733-41c4-bcce-b8d6aa9f57b0" xlink:to="loc_us-gaap_StatementTable_34b5b7c6-58ac-44ee-9abc-07801ba2e024" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aa55417a-dc1b-4df2-a6e6-b057e0a20d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_34b5b7c6-58ac-44ee-9abc-07801ba2e024" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aa55417a-dc1b-4df2-a6e6-b057e0a20d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aa55417a-dc1b-4df2-a6e6-b057e0a20d08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aa55417a-dc1b-4df2-a6e6-b057e0a20d08" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aa55417a-dc1b-4df2-a6e6-b057e0a20d08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aa55417a-dc1b-4df2-a6e6-b057e0a20d08" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember_dfc9836a-1450-4c87-9f38-f4a7630c2fb8" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_PreClosingFinancingMember_dfc9836a-1450-4c87-9f38-f4a7630c2fb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_2ebaff16-6c67-4f3a-9d84-8a5342cf2525" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_PublicOfferingMember_2ebaff16-6c67-4f3a-9d84-8a5342cf2525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_454d09bb-6d37-4d0a-b98b-16fa5da3749f" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_April2020EquityIssuancesMember_454d09bb-6d37-4d0a-b98b-16fa5da3749f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_90f8aa93-7118-4e2c-afbb-6772145587be" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_June2020EquityIssuancesMember_90f8aa93-7118-4e2c-afbb-6772145587be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_0e4467db-7955-4fcf-9093-db4c2fb271f6" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_August2020EquityIssuancesMember_0e4467db-7955-4fcf-9093-db4c2fb271f6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="imux-20201231.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:definitionLink xlink:role="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended" id="ib5bfd6ec5cc34b3a96b180e3e9713f78_DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:roleRef roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail" xlink:type="extended" id="i461c79e0824243a4a302bd09c5e81df0_DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22a8ae6c-2fc2-488a-93e9-d97d36c649a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22a8ae6c-2fc2-488a-93e9-d97d36c649a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6ee2d1f8-0083-4cb4-8754-c619c9a3e448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6ee2d1f8-0083-4cb4-8754-c619c9a3e448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f38fb45-7430-4f42-a17e-580c54f92431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f38fb45-7430-4f42-a17e-580c54f92431" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_64e19c4c-a881-4905-b453-100e0db46330" xlink:href="imux-20201231.xsd#imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_64e19c4c-a881-4905-b453-100e0db46330" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4a648642-dbf0-46a3-ade2-1192c3e66eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4a648642-dbf0-46a3-ade2-1192c3e66eef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b29ba77f-0fca-4b1b-a94e-8ab1f003dea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b29ba77f-0fca-4b1b-a94e-8ab1f003dea5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationSharesOwnedPriorToTransaction_6dcf704b-14c2-430b-9c39-e1f31207e1ee" xlink:href="imux-20201231.xsd#imux_BusinessCombinationSharesOwnedPriorToTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_imux_BusinessCombinationSharesOwnedPriorToTransaction_6dcf704b-14c2-430b-9c39-e1f31207e1ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_13cc8ea7-8e48-4d5a-95a7-3ea012ae6671" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_13cc8ea7-8e48-4d5a-95a7-3ea012ae6671" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3b01ccac-400f-479a-b40b-c6710863fbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3b01ccac-400f-479a-b40b-c6710863fbf6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_b8154c86-b859-4925-9216-fafc8859226b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_b8154c86-b859-4925-9216-fafc8859226b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_912f3c8c-3acd-4b8e-8a55-ca05fdb9b1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_912f3c8c-3acd-4b8e-8a55-ca05fdb9b1d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5c769525-470f-4883-b9be-e12f4ba3b61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5c769525-470f-4883-b9be-e12f4ba3b61e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5c769525-470f-4883-b9be-e12f4ba3b61e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5c769525-470f-4883-b9be-e12f4ba3b61e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5c769525-470f-4883-b9be-e12f4ba3b61e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdcc7a39-8bb0-450a-8e46-08e2b49d0cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5c769525-470f-4883-b9be-e12f4ba3b61e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdcc7a39-8bb0-450a-8e46-08e2b49d0cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_d3f35a1d-873b-4bff-967d-0904dccbf067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdcc7a39-8bb0-450a-8e46-08e2b49d0cf1" xlink:to="loc_us-gaap_PrivatePlacementMember_d3f35a1d-873b-4bff-967d-0904dccbf067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b35d037d-433a-4968-bbfa-27c0e164cf63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b35d037d-433a-4968-bbfa-27c0e164cf63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b35d037d-433a-4968-bbfa-27c0e164cf63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b35d037d-433a-4968-bbfa-27c0e164cf63" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b35d037d-433a-4968-bbfa-27c0e164cf63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e616375-ac4f-4908-b264-bc68c5dbfc11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b35d037d-433a-4968-bbfa-27c0e164cf63" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e616375-ac4f-4908-b264-bc68c5dbfc11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_008eec1c-5cda-4d95-a03a-135272d42043" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e616375-ac4f-4908-b264-bc68c5dbfc11" xlink:to="loc_imux_ImmunicAGMember_008eec1c-5cda-4d95-a03a-135272d42043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_979911d9-aae4-40b1-a391-5086ad6b0134" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_srt_CounterpartyNameAxis_979911d9-aae4-40b1-a391-5086ad6b0134" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979911d9-aae4-40b1-a391-5086ad6b0134_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_979911d9-aae4-40b1-a391-5086ad6b0134" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979911d9-aae4-40b1-a391-5086ad6b0134_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f191128d-9b98-410e-91c6-ee859bb641fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_979911d9-aae4-40b1-a391-5086ad6b0134" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f191128d-9b98-410e-91c6-ee859bb641fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_be09ce12-2c9a-4685-9aeb-3a9cc585011c" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f191128d-9b98-410e-91c6-ee859bb641fa" xlink:to="loc_imux_VitalTherapiesInc.Member_be09ce12-2c9a-4685-9aeb-3a9cc585011c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ec8c7bd6-4dea-47f0-8cab-d43870921b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_us-gaap_AwardTypeAxis_ec8c7bd6-4dea-47f0-8cab-d43870921b5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec8c7bd6-4dea-47f0-8cab-d43870921b5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ec8c7bd6-4dea-47f0-8cab-d43870921b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec8c7bd6-4dea-47f0-8cab-d43870921b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b12e5a45-83fb-4f54-a809-0da2a9c25945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ec8c7bd6-4dea-47f0-8cab-d43870921b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b12e5a45-83fb-4f54-a809-0da2a9c25945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_884c908f-6a87-4a22-b445-575e2ef8e5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b12e5a45-83fb-4f54-a809-0da2a9c25945" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_884c908f-6a87-4a22-b445-575e2ef8e5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_dei_LegalEntityAxis_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f" xlink:to="loc_dei_EntityDomain_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4960c2ec-5e84-4fd5-9f0f-84122b60af60" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f" xlink:to="loc_dei_EntityDomain_4960c2ec-5e84-4fd5-9f0f-84122b60af60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_5f27ea5f-5353-4ecc-a7cb-fd6861b8e106" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4960c2ec-5e84-4fd5-9f0f-84122b60af60" xlink:to="loc_imux_ImmunicAGMember_5f27ea5f-5353-4ecc-a7cb-fd6861b8e106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_f2449147-610e-4735-83ad-67d5121e2b86" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4960c2ec-5e84-4fd5-9f0f-84122b60af60" xlink:to="loc_imux_VitalTherapiesInc.Member_f2449147-610e-4735-83ad-67d5121e2b86" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ica390c8ce33b4fb7a2adf3f241b62d59_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="id600a15789664376a9f265760d89d269_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i63e6c212f97a40e286ab629688e376a7_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i2a97776451ca462bb8609da4dd900b00_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashEquivalentsInvestmentsMaturityPeriod_5139ae5b-805e-4159-a1e5-fd04bb6c8bdb" xlink:href="imux-20201231.xsd#imux_CashEquivalentsInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_imux_CashEquivalentsInvestmentsMaturityPeriod_5139ae5b-805e-4159-a1e5-fd04bb6c8bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6de7476e-fe7d-4e6d-ba2c-a9fe38d4e067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6de7476e-fe7d-4e6d-ba2c-a9fe38d4e067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_7c636d30-23cf-480f-8718-6c43672a4c21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_DepreciationAndAmortization_7c636d30-23cf-480f-8718-6c43672a4c21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_66208302-9968-4353-9d99-abcac8c61df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_66208302-9968-4353-9d99-abcac8c61df5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e1729a30-d654-4736-8b55-3b36766ff682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e1729a30-d654-4736-8b55-3b36766ff682" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_06115100-284a-4b83-9813-523556d784e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_06115100-284a-4b83-9813-523556d784e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases_1d9de533-58a9-4860-99fc-0abe2f3c4530" xlink:href="imux-20201231.xsd#imux_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases_1d9de533-58a9-4860-99fc-0abe2f3c4530" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8c50b435-4f36-4c3e-8458-793217aa4f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8c50b435-4f36-4c3e-8458-793217aa4f83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b38415ab-94b3-4c9d-a33c-24abeaab3402" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8c50b435-4f36-4c3e-8458-793217aa4f83" xlink:to="loc_srt_RangeAxis_b38415ab-94b3-4c9d-a33c-24abeaab3402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b38415ab-94b3-4c9d-a33c-24abeaab3402_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b38415ab-94b3-4c9d-a33c-24abeaab3402" xlink:to="loc_srt_RangeMember_b38415ab-94b3-4c9d-a33c-24abeaab3402_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e09903be-6d4b-4508-b75d-d97ed6de5ee0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b38415ab-94b3-4c9d-a33c-24abeaab3402" xlink:to="loc_srt_RangeMember_e09903be-6d4b-4508-b75d-d97ed6de5ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a3a5f7c-f1ea-4878-81c0-2039ac0d850d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e09903be-6d4b-4508-b75d-d97ed6de5ee0" xlink:to="loc_srt_MinimumMember_5a3a5f7c-f1ea-4878-81c0-2039ac0d850d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6b97638c-f62f-44e9-aa49-b463b1c09ad4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e09903be-6d4b-4508-b75d-d97ed6de5ee0" xlink:to="loc_srt_MaximumMember_6b97638c-f62f-44e9-aa49-b463b1c09ad4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended" id="iad416a93d6db41efb51153baeac6e63b_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_abceb42f-083c-43d4-8d75-46df8a1746ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0cfb1831-52e4-4a5c-85ad-04f7c150b339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_abceb42f-083c-43d4-8d75-46df8a1746ea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0cfb1831-52e4-4a5c-85ad-04f7c150b339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23e5ed86-2081-411e-8e1f-6a9838553a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_abceb42f-083c-43d4-8d75-46df8a1746ea" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23e5ed86-2081-411e-8e1f-6a9838553a31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ecd294a-d445-46c3-a7c7-e213dba39f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23e5ed86-2081-411e-8e1f-6a9838553a31" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ecd294a-d445-46c3-a7c7-e213dba39f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ecd294a-d445-46c3-a7c7-e213dba39f13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ecd294a-d445-46c3-a7c7-e213dba39f13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3ecd294a-d445-46c3-a7c7-e213dba39f13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c380759-a6be-4eb9-ac24-e85056f58133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ecd294a-d445-46c3-a7c7-e213dba39f13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c380759-a6be-4eb9-ac24-e85056f58133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_53b8fc7c-bc1a-4b90-ae02-419f0f4be676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c380759-a6be-4eb9-ac24-e85056f58133" xlink:to="loc_us-gaap_StockOptionMember_53b8fc7c-bc1a-4b90-ae02-419f0f4be676" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransaction" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransaction"/>
  <link:definitionLink xlink:role="http://imux.com/role/AccountingfortheTransaction" xlink:type="extended" id="i891b0876082a4a689149096986561bf1_AccountingfortheTransaction"/>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionTables" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/AccountingfortheTransactionTables" xlink:type="extended" id="i49e610f5111741cb9d7f8e3ecd171dcf_AccountingfortheTransactionTables"/>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail" xlink:type="extended" id="i77086875e83d49bbbd7e5e96e3173f9c_AccountingfortheTransactionAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_bc74811c-9a0c-4474-9d1c-8fd95c4c8381" xlink:href="imux-20201231.xsd#imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_bc74811c-9a0c-4474-9d1c-8fd95c4c8381" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2d605d45-f8ec-4421-8526-c0dc529a3a4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2d605d45-f8ec-4421-8526-c0dc529a3a4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_0e0997d4-0c84-4e64-acdb-19dec957a4d5" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_0e0997d4-0c84-4e64-acdb-19dec957a4d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e1bc4078-8a86-48ed-a164-29d7b9b385b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_us-gaap_Goodwill_e1bc4078-8a86-48ed-a164-29d7b9b385b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1b5e7178-0ed7-4c3d-b375-d457f45d74df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1b5e7178-0ed7-4c3d-b375-d457f45d74df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges_dc434922-4d04-4709-885f-4b58f2bafeff" xlink:href="imux-20201231.xsd#imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges_dc434922-4d04-4709-885f-4b58f2bafeff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc1d4940-8522-43d7-8a4e-047bf3522664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_us-gaap_AwardTypeAxis_dc1d4940-8522-43d7-8a4e-047bf3522664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc1d4940-8522-43d7-8a4e-047bf3522664_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dc1d4940-8522-43d7-8a4e-047bf3522664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc1d4940-8522-43d7-8a4e-047bf3522664_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480f5ed7-e577-4e50-a43c-dab30b5ee743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dc1d4940-8522-43d7-8a4e-047bf3522664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480f5ed7-e577-4e50-a43c-dab30b5ee743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aa965bdf-356d-4c63-b98d-14f078a9f95e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480f5ed7-e577-4e50-a43c-dab30b5ee743" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aa965bdf-356d-4c63-b98d-14f078a9f95e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_713549ef-2654-4d58-bf3e-d59f03a6bc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480f5ed7-e577-4e50-a43c-dab30b5ee743" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_713549ef-2654-4d58-bf3e-d59f03a6bc5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_581f938d-83b1-49ce-93b4-d4b88dd08f9f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_dei_LegalEntityAxis_581f938d-83b1-49ce-93b4-d4b88dd08f9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_581f938d-83b1-49ce-93b4-d4b88dd08f9f_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_581f938d-83b1-49ce-93b4-d4b88dd08f9f" xlink:to="loc_dei_EntityDomain_581f938d-83b1-49ce-93b4-d4b88dd08f9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_78a9c037-4d15-41f5-ad72-47620ba3856a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_581f938d-83b1-49ce-93b4-d4b88dd08f9f" xlink:to="loc_dei_EntityDomain_78a9c037-4d15-41f5-ad72-47620ba3856a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_8204038f-a104-41f7-adac-68844141edbd" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_78a9c037-4d15-41f5-ad72-47620ba3856a" xlink:to="loc_imux_ImmunicAGMember_8204038f-a104-41f7-adac-68844141edbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_30150b81-7336-4647-9ba1-d138b9697cc9" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_78a9c037-4d15-41f5-ad72-47620ba3856a" xlink:to="loc_imux_VitalTherapiesInc.Member_30150b81-7336-4647-9ba1-d138b9697cc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5af6c279-f2dc-410d-aabc-e383437f1459" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_srt_CounterpartyNameAxis_5af6c279-f2dc-410d-aabc-e383437f1459" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5af6c279-f2dc-410d-aabc-e383437f1459_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5af6c279-f2dc-410d-aabc-e383437f1459" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5af6c279-f2dc-410d-aabc-e383437f1459_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1fb693ba-a25a-45ba-8bc9-fdfefecbfb00" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5af6c279-f2dc-410d-aabc-e383437f1459" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1fb693ba-a25a-45ba-8bc9-fdfefecbfb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_96ee7c27-dc1a-45f3-b836-ab4fcd388672" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1fb693ba-a25a-45ba-8bc9-fdfefecbfb00" xlink:to="loc_imux_VitalTherapiesInc.Member_96ee7c27-dc1a-45f3-b836-ab4fcd388672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d9432e03-6ee9-4101-ac4e-234db2456a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d9432e03-6ee9-4101-ac4e-234db2456a41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d9432e03-6ee9-4101-ac4e-234db2456a41_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d9432e03-6ee9-4101-ac4e-234db2456a41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d9432e03-6ee9-4101-ac4e-234db2456a41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86c2b194-e9b7-4b9b-b5f0-ee86b83df7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d9432e03-6ee9-4101-ac4e-234db2456a41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86c2b194-e9b7-4b9b-b5f0-ee86b83df7a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicInc.Member_2587b62c-f419-46f4-8d5c-12e47064eabe" xlink:href="imux-20201231.xsd#imux_ImmunicInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86c2b194-e9b7-4b9b-b5f0-ee86b83df7a8" xlink:to="loc_imux_ImmunicInc.Member_2587b62c-f419-46f4-8d5c-12e47064eabe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail" xlink:type="extended" id="i7b9d4dbbe4a44071bc60c4ed7479a503_AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a8bfd8ff-9205-47ee-ab35-c6b7b15f677a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a8bfd8ff-9205-47ee-ab35-c6b7b15f677a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_fc552914-1e51-4b0f-aaf9-5490bb10c184" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_fc552914-1e51-4b0f-aaf9-5490bb10c184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_93db0608-f4ad-4f21-b4ea-a9015a731fbe" xlink:href="imux-20201231.xsd#imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_93db0608-f4ad-4f21-b4ea-a9015a731fbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9601c806-7df2-4e32-a9e6-27b8ffedf954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9601c806-7df2-4e32-a9e6-27b8ffedf954" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1aa0fcde-141a-4c82-8d2d-e27ff84429a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1aa0fcde-141a-4c82-8d2d-e27ff84429a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_285de4e1-48ae-4bae-86b2-222c579a3496" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_285de4e1-48ae-4bae-86b2-222c579a3496" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_96cb7027-7893-45ad-b874-73b35a373859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:to="loc_us-gaap_AwardTypeAxis_96cb7027-7893-45ad-b874-73b35a373859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96cb7027-7893-45ad-b874-73b35a373859_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_96cb7027-7893-45ad-b874-73b35a373859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96cb7027-7893-45ad-b874-73b35a373859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0635a09-c389-4381-a395-aafc854e2045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_96cb7027-7893-45ad-b874-73b35a373859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0635a09-c389-4381-a395-aafc854e2045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5a603166-aab5-4248-b55e-edb0b4e9d5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0635a09-c389-4381-a395-aafc854e2045" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5a603166-aab5-4248-b55e-edb0b4e9d5f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8e5f48ca-b20d-433c-a142-73153af11b20" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:to="loc_dei_LegalEntityAxis_8e5f48ca-b20d-433c-a142-73153af11b20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8e5f48ca-b20d-433c-a142-73153af11b20_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8e5f48ca-b20d-433c-a142-73153af11b20" xlink:to="loc_dei_EntityDomain_8e5f48ca-b20d-433c-a142-73153af11b20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ab7f4b74-a266-47a2-a7ab-6ff8c21dd62d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8e5f48ca-b20d-433c-a142-73153af11b20" xlink:to="loc_dei_EntityDomain_ab7f4b74-a266-47a2-a7ab-6ff8c21dd62d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_d3b03e10-1a83-4dbe-9c66-a23315420361" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ab7f4b74-a266-47a2-a7ab-6ff8c21dd62d" xlink:to="loc_imux_VitalTherapiesInc.Member_d3b03e10-1a83-4dbe-9c66-a23315420361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c555793-aeb8-4cde-98fe-233cfe30bd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c555793-aeb8-4cde-98fe-233cfe30bd87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_b4683265-d6c4-49f7-9166-ee9d2cacdec4" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c555793-aeb8-4cde-98fe-233cfe30bd87" xlink:to="loc_imux_ImmunicAGMember_b4683265-d6c4-49f7-9166-ee9d2cacdec4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail" xlink:type="extended" id="i71f9da51dfe8493896bfbbc8701d1ba1_AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aaed883c-5b57-46c1-b880-018bdcaa99da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aaed883c-5b57-46c1-b880-018bdcaa99da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ec8deece-9376-4453-82b2-c02679d92f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ec8deece-9376-4453-82b2-c02679d92f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_c8bd8072-8d7c-44a6-9de6-7fdbf4a5904d" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_c8bd8072-8d7c-44a6-9de6-7fdbf4a5904d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_76f25695-5a70-4b23-bc2f-feefde1a4725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_76f25695-5a70-4b23-bc2f-feefde1a4725" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_0d08b295-7c06-400f-9555-e53c9423c179" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_0d08b295-7c06-400f-9555-e53c9423c179" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e331b751-696e-4aa2-b5a2-dad831a60be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e331b751-696e-4aa2-b5a2-dad831a60be4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_d3b941ad-3b6c-473d-aeea-e9b71b4f9a32" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_d3b941ad-3b6c-473d-aeea-e9b71b4f9a32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0d50eb5d-930d-4ed4-ac16-366a00e4c9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_Goodwill_0d50eb5d-930d-4ed4-ac16-366a00e4c9c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9dfc0946-4a70-453a-aada-32a68078f0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9dfc0946-4a70-453a-aada-32a68078f0da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_21714080-b09b-4b38-8890-9a4d81aed687" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:to="loc_dei_LegalEntityAxis_21714080-b09b-4b38-8890-9a4d81aed687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_21714080-b09b-4b38-8890-9a4d81aed687_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_21714080-b09b-4b38-8890-9a4d81aed687" xlink:to="loc_dei_EntityDomain_21714080-b09b-4b38-8890-9a4d81aed687_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e96adba5-2300-42ab-aeea-ec9b289a84b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_21714080-b09b-4b38-8890-9a4d81aed687" xlink:to="loc_dei_EntityDomain_e96adba5-2300-42ab-aeea-ec9b289a84b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_f50a0c64-f9a0-47b3-95ff-533c6d51d3ed" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e96adba5-2300-42ab-aeea-ec9b289a84b1" xlink:to="loc_imux_VitalTherapiesInc.Member_f50a0c64-f9a0-47b3-95ff-533c6d51d3ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_410022db-0548-4e9f-9f4f-6d302bbf0e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_410022db-0548-4e9f-9f4f-6d302bbf0e59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_410022db-0548-4e9f-9f4f-6d302bbf0e59_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_410022db-0548-4e9f-9f4f-6d302bbf0e59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_410022db-0548-4e9f-9f4f-6d302bbf0e59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7d036422-ab6c-44be-844e-156b43edfd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_410022db-0548-4e9f-9f4f-6d302bbf0e59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7d036422-ab6c-44be-844e-156b43edfd78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicInc.Member_8b7f60d2-a4d3-4b18-8f9a-837c28240fbd" xlink:href="imux-20201231.xsd#imux_ImmunicInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7d036422-ab6c-44be-844e-156b43edfd78" xlink:to="loc_imux_ImmunicInc.Member_8b7f60d2-a4d3-4b18-8f9a-837c28240fbd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreement" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreement"/>
  <link:definitionLink xlink:role="http://imux.com/role/ELADSalesAgreement" xlink:type="extended" id="i0c510d2fcef744a1b08d53f30295d5f0_ELADSalesAgreement"/>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementTables" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/ELADSalesAgreementTables" xlink:type="extended" id="ie30d891763a748aaaf34e905e8564776_ELADSalesAgreementTables"/>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail" xlink:type="extended" id="if5be250baf584e1a8f9cce847bee0a1f_ELADSalesAgreementAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_11481af1-2300-4661-92a4-16c338279f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_11481af1-2300-4661-92a4-16c338279f55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit_2fb3f7dc-bf85-4822-aebd-0a5a2992c47d" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit_2fb3f7dc-bf85-4822-aebd-0a5a2992c47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration_9658aa16-f58d-4bd4-8a17-66fb41a57182" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration_9658aa16-f58d-4bd4-8a17-66fb41a57182" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow_24cf7cef-4823-426d-94c0-9e743820f12b" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow_24cf7cef-4823-426d-94c0-9e743820f12b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_1b993ffb-91e2-4f3d-acc1-b2c70e37c142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_1b993ffb-91e2-4f3d-acc1-b2c70e37c142" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_657b4d61-c2c7-4f3f-a17d-27d606c94667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_657b4d61-c2c7-4f3f-a17d-27d606c94667" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_3c25f1a7-702f-4459-b667-ae060b548bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_3c25f1a7-702f-4459-b667-ae060b548bd6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueAdjustment_9130b1ad-cc78-49e0-8545-5d5468c69a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_AssetsFairValueAdjustment_9130b1ad-cc78-49e0-8545-5d5468c69a4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2da2fed3-c719-4cc2-8266-981470085434" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_dei_LegalEntityAxis_2da2fed3-c719-4cc2-8266-981470085434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2da2fed3-c719-4cc2-8266-981470085434_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2da2fed3-c719-4cc2-8266-981470085434" xlink:to="loc_dei_EntityDomain_2da2fed3-c719-4cc2-8266-981470085434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5bb2a933-6aab-45ab-8e85-9af9cfd69227" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2da2fed3-c719-4cc2-8266-981470085434" xlink:to="loc_dei_EntityDomain_5bb2a933-6aab-45ab-8e85-9af9cfd69227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_1f552d61-9be7-4579-b6de-796b61ed2b1d" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5bb2a933-6aab-45ab-8e85-9af9cfd69227" xlink:to="loc_imux_VitalTherapiesInc.Member_1f552d61-9be7-4579-b6de-796b61ed2b1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_08044a75-b749-4938-811d-a0c4c3aea7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_08044a75-b749-4938-811d-a0c4c3aea7ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08044a75-b749-4938-811d-a0c4c3aea7ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_08044a75-b749-4938-811d-a0c4c3aea7ab" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08044a75-b749-4938-811d-a0c4c3aea7ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7ae25b5d-cc9e-4be6-ba69-cab4ba91ffb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_08044a75-b749-4938-811d-a0c4c3aea7ab" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7ae25b5d-cc9e-4be6-ba69-cab4ba91ffb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ELADRelatedAssetsMember_94782a12-2c84-4ab0-8df3-344ea1f99ee2" xlink:href="imux-20201231.xsd#imux_ELADRelatedAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7ae25b5d-cc9e-4be6-ba69-cab4ba91ffb4" xlink:to="loc_imux_ELADRelatedAssetsMember_94782a12-2c84-4ab0-8df3-344ea1f99ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_306d503e-0029-4bf9-80ea-486a6bb45379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_306d503e-0029-4bf9-80ea-486a6bb45379" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_306d503e-0029-4bf9-80ea-486a6bb45379_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_306d503e-0029-4bf9-80ea-486a6bb45379" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_306d503e-0029-4bf9-80ea-486a6bb45379_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d9714337-4c71-4f53-a462-154e2a92d5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_306d503e-0029-4bf9-80ea-486a6bb45379" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d9714337-4c71-4f53-a462-154e2a92d5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_63cf003e-45dc-4489-be1d-d8475370035b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_d9714337-4c71-4f53-a462-154e2a92d5a2" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_63cf003e-45dc-4489-be1d-d8475370035b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e" xlink:to="loc_us-gaap_ReceivableTypeDomain_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_fb6297bf-2854-45cd-bbe4-3894e3402aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e" xlink:to="loc_us-gaap_ReceivableTypeDomain_fb6297bf-2854-45cd-bbe4-3894e3402aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_6f5e4981-cb20-4035-85ed-a32165a1b5df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_fb6297bf-2854-45cd-bbe4-3894e3402aeb" xlink:to="loc_us-gaap_NotesReceivableMember_6f5e4981-cb20-4035-85ed-a32165a1b5df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail" xlink:type="extended" id="i31d5ecda95944c32aa32e8cc3e0b2900_ELADSalesAgreementEstimatedFairValueofELADAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0162ae79-ed16-454e-8871-5fd8100e81f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_14e5a1a4-d7d0-45e4-99f5-8d9a5f5f230a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0162ae79-ed16-454e-8871-5fd8100e81f3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_14e5a1a4-d7d0-45e4-99f5-8d9a5f5f230a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0162ae79-ed16-454e-8871-5fd8100e81f3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aabfbe7f-7129-45f6-a0aa-593c43ddc998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aabfbe7f-7129-45f6-a0aa-593c43ddc998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aabfbe7f-7129-45f6-a0aa-593c43ddc998_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aabfbe7f-7129-45f6-a0aa-593c43ddc998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aabfbe7f-7129-45f6-a0aa-593c43ddc998_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aabfbe7f-7129-45f6-a0aa-593c43ddc998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalDevelopmentEquipmentMember_21845260-872f-469b-971b-2f394ea501c1" xlink:href="imux-20201231.xsd#imux_ClinicalDevelopmentEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:to="loc_imux_ClinicalDevelopmentEquipmentMember_21845260-872f-469b-971b-2f394ea501c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SuppliesAndWorkingCellBanksMember_580d6af3-320b-4c9f-8a8a-e6c49a6fba6b" xlink:href="imux-20201231.xsd#imux_SuppliesAndWorkingCellBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:to="loc_imux_SuppliesAndWorkingCellBanksMember_580d6af3-320b-4c9f-8a8a-e6c49a6fba6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d3750da8-ae9e-49a6-9cb1-db7b1353486b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d3750da8-ae9e-49a6-9cb1-db7b1353486b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ea8c145-0b5e-467a-8a3b-fec71f019a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ea8c145-0b5e-467a-8a3b-fec71f019a0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2ea8c145-0b5e-467a-8a3b-fec71f019a0b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ea8c145-0b5e-467a-8a3b-fec71f019a0b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2ea8c145-0b5e-467a-8a3b-fec71f019a0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37ca11ca-f8d1-4696-9fb3-9f52c1813eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ea8c145-0b5e-467a-8a3b-fec71f019a0b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37ca11ca-f8d1-4696-9fb3-9f52c1813eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ELADRelatedAssetsMember_a7539df0-41e6-4062-9b70-097a4529424e" xlink:href="imux-20201231.xsd#imux_ELADRelatedAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37ca11ca-f8d1-4696-9fb3-9f52c1813eee" xlink:to="loc_imux_ELADRelatedAssetsMember_a7539df0-41e6-4062-9b70-097a4529424e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a711e3e9-a0b7-46d1-a250-302e18856bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a711e3e9-a0b7-46d1-a250-302e18856bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8613c615-e72d-4ff8-8f49-f8d8c3851ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a711e3e9-a0b7-46d1-a250-302e18856bc0" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8613c615-e72d-4ff8-8f49-f8d8c3851ae3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/BalanceSheetDetails" xlink:type="extended" id="i113d7474f8dc4e27a1465f0711f685a1_BalanceSheetDetails"/>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/BalanceSheetDetailsTables" xlink:type="extended" id="icc4205db63764cb5bd60d1e1c7a399d2_BalanceSheetDetailsTables"/>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended" id="i736ee4318fa440fc9a61daa2120e9d16_BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended" id="iec4b3184f45145439692eb29da221dab_BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended" id="ib4c4bc31c2cb4e479cf961de0d5eb110_BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended" id="i306f8afa82bc42619d6993bbc2c3ef35_BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommitmentsandContingencies" xlink:type="extended" id="iee2d8d0df1cf4c18a67a995aa558cc48_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i028146ab6db4411e87cf03213c1a7383_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i29e5fcb9e8874ad2a8eb551eecb39116_CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail" xlink:type="extended" id="i8bcefe222d054b2e95203d9018b1bd0c_CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"/>
  <link:roleRef roleURI="http://imux.com/role/FairValue" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValue"/>
  <link:definitionLink xlink:role="http://imux.com/role/FairValue" xlink:type="extended" id="i5322e2f5a47d45918008bc916a1a070c_FairValue"/>
  <link:roleRef roleURI="http://imux.com/role/FairValueTables" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValueTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/FairValueTables" xlink:type="extended" id="i73fd5129c1b641e38bbd374ac0a45445_FairValueTables"/>
  <link:roleRef roleURI="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="ieb6b84afa7eb40a98f6048661d7ddc31_FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4e4e041-4da6-4284-ba82-3055d5dd76c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_218ead45-77cc-413c-bfed-70fb0d654e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4e4e041-4da6-4284-ba82-3055d5dd76c5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_218ead45-77cc-413c-bfed-70fb0d654e41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_24d9b73d-57c1-4e99-8b75-fcb4405be765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_218ead45-77cc-413c-bfed-70fb0d654e41" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_24d9b73d-57c1-4e99-8b75-fcb4405be765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4e4e041-4da6-4284-ba82-3055d5dd76c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c078166d-5d09-4a1d-8e93-1ffae95a74ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c078166d-5d09-4a1d-8e93-1ffae95a74ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c078166d-5d09-4a1d-8e93-1ffae95a74ed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c078166d-5d09-4a1d-8e93-1ffae95a74ed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c078166d-5d09-4a1d-8e93-1ffae95a74ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c078166d-5d09-4a1d-8e93-1ffae95a74ed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1ece29b8-a630-489b-8a28-4d856246cf83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1ece29b8-a630-489b-8a28-4d856246cf83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d9f51015-ecca-40e8-9046-5df0ba135fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d9f51015-ecca-40e8-9046-5df0ba135fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_729f25d8-0945-4676-9a06-0b4e4abff15e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_729f25d8-0945-4676-9a06-0b4e4abff15e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fe554793-2694-4e27-9047-4a2ac3fcdec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fe554793-2694-4e27-9047-4a2ac3fcdec1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fe554793-2694-4e27-9047-4a2ac3fcdec1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fe554793-2694-4e27-9047-4a2ac3fcdec1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fe554793-2694-4e27-9047-4a2ac3fcdec1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0d935bd-c6fa-44fc-b021-4092bec200d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fe554793-2694-4e27-9047-4a2ac3fcdec1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0d935bd-c6fa-44fc-b021-4092bec200d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c679bc07-99e3-4d1c-9b77-4009fd97dfb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0d935bd-c6fa-44fc-b021-4092bec200d4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c679bc07-99e3-4d1c-9b77-4009fd97dfb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:to="loc_us-gaap_InvestmentTypeAxis_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1e327597-b79d-45aa-a97a-dbc929c1bf3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1e327597-b79d-45aa-a97a-dbc929c1bf3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9952de76-8465-4aa6-ba32-5da48c06237a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e327597-b79d-45aa-a97a-dbc929c1bf3b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9952de76-8465-4aa6-ba32-5da48c06237a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStock"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock" xlink:type="extended" id="iaada6d4630994cebbbfabaf9c6b58e20_CommonStockandPreferredStockConvertedintoCommonStock"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables" xlink:type="extended" id="i898056bd78fd45e8b069129195489696_CommonStockandPreferredStockConvertedintoCommonStockTables"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail" xlink:type="extended" id="i04ae55c8e37e44c484ff7529e911d75f_CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration_67722fcc-e96e-4bdf-a302-b593d0152f75" xlink:href="imux-20201231.xsd#imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration_67722fcc-e96e-4bdf-a302-b593d0152f75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders_96261e94-86af-40ef-9183-0647d732eb9b" xlink:href="imux-20201231.xsd#imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders_96261e94-86af-40ef-9183-0647d732eb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement_56f754ef-a295-446a-9dcb-ccf49413fb55" xlink:href="imux-20201231.xsd#imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement_56f754ef-a295-446a-9dcb-ccf49413fb55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_34338ccb-99fe-46f0-9d78-c9db10b0c8dd" xlink:href="imux-20201231.xsd#imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_34338ccb-99fe-46f0-9d78-c9db10b0c8dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7ee561c3-000e-4591-97a7-a4295fee392f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7ee561c3-000e-4591-97a7-a4295fee392f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f2c7212-fd3c-4470-a5b4-45a0720de9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f2c7212-fd3c-4470-a5b4-45a0720de9c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_70f407f9-fce6-463a-803a-290da0256b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_70f407f9-fce6-463a-803a-290da0256b02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_93034232-3eb5-407e-ab93-4fd16b813116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_93034232-3eb5-407e-ab93-4fd16b813116" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_350027ac-5091-423f-af62-c3972ef6f3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_PaymentsForCommissions_350027ac-5091-423f-af62-c3972ef6f3fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b8585d26-3936-4d3b-bce8-e1bcb5ecc20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b8585d26-3936-4d3b-bce8-e1bcb5ecc20e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a37d2c29-3651-4d95-a467-15fbd47af8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a37d2c29-3651-4d95-a467-15fbd47af8dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1c6d9a99-c5a3-4510-8a90-5e294caf92a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a37d2c29-3651-4d95-a467-15fbd47af8dd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1c6d9a99-c5a3-4510-8a90-5e294caf92a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c6d9a99-c5a3-4510-8a90-5e294caf92a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1c6d9a99-c5a3-4510-8a90-5e294caf92a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c6d9a99-c5a3-4510-8a90-5e294caf92a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1c6d9a99-c5a3-4510-8a90-5e294caf92a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2019EquityIssuancesMember_ddb3c5da-069a-48c8-ac04-e2be972a509d" xlink:href="imux-20201231.xsd#imux_July2019EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:to="loc_imux_July2019EquityIssuancesMember_ddb3c5da-069a-48c8-ac04-e2be972a509d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_December2020EquityIssuancesMember_0c0bc9ca-c69f-435f-88fe-487c4ab509b9" xlink:href="imux-20201231.xsd#imux_December2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:to="loc_imux_December2020EquityIssuancesMember_0c0bc9ca-c69f-435f-88fe-487c4ab509b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AtTheMarketSalesAgreementMember_0f912751-a970-4e7e-be1a-67c05150e97f" xlink:href="imux-20201231.xsd#imux_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:to="loc_imux_AtTheMarketSalesAgreementMember_0f912751-a970-4e7e-be1a-67c05150e97f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails" xlink:type="extended" id="i76dcac3ed521475687547a822814fcf9_CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_98b1e134-61e7-4aeb-a079-399da5946830" xlink:href="imux-20201231.xsd#imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_98b1e134-61e7-4aeb-a079-399da5946830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_406419ae-643a-4725-b840-45f02f5aa603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_406419ae-643a-4725-b840-45f02f5aa603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f273bf69-1133-42c1-8e26-3013e818b746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f273bf69-1133-42c1-8e26-3013e818b746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ProceedsFromIssuanceOfCommonStockGross_7e0ea55d-dafc-4a3c-a6e4-c66845774a36" xlink:href="imux-20201231.xsd#imux_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_imux_ProceedsFromIssuanceOfCommonStockGross_7e0ea55d-dafc-4a3c-a6e4-c66845774a36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e435fdf6-a1d9-480a-98b8-1824378a08d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e435fdf6-a1d9-480a-98b8-1824378a08d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_87914132-44d3-48c6-a928-dc91df39a171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_87914132-44d3-48c6-a928-dc91df39a171" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_80121e41-1c04-4ce3-a87a-85fd5c99e0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87914132-44d3-48c6-a928-dc91df39a171" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_80121e41-1c04-4ce3-a87a-85fd5c99e0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80121e41-1c04-4ce3-a87a-85fd5c99e0a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_80121e41-1c04-4ce3-a87a-85fd5c99e0a5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_80121e41-1c04-4ce3-a87a-85fd5c99e0a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61395c85-6123-42df-a5e0-08592262ee5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_80121e41-1c04-4ce3-a87a-85fd5c99e0a5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61395c85-6123-42df-a5e0-08592262ee5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_5ab4d594-ef83-4cc3-b449-03368dd2d2aa" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61395c85-6123-42df-a5e0-08592262ee5c" xlink:to="loc_imux_April2020EquityIssuancesMember_5ab4d594-ef83-4cc3-b449-03368dd2d2aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails" xlink:type="extended" id="i64d6401b79674bae92bcc1164587a0f3_CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbcd9c43-3e2d-4c86-a3e0-308f9cb6bc6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbcd9c43-3e2d-4c86-a3e0-308f9cb6bc6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_89031685-2708-4696-bcc5-699d7d325636" xlink:href="imux-20201231.xsd#imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_89031685-2708-4696-bcc5-699d7d325636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b74ef95e-76ab-4101-8910-d6afec57c715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b74ef95e-76ab-4101-8910-d6afec57c715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ProceedsFromIssuanceOfCommonStockGross_9dfb1be6-df3e-48bb-9fa8-8917d22f3dd9" xlink:href="imux-20201231.xsd#imux_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_imux_ProceedsFromIssuanceOfCommonStockGross_9dfb1be6-df3e-48bb-9fa8-8917d22f3dd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_152104c0-f761-4c4d-9258-48b37f04e64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_152104c0-f761-4c4d-9258-48b37f04e64a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock_ea6c9f9d-1e33-4884-8732-f88c55a39b85" xlink:href="imux-20201231.xsd#imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock_ea6c9f9d-1e33-4884-8732-f88c55a39b85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockNumberOfAdditionalSharesAuthorized_bc3520ed-2413-4c91-a6b4-054e2fbeac46" xlink:href="imux-20201231.xsd#imux_SaleOfStockNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_imux_SaleOfStockNumberOfAdditionalSharesAuthorized_bc3520ed-2413-4c91-a6b4-054e2fbeac46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0344608b-f392-415c-9bdd-2d20b987067d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0344608b-f392-415c-9bdd-2d20b987067d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0344608b-f392-415c-9bdd-2d20b987067d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d246683-0ab3-4ca7-be7e-8f10046dbff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d246683-0ab3-4ca7-be7e-8f10046dbff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_38282e2a-2e8f-4236-af46-53bf88507a57" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d246683-0ab3-4ca7-be7e-8f10046dbff2" xlink:to="loc_imux_June2020EquityIssuancesMember_38282e2a-2e8f-4236-af46-53bf88507a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_542b550b-03c6-441b-913a-49eaa9fca52e" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d246683-0ab3-4ca7-be7e-8f10046dbff2" xlink:to="loc_imux_August2020EquityIssuancesMember_542b550b-03c6-441b-913a-49eaa9fca52e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails" xlink:type="extended" id="ia673456d7219473eb6beca6a26ebf5d5_CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6b7dd713-e8d8-4eef-a48a-c9670a2db9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7c28f5c2-c6c7-4ae6-b8ce-a9c91fdbf3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b7dd713-e8d8-4eef-a48a-c9670a2db9e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_7c28f5c2-c6c7-4ae6-b8ce-a9c91fdbf3ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_51d75829-f3eb-45e0-8af5-d771e8f81934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b7dd713-e8d8-4eef-a48a-c9670a2db9e2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_51d75829-f3eb-45e0-8af5-d771e8f81934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_007f5693-8ad8-4e5d-ab5f-50a29da7425d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b7dd713-e8d8-4eef-a48a-c9670a2db9e2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_007f5693-8ad8-4e5d-ab5f-50a29da7425d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6474f86d-f8c1-4d1c-bd79-7759a57dd933" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_007f5693-8ad8-4e5d-ab5f-50a29da7425d" xlink:to="loc_srt_TitleOfIndividualAxis_6474f86d-f8c1-4d1c-bd79-7759a57dd933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6474f86d-f8c1-4d1c-bd79-7759a57dd933_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6474f86d-f8c1-4d1c-bd79-7759a57dd933" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6474f86d-f8c1-4d1c-bd79-7759a57dd933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e0a06664-42ce-4250-9b9c-b67135a2099d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6474f86d-f8c1-4d1c-bd79-7759a57dd933" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e0a06664-42ce-4250-9b9c-b67135a2099d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_e43f7a26-97a9-4316-9067-ba256a5924d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e0a06664-42ce-4250-9b9c-b67135a2099d" xlink:to="loc_srt_ExecutiveOfficerMember_e43f7a26-97a9-4316-9067-ba256a5924d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail" xlink:type="extended" id="i907d7c8c896b4416b88fa3c32782eeb4_CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail"/>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail" xlink:type="extended" id="i2e8323df15e7434d86b9186ec508ea2e_CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_69d727bc-735d-4e7c-b0b0-79a6ef2a3fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockSharesIssued_69d727bc-735d-4e7c-b0b0-79a6ef2a3fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ca4d4080-bfc2-4d03-b25d-ab8c9a4591ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ca4d4080-bfc2-4d03-b25d-ab8c9a4591ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c0331b11-5fee-4097-a1ba-6307e33c2e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockValue_c0331b11-5fee-4097-a1ba-6307e33c2e09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d700de97-0f80-4b69-b61e-40ac997a31f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d700de97-0f80-4b69-b61e-40ac997a31f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_579855a0-8c59-42b3-a72b-3c2628f38e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_579855a0-8c59-42b3-a72b-3c2628f38e18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a14b79cd-9fe9-442b-8692-0c0f40e74665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:to="loc_dei_LegalEntityAxis_a14b79cd-9fe9-442b-8692-0c0f40e74665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a14b79cd-9fe9-442b-8692-0c0f40e74665_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a14b79cd-9fe9-442b-8692-0c0f40e74665" xlink:to="loc_dei_EntityDomain_a14b79cd-9fe9-442b-8692-0c0f40e74665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2423be6e-e3e9-49ed-969e-a74ae9ae2c12" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a14b79cd-9fe9-442b-8692-0c0f40e74665" xlink:to="loc_dei_EntityDomain_2423be6e-e3e9-49ed-969e-a74ae9ae2c12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_d1bff4d5-fdf9-4b1f-a0cd-5f2efcdb1a75" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2423be6e-e3e9-49ed-969e-a74ae9ae2c12" xlink:to="loc_imux_ImmunicAGMember_d1bff4d5-fdf9-4b1f-a0cd-5f2efcdb1a75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c2090ba2-addb-4cfd-a7b5-263cc77321bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c2090ba2-addb-4cfd-a7b5-263cc77321bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c2090ba2-addb-4cfd-a7b5-263cc77321bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2090ba2-addb-4cfd-a7b5-263cc77321bc" xlink:to="loc_us-gaap_ClassOfStockDomain_c2090ba2-addb-4cfd-a7b5-263cc77321bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f36711e3-6b9c-4c71-bfab-8495183c6464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2090ba2-addb-4cfd-a7b5-263cc77321bc" xlink:to="loc_us-gaap_ClassOfStockDomain_f36711e3-6b9c-4c71-bfab-8495183c6464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA1ConvertiblePreferredStockMember_c5846d12-572f-4cd2-8f01-c68eefaceefb" xlink:href="imux-20201231.xsd#imux_SeriesA1ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f36711e3-6b9c-4c71-bfab-8495183c6464" xlink:to="loc_imux_SeriesA1ConvertiblePreferredStockMember_c5846d12-572f-4cd2-8f01-c68eefaceefb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA2ConvertiblePreferredStockMember_980fbab0-419d-4868-a515-25a640c1b8f9" xlink:href="imux-20201231.xsd#imux_SeriesA2ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f36711e3-6b9c-4c71-bfab-8495183c6464" xlink:to="loc_imux_SeriesA2ConvertiblePreferredStockMember_980fbab0-419d-4868-a515-25a640c1b8f9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail" xlink:type="extended" id="ia347311411d9443f908e520c24c7370e_CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e7ebd0fa-ebe0-40cd-8d85-bcb5e57b66ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a57c4633-f664-49c6-a70a-3777fdec0109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e7ebd0fa-ebe0-40cd-8d85-bcb5e57b66ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a57c4633-f664-49c6-a70a-3777fdec0109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b37f48e-fc50-4d88-b712-3485facfd4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e7ebd0fa-ebe0-40cd-8d85-bcb5e57b66ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b37f48e-fc50-4d88-b712-3485facfd4e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_aaa3b1ed-b8af-4dc1-817e-d67b4ba602e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e7ebd0fa-ebe0-40cd-8d85-bcb5e57b66ba" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_aaa3b1ed-b8af-4dc1-817e-d67b4ba602e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4787dcdc-1ed4-4d23-a811-a8b059c296b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aaa3b1ed-b8af-4dc1-817e-d67b4ba602e3" xlink:to="loc_us-gaap_AwardTypeAxis_4787dcdc-1ed4-4d23-a811-a8b059c296b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4787dcdc-1ed4-4d23-a811-a8b059c296b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4787dcdc-1ed4-4d23-a811-a8b059c296b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4787dcdc-1ed4-4d23-a811-a8b059c296b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a5efb19-4c57-4d0b-a8df-34039d9cf5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4787dcdc-1ed4-4d23-a811-a8b059c296b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a5efb19-4c57-4d0b-a8df-34039d9cf5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2dbbd1d8-7928-4dd5-accc-cf47d8c75abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a5efb19-4c57-4d0b-a8df-34039d9cf5fa" xlink:to="loc_us-gaap_WarrantMember_2dbbd1d8-7928-4dd5-accc-cf47d8c75abf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail" xlink:type="extended" id="ie62e5106c7c54175bbf2729dcaf7b013_CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9bd03992-79ad-4e2f-ae18-240736a4cc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc2c7410-d150-41da-b4a0-3e7b1e02c613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd03992-79ad-4e2f-ae18-240736a4cc2f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc2c7410-d150-41da-b4a0-3e7b1e02c613" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd03992-79ad-4e2f-ae18-240736a4cc2f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fd77e7a1-3ba0-442c-b8b0-152152d1fec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:to="loc_us-gaap_PlanNameAxis_fd77e7a1-3ba0-442c-b8b0-152152d1fec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fd77e7a1-3ba0-442c-b8b0-152152d1fec9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fd77e7a1-3ba0-442c-b8b0-152152d1fec9" xlink:to="loc_us-gaap_PlanNameDomain_fd77e7a1-3ba0-442c-b8b0-152152d1fec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fd77e7a1-3ba0-442c-b8b0-152152d1fec9" xlink:to="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_989c0962-fea3-4dda-ad7f-b26f2de60325" xlink:href="imux-20201231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:to="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_989c0962-fea3-4dda-ad7f-b26f2de60325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember_42b5dab7-5b16-4157-861c-f2043b1e9054" xlink:href="imux-20201231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:to="loc_imux_A2017InducementEquityIncentivePlanMember_42b5dab7-5b16-4157-861c-f2043b1e9054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_691609b2-b245-4a5c-9a1f-3a02539045c9" xlink:href="imux-20201231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_691609b2-b245-4a5c-9a1f-3a02539045c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0deeb96e-8234-43f0-9d42-7850f570ea6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:to="loc_us-gaap_AwardTypeAxis_0deeb96e-8234-43f0-9d42-7850f570ea6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0deeb96e-8234-43f0-9d42-7850f570ea6a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0deeb96e-8234-43f0-9d42-7850f570ea6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0deeb96e-8234-43f0-9d42-7850f570ea6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2d0f9e-115c-4dbf-aaab-9749856eaa50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0deeb96e-8234-43f0-9d42-7850f570ea6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2d0f9e-115c-4dbf-aaab-9749856eaa50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35d2f3f4-3798-4b51-b113-ca0397241c18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2d0f9e-115c-4dbf-aaab-9749856eaa50" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35d2f3f4-3798-4b51-b113-ca0397241c18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsforFutureGrantMember_ff089ec7-e80b-414e-8c0e-1309992f4578" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsforFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2d0f9e-115c-4dbf-aaab-9749856eaa50" xlink:to="loc_imux_EmployeeStockOptionsforFutureGrantMember_ff089ec7-e80b-414e-8c0e-1309992f4578" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlans" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlans"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockCompensationPlans" xlink:type="extended" id="i04cc3e9236d14371b92f8c91afc45f3f_StockCompensationPlans"/>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansTables" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockCompensationPlansTables" xlink:type="extended" id="if505fa46c5c24f4f96d75d953c7dec34_StockCompensationPlansTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_797a4e72-dd03-4a97-b150-6c72bba51a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_797a4e72-dd03-4a97-b150-6c72bba51a14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_95d3b254-4a0f-4bbe-b032-f690bd01e852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_95d3b254-4a0f-4bbe-b032-f690bd01e852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90ab3c42-26d1-4f03-843c-6ced02e278bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90ab3c42-26d1-4f03-843c-6ced02e278bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_511bc312-6e41-4280-9e34-c52351601ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_511bc312-6e41-4280-9e34-c52351601ef1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d369ad81-6a83-47f8-8dcf-4e6fed862dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_511bc312-6e41-4280-9e34-c52351601ef1" xlink:to="loc_us-gaap_AwardTypeAxis_d369ad81-6a83-47f8-8dcf-4e6fed862dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d369ad81-6a83-47f8-8dcf-4e6fed862dd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d369ad81-6a83-47f8-8dcf-4e6fed862dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d369ad81-6a83-47f8-8dcf-4e6fed862dd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be842eb6-8ea2-4500-aa13-843004189890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d369ad81-6a83-47f8-8dcf-4e6fed862dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be842eb6-8ea2-4500-aa13-843004189890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member_8beba506-a75e-499f-b8db-669592bc0a6d" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsVitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be842eb6-8ea2-4500-aa13-843004189890" xlink:to="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member_8beba506-a75e-499f-b8db-669592bc0a6d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockCompensationPlansAdditionalInformationDetail" xlink:type="extended" id="i663082ee30b94f9c96f02ff6c337267e_StockCompensationPlansAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans_d552499d-c8f5-4905-9ea5-9ef9a60f8808" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans_d552499d-c8f5-4905-9ea5-9ef9a60f8808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital_00239d88-82e0-4c8b-9137-22fa5e182307" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital_00239d88-82e0-4c8b-9137-22fa5e182307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fc8d5856-c7e6-4d48-87d7-34ec716ef8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fc8d5856-c7e6-4d48-87d7-34ec716ef8b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bec5ba4e-62b2-4957-86c0-1a40d6973fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bec5ba4e-62b2-4957-86c0-1a40d6973fc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_404463a8-f751-4003-8c52-d9a98f647a48" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_404463a8-f751-4003-8c52-d9a98f647a48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8c984587-d169-4f99-bd44-229586a73c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8c984587-d169-4f99-bd44-229586a73c5c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9f28c83-96fb-4341-9748-1c7811275071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9f28c83-96fb-4341-9748-1c7811275071" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cd76d847-8bdc-460e-aba2-4be87881cfc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cd76d847-8bdc-460e-aba2-4be87881cfc1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_c70b7a35-ba36-41dd-bb81-dafe47af9d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_SharePrice_c70b7a35-ba36-41dd-bb81-dafe47af9d87" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1944cfaa-8982-4bc8-b824-d1602c663b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1944cfaa-8982-4bc8-b824-d1602c663b7e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_218f4edd-a090-4a95-9d37-740694dec3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_218f4edd-a090-4a95-9d37-740694dec3d4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ac1663b2-1d83-4e2a-abaf-e8057f330f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ac1663b2-1d83-4e2a-abaf-e8057f330f92" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b963fd3-22dc-4f3e-a929-c75239349749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b963fd3-22dc-4f3e-a929-c75239349749" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_abf27a5a-8c9d-4a23-8bf0-7a9dc71448d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_abf27a5a-8c9d-4a23-8bf0-7a9dc71448d7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06bb98ff-f7e6-42d4-8940-949576d0085f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_us-gaap_AwardTypeAxis_06bb98ff-f7e6-42d4-8940-949576d0085f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06bb98ff-f7e6-42d4-8940-949576d0085f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_06bb98ff-f7e6-42d4-8940-949576d0085f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06bb98ff-f7e6-42d4-8940-949576d0085f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_06bb98ff-f7e6-42d4-8940-949576d0085f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncentiveEmployeeStockOptionMember_0006dd21-7f31-41dd-9636-6e99f6e3ec7c" xlink:href="imux-20201231.xsd#imux_IncentiveEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:to="loc_imux_IncentiveEmployeeStockOptionMember_0006dd21-7f31-41dd-9636-6e99f6e3ec7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NonStatutoryEmployeeStockOptionMember_9a1933e9-7f5f-45ae-8ef2-23222cd8d044" xlink:href="imux-20201231.xsd#imux_NonStatutoryEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:to="loc_imux_NonStatutoryEmployeeStockOptionMember_9a1933e9-7f5f-45ae-8ef2-23222cd8d044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_394a043d-a3e1-4033-8724-c6f9d842dbeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_394a043d-a3e1-4033-8724-c6f9d842dbeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c3032c6f-a25b-406e-b1ef-3c24417502e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_srt_RangeAxis_c3032c6f-a25b-406e-b1ef-3c24417502e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3032c6f-a25b-406e-b1ef-3c24417502e8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c3032c6f-a25b-406e-b1ef-3c24417502e8" xlink:to="loc_srt_RangeMember_c3032c6f-a25b-406e-b1ef-3c24417502e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0fce5d42-9af1-4b9d-a86b-552d0e526ec6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c3032c6f-a25b-406e-b1ef-3c24417502e8" xlink:to="loc_srt_RangeMember_0fce5d42-9af1-4b9d-a86b-552d0e526ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5c50d9b-fd28-4586-9543-0ccb16f1bc48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0fce5d42-9af1-4b9d-a86b-552d0e526ec6" xlink:to="loc_srt_MinimumMember_e5c50d9b-fd28-4586-9543-0ccb16f1bc48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6bac7246-507b-40d6-8a8f-a7eb1e0c4388" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0fce5d42-9af1-4b9d-a86b-552d0e526ec6" xlink:to="loc_srt_MaximumMember_6bac7246-507b-40d6-8a8f-a7eb1e0c4388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ab1e3481-3413-472a-b2d8-39046e82f04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_us-gaap_PlanNameAxis_ab1e3481-3413-472a-b2d8-39046e82f04a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ab1e3481-3413-472a-b2d8-39046e82f04a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ab1e3481-3413-472a-b2d8-39046e82f04a" xlink:to="loc_us-gaap_PlanNameDomain_ab1e3481-3413-472a-b2d8-39046e82f04a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ab1e3481-3413-472a-b2d8-39046e82f04a" xlink:to="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VSOPSBMember_36e57078-9af9-4c82-b190-ce9a1d70cb45" xlink:href="imux-20201231.xsd#imux_VSOPSBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_VSOPSBMember_36e57078-9af9-4c82-b190-ce9a1d70cb45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember_b8680622-ea11-45a9-a1b9-c810de9e819c" xlink:href="imux-20201231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_A2019OmnibusEquityIncentivePlanMember_b8680622-ea11-45a9-a1b9-c810de9e819c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VSOPAndVSOPSBMember_55b6a351-4bb0-4fed-adc4-9be49ee3ed7d" xlink:href="imux-20201231.xsd#imux_VSOPAndVSOPSBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_VSOPAndVSOPSBMember_55b6a351-4bb0-4fed-adc4-9be49ee3ed7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_dcb25e28-ef4f-4ebb-b8e4-71b4cabae9bb" xlink:href="imux-20201231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_dcb25e28-ef4f-4ebb-b8e4-71b4cabae9bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ExecutiveBonusAgreementMember_35b2ab87-e230-4366-a720-36889f17e927" xlink:href="imux-20201231.xsd#imux_ExecutiveBonusAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_ExecutiveBonusAgreementMember_35b2ab87-e230-4366-a720-36889f17e927" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_19c185fb-b9c6-43ac-a4af-a50a4a40b2f8" xlink:href="imux-20201231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_19c185fb-b9c6-43ac-a4af-a50a4a40b2f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember_c6c27eca-0a8a-4ad0-9f3c-f26f5bdf0a96" xlink:href="imux-20201231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_A2017InducementEquityIncentivePlanMember_c6c27eca-0a8a-4ad0-9f3c-f26f5bdf0a96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9d927cc9-9920-4e03-9971-89f47b21e275" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_dei_LegalEntityAxis_9d927cc9-9920-4e03-9971-89f47b21e275" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9d927cc9-9920-4e03-9971-89f47b21e275_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9d927cc9-9920-4e03-9971-89f47b21e275" xlink:to="loc_dei_EntityDomain_9d927cc9-9920-4e03-9971-89f47b21e275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a00b054-0fc5-4e3f-9ad9-18be3e8583c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9d927cc9-9920-4e03-9971-89f47b21e275" xlink:to="loc_dei_EntityDomain_7a00b054-0fc5-4e3f-9ad9-18be3e8583c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_c0ea7044-198b-433f-8fdc-629bc985f73e" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7a00b054-0fc5-4e3f-9ad9-18be3e8583c0" xlink:to="loc_imux_VitalTherapiesInc.Member_c0ea7044-198b-433f-8fdc-629bc985f73e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_84fb7ebf-eae0-4b9f-96ee-d93238132cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_84fb7ebf-eae0-4b9f-96ee-d93238132cc7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_84fb7ebf-eae0-4b9f-96ee-d93238132cc7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_84fb7ebf-eae0-4b9f-96ee-d93238132cc7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_84fb7ebf-eae0-4b9f-96ee-d93238132cc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9384f34-f532-4121-8576-bf6f5e86db8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_84fb7ebf-eae0-4b9f-96ee-d93238132cc7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9384f34-f532-4121-8576-bf6f5e86db8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac0460cf-3d17-427f-97cd-5156fa89ccf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9384f34-f532-4121-8576-bf6f5e86db8a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac0460cf-3d17-427f-97cd-5156fa89ccf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_70ab334f-f1bc-418a-9d08-2a33d27ba34d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9384f34-f532-4121-8576-bf6f5e86db8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_70ab334f-f1bc-418a-9d08-2a33d27ba34d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansSummaryofStockOptionActivityDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail" xlink:type="extended" id="i6a3806fc0e9e46ae8e878bc70d16e5c0_StockCompensationPlansSummaryofStockOptionActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0946b32c-fce3-43d5-81c3-9d3af671d2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0946b32c-fce3-43d5-81c3-9d3af671d2b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_12e88a11-5e73-4022-be31-900173dade8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_12e88a11-5e73-4022-be31-900173dade8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e9deb2e3-0e5d-440f-ae41-7558cc6627f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e9deb2e3-0e5d-440f-ae41-7558cc6627f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d799be99-d93f-4f06-b08b-936da2adb1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d799be99-d93f-4f06-b08b-936da2adb1dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0927cde-fe2e-426c-afa1-1dbcca3090f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0927cde-fe2e-426c-afa1-1dbcca3090f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod_7946ed8b-fcb4-47e5-81ce-29b7f64b4fbb" xlink:href="imux-20201231.xsd#imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod_7946ed8b-fcb4-47e5-81ce-29b7f64b4fbb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_91f27f92-863b-4245-a612-c7e9afccbd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_91f27f92-863b-4245-a612-c7e9afccbd4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_794ec42b-7e2f-44e4-a8f8-1bebb504096a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_794ec42b-7e2f-44e4-a8f8-1bebb504096a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_da450320-03fe-4125-815d-dcca5d00101d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5319e4e1-aed6-4487-9d6e-a2f3c0bae87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5319e4e1-aed6-4487-9d6e-a2f3c0bae87c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e32d297e-a816-4aa1-b427-3d3e5f9e9858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e32d297e-a816-4aa1-b427-3d3e5f9e9858" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f8158d27-f1c1-4055-8254-c25bfb0eb523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f8158d27-f1c1-4055-8254-c25bfb0eb523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_fef4ab61-14a8-406f-b5e0-321a04637db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_fef4ab61-14a8-406f-b5e0-321a04637db7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a734ee17-21c5-4923-8621-5ad9cdd62f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a734ee17-21c5-4923-8621-5ad9cdd62f46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_91da6ea2-f0ed-4a72-aad5-7229db0c116a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_91da6ea2-f0ed-4a72-aad5-7229db0c116a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4388d669-8fda-4cb2-8d55-386b6a45ed4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4388d669-8fda-4cb2-8d55-386b6a45ed4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice_0a96596e-aae7-4431-9b4b-06eaf19e0a2e" xlink:href="imux-20201231.xsd#imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice_0a96596e-aae7-4431-9b4b-06eaf19e0a2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa365f5c-6100-4298-95be-56ca8e5a8295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b2500ba8-2f6b-4105-83ea-650b8e93b321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b2500ba8-2f6b-4105-83ea-650b8e93b321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3708f3e1-4885-4ece-a0ef-3c86e8d94505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3708f3e1-4885-4ece-a0ef-3c86e8d94505" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3775605c-d277-4f7e-8e03-a97d49d3b9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3775605c-d277-4f7e-8e03-a97d49d3b9f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d7167a3d-da8a-49be-aec8-0e3d52dab1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d7167a3d-da8a-49be-aec8-0e3d52dab1eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5d62c1a6-178d-41cc-8371-845422135e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5d62c1a6-178d-41cc-8371-845422135e06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9e89ca5e-bf8f-44a3-8086-9fbeae737971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9e89ca5e-bf8f-44a3-8086-9fbeae737971" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ddf65722-b14d-4f18-994f-a11eaec775ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ddf65722-b14d-4f18-994f-a11eaec775ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_88bc767d-bda1-439e-9c32-662f022133f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_88bc767d-bda1-439e-9c32-662f022133f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ae98f16a-b45f-494c-ad61-11e6ccc06eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:to="loc_us-gaap_PlanNameAxis_ae98f16a-b45f-494c-ad61-11e6ccc06eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae98f16a-b45f-494c-ad61-11e6ccc06eef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ae98f16a-b45f-494c-ad61-11e6ccc06eef" xlink:to="loc_us-gaap_PlanNameDomain_ae98f16a-b45f-494c-ad61-11e6ccc06eef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_54ae051a-5f04-4250-a936-dbe4b2aca69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ae98f16a-b45f-494c-ad61-11e6ccc06eef" xlink:to="loc_us-gaap_PlanNameDomain_54ae051a-5f04-4250-a936-dbe4b2aca69e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_c38ad815-9e23-4a33-9a2b-173e496e0daa" xlink:href="imux-20201231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_54ae051a-5f04-4250-a936-dbe4b2aca69e" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_c38ad815-9e23-4a33-9a2b-173e496e0daa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VSOPAndVSOPSBMember_cc18acde-6b45-4969-ad44-55e8dddf5256" xlink:href="imux-20201231.xsd#imux_VSOPAndVSOPSBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_54ae051a-5f04-4250-a936-dbe4b2aca69e" xlink:to="loc_imux_VSOPAndVSOPSBMember_cc18acde-6b45-4969-ad44-55e8dddf5256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_928953c0-ae4e-4ed0-babf-b85dafa5c2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:to="loc_us-gaap_AwardTypeAxis_928953c0-ae4e-4ed0-babf-b85dafa5c2e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_928953c0-ae4e-4ed0-babf-b85dafa5c2e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_928953c0-ae4e-4ed0-babf-b85dafa5c2e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_928953c0-ae4e-4ed0-babf-b85dafa5c2e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_928953c0-ae4e-4ed0-babf-b85dafa5c2e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsImmunicAGMember_982901b2-f3ce-4660-b613-9857fe4a891f" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:to="loc_imux_EmployeeStockOptionsImmunicAGMember_982901b2-f3ce-4660-b613-9857fe4a891f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member_0e57a242-9c63-4ede-bfc2-8ecf98fe9988" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsVitalTherapiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:to="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member_0e57a242-9c63-4ede-bfc2-8ecf98fe9988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bec09d62-6b44-4afe-a23a-5ea6936704ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bec09d62-6b44-4afe-a23a-5ea6936704ce" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended" id="ibd9c4b4743bb4e88a65f4cc71c80ddf2_StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_443ffc1a-cd48-4779-8dd9-977f853df84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_443ffc1a-cd48-4779-8dd9-977f853df84f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c83153b-7bcd-446d-a8de-7477756d30bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c83153b-7bcd-446d-a8de-7477756d30bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95816fea-0f9e-4682-81dc-5f971d428800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95816fea-0f9e-4682-81dc-5f971d428800" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3b33fb1-654e-4f7e-8ad9-a81559ef624a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3b33fb1-654e-4f7e-8ad9-a81559ef624a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f69a5fd-5223-46d9-8ad3-c2a814240341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f69a5fd-5223-46d9-8ad3-c2a814240341" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_306c0f15-114f-46f5-854b-0e16b6d60b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f69a5fd-5223-46d9-8ad3-c2a814240341" xlink:to="loc_us-gaap_PlanNameAxis_306c0f15-114f-46f5-854b-0e16b6d60b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_306c0f15-114f-46f5-854b-0e16b6d60b21_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_306c0f15-114f-46f5-854b-0e16b6d60b21" xlink:to="loc_us-gaap_PlanNameDomain_306c0f15-114f-46f5-854b-0e16b6d60b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0886d3df-1c2b-4675-84e3-ce5b938fd2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_306c0f15-114f-46f5-854b-0e16b6d60b21" xlink:to="loc_us-gaap_PlanNameDomain_0886d3df-1c2b-4675-84e3-ce5b938fd2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember_e340ee7f-a9fc-4e6b-8236-bb9fb9f89e39" xlink:href="imux-20201231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0886d3df-1c2b-4675-84e3-ce5b938fd2eb" xlink:to="loc_imux_A2019OmnibusEquityIncentivePlanMember_e340ee7f-a9fc-4e6b-8236-bb9fb9f89e39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail" xlink:type="extended" id="i941dec11a17545f889b957f0178c01b3_StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5cc11065-26b7-4fdc-ab5a-bae959895e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f44261d6-b63e-40ab-b72a-f77dbf4eb339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5cc11065-26b7-4fdc-ab5a-bae959895e02" xlink:to="loc_us-gaap_ShareBasedCompensation_f44261d6-b63e-40ab-b72a-f77dbf4eb339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5cc11065-26b7-4fdc-ab5a-bae959895e02" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3d3d8078-99f4-4e10-b3ca-a411ac9112aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:to="loc_srt_TitleOfIndividualAxis_3d3d8078-99f4-4e10-b3ca-a411ac9112aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d3d8078-99f4-4e10-b3ca-a411ac9112aa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_3d3d8078-99f4-4e10-b3ca-a411ac9112aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d3d8078-99f4-4e10-b3ca-a411ac9112aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_854912a9-959b-47a3-afa8-01f2d82cf855" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_3d3d8078-99f4-4e10-b3ca-a411ac9112aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_854912a9-959b-47a3-afa8-01f2d82cf855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeMember_2129362f-8d33-450e-b513-9a37fdf0febb" xlink:href="imux-20201231.xsd#imux_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_854912a9-959b-47a3-afa8-01f2d82cf855" xlink:to="loc_imux_EmployeeMember_2129362f-8d33-450e-b513-9a37fdf0febb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0804269f-4aaa-4c91-9b75-ada0b127fd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0804269f-4aaa-4c91-9b75-ada0b127fd39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0804269f-4aaa-4c91-9b75-ada0b127fd39_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0804269f-4aaa-4c91-9b75-ada0b127fd39" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0804269f-4aaa-4c91-9b75-ada0b127fd39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d294982-332d-47c9-912d-0006450a1a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0804269f-4aaa-4c91-9b75-ada0b127fd39" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d294982-332d-47c9-912d-0006450a1a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8cd2431a-b6e2-42cf-88dc-68f7d31a268c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d294982-332d-47c9-912d-0006450a1a6a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8cd2431a-b6e2-42cf-88dc-68f7d31a268c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c62a5a7-12bb-4b9e-a0d0-410c2dbf3e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d294982-332d-47c9-912d-0006450a1a6a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c62a5a7-12bb-4b9e-a0d0-410c2dbf3e40" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxes" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://imux.com/role/IncomeTaxes" xlink:type="extended" id="ib9c90cecbce3467bb7c40a4a94b06139_IncomeTaxes"/>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/IncomeTaxesTables" xlink:type="extended" id="ic8db122b21894ff092d14d7f29e8e736_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail" xlink:type="extended" id="i02e864f8e34e419eaac3ec74c731a589_IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_491a0c77-0501-404a-b09a-2ba4e6ff1d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_99da5855-2506-4f51-a315-c5980001e17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_491a0c77-0501-404a-b09a-2ba4e6ff1d72" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_99da5855-2506-4f51-a315-c5980001e17d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_491a0c77-0501-404a-b09a-2ba4e6ff1d72" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_90530295-dd7d-470a-ba8f-aed6a8aa2349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_90530295-dd7d-470a-ba8f-aed6a8aa2349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_2e30c974-d9fa-4023-9606-8ec5e2dea203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_90530295-dd7d-470a-ba8f-aed6a8aa2349" xlink:to="loc_us-gaap_DomesticCountryMember_2e30c974-d9fa-4023-9606-8ec5e2dea203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e939b79f-3721-4adf-897b-5f835b3ef825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_90530295-dd7d-470a-ba8f-aed6a8aa2349" xlink:to="loc_us-gaap_ForeignCountryMember_e939b79f-3721-4adf-897b-5f835b3ef825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e248ddf8-216c-4e54-b34f-bfb776a0b859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e248ddf8-216c-4e54-b34f-bfb776a0b859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e248ddf8-216c-4e54-b34f-bfb776a0b859_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e248ddf8-216c-4e54-b34f-bfb776a0b859" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e248ddf8-216c-4e54-b34f-bfb776a0b859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e248ddf8-216c-4e54-b34f-bfb776a0b859" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_e58fd2c0-5829-48d3-8df6-4cc70fa30d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_e58fd2c0-5829-48d3-8df6-4cc70fa30d97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_7168213f-5de1-4f72-9bcb-32c78f404ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:to="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_7168213f-5de1-4f72-9bcb-32c78f404ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ForeignExcludingGermanyMember_889a102c-de93-4125-a9be-50e07a50c38a" xlink:href="imux-20201231.xsd#imux_ForeignExcludingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:to="loc_imux_ForeignExcludingGermanyMember_889a102c-de93-4125-a9be-50e07a50c38a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesIncomeTaxRateReconciliationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail" xlink:type="extended" id="if737700ceaef42ab9218e4f94a3f028b_IncomeTaxesIncomeTaxRateReconciliationDetail"/>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail" xlink:type="extended" id="i43bacf240856443ebc91a29abb004edd_IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="i97f8f9a739bd476e8f32ccde78e2e362_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2d23d94a-c6a8-40a1-a509-6ee276734fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_db22d322-4538-4a30-98e1-ca32b1e16e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2d23d94a-c6a8-40a1-a509-6ee276734fd2" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_db22d322-4538-4a30-98e1-ca32b1e16e6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_85e29ac6-3255-4c88-8a42-2118e0dba0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2d23d94a-c6a8-40a1-a509-6ee276734fd2" xlink:to="loc_us-gaap_OperatingLossCarryforwards_85e29ac6-3255-4c88-8a42-2118e0dba0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2d23d94a-c6a8-40a1-a509-6ee276734fd2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_8625e799-2b32-4b85-96c5-9bdfe8a84741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:to="loc_us-gaap_TaxPeriodAxis_8625e799-2b32-4b85-96c5-9bdfe8a84741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_8625e799-2b32-4b85-96c5-9bdfe8a84741_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_8625e799-2b32-4b85-96c5-9bdfe8a84741" xlink:to="loc_us-gaap_TaxPeriodDomain_8625e799-2b32-4b85-96c5-9bdfe8a84741_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_f4033740-863a-4785-b961-5e6a9d415f10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_8625e799-2b32-4b85-96c5-9bdfe8a84741" xlink:to="loc_us-gaap_TaxPeriodDomain_f4033740-863a-4785-b961-5e6a9d415f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPriorTo2018Member_b5cdfb6a-cfeb-4858-a1bb-237124e6bd73" xlink:href="imux-20201231.xsd#imux_TaxYearsPriorTo2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_f4033740-863a-4785-b961-5e6a9d415f10" xlink:to="loc_imux_TaxYearsPriorTo2018Member_b5cdfb6a-cfeb-4858-a1bb-237124e6bd73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPost2017Member_d6b222ac-10e9-4be9-ab43-9f98aefe98b6" xlink:href="imux-20201231.xsd#imux_TaxYearsPost2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_f4033740-863a-4785-b961-5e6a9d415f10" xlink:to="loc_imux_TaxYearsPost2017Member_d6b222ac-10e9-4be9-ab43-9f98aefe98b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d230c6a7-9e52-47f0-a6b3-896238cb6977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d230c6a7-9e52-47f0-a6b3-896238cb6977" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d230c6a7-9e52-47f0-a6b3-896238cb6977_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d230c6a7-9e52-47f0-a6b3-896238cb6977" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d230c6a7-9e52-47f0-a6b3-896238cb6977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_224b94a2-f55c-4086-be84-666922a8d76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d230c6a7-9e52-47f0-a6b3-896238cb6977" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_224b94a2-f55c-4086-be84-666922a8d76d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_b56f17b4-90ea-4c65-beaa-748cde3c43c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_224b94a2-f55c-4086-be84-666922a8d76d" xlink:to="loc_us-gaap_DomesticCountryMember_b56f17b4-90ea-4c65-beaa-748cde3c43c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_a5e11bcd-7133-46b6-abb6-c596d9b988a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_224b94a2-f55c-4086-be84-666922a8d76d" xlink:to="loc_us-gaap_ForeignCountryMember_a5e11bcd-7133-46b6-abb6-c596d9b988a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/EIBLoan" xlink:type="simple" xlink:href="imux-20201231.xsd#EIBLoan"/>
  <link:definitionLink xlink:role="http://imux.com/role/EIBLoan" xlink:type="extended" id="i1c93f66c1efd48efb206d3601cf27454_EIBLoan"/>
  <link:roleRef roleURI="http://imux.com/role/EIBLoanDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#EIBLoanDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/EIBLoanDetails" xlink:type="extended" id="i88f685ed3dc94cc69d6fc1eb0c0acc5e_EIBLoanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_31d752cc-507d-4b87-8413-9fc4ce774f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_31d752cc-507d-4b87-8413-9fc4ce774f2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityNumberOfTranches_1d75dbfd-4bb7-43c7-bade-49da95f19ee4" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_imux_LineOfCreditFacilityNumberOfTranches_1d75dbfd-4bb7-43c7-bade-49da95f19ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityTranchePaymentDeferralTerm_576ad346-ae23-4e9f-a270-7157da229332" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityTranchePaymentDeferralTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_imux_LineOfCreditFacilityTranchePaymentDeferralTerm_576ad346-ae23-4e9f-a270-7157da229332" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityRevenueShareCapFirstTranche_f9b854f2-fe6c-4506-bf86-9f9eabf26498" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityRevenueShareCapFirstTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_imux_LineOfCreditFacilityRevenueShareCapFirstTranche_f9b854f2-fe6c-4506-bf86-9f9eabf26498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn_952fdb67-c4c0-4694-9a3b-ccc98af9a22c" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityRevenueShareCapFullyDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn_952fdb67-c4c0-4694-9a3b-ccc98af9a22c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85a846d4-a0bd-4741-be38-59b1851b101a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85a846d4-a0bd-4741-be38-59b1851b101a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_85a846d4-a0bd-4741-be38-59b1851b101a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85a846d4-a0bd-4741-be38-59b1851b101a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_85a846d4-a0bd-4741-be38-59b1851b101a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9bdb0411-96c6-4a46-9486-8c738960b8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85a846d4-a0bd-4741-be38-59b1851b101a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9bdb0411-96c6-4a46-9486-8c738960b8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_eaf9c4b7-b32d-4010-a2c7-ca539d7f49c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9bdb0411-96c6-4a46-9486-8c738960b8a4" xlink:to="loc_us-gaap_LineOfCreditMember_eaf9c4b7-b32d-4010-a2c7-ca539d7f49c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d56f65a3-52c5-4d1b-a6a4-28be8283665d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:to="loc_us-gaap_DebtInstrumentAxis_d56f65a3-52c5-4d1b-a6a4-28be8283665d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d56f65a3-52c5-4d1b-a6a4-28be8283665d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d56f65a3-52c5-4d1b-a6a4-28be8283665d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d56f65a3-52c5-4d1b-a6a4-28be8283665d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5877377a-ddab-40e2-8bb8-e4b9c213c000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d56f65a3-52c5-4d1b-a6a4-28be8283665d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5877377a-ddab-40e2-8bb8-e4b9c213c000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EuropeanInvestmentBankLoanMember_c27454c7-3282-4725-8769-44ed89959d4e" xlink:href="imux-20201231.xsd#imux_EuropeanInvestmentBankLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5877377a-ddab-40e2-8bb8-e4b9c213c000" xlink:to="loc_imux_EuropeanInvestmentBankLoanMember_c27454c7-3282-4725-8769-44ed89959d4e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="imux-20201231.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://imux.com/role/RelatedPartyTransactions" xlink:type="extended" id="ifb2dc769399f430aaa7609428d1adf46_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="i28ed9bc24ba04af1aa7d7cd052db40ff_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8f935bf4-e671-4bc6-8420-49c85cd06e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SalaryCostsMonthlyBaseSalary_c19ef2da-638e-4254-af9e-eb8e7d94bd3b" xlink:href="imux-20201231.xsd#imux_SalaryCostsMonthlyBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8f935bf4-e671-4bc6-8420-49c85cd06e02" xlink:to="loc_imux_SalaryCostsMonthlyBaseSalary_c19ef2da-638e-4254-af9e-eb8e7d94bd3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f8ad246a-8d81-45aa-80e2-3c9dc1bdaf03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8f935bf4-e671-4bc6-8420-49c85cd06e02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f8ad246a-8d81-45aa-80e2-3c9dc1bdaf03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b51a9094-78a3-48ae-8d28-ad7c0650efce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8f935bf4-e671-4bc6-8420-49c85cd06e02" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b51a9094-78a3-48ae-8d28-ad7c0650efce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b51a9094-78a3-48ae-8d28-ad7c0650efce" xlink:to="loc_srt_TitleOfIndividualAxis_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dd229686-bbaf-4558-891f-ee28879471a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dd229686-bbaf-4558-891f-ee28879471a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_8a9d2f07-6577-49dc-ae04-559086af71f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dd229686-bbaf-4558-891f-ee28879471a7" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_8a9d2f07-6577-49dc-ae04-559086af71f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunaudited" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunaudited"/>
  <link:definitionLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunaudited" xlink:type="extended" id="i75ede667b6ed495db8b395844422a0ce_SelectedQuarterlyDataunaudited"/>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunauditedTables" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunauditedTables"/>
  <link:definitionLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunauditedTables" xlink:type="extended" id="i3954302e3fa5489e86032f5374d53f44_SelectedQuarterlyDataunauditedTables"/>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail"/>
  <link:definitionLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail" xlink:type="extended" id="i7ecb2e40f8b1484cba1ea9a20feb8aca_SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>imux-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5279c717-4640-48e4-aa74-73546e28db9a,g:602f65cf-bbe8-45d8-a039-a1d02730d21d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ecc89b2-c3c6-43d4-b378-bf56e9b0044d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs to be granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_06cf5bcf-987c-46bb-b273-6b3c0a5d2702_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow_6fea3233-b6e6-4a03-abfb-62eff0991f50_terseLabel_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount released from escrow</link:label>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow_label_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Amount Released From Escrow</link:label>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow_documentation_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Amount Released From Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" xlink:to="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_24cf4c28-b0fb-4c4b-9b43-f3891f6f2aa3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_71a06f1d-2948-49d2-a663-e7644433b705_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7552145b-25ff-441e-bf45-04bc1561bcf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cecc469a-853d-46f3-91cc-3a38beeef40a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7a434e9-707e-4322-878e-2abdfa34c6dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_757eee27-3f8d-42ed-b8d2-48fe32c6aa46_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LineOfCreditFacilityNumberOfTranches_7e251e20-0e31-4527-ab50-57c587a32aee_terseLabel_en-US" xlink:label="lab_imux_LineOfCreditFacilityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_imux_LineOfCreditFacilityNumberOfTranches_label_en-US" xlink:label="lab_imux_LineOfCreditFacilityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Tranches</link:label>
    <link:label id="lab_imux_LineOfCreditFacilityNumberOfTranches_documentation_en-US" xlink:label="lab_imux_LineOfCreditFacilityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityNumberOfTranches" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LineOfCreditFacilityNumberOfTranches" xlink:to="lab_imux_LineOfCreditFacilityNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ClinicalCostsPayableCurrent_e7b94295-b283-4e3a-a020-43ce9450c441_terseLabel_en-US" xlink:label="lab_imux_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical costs</link:label>
    <link:label id="lab_imux_ClinicalCostsPayableCurrent_label_en-US" xlink:label="lab_imux_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:label id="lab_imux_ClinicalCostsPayableCurrent_documentation_en-US" xlink:label="lab_imux_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalCostsPayableCurrent" xlink:href="imux-20201231.xsd#imux_ClinicalCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ClinicalCostsPayableCurrent" xlink:to="lab_imux_ClinicalCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_24bb432e-c336-43a9-acc8-19216d2e2cb2_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research &amp; development (&#8220;IPR&amp;D&#8221;)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a31e1038-0d6e-498e-b80e-3abd9fce6d54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a9bbe953-4c89-4016-be55-75c8411239ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a47aff81-fe2e-4c73-9e50-07fc181cbee3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_7d77cc99-7af1-450f-bf85-3020010e9234_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7684af9b-5df7-4962-b359-93998d86d812_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81b7ea74-8344-4a35-b198-b37ed184e75e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_9395e2c5-f9bb-484b-ba9b-18c44cfd6a1f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EmployeeStockOptionsforFutureGrantMember_55c5f3a7-65cf-4746-ac4a-8bf70cc9bb37_terseLabel_en-US" xlink:label="lab_imux_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options available for future grant:</link:label>
    <link:label id="lab_imux_EmployeeStockOptionsforFutureGrantMember_label_en-US" xlink:label="lab_imux_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:label id="lab_imux_EmployeeStockOptionsforFutureGrantMember_documentation_en-US" xlink:label="lab_imux_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsforFutureGrantMember" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsforFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EmployeeStockOptionsforFutureGrantMember" xlink:to="lab_imux_EmployeeStockOptionsforFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35881bcb-e01d-4210-a5d0-d0ec43fa9be5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital_dde96c75-ba42-41c3-a743-c10f221b97e9_terseLabel_en-US" xlink:label="lab_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of Company's total issued shared capital available for grant under stock option programs</link:label>
    <link:label id="lab_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital_label_en-US" xlink:label="lab_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation, Shares Authorized Under Stock Option Plans, Percent Of Total Issued Capital</link:label>
    <link:label id="lab_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital_documentation_en-US" xlink:label="lab_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation, Shares Authorized Under Stock Option Plans, Percent Of Total Issued Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" xlink:to="lab_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_57ed08b8-f17e-4278-9bdc-598d348ad794_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_de57721e-6461-4dff-bc11-42a25b6a9215_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalMinistryOfFinanceGermanyMember_3e717067-813e-45a3-a39d-c03dceb97b96_terseLabel_en-US" xlink:label="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_us-gaap_FederalMinistryOfFinanceGermanyMember_label_en-US" xlink:label="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Ministry of Finance, Germany [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:to="lab_us-gaap_FederalMinistryOfFinanceGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a4baddb2-2281-46d6-85ce-44a89f30ada6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_9c7379c5-65f3-424a-bc56-82b756b2c3d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_01fb8128-f5a6-454e-b224-dff2f81abe5b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_08799233-b2f7-4156-80f9-5bd54f6e0a4b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f0d2ba51-5aa0-46c8-b8b0-ce18726eba50_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1e3c974-d60f-4403-935f-fe83d74d2461_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0708da27-b6d3-48a5-ae31-ad7b3302d4b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2bbd83c7-8bcf-4d05-9465-8e969becbfb6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_VitalTherapiesInc.Member_d3c9313b-40c7-421f-8c30-397f2fb8dca1_terseLabel_en-US" xlink:label="lab_imux_VitalTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Therapies, Inc.</link:label>
    <link:label id="lab_imux_VitalTherapiesInc.Member_label_en-US" xlink:label="lab_imux_VitalTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Therapies, Inc. [Member]</link:label>
    <link:label id="lab_imux_VitalTherapiesInc.Member_documentation_en-US" xlink:label="lab_imux_VitalTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Therapies, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_VitalTherapiesInc.Member" xlink:to="lab_imux_VitalTherapiesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7420ce57-bf08-45c3-aad0-d699a9a8f4fb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6554ec23-d84d-4f59-baca-7aa844b971bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_96f587f1-8fb2-477b-b14a-b9691bd6b8f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4cf26798-5de8-4aff-82d5-4ebf739db300_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_24c5c4ee-3f02-4d12-9e81-32c1dcad3200_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8267e2c6-5a1a-4424-9e77-f24d715fb436_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7b3c6b30-a44d-43ce-af5e-38e18f4552dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8191e346-6484-400b-9a30-c6470e583301_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent_a9124733-8bba-454b-b6d0-a7c114a5a545_terseLabel_en-US" xlink:label="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian research and development tax incentive</link:label>
    <link:label id="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent_label_en-US" xlink:label="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:label id="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent_documentation_en-US" xlink:label="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:href="imux-20201231.xsd#imux_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:to="lab_imux_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6c812370-dd30-48b3-95a6-194791230d0d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e74d532f-72a2-4283-b2dd-6fccfc45806d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2c923873-8c2f-4624-ae10-56ce7e48271d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_37e7693a-7f47-4d2a-b7b8-114eeb8a68cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cc83f49d-9777-4b99-89a6-f989fdeeffd7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_55423bca-e392-4c4e-93ee-14d5ca27ae8a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4e9ffe86-5e83-4b87-ad31-cdcebb033e45_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_352dc672-22a2-4488-b382-810b08e38a45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical development equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5279ce02-657f-47b6-8f16-4669e27cf4b0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c2e4fda3-bedf-4ced-a836-0aee8872cab6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_c548aca5-d14a-429c-8591-17f5df46376a_terseLabel_en-US" xlink:label="lab_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_label_en-US" xlink:label="lab_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interests Issued Or Issuable, Exchange Ratio</link:label>
    <link:label id="lab_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_documentation_en-US" xlink:label="lab_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interests Issued Or Issuable, Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" xlink:href="imux-20201231.xsd#imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" xlink:to="lab_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_67e23aea-910c-4952-97ee-198d97df6950_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges_15aa9b09-b95c-4aab-9475-aa415912b583_terseLabel_en-US" xlink:label="lab_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs, non-cash charges</link:label>
    <link:label id="lab_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges_label_en-US" xlink:label="lab_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed, Non-Cash Charges</link:label>
    <link:label id="lab_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges_documentation_en-US" xlink:label="lab_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed, Non-Cash Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" xlink:href="imux-20201231.xsd#imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" xlink:to="lab_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_3e4cf539-2fb8-4614-ac6b-4a4ff60fce02_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_8aa5e6de-220d-4983-892c-f1b5f54bfdc0_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0e6194ca-03b9-4796-b09d-a21c5615ca32_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December&#160;31, 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_bd352bf4-d7a6-4f32-99c1-2688369c2096_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_81afe008-db72-4130-b0aa-e4b99d77d34c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_b0ab3cec-6b2c-42cd-92ec-7897edee5db6_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f4857711-a313-4e88-86f8-1fc8aa61ca59_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_9bfba7ad-e596-4126-8132-92d4e9af50fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e9a9fb51-9894-4f9f-a75a-979700eaf17d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0fa4a8b6-f9e3-4c94-bc47-2760df08a5be_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_92080ac7-11e5-4872-8b41-c2a14da4a951_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3efbd2ba-8046-44df-a1e4-61f6cc7a7874_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_OfferingCostsIncludedInAccruedExpenses_25db31e3-39a8-42cf-af25-86b3868473f4_terseLabel_en-US" xlink:label="lab_imux_OfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs in accrued expenses</link:label>
    <link:label id="lab_imux_OfferingCostsIncludedInAccruedExpenses_label_en-US" xlink:label="lab_imux_OfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Included In Accrued Expenses</link:label>
    <link:label id="lab_imux_OfferingCostsIncludedInAccruedExpenses_documentation_en-US" xlink:label="lab_imux_OfferingCostsIncludedInAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Included In Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OfferingCostsIncludedInAccruedExpenses" xlink:href="imux-20201231.xsd#imux_OfferingCostsIncludedInAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_OfferingCostsIncludedInAccruedExpenses" xlink:to="lab_imux_OfferingCostsIncludedInAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_556de868-95c8-4b03-b87f-a2f007ad919d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SaleOfStockNumberOfAdditionalSharesAuthorized_9de610b1-6d1f-496a-807d-682eb8c97613_terseLabel_en-US" xlink:label="lab_imux_SaleOfStockNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_imux_SaleOfStockNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_imux_SaleOfStockNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Additional Shares Authorized</link:label>
    <link:label id="lab_imux_SaleOfStockNumberOfAdditionalSharesAuthorized_documentation_en-US" xlink:label="lab_imux_SaleOfStockNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockNumberOfAdditionalSharesAuthorized" xlink:href="imux-20201231.xsd#imux_SaleOfStockNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SaleOfStockNumberOfAdditionalSharesAuthorized" xlink:to="lab_imux_SaleOfStockNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4ba40bf0-0dd4-4c21-b970-df7ebaafbb69_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration_85c5a3ce-e91e-4c58-877d-b95a8b16adfc_terseLabel_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration_label_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash Consideration</link:label>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration_documentation_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration" xlink:to="lab_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f44a0a18-9e67-4c56-9c05-97d929b2ae27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_June2020EquityIssuancesMember_34567d3c-963d-4d47-a7c9-1baef271005d_terseLabel_en-US" xlink:label="lab_imux_June2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Equity Issuances</link:label>
    <link:label id="lab_imux_June2020EquityIssuancesMember_label_en-US" xlink:label="lab_imux_June2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Equity Issuances [Member]</link:label>
    <link:label id="lab_imux_June2020EquityIssuancesMember_documentation_en-US" xlink:label="lab_imux_June2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2020 Equity Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_June2020EquityIssuancesMember" xlink:to="lab_imux_June2020EquityIssuancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_80e17a0a-7259-4ca2-8aa1-e9721d5ff599_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_26b22347-2a83-4787-8702-56c69db23a7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_37e64645-3631-47be-8ed9-95c485a29aff_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_41bab237-20fe-4a6b-a6e6-0d032eb9f890_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_15c74d03-efca-4301-bf02-2daed333c26f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of common stock in connection with Transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6c3e690a-2d5f-4aae-b35f-71d38f6214ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c6fb2187-f47f-4ee6-b1b5-2a36962b856a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_fa35ab38-ad5a-40de-852e-531b1dee0968_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_771a1c51-e39c-4f05-be44-6b96c22928df_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d490b0b8-71c3-4112-abba-21d9c918d709_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8b6bd749-e50d-4c59-b8a6-1fcdb8357fca_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_62628dc3-c250-476e-8c3a-0d3ca76d4177_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EuropeanInvestmentBankLoanMember_ab0af0aa-a80e-4d93-bb38-347bfbb2e349_terseLabel_en-US" xlink:label="lab_imux_EuropeanInvestmentBankLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIB Loan</link:label>
    <link:label id="lab_imux_EuropeanInvestmentBankLoanMember_label_en-US" xlink:label="lab_imux_EuropeanInvestmentBankLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Investment Bank Loan [Member]</link:label>
    <link:label id="lab_imux_EuropeanInvestmentBankLoanMember_documentation_en-US" xlink:label="lab_imux_EuropeanInvestmentBankLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Investment Bank Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EuropeanInvestmentBankLoanMember" xlink:href="imux-20201231.xsd#imux_EuropeanInvestmentBankLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EuropeanInvestmentBankLoanMember" xlink:to="lab_imux_EuropeanInvestmentBankLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6655e84a-c5b6-49be-a661-f2969c2f253d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_eb4bfa28-a49e-490b-871c-2c4de52388b8_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_a0ddcfeb-3335-4d6f-9f2f-d26246973246_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of rate change</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans_b1a2fa5d-0525-4e41-a6fc-395cba45d159_terseLabel_en-US" xlink:label="lab_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized for grant under stock option programs (in shares)</link:label>
    <link:label id="lab_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans_label_en-US" xlink:label="lab_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation, Number Of Shares Authorized Under Stock Option Plans</link:label>
    <link:label id="lab_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans_documentation_en-US" xlink:label="lab_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation, Number Of Shares Authorized Under Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" xlink:to="lab_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_42b01db2-286a-4f66-abd5-4a8bf990de78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_97c01b6d-f2af-4dec-aefe-1cb841fd2385_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0567f2bc-cecf-497b-94cb-37790ae56b99_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7f4d7579-e349-4537-8dec-1814ca736faf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6a6cce5a-2a1e-470f-a599-c7afef0b3f0f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_46675b1c-56ad-4ea4-a89b-07bf34e17692_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf569b86-bd35-4620-8013-2af1d31bdce2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_383a3476-92e1-425e-8c66-1ab07095eac1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issues in private placement transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_31f9ad68-4bba-4b31-86e4-409ea5af0622_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIB Loan</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88111c15-d2da-48d3-80a6-be38d654dfcc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_58afff56-6088-4683-8f89-476d99351e06_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_1e38376f-bb54-4cd0-9a62-f98fa3fed194_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1028061c-d3ed-4524-be75-0ffa3df09393_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a784857e-46b2-4b35-822e-bf63add6545a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_93b8b71d-b5dd-4e46-9236-7619d98ef495_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65a0c893-7f3d-4120-85ba-60a62752f3fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_07d8d7af-5cf7-4b0c-bbb5-8de8217164a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_67cf93d8-8368-471d-865d-e1ef34893934_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_8f791b3b-aa8e-4167-8ddb-127a4ea41994_terseLabel_en-US" xlink:label="lab_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash fee, percent of gross proceeds</link:label>
    <link:label id="lab_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agency Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agency Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="imux-20201231.xsd#imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_4ad68dd4-57d5-4041-83f7-ba6572003cac_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_f1dbfd90-f0a8-4b10-9e47-d9929548c2cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_018416b0-b6a3-4b64-9158-d160595c1de9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TwoThousandFourteenEquityIncentivePlanMember_27a7e121-7d23-4580-b35f-74773cffd0ad_terseLabel_en-US" xlink:label="lab_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_imux_TwoThousandFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_imux_TwoThousandFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:href="imux-20201231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lab_imux_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d7f6db71-9163-471f-a345-68e0d2a722b9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_876aa1a8-be26-4048-8775-f7c2b4a6e585_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_6ea350f8-cb02-4849-a762-a50b4d9cb444_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LineOfCreditFacilityRevenueShareCapFirstTranche_553cea3c-86ac-442b-919b-c8bd44034b86_terseLabel_en-US" xlink:label="lab_imux_LineOfCreditFacilityRevenueShareCapFirstTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, revenue share cap, first tranche</link:label>
    <link:label id="lab_imux_LineOfCreditFacilityRevenueShareCapFirstTranche_label_en-US" xlink:label="lab_imux_LineOfCreditFacilityRevenueShareCapFirstTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Revenue Share Cap, First Tranche</link:label>
    <link:label id="lab_imux_LineOfCreditFacilityRevenueShareCapFirstTranche_documentation_en-US" xlink:label="lab_imux_LineOfCreditFacilityRevenueShareCapFirstTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Revenue Share Cap, First Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityRevenueShareCapFirstTranche" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityRevenueShareCapFirstTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LineOfCreditFacilityRevenueShareCapFirstTranche" xlink:to="lab_imux_LineOfCreditFacilityRevenueShareCapFirstTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_63a9cc10-0205-4f5b-bc3f-4afbd4b57a04_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e5b7474c-9613-449f-b34e-5ae65788006a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_aa38ae27-b658-4021-b0e7-bf3ec2ff4489_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_c30f9dd7-5755-487d-823b-442f6bb82c65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2056b693-e7c0-4527-9fc1-23aab8d44346_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3ce08eaf-9c76-451f-aa39-2187aed18030_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_91b76c17-9f3b-4900-80d0-7d45a2a6df95_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of common stock in connection with Transaction</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_440e3654-a9d9-49a2-80e0-f7fcf37d6b81_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2d2fa2cc-e1fe-463f-9403-24e1497e5374_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_84dd8ab3-0433-47af-a7e4-d7d68a70ed4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b470bf37-30ba-47a3-9291-d04e5c15126d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_PreClosingFinancingMember_39234aaa-ba13-4906-8220-b3dbc909580f_terseLabel_en-US" xlink:label="lab_imux_PreClosingFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Closing Financing</link:label>
    <link:label id="lab_imux_PreClosingFinancingMember_label_en-US" xlink:label="lab_imux_PreClosingFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Closing Financing [Member]</link:label>
    <link:label id="lab_imux_PreClosingFinancingMember_documentation_en-US" xlink:label="lab_imux_PreClosingFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_PreClosingFinancingMember" xlink:to="lab_imux_PreClosingFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_40b6b09d-9716-4cd1-bdfc-36bbc67a385d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3fa07821-24c1-49e8-b8b2-b7f0fee19fda_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement_41b81e5a-862b-4766-8c2c-03e60816fcbe_terseLabel_en-US" xlink:label="lab_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price under ATM agreement</link:label>
    <link:label id="lab_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement_label_en-US" xlink:label="lab_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Of Common Stock That Can Be Issued Under At-The-Market Sales Agreement</link:label>
    <link:label id="lab_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement_documentation_en-US" xlink:label="lab_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Of Common Stock That Can Be Issued Under At-The-Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" xlink:href="imux-20201231.xsd#imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" xlink:to="lab_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7bd1885a-cff1-45f0-8ebd-7bc6a83de64f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_f04259e1-3c8d-4969-b0e4-d6a914ed1bb1_terseLabel_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:href="imux-20201231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:to="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_July2019EquityIssuancesMember_7cae0a17-df42-47da-9531-1d10a28f14dc_terseLabel_en-US" xlink:label="lab_imux_July2019EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2019 Equity Issuances</link:label>
    <link:label id="lab_imux_July2019EquityIssuancesMember_label_en-US" xlink:label="lab_imux_July2019EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2019 Equity Issuances [Member]</link:label>
    <link:label id="lab_imux_July2019EquityIssuancesMember_documentation_en-US" xlink:label="lab_imux_July2019EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2019 Equity Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2019EquityIssuancesMember" xlink:href="imux-20201231.xsd#imux_July2019EquityIssuancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_July2019EquityIssuancesMember" xlink:to="lab_imux_July2019EquityIssuancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_42f4461a-ec4c-49f7-9a78-82458dcde0fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock_410477f0-fbca-4f09-b771-289acc61c350_terseLabel_en-US" xlink:label="lab_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period on additional issuance of common stock</link:label>
    <link:label id="lab_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock_label_en-US" xlink:label="lab_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Exercisable Period On Additional Issuance Of Common Stock</link:label>
    <link:label id="lab_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock_documentation_en-US" xlink:label="lab_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Exercisable Period On Additional Issuance Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" xlink:href="imux-20201231.xsd#imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" xlink:to="lab_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_8d4de474-1d5f-4718-9f9e-64485fbe0e70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of ELAD Assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AccruedLegalAndAuditCostsCurrent_070531dc-1cf8-40af-8c2f-4ff6cc058ad7_terseLabel_en-US" xlink:label="lab_imux_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal and audit costs</link:label>
    <link:label id="lab_imux_AccruedLegalAndAuditCostsCurrent_label_en-US" xlink:label="lab_imux_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:label id="lab_imux_AccruedLegalAndAuditCostsCurrent_documentation_en-US" xlink:label="lab_imux_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedLegalAndAuditCostsCurrent" xlink:href="imux-20201231.xsd#imux_AccruedLegalAndAuditCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AccruedLegalAndAuditCostsCurrent" xlink:to="lab_imux_AccruedLegalAndAuditCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ed764ba7-041c-4508-91ae-d0708a89508c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f0f99965-1b4e-48d6-a00b-c8b867f621da_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6cd21d8f-9fb3-4758-b792-a8e11cc560d7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_488ad21f-48c8-4492-af84-d4346e71a396_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_181e6166-99ce-41ba-826d-ca9fdf036ed5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_August2020EquityIssuancesMember_7a5b8341-b818-4c16-aef9-36605ebaf82d_terseLabel_en-US" xlink:label="lab_imux_August2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2020 Equity Issuances</link:label>
    <link:label id="lab_imux_August2020EquityIssuancesMember_label_en-US" xlink:label="lab_imux_August2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2020 Equity Issuances [Member]</link:label>
    <link:label id="lab_imux_August2020EquityIssuancesMember_documentation_en-US" xlink:label="lab_imux_August2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2020 Equity Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_August2020EquityIssuancesMember" xlink:to="lab_imux_August2020EquityIssuancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eb973d0f-ef26-4784-b2e3-4efee8638251_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_DeferredTaxAssetsAndLiabilitiesGross_ff3a0261-1a42-4b6c-b104-87247fac04f1_totalLabel_en-US" xlink:label="lab_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_imux_DeferredTaxAssetsAndLiabilitiesGross_label_en-US" xlink:label="lab_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities, Gross</link:label>
    <link:label id="lab_imux_DeferredTaxAssetsAndLiabilitiesGross_documentation_en-US" xlink:label="lab_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:href="imux-20201231.xsd#imux_DeferredTaxAssetsAndLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:to="lab_imux_DeferredTaxAssetsAndLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_964645d5-c3fc-483f-94ee-69c6cf254736_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_DeferredStockIssuanceCostsIncludedInLiabilities_9dc20188-bdda-4c22-9ed2-85988303c5fc_terseLabel_en-US" xlink:label="lab_imux_DeferredStockIssuanceCostsIncludedInLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance and deferred financing costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_imux_DeferredStockIssuanceCostsIncludedInLiabilities_label_en-US" xlink:label="lab_imux_DeferredStockIssuanceCostsIncludedInLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Stock Issuance Costs Included In Liabilities</link:label>
    <link:label id="lab_imux_DeferredStockIssuanceCostsIncludedInLiabilities_documentation_en-US" xlink:label="lab_imux_DeferredStockIssuanceCostsIncludedInLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Stock Issuance Costs Included In Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredStockIssuanceCostsIncludedInLiabilities" xlink:href="imux-20201231.xsd#imux_DeferredStockIssuanceCostsIncludedInLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_DeferredStockIssuanceCostsIncludedInLiabilities" xlink:to="lab_imux_DeferredStockIssuanceCostsIncludedInLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2b1dff00-96f9-4942-9488-e8bc769b976f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_CashEquivalentsInvestmentsMaturityPeriod_49f830a3-1a45-44e6-bd15-470c47bf63db_terseLabel_en-US" xlink:label="lab_imux_CashEquivalentsInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, highly-liquid investments maturity (or less)</link:label>
    <link:label id="lab_imux_CashEquivalentsInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_imux_CashEquivalentsInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Investments Maturity Period</link:label>
    <link:label id="lab_imux_CashEquivalentsInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_imux_CashEquivalentsInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Investments Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashEquivalentsInvestmentsMaturityPeriod" xlink:href="imux-20201231.xsd#imux_CashEquivalentsInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_CashEquivalentsInvestmentsMaturityPeriod" xlink:to="lab_imux_CashEquivalentsInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7966cd9d-341d-49ad-bc4c-9d2264e7ec0f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_16470a36-c455-489b-9c1b-314a6c4e0d03_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_b258809f-6ea0-4084-a661-89a36cdbeaa6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_42d465fe-8999-42f1-8555-0205ee938369_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_374843e3-6392-41d2-bc14-2050bc33c5ca_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ExecutiveBonusAgreementMember_bdc46cfc-bb64-47ab-b659-642b9a1b85d7_terseLabel_en-US" xlink:label="lab_imux_ExecutiveBonusAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Bonus Agreement</link:label>
    <link:label id="lab_imux_ExecutiveBonusAgreementMember_label_en-US" xlink:label="lab_imux_ExecutiveBonusAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Bonus Agreement [Member]</link:label>
    <link:label id="lab_imux_ExecutiveBonusAgreementMember_documentation_en-US" xlink:label="lab_imux_ExecutiveBonusAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Bonus Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ExecutiveBonusAgreementMember" xlink:href="imux-20201231.xsd#imux_ExecutiveBonusAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ExecutiveBonusAgreementMember" xlink:to="lab_imux_ExecutiveBonusAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0f25c325-dff4-476c-9812-42356564fd54_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which compensation cost will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ca50bb1d-5fe0-46cd-810f-25296f00b87a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4551cef9-9a3f-461d-b05a-171ccc0b5647_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest portion</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_0679534b-2d27-4b3b-9198-32e7d7104f71_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable with Imputed Interest, Effective Yield (Interest Rate)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:to="lab_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7787757d-8700-4af4-9aaa-1618fc77a223_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_462cf073-71b3-47bf-acc7-6c0763dd81e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2eca5818-7cbe-4aab-9d1d-394f5e701af9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_fc4b4920-97a8-40f6-bda8-bedadd96fd0b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e456a16a-4858-4fa7-a897-44a44b7bee1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_c19ad6fc-e22a-40af-b36a-334857c6ffb3_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9f414416-b440-4430-b586-9aa1dbac7f2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_573997df-bb86-4d9b-9a97-c99700c5a16d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of net assets acquired in the Transaction</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_e1777010-0e35-4f1a-9fd5-1160a1ba90b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock cash dividends paid (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c2036e17-c5f6-4eb0-b391-d0606545b254_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ProceedsFromIssuanceOfCommonStockGross_adea8e98-a216-49e5-b1a6-7ccf69e6ca44_terseLabel_en-US" xlink:label="lab_imux_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, gross</link:label>
    <link:label id="lab_imux_ProceedsFromIssuanceOfCommonStockGross_label_en-US" xlink:label="lab_imux_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock, Gross</link:label>
    <link:label id="lab_imux_ProceedsFromIssuanceOfCommonStockGross_documentation_en-US" xlink:label="lab_imux_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ProceedsFromIssuanceOfCommonStockGross" xlink:href="imux-20201231.xsd#imux_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ProceedsFromIssuanceOfCommonStockGross" xlink:to="lab_imux_ProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_167750a8-6ada-43ee-b203-6871441c7017_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e7a400f1-7428-4f59-b560-a039647a6d43_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b8f81cd1-59ff-4ec6-9313-02341cc0b1e9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2723f3af-b177-4201-881d-92b0258a0487_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Quarterly Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_91cee27f-ab5d-4ebc-95f2-fd2a29a40f1e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5c30eae2-82ca-420e-ac1a-eafa053dc3a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9fe3da7a-873a-4573-a2fe-297db1d7a605_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_6993f955-327b-4afc-a09d-fd3f421d8aa9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_ef274903-ac78-4f9b-8403-48761fb631b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3163f822-9ed3-4d26-860f-471f2fdc6f7a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9c80f134-c138-4052-8f1b-128ed7553fb4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares owned by Vital stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_093b5790-9d8b-4ace-9407-ac7802510929_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EmployeeStockOptionsImmunicAGMember_4b957d04-ae08-462d-9a15-38e754feecfc_terseLabel_en-US" xlink:label="lab_imux_EmployeeStockOptionsImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Immunic AG</link:label>
    <link:label id="lab_imux_EmployeeStockOptionsImmunicAGMember_label_en-US" xlink:label="lab_imux_EmployeeStockOptionsImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Immunic AG [Member]</link:label>
    <link:label id="lab_imux_EmployeeStockOptionsImmunicAGMember_documentation_en-US" xlink:label="lab_imux_EmployeeStockOptionsImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Immunic AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsImmunicAGMember" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsImmunicAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EmployeeStockOptionsImmunicAGMember" xlink:to="lab_imux_EmployeeStockOptionsImmunicAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_PrepaidClinicalAndRelatedCostsCurrent_5c0b7654-6c6d-45bf-a57a-ef2484ce75e1_terseLabel_en-US" xlink:label="lab_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical and related costs</link:label>
    <link:label id="lab_imux_PrepaidClinicalAndRelatedCostsCurrent_label_en-US" xlink:label="lab_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:label id="lab_imux_PrepaidClinicalAndRelatedCostsCurrent_documentation_en-US" xlink:label="lab_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:href="imux-20201231.xsd#imux_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:to="lab_imux_PrepaidClinicalAndRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_34d8e71f-4ad0-4c50-97fc-cf81c1e13b81_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_364a76a6-b75e-400b-a8f2-acde1a7f0c22_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0abc38fe-4d3d-4560-95de-9301f5b2e542_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_58dca0ce-8c46-4c79-928d-ad6227955078_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1d8b3ed8-67b0-42db-8fd5-fe2bc2414d7c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_f4904ec9-2dee-457e-943b-8ba341e86b8d_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ef599422-4f6b-4cac-a419-18f99d3f2463_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_A2017InducementEquityIncentivePlanMember_c62d6489-0f49-4735-b5fc-d26c0c0840df_terseLabel_en-US" xlink:label="lab_imux_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_imux_A2017InducementEquityIncentivePlanMember_label_en-US" xlink:label="lab_imux_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_imux_A2017InducementEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_imux_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember" xlink:href="imux-20201231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_A2017InducementEquityIncentivePlanMember" xlink:to="lab_imux_A2017InducementEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_d228ce81-6c32-4566-bb76-cd237ce5ead9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares owned</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_e8df4ba7-3765-46d0-ae52-457ba5bfb959_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4496cee7-c9aa-4eac-8155-4a94869f9663_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_95e06a30-1772-4865-90fd-196a716a38cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_59c14a3c-cb35-4012-baa7-18a1ae36b326_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable_de289d33-e6cc-407f-b24b-176c975432c3_terseLabel_en-US" xlink:label="lab_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable</link:label>
    <link:label id="lab_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable_label_en-US" xlink:label="lab_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, And Equipment Included In Accounts Payable</link:label>
    <link:label id="lab_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable_documentation_en-US" xlink:label="lab_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, And Equipment Included In Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:href="imux-20201231.xsd#imux_PropertyPlantAndEquipmentIncludedInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:to="lab_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_72ea5637-0747-40b0-8dbf-13c09e542689_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b728d18b-499f-491d-a08c-84492259e2f9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_8a807beb-c64d-484c-87f1-9c1e82f8db9e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3c2267fd-7065-46cc-8f09-2aa61b307727_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d8907e5d-8230-49a5-9749-4df8d0ee6679_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_19a68351-b98c-4fe3-96a3-9e075f5abf8c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_1073d576-d0a1-4ee4-8572-8f14558ee6d5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c8818dc8-0ccc-429d-bd9e-72a9812e1354_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ef7bdf67-73e8-4bf2-8aae-64513423dba6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestFaceAmount_897879e8-ee5e-4964-92b9-a43a04b5db28_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of receivable</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestFaceAmount_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable with Imputed Interest, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:to="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_NonStatutoryEmployeeStockOptionMember_c1af9b82-0816-41c2-86d8-6f879c9a1384_terseLabel_en-US" xlink:label="lab_imux_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option</link:label>
    <link:label id="lab_imux_NonStatutoryEmployeeStockOptionMember_label_en-US" xlink:label="lab_imux_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:label id="lab_imux_NonStatutoryEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_imux_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NonStatutoryEmployeeStockOptionMember" xlink:href="imux-20201231.xsd#imux_NonStatutoryEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_NonStatutoryEmployeeStockOptionMember" xlink:to="lab_imux_NonStatutoryEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_a65df54a-75cb-4f04-9f32-578c05b1d4fa_terseLabel_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs owned prior to transaction (in shares)</link:label>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_label_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Awards Owned Prior To Transaction</link:label>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_documentation_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Awards Owned Prior To Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" xlink:to="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2be74423-4c55-4cb6-9473-ba3d27790700_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35421d54-53de-4a46-b5b4-f5c707c1b25a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5258b1aa-fc74-4d6b-acee-54e8d26d4fef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1949be01-2770-4437-8497-4cc8d6a1b2ec_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_46f59039-dbff-465f-8cdd-f3ecab8824f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AccruedCompensationCurrent_8959e475-47f8-4e5e-9f44-e6ca99512e9d_terseLabel_en-US" xlink:label="lab_imux_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_imux_AccruedCompensationCurrent_label_en-US" xlink:label="lab_imux_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:label id="lab_imux_AccruedCompensationCurrent_documentation_en-US" xlink:label="lab_imux_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedCompensationCurrent" xlink:href="imux-20201231.xsd#imux_AccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AccruedCompensationCurrent" xlink:to="lab_imux_AccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_d7702b44-3b88-46ce-ad81-1e151bda3e7e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a4f2ac11-4a1f-44fc-b52a-3fbb8aebbbd2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3b04dca4-cbf0-4cd5-9059-3810949754c9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_28acdf93-7afd-4d8e-9dad-ffe7dda6d1c7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_5cadc976-64b4-49c3-a02c-90788fbf88c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_df58b5d6-319d-4384-ac16-6cbbe587fcd2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a9257d7c-a9bb-404b-a45f-3cc6a6e7dc52_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ImmunicAGMember_1bb03d32-02d8-4036-ab43-a857e511eaf2_terseLabel_en-US" xlink:label="lab_imux_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG</link:label>
    <link:label id="lab_imux_ImmunicAGMember_label_en-US" xlink:label="lab_imux_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG [Member]</link:label>
    <link:label id="lab_imux_ImmunicAGMember_documentation_en-US" xlink:label="lab_imux_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ImmunicAGMember" xlink:to="lab_imux_ImmunicAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ec841e9b-7176-42bf-9a71-c8667410ea8e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_c0ba3bec-83bf-4424-ab36-2a1d0890f148_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_dbbe5a87-6d9b-4c34-b0a9-3d5210fc4981_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SuppliesAndWorkingCellBanksMember_333f6ed0-dff8-4720-b268-a30163264515_terseLabel_en-US" xlink:label="lab_imux_SuppliesAndWorkingCellBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies and working cell banks</link:label>
    <link:label id="lab_imux_SuppliesAndWorkingCellBanksMember_label_en-US" xlink:label="lab_imux_SuppliesAndWorkingCellBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies And Working Cell Banks [Member]</link:label>
    <link:label id="lab_imux_SuppliesAndWorkingCellBanksMember_documentation_en-US" xlink:label="lab_imux_SuppliesAndWorkingCellBanksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies And Working Cell Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SuppliesAndWorkingCellBanksMember" xlink:href="imux-20201231.xsd#imux_SuppliesAndWorkingCellBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SuppliesAndWorkingCellBanksMember" xlink:to="lab_imux_SuppliesAndWorkingCellBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6fd78ac9-4abd-4a3d-8c2b-c7cfbd42399d_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_b04794e2-73cc-4da9-884f-9ec25f7d5a91_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9bedb30a-1b1b-4a9a-b71a-9e7696b9a62a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_99450d0a-d686-4e16-93b5-00ee080d8398_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_92e7eb64-ace1-472a-9e02-8396cebfde26_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_1ce4706b-3200-4f0e-bfd4-8e00cbe2ec42_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_4d79c6d2-872d-4d9d-90dd-f3283cd89b54_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Data (unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_35880d8f-fa24-4a59-85d9-cd84ce89b7b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss before Income Tax Based on Jurisdictions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5f57edf-eac0-4447-9f0d-803472aeedb0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a1475236-0328-403b-8e6a-ffe95987524f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_4a1367b9-86bc-4780-95d7-2814481d0b58_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets, valuation allowance total</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_18d1c863-98b8-4451-967c-ffbf1d84efdc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice_2905bafc-2fb5-419a-a80c-d7073622404e_terseLabel_en-US" xlink:label="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled in cash in period (in USD per share)</link:label>
    <link:label id="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period, Weighted-Average Exercise Price</link:label>
    <link:label id="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period, Weighted-Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" xlink:href="imux-20201231.xsd#imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" xlink:to="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_65b1bceb-587d-448f-9e48-af7e150d69df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EmployeeMember_d0d5aabf-8126-4560-a287-64b2fdf767d4_terseLabel_en-US" xlink:label="lab_imux_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_imux_EmployeeMember_label_en-US" xlink:label="lab_imux_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_imux_EmployeeMember_documentation_en-US" xlink:label="lab_imux_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeMember" xlink:href="imux-20201231.xsd#imux_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EmployeeMember" xlink:to="lab_imux_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_cc426e38-b1d3-467b-aad5-2856789404e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_648f63d7-df32-4f65-8a88-d29c622dbb1e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_0c5e2b11-fabc-44b9-8294-f8f32a9d0991_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration from private placement</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_d79584c9-501c-4010-9616-f571705909a4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a3e5e057-5214-45e3-a59a-c944bf8da8b5_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TaxYearsPriorTo2018Member_28566b1a-90d5-4511-bf98-6541f2054c96_terseLabel_en-US" xlink:label="lab_imux_TaxYearsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to 2018</link:label>
    <link:label id="lab_imux_TaxYearsPriorTo2018Member_label_en-US" xlink:label="lab_imux_TaxYearsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years Prior to 2018 [Member]</link:label>
    <link:label id="lab_imux_TaxYearsPriorTo2018Member_documentation_en-US" xlink:label="lab_imux_TaxYearsPriorTo2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years Prior to 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPriorTo2018Member" xlink:href="imux-20201231.xsd#imux_TaxYearsPriorTo2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TaxYearsPriorTo2018Member" xlink:to="lab_imux_TaxYearsPriorTo2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_23d39281-65b0-4630-a144-c3753c2daa52_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases_f734f309-fd97-4cf7-bb0b-af96661bec44_terseLabel_en-US" xlink:label="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of existing operating leases</link:label>
    <link:label id="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases_label_en-US" xlink:label="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:label id="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases_documentation_en-US" xlink:label="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:href="imux-20201231.xsd#imux_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:to="lab_imux_LesseeOperatingLeasesNumberOfExistingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8f99173f-8851-4a0b-99e8-af4e3a013817_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9da5f84f-544a-470d-a106-fef02746f8d1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1f45377e-9681-430a-be66-13b4d76759d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f0215054-968c-432e-ad5b-60ad79114a91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a392cfcc-f943-448d-96a0-8d9dcafe7dfc_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock and Preferred Stock (Converted into Common Stock)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_26b5848a-5a16-497d-a7fc-e8ae81fa22c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8d3dba76-364e-4f5f-a70d-3f3d64afa80c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f98b4380-c5c6-4df3-9fdf-f2575e4ecf3f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_d08533f3-6354-4a92-93f5-040b0fc3b0a0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_39cd6d81-6152-4a78-ad50-827d4cb42db0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_32bae7b5-facc-4dd3-96ad-dfb58a09babc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f76bc06b-7947-4bdd-b1f9-6c2afe37b31a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_754d1088-abbf-47ac-9324-061f86b40db8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7c369186-5749-48e3-8772-565fbc310bfa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn_3c2ae9b1-bf2a-45f7-bf69-cb94b896079b_terseLabel_en-US" xlink:label="lab_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, revenue share cap, full loan amount drawn</link:label>
    <link:label id="lab_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn_label_en-US" xlink:label="lab_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Revenue Share Cap, Fully Drawn</link:label>
    <link:label id="lab_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn_documentation_en-US" xlink:label="lab_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Revenue Share Cap, Fully Drawn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityRevenueShareCapFullyDrawn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn" xlink:to="lab_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_889cbf19-f46f-4839-b64e-c9d47d885194_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ef2ddc4c-c5cc-4198-8691-57cb893cb4c3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A Preferred Stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_317ef4f8-decc-410b-b296-68dd6b57d811_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_0899f00b-6e09-438e-9f4f-9cd5e45b0532_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_943c5e28-68a7-45c8-94e6-adbb985997d9_terseLabel_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_label_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]</link:label>
    <link:label id="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_documentation_en-US" xlink:label="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:href="imux-20201231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:to="lab_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04c04a00-c8c0-42f1-a71f-5b6aaf246a40_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3326926d-5270-4cf2-bd14-8c252fed2ce6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_68daff62-15d4-4d68-9961-021e6a8a5819_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_fc76aa07-7c8f-4a19-ae90-c3c8ae7b67a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_bb6271a6-9692-4871-ba35-d820b53ea244_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Presentation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_990a0b43-10ee-4d02-a50d-be941b837b44_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d3b4d3c7-fea8-4583-b7bd-2d290f6ef364_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9fcfbf26-abdd-451b-a5f2-baa22d9ee526_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_baa2e84f-c38e-42c3-9f45-2625bbb09554_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8fbb571a-3510-42bb-ba88-ed6d803304dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_28ac176a-7cbd-492d-bc63-06c9ce56fd6c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_345a13be-176d-43c8-8617-403bdd268858_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c9f7501b-54bf-429b-87e6-11ebeb8835ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed in the Transaction with Vital (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9ebc7aef-10ef-4c49-9ac9-0b30caca8e18_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_635e3e60-30de-4546-b7fb-fb6705618cca_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9de5fc6f-3cc0-44a9-8cc3-7a667b0dfcfb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_bbf0fea5-4e72-4cd8-aae9-414d7a4b642e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants outstanding and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_08d9182d-c1ea-4830-aa0f-0807be0d3973_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f3d43cc6-34dc-4240-ac6e-c40d7948a595_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_bbd7de90-152c-4100-aea8-d87223c67075_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6d672df7-7297-4e6c-a792-b65d9ee10929_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_d162ee7e-b60a-4803-935c-658279a31efb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_e6c38852-39b5-4412-897d-4a33404b2e13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2fb83795-cf1b-4860-8acc-45a2e1284925_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_86928bf2-1b41-4be5-8aab-95684eabeef9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_75280a08-e028-4d72-8568-fa7efa38300f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ac1d6c45-0ba8-41cd-8bc9-811b6802da83_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_a3ded9fd-b8da-4cd7-bb8e-035b82b82056_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ee9a6a05-9720-4e79-8bc3-05add5473129_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_07daab84-8375-4271-b68c-ee64d947c9e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ELAD Sales Agreement</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f1494c82-3435-4b34-bf66-a0515cccf3e5_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_6387871a-d08c-409a-bca7-d4ce3595fc7a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of promissory note</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cff82f19-0290-43a3-84bf-a622ef051b4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_bdf45426-87b4-419f-b838-946ff34c8807_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_0abe5018-a71a-4238-a7df-30c8ecef7049_terseLabel_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding shares to purchase (in shares)</link:label>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_label_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Awards Assumed</link:label>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_documentation_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Awards Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" xlink:to="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3f4e9dd-52d6-4931-aef9-876862803755_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_65bb801f-ea75-4a5a-90ef-eafd385caaee_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_560521f7-dce0-4f6c-9ee7-1d665851aa22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10bc0b2f-f85f-4f3a-89cf-78068156c178_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_1e1134c1-a05e-4aa2-bdf0-c3bd779a3ee9_terseLabel_en-US" xlink:label="lab_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash fee, percent of gross proceeds</link:label>
    <link:label id="lab_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engagement Letter Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Engagement Letter Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="imux-20201231.xsd#imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_754c498f-3e76-418d-a783-39f94129e8a4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_b9c7b8f5-4d9d-4979-ab22-117041929290_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value of ELAD Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dab35a66-4ed2-4630-bac7-df07b36d2982_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8ea3dac8-dc51-4af5-beb1-23990dc6468b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SeriesA1ConvertiblePreferredStockMember_cf67b8b6-a103-4a6c-a9d9-60aa997fae14_terseLabel_en-US" xlink:label="lab_imux_SeriesA1ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Convertible Preferred Stock</link:label>
    <link:label id="lab_imux_SeriesA1ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_imux_SeriesA1ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_imux_SeriesA1ConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_imux_SeriesA1ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA1ConvertiblePreferredStockMember" xlink:href="imux-20201231.xsd#imux_SeriesA1ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SeriesA1ConvertiblePreferredStockMember" xlink:to="lab_imux_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_4a6c560b-e142-4664-8b0b-1d4643303348_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed in the Transaction with Vital (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LineOfCreditFacilityTranchePaymentDeferralTerm_d81dd4e8-da44-48ba-aa52-73ee3f5a4efa_terseLabel_en-US" xlink:label="lab_imux_LineOfCreditFacilityTranchePaymentDeferralTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche payment deferral term</link:label>
    <link:label id="lab_imux_LineOfCreditFacilityTranchePaymentDeferralTerm_label_en-US" xlink:label="lab_imux_LineOfCreditFacilityTranchePaymentDeferralTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Tranche Payment Deferral, Term</link:label>
    <link:label id="lab_imux_LineOfCreditFacilityTranchePaymentDeferralTerm_documentation_en-US" xlink:label="lab_imux_LineOfCreditFacilityTranchePaymentDeferralTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Tranche Payment Deferral, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityTranchePaymentDeferralTerm" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityTranchePaymentDeferralTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LineOfCreditFacilityTranchePaymentDeferralTerm" xlink:to="lab_imux_LineOfCreditFacilityTranchePaymentDeferralTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e233ab58-9f13-43fb-8aad-5c27ece7f83b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2da1927d-0e84-4ea8-984d-cef4061e3f48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December&#160;31, 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_f655c967-a475-4384-95dc-df6ee5e9bfb0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e220f3f-4b88-49b1-8a19-c8c7dbff2486_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_65f8f0b1-abb5-43b3-b02c-d98b49611d86_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders_8b817105-558f-4f5a-a076-3f0cf5f08406_terseLabel_en-US" xlink:label="lab_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum common stock shares authorized (in shares)</link:label>
    <link:label id="lab_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders_label_en-US" xlink:label="lab_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders</link:label>
    <link:label id="lab_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders_documentation_en-US" xlink:label="lab_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" xlink:href="imux-20201231.xsd#imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" xlink:to="lab_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d2ded313-65a1-46e0-a37c-1d6405383c26_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_96205f48-b9a8-41ab-b1e1-0b75e41edf14_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod_d3223a26-ad46-41c6-a858-f9bbb54dfe55_negatedLabel_en-US" xlink:label="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled in cash (in shares)</link:label>
    <link:label id="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod_label_en-US" xlink:label="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period</link:label>
    <link:label id="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod_documentation_en-US" xlink:label="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" xlink:href="imux-20201231.xsd#imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" xlink:to="lab_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8e168b66-97a6-4c66-a84a-a5b3232f7af9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_1a9fb5e2-b189-4268-83cd-cfb193a47c7c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_cae51629-5bd9-411d-ad45-02ba6b9db231_terseLabel_en-US" xlink:label="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in operating lease, right-of-use asset</link:label>
    <link:label id="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="imux-20201231.xsd#imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_571f489a-f8e8-43d9-839c-c621ad051666_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration_7a6dbe87-06a6-4bac-b876-7d8d1a477857_terseLabel_en-US" xlink:label="lab_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</link:label>
    <link:label id="lab_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration_label_en-US" xlink:label="lab_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price of Securities Under Shelf Registration</link:label>
    <link:label id="lab_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration_documentation_en-US" xlink:label="lab_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price of Securities Under Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" xlink:href="imux-20201231.xsd#imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" xlink:to="lab_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_992d2419-b31c-45bc-9136-3389f50bf3aa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1b58a887-a787-44ff-a136-18456c636b72_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_58a679eb-a369-4aab-98cc-185ca43835af_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiplied by the fair value per share of Vital common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1d681f27-95db-4e46-a519-ef40dbb8cc33_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0850fd97-2ed4-4619-8ad4-7705b4a1b96c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_OperatingAndVariableLeasesCost_b7ab6b42-e9dc-4df4-ab7c-5837d09f2440_terseLabel_en-US" xlink:label="lab_imux_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and variable lease cost</link:label>
    <link:label id="lab_imux_OperatingAndVariableLeasesCost_label_en-US" xlink:label="lab_imux_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:label id="lab_imux_OperatingAndVariableLeasesCost_documentation_en-US" xlink:label="lab_imux_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OperatingAndVariableLeasesCost" xlink:href="imux-20201231.xsd#imux_OperatingAndVariableLeasesCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_OperatingAndVariableLeasesCost" xlink:to="lab_imux_OperatingAndVariableLeasesCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_811385ba-fcfd-48dd-88a3-ebaf139b7612_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payment settled in common stock</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_61e82895-8255-4926-bffe-bd6bf19a467f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_72c1c6d8-fe4f-472c-b192-f378bd376fc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_6c1e9a29-f5c3-4ff3-bac8-2d2792e63de1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_CashAcquiredInConnectionWithReverseAcquisition_693ac35e-99a4-4e4f-976f-758541d19de1_terseLabel_en-US" xlink:label="lab_imux_CashAcquiredInConnectionWithReverseAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired in connection with the Transaction</link:label>
    <link:label id="lab_imux_CashAcquiredInConnectionWithReverseAcquisition_label_en-US" xlink:label="lab_imux_CashAcquiredInConnectionWithReverseAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired In Connection With Reverse Acquisition</link:label>
    <link:label id="lab_imux_CashAcquiredInConnectionWithReverseAcquisition_documentation_en-US" xlink:label="lab_imux_CashAcquiredInConnectionWithReverseAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired In Connection With Reverse Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashAcquiredInConnectionWithReverseAcquisition" xlink:href="imux-20201231.xsd#imux_CashAcquiredInConnectionWithReverseAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_CashAcquiredInConnectionWithReverseAcquisition" xlink:to="lab_imux_CashAcquiredInConnectionWithReverseAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_18e13c87-7f6c-4f57-a719-8a2600d0295f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_27b07ed9-9ca5-497e-bdaf-c6bcc28fdfa7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0b496d9c-9903-4b06-9e6b-6947e93cc20b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_477ea01a-67a3-45dd-9a87-2969097b7000_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ELADRelatedAssetsMember_73f1c935-b96d-48d5-b48d-2d35f6d5a72f_terseLabel_en-US" xlink:label="lab_imux_ELADRelatedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ELAD-Related Assets</link:label>
    <link:label id="lab_imux_ELADRelatedAssetsMember_label_en-US" xlink:label="lab_imux_ELADRelatedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ELAD-Related Assets [Member]</link:label>
    <link:label id="lab_imux_ELADRelatedAssetsMember_documentation_en-US" xlink:label="lab_imux_ELADRelatedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ELAD-Related Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ELADRelatedAssetsMember" xlink:href="imux-20201231.xsd#imux_ELADRelatedAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ELADRelatedAssetsMember" xlink:to="lab_imux_ELADRelatedAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_65192dc5-fc8b-494c-b71d-61c44c0ffe2f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_434285a7-5f33-4136-a297-90bb7a9c0bb8_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_3297e2d6-3c35-4486-9cba-355b4eb7a7f9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_60971b1b-be0e-449a-8c2a-f376346b3fb9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_33e49fe0-c67d-4bf3-8db3-65d4f73c6d69_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7499c0d2-65de-4591-837d-b95b68fdd5a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_99b6617a-69e3-4c16-89aa-3b636866957f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_ed8f3676-ba79-4096-a315-88f9f7640616_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d12f692e-1183-472b-b4af-ac027dd10ae8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ForeignExcludingGermanyMember_925ba956-a4fe-4bf6-b38b-35bcba3ed645_terseLabel_en-US" xlink:label="lab_imux_ForeignExcludingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_imux_ForeignExcludingGermanyMember_label_en-US" xlink:label="lab_imux_ForeignExcludingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign, Excluding Germany [Member]</link:label>
    <link:label id="lab_imux_ForeignExcludingGermanyMember_documentation_en-US" xlink:label="lab_imux_ForeignExcludingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign, Excluding Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ForeignExcludingGermanyMember" xlink:href="imux-20201231.xsd#imux_ForeignExcludingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ForeignExcludingGermanyMember" xlink:to="lab_imux_ForeignExcludingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2dbdb22c-004f-417e-88f7-8c713b6fbd96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_9dd46491-48e2-45c1-828f-49a97f1eb41f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash distribution in connection with ELAD Assets sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a77893eb-c698-4903-9e56-41723e48221d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e5c8dfc9-e24f-4ebf-92df-532b34c523ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_45f751a7-b005-4293-9231-16a8172c5f8b_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8cec46ad-cdf2-4a69-a7b3-e8edc068825d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_dea1ea7b-f0c9-41fe-8cdd-82518b413510_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_52daf41d-8fb9-4060-8c26-51b991f83a9e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e137d42b-9eb4-46dd-91de-8f921afe7cb3_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_57533d29-8e73-48da-8a4c-b6c10ff3bab6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SalaryCostsMonthlyBaseSalary_4c92814e-4196-4c39-a476-0370a8f14171_terseLabel_en-US" xlink:label="lab_imux_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base salary</link:label>
    <link:label id="lab_imux_SalaryCostsMonthlyBaseSalary_label_en-US" xlink:label="lab_imux_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:label id="lab_imux_SalaryCostsMonthlyBaseSalary_documentation_en-US" xlink:label="lab_imux_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SalaryCostsMonthlyBaseSalary" xlink:href="imux-20201231.xsd#imux_SalaryCostsMonthlyBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SalaryCostsMonthlyBaseSalary" xlink:to="lab_imux_SalaryCostsMonthlyBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_dc37ef2a-63bd-4ca4-a80a-d80a5188d5ce_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_130fcb66-accd-4686-9ab8-18d616c2f036_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officers</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c69eda97-c8d4-4259-87f3-7e41ce462acb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a3235304-0d15-4595-94a9-00cd1eddb356_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1b0b1748-04f5-49d1-b917-a90d86bc2f96_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_202b9a76-c8a7-4292-9d2c-566d280480d0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ec544ea1-eea3-4b0d-adb5-72e85d0c28ef_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c991ed47-8b3e-441d-bfb8-3927f0f197f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit_4c3b5575-1229-42dd-b9b1-fb43b40b4ace_terseLabel_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit</link:label>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit_label_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Escrow Deposit</link:label>
    <link:label id="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit_documentation_en-US" xlink:label="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" xlink:to="lab_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_274911c2-44a8-4f86-b31a-5fdef77448c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c31f86e0-6bf6-4cf2-80c4-468ad5a2c76b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c20e0983-eee0-4cc8-a443-5be5c2996a07_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_6fb82a09-fd80-47b3-8557-127e92b9f277_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b368d426-614d-46a1-95fb-1992a1b2109d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_808aac50-e07d-45dc-89ce-9f854ff2152f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_18078b30-1783-431d-a093-c14d36517233_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_8cc1675c-7916-47ab-87bc-4828287f3df6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_70f4d4fa-5eb1-466f-b502-7e2df1d4d4cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6da4ad24-1b59-4122-aebf-764ab4ab3563_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_12116471-3211-454f-a785-c81b7004fe77_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of ELAD Assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a800a80c-22cc-46e3-b449-0b7d29d10f5c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_LegalAndAuditCostsPayableCurrent_8852a73b-96b0-4cdb-886d-01f1ffc4d0d3_terseLabel_en-US" xlink:label="lab_imux_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and audit costs</link:label>
    <link:label id="lab_imux_LegalAndAuditCostsPayableCurrent_label_en-US" xlink:label="lab_imux_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:label id="lab_imux_LegalAndAuditCostsPayableCurrent_documentation_en-US" xlink:label="lab_imux_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LegalAndAuditCostsPayableCurrent" xlink:href="imux-20201231.xsd#imux_LegalAndAuditCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_LegalAndAuditCostsPayableCurrent" xlink:to="lab_imux_LegalAndAuditCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a6740ae9-989f-482b-9a64-fa1fa5989f7c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AtTheMarketSalesAgreementMember_a9e694a3-b1b4-4fb3-9030-89923ed1cd9c_terseLabel_en-US" xlink:label="lab_imux_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement</link:label>
    <link:label id="lab_imux_AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_imux_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement [Member]</link:label>
    <link:label id="lab_imux_AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_imux_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AtTheMarketSalesAgreementMember" xlink:href="imux-20201231.xsd#imux_AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AtTheMarketSalesAgreementMember" xlink:to="lab_imux_AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_e8425fb2-c39f-4540-a3db-fae105ca2cc6_negatedLabel_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable, Accrued Expenses, And Other Liabilities</link:label>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable, Accrued Expenses, And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b23fc475-78d1-4584-97d3-0a80789753fc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_443a22e4-7dfa-48c6-bb7e-d5c3a7dd7474_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_60556b34-9861-4791-bef8-de3707f4eba8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development (&#8220;IPR&amp;D&#8221;)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_412ac393-1bea-42e0-8d5c-f0578352af02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c9cda94f-a297-40ae-b572-541c7ccabe94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a362d292-1a50-4112-982f-d0a6c57a603a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_f9aa8169-12ac-4646-9a8d-3c47b12e176b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_SeriesA2ConvertiblePreferredStockMember_22f2359a-06c4-4bff-b1db-1a2701534bad_terseLabel_en-US" xlink:label="lab_imux_SeriesA2ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Convertible Preferred Stock</link:label>
    <link:label id="lab_imux_SeriesA2ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_imux_SeriesA2ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_imux_SeriesA2ConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_imux_SeriesA2ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA2ConvertiblePreferredStockMember" xlink:href="imux-20201231.xsd#imux_SeriesA2ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_SeriesA2ConvertiblePreferredStockMember" xlink:to="lab_imux_SeriesA2ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_TaxYearsPost2017Member_477c61f4-a178-4324-bdbf-19535299223d_terseLabel_en-US" xlink:label="lab_imux_TaxYearsPost2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post 2017</link:label>
    <link:label id="lab_imux_TaxYearsPost2017Member_label_en-US" xlink:label="lab_imux_TaxYearsPost2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years Post 2017 [Member]</link:label>
    <link:label id="lab_imux_TaxYearsPost2017Member_documentation_en-US" xlink:label="lab_imux_TaxYearsPost2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years Post 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPost2017Member" xlink:href="imux-20201231.xsd#imux_TaxYearsPost2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_TaxYearsPost2017Member" xlink:to="lab_imux_TaxYearsPost2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_f5a2a102-df07-4ae6-9dce-03a444a0c59b_terseLabel_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized, percent</link:label>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_label_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:label id="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_documentation_en-US" xlink:label="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:to="lab_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_ceb0c189-cc05-4b2d-8fd3-9d7de9c9ad15_terseLabel_en-US" xlink:label="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, royalties as percent of aggregated net sales</link:label>
    <link:label id="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_label_en-US" xlink:label="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</link:label>
    <link:label id="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_documentation_en-US" xlink:label="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:href="imux-20201231.xsd#imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:to="lab_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_AccruedClinicalCostsCurrent_e6400354-b9d3-4456-939a-fb6b33a489c9_terseLabel_en-US" xlink:label="lab_imux_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and related costs</link:label>
    <link:label id="lab_imux_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_imux_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_imux_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_imux_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedClinicalCostsCurrent" xlink:href="imux-20201231.xsd#imux_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_AccruedClinicalCostsCurrent" xlink:to="lab_imux_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_56ce9e82-504c-46d1-b991-33354fe3b59b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_868bd929-99cc-4bfc-8980-5f8dc2ed2b86_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b9d14d15-c63d-4d8e-9887-e31c9ebdd657_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9c5d3f38-6a31-41a8-8c56-0b204c1a21b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ab57546f-3138-44d5-9e46-1415835da965_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5f29ba4c-2102-4846-85c4-0c5fdb8d0d77_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_8e2a7d0e-c726-4a64-86a3-027fcdda71dd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20df8083-f3ed-4615-8835-8ea87c74a5e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_4fdd76b9-9ce4-4982-bf39-ad50726a6999_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e04dfad6-65f8-486b-a1e8-b569fea577c6_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A Preferred Stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_17825a3c-36ba-4f1f-9541-b0c1f0e03aec_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_A4SCSettlementAgreementMember_4747f2a5-a517-442c-89f0-b10516b1f77b_terseLabel_en-US" xlink:label="lab_imux_A4SCSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Settlement Agreement</link:label>
    <link:label id="lab_imux_A4SCSettlementAgreementMember_label_en-US" xlink:label="lab_imux_A4SCSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Settlement Agreement [Member]</link:label>
    <link:label id="lab_imux_A4SCSettlementAgreementMember_documentation_en-US" xlink:label="lab_imux_A4SCSettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Settlement Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A4SCSettlementAgreementMember" xlink:href="imux-20201231.xsd#imux_A4SCSettlementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_A4SCSettlementAgreementMember" xlink:to="lab_imux_A4SCSettlementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_90104f9d-dcc2-40ee-aa77-0077370b425f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eb32d94e-6b96-447c-a848-e63c73d01402_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_65df5eab-976a-4de7-a56b-d7d43d0279c2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a5db40e0-c9cf-4403-ac7d-4ff00d5b385a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_e826103a-3e25-451f-afed-4abc244435a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting for the Transaction</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_55cb6513-c939-400c-8ec0-a245d4c91e2a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c3447fc5-40b7-4f95-b6a2-c657b0279675_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f88286f6-1917-4121-80f4-a58620b9f091_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4c68f92c-df54-4700-b050-254dec06e380_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_April2020EquityIssuancesMember_d5b42d89-8d1c-4c5a-971d-2cbf290974b7_terseLabel_en-US" xlink:label="lab_imux_April2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2020 Equity Issuances</link:label>
    <link:label id="lab_imux_April2020EquityIssuancesMember_label_en-US" xlink:label="lab_imux_April2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2020 Equity Issuances [Member]</link:label>
    <link:label id="lab_imux_April2020EquityIssuancesMember_documentation_en-US" xlink:label="lab_imux_April2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2020 Equity Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_April2020EquityIssuancesMember" xlink:to="lab_imux_April2020EquityIssuancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_A2019OmnibusEquityIncentivePlanMember_0f936858-3f60-4f98-a375-acdf202aa41a_terseLabel_en-US" xlink:label="lab_imux_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_imux_A2019OmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_imux_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_imux_A2019OmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_imux_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember" xlink:href="imux-20201231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_A2019OmnibusEquityIncentivePlanMember" xlink:to="lab_imux_A2019OmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_December2020EquityIssuancesMember_e0a4b15b-9af3-484e-a9e0-18932f50c60f_terseLabel_en-US" xlink:label="lab_imux_December2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 Equity Issuances</link:label>
    <link:label id="lab_imux_December2020EquityIssuancesMember_label_en-US" xlink:label="lab_imux_December2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 Equity Issuances [Member]</link:label>
    <link:label id="lab_imux_December2020EquityIssuancesMember_documentation_en-US" xlink:label="lab_imux_December2020EquityIssuancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 Equity Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_December2020EquityIssuancesMember" xlink:href="imux-20201231.xsd#imux_December2020EquityIssuancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_December2020EquityIssuancesMember" xlink:to="lab_imux_December2020EquityIssuancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_68e2ff23-47f3-44ad-9464-61d4cc2cd586_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_VSOPAndVSOPSBMember_34694e81-1680-457c-9f84-9539ad05eb4e_terseLabel_en-US" xlink:label="lab_imux_VSOPAndVSOPSBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSOP And VSOP SB</link:label>
    <link:label id="lab_imux_VSOPAndVSOPSBMember_label_en-US" xlink:label="lab_imux_VSOPAndVSOPSBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSOP And VSOP SB [Member]</link:label>
    <link:label id="lab_imux_VSOPAndVSOPSBMember_documentation_en-US" xlink:label="lab_imux_VSOPAndVSOPSBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSOP And VSOP SB [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VSOPAndVSOPSBMember" xlink:href="imux-20201231.xsd#imux_VSOPAndVSOPSBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_VSOPAndVSOPSBMember" xlink:to="lab_imux_VSOPAndVSOPSBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9f47b9a1-3380-4bbd-816e-3d68ca2d77c5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_eb4994c1-a446-4544-89e4-0cd5eb6560b9_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_1ede65b5-8b60-46bd-b1bb-fddd176dd3ae_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_60c0b576-f6db-4b94-a6ce-a45e4107c32c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_ac612127-46c3-4b2a-a597-ca5e9ebacb96_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_033169b1-b7e2-4cff-9bb7-92c072e76a8e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a40a918b-9a96-4660-aa78-438e1b33d486_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_24004bfa-e373-44c6-bcf8-03336c86c83b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency gain</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1e15d3ff-48ae-443c-83a6-ba3277932f6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_769aae4c-aab9-478f-9828-88026752e557_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0f6e51c-1521-4fce-8400-ffa299aba32d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e79cf01-760d-4933-9001-b595f0563bd2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_868d895c-644b-4530-9de6-7b49c55ca74d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_EmployeeStockOptionsVitalTherapiesInc.Member_e21cc339-8fc4-4623-a208-9f21570f594e_terseLabel_en-US" xlink:label="lab_imux_EmployeeStockOptionsVitalTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Vital Therapies Inc.</link:label>
    <link:label id="lab_imux_EmployeeStockOptionsVitalTherapiesInc.Member_label_en-US" xlink:label="lab_imux_EmployeeStockOptionsVitalTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Vital Therapies Inc. [Member]</link:label>
    <link:label id="lab_imux_EmployeeStockOptionsVitalTherapiesInc.Member_documentation_en-US" xlink:label="lab_imux_EmployeeStockOptionsVitalTherapiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Vital Therapies Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsVitalTherapiesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member" xlink:to="lab_imux_EmployeeStockOptionsVitalTherapiesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9eccb22c-1b29-4339-8bf9-8d169ae4432d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e712e2b8-426d-4dc3-9cdd-0fb90455f34e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b1719c43-375f-4218-8470-2c1e2d251fbf_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_81cc2622-f76d-41f1-8b76-e72c23763136_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_7ec137eb-0b55-4eca-bf91-e977d9de0b7b_terseLabel_en-US" xlink:label="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, percent of gross proceeds from sale of common stock</link:label>
    <link:label id="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="imux-20201231.xsd#imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_741f5078-90bf-4da5-8283-26239b1747fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ImmunicInc.Member_a41580a5-d624-4177-8de9-e9ce276f7be7_terseLabel_en-US" xlink:label="lab_imux_ImmunicInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic, Inc.</link:label>
    <link:label id="lab_imux_ImmunicInc.Member_label_en-US" xlink:label="lab_imux_ImmunicInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic, Inc. [Member]</link:label>
    <link:label id="lab_imux_ImmunicInc.Member_documentation_en-US" xlink:label="lab_imux_ImmunicInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicInc.Member" xlink:href="imux-20201231.xsd#imux_ImmunicInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ImmunicInc.Member" xlink:to="lab_imux_ImmunicInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c42d42ea-6126-4343-b8ae-963c96fdae3e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c813065e-2fae-4031-845b-bf48a856c128_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ClinicalDevelopmentEquipmentMember_e7207638-4ec3-438d-a441-c9e150759eaa_terseLabel_en-US" xlink:label="lab_imux_ClinicalDevelopmentEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical development equipment</link:label>
    <link:label id="lab_imux_ClinicalDevelopmentEquipmentMember_label_en-US" xlink:label="lab_imux_ClinicalDevelopmentEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Development Equipment [Member]</link:label>
    <link:label id="lab_imux_ClinicalDevelopmentEquipmentMember_documentation_en-US" xlink:label="lab_imux_ClinicalDevelopmentEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Development Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalDevelopmentEquipmentMember" xlink:href="imux-20201231.xsd#imux_ClinicalDevelopmentEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ClinicalDevelopmentEquipmentMember" xlink:to="lab_imux_ClinicalDevelopmentEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9d2add54-c4d7-4891-b417-613c2f05b384_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8aac2477-d74f-4d4d-851b-286a7b3c5270_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_50f749ed-aa77-482d-bfe5-c4345551cb81_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_IncentiveEmployeeStockOptionMember_467743cc-700b-4aa4-82eb-3c3211f313d4_terseLabel_en-US" xlink:label="lab_imux_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option</link:label>
    <link:label id="lab_imux_IncentiveEmployeeStockOptionMember_label_en-US" xlink:label="lab_imux_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:label id="lab_imux_IncentiveEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_imux_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncentiveEmployeeStockOptionMember" xlink:href="imux-20201231.xsd#imux_IncentiveEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_IncentiveEmployeeStockOptionMember" xlink:to="lab_imux_IncentiveEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a896bcee-f461-464e-b15d-cb61227843b7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_36a2b2eb-f402-4d3c-82fa-8832b27fbf1c_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_59e0bcf5-95be-4925-8b49-2297d312adc7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_e1744a87-7b16-4550-8a1c-4c070c7e277f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of ELAD assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7123a526-ca4e-4fb8-895b-fdf3201a91aa_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_77d52c3b-9801-4335-8bcf-a4fba058a206_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c76e823e-089b-4a96-ab8e-529fc7f6c50d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueAdjustment_d9eb4d10-c7cf-4df3-925e-1acd11bb5bee_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueAdjustment" xlink:to="lab_us-gaap_AssetsFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8401e43b-4a48-4c3a-9a20-4b42806239d4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_816b4a13-5f8c-48e4-bdf5-fd010256335b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_59178d7f-f328-4bd5-984e-5f801f5c075d_terseLabel_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies and working cell banks</link:label>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_label_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Supplies And Working Cell Banks</link:label>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_documentation_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Supplies And Working Cell Banks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" xlink:to="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_668299a6-7125-41cb-bd24-fd5eb04688ea_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_0ed78235-aced-4d7b-9846-2b4b86e24e28_terseLabel_en-US" xlink:label="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="imux-20201231.xsd#imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ced26960-befe-42be-a83d-5f046e555f10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6d37e453-269b-4a58-8726-86de46164b85_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_BusinessCombinationSharesOwnedPriorToTransaction_e2b5e16a-ac15-44e1-b54e-4503461db27e_terseLabel_en-US" xlink:label="lab_imux_BusinessCombinationSharesOwnedPriorToTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares owned prior to transaction (in shares)</link:label>
    <link:label id="lab_imux_BusinessCombinationSharesOwnedPriorToTransaction_label_en-US" xlink:label="lab_imux_BusinessCombinationSharesOwnedPriorToTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Shares Owned Prior To Transaction</link:label>
    <link:label id="lab_imux_BusinessCombinationSharesOwnedPriorToTransaction_documentation_en-US" xlink:label="lab_imux_BusinessCombinationSharesOwnedPriorToTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Shares Owned Prior To Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationSharesOwnedPriorToTransaction" xlink:href="imux-20201231.xsd#imux_BusinessCombinationSharesOwnedPriorToTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_BusinessCombinationSharesOwnedPriorToTransaction" xlink:to="lab_imux_BusinessCombinationSharesOwnedPriorToTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c9701ab0-09e3-4ef0-b642-06f1e329e352_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bbd7b31e-3cb8-4f88-902d-7220e18b8e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_128be6eb-b710-4585-b5dd-2dbf6b32c7ff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0579e952-5bcb-43e5-a39b-33e409f680ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_PublicOfferingMember_86f92201-6aa6-40c7-ae7c-ea87eababb05_terseLabel_en-US" xlink:label="lab_imux_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_imux_PublicOfferingMember_label_en-US" xlink:label="lab_imux_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_imux_PublicOfferingMember_documentation_en-US" xlink:label="lab_imux_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_PublicOfferingMember" xlink:to="lab_imux_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78f51571-ec7a-4ae1-b6b6-dc334e9ee534_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_324d3ead-fea4-40ad-9b01-94224bce17d8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_797f74d3-07ed-4fd6-8ff0-8ac636e160ea_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_4de79b59-e2ef-42ab-89f4-06ceb9d87e1f_terseLabel_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other property and equipment</link:label>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_label_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Property And Equipment</link:label>
    <link:label id="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_documentation_en-US" xlink:label="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Property And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" xlink:to="lab_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bdefe62a-a0c9-4fbc-821c-5486a6636c0b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_VSOPSBMember_bb40a0cf-b1ce-40e7-9b23-c1ba20d11951_terseLabel_en-US" xlink:label="lab_imux_VSOPSBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSOP SB</link:label>
    <link:label id="lab_imux_VSOPSBMember_label_en-US" xlink:label="lab_imux_VSOPSBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSOP SB [Member]</link:label>
    <link:label id="lab_imux_VSOPSBMember_documentation_en-US" xlink:label="lab_imux_VSOPSBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VSOP SB [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VSOPSBMember" xlink:href="imux-20201231.xsd#imux_VSOPSBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_VSOPSBMember" xlink:to="lab_imux_VSOPSBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_582f88c2-df51-4352-a8ce-c80f42758dd9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Exercise Price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_9d40602a-e331-4dce-820b-8fc875826bfd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_1ade6e14-442e-4355-9650-ff0e4d5129ca_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_e42d8467-e487-4ca0-925c-6503d70579a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d7b0701f-b2a3-487a-94ff-868ce5f522a1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4dc28c69-b567-4e35-abc6-cb216e5302f2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1aa2488c-8ef5-4b1b-bb95-7f7e33eefcd0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_299f68fa-4690-4be5-830c-033646a7a0f5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_697b2bf7-9b7d-45f8-982a-38a9e5c0b461_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cbbdf129-7443-4029-b6d0-b9e38403d621_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_35d99fad-14aa-4ed1-b265-bc452cc23c23_totalLabel_en-US" xlink:label="lab_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fully-diluted shares (in shares)</link:label>
    <link:label id="lab_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_label_en-US" xlink:label="lab_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Estimate Of Purchase Price, Fully Diluted Shares</link:label>
    <link:label id="lab_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_documentation_en-US" xlink:label="lab_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Estimate Of Purchase Price, Fully Diluted Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" xlink:href="imux-20201231.xsd#imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" xlink:to="lab_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3c0bcf38-0373-41f7-8a2d-c04c0534fcc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b13a4637-da54-41f7-b9a0-96e14fde3d0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted-Average Exercise Price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_12288723-6fd0-4a3b-bc71-09cf9e026131_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_5257574c-98ae-49ab-a4c2-9c73c49cb7a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c29a382d-7ca1-4234-a507-7cc1c847a884_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_bc5d6201-6eca-4adc-b465-de6cc29498a4_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5720eabd-3d2a-4e77-8ec7-b9a07c2ce59f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>imux-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:5279c717-4640-48e4-aa74-73546e28db9a,g:602f65cf-bbe8-45d8-a039-a1d02730d21d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imux.com/role/CoverPage" xlink:type="simple" xlink:href="imux-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://imux.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_db96ce99-ded5-4b8d-9a11-d9a163cb6b39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_DocumentType_db96ce99-ded5-4b8d-9a11-d9a163cb6b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_d22807cb-eae4-4219-ae91-827502798f86" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_DocumentAnnualReport_d22807cb-eae4-4219-ae91-827502798f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1ab29c8a-2834-4899-b08e-a190b88330d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_DocumentPeriodEndDate_1ab29c8a-2834-4899-b08e-a190b88330d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e23b4689-4f56-4347-b800-304efe15dfd3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_CurrentFiscalYearEndDate_e23b4689-4f56-4347-b800-304efe15dfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_eb2038ce-3fae-46fe-aa59-c8459f73bf3a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_DocumentTransitionReport_eb2038ce-3fae-46fe-aa59-c8459f73bf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3a0e0123-4617-4ded-8a4b-bfec34cdd868" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityFileNumber_3a0e0123-4617-4ded-8a4b-bfec34cdd868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bae13fab-edf5-4398-8a38-13a698e9b41e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityRegistrantName_bae13fab-edf5-4398-8a38-13a698e9b41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a042e4fa-8546-48aa-b191-03ad2e40cf62" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityCentralIndexKey_a042e4fa-8546-48aa-b191-03ad2e40cf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_780a1712-4552-45b4-b771-7ba3a89bf521" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_DocumentFiscalYearFocus_780a1712-4552-45b4-b771-7ba3a89bf521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3bf20051-3b04-488f-af0e-7cfa1d696292" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3bf20051-3b04-488f-af0e-7cfa1d696292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_09d82d1b-3415-4555-9fdc-3a81b398e21e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_AmendmentFlag_09d82d1b-3415-4555-9fdc-3a81b398e21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_616afc82-ccd7-4650-b338-66296003fc03" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_616afc82-ccd7-4650-b338-66296003fc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ebe75962-f4d8-4d27-9d2a-cefdc93abd9b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityTaxIdentificationNumber_ebe75962-f4d8-4d27-9d2a-cefdc93abd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cf9ccff2-cd0d-4b07-9c8d-25cb54c80af6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityAddressAddressLine1_cf9ccff2-cd0d-4b07-9c8d-25cb54c80af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_3d8691b4-aeaa-4d7d-951c-6baf796cecbf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityAddressAddressLine2_3d8691b4-aeaa-4d7d-951c-6baf796cecbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_799e2fb3-6a7c-438d-9d28-8d679f88c19b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityAddressCityOrTown_799e2fb3-6a7c-438d-9d28-8d679f88c19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ba49a372-9f50-43ab-ac7f-834d6828ce8d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityAddressStateOrProvince_ba49a372-9f50-43ab-ac7f-834d6828ce8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5edc3271-c397-4e6b-af18-58289a628389" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityAddressPostalZipCode_5edc3271-c397-4e6b-af18-58289a628389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_188d358a-390f-4b96-94dd-5e018e907d57" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_CityAreaCode_188d358a-390f-4b96-94dd-5e018e907d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_67a1d09e-9771-47b8-a950-49ff9683ffca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_LocalPhoneNumber_67a1d09e-9771-47b8-a950-49ff9683ffca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bc6aaa9f-8853-4251-8162-e81b6aba7a99" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_Security12bTitle_bc6aaa9f-8853-4251-8162-e81b6aba7a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a78efadc-dcfe-4a2a-90dc-c466f20450b9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_TradingSymbol_a78efadc-dcfe-4a2a-90dc-c466f20450b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4acbd8d3-6419-40b5-b742-74b68fef8a02" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_SecurityExchangeName_4acbd8d3-6419-40b5-b742-74b68fef8a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_fc8a3dbe-b783-4a14-8e01-b25b5d965b76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_fc8a3dbe-b783-4a14-8e01-b25b5d965b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f154149d-c9d3-4c70-92b0-b2a1cc8c490b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityVoluntaryFilers_f154149d-c9d3-4c70-92b0-b2a1cc8c490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bf67a7cc-d177-435e-8d9a-07bec9ac899f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityCurrentReportingStatus_bf67a7cc-d177-435e-8d9a-07bec9ac899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_534d9f71-de3a-4d9b-bcf2-3673af86c16b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityInteractiveDataCurrent_534d9f71-de3a-4d9b-bcf2-3673af86c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4176d4e8-f7d0-4b49-9e5e-b9424154aeeb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityFilerCategory_4176d4e8-f7d0-4b49-9e5e-b9424154aeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e13d9b1a-e177-4411-9e33-ea90ed41d1e1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntitySmallBusiness_e13d9b1a-e177-4411-9e33-ea90ed41d1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ed9849b5-3e64-453a-83ae-562d5ca30848" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityEmergingGrowthCompany_ed9849b5-3e64-453a-83ae-562d5ca30848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_d38db4f1-ba6d-405f-acb1-3de51cc0a8ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_IcfrAuditorAttestationFlag_d38db4f1-ba6d-405f-acb1-3de51cc0a8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8403350c-96d9-448d-b6d2-3a57758187a3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityShellCompany_8403350c-96d9-448d-b6d2-3a57758187a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_73b96e32-f886-49ed-90c6-c027370eaa1e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityPublicFloat_73b96e32-f886-49ed-90c6-c027370eaa1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f24a146b-ba35-4c03-ab6d-3c29788ba998" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f24a146b-ba35-4c03-ab6d-3c29788ba998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_eab57802-58bf-4d9e-aa9f-f590548c7d90" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0302cf0c-658e-4035-872a-4383beaf76f7" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_eab57802-58bf-4d9e-aa9f-f590548c7d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0af9be0d-12d6-40f5-8162-4e66018a30d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e75c4d62-bafc-4b07-b0cd-fddc42196277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0af9be0d-12d6-40f5-8162-4e66018a30d6" xlink:to="loc_us-gaap_AssetsAbstract_e75c4d62-bafc-4b07-b0cd-fddc42196277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6974c3f3-4411-4733-89fb-b2d27aa7a93b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e75c4d62-bafc-4b07-b0cd-fddc42196277" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6974c3f3-4411-4733-89fb-b2d27aa7a93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74871d54-90b4-4922-bf57-872e7008c764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6974c3f3-4411-4733-89fb-b2d27aa7a93b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74871d54-90b4-4922-bf57-872e7008c764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_83cdc436-2f4f-4413-bf66-594c071063c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6974c3f3-4411-4733-89fb-b2d27aa7a93b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_83cdc436-2f4f-4413-bf66-594c071063c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_88df518d-9349-4124-b512-6bc8f68991c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6974c3f3-4411-4733-89fb-b2d27aa7a93b" xlink:to="loc_us-gaap_AssetsCurrent_88df518d-9349-4124-b512-6bc8f68991c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7d292fba-bae1-49da-9d8f-5a0bb7de210d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e75c4d62-bafc-4b07-b0cd-fddc42196277" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7d292fba-bae1-49da-9d8f-5a0bb7de210d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0650a103-26f3-4ac5-9e73-df1b53faff83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e75c4d62-bafc-4b07-b0cd-fddc42196277" xlink:to="loc_us-gaap_Goodwill_0650a103-26f3-4ac5-9e73-df1b53faff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f9c597e3-fc89-4087-b8a9-b93e3b29593a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e75c4d62-bafc-4b07-b0cd-fddc42196277" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f9c597e3-fc89-4087-b8a9-b93e3b29593a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_232f1bfd-5969-46a8-97e3-c8adb8c1a9f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e75c4d62-bafc-4b07-b0cd-fddc42196277" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_232f1bfd-5969-46a8-97e3-c8adb8c1a9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_edbc3af2-bc98-4dd4-b627-0c001920025d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e75c4d62-bafc-4b07-b0cd-fddc42196277" xlink:to="loc_us-gaap_Assets_edbc3af2-bc98-4dd4-b627-0c001920025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5192df1d-c0ac-4fa0-8396-0bedcb62f23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0af9be0d-12d6-40f5-8162-4e66018a30d6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5192df1d-c0ac-4fa0-8396-0bedcb62f23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b0fba902-4661-47cf-923c-695b9e13fb94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5192df1d-c0ac-4fa0-8396-0bedcb62f23f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b0fba902-4661-47cf-923c-695b9e13fb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_efae9e42-365d-4017-92aa-4d3faaf9a0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b0fba902-4661-47cf-923c-695b9e13fb94" xlink:to="loc_us-gaap_AccountsPayableCurrent_efae9e42-365d-4017-92aa-4d3faaf9a0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c35cb9ca-fb6c-4ee8-ad21-6562cf48f4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b0fba902-4661-47cf-923c-695b9e13fb94" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c35cb9ca-fb6c-4ee8-ad21-6562cf48f4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_05ac2a99-5067-4f7d-8979-4fe9876864f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b0fba902-4661-47cf-923c-695b9e13fb94" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_05ac2a99-5067-4f7d-8979-4fe9876864f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_12eedc3f-586f-4775-b620-e70114a15bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b0fba902-4661-47cf-923c-695b9e13fb94" xlink:to="loc_us-gaap_LiabilitiesCurrent_12eedc3f-586f-4775-b620-e70114a15bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_c0219fc1-74a0-4429-96f7-d41f0c746108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5192df1d-c0ac-4fa0-8396-0bedcb62f23f" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_c0219fc1-74a0-4429-96f7-d41f0c746108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3f0f3a8a-0ce5-40ee-b160-3f329f5137be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_c0219fc1-74a0-4429-96f7-d41f0c746108" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3f0f3a8a-0ce5-40ee-b160-3f329f5137be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_44bcf3b4-40b8-411f-bbf5-a0d77a674f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_c0219fc1-74a0-4429-96f7-d41f0c746108" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_44bcf3b4-40b8-411f-bbf5-a0d77a674f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d76f2870-e5ba-4ba9-a51e-b4131fc53a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5192df1d-c0ac-4fa0-8396-0bedcb62f23f" xlink:to="loc_us-gaap_Liabilities_d76f2870-e5ba-4ba9-a51e-b4131fc53a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3da3bfde-ccb5-4d36-b9a1-b40bef15d876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5192df1d-c0ac-4fa0-8396-0bedcb62f23f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3da3bfde-ccb5-4d36-b9a1-b40bef15d876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0e4d3492-a8fe-4e82-b358-096d87982c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5192df1d-c0ac-4fa0-8396-0bedcb62f23f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0e4d3492-a8fe-4e82-b358-096d87982c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fd980e15-9af0-4eb9-aff7-7f5ceeb8744e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e4d3492-a8fe-4e82-b358-096d87982c2d" xlink:to="loc_us-gaap_PreferredStockValue_fd980e15-9af0-4eb9-aff7-7f5ceeb8744e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_aa1b3c2d-910a-43cf-9d49-81ca4b68290f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e4d3492-a8fe-4e82-b358-096d87982c2d" xlink:to="loc_us-gaap_CommonStockValue_aa1b3c2d-910a-43cf-9d49-81ca4b68290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0534d832-5f36-461b-8059-c7bead92f6b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e4d3492-a8fe-4e82-b358-096d87982c2d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0534d832-5f36-461b-8059-c7bead92f6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_26aec257-ddc7-4f01-a549-d004b276879e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e4d3492-a8fe-4e82-b358-096d87982c2d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_26aec257-ddc7-4f01-a549-d004b276879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e66af92e-b142-4c03-8c55-ea7069148882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e4d3492-a8fe-4e82-b358-096d87982c2d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e66af92e-b142-4c03-8c55-ea7069148882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_57749b2c-5861-4834-b831-df9e38fddb71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e4d3492-a8fe-4e82-b358-096d87982c2d" xlink:to="loc_us-gaap_StockholdersEquity_57749b2c-5861-4834-b831-df9e38fddb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c7a2d720-e7b8-4cbf-8eed-97390a6d95e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5192df1d-c0ac-4fa0-8396-0bedcb62f23f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c7a2d720-e7b8-4cbf-8eed-97390a6d95e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_780dd4da-7537-4d31-806f-8a5c18d9f6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_780dd4da-7537-4d31-806f-8a5c18d9f6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_09e237ad-6521-42c4-bc69-9a955782e137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_09e237ad-6521-42c4-bc69-9a955782e137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_05af1f6f-2aa7-4be2-ae61-a7e46a1e3a26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:to="loc_us-gaap_PreferredStockSharesIssued_05af1f6f-2aa7-4be2-ae61-a7e46a1e3a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cac9fe8e-8b4f-41ae-b891-fc2bfade4108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cac9fe8e-8b4f-41ae-b891-fc2bfade4108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b8934d17-2b97-4a25-837f-7afa72979e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b8934d17-2b97-4a25-837f-7afa72979e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b05f85d5-5c1b-4fe4-908f-33009024ddd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b05f85d5-5c1b-4fe4-908f-33009024ddd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cbcf93a1-157c-4c68-93f9-191ffef16f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:to="loc_us-gaap_CommonStockSharesIssued_cbcf93a1-157c-4c68-93f9-191ffef16f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_034cd0ad-4767-4128-bc62-295401b88d09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2117d0a8-2958-4c93-bc63-f5d3bdeefe32" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_034cd0ad-4767-4128-bc62-295401b88d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a1a8c46d-ac9b-466a-a995-aec1ed6ce9be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9256d9e9-68e5-4346-b9df-43a2cf7e49b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1a8c46d-ac9b-466a-a995-aec1ed6ce9be" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9256d9e9-68e5-4346-b9df-43a2cf7e49b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5bd28720-8c39-4b87-b519-48f173e16cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9256d9e9-68e5-4346-b9df-43a2cf7e49b1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5bd28720-8c39-4b87-b519-48f173e16cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_28d4bb9f-b1b6-4533-87ea-15b063101605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9256d9e9-68e5-4346-b9df-43a2cf7e49b1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_28d4bb9f-b1b6-4533-87ea-15b063101605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c4621e7a-602e-40dc-8c48-c27148eb9257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9256d9e9-68e5-4346-b9df-43a2cf7e49b1" xlink:to="loc_us-gaap_OperatingExpenses_c4621e7a-602e-40dc-8c48-c27148eb9257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e9a4a709-eaa8-4793-8c1f-d15ed09ed637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1a8c46d-ac9b-466a-a995-aec1ed6ce9be" xlink:to="loc_us-gaap_OperatingIncomeLoss_e9a4a709-eaa8-4793-8c1f-d15ed09ed637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c7e5fa0b-f441-4369-b545-3b2e9503a226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1a8c46d-ac9b-466a-a995-aec1ed6ce9be" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c7e5fa0b-f441-4369-b545-3b2e9503a226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d50167cf-137e-4d48-824a-b277605c874e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c7e5fa0b-f441-4369-b545-3b2e9503a226" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d50167cf-137e-4d48-824a-b277605c874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4c23a61d-caa7-41b2-9027-51d74a159373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c7e5fa0b-f441-4369-b545-3b2e9503a226" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4c23a61d-caa7-41b2-9027-51d74a159373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1c03289e-0003-48b2-80f7-eedbd12a114e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c7e5fa0b-f441-4369-b545-3b2e9503a226" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1c03289e-0003-48b2-80f7-eedbd12a114e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e8fca0f1-c98f-44b4-81be-9af8e35233a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1a8c46d-ac9b-466a-a995-aec1ed6ce9be" xlink:to="loc_us-gaap_NetIncomeLoss_e8fca0f1-c98f-44b4-81be-9af8e35233a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2861e70f-f6a7-4d60-9f5d-5d3ec5d925d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1a8c46d-ac9b-466a-a995-aec1ed6ce9be" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2861e70f-f6a7-4d60-9f5d-5d3ec5d925d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5c8f940c-b711-4256-8881-1d82ef2d6c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1a8c46d-ac9b-466a-a995-aec1ed6ce9be" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5c8f940c-b711-4256-8881-1d82ef2d6c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b7189116-aa63-4ec2-be2d-52515fb012e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2479b0e3-1844-44ff-8a3a-f8bdc4ebad41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b7189116-aa63-4ec2-be2d-52515fb012e7" xlink:to="loc_us-gaap_NetIncomeLoss_2479b0e3-1844-44ff-8a3a-f8bdc4ebad41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_abc78812-90f8-4bf6-955d-05264f1d1bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b7189116-aa63-4ec2-be2d-52515fb012e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_abc78812-90f8-4bf6-955d-05264f1d1bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_61a77ca5-045f-469a-9fb7-b59999473464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_abc78812-90f8-4bf6-955d-05264f1d1bdb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_61a77ca5-045f-469a-9fb7-b59999473464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_64d27b2e-ba51-4782-8420-ef95148a456f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_abc78812-90f8-4bf6-955d-05264f1d1bdb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_64d27b2e-ba51-4782-8420-ef95148a456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_63d873f3-6557-4cbc-9506-255d089a668b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_63d873f3-6557-4cbc-9506-255d089a668b" xlink:to="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_587f6d3d-f2c6-4faf-982b-22246a1171ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_PlanNameAxis_587f6d3d-f2c6-4faf-982b-22246a1171ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7ef1950a-930f-43ac-aae5-aa21a6420fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_587f6d3d-f2c6-4faf-982b-22246a1171ed" xlink:to="loc_us-gaap_PlanNameDomain_7ef1950a-930f-43ac-aae5-aa21a6420fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ExecutiveBonusAgreementMember_28563487-61d1-4200-976f-95a83da5c9e9" xlink:href="imux-20201231.xsd#imux_ExecutiveBonusAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7ef1950a-930f-43ac-aae5-aa21a6420fe6" xlink:to="loc_imux_ExecutiveBonusAgreementMember_28563487-61d1-4200-976f-95a83da5c9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fc975f40-eadc-4948-bce8-3f010eaeb429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fc975f40-eadc-4948-bce8-3f010eaeb429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc975f40-eadc-4948-bce8-3f010eaeb429" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember_d248e71b-4d11-4cfc-9966-37953acfdaff" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_PreClosingFinancingMember_d248e71b-4d11-4cfc-9966-37953acfdaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A4SCSettlementAgreementMember_5805d7e1-194e-4114-bfbc-89bfca3085ef" xlink:href="imux-20201231.xsd#imux_A4SCSettlementAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_A4SCSettlementAgreementMember_5805d7e1-194e-4114-bfbc-89bfca3085ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_ced8162d-cd21-4d04-82c1-ef9f3212fbc6" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_PublicOfferingMember_ced8162d-cd21-4d04-82c1-ef9f3212fbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_90865ec3-7126-4cb3-848f-a1bcaaeebf99" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_April2020EquityIssuancesMember_90865ec3-7126-4cb3-848f-a1bcaaeebf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_380e999f-9397-49d5-8929-5b92f30955d7" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_June2020EquityIssuancesMember_380e999f-9397-49d5-8929-5b92f30955d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_7355881f-03ae-4dfc-adfd-48f4fe5b1d94" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b55e8c9f-7fb3-4b1c-9df3-5fbbe9b0df6a" xlink:to="loc_imux_August2020EquityIssuancesMember_7355881f-03ae-4dfc-adfd-48f4fe5b1d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_59eef9cf-46a9-40f2-9a31-0874a4482431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_StatementClassOfStockAxis_59eef9cf-46a9-40f2-9a31-0874a4482431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6846945d-44db-42eb-8126-432f8afa7175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59eef9cf-46a9-40f2-9a31-0874a4482431" xlink:to="loc_us-gaap_ClassOfStockDomain_6846945d-44db-42eb-8126-432f8afa7175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA2ConvertiblePreferredStockMember_3507984c-db37-4be7-ab0e-412c5bf34386" xlink:href="imux-20201231.xsd#imux_SeriesA2ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6846945d-44db-42eb-8126-432f8afa7175" xlink:to="loc_imux_SeriesA2ConvertiblePreferredStockMember_3507984c-db37-4be7-ab0e-412c5bf34386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA1ConvertiblePreferredStockMember_1b4452e3-8610-4b1c-9bbc-9dd54eed9743" xlink:href="imux-20201231.xsd#imux_SeriesA1ConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6846945d-44db-42eb-8126-432f8afa7175" xlink:to="loc_imux_SeriesA1ConvertiblePreferredStockMember_1b4452e3-8610-4b1c-9bbc-9dd54eed9743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_03a3b989-1071-4843-9c22-9077cff1d277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_03a3b989-1071-4843-9c22-9077cff1d277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03a3b989-1071-4843-9c22-9077cff1d277" xlink:to="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_7c754bf7-72f3-4bf6-bc0d-ad08a699ba0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_PreferredStockMember_7c754bf7-72f3-4bf6-bc0d-ad08a699ba0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4e7bd003-196b-4e3b-a658-1217eb791d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_CommonStockMember_4e7bd003-196b-4e3b-a658-1217eb791d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4b297d16-1d2c-4fcc-adac-ffb8dcfea1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4b297d16-1d2c-4fcc-adac-ffb8dcfea1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4a1eca88-9177-4e62-a426-2cfe8760fc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4a1eca88-9177-4e62-a426-2cfe8760fc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_40512782-6925-4f85-a1dd-58b29d8325a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5aca5a1b-d4f5-4eec-8b38-7f0b6112bad9" xlink:to="loc_us-gaap_RetainedEarningsMember_40512782-6925-4f85-a1dd-58b29d8325a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ce8d2429-660e-4f14-ae63-cc3e509de725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb76183d-710f-44cf-83c8-ce21a2435501" xlink:to="loc_us-gaap_StatementLineItems_ce8d2429-660e-4f14-ae63-cc3e509de725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ce8d2429-660e-4f14-ae63-cc3e509de725" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c6db8865-8f74-4333-b8cd-a9727353463b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_SharesOutstanding_c6db8865-8f74-4333-b8cd-a9727353463b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3253f9e6-1e24-4856-a2ba-6ff98f2bc762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockholdersEquity_3253f9e6-1e24-4856-a2ba-6ff98f2bc762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3f6be30-a9a6-4306-b1da-2e615095116e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_NetIncomeLoss_a3f6be30-a9a6-4306-b1da-2e615095116e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18a45ad9-5e23-4b58-9bee-d7dc61e1d56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18a45ad9-5e23-4b58-9bee-d7dc61e1d56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e37ee718-5542-4bfa-a7d9-4ecc90760159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e37ee718-5542-4bfa-a7d9-4ecc90760159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8fc017e7-a21a-45bc-9146-04d24ba6d2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8fc017e7-a21a-45bc-9146-04d24ba6d2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69fd2ae4-936d-42dd-a8a7-2f8b3a4392d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69fd2ae4-936d-42dd-a8a7-2f8b3a4392d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_94dd3467-4a64-468c-85d1-7a65c7368a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_94dd3467-4a64-468c-85d1-7a65c7368a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4622e06c-1b49-47bb-bf04-fbe7350a3b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4622e06c-1b49-47bb-bf04-fbe7350a3b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2c8f05c2-384f-46a1-91fc-70a585aecdb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2c8f05c2-384f-46a1-91fc-70a585aecdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fb858184-46cb-4354-9778-9382d7af18e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fb858184-46cb-4354-9778-9382d7af18e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f911fc89-b4e6-426b-9071-d9758fa77ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_SharesOutstanding_f911fc89-b4e6-426b-9071-d9758fa77ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_34c0f59e-d65c-40ae-bd49-0ce12f0e38b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f8a1c7be-e7e1-4a02-b486-f49a6b00d01d" xlink:to="loc_us-gaap_StockholdersEquity_34c0f59e-d65c-40ae-bd49-0ce12f0e38b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_52000cce-bf76-4c59-8d23-81a0cf58b583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f62f8a45-3fc3-4a62-93df-3b5129c405e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_52000cce-bf76-4c59-8d23-81a0cf58b583" xlink:to="loc_us-gaap_StatementTable_f62f8a45-3fc3-4a62-93df-3b5129c405e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_040778d9-6d56-4377-b82c-6508c4bf75fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f62f8a45-3fc3-4a62-93df-3b5129c405e4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_040778d9-6d56-4377-b82c-6508c4bf75fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_040778d9-6d56-4377-b82c-6508c4bf75fd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember_26a7a90e-e9e9-4880-b8df-1fe49930606f" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_PreClosingFinancingMember_26a7a90e-e9e9-4880-b8df-1fe49930606f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_673fdff7-049c-45a1-bb1a-dfbb76db4d90" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_PublicOfferingMember_673fdff7-049c-45a1-bb1a-dfbb76db4d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_9819868e-cc4b-4d48-88f4-68fe98d4eb50" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_April2020EquityIssuancesMember_9819868e-cc4b-4d48-88f4-68fe98d4eb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_00aeba5d-0a77-46f9-8c54-43e6dd344810" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_June2020EquityIssuancesMember_00aeba5d-0a77-46f9-8c54-43e6dd344810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_6496185c-9f0a-4d01-a256-68ecdc681d40" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14dd2b14-977b-4e7f-a872-27a4206759bb" xlink:to="loc_imux_August2020EquityIssuancesMember_6496185c-9f0a-4d01-a256-68ecdc681d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2b2a7a03-af0a-4a33-a99d-3fa2fd1e79ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f62f8a45-3fc3-4a62-93df-3b5129c405e4" xlink:to="loc_us-gaap_StatementLineItems_2b2a7a03-af0a-4a33-a99d-3fa2fd1e79ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51e7555d-ec1e-485d-a629-33595f7eba81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b2a7a03-af0a-4a33-a99d-3fa2fd1e79ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51e7555d-ec1e-485d-a629-33595f7eba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9ccfee33-68e4-490c-a6f3-0bf006cee5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9dce4da0-1294-4074-8b85-59a10c351575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9ccfee33-68e4-490c-a6f3-0bf006cee5ae" xlink:to="loc_us-gaap_StatementTable_9dce4da0-1294-4074-8b85-59a10c351575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3f99e116-82b2-4402-a79f-f53f22b339ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9dce4da0-1294-4074-8b85-59a10c351575" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3f99e116-82b2-4402-a79f-f53f22b339ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3f99e116-82b2-4402-a79f-f53f22b339ae" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember_1d466561-eeef-47be-baa8-309cfe5c582d" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_PreClosingFinancingMember_1d466561-eeef-47be-baa8-309cfe5c582d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_0929da6b-045e-45b4-9552-688bff3c2565" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_PublicOfferingMember_0929da6b-045e-45b4-9552-688bff3c2565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_0e9d2a3d-f66c-4f48-9b14-10a3886c3c8a" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_April2020EquityIssuancesMember_0e9d2a3d-f66c-4f48-9b14-10a3886c3c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_a42efb1a-a5e2-4be4-bcf8-2cff91989028" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_June2020EquityIssuancesMember_a42efb1a-a5e2-4be4-bcf8-2cff91989028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_44e52620-c48c-4e54-a954-752cd732ed31" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c4e5884-c9d9-4ab7-ac64-a15af596c061" xlink:to="loc_imux_August2020EquityIssuancesMember_44e52620-c48c-4e54-a954-752cd732ed31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9dce4da0-1294-4074-8b85-59a10c351575" xlink:to="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_097ca399-aeee-4489-8562-8b211eac3f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:to="loc_us-gaap_NetIncomeLoss_097ca399-aeee-4489-8562-8b211eac3f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c79eb954-19c0-4c14-b42f-2ab11d9870e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c79eb954-19c0-4c14-b42f-2ab11d9870e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_bd8f2fa4-0703-4ba4-afea-cad3c4ce55c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_bd8f2fa4-0703-4ba4-afea-cad3c4ce55c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_90756140-2c52-4bf8-855f-6c8c1a07152f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_90756140-2c52-4bf8-855f-6c8c1a07152f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2602abf4-879f-417a-8c59-7a3a58631856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_ShareBasedCompensation_2602abf4-879f-417a-8c59-7a3a58631856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d513e7fa-1b8b-4a6a-a995-2fbbf4dac34e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d513e7fa-1b8b-4a6a-a995-2fbbf4dac34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_0768b9ad-bba7-404f-a3f5-60bfc1fa6e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_868d1823-96fc-4f16-8f5b-504519825cd3" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_0768b9ad-bba7-404f-a3f5-60bfc1fa6e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6b1fe643-0f75-488f-aa25-c30a524848f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6b1fe643-0f75-488f-aa25-c30a524848f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c228bde8-f2fc-4a0e-aeda-09aa0803860c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c228bde8-f2fc-4a0e-aeda-09aa0803860c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_af08b854-07a3-4e5d-9a3c-50702a0a6f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_af08b854-07a3-4e5d-9a3c-50702a0a6f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5eed7c32-a068-47d8-a45c-823430140410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_796db25f-89d8-4757-bd88-d5c01d3b7d90" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5eed7c32-a068-47d8-a45c-823430140410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f111dc95-764d-476c-acb1-3080addf0144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_23c834d7-0963-45b2-ac97-094c1cfea5e3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f111dc95-764d-476c-acb1-3080addf0144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6f9bad1d-eac4-4144-8d0d-795020da07fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6f9bad1d-eac4-4144-8d0d-795020da07fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_23c19aef-7de0-46b8-964d-a1d264ffd270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_23c19aef-7de0-46b8-964d-a1d264ffd270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_b435c956-707a-4b7a-8b78-3b4db6e3338e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment_b435c956-707a-4b7a-8b78-3b4db6e3338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashAcquiredInConnectionWithReverseAcquisition_7a1bf159-8209-45f3-bebd-8f9a377b3b59" xlink:href="imux-20201231.xsd#imux_CashAcquiredInConnectionWithReverseAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_imux_CashAcquiredInConnectionWithReverseAcquisition_7a1bf159-8209-45f3-bebd-8f9a377b3b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_b073dc19-428d-4fa8-8766-828f4e8fc802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_b073dc19-428d-4fa8-8766-828f4e8fc802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_efe35d5b-cdc8-48ad-a560-f3b3320e3281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_448d13f4-4185-4827-87bf-6171700f6ce4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_efe35d5b-cdc8-48ad-a560-f3b3320e3281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_a3d351fd-732c-4a05-84d7-9a0c1596eebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_a3d351fd-732c-4a05-84d7-9a0c1596eebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fe739b33-3c16-4938-95d2-dab1eb96db55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fe739b33-3c16-4938-95d2-dab1eb96db55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f3d3c6db-d6df-4b47-9c0d-66fcb100ee67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f3d3c6db-d6df-4b47-9c0d-66fcb100ee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c314946c-8a64-4751-9f53-1646eb463c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_714baae7-fb5f-4951-9aba-a693b46f6bd1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c314946c-8a64-4751-9f53-1646eb463c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_733421d2-60de-4388-8543-c2b84d0d1362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_733421d2-60de-4388-8543-c2b84d0d1362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_57393539-3916-49fc-9e1f-34cffc98cfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_57393539-3916-49fc-9e1f-34cffc98cfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d55206e-6533-446c-b46f-a774767c260b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d55206e-6533-446c-b46f-a774767c260b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ddce115-1c5b-4384-a8fa-0910d523d013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ddce115-1c5b-4384-a8fa-0910d523d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0e72de27-f242-4c30-9fe2-de432f8bd19e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredStockIssuanceCostsIncludedInLiabilities_e5521ff1-be6e-4d29-91ad-847424c34d83" xlink:href="imux-20201231.xsd#imux_DeferredStockIssuanceCostsIncludedInLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_imux_DeferredStockIssuanceCostsIncludedInLiabilities_e5521ff1-be6e-4d29-91ad-847424c34d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_d21909c1-82f6-4ef2-a443-34e1c2510caa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_d21909c1-82f6-4ef2-a443-34e1c2510caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_7637a985-5ad7-4717-b225-71d78d34c49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_7637a985-5ad7-4717-b225-71d78d34c49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OfferingCostsIncludedInAccruedExpenses_549b998c-ffcc-4aac-a23a-06e47342305f" xlink:href="imux-20201231.xsd#imux_OfferingCostsIncludedInAccruedExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_imux_OfferingCostsIncludedInAccruedExpenses_549b998c-ffcc-4aac-a23a-06e47342305f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable_94f5ff1b-9a4a-49a5-9773-637cc514c8c2" xlink:href="imux-20201231.xsd#imux_PropertyPlantAndEquipmentIncludedInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_26dfd36c-b077-49cc-b619-e95596a0212a" xlink:to="loc_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable_94f5ff1b-9a4a-49a5-9773-637cc514c8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="imux-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a80ece87-2b1e-4d3d-9afd-8dae003ddf72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_34b5b7c6-58ac-44ee-9abc-07801ba2e024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a80ece87-2b1e-4d3d-9afd-8dae003ddf72" xlink:to="loc_us-gaap_StatementTable_34b5b7c6-58ac-44ee-9abc-07801ba2e024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aa55417a-dc1b-4df2-a6e6-b057e0a20d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34b5b7c6-58ac-44ee-9abc-07801ba2e024" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aa55417a-dc1b-4df2-a6e6-b057e0a20d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aa55417a-dc1b-4df2-a6e6-b057e0a20d08" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PreClosingFinancingMember_dfc9836a-1450-4c87-9f38-f4a7630c2fb8" xlink:href="imux-20201231.xsd#imux_PreClosingFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_PreClosingFinancingMember_dfc9836a-1450-4c87-9f38-f4a7630c2fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PublicOfferingMember_2ebaff16-6c67-4f3a-9d84-8a5342cf2525" xlink:href="imux-20201231.xsd#imux_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_PublicOfferingMember_2ebaff16-6c67-4f3a-9d84-8a5342cf2525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_454d09bb-6d37-4d0a-b98b-16fa5da3749f" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_April2020EquityIssuancesMember_454d09bb-6d37-4d0a-b98b-16fa5da3749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_90f8aa93-7118-4e2c-afbb-6772145587be" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_June2020EquityIssuancesMember_90f8aa93-7118-4e2c-afbb-6772145587be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_0e4467db-7955-4fcf-9093-db4c2fb271f6" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9c93ce4c-48a4-4f82-95f0-6784d50fc2cc" xlink:to="loc_imux_August2020EquityIssuancesMember_0e4467db-7955-4fcf-9093-db4c2fb271f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_26e3babf-e733-41c4-bcce-b8d6aa9f57b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34b5b7c6-58ac-44ee-9abc-07801ba2e024" xlink:to="loc_us-gaap_StatementLineItems_26e3babf-e733-41c4-bcce-b8d6aa9f57b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_42391861-39d4-4a41-9db1-4c50d5ce211e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26e3babf-e733-41c4-bcce-b8d6aa9f57b0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_42391861-39d4-4a41-9db1-4c50d5ce211e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="imux-20201231.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:presentationLink xlink:role="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_13ed4594-3407-4d27-9226-1edbbbbf0828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7787b736-797b-445d-a5fb-5dbab4aa6760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_13ed4594-3407-4d27-9226-1edbbbbf0828" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7787b736-797b-445d-a5fb-5dbab4aa6760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91670a41-c1be-4c22-96b1-e8acfe696e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91670a41-c1be-4c22-96b1-e8acfe696e32" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5c769525-470f-4883-b9be-e12f4ba3b61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5c769525-470f-4883-b9be-e12f4ba3b61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdcc7a39-8bb0-450a-8e46-08e2b49d0cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5c769525-470f-4883-b9be-e12f4ba3b61e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdcc7a39-8bb0-450a-8e46-08e2b49d0cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_d3f35a1d-873b-4bff-967d-0904dccbf067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bdcc7a39-8bb0-450a-8e46-08e2b49d0cf1" xlink:to="loc_us-gaap_PrivatePlacementMember_d3f35a1d-873b-4bff-967d-0904dccbf067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b35d037d-433a-4968-bbfa-27c0e164cf63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b35d037d-433a-4968-bbfa-27c0e164cf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e616375-ac4f-4908-b264-bc68c5dbfc11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b35d037d-433a-4968-bbfa-27c0e164cf63" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e616375-ac4f-4908-b264-bc68c5dbfc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_008eec1c-5cda-4d95-a03a-135272d42043" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e616375-ac4f-4908-b264-bc68c5dbfc11" xlink:to="loc_imux_ImmunicAGMember_008eec1c-5cda-4d95-a03a-135272d42043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_979911d9-aae4-40b1-a391-5086ad6b0134" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_srt_CounterpartyNameAxis_979911d9-aae4-40b1-a391-5086ad6b0134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f191128d-9b98-410e-91c6-ee859bb641fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_979911d9-aae4-40b1-a391-5086ad6b0134" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f191128d-9b98-410e-91c6-ee859bb641fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_be09ce12-2c9a-4685-9aeb-3a9cc585011c" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f191128d-9b98-410e-91c6-ee859bb641fa" xlink:to="loc_imux_VitalTherapiesInc.Member_be09ce12-2c9a-4685-9aeb-3a9cc585011c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ec8c7bd6-4dea-47f0-8cab-d43870921b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_us-gaap_AwardTypeAxis_ec8c7bd6-4dea-47f0-8cab-d43870921b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b12e5a45-83fb-4f54-a809-0da2a9c25945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ec8c7bd6-4dea-47f0-8cab-d43870921b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b12e5a45-83fb-4f54-a809-0da2a9c25945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_884c908f-6a87-4a22-b445-575e2ef8e5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b12e5a45-83fb-4f54-a809-0da2a9c25945" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_884c908f-6a87-4a22-b445-575e2ef8e5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_dei_LegalEntityAxis_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4960c2ec-5e84-4fd5-9f0f-84122b60af60" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c7d2afaa-ab1d-4ee2-a68e-401f3aad8e2f" xlink:to="loc_dei_EntityDomain_4960c2ec-5e84-4fd5-9f0f-84122b60af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_5f27ea5f-5353-4ecc-a7cb-fd6861b8e106" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4960c2ec-5e84-4fd5-9f0f-84122b60af60" xlink:to="loc_imux_ImmunicAGMember_5f27ea5f-5353-4ecc-a7cb-fd6861b8e106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_f2449147-610e-4735-83ad-67d5121e2b86" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4960c2ec-5e84-4fd5-9f0f-84122b60af60" xlink:to="loc_imux_VitalTherapiesInc.Member_f2449147-610e-4735-83ad-67d5121e2b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4c5ef5b9-7f4b-404a-b68b-a67a09fe45b9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22a8ae6c-2fc2-488a-93e9-d97d36c649a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22a8ae6c-2fc2-488a-93e9-d97d36c649a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6ee2d1f8-0083-4cb4-8754-c619c9a3e448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6ee2d1f8-0083-4cb4-8754-c619c9a3e448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f38fb45-7430-4f42-a17e-580c54f92431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f38fb45-7430-4f42-a17e-580c54f92431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_64e19c4c-a881-4905-b453-100e0db46330" xlink:href="imux-20201231.xsd#imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_64e19c4c-a881-4905-b453-100e0db46330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4a648642-dbf0-46a3-ade2-1192c3e66eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_4a648642-dbf0-46a3-ade2-1192c3e66eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b29ba77f-0fca-4b1b-a94e-8ab1f003dea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_b29ba77f-0fca-4b1b-a94e-8ab1f003dea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationSharesOwnedPriorToTransaction_6dcf704b-14c2-430b-9c39-e1f31207e1ee" xlink:href="imux-20201231.xsd#imux_BusinessCombinationSharesOwnedPriorToTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_imux_BusinessCombinationSharesOwnedPriorToTransaction_6dcf704b-14c2-430b-9c39-e1f31207e1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_13cc8ea7-8e48-4d5a-95a7-3ea012ae6671" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_13cc8ea7-8e48-4d5a-95a7-3ea012ae6671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3b01ccac-400f-479a-b40b-c6710863fbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3b01ccac-400f-479a-b40b-c6710863fbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_b8154c86-b859-4925-9216-fafc8859226b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_b8154c86-b859-4925-9216-fafc8859226b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_912f3c8c-3acd-4b8e-8a55-ca05fdb9b1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c66b274e-4403-4fee-a4ea-3c93f16688f6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_912f3c8c-3acd-4b8e-8a55-ca05fdb9b1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7238b524-34bd-4fe3-9e85-4d3984e4f82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bec4adc1-1b77-4af4-b8f2-8ecd641c5572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7238b524-34bd-4fe3-9e85-4d3984e4f82a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bec4adc1-1b77-4af4-b8f2-8ecd641c5572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_26ab27a2-9e82-4cb6-8af5-6e35972d246b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_UseOfEstimates_26ab27a2-9e82-4cb6-8af5-6e35972d246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_beeb1090-4261-405e-8f4f-cb379998cee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_beeb1090-4261-405e-8f4f-cb379998cee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_814aec72-d72e-403a-9452-2b39ac96e954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_814aec72-d72e-403a-9452-2b39ac96e954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2c02584e-d6ff-4930-96d5-69bcaac8718e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2c02584e-d6ff-4930-96d5-69bcaac8718e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6392b042-e6d6-44ab-bba9-399856d88ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6392b042-e6d6-44ab-bba9-399856d88ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8f75d9c4-0e85-4c9d-83cc-c2ef5271af1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8f75d9c4-0e85-4c9d-83cc-c2ef5271af1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1dda385f-4d5f-4806-b44f-b59f061aba93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1dda385f-4d5f-4806-b44f-b59f061aba93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c8983cea-fe74-41b5-9f99-ccf4d9a0388b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c8983cea-fe74-41b5-9f99-ccf4d9a0388b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_4d3d7ba1-85fb-4dc0-931b-bd7b84f10006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_4d3d7ba1-85fb-4dc0-931b-bd7b84f10006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_22eb47b5-c150-4c5a-b7e7-fe43b354ecdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_22eb47b5-c150-4c5a-b7e7-fe43b354ecdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f9a0083a-e920-4755-baa1-41a220b9c36d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f9a0083a-e920-4755-baa1-41a220b9c36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_af850e74-57ca-4ffb-9abd-5395c5066675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_af850e74-57ca-4ffb-9abd-5395c5066675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a30bb4ae-4e5f-4daa-b49a-3f7e578e4b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a30bb4ae-4e5f-4daa-b49a-3f7e578e4b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_884a11d0-a3c9-4d0e-bd98-e87c8bd51ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_884a11d0-a3c9-4d0e-bd98-e87c8bd51ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2be7b703-a98d-47cf-a6b8-cbea6d1f6532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2be7b703-a98d-47cf-a6b8-cbea6d1f6532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_954bcca6-625e-46ae-b8fa-b67a8982ea3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d4da922-e343-4085-9aa5-dc118fa46706" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_954bcca6-625e-46ae-b8fa-b67a8982ea3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ba715d5-bfba-4007-8bbc-450b3f0330f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_11e014fe-5c62-42c2-9cba-a7fe7409f2f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ba715d5-bfba-4007-8bbc-450b3f0330f2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_11e014fe-5c62-42c2-9cba-a7fe7409f2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d8e5e323-a408-43d1-9285-7fe629cbd0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8c50b435-4f36-4c3e-8458-793217aa4f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8e5e323-a408-43d1-9285-7fe629cbd0c8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8c50b435-4f36-4c3e-8458-793217aa4f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b38415ab-94b3-4c9d-a33c-24abeaab3402" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8c50b435-4f36-4c3e-8458-793217aa4f83" xlink:to="loc_srt_RangeAxis_b38415ab-94b3-4c9d-a33c-24abeaab3402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e09903be-6d4b-4508-b75d-d97ed6de5ee0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b38415ab-94b3-4c9d-a33c-24abeaab3402" xlink:to="loc_srt_RangeMember_e09903be-6d4b-4508-b75d-d97ed6de5ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a3a5f7c-f1ea-4878-81c0-2039ac0d850d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e09903be-6d4b-4508-b75d-d97ed6de5ee0" xlink:to="loc_srt_MinimumMember_5a3a5f7c-f1ea-4878-81c0-2039ac0d850d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6b97638c-f62f-44e9-aa49-b463b1c09ad4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e09903be-6d4b-4508-b75d-d97ed6de5ee0" xlink:to="loc_srt_MaximumMember_6b97638c-f62f-44e9-aa49-b463b1c09ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8c50b435-4f36-4c3e-8458-793217aa4f83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_CashEquivalentsInvestmentsMaturityPeriod_5139ae5b-805e-4159-a1e5-fd04bb6c8bdb" xlink:href="imux-20201231.xsd#imux_CashEquivalentsInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_imux_CashEquivalentsInvestmentsMaturityPeriod_5139ae5b-805e-4159-a1e5-fd04bb6c8bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6de7476e-fe7d-4e6d-ba2c-a9fe38d4e067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6de7476e-fe7d-4e6d-ba2c-a9fe38d4e067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_7c636d30-23cf-480f-8718-6c43672a4c21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_DepreciationAndAmortization_7c636d30-23cf-480f-8718-6c43672a4c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_66208302-9968-4353-9d99-abcac8c61df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_66208302-9968-4353-9d99-abcac8c61df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e1729a30-d654-4736-8b55-3b36766ff682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e1729a30-d654-4736-8b55-3b36766ff682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_06115100-284a-4b83-9813-523556d784e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_06115100-284a-4b83-9813-523556d784e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases_1d9de533-58a9-4860-99fc-0abe2f3c4530" xlink:href="imux-20201231.xsd#imux_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c41a212d-ec41-41cf-8830-d8ba19cfdd07" xlink:to="loc_imux_LesseeOperatingLeasesNumberOfExistingLeases_1d9de533-58a9-4860-99fc-0abe2f3c4530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_31dc773f-7200-49f4-986f-f4d4951bac80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23e5ed86-2081-411e-8e1f-6a9838553a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31dc773f-7200-49f4-986f-f4d4951bac80" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23e5ed86-2081-411e-8e1f-6a9838553a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ecd294a-d445-46c3-a7c7-e213dba39f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23e5ed86-2081-411e-8e1f-6a9838553a31" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ecd294a-d445-46c3-a7c7-e213dba39f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c380759-a6be-4eb9-ac24-e85056f58133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3ecd294a-d445-46c3-a7c7-e213dba39f13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c380759-a6be-4eb9-ac24-e85056f58133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_53b8fc7c-bc1a-4b90-ae02-419f0f4be676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c380759-a6be-4eb9-ac24-e85056f58133" xlink:to="loc_us-gaap_StockOptionMember_53b8fc7c-bc1a-4b90-ae02-419f0f4be676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_abceb42f-083c-43d4-8d75-46df8a1746ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23e5ed86-2081-411e-8e1f-6a9838553a31" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_abceb42f-083c-43d4-8d75-46df8a1746ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0cfb1831-52e4-4a5c-85ad-04f7c150b339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_abceb42f-083c-43d4-8d75-46df8a1746ea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0cfb1831-52e4-4a5c-85ad-04f7c150b339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransaction" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransaction"/>
  <link:presentationLink xlink:role="http://imux.com/role/AccountingfortheTransaction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c833ac26-5681-4e17-9482-3c64ffbcd4f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_93e29a69-f257-429f-8d1d-5e845940f3ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c833ac26-5681-4e17-9482-3c64ffbcd4f0" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_93e29a69-f257-429f-8d1d-5e845940f3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionTables" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/AccountingfortheTransactionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3abeb957-908e-4c9a-b3d9-9846a1cebf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_928bd6a0-3de5-4aa6-b6f0-254936dfc5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3abeb957-908e-4c9a-b3d9-9846a1cebf4e" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_928bd6a0-3de5-4aa6-b6f0-254936dfc5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0cfdd2e5-7eaa-4f81-bd45-2b70a1a4a6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0cfdd2e5-7eaa-4f81-bd45-2b70a1a4a6b8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc1d4940-8522-43d7-8a4e-047bf3522664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_us-gaap_AwardTypeAxis_dc1d4940-8522-43d7-8a4e-047bf3522664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480f5ed7-e577-4e50-a43c-dab30b5ee743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dc1d4940-8522-43d7-8a4e-047bf3522664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480f5ed7-e577-4e50-a43c-dab30b5ee743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aa965bdf-356d-4c63-b98d-14f078a9f95e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480f5ed7-e577-4e50-a43c-dab30b5ee743" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aa965bdf-356d-4c63-b98d-14f078a9f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_713549ef-2654-4d58-bf3e-d59f03a6bc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480f5ed7-e577-4e50-a43c-dab30b5ee743" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_713549ef-2654-4d58-bf3e-d59f03a6bc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_581f938d-83b1-49ce-93b4-d4b88dd08f9f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_dei_LegalEntityAxis_581f938d-83b1-49ce-93b4-d4b88dd08f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_78a9c037-4d15-41f5-ad72-47620ba3856a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_581f938d-83b1-49ce-93b4-d4b88dd08f9f" xlink:to="loc_dei_EntityDomain_78a9c037-4d15-41f5-ad72-47620ba3856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_8204038f-a104-41f7-adac-68844141edbd" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_78a9c037-4d15-41f5-ad72-47620ba3856a" xlink:to="loc_imux_ImmunicAGMember_8204038f-a104-41f7-adac-68844141edbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_30150b81-7336-4647-9ba1-d138b9697cc9" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_78a9c037-4d15-41f5-ad72-47620ba3856a" xlink:to="loc_imux_VitalTherapiesInc.Member_30150b81-7336-4647-9ba1-d138b9697cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5af6c279-f2dc-410d-aabc-e383437f1459" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_srt_CounterpartyNameAxis_5af6c279-f2dc-410d-aabc-e383437f1459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1fb693ba-a25a-45ba-8bc9-fdfefecbfb00" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5af6c279-f2dc-410d-aabc-e383437f1459" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1fb693ba-a25a-45ba-8bc9-fdfefecbfb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_96ee7c27-dc1a-45f3-b836-ab4fcd388672" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1fb693ba-a25a-45ba-8bc9-fdfefecbfb00" xlink:to="loc_imux_VitalTherapiesInc.Member_96ee7c27-dc1a-45f3-b836-ab4fcd388672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d9432e03-6ee9-4101-ac4e-234db2456a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d9432e03-6ee9-4101-ac4e-234db2456a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86c2b194-e9b7-4b9b-b5f0-ee86b83df7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d9432e03-6ee9-4101-ac4e-234db2456a41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86c2b194-e9b7-4b9b-b5f0-ee86b83df7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicInc.Member_2587b62c-f419-46f4-8d5c-12e47064eabe" xlink:href="imux-20201231.xsd#imux_ImmunicInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86c2b194-e9b7-4b9b-b5f0-ee86b83df7a8" xlink:to="loc_imux_ImmunicInc.Member_2587b62c-f419-46f4-8d5c-12e47064eabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_644e94a8-7679-4d47-a9d3-d97a705f6354" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_bc74811c-9a0c-4474-9d1c-8fd95c4c8381" xlink:href="imux-20201231.xsd#imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio_bc74811c-9a0c-4474-9d1c-8fd95c4c8381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2d605d45-f8ec-4421-8526-c0dc529a3a4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2d605d45-f8ec-4421-8526-c0dc529a3a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_0e0997d4-0c84-4e64-acdb-19dec957a4d5" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_0e0997d4-0c84-4e64-acdb-19dec957a4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e1bc4078-8a86-48ed-a164-29d7b9b385b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_us-gaap_Goodwill_e1bc4078-8a86-48ed-a164-29d7b9b385b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1b5e7178-0ed7-4c3d-b375-d457f45d74df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1b5e7178-0ed7-4c3d-b375-d457f45d74df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges_dc434922-4d04-4709-885f-4b58f2bafeff" xlink:href="imux-20201231.xsd#imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a686975c-7047-422b-be83-6778c8b1ef3e" xlink:to="loc_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges_dc434922-4d04-4709-885f-4b58f2bafeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1e34aa59-29ad-402f-ae95-ce5bed961025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1e34aa59-29ad-402f-ae95-ce5bed961025" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_96cb7027-7893-45ad-b874-73b35a373859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:to="loc_us-gaap_AwardTypeAxis_96cb7027-7893-45ad-b874-73b35a373859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0635a09-c389-4381-a395-aafc854e2045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_96cb7027-7893-45ad-b874-73b35a373859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0635a09-c389-4381-a395-aafc854e2045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5a603166-aab5-4248-b55e-edb0b4e9d5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0635a09-c389-4381-a395-aafc854e2045" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5a603166-aab5-4248-b55e-edb0b4e9d5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8e5f48ca-b20d-433c-a142-73153af11b20" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:to="loc_dei_LegalEntityAxis_8e5f48ca-b20d-433c-a142-73153af11b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ab7f4b74-a266-47a2-a7ab-6ff8c21dd62d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8e5f48ca-b20d-433c-a142-73153af11b20" xlink:to="loc_dei_EntityDomain_ab7f4b74-a266-47a2-a7ab-6ff8c21dd62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_d3b03e10-1a83-4dbe-9c66-a23315420361" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ab7f4b74-a266-47a2-a7ab-6ff8c21dd62d" xlink:to="loc_imux_VitalTherapiesInc.Member_d3b03e10-1a83-4dbe-9c66-a23315420361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c555793-aeb8-4cde-98fe-233cfe30bd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6169c74f-59b4-4b2f-8ebd-c6ff0cf4d49a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c555793-aeb8-4cde-98fe-233cfe30bd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_b4683265-d6c4-49f7-9166-ee9d2cacdec4" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c555793-aeb8-4cde-98fe-233cfe30bd87" xlink:to="loc_imux_ImmunicAGMember_b4683265-d6c4-49f7-9166-ee9d2cacdec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ad4df7-b19d-4a71-89e9-4a75cbf93838" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a8bfd8ff-9205-47ee-ab35-c6b7b15f677a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a8bfd8ff-9205-47ee-ab35-c6b7b15f677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_fc552914-1e51-4b0f-aaf9-5490bb10c184" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction_fc552914-1e51-4b0f-aaf9-5490bb10c184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_93db0608-f4ad-4f21-b4ea-a9015a731fbe" xlink:href="imux-20201231.xsd#imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares_93db0608-f4ad-4f21-b4ea-a9015a731fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_9601c806-7df2-4e32-a9e6-27b8ffedf954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_9601c806-7df2-4e32-a9e6-27b8ffedf954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1aa0fcde-141a-4c82-8d2d-e27ff84429a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1aa0fcde-141a-4c82-8d2d-e27ff84429a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_285de4e1-48ae-4bae-86b2-222c579a3496" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f269638e-0afb-4445-b8b6-26c086deaf8b" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed_285de4e1-48ae-4bae-86b2-222c579a3496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ab884c22-2579-44f2-b54e-f45c2917d9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ab884c22-2579-44f2-b54e-f45c2917d9fe" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_21714080-b09b-4b38-8890-9a4d81aed687" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:to="loc_dei_LegalEntityAxis_21714080-b09b-4b38-8890-9a4d81aed687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e96adba5-2300-42ab-aeea-ec9b289a84b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_21714080-b09b-4b38-8890-9a4d81aed687" xlink:to="loc_dei_EntityDomain_e96adba5-2300-42ab-aeea-ec9b289a84b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_f50a0c64-f9a0-47b3-95ff-533c6d51d3ed" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e96adba5-2300-42ab-aeea-ec9b289a84b1" xlink:to="loc_imux_VitalTherapiesInc.Member_f50a0c64-f9a0-47b3-95ff-533c6d51d3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_410022db-0548-4e9f-9f4f-6d302bbf0e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_410022db-0548-4e9f-9f4f-6d302bbf0e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7d036422-ab6c-44be-844e-156b43edfd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_410022db-0548-4e9f-9f4f-6d302bbf0e59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7d036422-ab6c-44be-844e-156b43edfd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicInc.Member_8b7f60d2-a4d3-4b18-8f9a-837c28240fbd" xlink:href="imux-20201231.xsd#imux_ImmunicInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7d036422-ab6c-44be-844e-156b43edfd78" xlink:to="loc_imux_ImmunicInc.Member_8b7f60d2-a4d3-4b18-8f9a-837c28240fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09cfab45-d0a3-437c-b8d1-c0e6592115ec" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aaed883c-5b57-46c1-b880-018bdcaa99da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aaed883c-5b57-46c1-b880-018bdcaa99da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ec8deece-9376-4453-82b2-c02679d92f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ec8deece-9376-4453-82b2-c02679d92f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_c8bd8072-8d7c-44a6-9de6-7fdbf4a5904d" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks_c8bd8072-8d7c-44a6-9de6-7fdbf4a5904d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_76f25695-5a70-4b23-bc2f-feefde1a4725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_76f25695-5a70-4b23-bc2f-feefde1a4725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_0d08b295-7c06-400f-9555-e53c9423c179" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment_0d08b295-7c06-400f-9555-e53c9423c179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e331b751-696e-4aa2-b5a2-dad831a60be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e331b751-696e-4aa2-b5a2-dad831a60be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_d3b941ad-3b6c-473d-aeea-e9b71b4f9a32" xlink:href="imux-20201231.xsd#imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities_d3b941ad-3b6c-473d-aeea-e9b71b4f9a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0d50eb5d-930d-4ed4-ac16-366a00e4c9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_Goodwill_0d50eb5d-930d-4ed4-ac16-366a00e4c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9dfc0946-4a70-453a-aada-32a68078f0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dade9d0c-fddd-4c52-a7ec-da8ea0a82915" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9dfc0946-4a70-453a-aada-32a68078f0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreement" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreement"/>
  <link:presentationLink xlink:role="http://imux.com/role/ELADSalesAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5623138e-71fd-4dbd-86f6-f47942a66104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_5f868516-f822-4b8e-bd42-775af6a8d9a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5623138e-71fd-4dbd-86f6-f47942a66104" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_5f868516-f822-4b8e-bd42-775af6a8d9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementTables" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/ELADSalesAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3f572014-5179-47b0-b116-775794737239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_8d5f7884-e23a-4ba7-8b23-a86978cb005c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3f572014-5179-47b0-b116-775794737239" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_8d5f7884-e23a-4ba7-8b23-a86978cb005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_eaa8c93c-7d54-4f40-b919-80bb5c472e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_eaa8c93c-7d54-4f40-b919-80bb5c472e1e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2da2fed3-c719-4cc2-8266-981470085434" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_dei_LegalEntityAxis_2da2fed3-c719-4cc2-8266-981470085434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5bb2a933-6aab-45ab-8e85-9af9cfd69227" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2da2fed3-c719-4cc2-8266-981470085434" xlink:to="loc_dei_EntityDomain_5bb2a933-6aab-45ab-8e85-9af9cfd69227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_1f552d61-9be7-4579-b6de-796b61ed2b1d" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5bb2a933-6aab-45ab-8e85-9af9cfd69227" xlink:to="loc_imux_VitalTherapiesInc.Member_1f552d61-9be7-4579-b6de-796b61ed2b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_08044a75-b749-4938-811d-a0c4c3aea7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_08044a75-b749-4938-811d-a0c4c3aea7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7ae25b5d-cc9e-4be6-ba69-cab4ba91ffb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_08044a75-b749-4938-811d-a0c4c3aea7ab" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7ae25b5d-cc9e-4be6-ba69-cab4ba91ffb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ELADRelatedAssetsMember_94782a12-2c84-4ab0-8df3-344ea1f99ee2" xlink:href="imux-20201231.xsd#imux_ELADRelatedAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7ae25b5d-cc9e-4be6-ba69-cab4ba91ffb4" xlink:to="loc_imux_ELADRelatedAssetsMember_94782a12-2c84-4ab0-8df3-344ea1f99ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_306d503e-0029-4bf9-80ea-486a6bb45379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_306d503e-0029-4bf9-80ea-486a6bb45379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d9714337-4c71-4f53-a462-154e2a92d5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_306d503e-0029-4bf9-80ea-486a6bb45379" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d9714337-4c71-4f53-a462-154e2a92d5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_63cf003e-45dc-4489-be1d-d8475370035b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_d9714337-4c71-4f53-a462-154e2a92d5a2" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_63cf003e-45dc-4489-be1d-d8475370035b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_fb6297bf-2854-45cd-bbe4-3894e3402aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_940b9dad-6ef2-444f-8e4f-5ee4fa365e9e" xlink:to="loc_us-gaap_ReceivableTypeDomain_fb6297bf-2854-45cd-bbe4-3894e3402aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_6f5e4981-cb20-4035-85ed-a32165a1b5df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_fb6297bf-2854-45cd-bbe4-3894e3402aeb" xlink:to="loc_us-gaap_NotesReceivableMember_6f5e4981-cb20-4035-85ed-a32165a1b5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e94f287e-0733-4817-87bb-47651ac41061" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_11481af1-2300-4661-92a4-16c338279f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_11481af1-2300-4661-92a4-16c338279f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit_2fb3f7dc-bf85-4822-aebd-0a5a2992c47d" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit_2fb3f7dc-bf85-4822-aebd-0a5a2992c47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration_9658aa16-f58d-4bd4-8a17-66fb41a57182" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration_9658aa16-f58d-4bd4-8a17-66fb41a57182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow_24cf7cef-4823-426d-94c0-9e743820f12b" xlink:href="imux-20201231.xsd#imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow_24cf7cef-4823-426d-94c0-9e743820f12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_1b993ffb-91e2-4f3d-acc1-b2c70e37c142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_1b993ffb-91e2-4f3d-acc1-b2c70e37c142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_657b4d61-c2c7-4f3f-a17d-27d606c94667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate_657b4d61-c2c7-4f3f-a17d-27d606c94667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_3c25f1a7-702f-4459-b667-ae060b548bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_3c25f1a7-702f-4459-b667-ae060b548bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueAdjustment_9130b1ad-cc78-49e0-8545-5d5468c69a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9cef7cec-c7a9-48fc-841c-42af2150eead" xlink:to="loc_us-gaap_AssetsFairValueAdjustment_9130b1ad-cc78-49e0-8545-5d5468c69a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_59d9e7c5-8077-4c52-9616-390d15cbde48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_59d9e7c5-8077-4c52-9616-390d15cbde48" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aabfbe7f-7129-45f6-a0aa-593c43ddc998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aabfbe7f-7129-45f6-a0aa-593c43ddc998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aabfbe7f-7129-45f6-a0aa-593c43ddc998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalDevelopmentEquipmentMember_21845260-872f-469b-971b-2f394ea501c1" xlink:href="imux-20201231.xsd#imux_ClinicalDevelopmentEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:to="loc_imux_ClinicalDevelopmentEquipmentMember_21845260-872f-469b-971b-2f394ea501c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SuppliesAndWorkingCellBanksMember_580d6af3-320b-4c9f-8a8a-e6c49a6fba6b" xlink:href="imux-20201231.xsd#imux_SuppliesAndWorkingCellBanksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:to="loc_imux_SuppliesAndWorkingCellBanksMember_580d6af3-320b-4c9f-8a8a-e6c49a6fba6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_d3750da8-ae9e-49a6-9cb1-db7b1353486b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_68ebd289-65f0-417c-94fa-c1e8cd3142de" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_d3750da8-ae9e-49a6-9cb1-db7b1353486b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ea8c145-0b5e-467a-8a3b-fec71f019a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ea8c145-0b5e-467a-8a3b-fec71f019a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37ca11ca-f8d1-4696-9fb3-9f52c1813eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ea8c145-0b5e-467a-8a3b-fec71f019a0b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37ca11ca-f8d1-4696-9fb3-9f52c1813eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ELADRelatedAssetsMember_a7539df0-41e6-4062-9b70-097a4529424e" xlink:href="imux-20201231.xsd#imux_ELADRelatedAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37ca11ca-f8d1-4696-9fb3-9f52c1813eee" xlink:to="loc_imux_ELADRelatedAssetsMember_a7539df0-41e6-4062-9b70-097a4529424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a711e3e9-a0b7-46d1-a250-302e18856bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e1034cc2-a88d-4a0b-bd48-bdcd6c53d99d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a711e3e9-a0b7-46d1-a250-302e18856bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8613c615-e72d-4ff8-8f49-f8d8c3851ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a711e3e9-a0b7-46d1-a250-302e18856bc0" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8613c615-e72d-4ff8-8f49-f8d8c3851ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0162ae79-ed16-454e-8871-5fd8100e81f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f97ab941-fd2c-49ec-ac1a-5d06f617b0be" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0162ae79-ed16-454e-8871-5fd8100e81f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_14e5a1a4-d7d0-45e4-99f5-8d9a5f5f230a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0162ae79-ed16-454e-8871-5fd8100e81f3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_14e5a1a4-d7d0-45e4-99f5-8d9a5f5f230a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12a04d13-caf0-4b56-84ac-309e73530cdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e848dbc1-04a7-46c1-92cc-85847a2b3454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12a04d13-caf0-4b56-84ac-309e73530cdf" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e848dbc1-04a7-46c1-92cc-85847a2b3454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5085ff1d-ddbc-4f07-8a3a-c72b3f713269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_923d3c54-0b01-4dfb-bba9-2fa7a8afc085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5085ff1d-ddbc-4f07-8a3a-c72b3f713269" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_923d3c54-0b01-4dfb-bba9-2fa7a8afc085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1b5f4dc7-249b-4864-a7b5-a6ed425d00fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5085ff1d-ddbc-4f07-8a3a-c72b3f713269" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1b5f4dc7-249b-4864-a7b5-a6ed425d00fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_f751566c-bce8-4c73-8aa3-8a7f96e05a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5085ff1d-ddbc-4f07-8a3a-c72b3f713269" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_f751566c-bce8-4c73-8aa3-8a7f96e05a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be0316da-18dd-430f-ae26-2c059c85cd4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PrepaidClinicalAndRelatedCostsCurrent_9a076cc4-73fb-400a-a649-9f35f71b8219" xlink:href="imux-20201231.xsd#imux_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be0316da-18dd-430f-ae26-2c059c85cd4a" xlink:to="loc_imux_PrepaidClinicalAndRelatedCostsCurrent_9a076cc4-73fb-400a-a649-9f35f71b8219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_b25bce89-3052-4d10-9ff1-6a9a3ba3cf69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be0316da-18dd-430f-ae26-2c059c85cd4a" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_b25bce89-3052-4d10-9ff1-6a9a3ba3cf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent_0d437af4-cae3-4c78-9a56-5b11ad07bb1a" xlink:href="imux-20201231.xsd#imux_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be0316da-18dd-430f-ae26-2c059c85cd4a" xlink:to="loc_imux_ResearchAndDevelopmentTaxIncentiveCurrent_0d437af4-cae3-4c78-9a56-5b11ad07bb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_264a3600-34f8-4045-86a6-3e991f35f242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be0316da-18dd-430f-ae26-2c059c85cd4a" xlink:to="loc_us-gaap_OtherAssetsCurrent_264a3600-34f8-4045-86a6-3e991f35f242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca89be3b-1473-4357-a897-61a501a0e76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be0316da-18dd-430f-ae26-2c059c85cd4a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca89be3b-1473-4357-a897-61a501a0e76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_912403d0-7d87-4b63-a258-10f0f5f5009b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ClinicalCostsPayableCurrent_4d398c38-dec8-4f1b-b8cb-7e1636345dff" xlink:href="imux-20201231.xsd#imux_ClinicalCostsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_912403d0-7d87-4b63-a258-10f0f5f5009b" xlink:to="loc_imux_ClinicalCostsPayableCurrent_4d398c38-dec8-4f1b-b8cb-7e1636345dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LegalAndAuditCostsPayableCurrent_4ba1a2a2-daa2-4886-8fb5-23b18ab21616" xlink:href="imux-20201231.xsd#imux_LegalAndAuditCostsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_912403d0-7d87-4b63-a258-10f0f5f5009b" xlink:to="loc_imux_LegalAndAuditCostsPayableCurrent_4ba1a2a2-daa2-4886-8fb5-23b18ab21616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_5eacaea2-2e80-4dba-af78-a682ba2f7bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_912403d0-7d87-4b63-a258-10f0f5f5009b" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_5eacaea2-2e80-4dba-af78-a682ba2f7bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_621dcbb8-6d89-44c1-b930-ac7cc6403362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_912403d0-7d87-4b63-a258-10f0f5f5009b" xlink:to="loc_us-gaap_AccountsPayableCurrent_621dcbb8-6d89-44c1-b930-ac7cc6403362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1efbfa27-8a69-416f-af9a-22d5b42cc3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedClinicalCostsCurrent_6cdd4029-f8ad-4b54-9195-8230a32456d6" xlink:href="imux-20201231.xsd#imux_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1efbfa27-8a69-416f-af9a-22d5b42cc3db" xlink:to="loc_imux_AccruedClinicalCostsCurrent_6cdd4029-f8ad-4b54-9195-8230a32456d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedLegalAndAuditCostsCurrent_6c727b68-f0dc-4e72-bb7e-ce99345500eb" xlink:href="imux-20201231.xsd#imux_AccruedLegalAndAuditCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1efbfa27-8a69-416f-af9a-22d5b42cc3db" xlink:to="loc_imux_AccruedLegalAndAuditCostsCurrent_6c727b68-f0dc-4e72-bb7e-ce99345500eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AccruedCompensationCurrent_d6611042-c009-4f6e-897b-4d0aa6a39d8b" xlink:href="imux-20201231.xsd#imux_AccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1efbfa27-8a69-416f-af9a-22d5b42cc3db" xlink:to="loc_imux_AccruedCompensationCurrent_d6611042-c009-4f6e-897b-4d0aa6a39d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0c43769d-c060-4459-8eea-fa28104fbc94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1efbfa27-8a69-416f-af9a-22d5b42cc3db" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0c43769d-c060-4459-8eea-fa28104fbc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bf9ba636-d4f3-45e2-909b-eecb373612a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1efbfa27-8a69-416f-af9a-22d5b42cc3db" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bf9ba636-d4f3-45e2-909b-eecb373612a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9335f57c-f472-43cb-9596-580c75146a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_3b66ed0f-7de1-4454-86db-26e10c5d15ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9335f57c-f472-43cb-9596-580c75146a78" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_3b66ed0f-7de1-4454-86db-26e10c5d15ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_bc240e68-7183-4fb3-a0de-3cd7d1701b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9335f57c-f472-43cb-9596-580c75146a78" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_bc240e68-7183-4fb3-a0de-3cd7d1701b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_64de11af-2951-4ec0-a300-d541f273f5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9335f57c-f472-43cb-9596-580c75146a78" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_64de11af-2951-4ec0-a300-d541f273f5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b436409-7a47-4cf6-8a0f-eb151bca7957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f04c2a3f-221d-41d7-b84a-173264ce2d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b436409-7a47-4cf6-8a0f-eb151bca7957" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f04c2a3f-221d-41d7-b84a-173264ce2d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a9910e6e-761b-4669-9d02-3251c19002e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_251f85ea-b277-4f5e-bf5f-ed4efbfc237c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a9910e6e-761b-4669-9d02-3251c19002e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_251f85ea-b277-4f5e-bf5f-ed4efbfc237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37a3e4e8-ea45-4006-a1af-e4c5a356b368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d8c74b17-4c8e-4f80-89bb-046af3701dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37a3e4e8-ea45-4006-a1af-e4c5a356b368" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d8c74b17-4c8e-4f80-89bb-046af3701dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_a715c3c5-411f-4bd6-b35d-008c9f6d946a" xlink:href="imux-20201231.xsd#imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37a3e4e8-ea45-4006-a1af-e4c5a356b368" xlink:to="loc_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_a715c3c5-411f-4bd6-b35d-008c9f6d946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_OperatingAndVariableLeasesCost_6fb52e82-26b5-4160-b964-fe0eb541c12a" xlink:href="imux-20201231.xsd#imux_OperatingAndVariableLeasesCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37a3e4e8-ea45-4006-a1af-e4c5a356b368" xlink:to="loc_imux_OperatingAndVariableLeasesCost_6fb52e82-26b5-4160-b964-fe0eb541c12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_5b7ca9a2-2346-4c8a-80ee-4acb448bae4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37a3e4e8-ea45-4006-a1af-e4c5a356b368" xlink:to="loc_us-gaap_ContractualObligation_5b7ca9a2-2346-4c8a-80ee-4acb448bae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_a64cd136-b7c9-43db-9eed-0c194e906bb5" xlink:href="imux-20201231.xsd#imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37a3e4e8-ea45-4006-a1af-e4c5a356b368" xlink:to="loc_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_a64cd136-b7c9-43db-9eed-0c194e906bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a43f615c-ec6c-44bf-bd90-11244580dfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37a3e4e8-ea45-4006-a1af-e4c5a356b368" xlink:to="loc_us-gaap_CommonStockSharesIssued_a43f615c-ec6c-44bf-bd90-11244580dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_47bd1fea-d75f-4c2d-92d7-42826338f826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37a3e4e8-ea45-4006-a1af-e4c5a356b368" xlink:to="loc_us-gaap_CommonStockValue_47bd1fea-d75f-4c2d-92d7-42826338f826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_710be5c3-be55-4d86-9c88-fff3db37ecb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_710be5c3-be55-4d86-9c88-fff3db37ecb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3ea2398-5a55-4f5d-bd8e-89f19d2c25c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3ea2398-5a55-4f5d-bd8e-89f19d2c25c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5b908fb6-ae9d-4e67-bd36-24ceec1a1965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5b908fb6-ae9d-4e67-bd36-24ceec1a1965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_14d3bb1b-0a41-4b1f-9319-16190b5ae93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_14d3bb1b-0a41-4b1f-9319-16190b5ae93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_10db4960-7862-4134-a318-9d65bb6cd349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_10db4960-7862-4134-a318-9d65bb6cd349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6d5cf594-0cc1-48d4-9e33-43dda30c965d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6d5cf594-0cc1-48d4-9e33-43dda30c965d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c9522f4-68f9-4ae8-902a-ad3a25bbc4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c9522f4-68f9-4ae8-902a-ad3a25bbc4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1f6ea41a-ecc0-4d67-a785-4e68403e42cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1f6ea41a-ecc0-4d67-a785-4e68403e42cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8982d40f-5e8a-4473-a0dc-a1311c46d59b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17c7d967-c1c8-40f5-b423-b9b5a7f1b357" xlink:to="loc_us-gaap_OperatingLeaseLiability_8982d40f-5e8a-4473-a0dc-a1311c46d59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1" xlink:type="simple" xlink:href="imux-20201231.xsd#CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://imux.com/role/FairValue" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://imux.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_33c0fec5-aa54-401d-be6e-94e3d27ef26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_75f74f28-1b15-42ed-a05c-ffe942683f78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_33c0fec5-aa54-401d-be6e-94e3d27ef26f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_75f74f28-1b15-42ed-a05c-ffe942683f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/FairValueTables" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_749564da-6fe8-47a5-b5b2-5b10d650ddc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d264a9b5-efc0-4df2-b1db-57915e2c8803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_749564da-6fe8-47a5-b5b2-5b10d650ddc1" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d264a9b5-efc0-4df2-b1db-57915e2c8803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f1480efa-0f01-4e4f-a2af-bbd24b765913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f1480efa-0f01-4e4f-a2af-bbd24b765913" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c078166d-5d09-4a1d-8e93-1ffae95a74ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c078166d-5d09-4a1d-8e93-1ffae95a74ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c078166d-5d09-4a1d-8e93-1ffae95a74ed" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1ece29b8-a630-489b-8a28-4d856246cf83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1ece29b8-a630-489b-8a28-4d856246cf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d9f51015-ecca-40e8-9046-5df0ba135fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d9f51015-ecca-40e8-9046-5df0ba135fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_729f25d8-0945-4676-9a06-0b4e4abff15e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c05462e7-564f-4d61-97d1-e21d8d49b6c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_729f25d8-0945-4676-9a06-0b4e4abff15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fe554793-2694-4e27-9047-4a2ac3fcdec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fe554793-2694-4e27-9047-4a2ac3fcdec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0d935bd-c6fa-44fc-b021-4092bec200d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fe554793-2694-4e27-9047-4a2ac3fcdec1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0d935bd-c6fa-44fc-b021-4092bec200d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c679bc07-99e3-4d1c-9b77-4009fd97dfb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0d935bd-c6fa-44fc-b021-4092bec200d4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c679bc07-99e3-4d1c-9b77-4009fd97dfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:to="loc_us-gaap_InvestmentTypeAxis_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1e327597-b79d-45aa-a97a-dbc929c1bf3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ea8ae1ee-c272-4b92-a0d9-e5b384424bdf" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1e327597-b79d-45aa-a97a-dbc929c1bf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9952de76-8465-4aa6-ba32-5da48c06237a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e327597-b79d-45aa-a97a-dbc929c1bf3b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9952de76-8465-4aa6-ba32-5da48c06237a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4e4e041-4da6-4284-ba82-3055d5dd76c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_bc91d506-9d13-43f3-a0d5-a004cbb3c0c8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4e4e041-4da6-4284-ba82-3055d5dd76c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_218ead45-77cc-413c-bfed-70fb0d654e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4e4e041-4da6-4284-ba82-3055d5dd76c5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_218ead45-77cc-413c-bfed-70fb0d654e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_24d9b73d-57c1-4e99-8b75-fcb4405be765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_218ead45-77cc-413c-bfed-70fb0d654e41" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_24d9b73d-57c1-4e99-8b75-fcb4405be765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStock"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d675c66b-0a76-4466-be0e-729b37901b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_06c66919-737b-4a95-b270-f868e8345d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d675c66b-0a76-4466-be0e-729b37901b1b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_06c66919-737b-4a95-b270-f868e8345d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f5556f32-9df2-4792-b21b-f35501eb3cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_c268e9e1-c6ab-4d13-91e0-8f5feb121969" xlink:href="imux-20201231.xsd#imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f5556f32-9df2-4792-b21b-f35501eb3cac" xlink:to="loc_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_c268e9e1-c6ab-4d13-91e0-8f5feb121969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f7074e45-39f5-462a-9ff8-244225f322c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a37d2c29-3651-4d95-a467-15fbd47af8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f7074e45-39f5-462a-9ff8-244225f322c7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a37d2c29-3651-4d95-a467-15fbd47af8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1c6d9a99-c5a3-4510-8a90-5e294caf92a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a37d2c29-3651-4d95-a467-15fbd47af8dd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1c6d9a99-c5a3-4510-8a90-5e294caf92a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1c6d9a99-c5a3-4510-8a90-5e294caf92a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_July2019EquityIssuancesMember_ddb3c5da-069a-48c8-ac04-e2be972a509d" xlink:href="imux-20201231.xsd#imux_July2019EquityIssuancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:to="loc_imux_July2019EquityIssuancesMember_ddb3c5da-069a-48c8-ac04-e2be972a509d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_December2020EquityIssuancesMember_0c0bc9ca-c69f-435f-88fe-487c4ab509b9" xlink:href="imux-20201231.xsd#imux_December2020EquityIssuancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:to="loc_imux_December2020EquityIssuancesMember_0c0bc9ca-c69f-435f-88fe-487c4ab509b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_AtTheMarketSalesAgreementMember_0f912751-a970-4e7e-be1a-67c05150e97f" xlink:href="imux-20201231.xsd#imux_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e28bf9b-a1a3-435d-80cc-91efbe65ecfe" xlink:to="loc_imux_AtTheMarketSalesAgreementMember_0f912751-a970-4e7e-be1a-67c05150e97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a37d2c29-3651-4d95-a467-15fbd47af8dd" xlink:to="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration_67722fcc-e96e-4bdf-a302-b593d0152f75" xlink:href="imux-20201231.xsd#imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration_67722fcc-e96e-4bdf-a302-b593d0152f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders_96261e94-86af-40ef-9183-0647d732eb9b" xlink:href="imux-20201231.xsd#imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders_96261e94-86af-40ef-9183-0647d732eb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement_56f754ef-a295-446a-9dcb-ccf49413fb55" xlink:href="imux-20201231.xsd#imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement_56f754ef-a295-446a-9dcb-ccf49413fb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_34338ccb-99fe-46f0-9d78-c9db10b0c8dd" xlink:href="imux-20201231.xsd#imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_34338ccb-99fe-46f0-9d78-c9db10b0c8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7ee561c3-000e-4591-97a7-a4295fee392f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7ee561c3-000e-4591-97a7-a4295fee392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f2c7212-fd3c-4470-a5b4-45a0720de9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5f2c7212-fd3c-4470-a5b4-45a0720de9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_70f407f9-fce6-463a-803a-290da0256b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_70f407f9-fce6-463a-803a-290da0256b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_93034232-3eb5-407e-ab93-4fd16b813116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_93034232-3eb5-407e-ab93-4fd16b813116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_350027ac-5091-423f-af62-c3972ef6f3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_PaymentsForCommissions_350027ac-5091-423f-af62-c3972ef6f3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b8585d26-3936-4d3b-bce8-e1bcb5ecc20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_85b34998-3a74-4004-a4d6-043e4ee4dc6c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b8585d26-3936-4d3b-bce8-e1bcb5ecc20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ec658824-dd79-42f7-bbba-8e52b8df5490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_87914132-44d3-48c6-a928-dc91df39a171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec658824-dd79-42f7-bbba-8e52b8df5490" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_87914132-44d3-48c6-a928-dc91df39a171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_80121e41-1c04-4ce3-a87a-85fd5c99e0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87914132-44d3-48c6-a928-dc91df39a171" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_80121e41-1c04-4ce3-a87a-85fd5c99e0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61395c85-6123-42df-a5e0-08592262ee5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_80121e41-1c04-4ce3-a87a-85fd5c99e0a5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61395c85-6123-42df-a5e0-08592262ee5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_April2020EquityIssuancesMember_5ab4d594-ef83-4cc3-b449-03368dd2d2aa" xlink:href="imux-20201231.xsd#imux_April2020EquityIssuancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_61395c85-6123-42df-a5e0-08592262ee5c" xlink:to="loc_imux_April2020EquityIssuancesMember_5ab4d594-ef83-4cc3-b449-03368dd2d2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_87914132-44d3-48c6-a928-dc91df39a171" xlink:to="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_98b1e134-61e7-4aeb-a079-399da5946830" xlink:href="imux-20201231.xsd#imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_98b1e134-61e7-4aeb-a079-399da5946830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_406419ae-643a-4725-b840-45f02f5aa603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_406419ae-643a-4725-b840-45f02f5aa603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f273bf69-1133-42c1-8e26-3013e818b746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f273bf69-1133-42c1-8e26-3013e818b746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ProceedsFromIssuanceOfCommonStockGross_7e0ea55d-dafc-4a3c-a6e4-c66845774a36" xlink:href="imux-20201231.xsd#imux_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_imux_ProceedsFromIssuanceOfCommonStockGross_7e0ea55d-dafc-4a3c-a6e4-c66845774a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e435fdf6-a1d9-480a-98b8-1824378a08d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9247c762-2f9c-475f-839f-7136edecd602" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e435fdf6-a1d9-480a-98b8-1824378a08d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e2cea080-36a4-40f1-b221-bb4441873449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0344608b-f392-415c-9bdd-2d20b987067d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e2cea080-36a4-40f1-b221-bb4441873449" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0344608b-f392-415c-9bdd-2d20b987067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0344608b-f392-415c-9bdd-2d20b987067d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d246683-0ab3-4ca7-be7e-8f10046dbff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ad6cf720-0a8b-4e7d-b26c-f618064b3f4d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d246683-0ab3-4ca7-be7e-8f10046dbff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_June2020EquityIssuancesMember_38282e2a-2e8f-4236-af46-53bf88507a57" xlink:href="imux-20201231.xsd#imux_June2020EquityIssuancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d246683-0ab3-4ca7-be7e-8f10046dbff2" xlink:to="loc_imux_June2020EquityIssuancesMember_38282e2a-2e8f-4236-af46-53bf88507a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_August2020EquityIssuancesMember_542b550b-03c6-441b-913a-49eaa9fca52e" xlink:href="imux-20201231.xsd#imux_August2020EquityIssuancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d246683-0ab3-4ca7-be7e-8f10046dbff2" xlink:to="loc_imux_August2020EquityIssuancesMember_542b550b-03c6-441b-913a-49eaa9fca52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0344608b-f392-415c-9bdd-2d20b987067d" xlink:to="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbcd9c43-3e2d-4c86-a3e0-308f9cb6bc6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbcd9c43-3e2d-4c86-a3e0-308f9cb6bc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_89031685-2708-4696-bcc5-699d7d325636" xlink:href="imux-20201231.xsd#imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_89031685-2708-4696-bcc5-699d7d325636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b74ef95e-76ab-4101-8910-d6afec57c715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b74ef95e-76ab-4101-8910-d6afec57c715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ProceedsFromIssuanceOfCommonStockGross_9dfb1be6-df3e-48bb-9fa8-8917d22f3dd9" xlink:href="imux-20201231.xsd#imux_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_imux_ProceedsFromIssuanceOfCommonStockGross_9dfb1be6-df3e-48bb-9fa8-8917d22f3dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_152104c0-f761-4c4d-9258-48b37f04e64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_152104c0-f761-4c4d-9258-48b37f04e64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock_ea6c9f9d-1e33-4884-8732-f88c55a39b85" xlink:href="imux-20201231.xsd#imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock_ea6c9f9d-1e33-4884-8732-f88c55a39b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SaleOfStockNumberOfAdditionalSharesAuthorized_bc3520ed-2413-4c91-a6b4-054e2fbeac46" xlink:href="imux-20201231.xsd#imux_SaleOfStockNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8e40a02a-824f-43f0-93e7-5ee2eb741097" xlink:to="loc_imux_SaleOfStockNumberOfAdditionalSharesAuthorized_bc3520ed-2413-4c91-a6b4-054e2fbeac46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bfd6c4d1-0e08-453d-99e5-655f8db73802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_007f5693-8ad8-4e5d-ab5f-50a29da7425d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bfd6c4d1-0e08-453d-99e5-655f8db73802" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_007f5693-8ad8-4e5d-ab5f-50a29da7425d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6474f86d-f8c1-4d1c-bd79-7759a57dd933" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_007f5693-8ad8-4e5d-ab5f-50a29da7425d" xlink:to="loc_srt_TitleOfIndividualAxis_6474f86d-f8c1-4d1c-bd79-7759a57dd933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e0a06664-42ce-4250-9b9c-b67135a2099d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_6474f86d-f8c1-4d1c-bd79-7759a57dd933" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e0a06664-42ce-4250-9b9c-b67135a2099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_e43f7a26-97a9-4316-9067-ba256a5924d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e0a06664-42ce-4250-9b9c-b67135a2099d" xlink:to="loc_srt_ExecutiveOfficerMember_e43f7a26-97a9-4316-9067-ba256a5924d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6b7dd713-e8d8-4eef-a48a-c9670a2db9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_007f5693-8ad8-4e5d-ab5f-50a29da7425d" xlink:to="loc_us-gaap_ClassOfStockLineItems_6b7dd713-e8d8-4eef-a48a-c9670a2db9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7c28f5c2-c6c7-4ae6-b8ce-a9c91fdbf3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b7dd713-e8d8-4eef-a48a-c9670a2db9e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_7c28f5c2-c6c7-4ae6-b8ce-a9c91fdbf3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_51d75829-f3eb-45e0-8af5-d771e8f81934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6b7dd713-e8d8-4eef-a48a-c9670a2db9e2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_51d75829-f3eb-45e0-8af5-d771e8f81934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b3644b4a-fb04-40ae-a248-3e4c7fae15d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0e284b01-f502-4932-aed9-217a13a8ac46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b3644b4a-fb04-40ae-a248-3e4c7fae15d8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0e284b01-f502-4932-aed9-217a13a8ac46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_21b2d1e5-7ecb-40b1-a35a-3aa2e65f0b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b3644b4a-fb04-40ae-a248-3e4c7fae15d8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_21b2d1e5-7ecb-40b1-a35a-3aa2e65f0b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8742e8b9-7a70-4b8a-9636-a60f1c70580c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b3644b4a-fb04-40ae-a248-3e4c7fae15d8" xlink:to="loc_us-gaap_CommonStockValue_8742e8b9-7a70-4b8a-9636-a60f1c70580c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_cf89e9f0-cf5d-4bd7-9a9d-07f64e751e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b3644b4a-fb04-40ae-a248-3e4c7fae15d8" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_cf89e9f0-cf5d-4bd7-9a9d-07f64e751e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1c631f5b-321d-4770-9589-0d85694e5ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b3644b4a-fb04-40ae-a248-3e4c7fae15d8" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1c631f5b-321d-4770-9589-0d85694e5ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6ef5cb60-18b1-4d31-89af-015e9b9dd4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6ef5cb60-18b1-4d31-89af-015e9b9dd4d4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a14b79cd-9fe9-442b-8692-0c0f40e74665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:to="loc_dei_LegalEntityAxis_a14b79cd-9fe9-442b-8692-0c0f40e74665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2423be6e-e3e9-49ed-969e-a74ae9ae2c12" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a14b79cd-9fe9-442b-8692-0c0f40e74665" xlink:to="loc_dei_EntityDomain_2423be6e-e3e9-49ed-969e-a74ae9ae2c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ImmunicAGMember_d1bff4d5-fdf9-4b1f-a0cd-5f2efcdb1a75" xlink:href="imux-20201231.xsd#imux_ImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2423be6e-e3e9-49ed-969e-a74ae9ae2c12" xlink:to="loc_imux_ImmunicAGMember_d1bff4d5-fdf9-4b1f-a0cd-5f2efcdb1a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c2090ba2-addb-4cfd-a7b5-263cc77321bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c2090ba2-addb-4cfd-a7b5-263cc77321bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f36711e3-6b9c-4c71-bfab-8495183c6464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c2090ba2-addb-4cfd-a7b5-263cc77321bc" xlink:to="loc_us-gaap_ClassOfStockDomain_f36711e3-6b9c-4c71-bfab-8495183c6464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA1ConvertiblePreferredStockMember_c5846d12-572f-4cd2-8f01-c68eefaceefb" xlink:href="imux-20201231.xsd#imux_SeriesA1ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f36711e3-6b9c-4c71-bfab-8495183c6464" xlink:to="loc_imux_SeriesA1ConvertiblePreferredStockMember_c5846d12-572f-4cd2-8f01-c68eefaceefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SeriesA2ConvertiblePreferredStockMember_980fbab0-419d-4868-a515-25a640c1b8f9" xlink:href="imux-20201231.xsd#imux_SeriesA2ConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f36711e3-6b9c-4c71-bfab-8495183c6464" xlink:to="loc_imux_SeriesA2ConvertiblePreferredStockMember_980fbab0-419d-4868-a515-25a640c1b8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0b09065a-0f92-4be7-bbce-4fa5757938e9" xlink:to="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_69d727bc-735d-4e7c-b0b0-79a6ef2a3fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockSharesIssued_69d727bc-735d-4e7c-b0b0-79a6ef2a3fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ca4d4080-bfc2-4d03-b25d-ab8c9a4591ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ca4d4080-bfc2-4d03-b25d-ab8c9a4591ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c0331b11-5fee-4097-a1ba-6307e33c2e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockValue_c0331b11-5fee-4097-a1ba-6307e33c2e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d700de97-0f80-4b69-b61e-40ac997a31f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d700de97-0f80-4b69-b61e-40ac997a31f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_579855a0-8c59-42b3-a72b-3c2628f38e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_da61c444-8bab-4887-aefc-7d1957709d24" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_579855a0-8c59-42b3-a72b-3c2628f38e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_57249bef-4973-44c8-aaa6-0b5301ff2e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_aaa3b1ed-b8af-4dc1-817e-d67b4ba602e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_57249bef-4973-44c8-aaa6-0b5301ff2e7d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_aaa3b1ed-b8af-4dc1-817e-d67b4ba602e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4787dcdc-1ed4-4d23-a811-a8b059c296b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aaa3b1ed-b8af-4dc1-817e-d67b4ba602e3" xlink:to="loc_us-gaap_AwardTypeAxis_4787dcdc-1ed4-4d23-a811-a8b059c296b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a5efb19-4c57-4d0b-a8df-34039d9cf5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4787dcdc-1ed4-4d23-a811-a8b059c296b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a5efb19-4c57-4d0b-a8df-34039d9cf5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2dbbd1d8-7928-4dd5-accc-cf47d8c75abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a5efb19-4c57-4d0b-a8df-34039d9cf5fa" xlink:to="loc_us-gaap_WarrantMember_2dbbd1d8-7928-4dd5-accc-cf47d8c75abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e7ebd0fa-ebe0-40cd-8d85-bcb5e57b66ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_aaa3b1ed-b8af-4dc1-817e-d67b4ba602e3" xlink:to="loc_us-gaap_ClassOfStockLineItems_e7ebd0fa-ebe0-40cd-8d85-bcb5e57b66ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a57c4633-f664-49c6-a70a-3777fdec0109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e7ebd0fa-ebe0-40cd-8d85-bcb5e57b66ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_a57c4633-f664-49c6-a70a-3777fdec0109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b37f48e-fc50-4d88-b712-3485facfd4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e7ebd0fa-ebe0-40cd-8d85-bcb5e57b66ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b37f48e-fc50-4d88-b712-3485facfd4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a463df30-74e5-4b14-97d1-4fc947e45632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a463df30-74e5-4b14-97d1-4fc947e45632" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fd77e7a1-3ba0-442c-b8b0-152152d1fec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:to="loc_us-gaap_PlanNameAxis_fd77e7a1-3ba0-442c-b8b0-152152d1fec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fd77e7a1-3ba0-442c-b8b0-152152d1fec9" xlink:to="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_989c0962-fea3-4dda-ad7f-b26f2de60325" xlink:href="imux-20201231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:to="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_989c0962-fea3-4dda-ad7f-b26f2de60325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember_42b5dab7-5b16-4157-861c-f2043b1e9054" xlink:href="imux-20201231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:to="loc_imux_A2017InducementEquityIncentivePlanMember_42b5dab7-5b16-4157-861c-f2043b1e9054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_691609b2-b245-4a5c-9a1f-3a02539045c9" xlink:href="imux-20201231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_86d23503-ba50-4cc4-af35-c77f2bda239b" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_691609b2-b245-4a5c-9a1f-3a02539045c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0deeb96e-8234-43f0-9d42-7850f570ea6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:to="loc_us-gaap_AwardTypeAxis_0deeb96e-8234-43f0-9d42-7850f570ea6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2d0f9e-115c-4dbf-aaab-9749856eaa50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0deeb96e-8234-43f0-9d42-7850f570ea6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2d0f9e-115c-4dbf-aaab-9749856eaa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35d2f3f4-3798-4b51-b113-ca0397241c18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2d0f9e-115c-4dbf-aaab-9749856eaa50" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35d2f3f4-3798-4b51-b113-ca0397241c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsforFutureGrantMember_ff089ec7-e80b-414e-8c0e-1309992f4578" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsforFutureGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2d0f9e-115c-4dbf-aaab-9749856eaa50" xlink:to="loc_imux_EmployeeStockOptionsforFutureGrantMember_ff089ec7-e80b-414e-8c0e-1309992f4578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9bd03992-79ad-4e2f-ae18-240736a4cc2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_474fdde4-9734-4904-87ad-51aa17d139ff" xlink:to="loc_us-gaap_ClassOfStockLineItems_9bd03992-79ad-4e2f-ae18-240736a4cc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc2c7410-d150-41da-b4a0-3e7b1e02c613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9bd03992-79ad-4e2f-ae18-240736a4cc2f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bc2c7410-d150-41da-b4a0-3e7b1e02c613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlans" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlans"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ecfdd66-045d-4189-b8e9-33931a3241eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_89d04440-11a6-4eaf-9e2d-e858a7dc7d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ecfdd66-045d-4189-b8e9-33931a3241eb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_89d04440-11a6-4eaf-9e2d-e858a7dc7d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansTables" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c86d20fc-9296-4085-ac62-60558d1b761b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_511bc312-6e41-4280-9e34-c52351601ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c86d20fc-9296-4085-ac62-60558d1b761b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_511bc312-6e41-4280-9e34-c52351601ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d369ad81-6a83-47f8-8dcf-4e6fed862dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_511bc312-6e41-4280-9e34-c52351601ef1" xlink:to="loc_us-gaap_AwardTypeAxis_d369ad81-6a83-47f8-8dcf-4e6fed862dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be842eb6-8ea2-4500-aa13-843004189890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d369ad81-6a83-47f8-8dcf-4e6fed862dd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be842eb6-8ea2-4500-aa13-843004189890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member_8beba506-a75e-499f-b8db-669592bc0a6d" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsVitalTherapiesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be842eb6-8ea2-4500-aa13-843004189890" xlink:to="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member_8beba506-a75e-499f-b8db-669592bc0a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_511bc312-6e41-4280-9e34-c52351601ef1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_797a4e72-dd03-4a97-b150-6c72bba51a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_797a4e72-dd03-4a97-b150-6c72bba51a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_95d3b254-4a0f-4bbe-b032-f690bd01e852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_95d3b254-4a0f-4bbe-b032-f690bd01e852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90ab3c42-26d1-4f03-843c-6ced02e278bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da09c1a3-bbeb-4046-bc8c-bad4e680e4b6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90ab3c42-26d1-4f03-843c-6ced02e278bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockCompensationPlansAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d34220a6-af69-4f09-90d2-4abcda67ad7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d34220a6-af69-4f09-90d2-4abcda67ad7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06bb98ff-f7e6-42d4-8940-949576d0085f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_us-gaap_AwardTypeAxis_06bb98ff-f7e6-42d4-8940-949576d0085f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_06bb98ff-f7e6-42d4-8940-949576d0085f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_IncentiveEmployeeStockOptionMember_0006dd21-7f31-41dd-9636-6e99f6e3ec7c" xlink:href="imux-20201231.xsd#imux_IncentiveEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:to="loc_imux_IncentiveEmployeeStockOptionMember_0006dd21-7f31-41dd-9636-6e99f6e3ec7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_NonStatutoryEmployeeStockOptionMember_9a1933e9-7f5f-45ae-8ef2-23222cd8d044" xlink:href="imux-20201231.xsd#imux_NonStatutoryEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:to="loc_imux_NonStatutoryEmployeeStockOptionMember_9a1933e9-7f5f-45ae-8ef2-23222cd8d044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_394a043d-a3e1-4033-8724-c6f9d842dbeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0451124-948a-482c-849a-80d0f469fb9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_394a043d-a3e1-4033-8724-c6f9d842dbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c3032c6f-a25b-406e-b1ef-3c24417502e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_srt_RangeAxis_c3032c6f-a25b-406e-b1ef-3c24417502e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0fce5d42-9af1-4b9d-a86b-552d0e526ec6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c3032c6f-a25b-406e-b1ef-3c24417502e8" xlink:to="loc_srt_RangeMember_0fce5d42-9af1-4b9d-a86b-552d0e526ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5c50d9b-fd28-4586-9543-0ccb16f1bc48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0fce5d42-9af1-4b9d-a86b-552d0e526ec6" xlink:to="loc_srt_MinimumMember_e5c50d9b-fd28-4586-9543-0ccb16f1bc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6bac7246-507b-40d6-8a8f-a7eb1e0c4388" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0fce5d42-9af1-4b9d-a86b-552d0e526ec6" xlink:to="loc_srt_MaximumMember_6bac7246-507b-40d6-8a8f-a7eb1e0c4388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ab1e3481-3413-472a-b2d8-39046e82f04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_us-gaap_PlanNameAxis_ab1e3481-3413-472a-b2d8-39046e82f04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ab1e3481-3413-472a-b2d8-39046e82f04a" xlink:to="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VSOPSBMember_36e57078-9af9-4c82-b190-ce9a1d70cb45" xlink:href="imux-20201231.xsd#imux_VSOPSBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_VSOPSBMember_36e57078-9af9-4c82-b190-ce9a1d70cb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember_b8680622-ea11-45a9-a1b9-c810de9e819c" xlink:href="imux-20201231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_A2019OmnibusEquityIncentivePlanMember_b8680622-ea11-45a9-a1b9-c810de9e819c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VSOPAndVSOPSBMember_55b6a351-4bb0-4fed-adc4-9be49ee3ed7d" xlink:href="imux-20201231.xsd#imux_VSOPAndVSOPSBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_VSOPAndVSOPSBMember_55b6a351-4bb0-4fed-adc4-9be49ee3ed7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_dcb25e28-ef4f-4ebb-b8e4-71b4cabae9bb" xlink:href="imux-20201231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_dcb25e28-ef4f-4ebb-b8e4-71b4cabae9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ExecutiveBonusAgreementMember_35b2ab87-e230-4366-a720-36889f17e927" xlink:href="imux-20201231.xsd#imux_ExecutiveBonusAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_ExecutiveBonusAgreementMember_35b2ab87-e230-4366-a720-36889f17e927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_19c185fb-b9c6-43ac-a4af-a50a4a40b2f8" xlink:href="imux-20201231.xsd#imux_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_TwoThousandFourteenEquityIncentivePlanMember_19c185fb-b9c6-43ac-a4af-a50a4a40b2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2017InducementEquityIncentivePlanMember_c6c27eca-0a8a-4ad0-9f3c-f26f5bdf0a96" xlink:href="imux-20201231.xsd#imux_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6a2d5e5b-8b87-4719-b287-f9711741cab4" xlink:to="loc_imux_A2017InducementEquityIncentivePlanMember_c6c27eca-0a8a-4ad0-9f3c-f26f5bdf0a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9d927cc9-9920-4e03-9971-89f47b21e275" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_dei_LegalEntityAxis_9d927cc9-9920-4e03-9971-89f47b21e275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a00b054-0fc5-4e3f-9ad9-18be3e8583c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9d927cc9-9920-4e03-9971-89f47b21e275" xlink:to="loc_dei_EntityDomain_7a00b054-0fc5-4e3f-9ad9-18be3e8583c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VitalTherapiesInc.Member_c0ea7044-198b-433f-8fdc-629bc985f73e" xlink:href="imux-20201231.xsd#imux_VitalTherapiesInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7a00b054-0fc5-4e3f-9ad9-18be3e8583c0" xlink:to="loc_imux_VitalTherapiesInc.Member_c0ea7044-198b-433f-8fdc-629bc985f73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_84fb7ebf-eae0-4b9f-96ee-d93238132cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_84fb7ebf-eae0-4b9f-96ee-d93238132cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9384f34-f532-4121-8576-bf6f5e86db8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_84fb7ebf-eae0-4b9f-96ee-d93238132cc7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9384f34-f532-4121-8576-bf6f5e86db8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac0460cf-3d17-427f-97cd-5156fa89ccf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9384f34-f532-4121-8576-bf6f5e86db8a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ac0460cf-3d17-427f-97cd-5156fa89ccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_70ab334f-f1bc-418a-9d08-2a33d27ba34d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9384f34-f532-4121-8576-bf6f5e86db8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_70ab334f-f1bc-418a-9d08-2a33d27ba34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b13fbf-eeaa-4788-bd83-c3b216295f26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans_d552499d-c8f5-4905-9ea5-9ef9a60f8808" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans_d552499d-c8f5-4905-9ea5-9ef9a60f8808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital_00239d88-82e0-4c8b-9137-22fa5e182307" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital_00239d88-82e0-4c8b-9137-22fa5e182307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fc8d5856-c7e6-4d48-87d7-34ec716ef8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fc8d5856-c7e6-4d48-87d7-34ec716ef8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bec5ba4e-62b2-4957-86c0-1a40d6973fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bec5ba4e-62b2-4957-86c0-1a40d6973fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_404463a8-f751-4003-8c52-d9a98f647a48" xlink:href="imux-20201231.xsd#imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_404463a8-f751-4003-8c52-d9a98f647a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8c984587-d169-4f99-bd44-229586a73c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8c984587-d169-4f99-bd44-229586a73c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9f28c83-96fb-4341-9748-1c7811275071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9f28c83-96fb-4341-9748-1c7811275071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cd76d847-8bdc-460e-aba2-4be87881cfc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cd76d847-8bdc-460e-aba2-4be87881cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_c70b7a35-ba36-41dd-bb81-dafe47af9d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_SharePrice_c70b7a35-ba36-41dd-bb81-dafe47af9d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1944cfaa-8982-4bc8-b824-d1602c663b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1944cfaa-8982-4bc8-b824-d1602c663b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_218f4edd-a090-4a95-9d37-740694dec3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_218f4edd-a090-4a95-9d37-740694dec3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ac1663b2-1d83-4e2a-abaf-e8057f330f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ac1663b2-1d83-4e2a-abaf-e8057f330f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b963fd3-22dc-4f3e-a929-c75239349749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1b963fd3-22dc-4f3e-a929-c75239349749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_abf27a5a-8c9d-4a23-8bf0-7a9dc71448d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca133d07-98fb-4450-a149-52c08bb5f874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_abf27a5a-8c9d-4a23-8bf0-7a9dc71448d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansSummaryofStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_42d86dfd-5fb5-472e-9fde-5da22a3886f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_42d86dfd-5fb5-472e-9fde-5da22a3886f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ae98f16a-b45f-494c-ad61-11e6ccc06eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:to="loc_us-gaap_PlanNameAxis_ae98f16a-b45f-494c-ad61-11e6ccc06eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_54ae051a-5f04-4250-a936-dbe4b2aca69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ae98f16a-b45f-494c-ad61-11e6ccc06eef" xlink:to="loc_us-gaap_PlanNameDomain_54ae051a-5f04-4250-a936-dbe4b2aca69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_c38ad815-9e23-4a33-9a2b-173e496e0daa" xlink:href="imux-20201231.xsd#imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_54ae051a-5f04-4250-a936-dbe4b2aca69e" xlink:to="loc_imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember_c38ad815-9e23-4a33-9a2b-173e496e0daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_VSOPAndVSOPSBMember_cc18acde-6b45-4969-ad44-55e8dddf5256" xlink:href="imux-20201231.xsd#imux_VSOPAndVSOPSBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_54ae051a-5f04-4250-a936-dbe4b2aca69e" xlink:to="loc_imux_VSOPAndVSOPSBMember_cc18acde-6b45-4969-ad44-55e8dddf5256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_928953c0-ae4e-4ed0-babf-b85dafa5c2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:to="loc_us-gaap_AwardTypeAxis_928953c0-ae4e-4ed0-babf-b85dafa5c2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_928953c0-ae4e-4ed0-babf-b85dafa5c2e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsImmunicAGMember_982901b2-f3ce-4660-b613-9857fe4a891f" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:to="loc_imux_EmployeeStockOptionsImmunicAGMember_982901b2-f3ce-4660-b613-9857fe4a891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member_0e57a242-9c63-4ede-bfc2-8ecf98fe9988" xlink:href="imux-20201231.xsd#imux_EmployeeStockOptionsVitalTherapiesInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:to="loc_imux_EmployeeStockOptionsVitalTherapiesInc.Member_0e57a242-9c63-4ede-bfc2-8ecf98fe9988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bec09d62-6b44-4afe-a23a-5ea6936704ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2f863ff-fede-45c0-95cb-244afe885f50" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bec09d62-6b44-4afe-a23a-5ea6936704ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df30af9d-5ea4-41f4-a76e-5b2b97773ae9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0946b32c-fce3-43d5-81c3-9d3af671d2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0946b32c-fce3-43d5-81c3-9d3af671d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_12e88a11-5e73-4022-be31-900173dade8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_12e88a11-5e73-4022-be31-900173dade8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e9deb2e3-0e5d-440f-ae41-7558cc6627f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e9deb2e3-0e5d-440f-ae41-7558cc6627f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d799be99-d93f-4f06-b08b-936da2adb1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d799be99-d93f-4f06-b08b-936da2adb1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0927cde-fe2e-426c-afa1-1dbcca3090f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0927cde-fe2e-426c-afa1-1dbcca3090f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod_7946ed8b-fcb4-47e5-81ce-29b7f64b4fbb" xlink:href="imux-20201231.xsd#imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod_7946ed8b-fcb4-47e5-81ce-29b7f64b4fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_91f27f92-863b-4245-a612-c7e9afccbd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_91f27f92-863b-4245-a612-c7e9afccbd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_794ec42b-7e2f-44e4-a8f8-1bebb504096a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_794ec42b-7e2f-44e4-a8f8-1bebb504096a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_da450320-03fe-4125-815d-dcca5d00101d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ddadd1a2-bbe6-44c1-af45-7edec1f92748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_da450320-03fe-4125-815d-dcca5d00101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5319e4e1-aed6-4487-9d6e-a2f3c0bae87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5319e4e1-aed6-4487-9d6e-a2f3c0bae87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e32d297e-a816-4aa1-b427-3d3e5f9e9858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e32d297e-a816-4aa1-b427-3d3e5f9e9858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f8158d27-f1c1-4055-8254-c25bfb0eb523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f8158d27-f1c1-4055-8254-c25bfb0eb523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_fef4ab61-14a8-406f-b5e0-321a04637db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_fef4ab61-14a8-406f-b5e0-321a04637db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a734ee17-21c5-4923-8621-5ad9cdd62f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a734ee17-21c5-4923-8621-5ad9cdd62f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_91da6ea2-f0ed-4a72-aad5-7229db0c116a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_91da6ea2-f0ed-4a72-aad5-7229db0c116a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4388d669-8fda-4cb2-8d55-386b6a45ed4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4388d669-8fda-4cb2-8d55-386b6a45ed4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice_0a96596e-aae7-4431-9b4b-06eaf19e0a2e" xlink:href="imux-20201231.xsd#imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice_0a96596e-aae7-4431-9b4b-06eaf19e0a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa365f5c-6100-4298-95be-56ca8e5a8295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bda142ad-86ab-41f7-9645-c41381f27899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aa365f5c-6100-4298-95be-56ca8e5a8295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b2500ba8-2f6b-4105-83ea-650b8e93b321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b2500ba8-2f6b-4105-83ea-650b8e93b321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3708f3e1-4885-4ece-a0ef-3c86e8d94505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3708f3e1-4885-4ece-a0ef-3c86e8d94505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279382eb-7094-4610-b689-aa86620c111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3775605c-d277-4f7e-8e03-a97d49d3b9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3775605c-d277-4f7e-8e03-a97d49d3b9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d7167a3d-da8a-49be-aec8-0e3d52dab1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d7167a3d-da8a-49be-aec8-0e3d52dab1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5d62c1a6-178d-41cc-8371-845422135e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5d62c1a6-178d-41cc-8371-845422135e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9e89ca5e-bf8f-44a3-8086-9fbeae737971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9e89ca5e-bf8f-44a3-8086-9fbeae737971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ddf65722-b14d-4f18-994f-a11eaec775ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ddf65722-b14d-4f18-994f-a11eaec775ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_88bc767d-bda1-439e-9c32-662f022133f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0018d56a-a834-4002-ac08-effd48cf0449" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_88bc767d-bda1-439e-9c32-662f022133f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28cef514-2e24-4296-bbfd-65ea304169c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f69a5fd-5223-46d9-8ad3-c2a814240341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28cef514-2e24-4296-bbfd-65ea304169c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f69a5fd-5223-46d9-8ad3-c2a814240341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_306c0f15-114f-46f5-854b-0e16b6d60b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f69a5fd-5223-46d9-8ad3-c2a814240341" xlink:to="loc_us-gaap_PlanNameAxis_306c0f15-114f-46f5-854b-0e16b6d60b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0886d3df-1c2b-4675-84e3-ce5b938fd2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_306c0f15-114f-46f5-854b-0e16b6d60b21" xlink:to="loc_us-gaap_PlanNameDomain_0886d3df-1c2b-4675-84e3-ce5b938fd2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_A2019OmnibusEquityIncentivePlanMember_e340ee7f-a9fc-4e6b-8236-bb9fb9f89e39" xlink:href="imux-20201231.xsd#imux_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0886d3df-1c2b-4675-84e3-ce5b938fd2eb" xlink:to="loc_imux_A2019OmnibusEquityIncentivePlanMember_e340ee7f-a9fc-4e6b-8236-bb9fb9f89e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f69a5fd-5223-46d9-8ad3-c2a814240341" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_443ffc1a-cd48-4779-8dd9-977f853df84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_443ffc1a-cd48-4779-8dd9-977f853df84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c83153b-7bcd-446d-a8de-7477756d30bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c83153b-7bcd-446d-a8de-7477756d30bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95816fea-0f9e-4682-81dc-5f971d428800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95816fea-0f9e-4682-81dc-5f971d428800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3b33fb1-654e-4f7e-8ad9-a81559ef624a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e77f1eeb-5232-4d65-be5c-7fd4aa9d1f6c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a3b33fb1-654e-4f7e-8ad9-a81559ef624a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c35e31c5-2ef2-48ee-ab83-8c26d8b21677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c35e31c5-2ef2-48ee-ab83-8c26d8b21677" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3d3d8078-99f4-4e10-b3ca-a411ac9112aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:to="loc_srt_TitleOfIndividualAxis_3d3d8078-99f4-4e10-b3ca-a411ac9112aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_854912a9-959b-47a3-afa8-01f2d82cf855" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_3d3d8078-99f4-4e10-b3ca-a411ac9112aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_854912a9-959b-47a3-afa8-01f2d82cf855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EmployeeMember_2129362f-8d33-450e-b513-9a37fdf0febb" xlink:href="imux-20201231.xsd#imux_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_854912a9-959b-47a3-afa8-01f2d82cf855" xlink:to="loc_imux_EmployeeMember_2129362f-8d33-450e-b513-9a37fdf0febb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0804269f-4aaa-4c91-9b75-ada0b127fd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0804269f-4aaa-4c91-9b75-ada0b127fd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d294982-332d-47c9-912d-0006450a1a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0804269f-4aaa-4c91-9b75-ada0b127fd39" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d294982-332d-47c9-912d-0006450a1a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8cd2431a-b6e2-42cf-88dc-68f7d31a268c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d294982-332d-47c9-912d-0006450a1a6a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8cd2431a-b6e2-42cf-88dc-68f7d31a268c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c62a5a7-12bb-4b9e-a0d0-410c2dbf3e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d294982-332d-47c9-912d-0006450a1a6a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1c62a5a7-12bb-4b9e-a0d0-410c2dbf3e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5cc11065-26b7-4fdc-ab5a-bae959895e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efb7bf2a-6980-4853-9ad0-6d4457032648" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5cc11065-26b7-4fdc-ab5a-bae959895e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f44261d6-b63e-40ab-b72a-f77dbf4eb339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5cc11065-26b7-4fdc-ab5a-bae959895e02" xlink:to="loc_us-gaap_ShareBasedCompensation_f44261d6-b63e-40ab-b72a-f77dbf4eb339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxes" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_41b4c975-2de8-4498-9ef7-a4489ca2b751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_51c04440-0ddc-41c4-afd1-21aac62f28af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_41b4c975-2de8-4498-9ef7-a4489ca2b751" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_51c04440-0ddc-41c4-afd1-21aac62f28af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f5426b94-57f3-484c-9828-507bf84213c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_65b80792-ed50-40b8-9538-ab8a41f77d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f5426b94-57f3-484c-9828-507bf84213c6" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_65b80792-ed50-40b8-9538-ab8a41f77d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_da702a89-9353-4c4e-bde3-a742b31e680f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f5426b94-57f3-484c-9828-507bf84213c6" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_da702a89-9353-4c4e-bde3-a742b31e680f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_91a8ec2e-72e5-408e-a2d4-87528470371e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f5426b94-57f3-484c-9828-507bf84213c6" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_91a8ec2e-72e5-408e-a2d4-87528470371e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0d0195a6-cc4d-4b6f-850b-a0f97e79a2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d0195a6-cc4d-4b6f-850b-a0f97e79a2af" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_90530295-dd7d-470a-ba8f-aed6a8aa2349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ba8995e9-4152-4dfd-9d8b-8c69dd1590a2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_90530295-dd7d-470a-ba8f-aed6a8aa2349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_2e30c974-d9fa-4023-9606-8ec5e2dea203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_90530295-dd7d-470a-ba8f-aed6a8aa2349" xlink:to="loc_us-gaap_DomesticCountryMember_2e30c974-d9fa-4023-9606-8ec5e2dea203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e939b79f-3721-4adf-897b-5f835b3ef825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_90530295-dd7d-470a-ba8f-aed6a8aa2349" xlink:to="loc_us-gaap_ForeignCountryMember_e939b79f-3721-4adf-897b-5f835b3ef825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e248ddf8-216c-4e54-b34f-bfb776a0b859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e248ddf8-216c-4e54-b34f-bfb776a0b859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e248ddf8-216c-4e54-b34f-bfb776a0b859" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_e58fd2c0-5829-48d3-8df6-4cc70fa30d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_e58fd2c0-5829-48d3-8df6-4cc70fa30d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_7168213f-5de1-4f72-9bcb-32c78f404ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalMinistryOfFinanceGermanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:to="loc_us-gaap_FederalMinistryOfFinanceGermanyMember_7168213f-5de1-4f72-9bcb-32c78f404ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_ForeignExcludingGermanyMember_889a102c-de93-4125-a9be-50e07a50c38a" xlink:href="imux-20201231.xsd#imux_ForeignExcludingGermanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_518ce0bd-9c75-459a-8d66-90e74664cbe6" xlink:to="loc_imux_ForeignExcludingGermanyMember_889a102c-de93-4125-a9be-50e07a50c38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_491a0c77-0501-404a-b09a-2ba4e6ff1d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_7bbcea6c-b223-4fa0-a020-ae908d1f41b8" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_491a0c77-0501-404a-b09a-2ba4e6ff1d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_99da5855-2506-4f51-a315-c5980001e17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_491a0c77-0501-404a-b09a-2ba4e6ff1d72" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_99da5855-2506-4f51-a315-c5980001e17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesIncomeTaxRateReconciliationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0177b8f4-2b71-48d7-83d7-ff831d53be01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0177b8f4-2b71-48d7-83d7-ff831d53be01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4c78798c-10b0-40ce-a339-2d71cdd8c474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4c78798c-10b0-40ce-a339-2d71cdd8c474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_95f0dfd0-564f-4935-95e4-789013e79d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_95f0dfd0-564f-4935-95e4-789013e79d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a0c74c84-44d9-4685-9eb3-c5d5681bcdca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a0c74c84-44d9-4685-9eb3-c5d5681bcdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_cce898e6-15f0-4ceb-ac81-d023b94e9e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_cce898e6-15f0-4ceb-ac81-d023b94e9e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_748bcebb-d607-4691-9ac3-4fd75cbc252c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_748bcebb-d607-4691-9ac3-4fd75cbc252c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62ef7b33-e0c7-47a2-ae12-a279f3eef5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62ef7b33-e0c7-47a2-ae12-a279f3eef5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a066812b-96a8-4dc1-98de-9b83881c6851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97beb1ca-8d6b-4ec4-9557-b0905bdcc3ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a066812b-96a8-4dc1-98de-9b83881c6851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b5057247-a878-4e55-838a-bc4fb29dd782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_c6d0eef6-adfa-4488-b476-04913c40707c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5057247-a878-4e55-838a-bc4fb29dd782" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_c6d0eef6-adfa-4488-b476-04913c40707c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_ddb8ec4a-b3ce-417f-90ab-4fd87ca6e744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_c6d0eef6-adfa-4488-b476-04913c40707c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_ddb8ec4a-b3ce-417f-90ab-4fd87ca6e744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e489df03-b2fd-42a9-8249-983f88b545d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_c6d0eef6-adfa-4488-b476-04913c40707c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e489df03-b2fd-42a9-8249-983f88b545d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_22b1ab0f-3ab4-4595-9fde-890504effe9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_c6d0eef6-adfa-4488-b476-04913c40707c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_22b1ab0f-3ab4-4595-9fde-890504effe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_b587151d-03ab-405d-a552-82f02e543d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_c6d0eef6-adfa-4488-b476-04913c40707c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_b587151d-03ab-405d-a552-82f02e543d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b0dd7a30-006b-4d25-aac3-9c99e2526a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_c6d0eef6-adfa-4488-b476-04913c40707c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b0dd7a30-006b-4d25-aac3-9c99e2526a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_362aba1d-a40c-4c92-86f5-044dade3bd03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_c6d0eef6-adfa-4488-b476-04913c40707c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_362aba1d-a40c-4c92-86f5-044dade3bd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_39da731c-9173-4b8e-8989-f2aab82a58bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5057247-a878-4e55-838a-bc4fb29dd782" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_39da731c-9173-4b8e-8989-f2aab82a58bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8e11327b-bad4-41d4-91f2-516afbe706e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_39da731c-9173-4b8e-8989-f2aab82a58bc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8e11327b-bad4-41d4-91f2-516afbe706e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e5d84de2-396d-4576-aa66-fd076bc2ef89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_39da731c-9173-4b8e-8989-f2aab82a58bc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e5d84de2-396d-4576-aa66-fd076bc2ef89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_4960735a-7b66-4885-a6d6-422f7167754c" xlink:href="imux-20201231.xsd#imux_DeferredTaxAssetsAndLiabilitiesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5057247-a878-4e55-838a-bc4fb29dd782" xlink:to="loc_imux_DeferredTaxAssetsAndLiabilitiesGross_4960735a-7b66-4885-a6d6-422f7167754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cea3168b-d4ee-4541-9939-bb1155d578e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5057247-a878-4e55-838a-bc4fb29dd782" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cea3168b-d4ee-4541-9939-bb1155d578e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3f190aed-f5de-4534-a1d1-eae01e75379a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5057247-a878-4e55-838a-bc4fb29dd782" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3f190aed-f5de-4534-a1d1-eae01e75379a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_142d9f30-8613-4bbc-9605-2fa7093fd16a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_142d9f30-8613-4bbc-9605-2fa7093fd16a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_8625e799-2b32-4b85-96c5-9bdfe8a84741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:to="loc_us-gaap_TaxPeriodAxis_8625e799-2b32-4b85-96c5-9bdfe8a84741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_f4033740-863a-4785-b961-5e6a9d415f10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_8625e799-2b32-4b85-96c5-9bdfe8a84741" xlink:to="loc_us-gaap_TaxPeriodDomain_f4033740-863a-4785-b961-5e6a9d415f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPriorTo2018Member_b5cdfb6a-cfeb-4858-a1bb-237124e6bd73" xlink:href="imux-20201231.xsd#imux_TaxYearsPriorTo2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_f4033740-863a-4785-b961-5e6a9d415f10" xlink:to="loc_imux_TaxYearsPriorTo2018Member_b5cdfb6a-cfeb-4858-a1bb-237124e6bd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_TaxYearsPost2017Member_d6b222ac-10e9-4be9-ab43-9f98aefe98b6" xlink:href="imux-20201231.xsd#imux_TaxYearsPost2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_f4033740-863a-4785-b961-5e6a9d415f10" xlink:to="loc_imux_TaxYearsPost2017Member_d6b222ac-10e9-4be9-ab43-9f98aefe98b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d230c6a7-9e52-47f0-a6b3-896238cb6977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d230c6a7-9e52-47f0-a6b3-896238cb6977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_224b94a2-f55c-4086-be84-666922a8d76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d230c6a7-9e52-47f0-a6b3-896238cb6977" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_224b94a2-f55c-4086-be84-666922a8d76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_b56f17b4-90ea-4c65-beaa-748cde3c43c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_224b94a2-f55c-4086-be84-666922a8d76d" xlink:to="loc_us-gaap_DomesticCountryMember_b56f17b4-90ea-4c65-beaa-748cde3c43c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_a5e11bcd-7133-46b6-abb6-c596d9b988a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_224b94a2-f55c-4086-be84-666922a8d76d" xlink:to="loc_us-gaap_ForeignCountryMember_a5e11bcd-7133-46b6-abb6-c596d9b988a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2d23d94a-c6a8-40a1-a509-6ee276734fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_577740db-1f7f-4bea-b763-85e275bb90c9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_2d23d94a-c6a8-40a1-a509-6ee276734fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_db22d322-4538-4a30-98e1-ca32b1e16e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2d23d94a-c6a8-40a1-a509-6ee276734fd2" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_db22d322-4538-4a30-98e1-ca32b1e16e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_85e29ac6-3255-4c88-8a42-2118e0dba0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2d23d94a-c6a8-40a1-a509-6ee276734fd2" xlink:to="loc_us-gaap_OperatingLossCarryforwards_85e29ac6-3255-4c88-8a42-2118e0dba0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/EIBLoan" xlink:type="simple" xlink:href="imux-20201231.xsd#EIBLoan"/>
  <link:presentationLink xlink:role="http://imux.com/role/EIBLoan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b8c362a7-5f8b-47a7-8cd7-e201b5ff5d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_21e69343-3b28-4d5d-8ee7-113bb007e4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8c362a7-5f8b-47a7-8cd7-e201b5ff5d00" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_21e69343-3b28-4d5d-8ee7-113bb007e4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/EIBLoanDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#EIBLoanDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/EIBLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ba916036-d1cf-492d-ab8f-9955a4b4bab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba916036-d1cf-492d-ab8f-9955a4b4bab4" xlink:to="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_85a846d4-a0bd-4741-be38-59b1851b101a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_85a846d4-a0bd-4741-be38-59b1851b101a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9bdb0411-96c6-4a46-9486-8c738960b8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_85a846d4-a0bd-4741-be38-59b1851b101a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9bdb0411-96c6-4a46-9486-8c738960b8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_eaf9c4b7-b32d-4010-a2c7-ca539d7f49c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9bdb0411-96c6-4a46-9486-8c738960b8a4" xlink:to="loc_us-gaap_LineOfCreditMember_eaf9c4b7-b32d-4010-a2c7-ca539d7f49c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d56f65a3-52c5-4d1b-a6a4-28be8283665d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:to="loc_us-gaap_DebtInstrumentAxis_d56f65a3-52c5-4d1b-a6a4-28be8283665d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5877377a-ddab-40e2-8bb8-e4b9c213c000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d56f65a3-52c5-4d1b-a6a4-28be8283665d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5877377a-ddab-40e2-8bb8-e4b9c213c000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_EuropeanInvestmentBankLoanMember_c27454c7-3282-4725-8769-44ed89959d4e" xlink:href="imux-20201231.xsd#imux_EuropeanInvestmentBankLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5877377a-ddab-40e2-8bb8-e4b9c213c000" xlink:to="loc_imux_EuropeanInvestmentBankLoanMember_c27454c7-3282-4725-8769-44ed89959d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b2dfb623-48fd-4557-9d91-bf391398c7bb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_31d752cc-507d-4b87-8413-9fc4ce774f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_31d752cc-507d-4b87-8413-9fc4ce774f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityNumberOfTranches_1d75dbfd-4bb7-43c7-bade-49da95f19ee4" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_imux_LineOfCreditFacilityNumberOfTranches_1d75dbfd-4bb7-43c7-bade-49da95f19ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityTranchePaymentDeferralTerm_576ad346-ae23-4e9f-a270-7157da229332" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityTranchePaymentDeferralTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_imux_LineOfCreditFacilityTranchePaymentDeferralTerm_576ad346-ae23-4e9f-a270-7157da229332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityRevenueShareCapFirstTranche_f9b854f2-fe6c-4506-bf86-9f9eabf26498" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityRevenueShareCapFirstTranche"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_imux_LineOfCreditFacilityRevenueShareCapFirstTranche_f9b854f2-fe6c-4506-bf86-9f9eabf26498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn_952fdb67-c4c0-4694-9a3b-ccc98af9a22c" xlink:href="imux-20201231.xsd#imux_LineOfCreditFacilityRevenueShareCapFullyDrawn"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cced73c4-bb59-48d5-af44-e26531929a9d" xlink:to="loc_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn_952fdb67-c4c0-4694-9a3b-ccc98af9a22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="imux-20201231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://imux.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1e693159-dad5-46c7-8a55-ae78c2658833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b0930cff-d7e4-4e41-9396-bac66d822619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1e693159-dad5-46c7-8a55-ae78c2658833" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b0930cff-d7e4-4e41-9396-bac66d822619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="imux-20201231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f7858f63-bd89-4948-b4e5-3a8deb58e1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b51a9094-78a3-48ae-8d28-ad7c0650efce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f7858f63-bd89-4948-b4e5-3a8deb58e1c6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b51a9094-78a3-48ae-8d28-ad7c0650efce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b51a9094-78a3-48ae-8d28-ad7c0650efce" xlink:to="loc_srt_TitleOfIndividualAxis_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dd229686-bbaf-4558-891f-ee28879471a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_aa55cbb4-5b4a-4a4c-aecc-0f04265143f2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dd229686-bbaf-4558-891f-ee28879471a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_8a9d2f07-6577-49dc-ae04-559086af71f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_dd229686-bbaf-4558-891f-ee28879471a7" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_8a9d2f07-6577-49dc-ae04-559086af71f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8f935bf4-e671-4bc6-8420-49c85cd06e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b51a9094-78a3-48ae-8d28-ad7c0650efce" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_8f935bf4-e671-4bc6-8420-49c85cd06e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_imux_SalaryCostsMonthlyBaseSalary_c19ef2da-638e-4254-af9e-eb8e7d94bd3b" xlink:href="imux-20201231.xsd#imux_SalaryCostsMonthlyBaseSalary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8f935bf4-e671-4bc6-8420-49c85cd06e02" xlink:to="loc_imux_SalaryCostsMonthlyBaseSalary_c19ef2da-638e-4254-af9e-eb8e7d94bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f8ad246a-8d81-45aa-80e2-3c9dc1bdaf03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8f935bf4-e671-4bc6-8420-49c85cd06e02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f8ad246a-8d81-45aa-80e2-3c9dc1bdaf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunaudited" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunaudited"/>
  <link:presentationLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_37cfe18a-7a41-4026-a1f5-6f18734381e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_ecfa426c-3cde-4f9c-bbac-bba0578269a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_37cfe18a-7a41-4026-a1f5-6f18734381e5" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_ecfa426c-3cde-4f9c-bbac-bba0578269a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunauditedTables" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunauditedTables"/>
  <link:presentationLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_a5fb939d-813b-40b6-baa0-0b9318e08c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_147f0cf0-b130-46b0-aa5d-acf1e6c5767b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_a5fb939d-813b-40b6-baa0-0b9318e08c25" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_147f0cf0-b130-46b0-aa5d-acf1e6c5767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail" xlink:type="simple" xlink:href="imux-20201231.xsd#SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail"/>
  <link:presentationLink xlink:role="http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_53a67039-bac1-46a2-abba-2619a8efea56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_128a665b-baeb-4f45-b61f-bc912f0d7459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_53a67039-bac1-46a2-abba-2619a8efea56" xlink:to="loc_us-gaap_OperatingExpenses_128a665b-baeb-4f45-b61f-bc912f0d7459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b515d3bb-40b8-4407-b37a-e60a9ee54918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_53a67039-bac1-46a2-abba-2619a8efea56" xlink:to="loc_us-gaap_NetIncomeLoss_b515d3bb-40b8-4407-b37a-e60a9ee54918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_ee0f0268-b11f-4564-b752-0cd51c0fdf64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_53a67039-bac1-46a2-abba-2619a8efea56" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_ee0f0268-b11f-4564-b752-0cd51c0fdf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>imux-20201231_g1.jpg
<TEXT>
begin 644 imux-20201231_g1.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M:V5T(&5N9#TB=R(_/O_N "%!9&]B90!DP     $# ! # @,&  *NF@ $)64
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M@%$SJ-A")76ED&%B0[-TM";'Z$G04X4GAQEYP%*@L&-Q@7)D14=79R@2  $
M!@D" P0&!P4&!00#   !,0+2 P31DC.3TS24!35!-I'4E8 1HW5@(:$RL[1P
M$G*RPW0&0+&B$W.0T,&#%'; 46%Q(C"!0E/@(T/_V@ , P$  A$#$0   +_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              !^(>6_GZ
M
M
M
M
M
M      !^^>G?OX      .)O#RJY_/[P
M
M
M
M
M                                                           .
M]//PLX_1Z0     !YI^?O#_AY
M
M
M
M
M                                                      >J?OYV
MOY^(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       %)(AQ
M /7RTF6"0                          4&S@\TU      1T%!LMFDZQEN
M%CDNA       \7.:#K\] *'1#H:J
M                              !\N9E@  .QS0T            .$#[@
MZW                       !2Z(20#U<L^%B@         X0,_,M2EE8S!
MSMPT'    5Q2E\:#A*^      #,$)MBZ*                  5J2JT ?6D
M]A;6/["B&<;FD(              "/ J)%UTZ?                    *Z
M)4R /IR=<MUGZ11J(Z#2L              (6BM0?4%GLE9
M                ,\LXX .E2W>2[G,!G1EE8M2@             ^#*CA'D
M2/ELT]                      ,H0K!$E1^@<"GPIK(%F(
M              QQ2( WN0     0@&.,:/9<5,>TM0E]D      %,(S1#7Z)
M_C.+(+#9'
M           /B3%[!S4<K'<IZR2&&M<            80Q-\:W8
M              ,L0JA$D!^X<%'G1JL%IX        $0!C#&AV7O3(@) S3<
M   !5=*$YIN$SP      , <M>FIV                  40C/$.Y3UDY".?
MB^Z:#9D"D8!N<@             ^1.&#.!*S1M<DGX
M !2",X0[:/9#DPYT+SQHM&2(0@F[R             "N:9)IT6?@GDAK+%CP
M                            &**1ODD!^:1WG[QLSGK!B#%[PT/
M         9*!7(.ZC@,G[-?D_P!                     90A6"-W@Z (:
M#&>+;IJ-E+HD7/*3BDNM'&Q4!.%B0DN#G4 .+RE^>7EN\KYDT9.T4NB1<\I.
M*2ZT0.%8@^')FBV,?9%44_#.W2L\2EELTIQ'"Q:W)D0     #'%(@#>Y(7""
M4L4%1H_-+A)*&".@IO'^A,Z93QH]ET4I=$M183/\2K"0(GK!:?)FP1&%4 \/
M)5RW*>0&?,4Y2_672"%XX$+L(."BHB<9$EI<'/?#CLJC$]17E.'BR\6,
M                                                     40C/$-;
MHL? CP*B!R>2-ENHZI()2%PLX%+@O>GWI2V.$"V&12G4Y:"/^2L65[STPM8D
MQ)7$,I4DE-'(L'                       &6(50C<X.P"*@Q7BTZ:K92Z
M)%SRDXI+K1&T5$CGDF^+81^P?\E7DK]GI!:-)MR( QAC0[+WI36.BRT\5T2,
MPGV*?![270#LDB4*]I:>.WSGLIP$>Q(67 SIX_G*JI!*?4%A@LE'_1@#EKTU
M.P                 "B$9XAK=%CX\9,/HZ1-MHR!2, U9BJ4=IEU$]D/\
M,JVD!Y^T6!"S(?Z'*)3>.'CO\M[G70(PBHX>&DZ!:R/T  4 R@& ;7))^
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M<)'C4(**Q7!-[DCL,:,^)).R)$DJ-E@B6,<8ZK.N3@ \@-C,F_
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MX&H0543*U-(TNU@
M          %$(SQ#6Z+'Q%@4DBWZ3+F2Z5T3?$,_<HAEZHO6'%1B_%O$U!2"
M(QYBQZ:GIA7EELU<3R4Q/"0<V&#"&)OC6[                       !EB
M%4(L]GWQ"Z1T&BZ7FS"&/QS7")<S,,*T)MSG8QG E(<VH3&S)AS8.. C+.+1
M)8R,88T.R]Z88Q)^:_1F"%0(V+2<LR%"OH;XQ3R,T0U^CB$RXS3/+E)2@*DA
MIOE=,Y%-#\A*,;XO$&C@8 Y:]-3L                  HA&>(3\'8I&P0T
MEM\U&3(%(%3;F.\#$C/C#<=*3IP":+!$@8OQ=(+BYC0%K\T02/D@!+H1F5$
M)MSG4QF@E,\W!CN@  SPRB&;7))^                    4@C.$)XCMLCN
M(4RT^:K)DB%<@VPR2DQ4SE0W72F(1?&C41M&)\7"2\L8L!:/-&(XH*\)<C,T
MD@!-N<ZF,T$IGFX,=T  'QYF9E0,T@2[N
M #%%. RSV?EE?DY<-=PD=,08L,FNR0$F0&7V"]H9UY8:+3!G/E'$V12HX4G3
M4B+/!3@/1BT6899:K-34\-,2@EP-=D  X(,0X_/+KQI-
M     &4(5@B68_8/:"S:7D3]0PAB90UY09$I!\;S8/G3 I+3I)J4+3:9)7R.
M0Q(B]X:'AA#$RAKR@X_,YX@).3#_ !)EC8Z,<4Y -ODX_,,<N^&CX4PC-$-;
MHL?      QQ2( WN2B$9XALYDPI0#* 9L\E"<JO&^<?5$"QCX&CV6_3"'+GA
M=9,6HOO&@T #QLSKRN&<-'[I[^;G)3",T0U^B?XRA"N";W)C2G'QN-@Y=,*D
MN.EQPQQC1U+P9 "9 IH]EWT
M                   HA&>(:W18^/G3/M*N)'H?N'G!O<% ,HAFV>24E5<R
MKS4:+;P,&HG:-!@QJCV4]:!S@>\FZ>80Q-\:W8
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M1FB&OT3_ !E"%<$WN3(?(2C=K/JB+HQ3"\L6HS'&-'LN^D )D"FCV7?0
M                                                   "B$9XAK=%
MCXI]F867[2Y:9X!4D-[@H!E$,V^3O\KCF1^:()>W.?3"?+$YHS&*X70BYN ?
ML$LYA#$WQK=@                       RQ"J$;G!V   80Q-\:W8,:\XL
M-:0 'U1BN%SPTO#SDJD$F)Z:8PQH=E[TPQB3\U^C,$*@1O<'H!EB%4(WN"H$
M9HAK]$$9GPFQR3?D31#.64#'L//#4D.NS$K+OAH^& .6O34[
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M(%-'LN^@
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MR(:RY5!("3;"/X3.?*6A\ =#FA8712'@RC2_87#2$$RQ"_87#0
M                                             "ET42S4#)]CA(R%
MB-TE )SBO@:W16**71L-';X(0C.(.)"VX4JR<PUNR*0S'"$<_H+$YJ+G6!F<
ME2HL!&LR                       9M96:-E$ZH  ,74F&-00'Q)G)E.8^
M".XS3!+*A"X99!'"?6%S(TC"+XR52]H713&M)%S4[,Z,JQ&V"?<&;65FC;!*
ML1GMFIV3?%"XH3GF!V2:<Y9(**QGI'_)=<*UQ.T:>9B#%F4TE
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M$9D1#"?W%D4U#SI8 %'@S\SQH]Q-#0NI@
M'S9S>=,'[@(S"MJ3>$X)5U,I$T>R[Z  #XT\M.A                   >*
MG[AZ<   #_,YA/8#T( _#/ 3IH      ^3.=SJ _4
M                                            /XSF<Z>/]@  #G,J
M'$BI9H([C$>+>YI]@'@)^T>R                                 'Q)
MX>=0'^P!_P G,9ZL>D          'RISR=1']P!Y&?\ 1ZT
M                >4G\I[   ?*G-YT4?8  ^#/&3IX_T
M                  /+S\D]F  /F3FLZ&/M  ?!GC)T\?Z
M                             ',I[\?N  'B)\:=-'^P .>SZ8]>   /
MGSFTZ4/W@                              #D QCSFPDJ(S3K4V4CL,
M
M                                               _!,<LAE)1#A8_
MA->8FY
M
M
M                                                /!RMV<B'9Y8^
M/:@
M                                                   #X\KCD>QT
M(6)SL8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                             '#'AY\9^/D
M                                            /S#^?\
M                                             #_ _+
M                                              /RC_'\
M                                               #^<_,?H
M                                                 'Y!_D
M                                             #J#R\9F_;ZP
M !!_ZO;#KZ?8
M /TOU_2
M  #_ &/U0
M    #]7]_/\ <
M        '^Y^F
M         ?K'^H
M     .Q_/PG\]WJ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                           $
M6 )3SDLXT!*2?; C"//3V D?.$#F\DW/2 <-G,A)6>J   \O/-SI@ '\YR^>
MW'W0 /C3P4ZB/Z@                              #^4^?/J@
M
M                               "JQ.&H."^35?8
M
M                                                   %V2M^^CSC
ME\7                                              $C.HY.>@\3D
M@      Q!@;?)1",\0&N06,#\4PACQHG^-?HS!"H$;/)+^#-#*89L<DWX /Q
MS,K*AY^&2H&K.2@D.1E.$>Y]L7:C14/]"@D4-SSP[7-1LL#        SORN*
M:UAV< 0:&:@7/2YZ   5>2!LT:B. ^P.[RFN<O%\D   @;*:YJ&     'Q9F
MXE2 \L).C0,+5P  !\28O9M=            J&D>1?\ P
M                        "&(SX0#[0G@+KYZ0#.S)^"RH 1?&? :L /-R
MA$58#E0[1+5)>Y/O#Y$R<@#] E/+OYVZ"I$<,E\, &3B:/9(F
M       "JQ.&H."^35?8
M
M                           %V2M^^CSCE\7
M                         $C.HY.>@\3D@      Q!@;?)1",\0Z#+M1H
M%D.1C8'IY,F:_1F"%0(V>27\&:&4PS8Y)OP 56S*K+Z1.P9;1.<:TIC5G)QH
M\E.XK2&O4=3F+@6WBX69I!\^;<@       ,L0K(FAL7<P#-9*?A>M+_@  !4
M"*X)J=F<&=?E[TBV//28L   K@E$,U^@    "A@5WC4V.D"LR991M#$GX  /
M/S!'-_@           $9AXB30@
M     %<$R_#4#!SJ4FSZDUZS]@R!2UZ7/0"$ R13=Y/YS)(.9C10)-"*<SC2
M0TUCSX$P1S4#.MSX,JVE<XV8CMLH!D8!J=@ P1C8Z)?P
M  56)PU!P7R:K[
M
M                      NR5OWT><<OBX
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M%-(O'G9I1T(<R24O)'5Q_P E.<KD'NI=E)=R$$Y?++QPD45CC(FT+PI]4
M                                  5P3-$-OD \A,1PTFRU,9 I:]+G
MH!" 9(IN\E9<S%#;1.@@#AXQ+C6R)P#!'-OD[_ ,EX[]-*0H!D8!J=@ P1C8
MZ)?P                  56)PU!P7R:K[
M
M                                          NR5OWT><<OBX
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M!GB&VZ4W", TO#%U+A),D49R8(T!0
M     "N"9HAM\@ R_3U(TL#(%)M"T. 11&=$;O)FDGR9IQ  &283<E[HP1S;
MY._P"GV453:N* 9!,:"P ,?<V2"7\                  %5B<-0<%\FJ^P
M
M
M       +LE;]]'G'+XN
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MBSX1>&/2;F)]0#&[+[!$:5S34;.]2%DE6*:1& :7A@R&D26VCR XW)7P
M                                "N"9HAM\@ SN3A0U,3(%."CK4 \=
M.(C=Y,HHEO- 8  R^#I4T,C!'-OD[_ *VYF,&Y>4 RDX22@ A/-FLE_
M             !58G#4'!?)JOL
M
M                                 "[)6_?1YQR^+@
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M&1@&IV #!&-CHE_                  !58G#4'!?)JOL
M
M                                                     "[)6_?1
MYQR^+@                                             "1G4<G/0>
M)R0      8@P-ODHA&>(;/)1T*P1Z@;FYAC$GYK]%' SEB[D:,QR*8Z!QP;J
MQ[T #+&*I!MJDAID&D%IM]&'B6L34S(&#'P+VAZ44 36F+*1F7E-<VAR7$
M     RQ";XNYF'Z7K"LH:Y9FAG8!?\,$8W,3H@@V,H\W.2H$5P34[,X,Z_+W
MI1".0#1\,,8UX"5D&7 32$GI1#-?HPI#6\)GP1;'U!)" #!N-?PF5 ,T\_6+
M-QG!FU0#G<I\%T\P1S?X,J(G +SH.1C@<FQ,44U.R7\@7,Q<VT #&K-  Z].
M[#I\AR,KXT4C@HC -%8B()W3P4I8%00VQ
M          "N"9HAM\@'C9B,&HF6.#(%+7I<] (0#)%-WDJ8F=<;:IZ4 1\&
M)P;/)(J8(YM\G?X!DG$O9H;% ,C -3L &",;'1+^                  "J
MQ.&H."^35?8
M
M                  %V2M^^CSCE\7
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MQY5-*V!L_G6!0#(P#4[ !@C&QT2_@                  JL3AJ#@ODU7V
M
M
M      !=DK?OH\XY?%P
M    !(SJ.3GH/$Y(      *Z(+%Q&H16%@8^2()B2LE3*WI[(3O \A*M)&>>
MBD_Q/"   16%8 ^#)SBQ\?\ 1^.59R(LZ1+7IVL#ATJC'.Q+86FC]X
M %) DE+)1$L4+32S.B"G(>_%IT@$* !_R79"NR:7Q 21#%V\AL,\DN4GUAX$
M6\3#&+M!4X/2B_X64B(8K&%^P^',\\K-G0A><+5@ !\J4/BKL>'$EQ=!+.P(
MAC.5.!2=,T=#VPR[C4[!36*4A\Z6K2_*?J&<J7;SOL$7AG&D9Y)L:)Q+">!F
M;<0<GII<3+N96U.+BXV5D2AF<G$J!HZ$DX
M          !"B9V8!]F3W%XL].!G!E@XLW $6!G9FLV#P,SZ2L$<PD@)<;+O
MI^H?'F1J ?H$JQ>G.[05 CA OV  R-#2L)'P                  56)PU!
MP7R:K[
M
M              NR5OWT><<OBX
M            D9U')ST'B<D
M            PQC8Z._P
M
M         5EYF53PMR+@F
M
M                            !<3KZNZ\^Y7&@
M                          !W_JR1WW?%Y"
M                          !AC&QT=_@
M
M
M
M
M
M          '#!V.?0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  '\IR^>Q'I
M                                            *MLVJCX/9*P#
M
M
M    OE5?=A[HK$=G
M                                        42SE<T7  8@QKQ')!0H-
M:4           $:A\&2SE4HK[&E\        ?\E' H>GFI\F6-#3A.M    8
MN9K2D;Q2<-6LC4/@R6<JE%?8TO@
M        "'0H'@'VA/ 7,3[8&?&3Q%CH C,*!QJ2 ^)**!5@.5#M$M4EXD^L
M/DS*P /T"4\NPG78*H1Q&7F0 95YHDD@X                  *K$X:@X+Y
M-5]@
M
M           7Z*L^QAT?B&T
M                                               ,\,Y -/L & .;
M7)R 9X9L=            HA'(!H^'%!RZ2\@       %(@HMFJ03HGB)FK'#
M)K_@   PQC8Z/7B/(FN*(1R :/AQ0<NDO(
M               !7!,O0TRP<ZE*TZ%-<,_2,@4M>EST A ,D4W>3_,R<C@X
MT.B34BF,Z<EC-6$\_,$<TRSJ\^#*N!!2;+1V*4 R, U.P 8(QL=$OX
M            *K$X:@X+Y-5]@
M
M                                7Z*L^QAT?B&T
M
M        ,\,Y -/L & .;7)R 9X9L='\92,*V)TH7H"9D_Q*;16E.FR\22PG
M'!22)T"J^:@A!L4N3G4F6+SI&L9EAYN7W21\B\):BI :,P/\3-9+]QU 4DBO
MF=REZ,D/ !\^88QIGEHH \+,OPT[SH@JZE/8_P"2W&6L@88QL='G97E)SC,L
M/-R^Z2/D7A;Q.!B@,<$DPQ?V/;
M     "N"9HAM\@'AYB/&F*6C#(%+7I<] (0#)%-WDK8F74;99TP <"&)Z:ZA
M-28(YM\G?X/^3) )-S2** 9& :G8 ,$8V.B7\                  %5B<-
M0<%\FJ^P
M
M               +]%6?8PZ/Q#:
M                                                   &>&<@&GV
M# '-KDY ,\,V.C/^("S1H(EC.B-P\HQ%= T-R/@SDC9C/*C&G+"A;I+#AB*&
MF.=WE$T[W+YYGI'.!H>$$)7!--$PPC9Z)+2#PS!#:\,V$X*+[!#J4&S:O/?
M"*PQ7#>>/6   5A3.M--X_M,T(O:%NHPQC8Z(P"B&:K9GI'.!H>$$)7!-3LQ
MNRVB6#BDH?I&E\                                       5P3-$-O
MD &7B>T&E,9 I.T6H0")0S<#=Y,U4\Y-/   R/B=$O8&".;?)W^ 4\"C4;4A
M0#(/#1  !C<FR,2_@                  JL3AJ#@ODU7V
M
M                                                      !?HJS[
M&'1^(;0
M                               SPSD T^P 8 YM<G(!GAFQL85AKF$Q
M8*5!:%,5HV,"4<&7P3*%C0QLS=+/0#PLAO+ ASJ4>B-,U.RB$<@&CX5 BN":
MG9EL$LQ?!,WTZ[+IYA8&YF=* R."XF6M "$PQ\S>_   ,AXN"EMP%5DI1FP$
M88QL=$8!1#-?HHA'(!H^%0(K@FIV8@)<-+JIZ(<<$CX
M                     !7!,T0V^0 9W)PD:F9D"D<ATV >5G*AN\F482UF
M@0  9?1TB:&A@CFWR=_@%;<S%C<Q* 92&.^P 1&FS:2_@
M   JL3AJ#@ODU7V
M
M                      !?HJS[&'1^(;0
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M0#(P#4[ !@C&QT2_@                  JL3AJ#@ODU7V
M
M                                                      !?HJS[
M&'1^(;0
M                               J(%%HVCC_ &!$,8X)O!D&IGAFP\8-
M)M3DA8*$!;I,2LVS#OX$$1V(?,F2*;?(*2!6A-9D^T*71 2:G91".0#1\*@1
M7!-3L_#,.PT+2I@:Z)QJ8=QO GK0*\)*,=L '_)B;ETDO @%?LR@C<],?<OL
M%G0%00JBFMJ88QL=$8!1#-?HHA'(!H^%0(K@FG:5URSL?-E3<SCC==
M                                 *X)FB&WR >5F(P:=)92,@4M>EST
M A ,D4W>2HR9[1MGGW@!P@8D9LP$E9@CFWR=_@&3<2@FB@4 R, U.P 8(QL=
M$OX                  *K$X:@X+Y-5]@
M
M                                         7Z*L^QAT?B&T
M
M                 /!3%*+-Y;7.5C/U)\#2L( 3/#-CHS(SS T,2O&4$3;@
M,R$^4-"\C-,P(V(CXLR13;Y!3"*B!J.$?YFWG=)JKE,HK]FDP0!E<$U.P9S9
M3N-)TML R/B2LO4$+)FW&T:=,  K6F5<7WB>HCT,[HOW%STI-%0(U S\TRTC
M0(+2QAC&QT1@%$,U^BC45^S28( RN":BIAZ&D*3G%5@J*&S@
M                           5P3,,-7('A!1./P37Y/[#(%+7I<] (0#)
M%-WD^1,;4[U-# D#(Q#-$)=#32//S!'-7(['/CRJ<55#:'.Q"@&1@&IV #!&
M-CHE_                  !58G#4'!?)JOL
M
M                                           "_15GV,.C\0V@
M
M                    (Y"A81(GIA99+QY]01H%7LO9GE9GHD$)W^:"A*:>
M<F?R5[SL$OE$Z)R$4ES0E!\69SI!J3-%ULS_ ,O.'<!G@ED4DB(JBXV",(I#
M&C,>H \#,]4A!._2_P!$MH  ()BCZ1W':)<I+.0/\2CD57#[ M^%PH&=H7M#
MD$KCEXTX0,\$LBDD1%47&R#HH3G%Q)2:$A)"
M               0?F<* ?:$]I>W/8@9J98D+1 !%$9PIKK@YI,\,K!',1(
M7&R]F?O'QIC[@'Z!*L7PR1$%.(X&-!8 &/L:;Q)6                  "J
MQ.&H."^35?8
M
M                  %^BK/L8='XAM
M
M
M                                                          5@
MIIU-PF20@6
M
M                 !>JK([!O0V)[+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                           '-68ZL\9R+!@
M
M!]!\G(]MZWWV
M
M                      /.2+P_:)1SZ@      ^//WC](     '$!\Z2 @
M        'P)]T?Z
M                    YO.6CL$]T                            !58
MG#4'!?)JOL
M                                ='X?M"_15IV,
M
M                                                      *8!G>G
M5I^.>7&H*6.      9 I>\+'P    !X"8Z9J<DN(    *P)E"@'W)/H:3!)F
M#!&-SDZ
M  !7E,J  ^T)X#1<)"09,A:2+A(!"X94!N! X",QD@>.MSDLL'&F@=QGP9AA
M 'Z!*>:!A8.!1#(TS3H !A@FNN2S@                  JL3AJ#@ODU7V
M
M                     .C\/VA?HJT[&
M
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M^35?8
M                           Z/P_:%^BK3L8
M
M                                                #'O+&)?? !1
M+(1_X4_SJ<A\-5HJ4E',\I+/!H$'W!D"EC4KMG,1;E+T)' 4/"4,J4'OIH^$
MOH !%P9OI'"2J&D<2"@ K F>&;70!_"8H)>A+E9E7FGP?1&<Z5QSW8OA%I@%
M6,H\GG):]+RY^H1R&>>11':9>S+$1\N9V96I/8B],6P@5BRB^>1EJ$O8G[P
M                                     !7!,T0V^0#\\Q42[Z703(%+
M7I<] (0#)%-WDIVE$,VLC]P \I,/HTPRRP8(YM\G?X!F7GB!J?E ,C -3L &
M",;'1+^                  "JQ.&H."^35?8
M
MZ/P_:%^BK3L8
M
M                     #!4-;TGN  ! "9(9=X+8IS$9E1K4'3YFG':YI!&
M0*>5FH6?DF/B;&!YN8S1H2EQLH^D+1KE@ &.Z7%BU84Q"OZ:SH *P)GAFUT
M#,7/L#2X,$8W.2HT5X34-(^#(G-K\A[,R4U8SHTS!2S67DS(Z+"!<;(03+B-
MW4IM%6LU.SAXR%S:$(WS+5-6(ZU,R0G^+Z8
M             !7!,T0V^0 9HI\<:=9D"G59.D <"%/XW>3,"/:S22  ,IPD
MQ+^1@CFWR=_@%4,STC;I* 96-+>( ,Z<V5B7\                  %5B<-
M0<%\FJ^P
M                             !T?A^T+]%6G8P
M
M                                                   & V;*Y,:
M " $S.3;$!EQ$QQ>/!$P9&9N9F0*7.BV #'Y+YQUR9*YN2G_ $0X&6P;6P !
MCFDAY=R)?SXD]H !6!,\,VN@ 9M)YV:;1@C&YR5"BE@:*!/X?H'JAEC$J!<]
M!7;*9)L-$7AVF<>$2QE1F_P4RBBB:+98$/H#TPS"CM8N[@@4**!LM
M                                %<$S1#;Y !G8G%AJ0F0*?IDM8!QV
M5QC=Y,I(EE- @  RXCKTT(#!'-OD[_ *UYF8&X^4 RIJ62@ 4GC9>)?P
M              56)PU!P7R:K[
M                                                '1^'[0OT5:=C
M
M
M          8@!HVEI( %"\GB/SS/#-CH&0>78"T@#B4Q-C>C,@4O>%CX&0*7
MO#K\RQ#:Z!$ 98AM=  '%!1T*XYQH7P"]* "L"9X9M=  R-BP<7NS!&-SD]B
M*9A5I(4RP8:C)D?GE9V. =SFFH9XY3^)9B7LHOF_P?EE-XJOD(9/4:CYE,G+
M)VR =<FH$                                       5P3-$-OD &4H
M2JF@L9 I:]+GH!" 9(IN\F;><_&HB  8QI<K+@Y@CFWR=_@%)(JL&PH4 R,
MU.P 8(QL=$OX                  *K$X:@X+Y-5]@
M
M    #H_#]H7Z*M.Q@
M
M                          ,ULC6-<$_L!'P8IYM!'&QGAFQT#+H)7"]V
M"MJ9ZILZ&0*7O"Q\#(%+WAU^98AM= B ,L0VN@ ?,E(0O.G^A#L8U1O?'T !
M6!,\,VN@"(0QOS::)(3!&-SDKRDM))B>/F/V7H"KL3(%[T$11&X39F**;D)[
M\<BF&";_  5@R2TE//*S(C+EI7U)$2_X"*@B@+6P
M                  !7!,T0V^0"/0Q838D)A3(%+7I<] (0#)%-WDKSF4,;
M71VN 00&12;=AT28(YM\G?X/AS&U+@9=_* 9& :G8 ,$8V.B7\
M        %5B<-0<%\FJ^P
M                                          !T?A^T+]%6G8P
M
M
M    ')ICG$F!:P/(RC86SS0C( 3/#-CH$#AE3FD:>_&=67D"WH9 I>\+'P,@
M4O>'7YEB&UT"( RQ#:Z  ,8TLTEC KDE90V>@ 5@3,:+DX.>RJ07O"]V#!&-
MSDIE%<@OP'-IFV&ND<QF6J:3)Z 9TIH(%APP[#2A.IBE\5N#9#(%2K 7_CPL
MS:C6,/BS*1-),]D,[<O:%M(
M  K@F687M >$%08M@FC8#(%+7I<] (0#)%-WD&7R00%Y0D#(Q"A^:#1<O//S
M!'+VAT.?'E88^X-?(^\* 9& :G8 ,$8V.B7\                  %5B<-0
M<%\FJ^P
M                            !T?A^T+]%6G8P
M
M                                                   YY*6!#R>S
M%H\LS X0( BW8 5]2GL?CEH$M5 J8DX)(:"IB3@GK)6++E .2RL67*  #A H
MW'"!(&7F#M0 $:A5M /NB?XF% *,!=C/WBD<0<GIQ;S+"@("BG&?QEL,LM @
M%*81T27;RO\ GU1<!*41 ^>@%MLL; @J*9Y\Z6JRSX
M                     ",XIZ 'VA/<6&@"FD2ZDW !PD4\R_R#^4J:E8(Y
MB) "X>3O@^=,^4 _0)5BU,?8 KPG*Q;' !GR%U [+                  !
M58G#4'!?)JOL
M                                  ='X?M"_15IV,
M
M
M
M                                                           (
M+)-5]1@;JB8
M                                 /8L?S>UA!NX$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                      #S$Y$)"0      #X\_,.-B0P   'QY]@    ?!
M%?L^$)P#KP             $6!*>?G%?@ %@<_1.!#J<]4 /*SE@[[
M
M
M
M
M                                                ./R#0LQ'^)XZ
M=&'R)]F?A'^Y^4>,'20.<ST0^K*@1;0/"CK\\S/1#^@_Y.7CVT_<*?Q;^/\
MDY\.GC^ _,/C#UD%5<F2.G"GZ7<#\8\).C#^\^!/-SH8^;/\3PXZ;/\ $Y>/
M?SZ@^1/%CI<_"/SC\4^T.<#IT_V/E3_DJ6EOX_Q.12)P$L9T4?.'C9T"?4',
MITJ<L$0)8^
M
M                                                      (:Y"P=
MCLVY&4
M
M             "SY"RV3ZOX>8X_(- ?E'SY)L0?ETHJQ$UI 2=F'DI[H?&G#
M1-<5E"SL1\GK)XN<DDPAPT=&D6Y8U*G1:]*_Q(\<3$T16R+(Y)P"LZ>8$P9W
ML<[E/LG%(^2R$5SCL0_-/]#FT^_.P3B\ZO(N2U05?SO\Y_.Q2)@L2D$)WD<)
M%BPK0'0QS,7+ "%H$TI3#.M#Z0FD*WY(N1=%FXB!+'P
M                       .$CBT ^P)73[(  YP.$"7X
MX(*ZI\F3>$R(   .$#X\D?           (X#[ [O        !\N5SR.@ZE+(
M1T0") [0.GP    "%$E./8         #X\A1)W@ <('QY(^       #P$B^
M/M"4T^^ (L#IDZV /'2+XFC .:RN6<J':)8H/>@?PD)P!^@22G10!Q ><DDH
M (3B5T]4                  !58G#4'!?)JOL
M
M                                              #0OJ;[+'I'$91Q
M^0: L$GP!$$?'$VQ7-._2.8]\(\2?$B8),"< J0EF0@T.8BX"1G'A9[D1CD;
M);X*S1,$?GDQA4R)93PDEF*O1*<3*'%A&N1!EKLAM+-)4M/MR?4ZF*?IV(2W
MGK97H/LSP,E-/%3M@D9*?A)P=#'ZQ7-.UB+\D[)[CIHIUEQP A:!-*4[BXB5
MP27XX?.+R+<M\$0)8^                                        !G
MAE.HD7!RZ?&&NH2=@ KRE'XUFP              5S3+*+'1]*5NBTZ:6
M!1".0#1\           ,\HZT+P(       !PT9'A_43D'!9#<:UQ-:9(A<]+
M/P    !BBFIV2_@        ')9C8FX$5M3BXN-E'XY+-#4       %<$R?28
M8'.IS ::Y:,!D"EKTN>@$(!DBF[R"LJ9<!,*2:$4Y%@:FI9"//S!')AC[@^#
M(RB\8:#I_P!% ,C -3L &",;'1+^                  "JQ.&H."^35?8
M
M
M      &A?4WV6/2.(RCC\@T!88/,B($F.*J!-X?]GUQ+60N'[Q*\0/'N)$\6
M9B#0Y"+A!!:>C$,1<H*I98U*S!.6<<D_93H)VCG$G+ *9A;@/4BF&6-R$,MA
M%.D[M)$R0,J!G:)+\>FE><[C)?2J>>]G;!,(4Y25,Z9/42*\L8D)IXH2''5Q
M4G+G(!"T":4J EOXK@DB1"$6WBE,6I"($L?
M                SPSD T^P?\F6(>BFGP >:GI0 !\N?FGW0/'SU@_H /SS
MR$]N  /GS^4^J    ,<TNN%M8' )B2FVN2 @^!/+3I %$(Y -'P \9/8C_0
M'Y9\Z?;'_)S">Z'U@ .:3TX](   /@3] ^N !\V?2   &0T=PFGD?I HQ%/8
MVIC)$+GI9D/@SU8 'GIYJ=& &**:G9+^#XL_)/2@ #Y4_'/0@ ?-GT@  *01
M& :7@ !Y6?$G10     *X)FB&WR 5;S+<-JHD),@4M>EST A ,D4W>3BDQ/C
M2U+<0!2",_4VXSV0P1S;Y._P1F&/&:0I;** 9& :G8 ,$8V.B7\
M         %5B<-0<%\FJ^P
M
M                             -"^IOLL>D<1E'@Y' "4\^/.$"6<K %E
M<_2*UYYT3,'[Q!L?J%EPKY$C)\&=)D)!_"2,G/!XN>EG;9PR2E$4YYH28G5Y
MX^2/@'(975/_ $D[.ZBJP=ADAQ*X5FS^,G%.?3N\^P(L#]$C;/N2R:5I#Y<E
M_/Z3V Z_*]ASH2*DIA6-/9CUTGL (^ 2#D$!.^1,'<I7I/I#^\DH/E26<
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MY0#(P#4[ !@C&QT2_@                  JL3AJ#@ODU7V
M
M                                                       !H7U-
M]ECTCB,H          K+'0Y':6:3HL        ''Y$"6/@
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M8DYO"F=.?/FET<UF. 6XRYX8HQN\E((C -+PHA'(!=E,:\W/3ZHSRB3\M[
M   K@F:(;?( ,X<Y>-1DR!3E4[I / 2+\W>3+ .^S1$  ,MH['-!XP1S;Y._
MP"L*9L1N+E ,ID$O  *ZALSDOX                  *K$X:@X+Y-5]@
M
M
M    :%]3?98](XC*          /\#CP]^/3         #\T^;/M@
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M-DPE_                  !58G#4'!?)JOL
M
M                                           #0OJ;[+'I'$90
M!\F13DP@        .)SL _8    .0#^ [.!P:>K'3@     !_F12'+)*"=B'
M"!Z^?8'L !^.<?G;   .0SKPY /I#IL\W/$SY [8. B0@'"!VN?L
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M-0<%\FJ^P
M
M                -"^IOLL>D<1E 'YQ^B#^0_[/Z ?RD/!XZ3YG\!_4?Z@_
ME/Z@?G'Z)^:?I _./[S_ * *IQ9D/30#\D_6(X#G FN!6;(\R[@?^%",GK)\
MC\D_6  !_$?[G^P!6!.BR1,K6%FHKEEE$^Y/<S^,_P!3\DX:) C\\_K/]0?X
ME;$LJ%9LC +RYQ*13G#);]*;9=+!4"+6!Z:
M            9X9R :?8 !S^88QO<@K@E$,U^C'%-#PG^(P#)%-OD&>&>?DT
MY3Y-=L%/@IF&QT98A8^+?H/QS#L+*)[<:-@ /(S"G-A4F?!^>8OY>H.1"#\U
M8P49#PT]0.0"Y&8[)N6GJ1\*9>AI@E <Z_+WIX^86!M<G>Q_R8SI?R(O"<4G
MP!D&%Q\A7.ORWZ8HQN\@X_,48W>3#(-80FS/BS%&+^!;] !C6DW1I+'_ $#.
M'(G#7;,D0N>EGX&2(7/2%LX_-.(%94S^S9N,44U.RC62[%YT&5T2DE_PPAC:
MY.P 80QM<F4.7ABUD?XF/26("YX8HQN\E((C -+PHA'(!:I*_P"7TP4RBM&:
MR(    *X)FB&WR 5>3+J-MH[!,@4M>EST A ,D4W>2-0Q:36=+$@!24*+IMC
MG^Q@CFWR=_@C<,<LT[RS04 R, U.P 8(QL=$OX                  *K$X
M:@X+Y-5]@
M
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M0#(P#4[ !@C&QT2_@                  JL3AJ#@ODU7V
M
M                                                      !H7U-]
MECTCB,HKSG=Y)24[C\XD)/ACR \-+D)"X>F$))<// "OL<P%R<K-DU)PH?='
M0Q&:10$KYRT>I'X1:(*AQ:D/33YHAT/!R/8G_.9B<L%9L[..;3Q\[G/+CK<Y
M$(12[$5)BS:0MG*!<,/)RM46KC\DIQES('RQ^*5123(Z9(%"XZ5E284@S/*B
MX,<]'ZQ[>5PBP^?O%9LFD*V9-J<,'#);]*.Y/(""$NN'IH
M                      !'@?'DGX !\^08D]P.<#A E^(<20\]_/+R)$F^
M!'@?GDCY$(5W234LL%:4DO/RSI Z_ *N)1/-CX   BL*]I\>2YEA _2!S656
M#Y$LX'?)P@?'DCY_*5H2+XEG+'A_L1P'V!W> 5Z2&P[K+0Q]P""P@[/3BSJ=
MJ$<!]@=?D*).\#X\A1)W@<!$2A+"9SI;/+30 !X^5D3AX[]+-1Z0") [0.GP
M1(':!T^<LE68^!+%1*F"%$E./7BLF1K%@XDG*QY9@(DR:X^P!!"37'V!R&0L
MDB93D.T2[20HD[Q^&5MSO$Z$/CR1\XF*R)Y:3F$YH    !S@1( 'V9+F>L $
M0)U>=G@'AY$B3O '%A6_.820$LI'KP/SR!$ _0).CK0 X /+R4\ $"),<>P
M                  JL3AJ#@ODU7V
M
M                                     !H7U-]ECTCB,HKSG;A)45$
M6>SSP\6(-"WZ0M'IA" 7$SC,B+.1BW\5FR<LCS/3#W,C-(\"UH<MGQA%(6I2
MG*6S3TTBJ."R?,J8D^1S,3E@K-DTA7!/TB;HX_(FBV<5G"T^5^CE4LHE9<N$
MG+Y!Z6; 4IBXJ>B%:XD*(223(Z9(-"WZ5FR7X@T/)RX(<)'JAT\5I2RT"LV3
M2'U13C)=#ADM^E-LNE@J!%K ]-
M                    (RC-U+>9;,                          ,B L
M[%V,B>,C<V<3KX                   &8N=+&A\</F0L:K1,&
M                                           <5[&T1S=F&K@
M
M
M  )3](2[_6]'VUYSB4_1)S3ZD@B/X"R80F%CXC#/N3SLAW/_ $LVD$18^(-"
M5@XV/N3U<X9/J"+D_,+1A7?/ACPPMDGW1S85C3ILYK+%)71+@8(-"3LBM/7#
MJ$YO(P#[0\N)GCHXJ$EYLC2(5S_0LO'N8.-RMT?3G4)9%*X)W,>YD4Q8^(-"
M1\BF.U2&@_A+5AYZ<(DK((-"3LZ0($S[XY2+'Q6D+/ *X)8$/N@
M                                            #(4)3S2(/U
M                    "+XSJR- ZV+[A8R                    .,S.2
M(?CW(NZ%M0
M
M
M            %><DR.Y@                       ?P%<TZW)B@
M
M
M
M
M
M   >%'H9]D                       #_ XH.W@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        "L%-
M.IN$R2$"P
M
M                +B%?=W'S7V<6
M             !T=B.SNM\"W,
M  .32C&0DG[18!+R9ZL 5P2GP<*'399*+D9]001$'I>? !6O(["[&4?B=,FN
M*8I%Z =<EL8[]    *\18= !"P1>DI!-"
M                             "+PIC 'VA/ 68C_ &!2B)BR=( X#*8Q
MH:@_G*D)5@.5#M$M4EK(_P!#YLSIP#] E/+:)Z8"N"<F%O$ &=,7@CM<
M              %5B<-0<%\FJ^P
M
M                                  +HE=-ZWS'V\2
M                               !TOANU.P]?[L
M                    Y$,;,FX+>Y^.4DC\$UZ3](H^% $OC$TIP@4/"0\U
MI3@(Q.C<>.N #'/+-I?#,<4N>EOTR1#T@GV/X2(,J\FM43Q@  $01CJF]. 9
M\Q4K+))7_+29H(@
M          %<$RU"_8#G4J$D^YJ"'_1D"EKTN>@$(!DBF[R#,_*U1?.)-2*8
MH1EKDTCCS\P1R_8='GP96,/&S8:/=B@&1@&IV #!&-CHE_
M    !58G#4'!?)JOL
M
M                        "Z)73>M\Q]O$@
M                      =+X;M3L/7^[
M          ,SLXR-8\_Z!YR8B!J)DIIB*FNH3U@')IBF&E*6P#'C+99=1!PL
M8A!MZG=9CBESTM^F2(6/B[Z 4(BI\;3P !SJ9%)$6?MF]R#ELP]#;@.SSQ<Q
M"C:?.O@
M  5P3-$-OD XS,3XU:RQ$9 I:]+GH!" 9(IN\D$!D@FTT2!@$1!C.&RJ2BF"
M.;?)W^#\$QX2PV:$)0#(P#4[ !@C&QT2_@                  JL3AJ#@O
MDU7V
M
M           !=$KIO6^8^WB0
M         .E\-VIV'K_=@                                    &&L
M:4):(  !3(*91LV  &:.>8&H.4R"I>; X*/!6=->D&.*7/2WZ9(A8^+OH!QR
M89IM[D@( /XSPLX0,;4WN00J&4J;BH!BTFA$6=
M                                  5P3-$-OD &5\=AFC\9 I9Q+A(!
M"X95)N\F<2<D&I:  9!!8N+Q)@CFWR=_@%+PIC&SX4 R)0TYP 881L?$OX
M                *K$X:@X+Y-5]@
M
M                                    71*Z;UOF/MXD
M                                 #I?#=J=AZ_W8
M                     !@'FR^3(@  STR-PU3P "AP0'FMN<XF&P;;IVP8
MYY<L+@@,<4N>EOTR1"Q\7?0 8&QL($W(  . #%%-[D'/)AN&Q\2UD6!C%&F.
M6_0                                                       5P
M3-$-OD &=F<+&IJ9 I"8?: 'X9^X;O)E*$K9H(  &7T=&FAP8(YM\G?X!6Q,
MQHW,R@&4+SU, '@ALZDOX                  *K$X:@X+Y-5]@
M
M                                                           7
M1*Z;UOF/MXD                                             #I?#
M=J=AZ_W8                                    !@\&L\3T@ CP/:RF
MN0*&MN  9OYS0:BX,I8GH+3!BDFYF>V QQ2YZ6_3)$+'Q=] /)3!G-L\I/%4
MH&IB6" < &**;W(!4(,Y,[%/XSZ T"BT
M                            "N"9HAM\@ S+S[ TH#(%+7I<] (0#)%-
MWDR]#I,T>  #) )YR\P8(YM\G?X!4M*&9M/% ,C -3L &",;'1+^
M          "JQ.&H."^35?8
M
M                              %T2NF];YC[>)
M                            Z7PW:G8>O]V
M                9"Q.^:!0!^.8AQI8GJYDXFXF>^ 'SYB<E]PN% J]E$TM
M7D+IJ4@&.*7/2WZ9(A8^+OH!5E,WHW$SD0\'!W*>M X ,44WN0?GGC9]H<NG
M9AA]&PH2#@
M     K@F:(;?(!\Z8EQHAEK R!2UZ7/0"$ R13=Y*8!2&-J0_4 .93#N-> F
M+,$<V^3O\ RZ#VDTKB@&1@&IV #!&-CHE_                  !58G#4'!
M?)JOL
M
M            "Z)73>M\Q]O$@
M          =+X;M3L/7^[                                     *V
M)E;&JJ6/CY,SRRMZ;/Q] 8^I[N:;)V$>3F=>0'FS ?< ^-,- Z'-)8LB &.*
M7/2WZ9(A.D7*3^4B',Q0OU%T,   X ,44WN0>#F&@;;IV450RE";#0
M                                                 !7!,RPV40>$
M%!TB -G ^H,@4M>EST A ,D4W>3R$Q8BR>:'1[D<NF8(?V&LB>?F".;*)W.?
M'E4XH'FSD2/E ,C -3L &",;'1+^                  "JQ.&H."^35?8
M
M
M      %T2NF];YC[>)
M    Z7PW:G8>O]V                                     "H69VA\&
M?*DX1I\'=8.;3-B*MI[L>,EC0TMSL8 &<V5NS:*/W@#):+>!:U,LTK\ '7I<
MY+H)_P!   '#!CS&X  4;"C2=SGAIK DF8
M                             !7W,LX ^T)[31+.S092A9\+=X!#499Q
MMC CN,S\@%.@CR<MHFCL>M'PIB  'Z!*L:"Q-Z"C&1NFE\ ##_-:4E;
M             !58G#4'!?)JOL
M
M                                 "Z)73>M\Q]O$@
M                               =+X;M3L/7^[
M                    /S3C(]?.@   ><G*!U&>I                 'E
M9SD=JG]@
M              /&3G(Z_/M                             5;9M5'P>
MR5@&
M
M           !<JKRO'^9^WB@
M         .D\.VCU[@.Z0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M        //\ E<;^3^[AP
M                                          !_5X>[V+'\V
M
M
M
M
M      JL3AJ#@ODU7V
M                                        /:\;SS0,JH[(@
M
M                                R' :\937*-H-4DEQ!CV'+!-<:AAG
MEE7DU=R4,%  JB&J"2\@ %><I4'EY9:+K)_8>3E!TA7.HR[43J@H^$8P![B:
M)8       *1Q3V /L"R*7W3Z@        I1'Q)>3      *H9$.:&@
M                                                       !P&4?
MP =/%K<DG (ZBCT1#GTA-<7=3LL%<$K@@']A(F6ZSW(
M          %5B<-0<%\FJ^P
M                                            ![7C>>:!E5'9$
M
M                                    &(,#;Y*(1GB'TYHU%V<X6,/
M^J)U#7Z,P0J!&SR2_@S0RF&;')-^ "#PQZ"2 DO*S!H,E]DR[RJ"6A2!4YT-
MJ$D=,4,\X.R0=*FM*       #/#(L#0,!RX9J)<#+YH       !% ?DDNH
M   !'$<RDVX
M            !" 9!IH: $1A52-I@D%(B#'S+3)::/GRG<0@FQH2%E ,K&EO
M$'XY5Z/.S98/]@  <@$=I.B                       56)PU!P7R:K[
M
M                    'M>-YYH&54=D0
M
M            8@P-ODHA&>(32DBQJ>E4$SKCY4D_-?HS!"H$;/)+^#-#*89L
M<DWX ,RLIMFYF=BF4L0:FYF8<I9D-+8J4F6Z:C);3,%(T[RV4         9X
M9R :?8!06(1S6A(P"CL<X%@(NDG]ASZ47R+PEH+Q)[H0$G-IQD?O$G)\^6'C
MP\I1$49VF7.R1L%0DK5'L)=5)E2&$X@+/IQ643SAPF>+R)]P
M                                               0@&2*;O( ,5TO
M&EQ4QY";<T9 #_$R<CU8U/2@&1@&IV <+F'>;D)VN  "F$0@FGV
M              56)PU!P7R:K[
M                                                'M>-YYH&54=D
M0
M                                        8@P-ODHA&>(7;2KJ;BIF
MVG)Q 22?FOT9@A4"-GDE_!FAE,,V.2;\ &5(58C></7#,9*=INK'40(;BA^5
MH#:3/1S#=++Y'X20FB(2;@       SPSD T^P>:F4 2HFBP8?QH6G=Q0!+7Y
M<S,<LGJ+/95B(.S8T*2!0U+/9; (#SS\T/#+*/12VP0A%-<V_2KB4+31C.'C
M.<-L4J?$()I]F-J6ER<HI&DBYHB
M                          $(!DBF[R ?#F(L:<Y+X89)N!'>0 *XIE:&
M\*4 R, U.P"& Q^3=3,U,L\%H8&8^3)E%P\>)%C6E.E@
M     "JQ.&H."^35?8
M                                        ]KQO/- RJCLB
M
M                               #$&!M\E$(SQ#4V,LDW!S*,+=Y0[)/
MS7Z,P0J!&SR2_@S0RF&;')X(1^ EK(8#-X+/9+B463SDV^3O\&&,<@$O!KX$
M5ICTD\!,(4Z#IXVX3ZP       SPRD6>[@\!):36@/M#"D-6,LG'+AXN<5F:
M(;71_H?SF(8:IQ!>5PS6Y!0#//S0\*P)8$/=B.0Q)C?X*,!5B-3,D)(:238J
M1$()I]F%(:"1<)/.#A<EO
M                    (0#'N+*H/Y2)$G5-1@A6,>$WS0 "+8Q4#>\*'Y3>
M)H@?(D%9I(ENPKG&<(;4A_08F9K;E=<A!-/L                       J
ML3AJ#@ODU7V
M                                 /:\;SS0,JH[(@
M
M                         Q!@;?)1",\0V<3(=-#PS4C8Q,F\D_-?HS#"
MGT;-I,6#,W*9YL@E#LK! N^&C 9[I42/?3HT@H-W8Z"!\R5*3,#+[AH$'A)[
M,?2&<F4<S9S)A0      #/#(^#2#!]4=+ %34HMD<A8.-!0@[*[)JH@&/N7E
M"/8C -+P% ,\_-#PJ5E%4Y[)-RND;_!XJ9VI5H/9RUX7^BG@0@FGV5U2@21"
M$YA?A)[@
M      "$ R(35?!_.0>%&TVVSG Q8C>D/2  5_3)L-Y4H!E?LOA ^;*;!S8;
M#A_R8S)HWG?!D>&V(4PB$$T^P                      "JQ.&H."^35?8
M
M                      ]KQO/- RJCLB
M
M             #$&!M\E$(SQ#9Y,]<CX. #>%,.XD_-?HSS2AR:CA;</^3'K
M('3<#/VCQL'1AR:13%EX]@,B(C@-B@Q6B[\7^SATPZ2YR60RM^: QUL9T91C
M-L,DU       ,\,Y -/L  YD(\R:<Y?*'I"X772DN;" /\S#T-7H@7(P#2\!
M0#//R\D8@!L;$N9X28/IO\$/1V.=;$01EI%^H\*(032G(92>X\1*;!20-P0
M                                                          A
M,D4W>0 85AJKD[QA@&F:6D  9NYP :PY0#(P#4[ (9C'A-[<%+HB<.B#JTNY
ME,(A!-/L                       JL3AJ#@ODU7V
M
M     /:\;SS0,JH[(@
M                                                         Q!@
M;?)1",\0V>2L\9\Y/:;!9AC$GYK]$/QC6'H)98.+2!0G?-AD  K7F2N6.SMH
MIW&B*7JS%?.("YJ0)D(9K?'TQD-D[1-\4NB7<V*C_H       SPSD T^P #@
M@QKS7&)$RB"1C&G"8EQI6ED0J"E,\V@"D@1@&EX"@&>?EX8Q##8\.I2@J4Q3
M=H*-)'B:2!X89+!I%$=1"":59AY&JT31E10IS&S(
M                                       0@&2*;O( ,4<T:BR<48BD
M&:K!."?QE6<S$C8")CR@&1@&IV <!&((;]!^@<8F.:>^&Q\>C%/PK'FKF
M                    56)PU!P7R:K[
M                                                      'M>-YY
MH&54=D0
M                                              9M8-)0K%E3@T0#
MF<HKED M]F:"=I%^P%>LHQ$9YZ*3_&@$=.   IC%+H^9+7I?3/U". SL2(LZ
M1+K!;X!4=*29SH3:&BV=E        J<'@)=%  !41*19X 3%&D2=G$*QG;G!
MI+L:-1(&5M3BXN-@JQ'RI;'*8Q2".BB^05PSH0O;&;J00'WY;O+T)7?(VBZ*
M5N2@V<>$GAHU$HX
M             !#499QMC  R6"P87FS_ !*+!11/G3\L[U-)0L$ HQD;II?
M'A)B>&M,3)@P[#15+7P.(C'>/=#9D/I@                     "JQ.&H.
M"^35?8
M                            ]KQO/- RJCLB
M
M
M
M                  ?FG&Q]V=0       QLS2K)H0#_ #/R3]H
M             %=>6U940V_86
M                                               #U?@\QNE5T7K@
M
M
M
M                                             #'%-'LF_
M
M
M
M
M
M                             (<21X]P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     !X!E6N/
M*.=PX                                       >@\3DOJG"9>
M                                    !_IX^7WO%Y$
M
M                                                         /.R
M(H_G)8SUX    _S/ SH ^+/PSU \;/1#Z    \S/U#[@     _+/DP#](^N
M        !%X>JG=P  !S*1:GMY+&?I         '@9[H?T
M                                                          %5
MB<-0<%\FJ^P                                      !*YHN8DX,:I
M^                                          ?J^C[)1=*2T
M
M
M    J2F;4=DGZ!'\:"1>%   !Y^8(YO\%,(A!-/LQQ30\)_@  #-#)/R[Z
M   5@3*9/:P>:DC)J.DQH       !&L91QKK'8@  *4QGLDDYR<?=FK.2S@
M       P1C<Y.@                                1F&=N #IXMY$]8
M!!H4,2(<^D)KB^H2U@JA%4$ _L)$R[>=V@
M JL3AJ#@ODU7V                                       )7-%S$G!
MC5/P                                         #]7T?9*+I26@
M
M
M      @6,EDU?2PD"(@Q_369)X   #^<X(._RF$0@FGV8XIH>$_P  !S0?3G
MN     !6!,\,VN@?/F:Z1DFOP        0 '?A(&  #E,Q#C9X))3^<S<2,8
MUSP        8(QN<G0                                (0#(=-2, B
M,*$9LY$K97],E OC%IH^?*=!3J-AXE_* 97E+S /QRI\0Z&V<?J   C8(MBS
M@                       56)PU!P7R:K[
M               $KFBYB3@QJGX
M        !^KZ/LE%TI+0
M
M                             9-1+::%  *I)T<6*"B8=\EKH&:F6["9
M(R<C6[*81"":?9CBFAX3_%7\HGG*!+@:*Q(R4ESN8M!&/L7*RCB?)E] MD
M%8$SPS:Z *<!38-D8\I,[$KOGWQ:W+Y)\F9%!=#*"YKQ&9,6@BDV;0Y$$9V)
M'@3G&B@=>  A@,C4W+3[P'#A7;+>IDE&BT2V@SQR5 \8/'R%LAP)M33;/4B)
MHSH3CHN#F>.;G)!20CG(Y_8:6A1"*>)_R6XB^Z?J&4866BE,?K&@X5&"$<FT
M-.4]&(XC.3(J288T4"0D                  $(!DBF[R #&)+JI<A,74ME
ME[\ &8(<JFM*4 R, U.P#D,PPS<5.XP  4PB$$T^P
M   "JQ.&H."^35?8                                       E<T7,
M2<&-4_                                          /U?1]DHNE):
M
M
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MUBU@5""EL;3Q_4                  0@&2*;O(!S:8G!J]'>1AZ&Z(=:
MK]F2T;TI0'(P#4[ *YYEF&Y697)95+E(,E@L1%)0\>)%C6E.E@
M           "JQ.&H."^35?8
M   E<T7,2<&-4_                                          /U?1
M]DHNE):
M
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M%L8J!O@%#LI#'?8/D2,TU,BU00F&58;=1^X8?YL1%: A!-/L
M           JL3AJ#@ODU7V
M  )7-%S$G!C5/P                                         #]7T?
M9*+I26@
M
M                Q(30 +;P *1A7W-7LS0R3\N^@Q]2^83_ !@CF_P4PB$$
MT^S'%-#PEX,G(Y8)?S[LY$-;LS0R3\N^F",;G)T #!&-SDIS$#H-!PC@,\,V
MN@#G\PFS:7(K#-N)0"6$KL&CR3_&".;_  #C\Q1C=Y!0/*<1,D #3,.KP",
M\[)@P?\ )4O,P4W>#T(P]C6F*+!-R78S/#/0"_X#/#/0"0TJQFL6 8.QN$E8
M(K@FIV#$0-5XF1!!$9GAM0&(,:W1)^0 F>&;'0,P0D^.C#/G)S@ :)!)F
M               0@&1B;)P/YR#PS-#;>/C3$T-X@]L !7),L@W;2@&0I&C4
M#YLI*$'9M) R "].2!F70;-A3"(033[                       *K$X:@
MX+Y-5]@                                      "5S1<Q)P8U3\
M                                       _5]'V2BZ4EH
M
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M0*417W-64Q!C6Z)/R $SPS8Z!F"$GQ+V9NYMD'_1\V4-R]4>A
M       $(!DBF[R ##(-2LL &'L:!1<+ !E_'SIJ1E ,C -3L B",;4WQP5%
M"OP>O$SI;W*81"":?8                      !58G#4'!?)JOL
M                                2N:+F).#&J?@
M                         'ZOH^R472DM
M
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MM'<IL;'[Q4:*CIKBG_0                      *K$X:@X+Y-5]@
M                                "5S1<Q)P8U3\
M                          _5]'V2BZ4EH
M
M                                              !XF4X"&\];+.!/
MH5]2S,?EE+XBX+(A\J3#G;Y2>+OI$H<>%BXJBD[9V^4\"O>2S%R,I"EFD\3.
MC"8<I/%RD^X!2>+E)]P ".@K,@'ZQ+,3^G^AQV4/3R0MCGJ96=- TI/%WT'E
M94.+HH!QF4?3C(G:+DY^T  <SE- BE/62P\6EC]0 P^32F+, ()3]PF^!!*?
MN$WQRN42SG@N3$.Y<-(Z#@0LE %:4JQ'UY;?)Z04\BT"=&'$!!(6N@5T3HLF
MC.<RCR1V$RA=5/O                   11&<*:ZX ,R<F3+HH*IY1!(F#[
MPG\-$@E5!3B.!C06 /(3(C-+4F%!B*&DJ65@<UF4(<V&SX?3
M          %5B<-0<%\FJ^P
M !*YHN8DX,:I^                                          ?J^C[
M)1=*2T
M
M                                                         _G(
MG#*.-L@_4
M  ,;LTFR:D                         @7E#7=%CN^(@
M                          [ZU9(V4/2DM0
M                   /[_5]/=6LI @
M
M
M                     4&BEX:619V
M                        !CBFCV3?@
M
M
M
M
M
M        ''!T>?<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 \ RK7'E'.X<
M
M      /U/1]?86O]V@
M
M                            ?B@_:
M
M                                 !58G#4'!?)JOL
M
M        >UXWGF@951V1
M                                                           !
ME& U<RHF4L0:>)*2#)L.6"8XTK"@V5J34/)*P43"KP:;I*Z  02%.L\;)Z"Z
M:?O$3!4J !;I)4SR<HN$29)F7F#IP        B",X,@@/YR9HT1"P$
M 00DUQ]@     5KBM@:4    ($2<X^@      /#R-$F>.*#*]-AD      %7
MD@;-&H $%IFK@'VA/ 7V#HX&-@:UIU$
M     #Q,QL388.H@  #@0\E)50      0Z'8QV*9[1(P7#0      9*AH2$P
MX                *K$X:@X+Y-5]@
M                                                   #VO&\\T#*
MJ.R(
M                                           ,08&WR40C/$/W#21+
MI9QB8:I^\3P&OT9@A4"-GDE_!FAE,,V.2;\ $31C,$CQ)&5EB]\:&Q20,Z(D
M2 -)\L,F1H0#%@,@5)8S9(/^@      ".0QH2]8783] J;&<2;.!)6
M#"&-KD[      .#3@XGC   !@C&YR=       $(!FB&ST>3E=LL^       J
M!%<$U.P 5P3,4-:H'.I1Q.&C9*/LBK:64#T(
M          '/YA#FYP=@   %((C -+P      &4(6O2U\1"'LA(N      #&
M%-+LF_                !58G#4'!?)JOL
M                                                         >UX
MWGF@951V1
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M0X.'#JHG:,V@MZ%+4^3+M1->"M*51#YLL,%Q4_L,84TNR;\
M   %5B<-0<%\FJ^P
M                                     ![7C>>:!E5'9$
M
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M1/P7<2@02?EWTP1B?HO7D*!2;-Q\AH,H$TP3ZXSIR]06VC&%-+LF_
M         !58G#4'!?)JOL
M                                            >UXWGF@951V1
M
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ME"%KTM?&:&2?EWTP1C:")-S^$P/#=?.<#DDFW/!S,^)?"]Z8PII=DWX
M           *K$X:@X+Y-5]@
M                                             #VO&\\T#*J.R(
M
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MUZ6OC-#)/R[Z8(QN<G0 ,$8W.3R,S3"'(Z\/BRVN7O3&%-+LF_
M      !58G#4'!?)JOL
M                                         >UXWGF@951V1
M
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MFADGY=],$8W.3H &",;G)G0GWQI#'[1FBG?I>],84TNR;\
M  %5B<-0<%\FJ^P
M                                    ![7C>>:!E5'9$
M
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M*M! ::;Y\*91I>R.DC, -< ZO,V D#+^1AY&JT31E10IS&S(
M    <_F$.;G!R 98AM= B ,L0VNBE(5J33'(\S+0-9 ZO,W0E4+ZIAY&HF31
M%1PJ<&R494Q*,7B3/-)/R[Z8(QN<G0 ,$8W.3.Q/XS0L(.3,L+@!H0F-6:79
M-^                "JQ.&H."^35?8
M                                                     ]KQO/-
MRJCLB
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M0OF$;9V.6+C,K-(0]0!F5FD(>!F:,1[%C LLE#0T^RF06]21<
M     %5B<-0<%\FJ^P
M                                       ![7C>>:!E5'9$
M
M
M
M
M     @7E#7=%CN^(@
M                                       ]-X;*[=,"+H0
M
M
M
M
M
M
M
M
M
M/RSY, _2/K@       #G\]\/]      #^$^-  /UCZH          '@9[H?T
M
M
M
M
M
M   %8$RF3VL'FI(R:CI,:       8 YO<'H      !" 8Y1]V "U.:B0
M    !2Z+5YTL8(QN<G0
M
M
M
M
M                      !6!,\,VN@?/F:Z1DFOP       < '>Y_0
M 0@&2*;O(           ,08UNB3\X(.YS]
M
M
M
M
M                                      K F>&;70!3@*;!LC$?QG1D
M.YUJ7C"U(5$SD(AQ)'CQXF(*:I? *4!K&GU!18*B!]472RY.0XE-LZ;(B36-
M (0#)%-WD  J)G-1>!!0;)7"?(R\"R04PC[0T3"PT<\F;,0!G:YH<%9$I<DH
M!K#F;4:F1]\9\)5./NRYV7=2*0HV'=)5).ES2K)>P
M
M
M
M
M                                     "L"9G!?(!X.5,#2@+$AE3$L
MQ>5(G#(;-V<I %#TTDRP$9EQPH:0!,X82)O<%,HJK&IV?!F38:'A[P9&Y?#+
M71*2 0@&0::&@ +E)26.0#1\!F"$WQ9],-,OB%[@J6%*@VFC)\)!31&*^!F
MFT^8RAJ8$X9@R&YR4AB%$U*3R(R8B\@24F.D:4I;C*&9$H:S8
M
M
M
M
M                                             !6!,R0NN@^'*S9,
MX:?1P0>SG%Q&$999NJ%,(C$-/@&2(6P2WT# '-[@QI2\V6  4WCCLMS&:.;6
MP !" 8_I=% !H(%*XY -'P&8(3?%GTQ #>A/WCC,Q5#;],)PW73H %8$L:&*
M@:W1)^8(QN<F,N:DY.""G05ER^ 9<!MO @T,U(V>
M
M
M
M
M                                     "L"9X9M= '/YA-FTN50RFF3
M'$R)1(-TTIA'(!H^ R1"YZ6?@8 YO<&&D2['O@!-L3CF>&;'0 !" 9(IN\@
M%$(Y -'P&7H3G%GTQ1C=Y!Q^8HQLB&-:;PX !B#&MT2?F",;G)AH&VZ=I JQ
ME+LT(3-$-GH$(!FB&ST
M
M
M
M
M                5@3/#-KH XB,.XV43'&-S@Z>/'3"!-V IA'(!H^ R1"Y
MZ6?@8 YO<&."7[BT@"N6?K'T!GAFQT  0@&2*;O( !1..$#2@!CCEOLL^F*,
M;O(./S%&-PLPG#<E.K#Y<RJ34J,5HUNB3\P1C<Y,;<TMBPD#/C.=2W.9HAL]
M A ,T0V>@
M
M
M
M
M     "L"9B!;Q!\J5K"P":91AJ%^(D)*=A7A-6DAX.0#1\!DB%STL_ P!S>X
M*IY0Q-$@\+,]0UJ#FXSPS8Z  (0#)%-WD  K@F8D:*I$*4[#0F+/IBC&[R#C
M\Q1C=Y,RDY,+KY5/.'C6[,5<M%%Z PQ#<Y*E!2Z-"P\",[TUWCQ$S1#9Z!"
M9HAL]
M
M
M
M
M  $=!69 /UB68G]/]"'0I3GJI=%(BCPPF./+"?8%7TEK)%P4@B["?N%9LJR'
MK)<?)ASB @D+70 !QV5?BZ*  "I*0;DX1V6=5$BY4.+HH/*RH<713Y$I*$.9
M* 7>SVH@+*Z9>.*F!<I/N"IV5N#V4N,DQIQV5[2VL#CLKVEM8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M       'P7Y^\Q^/Z
M
M
M
M
M                                             !][^NG/+Q
M'!7AYUC_ )_<
M
M
M
M
M                                        !WIY^%G'Z/2      /B?
MS]YV\?T
M
M
M
M
M                                   #[;]_.B?+\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M               XVV%H[^+V^@             >K\%F/O\ BNQP
M
M
M
M
M
M             ,\^V/K3^<<QBX             G0C+8):G@];X
M                                           !YMS&+<B9]I@
M        #KO =S^D\/E(
M
M
M
M                                &>?;'UI_..8Q<             3H
M1EL$M3P>M\
M   \=R#">!]I1U              [XU;(KV+'\V
M
M
M
M                                                    SS[8^M/Y
MQS&+@            "=",M@EJ>#UO@
M                      'CN083P/M*.H             '?&K9%>Q8_FP
M
M
M
M
M           &>?;'UI_..8Q<             3H1EL$M3P>M\  _!,VD\#/C
M"U26N@      #-K-)0  K%EG0   JQ'4Y/L             4$B_:
M           #QW(,)X'VE'4             #OC5LBO8L?S8  #.S-$P
M           $6!U.5>BS<=?@          &?2:"P        !7;/LB?(
M
M
M
M                        &>?;'UI_..8Q<             3H1EL$M3P>
MM\  IS'G9==/\3.^-$<K+D#):_)<RLR1Z$QY%P=(EK0K D>ATJ6\C+&-3L@^
M*]Y:"/AS,8-1\_6*M)/L3LD8A5K/*">@L? XQ*6IV:7-RO*?BDIYWR"MR5\R
MU*36E7TXB.I2UT1=%7DF=);SR4IP$HQ;P*VQ83*YY',2#EGHB>*RY,Z3"'5
M             !X[D&$\#[2CJ             !WQJV17L6/YL  !DB&IN1O
M$69,$2W@^3(3"- E')QR#(YL+,!77.:2T4<6'(I#R6=SM KID;Q9F.CR*H\$
M)H"JX=&EHXS'27PL DCISP5628DG\(,CXXY/+3Q^@#S<J+'KI; (M#X$]L),
M3\D@N(YB1TGC,L0U.RNF1O%F8]Y(PB,$EB)6R&0X$.[2=4Y=*SA,D2YG(96N
M.=21DL_
M
M
M                                    SS[8^M/YQS&+@
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M9T)JTF/*:?)GRFJ69GY>A*51>C,]XO<E#4MZEGX
M
M
M
M       &>?;'UI_..8Q<             3H1EL$M3P>M\  SBRW"3)@J9GC1
M(J6'#/E+691G-/\ ,L0U.S/#+GIG5&JH0U%>LAM++!6^))SAHT"S.;+RQGPD
MXQS 3\$)IHK%.H[7+'P,KDU1CF$S^3R@TN3T(%18Z-++A0D+.A0I-3TH!DR!
M"N:"A4C/<BL>:;1%$5>"*<TO#/!-+XS@RR>0KE]4IR$KA-^
M >.Y!A/ ^THZ@             =\:MD5[%C^;   9(AH>%;DOBF6&:G@.?S.
MC--PJSGYI5F-4,RNB4@' Q/R=/EEXRZC1#*,Y]:0ZFF04NC1$*Q)7W.&RU(<
M@$WQ6"++!6#-& @F(<2",U0RN"<@%OT&5T:HH,K\E$+6I*.#S\S)#4;*TYS<
M5K325*'9]:0ZFD05.C0$,L0TNS.[-,0S@RTZ9[)8(.0"<(A=-)PJ2GKA9^
M
M
M
M                          !GGVQ]:?SCF,7             $Z$9;!+4
M\'K?  (0BCD:51&P4G"ZV5E2_:9;!J"F;D:?9EB&IV9X9<],EHV"BFL3'E/@
MO8%5LORF?,:'YE6&EB9W)IH%$8N&F:L:FYF@EMHL? RD#3+*WY^,0 FEV>@
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M+PS@RZL4"348*AI.29T)J\F=&3X%GX
M
M
M                                                          %/
MR?\ 2A\9R/!             "4[2$NYZ(O6(@ " PJS';)=5/7BJB0OEM,E?
M*]I8N*VI9*()26HRV29T[U+@A6U+)16/((2UJ3,E2DEI/'RKL6(BQH0M%6(G
M")A3OL' A3&.^2Y>5W2PD?N %7,@Y+7),R5M2R40@DEA$807GDY9E/>RH$2U
M%N K:%A,@D+"9 23+$(A".> %LDF)              /'<@PG@?:4=0
M        .^-6R*]BQ_-@  *>A9 (SB?PJ;EL@'/YEB$H)*B7*2IP6QSQ<HB'
MG1>#*\Y#(?\ 1;C)#2A"=RGQ):&.#BR 5>ROV3='(18^*P),63<D.A5Y)1RZ
MB5."V.1G'C1,L"/0I%'LY?!(.274ZI!Y^9,9+421ET\J<%B$H0G<I\269#E(
ML/%3@M!E;\M"%9TG\(2RL22Q%RXK[E74E8)YR5,
M
M
M
M                                 R[#43                  /^3+
M))#C@<T[#[8    _A,KLDJ.%33P/H@             #^#V_-\O]O%
M        ?4?%RO\ ?ZOI      '/YGAFEX    5 CK\L?
M  'GYFB&GV
M
M
M
M                                    #QL]D      /&SV0
M                             '\YYV>F    'QY_8?2
M    '^9YF>H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    _]H " $"  $% /\ \^G_ /\ !BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)
MBA,4)BA,4)BA/GX>/]>/_P#7_P!)/R__ -OZWCX?/PX<)PX3APG#A.'"<.$X
M<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#
MA.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<
M)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A
M.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)
MPX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.
M'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)P
MX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'
M"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX
M3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"
M<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3
MAPG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<
M.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3A
MPG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.
M$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3AP
MG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$
MX<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG
M#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X
M<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#
MA.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<
M)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A
M.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)
MPX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.
M'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)P
MX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'
M"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX
M3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"
M<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3
MAPG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<
M.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3A
MPG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.
M$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'">$'AX>/_OEG
M%%A.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*
M<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ
M3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.
M*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XI
MQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%
M.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4X
MIQ3BG%.*<4XIQ3BG%.*<4XIQ3BG%.*<4XIQ3B^)Q?$XOB<7Q.+XG%\3B^)Q?
M$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XO
MB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7
MQ.+XG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+
MXG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%
M\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3B
M^)Q?$XOB<7Q.+XG%\3B^)Q?$XOB<7Q.+XG%\3BQ'%B.+$<6(XL1Q8CBQ'%B.
M+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q
M8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+
M$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8
MCBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$
M<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q8CBQ'%B.+$<6(XL1Q(C
MB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<
M2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB
M1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2
M(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1
M'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(
MXD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'
M$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(X
MD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$
MB.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD
M1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B.)$<2(XD1Q(CB1'$B
M.)$<2(XD1Q(CB1$,?CXQ?UO-_,OR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+
MQ/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/E
MXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR
M\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y
M>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\
MO$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXGR\3Y>)\O$^
M7B?+Q/EXGR\3Y>)\O$^7B?+Q/EXF&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(
MPQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(PQ&&(P1&"(P1&"(P1&"(P1&"(
MP1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(
MP1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(
MP1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(
MP1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(P1&"(
M@AB\(O\ VX5:[_J/Z 9-_P#P?EZ>?]O^D%KO^H_H!DW_ /!^7IY_V_Z06N_Z
MC^@&3?\ \'Y>GG_;_I!:[_J/Z 9-_P#P?EZ>?]O^D%KO^H_H!DW_ /!^7IY_
MV_Z06N_ZC^@&3?\ \'Y>GG_;_I!:[_J/Z 9-_P#P?EZ>?]O^D%KO^H_H!DW_
M /!^7IY_V_Z06N_ZC^@&3?\ \'Y>GG_;_I!:[_J/Z 9-_P#P?EZ>?]O^D%MD
M]DDJI7K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&D3K&
MD3K&D3K&D3K&D24<YRD'D_O^1/W_ ")^_P"1/W_(G[_D3]_R)^_Y$_?\B?O^
M1/W_ ")^_P"1/W_(G[_D3]_R)^_Y$_?\B?O^1/W_ ")^_P"1/W_(G[_D3]_R
M)^_Y$_?\B?O^1/W_ ")^_P"1/W_(G[_D3]_R)^_Y$_?\B?O^1/W_ ")^_P"1
M/W_(G[_D3]_R)^_Y$_?\B?O^1/W_ ")^_P"1/W_(G[_D3]_R)^_Y$_?\B?O^
M1/W_ ")^_P"1/W_(G[_D3]_R)^_Y$_?\B?O^1/W_ ")^_P"1/W_(G[_D3]_R
M)^_Y$_?\B?O^1/W_ ")^_P"1/W_(G[_D3]_R)^_Y$_?\B?O^1/W_ ")^_P"1
M/W_(G[_D3]_R)^_Y$_?\B?O^1/W_ ")^_P"1/W_(G[_D3]_R)^_Y$_?\B?O^
M1/W_ ")^_P"1/W_(G[_D3]_R).HX/,FG_O% V+E>6\^DO3I>>G2\].EYZ=+S
MTZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2
M\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GI
MTO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EY
MZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I
M>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+ST
MZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\
M].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GIT
MO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ
M=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>
M>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ
M7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\]
M.EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO
M/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=
M+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>
MG2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7
MGITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].EYZ=+STZ7GITO/3I>>G2\].
MEYZ=+STZ7B@0PP5Y^J!KO^H_H!4+_?OU0-=_U'] *A?[]^J!KO\ J/Z 5"_W
M[]4#7?\ 4?T J%_OWZH&N_ZC^@%0O]^_5 UW_4?T J%_OWZH&N_ZC^@%0O\
M?OU0-=_U'] *A?[]^J!KO^H_H!4+_?OU0-GFDMY&E.H9 =0R ZAD!U#(#J&0
M'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZA
MD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.
MH9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(
M#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0
MR ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'
M4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD
M!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H
M9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#
MJ&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R
M ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4
M,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!
MU#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9
M =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J
M&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R ZAD!U#(#J&0'4,@.H9 =0R
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MC_B90O\ 0?U]M=_U'_$RA?Z#^OMKO^H_XF4+_0?U]M=_U'_$RA?Z#^OMKO\
MJ/\ B90O]!_7VUW_ %'_ !,H7^@_K[:[_J/^)E"_T']?:(*G2=!T_F,30S&)
MH9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&
M8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,
M30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T
M,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,
M8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)
MH9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&
M8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,
M30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T
M,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,
M8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)
MH9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&8Q-#,8FAF,30S&)H9C$T,QB:&
M8Q-#,8FAF,30S&)H9C$T,QB:%6KTGTXI7_W:W1]'Y(HLDRNTB97:1,KM(F5V
MD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$
MRNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,K
MM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2
M)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB9
M7:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5V
MD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$
MRNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,K
MM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2
M)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB9
M7:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5V
MD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$
MRNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,K
MM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2
M)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB9
M7:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5V
MD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$
MRNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2)E=I$RNTB97:1,K
MM(F5VD3*[2)E=I$RNTB97:1,KM(F5VD3*[2),^5@Y&9?J@:[_J/Z :A_[_\
M5 UW_4?T U#_ -_^J!KO^H_H!J'_ +_]4#7?]1_0#4/_ '_ZH&N_ZC^@&H?^
M_P#U0-=_U'] -0_]_P#J@:[_ *C^@&H?^_\ U0-=_P!1_0#4/_?_ *H&N_ZC
M^@&H?^__ %0-=_U'] -0_P#?_J@HU4ZLH/D<QBEF8Q2S,8I9F,4LS&*69C%+
M,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,
M8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*
M69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF
M8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,
M4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+
M,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,
M8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*
M69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF
M8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,
M4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+
M,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,
M8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*
M69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF
M8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,
M4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+
M,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,
M8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*69C%+,QBEF8Q2S,8I9F,4LS&*
M69C%+,QBEF8Q2S,8I9F,4LS&*6<US/F\YS7_ +LN-GE<MYZE.GI =/2 Z>D!
MT](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI
M =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#I
MZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2
MZ>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T
M@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T
M](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI
M=/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ
M0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z
M>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@
M.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T]
M(#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =
M/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0
M'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>
MD!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.
MGI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](
M#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/2 Z>D!T](#IZ0'3T@.GI =/
M2 Z>D!T](#IZ0'(<MR_CR_[7EC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8_
M:\L?M>6/VO+'[7EC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8_:\L?M>6/VO
M+'[7EC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ
M^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8_:\L?M
M>6/VO+'[7EC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8_:\L?M>6/VO+'[7E
MC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8_
M:\L?M>6/VO+'[7EC]KRQ^UY8_:\L?M>6/VO+'[7EC]KRQ^UY8J_RO*\OEOTA
M-=_U'] ,O_\ &_+M9?\ B_I":[_J/Z 9?_XWY=K+_P 7](37?]1_0#+_ /QO
MR[67_B_I":[_ *C^@&7_ /C?EVLO_%_2$UW_ %'] ,O_ /&_+M9?^+^D)KO^
MH_H!E_\ XWY=K+_Q?TA-=_U'] ,O_P#&_+M9?^+^D)KO^H_H!E__ (WY=K+_
M ,7](37?]1_0#+__ !OR[67_ (OZ0FQ<URWD4EZC+SU&7GJ,O/49>>HR\]1E
MYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/4
M9>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+S
MU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR
M\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ
M,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EY
MZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49
M>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU
M&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\
M]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,
MO/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZ
MC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>
M>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&
M7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]
M1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O
M/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC
M+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>HR\]1EYZC+SU&7GJ,O/49>>
MHR\Y#S/+\.6XOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\H
MXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'
M%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HX
MOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%
M\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXO
ME'%\HXOE'%\HXOE'%\HXOE'%\HXOE'%\HXOE%81P1<M_[Q0\A(IW-?+Z.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ
M.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JXZ.JX\
MVDZJ\GR_U]M=_P!1_P 35C_J/Z^VN_ZC_B:L?]1_7VUW_4?\35C_ *C^OMKO
M^H_XFK'_ %']?;7?]1_Q-6/^H_K[:[_J/^)JQ_U']?;7?]1_Q-6/^H_K[:[_
M *C_ (FK'_4?U]M=_P!1_P 35C_J/Z^VN_ZC_B:L?]1_7VWRN*3I>F>[R:'=
MY-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>3
M0[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.
M[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\
MFAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H
M=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=
MY-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>3
M0[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.
M[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\
MFAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H
M=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=
MY-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>30[O)H=WDT.[R:'=Y-#N\FAW>3
M0[O)H=WDT.[R:'=Y-#N\FAW>30JA54[YRF?_ ':WD-$595'+=HE+.T2EG:)2
MSM$I9VB4L[1*6=HE+.T2EG:)2SM$I9VB4L[1*6=HE+.T2EG:)2SM$I9VB4L[
M1*6=HE+.T2EG:)2SM$I9VB4L[1*6=HE+.T2EG:)2SM$I9VB4L[1*6=HE+.T2
MEG:)2SM$I9VB4L[1*6=HE+.T2EG:)2SM$I9VB4L[1*6=HE+.T2EG:)2SM$I9
MVB4L[1*6=HE+.T2EG:)2SM$I9VB4L[1*6=HE+.T2EG:)2SM$I9VB4L[1*6=H
ME+.T2EG:)2SM$I9VB4L[1*6=HE+.T2EG:)2SM$I9VB4L[1*6=HE+.T2EG:)2
MSM$I9VB4L[1*6=HE+.T2EDU3ZM)'Y?H<W/0YN>AS<]#FYZ'-ST.;GH<W/0YN
M>AS<]#FYZ'-ST.;GH<W/0YN>AS<]#FYZ'-ST.;GH<W/0YN>AS<]#FYZ'-ST.
M;GH<W/0YN>AS<]#FYZ'-ST.;GH<W/0YN>AS<]#FYZ'-ST.;GH<W/0YN>AS<]
M#FYZ'-ST.;GH<W/0YN>AS<]#FYZ'-ST.;GH<W/0YN>AS<]#FYZ'-ST.;GH<W
M/0YN>AS<]#FYZ'-ST.;GH<W/0YN>AS<]#FYZ'-ST.;GH<W/0YN>AS<]#FYZ'
M-ST.;GH<W/0YN>AS<]#FYZ'-ST.;GH<W/0YN>AS<]#FYZ'-ST.;GH<W(I)-8
M8?U]M=_U'\H+G_U7Y5YK_P ;]?;7?]1_*"Y_]5^5>:_\;]?;7?\ 4?R@N?\
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MC_B:L?\ 4?U]M=_U'_$U8_ZC^OMKO^H_XFK'_4?U]M=_U'_$U8_ZC^OMKO\
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MP_ X?@</P.'X'#\#A^!P_ X?@</P.'X'#\#A^!P_ X?@</P.'X'#\#A^!P_
MX?@</P.'X'#\#A^!P_ X?@</P.'X'#\#A^!P_ X?@</P.'X'#\#A^!P_ X?@
M</P.'X'#\#A^!P_ X?@</P.'X'#\#A^!P_ X?@</P.'X'#\#A^!P_ X?@</P
M.'X'#\#A^!P_ X?@</P.'X'#\#A^!PX3APG#A.'"<.$X<)PX3APG#A.'"<.$
MX<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG
M#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X
M<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#
MA.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<
M)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)PX3APG#A.'"<.$X<)@A,$)@A,
M$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,
M$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,
M$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,
M$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,$)@A,
M$)@A,$)@A,$)%#X>'A_6\O\ _P ?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\
M_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^
M?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?
M/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/
MGX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'
MS\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#
MY^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!
M\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_
M^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@
M?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P
M/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX
M'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\
M#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^
M!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_
M ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?
M@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/
MP/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/G
MX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!\_ ^?@?/P/GX'S\#Y^!BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4
M)BA,4)BA,4)BA,4)BA,4)BA,4)BA,4)BA(XO#QA_]N%;B/U/_0#5?_F?EZC_
M /6?T@W$?J?^@&J__,_+U'_ZS^D&XC]3_P! -5_^9^7J/_UG](-Q'ZG_ * :
MK_\ ,_+U'_ZS^D&XC]3_ - -5_\ F?EZC_\ 6?T@W$?J?^@&J_\ S/R]1_\
MK/Z0;B/U/_0#5?\ YGY>H_\ UG](-Q'ZG_H!JO\ \S\O4?\ ZS^D&XC]3_T
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M?^@%$/HM^J"XC]3_ - *(?1;]4%Q'ZG_ * 40^BWZH+B/U/_ $ HA]%OU07
M*>G\X4KHBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#HBM#H
MBM#HBM#HBM#HBM!%_(\[E4=_]V7*\6Q+DQF.;9NQFV;L9MF[&;9NQFV;L9MF
M[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV
M;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;
M9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9
MMF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQ
MFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[
M&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;
ML9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9
MNQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9M
MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQF
MV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&
M;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQFV;L
M9MF[&;9NQFV;L9MF[&;9NQFV;L9MF[&;9NQ)W/H//YO^ONXC]3_\3(A]:?U]
MW$?J?_B9$/K3^ONXC]3_ /$R(?6G]?=Q'ZG_ .)D0^M/Z^[B/U/_ ,3(A]:?
MU]W$?J?_ (F1#ZT_K[N(_4__ !,B'UI_7W<1^I_^)D0^M/Z^[B/U/_Q,B'UI
M_7W<1^I_^)D0^M/Z^W>-S4M9:VR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,
MB:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(F
MOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\
M9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1
M-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37
MXR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,
MB:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(F
MOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\
M9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1
M-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37
MXR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,
MB:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?C(FOQD37XR)K\9$U^,B:_&1-?A,V
M8+=2RD?^[6[HG15>A57ZB*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B
M*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ
M(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GF
MHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>
M:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBI
MYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*
MGFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(
MJ>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFH
MBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:
MB*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIY
MJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*G
MFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J
M>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHB
MIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B
M*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ
M(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GF
MHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>
M:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBI
MYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIYJ(J>:B*GFHBIY3TQ\V<2
M#]4%Q'ZG_H!H?_2OU07$?J?^@&A_]*_5!<1^I_Z :'_TK]4%Q'ZG_H!H?_2O
MU07$?J?^@&A_]*_5!<1^I_Z :'_TK]4%Q'ZG_H!H?_2OU07$?J?^@&A_]*_5
M!<1^I_Z :'_TK]4%Q'ZG_H!H?_2OU0*LW--%EG&1) 3(D@)D20$R)("9$D!,
MB2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D
M@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("
M9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1
M) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20
M$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,
MB2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D
M@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("
M9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1
M) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20
M$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,
MB2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D
M@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("
M9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1
M) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20
M$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,
MB2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D
M@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("9$D!,B2 F1) 3(D@)D20$R)("
M9$D!,B2 F1) 3(D@)D20$R)("9$D!)=R'+RJ7_\ NRY< J&?R=2NMZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.
MMZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT.MZT)
MSS_/0\]ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8
M'J,P/49@>HS ]1F!ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8'J,P/49@>HS ]1
MF!ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8'J,P/
M49@>HS ]1F!ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8'J,P/49@>HS ]1F!ZC,
M#U&8'J,P/49@>HS ]1F!ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8'J,P/49@>H
MS ]1F!ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8'J,P/49@>HS ]1F!ZC,#U&8'
MJ,P$PYGF?/Y_](5Q'ZG_ * 9W_Y_Y=2O_L/TA7$?J?\ H!G?_G_EU*_^P_2%
M<1^I_P"@&=_^?^74K_[#](5Q'ZG_ * 9W_Y_Y=2O_L/TA7$?J?\ H!G?_G_E
MU*_^P_2%<1^I_P"@&=_^?^74K_[#](5Q'ZG_ * 9W_Y_Y=2O_L/TA7$?J?\
MH!G?_G_EU*_^P_2%<1^I_P"@&=_^?^74K_[#](5PF7\_SBF>ASH]#G1Z'.CT
M.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH
M]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<
MZ/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z
M'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT
M>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.
M='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]
M#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z
M/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'
M.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>
MASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.=
M'H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#
MG1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/
M0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.
MCT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>A
MSH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='
MH<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G1Z'.CT.='H<Z/0YT>ASH]#G
M1Z'.CT.='H<Z)UR_G^//_MN8/VW,'[;F#]MS!^VY@_;<P?MN8/VW,'[;F#]M
MS!^VY@_;<P?MN8/VW,'[;F#]MS!^VY@_;<P?MN8/VW,'[;F#]MS!^VY@_;<P
M?MN8/VW,'[;F#]MS!^VY@_;<P?MN8/VW,'[;F#]MS!^VY@_;<P?MN8/VW,'[
M;F#]MS!^VY@_;<P?MN8/VW,'[;F#]MS!^VY@_;<P?MN8/VW,'[;F#]MS!^VY
M@_;<P?MN8/VW,'[;F#]MS!^VY@_;<P?MN8/VW,'[;F#]MS!^VY@_;<P?MN8/
MVW,'[;F#]MS!^VY@_;<P?MN8/VW,'[;F#]MS!^VY@_;<P?MN8/VW,'[;F#]M
MS!^VY@_;<P?MN8/VW,'[;F#]MS!^VY@_;<P?MN8/VW,'[;F!+O*\WR^?_P#>
M*&=5C2%-^?W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!
MW33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=T
MTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,
M#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [
MII@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:
M8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!
MW33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=T
MTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,
M#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [
MII@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:
M8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'=-,#NFF!
MW33 [II@=TTP.Z:8'=-,#NFF!W33 [II@=TTP.Z:8'+J6G'-^?\ K[N(_4__
M !,EGU/_ %]W$?J?_B9+/J?^ONXC]3_\3)9]3_U]W$?J?_B9+/J?^ONXC]3_
M /$R6?4_]?=Q'ZG_ .)DL^I_Z^[B/U/_ ,3)9]3_ -?=Q'ZG_P")DL^I_P"O
MNXC]3_\ $R6?4_\ 7W<1^I_^)DL^I_Z^WO)"I:AJ!EA7XRPK\985^,L*_&6%
M?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7X
MRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L
M*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"O
MQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\9
M85^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%
M?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7X
MRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L
M*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"O
MQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\9
M85^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%
M?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7XRPK\985^,L*_&6%?C+"OQEA7X
MRPK\985^,L*_"=MP7*5*!_[M;UFKR:)WS^9Y 3,\@)F>0$S/("9GD!,SR F9
MY 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0
M$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,
MSR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\
M@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("
M9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9
MY 3,\@)32W)/6'G]84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=
M84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=
M84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=
M84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=
M84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=
M84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R=84R05;3?
MF1_K[N(_4_\ *#//]D_*LN_[#]?=Q'ZG_E!GG^R?E67?]A^ONXC]3_R@SS_9
M/RK+O^P_7W<1^I_Y09Y_LGY5EW_8?K[N(_4_\H,\_P!D_*LN_P"P_7W<1^I_
MY09Y_LGY5EW_ &'Z^[B/U/\ R@SS_9/RK+O^P_7W<1^I_P"4&>?[)^59=_V'
MZ^[B/U/_ "@SS_9/RK+O^P_7W<1^I_Y09Y_LGY5EW_8?K[>*WQ45>KC)$XDR
M1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3
M)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.)
M,D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$X
MDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3
MB3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1
M.),D3B3)$XDR1.),D3B3)$XDR1.),D3B3)$XDR1.)&YMF5]/)UV\JD[>52=O
M*I.WE4G;RJ3MY5)V\JD[>52=O*I.WE4G;RJ3MY5)V\JD[>52=O*I.WE4G;RJ
M3MY5)V\JD[>52=O*I.WE4G;RJ3MY5)V\JD[>52=O*I.WE4G;RJ3MY5)V\JD[
M>52=O*I.WE4G;RJ3MY5)V\JD[>52=O*I.WE4G;RJ3MY5)V\JD[>52=O*I.WE
M4G;RJ3MY5)V\JD[>52=O*I.WE4G;RJ3MY5)V\JD[>52=O*I.WE4G;RJ3MY5)
MV\JD[>52=O*I.WE4G;RJ3MY5)V\JD[>52=O*I.WE4G;RJ3MY5)V\JD[>52=O
M*I.WE4G;RJ3MY5)V\JD[>52=O*I.WE4G;RJ3MY5)V\JDY.@:G\GF_P#W:WK-
M7DT3OG\SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR
MF9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F
M>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD
M!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3
M,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/
M("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR
MF9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F
M>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD
M!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3
M,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/
M("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR F9Y 3,\@)F>0$S/("9GD!,SR
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MPZ^JPZ^JPHV8\[-9!^ONM_\ =/\ F6[OJ?\ FM0_]6_YJ>?ZM^ONM_\ =/\
MF6[OJ?\ FM0_]6_YJ>?ZM^ONM_\ =/\ F6[OJ?\ FM0_]6_YJ>?ZM^ONM_\
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MN&+]L5V*K"RE[1_]IWO/VLB$VV7^.>H#13NWB]M!=:U?FS9_W8JTIM7S=?\
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M&^+^JA=!N.*K<P<H6G?:RW'UX2IKDKNA,;7MR!:*+D$V<.RY?%F4^=K<L&U
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M\PG]W\H6D96G]$&YOI&5U?9#-D-]K+LOM8-DQ]_=]>H)A3-GPV-=.2WFJG_
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MM<NA)CN8[6K3[6RY[9"S>RJZ?0UN.TZT*UA)=\7]+=D-]TY<)^_JW/;\>=N
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M6/R?NP/9*M.^Z;^#?$<OR4*P[-7E.:YF[6;H[WUVN6U'WO7I#0(O)&@1>2-
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MJI5W8X8Y,+>]LE6?I66G?:R^.Z>N04Z^VX5LJV13*H5=-\X;-OW</P*O]4K
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MKI;,SHI\\RUS?X]FV3SN=4[S]@_:[HMSZ.2ACC*:>I[=,V(&XMZ0W:P.2GR
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M9_-U&&R?9)7B[(MZ7)C02*IN;YPV;?NX?@5?ZI6!_9M_LU^C[C?\3,Y^[O\
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MN:>HKRFZVT6GJ*S5NHZ6U\OJW7 2ZHP]7GR2!M:131)6T+;9]=BWU9N28Q>
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M-\]R7(>5?3G,QE;&+-C0&\U,U,F$TEDH\GR//\GF?)^'-<]R7(P_"73B4SB
MY&<R>9^;\)C.)3)X((X/-@^.X5^LJ*?1KXRZ?R*<1EW"=3FG;>UAZJ*EJQHG
MPW%9;AK.H&?OV(HH88795O4CS'0[?3[:CFI_(N1YS\7/S.72KR.7YCE^;\CX
MWI'U5?/*Y919'1^C*.J"VPQ*I9/<18C4]N13&$NE\AW[9FE^_&\!GZ:/631M
MC?Z-:VBISTQE\KY?E>:Y7G>7JBG^2JVF6;VWT.9!4Q,9M*I1Y7D>?Y/,^3\.
M8YCE^3Y>USRW,NPN)&XK&(N-K:WTY673'D)O+[E_V&[=_P#TV_%][M$_Z8T/
MWF_AN /O(13Z-?DO?%_5394^Z;^%V7VL)1]4OANP/9*VN/OKFY"][7:X^Q07
MK?:/M.^Z;\-\7]5-D-]T^\WJ&H9+:<VLR:IHIEZ'X;Q1]"?).PG;>^]J;R3W
M<-E3[67PJ&GY)5D@N%M0GC%'OW_;N_EO-M4;*UE459+O^!?TBDC@4'5U+*U0
MU5;$ES*A+E["/A-IM*I!*KY;R*)?C=*V:""SI-K9&]F:I/*H1O:2O?IMJUS#
MX;PVYW62+<KLXZE=NXQQV^+^ENR&^Z>]^U&=/3M6-97>>-=<NB"S)TXE'Q3U
M+H5&$X4#=]W8YZHS3.87;G6Q;WG[I]CI]+1PJ029PB!5U1BAM^5ZV.^"B;B3
M'R..#RX+^KXI2_VZ1M,F?S5LEJ3<)7W;GELJX7MU[H*A726.?#<^IDBB4WE=
MF5+ZFY*TWO>?NGV.GTMN%?8(T_[IOA<*^P1I_P!TQ<";!.F7O9V^S\J/?E;%
M%'46ADAH"ZN]OG;B+_\ 94^UE^"_=;?G=M>XAM3[W]#-:F$$<'F0?#=E7I:(
M<+,-L[;EG;\[DANO_>UVAOLV_#=?^]KM#?9MWN+6)QY5:;.1^M--^>7\-UP^
M63-3M=6#F?S5ZEULO6>[?8']FW>>U#4,RNH[(A-4T\I _ANZ'SI\ZRX=L8_@
M[#[IK>OV"?!V'W36]?L$W&;8)TUN\)M'WY4>XRW"<QS'+\GR^XLN,4U<@N3[
M&,N%?8(T_P"Z8WO/VL[)C[^S?%_2W9#?=/N'7M.RM[6^K!&Y$>8]^X?\-ZFF
M:*\\PS:/R^IN=O/?TMV![)5IWW3?CN#K_B76[TC1)&55<\M; F?42P=G)NCO
M?7V2_P!@OQW(?LE-/^Z8N[,$E5RQ@=34VH*,*/8)ODI;=%07X[JR][1*5H];
M;8:JER5X2/I10J$)0K/TK+3OM9?"YG=,:U:Q0EZ#N5;?8Y[:T6T)NPU@)OG#
M9M^[A^!5_JE8']FW^S7Z/N-_0"CGTA+^E7572*1-VE#Z;G2=KM99<0URE+0]
MQ.I762&YF_;E&2)(EEJ]Y;\I,M;%'MVMY=;J>KR+VT(N#.%K)$[MO.,%N*W,
M.9NH,96I&:?MNV]%]5VA[L5QN:-!II*+-+IG82!8FK/FM'><Q9W=//10)YCE
M:U0>ZWSMN2XQ<1YC<$5K65'B,(T^>ZLECNV(. M<3BE)\_R\[S[K[2RUL53^
MU.Z^J'9M8NL7&*P;QSE&V-G)+I+%&3E^UFNJ6M.'I1U"$ONN!N1<VX^76:+@
M-'RIZKC%[6R<HI]&A1JYDB8)]0DJ>[>?5.K-OPJ5*2NT,^-P$R7:\0RY??4K
M>;!W*.=3SX;BLN!(U,Y>TYHRV<NXMM-S)>HF\,P0)$?/HNT/M]/MJN?/0<DH
MSII3MZ:[F\FF=6/8LWKV_B@YLX)D-A%R]0UAY).*_4-^-VBZQ<0YQFM$)!:%
M=<\ZGEH9H^"U#Y3 GER1[*#G-<UR_)<K;4E?FNCN>_!8T22MP-%(:W=&6V4T
MTOWX[\-45+2;1+1\ZG-16]JM=HM+?KE'*6<'=.NY6I^3=79N<_7-6<A5;>+!
M==UQ5RO76KB'/LVHE(K.KHG@4XK:6O8LW*4V];I"Y!"RZ(MO8ED5FI$(4?9"
M;BL<.R7,K:PL=O6[C)_<O^PW;O\ ^FWXOO=HG_3$/4RAD=NPZK=ODU6[?)>0
M<$CKD7.(I]&OR7OB_JILJ?=-_"[+[6$H^J7PW8'LE;7'WUS<A>]KM<?8H+UO
MM'VG?=-^&^+^JFR&^Z>\JP3S;E5O&G9^Y%ASF6Z[W7]C0SL-Z\XJMZ?0*U5<
MJN_)O;X>#.F"/.LI7K)'>4D.\D]W#94^UE\=ZJRZ*D%U\WF.8\Z"QHR#P8!;
M&_#N:MO=63J9VVQU#IV&+2@^]H=O2$DK3?'U_P ]*;B6X*N3W**?M$V.'8W5
MU/09#TU;2B[LFOI,]%N-QNW2Y:U:Z!A6\Q<"B2<.3WN<SF5%>1RCO;FSN+,U
MM&F[5C&M\7]+=D-]TYN6["->M%5VT7N(7A6GY)YN^#0CPIN[-N+7I74J?VO]
MAVNE\5PWO/W3['3Z6_#=56**XJFK;6EY%XEIBO:/WPB-<S3MS[=BN\?2F%BB
MR>J]UQPE/4_(Z2D&ZHM)UH_=L-N&YV[*U>MB8;X1/_/D;LM[$M%7TP@B#.YN
MG._MZLPH6WNS7>\_=/L=/I;<*^P1I_W3?"X5]@C3_NF-S#8,JZX/+V;/H>Y:
M<</3V]]<ERU+7 +X%S>\E.;E=MQ5+8E;[*GVLOP7:+5:%79VR/VMSNSMLK&Q
M'<672K?],\GO<WB02A]6YLNH/GI2W%:_=G=!6BVI;@0"UVV(W7_O:[0WV;?A
MNO\ WM=H;[-MP-D24W$FDO<9"ZBURZ-CF\[<FCM"J]O@:.\NFGBO3>3=B=!M
MOK+LPM9MS+UGNWV!_9MW@%KE1'*)!:XNLN<M.+I)]\(C'F4H_?=DW%GIR-WU
MD!W;(;?%B"^!'9EJQA#K/*?&SMV'W36]?L$^#L/NFMZ_8)N&+)OE794$3]0W
MPVG7;)AO<762*E+BNY;N27(:/?#:P7RWRV78QEPK[!&G_=,;QEL59+3;0MCW
M,7!6J7)6%MP<M=WQRN^+^ENR&^Z=Z+5Z >ZU1S#;G2VP7>-&WK2\4%1ZF;X-
M-.7IZY==6=S==5_:H6<J_8FD']+=@>R4DZI5VARI_P HZ^N?RCKZXM5_Z\>X
M"1M\;,Y-Y:J;?K;U4Y:WE'PW1WOK[)?[!?CN0_9*:?\ =-\-PYMP(']\]4=-
M+LU19&P;M"[FWF3?S=7>>E/ W3-VUVE/LK86[6XTL]EZS6BMHA !6?I6)/N/
M+SB')9_*.OKE:;E6][7LIJJL5V= J5A#:VJ#RU>_#?.&S;]W#\"K_5*P/[-O
M]FOT?<;^@%'/I";A;Z.6BZ"EU!L#&=2[RT/O6W<E7E?-W-H=PHC4,*H7VT)5
M!-=O54W.\JLCZ:1DE?WL(((/*@OQ?9'98]OE3^0\ISU[T=;1<J41LNWCJJ8>
M36#CZ.D*@WN3<5C Z9EM)LEOQPP^+([),GE\L8)<O^PW;T_1RJ'4TTG]US^0
MLC@]&\0C+L&VVG5FGB<6V=O4G$IF-7E_=/I13CID4^C165(TO7M*<[<.M>,.
M\^I=P=0WG>9:QJJJZ[NLWB/;DV__ -F_PW%9SR#0.,LP;?U>8YVGU^Q9)I6J
MH/S1R7-]LT;?3[:G&5G;;9NK%6;@MN?(%Q5[=;O?K!%H88D9I?E?-MUW@GX+
MIX-R:5M]T"B@\ITW(^6YJ]3####"O5%RI1T0V]553#E5A)_+HYQ(K&LP\F0O
MP^%9US12<4ZGBNI.KO)M+]^/< ?9O9W]N1N-,RJK+Z)N*>7\B'F$7B\8K:FW
MJ^LKHN6\MR=ZX<NV!)7:)XWAOB>M@2\O5U+-UO7VE::D]%TP;BLM^_9%<40"
ML[<SRG/KW1CFK4FW?_TV_%][M$_Z90J'TFY&YQ_'_9N?Q_V;ET!GZ:,I7U%/
MHU^2WQVI&"W(IJRJS/;9MVJG^&K*6D-<TK*=L-8VD<U^#L&CMZ?"B37+"MIY
MER[#D; %H]W*VM<:XA++D)%K1E-7$I&D^W#LQH<J?P?':D8+<BFK(;1]O:W%
M51<AL<6][HWG3/8^H'YM0,SVGUJMJL\E,IE4@E3I-IA::<VJ5LBTBTNTU0[R
M;*5LJX"KC*F%-.MVI9\=WHH:*4K:(V]##_%_=T;\;Y;*EM>X?S:E[(YGLWYZ
ME=C^WCD^>:GM;;/[7)E)I-)Z=E/P=2SULKW$K7/93L:K2>I?LCFB26:L5MAL
M>MO4J/CMF,BN1RID-H^WM;BJHY[D>2F?)/0VH%K!UT_Y78](G!-F9[5RT^T>
M?<OR_+\GRX]ZT?;VN.U4QRV8R*VY*OB^C;%VKWPU/S^QZ1/S)HV39Y6N$5GR
M;IDG*.4/\'Y;<ZUO<!J>J=C^WOFYBD.R<9%37/LJMWLTMY4$/>M'V]KCM5,<
MMF,BMN2I0Z!I-5: I/;-61:'JGX*'0-)JK0%)[9JR+0]4_!X5K*WP_CQAVCU
MF&&<,UM3V];?_F;P!2^0KN\3L]TTYZA+/GX5R;ZASFD]<3LXK7"L37E]CPC4
M,Q;;L]K5*,S9)4=2=!:"^#L+%-JQ\*VM"9FVQAJ-_!V%BFU8^%;6A,S;8PU&
MQV[)FJOM3):ME&QNKIO0&R&:S+IDP*RU;JMKQ?!:]NO9Q<2KB H(D[74:C@@
M\R!\6U#MAN^K*D]C^WODYM;^L/VU+;TQ7]OR,NF1Z:;,NTU,*L;2W9,&EH-5
MFV:LBUQ5*>4#2:54!\*LVS5D6N*I3R@:32J@!V#!F9/FI^<[2.R]-)VSVRA:
M^8E46]^4OD)JY#8_)ISTJ;ZH= TFJM 4GMFK(M#U25-3%-5K3BQ;2BSDJ]6V
MX+(K#+655OCMF,BN1RID-H^WM;BJH>Q;G9?<0H=7-DZQ^I)C2VQ^;]RDS81M
MU;7EOBIOZ;L&CMZ?"B7\7&Q0?Q<;%!_%QL4%$;:ZR(G\T1U!D/;Q2?Q='85M
M//179DMO5H%NB@?BY%N",.Z1*D]LU9%H>J?B[^W2R%^\A679:VZJSF<OV.Z.
M^7SK=]GK:C2"8H>@"'MHH#X3:5<A/)5_%QL4'\7&Q0?Q<;%!*]L)8PD_/MO8
M:RUG_E_%\]KAB=R@9M92ME6_E<_!-ML-8VGDU0%!$G:ZC7]FOT?<;^@%'/I"
M;A;Z.6?52DRE,.G,XE5.R>VQX<TYF[9=DI[RD4N?R1O+4ZDDRY4&S=OJ26\G
M*-P='X.T]^,OQ?9'98]OE>9I"T.]+Y'G^3S/DW#%FE"%,VV]:63'DJ;5GWXC
M<5C*_LWOQ?9'98]OFY?]ANWI^CDEI^C&^7HLK[:1WDV9 S-)4VG27/28%M^%
M;E-.*>7V5>DR@.[13Z-%YA5:K2QC5G:WPV]3$ DB<H@BDFMA57+*[NTWB/;D
MV_\ ]F_PW%9;]^R*EN9\NW+>,9OR_,O_ +N%XCVY-OI]M3&4KE%RA_U"M%:T
MF?E7\U I*HG)HI]&MP*@47G2ZY(^.-QK061(+Y3:6LO+YWS&G7D.2YWDIGR3
MWEFE"!M1V]263'PYOX.5DU66VKGR3JO0*WIZ7Y7;TYYU/V?V\3=OS,FE^_'N
M /LWL[^W(TOWXS<5B+>VGMZOK*[KFO!JEYSR//\ )YGR7_OIIUB29,Z<--W4
MM]&31>#R;N_PW%9;]^R)W+:*2=J@J<+XH+3T]V[_ /IM^+[W:)_TQH?O-_#<
M ?>0BGT:_-LCO06FY_)=RM=KH>Z$\/:+6\N;:PPK^Z[D)%EO:%=LVN=\9N\Y
M:QR_,<OSG+W(+TS$;9R?JC7CBKG[XV!M.D#%V8_VC>"(6LJ#W&=JA>]11O5,
MR6>26I92]RYJR&WE1%SY^JCW47T6(V"S2W';1_-+F6"-Y=I5FBRQXT66/&BR
MQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/
M&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT
M66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BR
MQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/
M&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT
M66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BR
MQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/
M&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT
M66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BR
MQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/
M&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT
M66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BR
MQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/
M&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT
M66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BR
MQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/
M&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT
M66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BR
MQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/&BRQXT66/
M&BRQXD$EY&FI$;A;Z.($V]_[9$D5.L;S;[93;F8/(&-):_EC5$OB2>@YI>>8
M!+*K0^[E<LGK56S)^TA%G#L*=C75VHNU-X6%S;6K82(*@WAG=R^W-*'OT>G2
MHWJV82*<MANKW,:O0)#J$;>D:AL*=C/;M1>@9VXUV0V"CJC3MM-VIO"PN;:U
M;"1!4&\,[?&FM:K"TJS>U-?&J)K<VMH2UZ<FI=P][ULTEE#$[D-QA54U3FCT
MBH%^]K-<*-6^1NIOIJ1+G V77<RR7I?)IE3J:#N6V4V[1 4NH^[E;8J#D4.N
MT7&.9KQC+V6(/%7]#ZW=8Q9M2$WDFFU#\+T#.W&NR&>T#5B6-9O'6_5B=-/;
M/;)5#:0EMR9'5'7YE=G=KZYM70]U%N1W;2G)RYPU]-Q'*.MLO+=0Z+6OJH>'
M4".O70[DG%M9M/-W\QQ3RRY';TD#XZ 3:N[TK'Y)4C>KLMS&I&W-]H)KR-_!
MZC)TK>RF7ELYNT, J3GU]OMJ_P FQNRM4<NK8;PPIV-"W:KP#;%J=(VFVRCJ
MCH"RMO#"G8T+=J+T#.W&NR$P36M:=8]9O9$Y]JBEW)[>TD?"GM!+!>N9Y(::
MM_W#[AZS4/1=,IQ1KC_%4?%!;1C/:\:.W[X7H&=N-=D,]H&K$L:R7=;:%=N4
MG]F=H[A6HTU=IM^NZ<TZ:EN3YF74RW*WB\.@[FGPO ,*=BZ1RR7R:94ZFGYM
M6/;77K_(56VGL\G45HJ,CDDFIF2_W6ZE::;)=G0IX.U!NOMKGNE_>&ICRVY;
M9Z\DXR=V5=NPWFU+X_VE^3"VXW'F[/BVAMR%O4]\ZU=>*3+GD+V[EY1P<XLL
M;6])+?E8_INW"WT<MH?8;_<)I,/)E$L>O>I0U0FV67&I<R@39O\ T;EU;.AC
MEY2GJ?4<E-%?W#FN5Y?G>5I&VXQBAZB_]PX;Y5=UO2KA.\:NG>-73O&KIWC5
MT[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.
M\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&
MKIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ
M=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>
M-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5
MT[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.
M\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&
MKIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ
M=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>
M-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5
MT[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.
M\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&
MKIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ
M=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>
M-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5
MT[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.
M\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ=XU=.\:NG>-73O&
MKIWC5T[QJZ=XU=.\:NG>-73O&KIWC5T[QJZ5;.ISY<Y]=GAZ[/#UV>'KL\/7
M9X>NSP]=GAZ[/#UV>'KL\/79X>NSP]=GAZ[/#UV>'KL\/79X>NSP]=GAZ[/#
MUV>'KL\/79X>NSP]=GAZ[/#UV>'KL\/79X>NSP]=GAZ[/#UV>'KL\/79X>NS
MP]=GAZ[/#UV>'KL\/79X>NSP]=GAZ[/#UV>'KL\/79X>NSP]=GAZ[/#UV>'K
ML\/79X>NSP]=GAZ[/#UV>'KL\/79X>NSP]=GAZ[/#UV>'KL\/79X>NSP]=GA
MZ[/#UV>'KL\/79X>NSP]=GAZ[/#UV>'KL\/79X>NSP]=GAZ[/#UV>'KL\/79
MX>NSP]=GAZ[/#UV>'KL\/79X>NSP]=GAZ[/#UV>#<9C,.=G?Y,>2^-K; D@>
MGO65?G<\K;<]7O*VF*<[I&]NGW/,-WJ/+3>H$17)('))?\;HNYN87;GG;A=X
M9=?569\[N3KW4PYQ)-VY>?3B9L"WE;8%DG%$UO1BE4B7Z+ISB+22#VW]W>I+
MNGP?@O\ -^J=6>9Q:AW/CP;F;ZBZ+NMW!L#?M8>NFU_=T:(7C-S^O%LU^W\W
METY_-Y=.?S>73B$;WY-9E-&(70&07):/_HJ?N@K4"3+W^!Y.X.M0L?GW\T>U
M/ZNS/<$6I'R3_P#.5XQ_57VS&$_S>73G\WETY_-Y=.41OA5CY.:,5W6ML1X-
M0\OS'+\YR_PNX;IM?;<5PFPK=I42[XW/XW1GAU*P)A*.;T)SJFJ[\.;YOE>0
MY6X[N[V5M7G:T;N>\FILUY+<G7NI?SB&;O\ N[I?SMN'=J,1>#//)\[RN8\H
MK*>>;3%(?S>73G\WETY_-Y=.2K>^N2\GGVH[SUB*MSQ'UG25P2=_#<$7O%4L
MV%CO<CK==>>?^"L=ZZZ*F:NMQNGG[W&._P!FOT?<;^@&L/\ N_RZVC_O?R6^
MUZB.6]VL7%+BSD;F[C+1>UD=#<!I))]I99:3N1K%M&[-2DRF\MMVW.6G^5L$
MWHU M5N4DTYE-12<W1]^ZKFZ\RV]M"]/"69C>RM3&6T])MJ_8UE<I=/LS[>2
MFT_<NM,/%M5*A8 OMJ1:[621SN35-);L;-N6?U;PD,]J:@:L84Z.2/69C\=Q
MH\'P>7=OV43*_"2T$;D+WM=E3[61NO\ WM;!=@M(KPB1?PAFLDRV03:_-Y%[
M^SL?HW:EDK5E>FBK983O-4I=N;/^.\?=I0^UBUJ@)Q-*A6GX[IB_37LM4.WW
M:V>K<XKOD=DB]OS*8N/68W[VM>>VNE_A0IVH?YQW8'LE,X1"5.:=W_"&:R?P
MAFLBX;'[GO)DK_[9+RK9BE[<'<%UPS12X(X/,@-T=[Z^R7^P7X[D/V2FG_=-
M\-SE?PK!QJH,&MT.QN6+.T+9<LVH&1>;M8K&?F2AZ&RU;!6M//.9 YNW\MNV
M#O[5>CBC"L_2L9QL]6W.::)_"&:R5[L>DGYN57-]O?<&M?R.TE=]<G::7=LC
MD4A=\@AOG#9M^[A^!5_JE8']FW^S7Z/N-_0#6'_=_EUM'_>_DO>1O]F:ON^V
MO5JRE;BCUH((/+@^"O)*GB\I;<":7/6*/3VMCHYZYVSW<8>%3S!F1*(H%=K.
MI%@2SY0MK1I/Q>\R]#K@#:'AM<4=E#G]H>_*;.BMXFY#99XLINR[+EY?@H[1
M_A<T=KR3%V#>5Y4]JV?VRF?RUA3"C<A>]KLJ?:R-U_[VNR&^UGX[P>TY2/E4
M794?U.+<5Q?\+OU"JE(VEK#N%+S2X\G5U8U?7]1)1]4O@]YQ/+-'9YR_E*.X
M-8+?3(THMX-)'$M]29U:(+ZF-?,@>&P%T/(/493^<-V![)5IWW3?B_IC*'W%
M6ON10)0FKK[MB']3A\]K\W1WOK[)?[!?CN0_9*:?]TQN-+A$UMYVR4#1%0G*
MK;;0MS(1;":U\;TMJ].+K+-I](JBHBI[#S[9C<,MBJS]*RT[[67PJFEJ9KFF
M;_UL7E[7;_\ 9:OZG'+58;YPV;?NX?@5?ZI6!_9M_LU^C[C?T UA_P!W^76T
M?][^2[C*U<\XQ_.T/0'D$EM!_BWJR^3&B&+6 &XRMTMW[\.]6;G*J!>ULQEA
MF%%7-S><LK\569EMHWB0L]NX_#>LO!\:/;[MC&69Q;LOPW(7O:[*GVLC=?\
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MO($ 7&K)=,9?-Y>.?=2WUF2./+WL59^9/8=X'>'AG#+M[#S?.U V]S"#N[2
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M<;[D.JF@5=*9 YMZ"RTWMX+TE5REQEK^X>TF36_+N#[K:%76?;MJ)7<FV?\
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M')6<K+R8V=*;'4-*;J]E&W>;)6H_,J&4[,N[',)FR+98HO0=0)@ER<(HG_\
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MVY8%8=:T6X4ITS8D8-V7<>;4^QUVQT^EI?W]Y+;>>R5_8K]'W&_XF;7]Q?\
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MN+;?C]TFF;A4"DE/[AC<5LZE;1;!C+*O>_=+_L+LOM8+>OV"7^/9MLI^[?\
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M>=S];R0?+-]U-<0;[8[0%WC#K".R/D4CYAZ)O.)9).<M1;0WV;?U1+']7?\
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M_,Y?> 73&[52@>S9C@BM([WF"/Q:MMII]))[9+WQ?U4M\IO(UDLN6,70<Y9
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M59>.&G*K+QPTY59>.&G*K+QPTY59>(DW-;3-L2T)AIMMI*&?<RRRA+332?\
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M#\"']'IO_19_>]D/9/D*/S<S[ 7_ "('X$/Z/3?^BS^][(>R?(4?FYGV O\
MD0/P(?T>F_\ 19_>]D/9/D*/S<S[ 7_(@?@0_H]-_P"BS^][(>R?(4?FYGV
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MSU5JY'.)>PV7"^4J_ Q+0"F=2DS,T>=CHN.;%,8A3.'KYR1,@"( )C!V]?\
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M'TGAW/=-N&1<3UJ0<+ND:AFW'D86S6+XLI'/S49&WG&47*N)5,H"55W!LE"
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MQF#%6(J-^WWXVWVTQL4W@8'XS;8,U4^![N6;2SE8GA2S6!DR2Y)#<5G! '@
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M'_ SCNVNV[_-M2L^<+<2U258AZ9296)KX-X:*@6,1&OY-<'SABPCHA%-+G
M2D*!0[0!K"^\6L[H,MY2G\+O+E(1-'MM,ID5 2[VVXYN&/TG#U_$+C(-U(,;
M9X0;\V \IRU3*;X F[%QR5D*Q1=0H6/JO/76ZVN;<%:0U:JE7BW4W8)Z5=&
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ME,$M;BMF]JES/EMLF0H&_8U1>.%#N6F.<Y!8G4S7HQ$ZAB!$U[(E1D9!3D%
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MJ;&)B6+.+BXMFVCHV-CFR+*/CH]DB1LS8L6;8B3=HS:-TBII))E*1,A0*4
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ME\X4,SDHUXZCY&/=-WS!^Q<*M'K%ZT5(NU>,W2!TUVSILNF4Z:A#%.0Y0$!
M0UM#W-2RZ;BRY9P91YJ\+(\T"!\C1D:6MY)[G*B4J9&Y;Y"R()E "B4@  @
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MY>]MT"VW#XOLBB;4LE69&A2#->\)M':PI*]PV+&BTNR<-@4Y"RAT%.0HL@@
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MNB'7-E4592E>W!XI>$40Y8@"9GK+GV:AOQ@BY/P[?8WP_3_CO[.G&MR_W?\
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M]^W'%W8WRNRH(E=+YYQHW6<E2(#A9NUQ[(*MD%5@+SBB+=1XJ9,HB)2&5.(
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M2+C77A9&OVRH3DG6K-!2!"'3(^AIZ&=,I2,>$(H8H*H*D. &$./;U[<.[_\
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M_2!C[[$,7Z]VG]__ &;_ +Q6.>QOB^Y_N7^Q>Z]C?!]W_'OVBK]C:C][]O\
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MPWDFRS4+BC']-QW#(PU:I<]+O#DBJU'5^(#N9H@J8G.<VF41'B8H"(]C/GW
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MN(/)<C3XC$N.)IB\5CY:"M.9;-$8X-:()\W60<M+!3*_87\TP53$3)NX],W
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M=RZ<KJ%(FF0ICG.8  !$=8WQ??XQ..SSEN4=YYSVU,FGW7 WF[1<.TBL?KK
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M#.07R*)%!"-E7MBD*](/%133;N"0R <LSGX.J1M[]Z"E>HNWT&)CJO!;K*K
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MBJEX>\)^@"7_ )]@>Q[Q/]?]N'S=S#V-\/WO]RWVSW76QG^TS^YYN"[& _N
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M0<R<H[$HD9QS-=<_ B9A#!FVC'XJ*T[!6*Z1BZ"?.&Z39[,-J=7V,*K8)-%
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M\P=A7).66M7=3,]BQ:(;6)Q0JU/HPCB51CG!VQ'(I&7*@H) ,!#</^6GO_\
M]S?<5_1SKW?-%O5:L%+NU+V0;4*G<:=;(:1KEJJ=JKF!J##V&M66O3#9G+P5
M@@I=FLU>LG2*3EJY2.DJ0IRF*'8B'5BDS8AW-8YB7D;B;/T-$EEEFT4Y<B_6
MH>1:Z5Y&!=:"Z?F.L@F+A%]#NUE%V2Q"KO6SR192NT>]9VJS9T9&+R#M<8OL
M\0,\W Y2>$&]:IS%?*,$U 3?"\,5^-.4 $W)Y <O2%?J&P3>3-2C@R8<VCMJ
MS"W:M4U%2(E<R4D]J#:,B6(*J%*9PZ610((ARCAQU1=T'O0("!IM*HLE&6ZE
M[3R2T'<+)>K Q51D8-UFE]!.Y>JP5)8JE275KZ+IY(2:@=S2!6*2:S=UN%F(
MQP5W&RN<<LR4>Z(50A'+%]?9]TT<%(J0BI2K(*E, &*!@ >V #K;C^H&XC[#
MKQV&6/\ -39Y3,GTA.4=88SY4V+1Q=\9RTFDF#IHLT<J-F]PH<PX;(&E(%RL
MBFZ!(JC==F[(B[2F'UMPG.9QPLU</%(K/>WZ(F\B4HT0@8ZB3VZPL9'J7'%[
MA-J*?='AM@VC@<G%)J]> 7G#&(<IB'(82'(<!*8ABB(&*8H@ E,40X" ]L!T
MSC8UFZD)&0=-V+!@Q;JNWKYZ[5(@U9LVJ!%%W+IRNH4B:9"F.<Y@  $1U7+)
MDV@63:)MK74;OYS+69:V\@[?.0X.BD5:8QQ-+*15PLLI(-P,HU?/D8V!%$.=
M[M4-S:*U%VP[;:G\5\=4ENHNNZ>K)OK1=;5($1&Q7Z\S1$&QIVX69T@51ROS
M:2"29$FS5)NS;MVZ6LV;O]EN(K%N)P'GN[6G+EDHV+(X)[*6(KY;WBUEO$,.
M-XT L-LJ,S97CU[#KP#-Z+)NIW$Z10%)NL\<0-OPEEVJ3K0QR.X6R8VN4%+-
M3IK*MU"N(Z4A6KQ R;A Z9@,0! Y#%'M@(:V6Y&FL&YAB,>PC7<*^FKW*8SN
ML?38AE.;3\[0L*\E+0[A$H1@UEYB1;M&JBJY".'*Z:28F.<I1_P? 9 V^;.M
MT^=J&CM8Q/7EKMAO;WEO)]12GXZX93<R$&I9*349R&),,&T@W46;"L"R1%TS
M&* '*(_\M/?_ /[F^XK^CG6SFJ6N#F*Q::QM7V]UZRUJPQCV%GZ]/PN)*C&S
M,'.0TD@VD8F8B9%LHW<MG"::R"R9B'*4Q1 /P=P<[!>[FWWS4)-9ORO+0\Q$
M[0]P,C%2T5(WR?>1\G&2#/'JS1_'OVBQ%45DCG353.!BB)1 =8#R9G/9/NWP
MQCB&I&=VDOD#+&V_,>.J1%.IC#EQBXEM)6NX4R'@6+B4DG23=N15P4RZZA4R
M 8Y@ >Q<<5Y2J,#?<<Y!KLK4[K3+/'H2L!9:Y-M%&4I$RK!R4R3AJ[;*B4?Q
M&*/ Q1 P (6?,?NS@=9\PLY,\FG&WF=FVK?.F.$A$SA>*I<G,K-(K,-98I%4
M%J4SEK9RI\TU!M*K@=VH^HN7\;W[%-WBS"23IV2:?8:-:HXX&,02OJ]:(Z+E
MVA@.40X*(E'B AV&-?VJ;:\F92:NW',.KNVA%('%L&!'963A6PY2LIHB@PW<
MRW*XI+2!7*G-'!)-0Q#%!3.F8)Z!S5O6M$"M"NKG%-'04'"\!*(BG-5/$J<J
MW:R<A)3:1N9E+&\;M7CIJ'<K9NS;*.RO=1-3F)IOC#<-BE27F,#YI)&>$TX9
MU*MDRS-"N\>B=)W,8WN"[)J9T"!@>QKQL@\;"<".&CR9B=S6W2\0-1C'AF\?
MFBJ13^ZX+LK8ZRJ;%]#91@FB]=:J22*8+$CI,\=-()G*#ED@<1(&HJDXWIEL
MR#<YUP5I!U&D5V8M=GF79Q "-8J @6;^5D7!Q$  B*1S#_V:IFXSWFE/DL-8
M,K[Z'M,!MIF5$VN6<P.&+Y!\C#Y1ATQ.[Q9CUV5 4I%@Z,A9GJ8G0!"/*8CL
M8^&AH]C$0\0Q:1D3$QC1NPC8R-8-TVC&/CV+1-)JR8LFJ1$TDDR%333*!2@
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M%1M<$^2,)5&DO7Y]FPE8YP00[9%4B&U&U^N1$I/STP\0CHB$A(]W*R\K(.E
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M2>9QPKDG$S6T.H:>RFM+MJZXOM:@$9MQ%(R+<[DC853(%73$X% Y>.M^^/\
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M$I#" =H1#2T9A[$>,<41KDI2.(_&M"JM%8KD(H=4A5FE7B8M!4I%5#& #%$
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M712E=-4E  #\ 43*;\90$$D$$DT$$$R(HHHD*FDBDF4")I))D I$TTR% "E
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M4/-JE$=.YG&LSN:VZBNL*B%;QYE*'MU.:D.L!U4BM<Q4W(MP.4J7$B7_ *\
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M-2K>UU>T0%<RED.PW"'A[&7+&.HDLW'L9AXY0:R01DBNASI0 _-+'+QX"/\
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M8>&K;%XZ8%W(YVA5Y:<L**1CHEE,?8?%9E'UIFJHF"S9U8UI!PNW4 J\2S5
M0!65R5[P#=$L*ZQW"D/1LIS^(JB*QC$."A:/B->C4U,R)B!S7)8!S/$>1R>4
M;BVD(W=#N)CW[-9-PS?,LV9*:/&KA(P&27;.4+,FL@LF8.)3%,!@'\0Z9NL=
M[_=QC]NQ4Y3>$RG=E\Z5E-(02*=HE6\UH7^$;,S%2[2:*"8$$QC$Y)S&,,!C
M3WFN(8>'BGO<$67<K@**E 0BW K(M1E\E8<>OY=VXCU$CF<OG]:=BJB*8E;0
M:H* "53ROB*\5?).-;W#MY^G7FES+&P5FQP[D3E3?14M'++M'*954SIJ !N6
MDLF=,X%.0Q0U=IV,4*C)0M1LDM'K'336(D^CH9Z\:*&15*9)4I%T2B)3 )3
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MC/962>/#BF03*CR2\%(.^TZJW>$5*H16'MU>B++%J$6*!%BJ1\RS>M#E5('
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M'(8#$.0P 8IBF*(@8I@'B AVA#62_H_N7S<DNQLHSGDS EXF,CYGVD;;\L9
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M2OU_N/SBD=>[V^@"(_GV>_P/A[Z$TOGU;O\ J!5[]1J=_,R'^+]2_P#91/\
MXZK_ '?WEGW_ />1^\5D;7NT_O\ ^S?]XK'/8]W9^O\ N/\ F[A[L>X0W3L&
M/+^,VTB[;?[5)%2X=S?$:^/,BT!BLN"?PN[OVB651(@G[7<Z@@';,.MN;)Z^
M485O/\'D7;O95$U.3W1\=ZPXL%(8G2$ *X3>Y6IE?3$HF+R.5S@<H2 0VMIN
MV-@[YB0S;G>Q93F4T%^"R]4P7330PQKY I_%\A9\PQ[I,3E^&O%!R#?DS@.Q
M2B+LBOH>KYFC\V6 BQ"'8EB< Q<GF8$I)-0BB2S&3DJ0V8F2.42+F=%2-VCC
MK?#][_<M]L]UUL9_M,_N>;@NQ@/[@&+/WBMU78]WM] $1_/L]V=J/W/VWVT9
M2[&PC]0,A?;CE'\'#.9H%H\?-<!;EX%:Y @BHHUBJ;E"HV2G!/OE")G*@FC>
MDX&/()Q(05),"\>4)2CK8=/XXE(U\CCG;MC+ ETCF2[<SRNY&P94(;&MPBYM
MFD//1LD^?5\LHF18I%%V,BW=%Y23A,Y];Y<L8GD&,Q1'61JI0XN:BW#=Y%3L
MAAG%&/\ #-FGHE\T*#61B9NTT!Z[:N4A.FY;K$5*=0IP.;:8>):/%83#SB_Y
MQNTBT145+"U^BT.>;P[MX8B9R(LY/(,Y"19CG$A>7(% !Y0E*.K!:YO=IL_<
M3-GG):PR[CNK-IN?DYI^XDGZW*7QBLL;G73DYN)SG,/'MF$>WK.6;\YY6P?D
M]QDC#;3%52'%BE[4E8-%>[05NL027QMJ-;;!'R9ZPPX<R=4_.-R\2@';[$!2
M[ ZCQMV1MT&+&= BU0;K2:CNL0EVL5CFF*!P,Y;LXR ;*-7+L@ 5,TBB@<P=
MTE*?4A:YUJX;QV<]V&9LJU ZZ!T2NZW&5C%^%UG38QOY0W&T8@DR<X':Y:9B
M_P#HZWKUFJ-'CZQ4RGT_,S1HS24<'5B<,9(I^2+H91LBFHLLFA0:[*J!R>'(
M4(4XB)2B4=$PM 2D:7(^WC-62HO(=;*NW+-IQV29QQD*EVYRR(;NGP+/-)5W
M'-7)PY*KF$=)%'\B(!JF8_HD@QFIG;SMII>-<FR3%=NX+'WR:NM_R.:HJ'0*
M<#+5^K7&,66XJB9)T_60,FFHB<3[3<"UEH\=R>4]P>)ZFJ9BBHLK&0CZYQ!K
M-85BI)JG3CZQ6DG<BZ5Y)@1:M5%!#@4?[QKGW0,-?/;+VO><1L'&FE,I[4MV
M->W<U%--MQ6;Q%,PW5XZ_@5T*8J*HN<1DM2O<R1A%1VS;"8H\$];:+%)3'@G
M'F=)A;;#E#G%#(M'%=S,ZCHBJ.)!?CS+2/K^6F5;E7"R@"FFW8*<H2%$3E[%
MAN-JE6<#5ZG!RUELDY(J\S'PT#!,'$I,2KY80'FF<='M5%E3</@D((ZW$;D5
MF<M(3>X7-MFL-2KXE6D)=E7)::\#XRI+9,@'7=+5VG-HR(;D* F,5L0H!^(-
M>Z"V?1YF9)[!^Q-ZRO"#-1%1)S?;1D9]8,C6)$S<!0%G9\HKSSM'DF4[1AXG
M.(<LWO1/[$W_ !<=BU5M#9-@-TA7['.0B+E;(&0R*N$HF3=,$UU2$1Y!5%2-
MP,8 [0"/:UBK)+YBWBWV0L;T:\/(UHHHLUCG5LK$7/.&+95;@LJW:+/Q3(8_
MPC%* CV^QNIW(P4''V>;V^;;\XYOAJU+.'+.*L,KBC&-HOD?!R;MF NVL?+.
MX C=91(.<(FH(E^$ :P#A*6V:8+@HO,6;,5XLDIN.OE_<R$-'Y!O4#4GDJQ;
MN40;KO(]O+F62(I\ QR !NT(]C ?W_\ %G[NNZK5C^Z!F7Y[8AUAW-N.,24O
M,$IDS-B>+'T)=YN<@X^,CST6VVT95HX@2'<+/ <5PB/(/\#D*&'\8!K#N2<D
MX=H^'7V':/.T>-C:/.STZUF6L[/$GE7SY6>(19!P@L3FRE3^")>V/;UGBMXU
MP1CO,B&>)R@S<LYO-CLL"K JT%A:F#-".) $.1RG($M2AE!5[912+R?QCK<W
M9,E86H>&U\#V/%\)$MJ-/V">2GDK]&79^\7D3SY"';*1YZJF5,$NT8%3<K\0
M:V[67^K/_60_;[8,CP7<7[9OV/\ Q3_9]'4]_P!U=T_LIREX=\+_ !LY'(YM
MGW/W/QY2G+X$SAC/^J1_5R_8UC^O7KPW^WK]K_QD\/6,\!X+\&_L7Q?X'[DY
M'/<_W0ZYSCR>;+_G=C.&#O\ [VS\:OV,Y@R7BCXT?UQ? ?QD_9W=)JH>'O G
M]5B8\#^&/ _='<O=;KN?G.;YY7D\LV -U>YB5>5NW[D<+T/+.+]ME'=MKSE>
MU.KG3:_:WD' \^C6(\:_5E)\C9Y8Y4L/&<2  <'2R+-1Z3;7M?VWX@I(J'*R
M+E(^0,SWTR:3@AD'"DW!VG$]4:=U($$%FXPKH4^7P(N(E YFA=QFV/;7F&F=
MT)B]2QK^T'#-Y! ZANZ!0GY:TY5JRO,)" HIC!IF,)1 ZH\H#$?V3;G<'D5D
M:IQ[)YDW U]2:0N5<?\ =0H(#(+Q:#MVQM%/4?+E10G(E=TP,H<B2YF[H3-B
M:W&_2!MW^V^D:V,_VF?W/-P79L.%JFREMV.Y>N&=,K!C/&,]&0](Q_-MP4(,
M%D_+3EI.1L#/).B"DYC(J/G)-@H0Q'K=J?D =8V-,$[0,:UT' JLF<G4<J7Z
MRE1_+%!K(V!WE>OPKU/DG((F0AFA^63CQY(B348WW.;3]O>5:D5PBC)N\/2-
M^PY="LCF(1P_(M:;%EVLR4@V*8RA6Y64<BXY)4A41XBL#E7;K?W4)E6"C0D[
MIM^R8BPK.7ZPS)W,FZET(1"2DHVWU5NZ=IIFEH5V_:(G533<BW64!'\+,[65
M,X,QA,2;?XRM LB9),D(KC.(F5RM#B4H.&XV.7D!$X"8 5$Y./$H@&[/'L<Y
M8CE6N;M1N5O:$!$)(F/KKAW&\)CERX,"@KJ,5;'0;25$!(!"*$5X"(F, =G<
MUN:VJR>W*(PUG"U060(R+OV1++6+2UM\Q2ZT&3G$C&1..IYB!9K)2$M()*%<
M&,=)V7EARP,(W';9NHE,;RER<[D+[DBH&Q?99:U0#3']IH>*XYJT=R,Q7:RX
M2F/CA7II51$K<R9454C <3',!=7+.VX3)%9Q/B3'\;X4M=VM;PS6-CT#JIMF
MC1L@W2<R4Q-2SY9-JPCF*#E_(.U4V[9%590B9IJJ^[[VOUF0KD>Z6:1^8=SK
MF?=*6-$G!(S^+P_09RKNX-J8Y3*-57UE7653,05V2!@.CH9,9?;4=EW4=Q\7
MC8/X0X)&$PE8@N2VDL'<J?'@ ]W<_P!H.*@]OC$5G?\ [5JZE7'JQ&TAEK:V
M]F&3R *82HI.W^'LD6"?&=:B)^<=K-+4U613(84&3@QBI!3\^[;\F5G+6);T
MQ![7K=5W1U4#*$ H/8>8CG:368K5FAES"A(14BW:R4<Y*9%R@DJ4Q R7]']R
M^;DE^ PE]R%Z>2F2;/'K2&/\"8Y;L;'EZZMDU%FY95.#<2$='5:I]UMU$AF9
METP8**(JHMSN').YQE$-LFTS;SBVI&6<MXQSF21R#F*YBS %$FTD9>IV3$%;
MC9)7X"PMSLI%! 1%(3K@'.F24R7@S:%DNN&6(H\CXVHY1H-BYHHD R$986F5
M)^(9E4(!N)G$0\,!Q 0'@ E&NX>O:$IM$W&611G'P6/\J3\5*X^O$\\.W;H0
M&.,OMVT'&2\X[>K@BUCY>.@G[]4Q4V:+E01*'8W/[7ZYM"PG;X' F;,@8KB+
M1-WB],9>?CZ=/O(=M*R3-@B+-L\>)M@.H1(>04P\ [6L!^\OW@R43B>*S'AK
M'=]0QW4EE;!/V6_WZN)3C+&6+(B1<,Y*TS2QA5$G.G22:LT%7;Q9NU0673D4
M]JVVS;[B3&B+HQ8@<O-KKEK)4@W1.H1)W)R=?N6.J=$ED$A!11DC%O#MC\"%
M>JE*)S[8-V>8HFEP>2LR52S2]KC,>1DS#4YL\@<B7&G-C0L98+!:I=HFXCJX
MBJL55^OQ<'4$G(()4R7',^<<@U7%F*Z!$J3=OO5SEFT- 0C JB;='GG3DP"X
M?2#U=)JS:(E5=OGBR3=NFJNJFF:8I_N\]M$7>XJ+>.&K3-FYAQ8(N L0-SJ(
M=V0.&:5*UZU$@WAB@LU<R5CC'YT# "\<V4$Q2^$D)?;5',^>:J^ &>#^7$<A
M B)56_/2%M?3W,O3)&,J/=O. *AN;,F % L7";Y]I5'M=864:MI'(.V*4FJ=
M:8AJF42+R:F-<EV*VP=OD'/ ICI)6*O(%,)C$ "\E((O.^U/*T#E*@OE@CI,
MS#GX^R4ZPD;HN7=3O=4DTFL_4;,R27(<S5Z@F*R)R+H&5;*I+'T910Q2$(4Q
MSG.8"D(0H"8QC&,( 4I0#B(CV@#5GPMLFQNSW=9#J[Q]"6#*\G9EJUM^A)YD
MH"#AM6GT0S?6/+B;%VFHDNNP4B8I42@=G(NTQY0'?PB>UJ@,C&4%.$JV%I9^
MP(4Y@$@"XO&0+A+',D4. #W2 #Q$1#\7"/2SY@/;/G*J)*-_"05J-N^'KX[2
M)S1'/<UE:6>ZU!JHL0AC!QK:@%5-Q_S  @2ZV#)J8I&9*9%M)3(^WS(Y8]AD
M.M,%C-FBME@E(]V[B;U0PEG -BRL>IRT#G1*_;,57*")]8/R7_5Q_K&_MFR!
M8J+X%_:_^R#XM^ *ZG/^%/"7[+LH>&.Z^<YKF.8:\WPY7.&_S=97P;_4^_JZ
M?LPP^IE?XT?U@?VN^'.;NE6J'@#P)^Q+&'@WC\9>Z.ZNZW'_ ''-\S\/EETK
MG'=1>S5Z*?NG,11:/ -4YS).4;,W; Z/6Z!5NZ6AI-T@D<AG3MPLUBXXBJ9W
MCI JA!-(,]I>U[!N(J.584H^4S.O;LO9"=MTC%Y#X_Q:L.-:?!K/.2(G:&9R
MQ4"FY!7"@ASHHOI"4VT6AJEQY<-.X/,WC7/;*/Y96LV^NRY> !P_)ND^T(_Y
M>'"$H?O#=OC'#C68=,6)L[8#<V"S42$<.3<TN]MV*K&XF;U#5UH8 .=U%2UA
M> 4W)!D8"B<:MD3'=I@;O0[O Q=HI]PJ\HSFZY9JY-LTG\3-PDLP5792,;(L
MER*)*IG,0Y# (#_B9N-^D#;O]M](U[M/[_\ LW_>*QS^!DS;]FJK,;IBS+=1
MEJ7=*Z_(0Q'D3*H\@'+)<Q#GCIJ(=E2>1[U+@X8OVZ+A$Q54B&#<-M(NZZCZ
M9P?DB7JK*951*V-9ZBY3;3^/KD#4HF!HG=*%,1LL1+B(I$> 0>V Z<X&NLLI
M*W[91>"8H:+N7/=3]QABUL5K3A]9X8ZHJI)P@HS=<9) F5).-K[8I3&,!P+K
M?-_9F_<\V^ZW7?>_<?8QB[\#?O\ J!CW[<<7:VU?3_AO[1:YV+#C&C3*T1E#
M>99AP!%N62ADI&-Q<M$NIS-<L@?B5/N62J;=*LN.V*I268#I@ D%1/ 6TS'2
MY6-ISGD:%IB<THS5D&U6@5!5DKC=7S!!1%=Y&TBG1S^7=)$.4ZC=D<I1 1 =
M8PVTX$JK6H8NQ166=<K\<B1,7L@LF KR]EL+U--(\O:K3+K+R$F]4#G';UPH
MH;ARN =G+.U/+L>Q[BNT*N^H=O78)O93%V58AH[/0LEUX_%-TWDJW*K\EP1%
M5$9"+<.X]4PMGBY#Y,PIDJ)-!9#Q%?K=C2\0QC"IX,ME(GG];L#(BHD3Y]%"
M4C52D4  *H0 ,':$-82<VV3-+9(VW/I+:W>GSAT#A_))XOC(-QCR7>\OB\4=
M/,3V""2<N5C**/'[=RL8YCF, 9+^C^Y?-R2['NT_N ;-_P!W7'/X'Q^Q-7&M
M9V_[P869R]18*,;),H.H9$BY-LQS/1(-FB5-%K$L)J7CYQJ@B1-LR:6))FB4
MJ;8 #,^Q&RRRAJ)N-H[[*^.HUPYXI1V9\3,DU9Y&)9G53(12YXH.]7D52@HJ
M8*LR*!0(4YBZ]UW_ &V?^$?5C^Z!F7Y[8A_!R5^O]Q^<4CKW>WT 1'\^SW^!
M\/?0FE\^K=_U J]^HU._F9#_ !?J7_LHG_QU7^[^\L^__O(_>*R-KW:?W_\
M9O\ O%8Y['N[/U_W'_-W#W8V9WMLP*[FML\%@S-;%1),!?$C7]VM.&[&FDJ!
MB*=PI1&5SO7*?PDQ*Q*H8HF2(8N$L]5H%#6'">6\<9:@R)+&0.K+8ZN$/;X]
M$JQ1*9/GG404HCQ[0#JN7*L2",M6[; P]FKTHW$1;R4'/1[>5B9! 1 !%%XP
M=IJ%_P#A3!J"PRR?%4B=LFWK'=1?QQ3$.#2[9)5E,NS+M3DG,9-9_3;=7""0
MP%'D-R&X<#<1W6[EWS+NB.P=@.!QI$K*_!39VW.MR))-Y!KV@,J\;U7$$LU-
MP,)$TI >67E'3,7?#][_ '+?;/==;&?[3/[GFX+L8#^X!BS]XK=5V/=[?0!$
M?S[/=G:C]S]M]M&4NQL(_4#(7VXY1_!RKMMSA7OC1BK,=/DJ7<8@BXM'G<#\
M"*M92(?E(H>,L$!)MT'\<[*43M'[9%8H"8@:D,$6N_TG)M-LC5Y;<27&O62N
MJ6V5H1W9$XX^1\<-)1S:,=69%-P1(X/&Q(R25354C'3M));F9ZQ[/\[V#&#>
MW=R_'.FN(^"N&.KB=D0Z;)W8:%<8R<K#F88H*G3;R2;=*3;)*'(BX3(<X&G\
M17'<5&X^H%NB7D%<(K"N/ZKC>5L\-((KM9"*D+E'LG5W9QLDR<G;NF["29H.
MVYA36(H0QBFKU79OH.+=V2<B8%K)V:=BJO6XYS,/V\>@^L-FG73&$KL&T5<
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MA:M:9J"914-:X.UPT4_6C)-%@P4348+-72('!NX=YN]VO?YIY,5"'I\EN*P
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MZO<X_P!%VO;WH'J]SC_1=K>#@/ >\&G9&R]D:G4N-I5*C:7EB,?3SZ,RQ0+
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M15%!U8)J+A&R[CE]SHN)5\@P157YHBBG,IJ+@)N24QN2 \ $=8MP7C2(:P5
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M_P!Q^<4CK;1]W_#7V=5SL>\K,<Q2 .P+>,0!,8"@)U-O&14TR@(B <HYS 4
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M<?8QB[\#?O\ J!CW[<<7:VU?3_AO[1:YV*KN1IT2I*W+93D!Q=)=%LS[L?\
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M^._LZ<=C;#OIK$29*-R_597 F5'K9!0K4EZQORK)CJ3D5S&,0\M:J/,R+),
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M),\9M%0.D52UV/.>'8"KHM2OE;)-9-I45 ),CH"Y(\4F'TVA'$:G;%%0%!4
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MR99RK%IK(.75<Q#BFJX4%4"H)F4C%;%:[5FYPY:F> 8#KI,V:RC<>! 14X*
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MD[6L@9ZLD7SA%5&5:KM8?3],IZSYN4Z0O)R0[JCU#%.,4[ #):I&VW;30V-
MQ=16JA6;%$YWLQ/S3T2JS=OM\XX 7]DMUA=EYUX]<&$QN!4DRIH)(HIW&O1X
MHE?SU5L,,Q%P<R;<'DI$/&+85U"D4,FB"RY>48"F$"\1X#^+7RCV@>N6[?T0
M]FX;G=@UCI^ L\VEP^L-_P ,VAN[CL(93LSI8[R1LE?DX5I(/<472<4.H9V1
M)B\A)-X8BITXY4[MXN^@;7[O[<5;3,W1VZ4MA2DN\_04BERP!!\QD\+FO*7<
MKE,Y3@"P(K)@/)633.4Y"H0M4]W5NLB7CAP9LFME#%4[A&)*H3N7B9>>S0E0
M(-JW'NLG!55R1(W _ P\VIR*YF7WHMMJ<M!0#QI,1>U;%4Z[FVMC>ME$ET6F
M8LD(-HYHG!HJIF*XAZZ9SW<42\J523!5NK#UNMP\77J[7HN/@X" @X]I$PL'
M"Q+1%A%0\/%,$6[&-BXUBW31;MT4R)(I$*0A0*  &MW.Y'&4]M>0Q[F_/V2L
MF4Q&T95MT58DJY;;*^EHLDU&M,7RC5C)%:N"@JDFX7(0_$ .8.WK:CM@RVO6
MW.2<+XL84VX+U"3=3-95EVTG*/%#0TH]C8AV]9\T\)P.HV1,(\?@]E'%6=6+
MRL7FI*/I3#F<ZDSCCY!Q7/O4DBN@9F?)BA8:7/BV1)-03DY&T@DDFHFHU>H-
M'K:8-CO$D;NYQFV6>*1%_P  3,>_G7,<F8RC$DUB6QO8C(S"><-0XK-HUI-,
MD5@%--ZOQ3.H,(7W;.^L'@/%6(K*[4LX(Q'/(G.F<X3ZU(3@19B9,>0X!SW.
MH7@8IQ*(",4.1,20>TK&[APGX4ON>K-"H3"#,B@=WDA\55&0L.17LPDAVVZ4
MBRAV#E0P%%ZF '.1_1,,H.KQE.[ECW.8\_6R-8M+QD:08)_ZK&M6K51VE3Z#
M$+G4/'03=PNFW,J=5==VZ.HY/K(NV[<+3&=\Q-E"#/"6:"<J*M7*8D62>Q<W
M"2C8Q'L)9*]*MD7L>^0,59J[0(H4>UP&>GMES^L[Q,.*.G+J BAL=9QKG:OQ
M?*5< RM-:N4C 4>S+1S82(D>0<NHZDU2&4+%,^41'1HN6]V[O9=N2F6**M6V
MUY9O,<(HJ<T<2R]*JU@B3E,8.)!!<04+\(HB7MZ:1U2]WON,KYWBA2 ZR]4"
MX&CVY16<H&5=O<VO: @W33%H<P@8>6)!(8I1!5+ETS=![QNQT7+.0Z<Z8V3'
M^VNF$6L.+JK:&B@.XJ?RE:99HR2R++03CFU$85FR)"(OD 45=RB @D&MMF/M
MK\ABMA/8FRG;+E:3Y3MDQ4X]2(FZDE",RQ3B'JUI4=O >$$3D.FD4I.V!A'M
M:SEF/<[*X-?U+(F 5L9P">+;Y8+7,$L:F1*3:2GD&<O1ZN@VC?!E?7#G2K*'
MYT2%Y' 1,&B;A<)W"OX$WDQ<&WA)"RST;(.<99MBHINDUKT7E,D&B\FZ_.5]
MLF#=G9(]E(.RL !HZ9O$TF8LG<9+[*<@9-BTU% CK5@9_7LSPDTV3,4G=C1A
M1Y63M\6F<XB!492+CW0@ FYKD"!A;Q[7W:^_%)=R8Q4U)+:5GB&9%$I#*"+B
M3EZ(QC6A1*0> JJD 3<"@(B( ,0.5L:U_:%C)PX(,M>\UV.!?6-%B0X@\""Q
M/2YF:NS^83)P%%"5)!,UQ'AW80 $P(X0P''.)BP6!PRG,PYDL;1FG?LP6YFB
MY1:RE@5: *,97X!%ZNA"0S<PLXINJH("L[<O';K_ !+S5MSVN8^_:?F6VW##
M,K7J=\:Z12O"#"J94JUDGU_C#D.RU*JM.X(6-66Y*[Y,ZO(Y"8'4$I1]AG_Q
M,[//_,%KV&?_ !,[//\ S!:]AG_Q,[//_,%HL?/;8:9C-H*B1!G+ON+V_OXL
MA5$W)SK&1QQD;($T*:!D"D. ,Q.)EB<DIB@H8D+=?>*[B8N\,&#A)TZP5MO"
MP1M?F0(0YRL[)F:U1U=M'@]10Q2.6T5 Q[D2E-S,B01 X4[#&#L?57%F*Z!$
MIPE0HM,B6T- 0C JBCA;F6K8H"X?2#U=5T\=K&5=OGBRKAPHJNJHH;L;K-R^
MVC:G^TK"62OV&?$JZ_MSVVT[PU\3MMN':!8__F<O^8JK;8[P=;:J_:?ZVP0Y
M[F.=2Y:)TU#[@\7[R<1?L=O5XW'K7VKP?Q^QAD+PI4S8QH5>+*^$\676\0[+
MC,0KE'F'#A%S^2Y?-\@Q#&[.[G;GMYIO[0<RY/J%.BZ-3OC%5*GX<?Q65:'9
M'Z'QAN\[6JK&<Q"PKE;E/'S<AN:Y!1%0Q"FP?=;3LH\%UFGY?QI:;%)_UD-I
M#WP=!5^Z0LM+ONXX[/3N0=]R1[113FD$E5E.3R2$,80 >Q;, [E<95O+&*+F
MW*G,5>QMU#=SO$"J!'ST!*M%6TQ6+1#J*BHQE(]PV?LU!Y2*I!$>-@O/NY\A
MP.?\:N%G+V,PME6PP]!S=7DSE.JC"Q5RDDXC%F0&J0IB4'CUW6'!><23[F7$
MJC@5XO,6R'=#2106.W++/,+7R1JKU5,!,H$3<X.%DZC-%(4HB)F;U<H!V^.F
M\;%8GR7)R#Q0$6C"/HEI>/72H@(@DW:MHI1==00 1Y)2B/:U&M,5;%-P249*
M&1,VM^2Z2]PO0Q:**)D._2NN7/B57'[5N53EF!HX<*F*40(0Y@Y.JWF?WE]Y
MK>:K'#N&TM$;9L9J2)\1-W[=0%VO[4;O*LHF<R*W3XE%:&8,HR-Y]+D+NI)H
M<Z)X>MUN'BZ]7:]%Q\' 0$''M(F%@X6):(L(J'AXI@BW8QL7&L6Z:+=NBF1)
M%(A2$*!0  U>(2*0[JDYBGV:*CFW.HH=T/Y"%>M&:'/.%$6Z//.%BEY2ARD+
MQXF$ XCKV&?_ !,[//\ S!:]AG_Q,[//_,%KV&?_ !,[//\ S!:0:.]E\?!M
MUN=YR4E-RNU!9@UYM%14G/IPN<)B3-SYR F7FFRG YP$W))RC%CY;>=N.Q/A
M.DE4!9[5<,EE\MY-?I)F$%(]21F8FGT*KJ. [:;Q)S/@0/\ .;"/:!7$6T[&
M+6GL9=9H^O-YF5RV#*&3I=BFNFTEL@79P@B_F3,0=K]QLDBMHJ-[H6!DT;E5
M4 W8V&?U*L&?MH_8O_6C_:7_ /;-P[CKXM?M%_JZ_$WK8R#1/#'ACXB2OB_N
MKN?N7\OS7.H\Y-YVW=;:/V2XJ=[<,ET)O:?VR[?[YSELL%IQQ(Q$5X#QEE6Y
MV,G=;*!=GY\S,&R?-<#J%,8@&_ O$U%[(>ZHR8M]EE(YS_65VA(=T,)":>NV
MB_,N,_(N$>>;K%-R5"%.7CP, #Q#6SG;]G2J?$;+N*L01U6OM2\.UJS> 9U"
M6EW*K'P]3YBP5F4Y"#I,W.LGKA$>5P _$! /\#8>^A-+Y]6[_J!5[]1J=_,R
M'^+]2_\ 91/_ (ZK_C)OA^]_N6^V>ZZ]VG]P#9O^[KCG_I=Q/)4/&E_NT<RP
MZDQ>/ZC3;%9&31Z%UM3@6;EU#1SU!!T""Q#\V8P'Y!P'AP$-=0.:_57>O,6N
MH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_
M57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>
M8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@
M<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5
M=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYB
MUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S
M7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5W
MKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+7
M4#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?
MJKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O
M,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0
M.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^J
MN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q
M:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU Y
MK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[
MUYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%K
MJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FO
MU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7
MF+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH
M'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_5
M7>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8
MM=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<
MU^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=
MZ\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBU
MU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7
MZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WK
MS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74
M#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?J
MKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,
M6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.
M:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN
M]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:
MZ@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK
M]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[U
MYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ
M!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU
M5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F
M+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'
M-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57
M>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M
M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U
M^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z
M\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU
M YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS%KJ!S7Z
MJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#FOU5WKS
M%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JKO7F+74#
MFOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:Z@<U^JN]>8M=0.:_57>O,6NH'-?JK
MO7F+74#FOU5WKS%KJ!S7ZJ[UYBUU YK]5=Z\Q:@3MH&9<$3I=304,A%OEBIK
MHQ")%D3F30,!54CAP,4>V4>T.ODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8
M/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VOD
MS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>V
MODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/
M>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C
M2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@
M\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3
M-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:
M^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(]
M[:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-
M(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#
MR-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,
MV#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMK
MY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCW
MMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(T
MCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMKY,V#R-(][:^3-@\C2/>VODS8/
M(TCWMKY,V#R-(][:^3-@\C2/>VODS8/(TCWMJK-G2"S9PC&$(J@X2.BLD?G5
M1Y*B2A2G(;@/XA !_P 9-\/WO]RWVSW77NT_N ;-_P!W7'/_ +U%.6NU^[OV
M,6>TV>8D[#9;+8=I. IJ?L,_-/5Y*9G)R9DL?N9&6F):1<J.'+EPHHLNLH8Y
MS&,81&M46BUJOTNDTNOPU3IU.J<-'5RJU.JUR.;0]>K5:KT.V9Q$%7X*(9HM
M63)JBDV:MDB))$*0I2A_]5-MS(23QK'L&:*CAX^>N$FC-JW2*)E5W+E<Z:*"
M*90XF,8P% /QCI2*L>\C:K 2B)2G5C9K<-B.*?I$/QY!E&;ZWH."%/R1X")0
M >&C/L4Y5QODUB5NB[,\Q[>:Q=&I6KA-!9NY,XK<I)(@W71=)'(?CR3%4*("
M(&#C_P!'6(48N9E8U%3"Z2JB3"0=LTSJ?'FVDYPY&ZR93'Y)0#B(<> :^5-C
M\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5
M-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:
M^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]
M]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY
M)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/
MRY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4
MV/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUK
MY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGW
MUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+D
MGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_
M+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE3
M8_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6O
ME38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??
M6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2
M??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\
MN2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-
MC\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^
M5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]
M:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)
M]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/R
MY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V
M/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY
M4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWU
MKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DG
MWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+
MDGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38
M_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE
M38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6
MOE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2?
M?6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N
M2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C
M\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5
M-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:
M^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]
M]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY
M)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/
MRY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4
MV/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUK
MY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGW
MUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+D
MGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_
M+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6OE3
M8_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??6O
ME38_+DGWUKY4V/RY)]]:^5-C\N2??6OE38_+DGWUKY4V/RY)]]:^5-C\N2??
M6OE38_+DGWUK:XX<*J+KK[=<)++KK',JLLLKC2LG5555.)CJ**',(F,(B(B/
M$?\ HJV'L=M>Y_<1MZ8W"CY\=VUG@[-62<3-;0ZAI[%B,0YL3>A66 1FW$4C
M(N"-CN05,@5=0""4#FXYMHNXO=WN?S]28G9!DFV1=.S7GW*V5*K&VICGG;7#
ML;+'UZ]6R=B&=@9Q$Z^:I/4T2N4VSQ=(IP(LH4WX'_,LW_\ ^^1N*_I&UL(R
M!D:WVB_WRX[6,.V&W7:[3\M:K=:9^3I\<YDIRQV2==OYF<F)!R<RB[ETLJLJ
M<1,<PB/'6]"^XOO%PQO>H'^KIX#NE"LTU3[9#>%-V."8:3\%6.O/8Z8CO",/
M(N&B_,K$YYLNHD?B0YBCL?HV1]V&Y7(%*L%ZO;>>I]VSKE&UU:;;M\-9(?-T
M)>OSMI?Q,DB@^:I+$*LB<I54RG  ,4!#^^,4SV[.8OD1'YFE+;$4DU&I#VZ*
MKO*4T@7LX6129N6PQZ::%D:\V8W'G!$P!_FZR-0=J$[DB7L.+*O%6^V)WC'L
MA3&J,-,RQH5D=BZ>.W)7K@SXH@9,H )2]OL8.M>%\J9(Q#:9#?/C2O/[+B^\
M6>@3[Z =X"W-23J#>3-4E(F1<P[F1B6KA1L=0R)UFR1Q*)DR"%@I^8MR>?<L
M5)+:EEN93J^2\QY$O==3EV5QQ2@SE20EIL<K&$DFB#Q8B2X)<ZF14X%, &-Q
M_O$RBABD(0ICG.<P%(0A0$QC&,80 I2@'$1'M &K7MO]V.SI^2[S7GC^OW7=
M1:6A;+C2O3#)5TPD([#59*JE'9%D(YVF EL#]1:O&.F(-V<F@H5R5W:]T6X[
M+N;I-TZ[K3:7FZ2\C68A0/\ -1K-*2<-Z;4F*9A$Q6T6P9MR',8P$ QC"))N
ME84RW<(93D<W+U;&]QL$8ISB1%T^0_B89VU/SB*A3EX'[93 (=H0TU=$^-^.
M+Q7W!7;)R3PU4+7".PY:9'+58/!TO&N #E% Y!(;\8<?QZKM6SS=Y[>AMV3=
M-FL[3<PSKB7RS 1!E2E=/L?YGDROK::29H<.88SZTO%BDF""2;/E\^2G;EML
MEU3MV/;8F9J]8O"-V%OH=J9HMU)R@9"KR+MZ>M72O'<D!PV%59!9%1)TT6<L
MG#9RM_<-YE?K^\S=;!0$%NMW$0T)"0VXC+T9$0T1&9>N#*-BHJ-97!!E'1L<
MR0(B@@B0B2*1"D(4"@ :]W?:[7.3%GM-GV,;2;#9;+89-[-3]AGYK 6/Y*9G
M)R9DEW,C+3$M(N5'#ERX446764,<YC&,(CN O.*;_=L976-O6!&\=<,>VJ=I
M=I8-Y+,M-8R*#*P5M_&RS5%^Q7.BL5-8I54CF(8!*(AK9?0LH;J-Q^2*+/?U
MB_#E+ON<<G7"IS/@O:=G:9C/"M<L-GD8>1\'3$<W=H<\B?F7*":I.!R%,&L4
MSV[.8OD1'YFE+;$4DU&I#VZ*KO*4T@7LX6129N6PQZ::%D:\V8W'G!$P!_FZ
MR-0=J$[DB7L.+*O%6^V)WC'LA3&J,-,RQH5D=BZ>.W)7K@SXH@9,H )2]OL8
M.M>%\J9(Q#:9#?/C2O/[+B^\6>@3[Z =X"W-23J#>3-4E(F1<P[F1B6KA1L=
M0R)UFR1Q*)DR"%@I^8MR>?<L5)+:EEN93J^2\QY$O==3EV5QQ2@SE20EIL<K
M&$DFB#Q8B2X)<ZF14X%, &-Q_P 5<P[H=NC^MQN5J7;,10\&[ME>;VF$397+
M)M9JTV5S#.E4$7"BD3**@F83!S9Q P=L-?+7 'J)@O.>OEK@#U$P7G/7RUP!
MZB8+SGHKVQ1^U3)+ 5$A4A[9AN?BVH)%3<IJD;NJ#D:F2*2BHKE.!CJJ@51%
M/X(DYPBD11=]F!IK;0ZDED&1,R8SEI+*N+&[E44BF>VRI&AV.1:=$E$3!RX\
MMH4 >2)RD()SDJ^3\47>JY(QS=HEO.U"\TB=C;-5;+#N>4",C"SL0X=QT@U,
M<AB"9-0W).4Q3<#%$ [&Y[:CM^M&(([$6*OV+?%)G:<31-FG4?CSMYQ+DB>[
MNFW+Y%=[SEFN#TZ7**'-HF(F':( ZSQES=9+4N7N./\ <&KCBNKTFGLZ9'I5
MDF.*/9BI.V+-PX3=//"D\X'GA$!Y E+P^#^!NJW0X->0;#*V)*I4I>G.[)"H
MV*$1>3&3J157IG\,X421?)FB9YP!2F,')4$IOQEUABA6.Y8(5KUWROCJH3J;
M3"$(U=*0UEM\/#2A&SHDD8S9P=B].!%  1(;@/\ D[-KRCE6Z5G'>.:+"O+%
M<;O<IEC7ZQ6H-@3G'<G,3$DLW9,FJ0< XG.'*.8"EXF, #.8V]V5B&'M+./>
M.HX^Y+/T5-)PLPFD8Z R..,.L7]?G"LUNTLSD+(\;*B'P5X4-*RMO]X+N*K)
MSK'528X7N']7V*;$$Q!3;I1^#6N/4%442IE* K JH8.(G,8QCF,VD(W?9O)C
MW[-9-PS?,MSV;6CQJX2,!DEVSE"[IK(+)F#B4Q3 8!_$.F;BL;\,R7=FV4Y3
MB(SF\B,^LI)$02!1J\>9?BKC/))JE1 .<;/&[@G$PD4*8QA&OXR]Y5B"+Q2K
M(=PQB>Y#!S:>EZ&@^462;&?Y#Q-(.)RW5N+!$!6<R$&_FS"L;DDBT4>)R5K(
MF-K=6[[0KG#LK!4KG3YJ/L58LL'(I%78RT'.1+AU'2<>[2,!B*HJ'(8/\O8N
MD_&F3+(0=3L<PP,LF"J17L9#O'K4RJ0B *)@N@7E%'\8=K7RUP!ZB8+SGKY:
MX ]1,%YSU\M< >HF"\YZ0>.Y_;A.-T>=YR*E<&MT6#KG$5$B<^I"6:'DR\P<
MX*%YIRGQ.0 -RB<HIHJ'WO[.JNYKSMPFG,9!VN6&9AY*%;F6(4[EGBC*DW9$
M9_D(F$1(:X,!XE[7*X\ ;YGVF9AK>5J@51LRL#-@9>-M]$FW")EPKF0*7+),
M[+3IP")G,FF];)INTB\^U.NW,18W8V0?U29O'\/^WC^LK^T#X]41A=NZ/V7_
M + /BIX+[M=-O!G,_M$DN?Y/*Y[E)\>'-AQF-N^Y^QXLE<;,MOF1<CH-:;C&
M,J$N%FK5EQ]%Q:II5F]<*F9D:6-R!T>3P.82CQ^#^#<X&.NF!"Q\):[%$,"J
MX,@U52LXV7>,FI551DP%10$$2\HP_C'MZVD[E<QNH=[D_,6*(^WW1W 1*4%#
M+S+B4E6BIX^(04518-Q1:$X)E,( /$?\O^!\/?0FE\^K=_U MJ_W<,'_ &95
MC_HJ]W;]'^X[YQX@UGS[@&4_WBMJOX7NY?N@8/\ F3%ZWS?V9OWP]ONMA'T@
M9!^Q#*']\^[L_7_<?\W</:WP?=_Q[]HJ_8KF#-V]*F+WCBJ9(B,L0D1"7.U4
M9TVN\%6+A3XV24EJA*Q$DX;HP-[DDA;G4,@<RQ3F*)TR"5UG_:GB.U4C)[RD
MSF/7$S,Y9R3=69JM8W\))RS((>V626BRK+O*\U,58$N=(!! I@ QN/\ >+/W
M9VW"WK0V3LNU5O9-T-MKT@",M3<03Q%TX'$;=XR/W3$SV5$$C/)@O.(N$ZR"
M*)B*-IH3%IFV#;O"(NK)8"N)FUW"93?)TK%U"BCHA8<@7N39-79XV!B@<)(I
M%*0R[^0<MF38JCERBF:!=M<35?<1N!0;M'%BW"9PJT-;;#X;2(D=5;&]5F4Y
M>LXGBV[H%.YO!:8RXH*<V[D7G # 5-,I2$(4I"$(4"D(0H 4I2E*  4I0#@
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M9P<Y"S?M0VZY>O;B)S/,1<4XN62L04^YV=:,C$HU1*.CU9N:7,B@4PE13$"
M(@&OD7N ]>TYYKTJTJLUNLQC* W7*UEZQEZN3?!T;DF;K/F%\QS;&SIND<G
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M;%*+%.=*-@J_'.9:7?JD2*=0R;./:**& H"80+V@$=;@=U=_6>&L><LH6>\
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MP_C>L9D_:MX3NE6N5TE9Z&_9YA').567<+"62+'K^$9"C)-%><'X**YS%^$
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MMG_A'U8_N@9E^>V(?P<E?K_<?G%(Z]WM] $1_/L]_@?#WT)I?/JW?]0+:O\
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ML;_M5Q%(V"!M+RI?'"^T;GIZLKJN81]X>QO::?9D^XEEC&YHKTJ*G'@H0X
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M]V/6D0Y4('(X"5$W;U_S"< >5YWS#K_F$X \KSOF'7_,)P!Y7G?,.O\ F$X
M\KSOF'5\E(YPF[CY*YVB08.TA$4G3-Y./G#5PD(@ BFL@H4Q>(!VAU[O;Z (
MC^?9[_ ^'OH32^?5N_Z@6U?[N&#_ +,JQ_T5>[M^C_<=\X\0:SY]P#*?[Q6U
M7\+W<OW0,'_,F+UOF_LS?OA[?=;"/I R#]B&4-*KKJIH(()G6666.5-)%),H
MG4554.)2)IID*(F,(@  '$=;F-RTT_=2+C-N;<CY"8'=BZY3&N3]HD7-2@VR
M;TQW3:-KE6%G'M$#B)F[5LFG_P"AK9M1&,2WC;-D/%D'N!R0X(4O=TI>\Z,&
MN0G9IA4GP%Y"NP$O'091#B!6T2B0!,!.4/8W#;G:COQ+A.&SWE*SY6/B\FU-
M.])U2<NKP9RU()6M+<;2$Y9&1M#QX]((13/FBN02Y)N1SA\);<;MEA'*+';+
MBDU4D<L'I[JBHS%5J(R;UA(JT\UKO[B&+"5<J+8Z1)-X"G<HG3!,IRH)Y[W+
MW518UESGEJ]Y.D&ZRAE2Q2=ML+^6CH!IRE%N:C:Y%N$6#1(#&*BV;)IE'DE#
M6R_$$%&MV$L[P?2LH9$731(1Q)Y1R_#-,D7]R\<\TDX?]P3]D5CVJJP J6.9
M-TN!2IE(7L8RSS7(A.,9[H-O\'*VQTBU,DG-9,Q/-2%"F9(RY0*@LX#'@51!
M0H?E"BB!SB/.%UO3V^NWRSIGB+.N/LH139<ZBO@UMG*CR=><-FAE"B"#%9_@
MU5<$2&Y!5U5E.2!U3F/[QK[H&</F3*:V_;>XQZ:-DL[YMQ3AJ/D2)D6-'OLH
M7N!I#1Z5%4Z2:IFKB<*H!3&*4PEX"(!V]4##F+:W'T_'&+Z?7J'1ZO%I DP@
MZO5XMM#PT<@';,IW.Q:$ RAQ,HJ?B<XF.81'65-MN74IQ?&>8ZF]I5V;UN97
MKTVX@9!1%1XWCYEL11=BHN" $,8I1Y28F*(" CK%NY7$=*R]^TS#MF2M])4M
M>6Y>QP#6P-FCMJQ?/H59B@D^-'G=\^B!C@!%TR'[?)X#I<^7=T6W7%9&Q3G<
MGR/FS&E'*W*F"XJ&7-9[-%@D5,&JHF$W  !,W'_-'AB[97M6S'2MPMP5SE Y
M>R-=L8RR5LQU3*U1ZE=8*,@VUUBE#5NPV:TS=R263\&N7Z+1E'. <<VHX;"-
MC^Z!F7Y[8A['N[/U_P!Q_P W</:WP?=_Q[]HJ_8P']__ !9^[KNJU8_N@9E^
M>V(>Q7]SE<B.XJ#O0Q^WLSYR@DHFS)F3%3>&I.1&:9 $R*2CZLK5J55,'(%=
MW).#B43 <YMW.QFPRO+<4FP5[<KC".65!5P:"MZ#/'F6$6P'X*MHN$G82KKE
M3+RDA<S2Y^!#G,*FMMVQ^N2QE*_@V@O,U9(9-CIBV6R3EA8\348V3(816+)5
M+'M=,\0Y($)W/:3<1./ $]S_ +P*U1)2R-QEFFV?#SQRW!-RC6:WX(O67Y=H
M99N)EXVP6)U7&"*R*A2E<0;U(X&$ Y&X?<3)HMW3#!&#\JYA=,W7/"@^3QM1
MIVX>#U"MC%=*]WFAP1 B0\Z<QP*3X0AJ>M=B?/K5D#)=QE+#.23@P*R5DN-R
MFUY*3?+G'D@H^F)N2.H8>UQ44'6 -KU$:LV]<P=BNH4!)=DB5$DU+P\4@6T6
MIR4J+?G92XVA1Y*O513(99X\54$H"80[.;9*M1"<%7MQM,Q[N391[=J9LT/,
MW9E(U3(,NW,8 [J4LN4*%.2;E4!$!>O%B]KD\ D,=2KY9PIMXW-97QQ!-%CJ
M*=QU.U15,S(S% QB\V1JO:<E3(%(!A,4Z9Q$  Q>/9W]-F#=1TNGC2G2!TT@
M 3%91.8<<2LBX'B(?DV<>S55/_V$(.L>.W:Z+5JUO-2<.7+A4B#=NW0GX]59
M==94Q4T444RB8QC"!2E 1$>']PW&Q2L@L[JNWJ-H>WNDM3KK*)QS.GUEG8+F
M@FD<XHH&5RE;9XX@F4H&*)>5Q-Q$;%N==1J(7C=[EJSR19D4$RNC8PPM+3&,
M*C""H+<C@46EY8VIY_WATS@^+P !*(CV)'.2\<W&W;3\R8SO$/.@#<K]M5\H
MV>+PG:JZ158Y5!BYR8O$&\732 RAG$2V./ B9];2@9O'"$%EYQD+!]Q9(+G;
MEF(B^X^L1J^S<B0#E5;L<C1$'("F8IBG.R*'P3<#EUOA^]_N6^V>ZZ]VG]P#
M9O\ NZXYUN-^D#;O]M](UL9_M,_N>;@NQ[NS]?\ <?\ -W#VM\'W?\>_:*OV
M,!_?_P 6?NZ[JM6/[H&9?GMB'L;Q\*Y%BGD9-5W/^29B*6=I"F%@I%TLK^Z8
M]MS(>24JD?;:3/L)!$0X"4KCD& IRF*&(ME/O"7-DQF\PC6X?&F*-PT379FY
MT67QG7D$8FD5C(T16T):WU><IT,1O%-7K*.?1CB-:)'<F9J)'.X3?[:MS6"\
MY%,W[I688SR?4+9.QR8$YPY9JMQ4LXL$$X33^$=%ZU05(40$Q0 0U;<(9XH%
M?RCB:^-XUK;Z):6ZCJ"GT(>:C;'%D?((K(*F[@G8=JZ2$IRF(L@0P#VM53.F
MW[9SB#%67:-X=^*5]JT=+(3L#\9JU,4^>[A5<R[I GA2LV!ZR5Y29N*+@X!P
M'@(?XG[C?I V[_;?2->[3^__ +-_WBL<_@^[U=IH-2R*^-=P3=TY(DD#U9DU
MM&+E6"#A8"\^HU;KO')D2F$2$.JJ)0 3'XVY9NV<+HL-G&8G;Y5%%15-DU/D
M'"[$CEV<A3%;-SOGJ*('.)2BJL0G'E&* ZWS?V9OW/-ONK#?MJ>V+)F<:=5+
M(-0L5@I#&.=1\19BQC"9-#.SO))D<KP(N4;K\ *(<A4O;U_R]MP'D>#\_:_Y
M>VX#R/!^?M?\O;<!Y'@_/VK=FS.6S#,F-,4T)FS?W&\V2,B4(2OLY"580;)Q
M(*MY=PL1-S+2C= O)(;\HJ7_ "=O6VKZ?\-_:+7.Q:D7#EPNBPV\8+:,4EEE
M%4V34\9.OCMFA#F,5LW.^>K+"0@%**JQS\.48PC[SN5.W3-(,V>S2/:NQ >=
M092:VZ=R_;D'CP!-TO$MC&[7XT2_A810;.45UHS85BEE())*%.=F\4S[N>DB
M-G!0'BDL9A((+ 4>WS:I3?B$-;YGQ&S@[%M@?&;1P\*BH9J@Z>Y!DEF;99P!
M112<.T6"YTB&$#*%04$H"!#<,E_1_<OFY)=CW:?W -F_[NN.?P,_JND&JR[/
M)6WIQ&J.$DE%6KTV8JHT478G4*)T'1HYTX2$R? XH**%X\DQ@'8JQ8MG#U\]
MWC[8VC-FT14<NG;ISFRD(MVS9NB4ZR[A=8X$(0@"8QA   1'L>Z[_ML_\(^E
M\2;8<26S-&2&U;D[>O3Z:W:NI=*LPSJ-92DR9-VZ9I=QLG<NV3./+X@98O:U
M_P O;<!Y'@_/VO\ E[;@/(\'Y^U_R]MP'D>#\_:_Y>VX#R/!^?M/HN1;J-)"
M->.6#]HL  JU>,UCMW3=4 $0!1%=,Q3=L>V&O=[?0!$?S[/?X'P]]":7SZMW
M_4"VK_=PP?\ 9E6/^BKW;%V2*Z4;O(W=95GI@1_U)FM'.MO<M&%,N'XG4F24
M=\"&_&1H(E_$;68&3U?FG-BV*98AHA/D&-W3((9PVVV!5#B4!!/DQ4$Z4XFX
M!^3X?C$ _ DYN57[EC(>/>RLBYYI9?N=A'ME';Q?F6Z:SA;F6Z)C<E,ACFX<
M"@(\ ['NYJ^Z*Z3>-]DVV5^_;O4>8=,Y&<P_49V0CUD>T*9HY[)*(<!^%P3[
M?;XZWS?V9OWP]ONMA'T@9!^Q#*&MPDW%+]RR</@_+$K'.>:17[G?Q]"GW;-?
MF7":S=;F7")3<E0AB&X<# (<0[&'X*,3,C&PN+<?Q,>B=118Z3&.J<0S:)F6
M5,954Q$$2@)C")C"'$1X_@;T9B,<&:245M-W&24>Z(5,YVSYCA^XNFC@I%2'
M2,9%=(I@ Q1*(AVP$.Q'NHC9GOU6B7+%HXBU6- RL+)6.6;IJ,E&?-)@EW*=
ML8HI\GX/($.':U[%^_\ ] ,M?P->Q?O_ /0#+7\#3=2R[!][UA.S*H1H><Q+
MDB6.U(L)#+%;F?LG H%5%,HF O #"4./X@UOO_K0;<LV;?X'(E3V^?%?]JE'
MGZ9'VV7J4QE[NSP5X8:MDY)Y L[.'+Y'*,B1[V^ '[?O&ON@9P^9,IKW:?W_
M /9O^\5CGLY)W YRN,;0<38FJLC<;O:I05#(1T3'$*!4&C1 BKV6FI9ZJDSC
MF#5-5Y(OW"+5NFHNLFF:QTG9 Z=;.=OR+YZQA)]@TAI3<5=X<#<RWE;5<7)9
MF(QVL](D5PG'U@J;J/.H9$\N_* *"^BR67>;O%LKM;D2$6C+9MW 3*ZSTZBH
M).8])>V.S&<G.82D,3X0B/ -,$ZML"S97$G_ #1@=9=1K&#$6:*B!7)EWZ69
M+%1GC7F4#<3)"D+CE@*14S+?D]4;=CNAR;B]2X9"W!TG"45A?&JLO;#U]E:,
M;9>OSZP6N^OF<#$$F(U;&2+0D?&-I)JJ1Z97NXHI D>Q_= S+\]L0]CW=GZ_
M[C_F[A[6^#[O^/?M%7[& _O_ .+/W==U6K']T#,OSVQ#V,H72O0_A')>T288
M[E:HHV9\](*U&LM'D-F2*%TFDJZ;PZ6,IA]..$R@)%G, UYSD@0#DVEWQY(F
M84C)UV2VZY+*=T#-@M4,Y'0I#-],+F$I"1-2O#V&GUN5\$/!("/XM2M@G'[6
M*A(.-?3$Q*/E2MV4;%QC55[(/WBYQ B+5FT0.HH<>T4A1$?Q:W#[BV[2:G9O
M<1G&:=X_@#(*.ITE3=2B%2P[2$6R?.*N'T%1(Z'B$4R\3&%N4 #M\-;8]I\8
MDS*_Q)B^&875XPY!FLQD^P'<6W*D\@H3CSK>:R)/2;E$1$PE04(7B(%#7O#'
M4>X,V75VY6J-44*5,PF8S+N,AY-N(*$.4"NXU\JD(\.4 '$2B!@ 0AH"N,'T
MK89R6CH>!BXQ%5Q)24S)O$646PCT$0%9=\\?+D32(0.490P ';'7L7[_ /T
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MQ2%$K*&SQ>XB,;@"92%$K2-8I) /#E"! $PB(B(^[[:Q:146RN$C22I"K*N
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MYOA 7DD+NWP0^=)ME\O;=Z[?8@JJIB _E,,7UO''CVY.4":SP8?++QR!1 3
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M#L[K<ES4TUC;E?\ &MEP/AN..LB62G<L9B@):H5\L.V6,4KY:IQKM]8W:?\
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M> ;.7E<5:F>+.Y#<9BBO/(M$B(N%23\+8[3$SE;=(-_RBB$@V;+)IB!C$ !
M=7W GN],M0>?MSF0(>5J!<MXW=GE<48+BI5JLQD[I&7Y!(8&_P!\3:K"$$A"
M+/6#5R/=CQT7N=-F]P]M8QVSDCIW.Q-9C*%O;-E'3?'&((5^R7R/D.66$HMT
M2P\.X%)D5<Z1'TPZ9LBG!5TGQJM#J$6WA*E2:W!U&KPK0!*UB*[6XQK#0D6V
M*81,#>/C6221 $1'DD#4UO[Q;5G3O;ENOGBRF1'T2U6698RW%NV_*M+6?$A#
M@QC<O*-CSS%TH<2KRZDF@() FV*K8MJ.[D;5*;0[S9E+?3[M7V#VTS.WZ\2H
M-VUD<FJ[4%IB9QC;$T$W;]I%D6>Q\BBHZ:LW2CYT MK/1-_FT&6BW**"XHO=
MP6,:Y.,"N0.9!.;J]FLD-9J^Z5*F801?,VZWP1^#VAU/JXES)3=YF<CL7!*3
MB_;]:&=NJ#V5%$W<CRZ9I@4)O'E9K+=P8@.3-'4I+B4?]78+ !S)S%E6C9C,
M6Z;=UEPG<4%!HJF%]8;"NC'PE>ATG3A5&OT>CUYH@S;BX6*RA(&-*995-LV.
MH7!^TRNNV<W-TN#7G,H7!FAS"=XRY;W)IW(%D3Y::;DT7X9<BQBBK@*Z$,R9
MH',8R7$?>-?= SA\R937NT_O_P"S?]XK'/9VU[I:O$O)AKM7RQ;:W>P9%<*#
M7Z%N"C:G&JVQ^D3_ %<(MI>\:U^-.H;BHFM+(\D.0*I@<9.R9 S5DP'F.DJ8
MES,VK:9'5BK$4O/1$_7\C0,4H=$LZ^I\M%B5=ESJ9W$8]=@CRG (D,UOE"W^
M[2W5><LTGZI+)G&@T"Q1+=9(ZZ?QEI>0)JKW.J.!23,849-@T6*!#<2AR1X3
M 5K/<3NPR6W:KC!8XVQ.6N1(^5>@'-MO".6V:G[)(6)[I,7NA4DN\?$1Y2B#
M-R8H)FRSO6R92II+%F'(VKU5A7ZBTE)'%6V_']KLSB,H-0>6-=LW;.+-<[$[
M64</W0(OIU^5=1)!%FU3;,VMTW'Y6I>%Z+<]OF5<;1E]R+.Q]4HS"V2TK1[+
M%M++;IIPS@*NSD&%2=II.WZZ#870I(B<#JD 7M]V\9EQ?G2B1U@?51W=\17J
MM9%IY+)&,XZ0D85.SU*2EH-S(,6<NV.LFDN<4P6*!N CPUL+O[=MRZU6<SY@
MI\L\X+?D)R\T>K35>;<HJ1D [K88\E#<#*%./,_!*8 .),PR6[*<EJ-BG.^(
M6E)2R;&UR?MS*E6VM6EE8X7XRP%4CIBSGKL\R,\;&=,63U5J]!MSB16QUW#>
MX4;:#N)@<V6B@UUG:[?&P=2R/!D@X"0D@B&3YQ(7"FUR,5,YD1YLJ*2RBX@
MFY'( 3!@/[_^+/W==U6K']T#,OSVQ#V=M6_2K1/-0N8:N[P!EAVT:\VV2R)C
MHCJRXYF)1T)A%Q,7&@24@P3*  !&E1)_E$1'#FU&P6!1YB#!61\OY.Q_"CQ(
M:.G,TQ^/&=H;+F()2.H]FYQ_W4Q*<ICMG$O("4W)<"4+-NBLD29G?=Z60G%A
MCEW"!V[Q+#&(W4W1L>,U$%5#J$+(6Q>T2R2P%2!VQDFAP*8A4U#]BY97I55=
M%VF;J[5/9(Q-8HYJL>!I5WG7"\YD+"\HN4G,P\E7YIPX?PC<W!-U77" ('55
M9ORMX[8KOVF+%%80A)9ZZP+G=G&REL0Q6UGY%61E\=9!A8E!_9#T'PP\7>1<
MBP;O5HM5RHV60[A%)5D6W5SW@&S%_7N9.NO('W,8<8>#RHMDWBZ<PTDKBS>P
MCIJT5*HLB[2061(8!.4H"&K76]I&0ZKO'W-2#%Y%4V-QL^5F<*TR5=(J(M;C
M>\J,T%*O8X6'4$5R15=<R3R262(V55CT5A?(PV-*;X8RCN'W-Y0F++<+A-&<
M.4V[^SS#FQY%RI>Y))-08^MUY!T[E9-P!1$J*8IHIG5.DB?!FU+%95#4C!V/
MX>EQTBX;(-'UCDT 5?VFY2S9L)FR,Y=[6_?3#\$QYONQ\KR?@\/P8+*6"(R+
M)O/VZQ\HKCM%XY;Q2.8,<O#J25CPS)2S@Z#1I,#(E\(UAT\.#-K)F<-5#-T9
M-P\;Q]BKLA>L)YVPG>A69O$0E:=D''&0:=*G0<(+MUR,Y6#GH.59G0<MER%.
M0Y3I*DX<HHP6/_>68AM$'>(]NUC5=P6 8./G*G:13%)#PU><4O)6*F*?(&;D
M,L\6KZTNV=.3#W-&,41*D1&3;;Z:Y&E4Y)5&-AQ#N%K\FV6YI)51!9C+8D:J
MJ<R*O(%5+G6YSE,!%#@ CJ6;;2X7)F[S)"S-4M;5+3[+AG$[5\=N;F7%HL.3
M8>#R"#=JY.41;L:TN+D"')SZ'$JNK'N-W,W UHNTZ5*(KM=B$73"DXZJ35=9
M2&H6.:VJ[?! UF,.Y.<""JLZ>.E573M9P[7674#W@V[RH*5S<3D2IKQ&!L63
MS0Z5APKC:TLR!-7"WLG!2J064,A12O<A(\Q"NX.#450<F*ZD';-GJB>\;PG6
MGE@O&W2KN*!N&@H=D+N3DL"C)R%AKV0T&[<0<+IXFLDO(!*\A)=3P1,F=J&1
M:Q2IA<Y*:PTID' 64X^,J.X;$L<^19/K'7HUVX<P%RJ9WJB46ED3'SA^Z5C.
MZC$;NVSQXQ45;E>=U-XNRX]WPX$K#Z19HN'%$S/?J_A#(T2Z%N+A[&NZAE!_
M69"0<1?(.1=>-[O8")!.DX42$JAIJRWW>MA&\R\2Q5<M<<8(N]>SEDJ;?=S%
M<L(5G6<;R<Z6'?2X*I@@O,KQ<<0%2J+N44>*H3FX*R0SBD8UK,.ECS ^+U7:
M+U2C8TC'[V00/-.FI$VLC=+7+/UY*7<D Y2K+$:)*':M&W"9W 9JJZE=W&;Q
M%*_;GL'*MU$)_'N$81LX5QA3I9HY2!:'L%@6EGL_)H%$IRIOF#9T0CEB<A-;
MX?O?[EOMGNNO=I_< V;_ +NN.=;C?I V[_;?2-;&?[3/[GFX+L;"[^W;<NM5
MG,^8*?+/."WY"<O-'JTU7FW**D9 .ZV&/)0W RA3CS/P2F #B3,,ENRG):C8
MISOB%I24LFQM<G[<RI5MK5I96.%^,L!5(Z8LYZ[/,C/&QG3%D]5:O0;<XD5L
M==PWN%&V@[B8'-EHH-=9VNWQL'4LCP9(. D)((AD^<2%PIM<C%3.9$>;*BDL
MHN( )N1R $P8#^__ (L_=UW5:L?W0,R_/;$.K;0;8Q+*5:\5F>J%EC3G,F21
MK]EBG4+,L3'(('(5W'/5$Q$!X@!NUK,FV>[J2D7=L%9(=-:S:T$W$4K9*V@[
M2G,:Y,KZI>;509VVL+L)9H<@@= 5P(;DJIG*6B5#>;E>N[5=T\!"Q<!?5LE@
MI XAR/,L&Z+)UD"F9&3:_%*M,;"<I73J*FUHI>.=+*H("\;(E=G/:GF__92A
M6B-4GOAT=TN#C11VK@R:;99%ZG>3(."NE52$1YLQA5.<I2 8Q@ <Q[.]@MX4
MSWE+.U/LF);_ )@@(J9BL5XOQ];8QQ!7L*_89V.C'%_NEBK<@LPCE89-6*9%
M=J/!D>Z6J;1;;=CZ'@WSW'&,+]6,YYUL!&ZPQ-=Q;B^?C;+(,I-\F0Q6;J^2
MS)K7F'XSB\E"'Y/-IJG)_B?N-^D#;O\ ;?2-;%<OY,GV]4QQBK>/MCR1D"T.
MV[YVUK=(HV;*19[7/N6D6U?23IO#P,6X<'3;H++G*F()D.<0*/M[T#U>YQ_H
MNU[>] ]7N<?Z+M2,A6]PMTSS8&+<RR-*PWA3)ZDO(J"BFJ@@SL.3*YC3'8J+
M\YR?AS9 2,4P*<D0X"VQ?"0+C &T*M3"4O"X7C)]28G<@34><!C+;F2R-F\<
MTL+R/5**\=#MFZ<5%*G PB]=))OM1DG=H&68;-L'3T//;@[I_K$<TM2J)BRD
M1A&KR28I+.;->"(%+(G:'!2&A#J.3J)+JL".&,3$L6<7%Q;-M'1L;'-D64?'
M1[)$C9FQ8LVQ$F[1FT;I%3223*4B9"@4H   '8WS?V9OW/-ONMUWWOW'V,8N
M_ W[_J!CW[<<7:VU?3_AO[1:YV+GC+(E=C;=0,B56P4B[5691%Q$V2IVJ*=P
M=A@I)$IB&48RL2^505 #%,)#CP$![>K%C28CYJ>V^7V2F;-MJRXX:JJQUQH8
MO 6)5IF53028ER5CY%XBQG6H D<Y^:?)I%:/6PBWVZ9TKE@SKLLD)AW)1E<B
M'[<N2<#R<P^7D9Z6Q2:7<-HB:J\](NE7<C67CADW._5.]:.FBZKTC^+D<2[V
M,'L)J331 *!E6W,,+Y);O5#'36CBTC*:E4FY9PT73,0ZL:F^:&^"=-91)1,Y
M_#O[7L7^!/!_A;PS\?ZIX*\%=S=V>$_"'A;N3P?W)^5Y[E\WS?PN/)[>IE]?
M]W&-,D7.,;N.X\2;?9^*S=DB5E44S*I0+AA17TG 4R0<D+Q*I9)&%: 42B98
M.6F!HA[.1*F*-M>,'C\V%L$,I4)8L<[>I]R/\@7^92;,4[1D2<9E!+EE2(RB
M&0]R,R<3O';VH>\3W+TQU&;9,*V)O8<#U^Q,E$$\]9AKDB<T58V;)<I5'^,<
M4SC '2[HP UE)Y!!DF+E%M*))ZR7]']R^;DEV-BN(,F;V*15,CXJV<;8\;Y
MJ[NBYC=NJW=Z-A.D5BUP#EW%XX?1KIQ#ST6X;G4;KK(',F(IG.00,/M[T#U>
MYQ_HNTI)&WK,+2YYM8[2$I>&=P%@E7ZB/-\INF9'%B,2P4."O$AGSIHD?@(
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MLTDVI5HN3V+7RR)E<*(MI7'ERQ3D.*?)EY0INT5JA?)9RT;KD#E%!VDV5+Q
MIR%/\'3-$FSYYC2'<*%(ZLV7LFXIH\?%E.LY0!9Y!+7-[>W"8':'$09P[HX$
M$AQ+R%4A/4=R&]N\5O<[GBG/&<]1L:5N(>([?\;VADL5=C8W9K&V:V#+EDAG
M")%XY9^QB(QBN(J#'N7"39VCV-PN:Z]N=VHQ$!F#.66<I0<5,N,O!,1D/D"^
MS]LC8^5!CC5VR"29,I8B:_,JJI<Z4W(.8O 1VF[<;7+0\]:=O^V?!&$K+.5X
M7IH":G\4XMJM$F9:#&2:L9$8>1D8%19L+A!%;F3EY9"&XE#*FT7%%QI-#NU\
MLV+IN.LN0C3I*LS;T7(5>N$BD]-6XB<E@6>,8@Z2/-MCEYTQ>4)2\3!MWWDY
M0W!;;[Q1<._M;\.5>@KY./;)3]H."\FXLC/!);#086''N*8O#=POSSE+_5D5
M.1RC\DAM9(VF9>>/("-M_@R=IM]B6#62GL9Y&K3@SVIWF%9/%6R+U1@L=5J]
M:\\W&0BGCMISR//BJ1[&XUL^V;,E2%T["'M$;DJ9I$BK'IF3[D5GJS<JDQ&(
MDG2:@B9NT>RB*1B&#N@P<DQMP^6=TT_A$[;,>,:=2JW4L9W*R6^S1$C#V-2Q
M2;BSJO:17JTT:II*D02%C(2!E5BJ<0(F4AU<:[<<+9!QOC:TTK<Q3LVOYS*!
M[.G .X"N8MS+1'42S&IP%BD1F%Y')#59,#H$1YE!7B<#<@II7<[F/.6 <B5)
M_@V^8M3@,9K9$4L9)BUV"CR[.0.6TTFOQG@ULA5UBJ\%Q5Y:A.200Y0AJ#F+
M++NL-;F\=0KF&QCGZNP[28<&@U%GC]+'^3*ZJLP/=\>DEWZSQLB1VRD(IXLJ
MLS<D3</6SR1;T#$N.MS-4;.CE9VW#66J5&J+L5'!$6*SNHY;E,:6Y)\H18G=
M"#1H_2;& X\\HB3GA0CD?=\YT(X<."MDU';>IL&)5#'Y &7E'UG;QK9N!OQK
M*+$2 .V)@#MZAU-Q"6+=GV/U5D5IR5N%UKF5\@DBU!)Q4K5"Q).6*$D98Q%
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M)M_;U?'S,H\Z!ORLD0>; Q^')*80K>9?>A76OW0\4X;2T=M5Q3*OW56=.D%
M6;H9=R>F2+=3+-,P?EX:OIIMU3 7E2JZ(J-SU^ETNOPM3J%3A8RMU>KUN,90
MM?KE?A62,=#P<'#QR+>/BXF+CVZ:#=N@F1)%(A2$*!0 .Q>X>,;F=R4K3;/&
MQ[4ADR'<OGT(^:M&Y3JG(D4RRZI2@)C 4!'MB :]@C('K!PA_2AKV",@>L'"
M']*&O8(R!ZP<(?TH:0CFFPRX(N''.\VI*Y7V]P; O,HJ+GY^5F\N1\8UXD2$
M"\ZL3EG$"%XG,4HQ\CNYS#A_;-104 TG$5%^MFS*ZY4S"8S5K%PO@3'#!-T0
M.25V:QNSH";E"T5 .2+S&6U?'ZT8_L9F+G(V5K@\;V++64I&-*N6.=72UIL8
MY$6,65TKW%%QS6/AV1EE5$&A%EW"BO8V _U.<!V#.'[(_P"M3^T7P%8*/!?%
MCX^_U;_BCW5\<[16^ZO#7Q+E.1W-SW([D-SG(Y1.5.9HW6;7;5A[&#K;5D^D
MM[;,VK&TRS4M,[:\:OXF(!G4[I/R@+/&<(Z.4XH D4$1 Q@$2@/X%ZEXS8??
MG<;*W&SR4>Z)?\)D(Y9/IM\Z:."D5R:10I5D%2F #% P /; !ULPP;FRHO*%
ME;&F'(VMWFG2#R*D'M?FT9>8<*L'#V#?RD2X4(BY(;E(.%2?"_SN/'_ ^'OH
M32^?5N_Z@6U?[N&#_LRK'_6AQ(\J]-M5D:-\-)-G#J!KTO,-D'/QWM:O<ZR\
M>S<))+\TH4W(,(&Y)@'AP$-=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1
M_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^
M:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>
M1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S
M^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5
M>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>
MS^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=
M5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0
M>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]
M=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_
M0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:
M]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1
M_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^
M:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>
M1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S
M^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5
M>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>
MS^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=
M5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0
M>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]
M=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_
M0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:
M]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1
M_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^
M:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>
M1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S
M^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5
M>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>
MS^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=
M5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0
M>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]
M=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_
M0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:
M]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1
M_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^
M:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>
M1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S
M^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5
M>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>
MS^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=
M5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0
M>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]
M=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_
M0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:
M]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1
M_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^
M:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>1_0>S^:]=5>
M1_0>S^:]=5>1_0>S^:]=5>1_0>S^:];8H^0:N6#]AMYPLS?,7B"K5XS>-<;5
MI!RU=-ERD6;N6ZQ#$.0Y0,0P" @ A_\ 59=BJOFG*451)Z<APGXJ.?Q-FD%'
MD0+UU' ](K"0DFW(07C)5/DG.4_$G'APX"/M%5ST:O\ T2U[15<]&K_T2U[1
M5<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5S
MT:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST
M:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:
MO_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]
M$M>T57/1J_\ 1+7M%5ST:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$
MM>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M
M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST:O\ T2U[15<]&K_T2U[1
M5<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5S
MT:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST
M:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:
MO_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]
M$M>T57/1J_\ 1+7M%5ST:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$
MM>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M
M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST:O\ T2U[15<]&K_T2U[1
M5<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5S
MT:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST
M:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:
MO_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]
M$M>T57/1J_\ 1+7M%5ST:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$
MM>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M
M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST:O\ T2U[15<]&K_T2U[1
M5<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5S
MT:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST
M:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:
MO_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]
M$M>T57/1J_\ 1+7M%5ST:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$
MM>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M
M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST:O\ T2U[15<]&K_T2U[1
M5<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:O_1+7M%5ST:O_1+7M%5S
MT:O_ $2U[15<]&K_ -$M>T57/1J_]$M>T57/1J_]$M>T57/1J_\ 1+7M%5ST
M:O\ T2U[15<]&K_T2U[15<]&K_T2U[15<]&K_P!$M>T57/1J_P#1+7M%5ST:
MO_1+7M%5ST:O_1+7M%5ST:O_ $2U[15<]&K_ -$M>T57/1J_]$M5JE57/,!,
M6BX3\-5JW$(UZ[HK2D_8)%M$P\<DL[J[=JDH^D7::13*J$3*)N)C '$0_P"H
M,O=<T92QSB&FMC&(YMN4+O6:!66YRIF5,5>>M<G$Q21BI$$P@94! H"/XM'B
MYWW@V"G[E-8Z!E:2YM63(X3D216,8DQCBLVN(51$BY0!0JXIF.!B@83$.!4H
MZK^\*VZ1[E=11)+]H-I>8C;&43.W()1?97BZ4Q)RS.2\@3* "G PEX@0_)C[
M?CZWU>]U*73%:)M%-GXFSUV32 >2*L?-PCM]&O4P-VA,FJ8./]V7BIN\4^'D
MVO-=TQTK9H6/?M^?13<(\^S=O47"//-UB*%Y10Y1# 8.T(#I.3@I6-FHU8RA
M$9")?-9%BJ=%0R2Q4W;-59 YDE2B4P 81*8! >W_ '6MT?=9NAQ9@^XVZOGM
M=<K-TF'"$U)UHDBZB G4X]@R?.$8M:48N&Z2RI2$65;JE()A24Y),1[8MTV.
M<VY'-"R=D5JM#+8I9\RK\."/A*<E%O 23&(B6RSE%'NATJBD9RX10*85EDB'
M_O,R:F2:"0Y#&(<A[C72G(<HB4Q3%-(@)3%$. @/; =)+H*IKH+ID6161.51
M)9)0H'3524()B*)J$, E, B @/$/^@,L;GW=3MOP=(GY/(89@SCC'&CTW+!(
M2<EK=+1"KFY0+$$.!>WRR_\ :&FS%#WCNS9-9TLF@D=[GW'D8S*=0P%*9S(2
M4XT8,T0$?A*+*D3*';,8 T*^!-Q&"\W(%345%;$.6Z!DI($DBI'55%2F6":(
M":9%R"8W'@ '*(_C#_#>'OH32^?5N_Z)]J_WC\'_ &FUC_J#7':#[O=2JY W
M%5TSR REGR4;L+3CG"-B3,9L\J=,A51<0^0\I0"A3 _,]*M PCLI6KA&0=%>
M-&;W)VXS,&2,Y9'FG!R>'[]9)6S/T"NE2\W$5]DY5490$.F8")MHZ.0;,FY"
ME311(0I2@TLV-=@>Z::K<BU,^BK#)XCM-0@YAD46P \A):YLJ^PFFJHNR\VH
MU46(KR5.0)N:5Y#VPY:V';IJK6HQ$SB4M1<.7*P5.*;D1(N9>5M57C)JO1B)
M4U.V9=RF4# 8O'E$, -,E[3\[WS$$ZF\;NI>)@Y91Q2+DDW.F8(V^T"2[LIU
MVBU 2*',R3)P!! ITQ(H4ARO,1Y1B8'$&]:@P/ABS4"-=N/BAEFKL"M&\ED;
M%)I$ZCUJ5D]<%"5KZZSEY&%53627=MC**-_[IOF_LS?N>;?=;<OI W$?;?=_
M[IEK<WG">+7L88;ILI<;*[(9L,A( S(5&*K=?;.W+-&2M5MFEV\9%,Q5(+R1
M=HH@8!. ZL5DJ=*E+_GC<?=!9T?'T.N96NXOQO"E[DKD M,+I-F%?Q_C&H($
M&2EW14$S\VN^<B+APH)R8SH:B-XS/?"Q4WG_ #@\8%:2^0K4Q;*$;14,V.99
M:OXYJAG:Z4-%@H82 JJY<&4=N%U#?W*Z?> P3_/DI^ 2:QGD.\XZF4UDG"<M
M1;;/U&3(X0 Y45R/Z_(1[HJR)5# 4P'Y10,/ >V.HEE?LM2&\?$"3A$)O'&Y
M&6?VFTJL@%%-R>L9M6*\R=!3 M40(W,_=344@814-'*F$>*V4MN]@>1=MJO@
M]AE["=P[E9Y*Q-/OTUC-49EDV669S=7F^Y53Q,XP.JPD$TSIF%!Z@\9->QDK
M]?[C\XI'6VC[O^&OLZKG^-^X2S4:U62EV-G?, (M+!4YR3KLVU2>9II;5VDV
ME8=TS?H)NFRIDU"E4 #D,)3<0$0U[2N?_7)D7I'KVE<_^N3(O2/7M*Y_]<F1
M>D>BS6.]YNZNC2P*)*C(5/<)EJ =*F13<HI@X5B[:V%RF5!XLF)%.404UE""
M E.8!B(O<5.PN];$!%D$):O9,:1=6RFPC0%(%E:GEZJPJ#]26X$$><L;&Q)G
M QB@5,1*H0N9=L5R6>+PYF##)6+;2FSB<I8DL$@DNJUA;S76SV0121D"M%C,
M))DN[BI(B*G<[@YT5TTNQO7JU*SAE^GUF+_JW^#*[5LEW2OP4=W;M(P+(O.X
M8B)FFD>T[KD':JZO-IEYQ94YS<3&$1W22V1[[=,@2C#=FO'L9*[6F<M<@RCP
MP]C-R#%H\G7S]PV9@X7.IS1# 3EG,;AQ$1_ WT6:H6&<JMDBJ)058NP5N6?P
M<W&JK9JQFU5582L6X:OV:BK9<Z9C)J%$R9S%'M"(:VYL7VXS.[UD]SOB%H\9
MN\O9 <M7;5SD"O(N&SENM83HKMUT3B0Y#@)3%$0$! >R]SQN8M:S-%ZL[A\<
M8XKA&TCD?+=N;M!=A5Z/!+N6J:QD4S$.^D'2K:,C$E"&=+IBHB52<@:MDF8V
MDX!<O'1(;#V ;)+5N:>0ZACIH-\CY<CO!%YOCQ5H?FWB"1XJ!<C\((M,=)UR
MA5"Z9*NLPHN[2@:A 3ERM,HJ=4#.G*<7#-)&6?*&66 5#@0PB8_;'B.@L"WN
MZ]]:,"9FC(A-J[1L_IQ Q[@A%4'P21\? S%FNFH4Q%>7R#%, @(@(:+&V2#N
M^+;_ %UPB[*PFXR>I%P@G9#"+=R5J_0C)J,<%,41(?DD, AVAU7ZWE:]RF\O
M;\T[ACY/&N<9YY)WR&AD%DBJJ8\S4Y0DKM#2B#%($&R$P:=AD40Y!&*9N"I(
M?<-MBMZDU +. AKE39U)M&9"Q=<4D$W#VF9!KJ#Q\$3,()*%40626<,9!L8K
MAHNN@<J@ZR.N@JH@NA0[>LBLB<R:J*J=?D3IJI*$$ITU$SE 2F 0$!#B&O:5
MS_ZY,B](]>TKG_UR9%Z1Z]I7/_KDR+TCTA*PFZC<?#R;7G>YI&*SADV/?M^?
M14;K<P\:6=%PCSS=8Z9N28.40PE'M"(:BG2>ZJT;A:BR<)J2F/\ =&*V:8VP
M(%6(H=L\NT^Z2R['<H@&*!V%C:& #=OE   #;%<E'?U>-WC"+6>R&#;/.MY6
M(O[:-:*NYB?PK;S-XWXWLV#-N=T\B7+9I-1Z(*'!%TT;J/A['NS_ -FF2\@8
M[\.?UR_#7Q%N5BJ7ACP9_52\&^%/ $E'^$/!_A!?F.=Y?-<^IR>'+-QL-?R#
MF+*=[@2;3,O2!(2Y9"MMGB"2#:YXG2;OBQLW+OF97B";A0I%0)RRE.8 $ ,/
M'\#(R"&Y'/:*"-[MR2**68<AII)))V"0(FDDF2Q 1--,@ !2@   !P#6P>QV
MF<F++89?!$4[EIV?DWLS,R;HTW.$,YD)217<OGK@Q2  G4.8P@ =OM?X'P]]
M":7SZMW_ $3[5_O'X/\ M-K'_4%88GPG8W$#NKW:)V.FT">BUUVTOBW&<4V:
MMLFY4CGS42K1=H01FFL17U04071D9 \@W.8\6<AL9[;L"U5U>,NY>LR5=JL*
M18$$3+F1<2,M-S<BJ!D8JNUR%9N9*4?*_DF;!JLN?X)!U7;&E68'..[15BBX
MN6Y*ZP#1W*Q4LLB4'D1AN&D0?)8QJK4YCID5:F&9?D,(O7:I!200[&1-R.U#
M&U;QKOHI\7(W)-O3(QI78+<TE&I+2$S2[K$1C=&-7RA--2J> [ *9'3F1*BS
MD5C-%2N&.-L^8<L,E0\OX7NT;;:I+IE707CYN$<F(ZB9EB)T#/H67:BO'RL<
MO^0?L'"[5<IDE5"#MXW;TA!-C#9OQO$6E[#)+&<EK%O:J.8#(--%T<"B[4I=
M]AY*).KP %3LQ.':$/[IOF_LS?N>;?=;<OI W$?;?=_[IC3"+S=Q8]N6(*5:
M'=YM=/JN+F5W5R=;TF@1]4?666>WVJ\S#TQFY>G:1Y$#I*O'HN5C'40:<Q;D
M,=2LAEW.F2%%&N0]P5N@F,'9).JMI 'L'0*M LWTNVIE+CSH(N739)VX7E9(
M@.72QR(L6[/^YW3[P&"?Y\E->[E^^!@[Y\179?P6X;;3@W,T?)%4!P;(N,*?
M9Y%-50. O&$U)Q*\S%21![:;IJX1<IF[9#E'MZN.]GW=,=9G6&Z2U?63.FW"
M4E9*W2F+JFU("S_(F+)Z44>VB>H-=;E,O.1THY?R,2V*H_(Z58D728XWW3X4
M?K'D:J^)&7NDJOUV,#E7&,F\9GN.-K.*2:Y!C9]HT(=NN9%8T=)(-7R1!7;)
M\,3[B<0319_&F9:+7[_3Y+@4C@8JP,4G8,))N4ZG<,U#N#*,WS8P\MJ\051/
MP,00[#R1D/=W;1GC^0=.'KUVXPG2E7#IVZ5.NY<KJ&C!,HLNLH8QC#VQ,(CJ
M'KE?C6<- U^+CX2$B(Y C6/BHB*:(L(V-8MD@*FW9L6:!$DDR@!2$* !V@_Q
MOW&_2!MW^V^D:]W-!3L9'S4)-;[]H<3,PTLR;2,5+14CN!QZSD(R3CWB:S1_
M'OVBQTED52'353.)3 )1$->S1M_]36.NCFO9HV_^IK'71S4A"9@V*[8K($F4
MQ7$_%XDJ='O20&2*B<8W(]!CZQD"',=-,@&%I)H"/-DXC\ O"T[QM@;VX7K;
MU5$W4SF/!]H=_&.]86KI!%5:\T^RB"4E>L9Q)3<B1;O$U9N#;D!XJYD&HNUH
M^@;GL+OUG'@5TG"9+Q^N]5:U_+.+9)XU/;*!82E*JD4LBV;E6CW9DE3QDJ@V
M>)D,= "FQ/N)P].(V/&>9:+7[_4)1,Z)EO!D^Q2=C&R:*"JQ6$]!NC*,9%H8
MW.LG[=9!0 43, :WS?V9OW/-ONMUWWOW'V,8N_ W[_J!CW[<<7:VU?3_ (;^
MT6N=C(F:<JV-G4<:XII=DR!>[,_!4[:$JM3B74U-R!D4"*N72B#!F<4T$2'7
M74Y*:9#',4HWS<9?7$M$41!T[JV!<6O'B:[#%&(V#U8]?KY$FQA9+6:6 PR,
M\])RA>RKA42"5LFV11AMWV]U&V47:*NX!?%^.89XM6KSN,%B[.D[F5YDA?"E
M-P^5PV,V[L:@C*S8\X+!9FB1-ZJRQ?MIPKC?"%#9)MBC7\=56+KB,DNU2,DG
M)V!ZR;DD[/.*%.85I"16=/G!SF.JJ<YC&'3S&&ZC!..<WTUTBLD@SNT @ZEX
M)1<HD/(4^V,Q9VVD30$,)2/X=\Q>I@80*J &'B7<MMOD+1DW9):K UAI%2>
MDG>=O%IG7)TH6MWJ18MFZ4YC^>=F*UA+$=% Q'ATHR0#NQ1DZE*5GBJ/9:5Q
M18'4=3=QF+VJP'C\D8F>OR#*%28KJ)M2W:G&4-*5Y[RDE$'Z(MSJ=Q.WR"])
MR?CV?8VN@9'J-;OE'M$8*IHVR4^WPS*PUF?CS+)HK&8S$+(H.$A.0AA34#B
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MG,LUVYN\?[-\;***H1$32:M7LE9'6C3*&,0;+D7)D%-L5)0Q1 .>A(:" A0
M  3<5#'EE_>+;KB.E%DES),LL6".C .B"92%)"QZ[6&31$$PY:94 34'B)BB
M)C<6#F<W$0.X:K-%@4<T?/F-J=8F$@4RA3J@M;Z?&T?*"1C)@)2 2>!(G'B"
M8Z5PY/U93;UN[AH-Y/.L12<X2P57(D'$$ \Q8<1V]1G%N)=2+;\'3^$>M4)-
MBV$RB1G[9NY=IZM.0\@V:#I=%H]?E[7<+=9I)I#5VLUJ 8KR<U.S<L^519QT
M7%Q[919=94Y2)ID$1'@&K5BSW8L1!XFQ3#/'L,TW(WZIL+9E2_F:..9^,M(H
M]N9O*=CRKORD4[E2F8R7F'#8R3A0L8N)VB2DS.>\?WH,7BJBJID:7N&R9C>)
M RW-\L$X''=AJT&BF7F@Y!"-RD3XCR0#E&XL9*K[]<W71!H9(%X?.$LPSY%R
M;4AP%5F^#,,=<Y%,KD@"0R[9PW>% >*:Q#<#!#;6]U=2J> MVDNW4+096KOG
MZ>'<[/&B!G+N%J[>PO9&:H60 :D.HA"O'\FA)$0.9J][H.1B'8E]O6%:U&[E
M-X;-JF:?J?AA2/Q7A4[UJ5PP_:M8HL5).4M2R2Z2Z=8BQ2=]RB)WKV-Y;7NF
M4D%MW4UAR!?+.3L*3@"K5;&$'7V[D%"BRBY]C%OLDO$4"*\$E)*>?N2< $%>
M4 &TE-5WW@6=IIPFL14S/)4C 9>AU@*).4BK#93@;A&@BH4G 0(F00XB(" C
MQU6L/>\\Q[6:*67690T?NDP_'2K:JLGJIV[1!WEO%SAS-/8ABX$3K/)J <J-
MT#B !#HH<M9*OW2EV"%ME0MD+&62KVBMR;*:K]CK\TR1D8><@YB.6<1\I$RD
M>X37;N$%#I+)'*<AA*(#_BAN-^D#;O\ ;?2->[3^_P#[-_WBL<_@2<%.QD?-
M0DU'O8F9AI9DVD8J6BI%LHSD(R3CWB:S1_'OVBQTED52'353.)3 )1$-;G=L
M5?;N$,=UNZ)6[$(N%57)OV2Y)BF-[HD:+Y?\M(N*M$3H0KIP8 %9[&K&X=O6
MX3:%9I5P_>;7,H0URH*;M7B$?C+/2$_)*5Z+(/;.SALDTN>D5A[8D5GB@(\!
M( :WS?V9OW/-ONMUWWOW'V,8N_ W[_J!CW[<<7:VU?3_ (;^T6N=C$>TRJRJ
MD?/[O\F/'=Q!LY$BSC#^#0@;-.Q"R:2?.H)S>1;%5S <54RK-V+E'D*D.IS>
MV[:U((/#T*U7 ;/F%VR<+L5F.': R<7#(A$9-M^7BI"=@8D\2P<%[:<E(M_^
MW5>IM1A(NLU.I0<36:Q7(-DWC86OUV!8-XJ%A(>.:$2:Q\7%1K5)!N@D4J:2
M292E    _ R=@3,%<:VS&.7J38:!=X!T4H ]@;)'+QSL[-P8ASQ\LQ!8'#%X
MEP79/$DET3%53(8-PNU:YKF>SN"LK6['WA@4#-4[+"Q$FK\5K<V;' %$&-PJ
MZS.4;E, &*@[( @ \0TWQ%:I5:2M6T3*UEP^R.[.=9\?&<^U8Y$QVHLN=0XG
M:QAK+)PK,G H(LH9), Y)2B.2_H_N7S<DNQ[M/[@&S?]W7'/X&(]Z./H1O$5
MS=]6YN'R<VCD$T&1,WXG1@F;NRK)()HMVCB_T.<C#'*4HG=2$._=JF,JN<15
MVZOI5PE0=X^+[337,297D1H9-Q7#R^4Z!87/'@ /&M?AK)$-PX\#J3G)X";D
M<->Z[_ML_P#"/JQ_= S+\]L0_@Y*_7^X_.*1U[O;Z (C^?9[_ ^'OH32^?5N
M_P"B?:O]X_!_VFUC_J"Y;RF]7,Y>Y+R;?<@.W!R+IG<.KE:I6Q.%S)N5W+DA
ME59(3""BBAP$?A&,/$1V9)),NYI.]1^6<ESS@S,6*TF]N.:\AO(AZNF*JPK<
MU4$8QJDMQ_+MVR:@%*!@*7\+?-_9F_?#V^Z/=L96J6IEL-5<@4H)^#<F9R:5
M:RE0;-B^^1K=V3\JV+8*)<9*/5.F)5").C"0Q3@!@HVZOWE4M>H&&R1$QMOQ
MIM=I,D-/G3TF6:IO8*PYIMY4%Y^&=6F.<%=-Z]$#'R,>V,@=X_3=*.(YKCG,
M6#MG=>HN3\33S2ST"Z(Y.SG.S4%.LB+IMWZBUHRA-I3)@3<G*9-^1TDH4W Y
M3!P#3UKB>?\  6YC=!*2F(<,R;<Q@DZ9#I1J3O*>58WDG2$DA2JY(MV<<L4_
M+:3DU'N!(HFBH0<<;6L>R*T4I;73^W95R2_:.9EMC?%D NV<WO(,J@"J9Y)\
MD#U%G'-U5D"2,[(,FJCA ' KDKE6PIMFQO,6R$9MDY+-F4ZG6<BYOM4FD4@N
MIJ7R!.PJCV+4?N2\\+"'3BX=N<>#=FB4 *#VG9TVM8#RE /F:C$S:WXKILF\
M9)* J +0DR>(+-5Z0;F7.=!TP<-G3=0PG24(?MZJVY+;":>D=G68+4I4S5B=
M>.IR:P/DIRQ?34?3%K"[.K(V"BV>+C'BL(]>F4?-C,U6;Q9=7N=RZF?=DY/L
M;J2Q7FF-M-]V[(2CM9<E#R[5HQ_;+K4(/G1YJ/KN2:<PD)-5$3@DG-1)!03Y
M^2<F4UOF_LS?N>;?=*XU^.4I0=ON#8.)FLUY-YM27?U&J3\Y-.X+'^.HYZ5>
M*)=+[-A*KLB+\A@S(E(2"I'"B0-7<36\.[.\+O9>.9IMWF2\H4N!RSEF=<&9
MD9R#^2R#?H^<G&?A?DF4791IV$40ZA@1:(I\"!9:/D[:QB6GV:8C7#>"S+B&
MB5/&>8*;+ T*VBYN)N56AX]W+EB3I)'+&RQ9"(< F":[50GP=9XVO7IVB\MF
M!\I6K'KR:8%.@TGD*_**I0MIC4S'.LV8V:%%M(MR''G4TG)2GX' 0#97N(MK
MYQ+7.WX;85N]3;Q?NEY8;[BB;F\07FRO%A$PF>62V4-X^5#C\%1P)?\ )KWA
M/T 2_P#/L#HDK7Y>4@I1-N_:)R4/(.XQ^FUE&#F*DVQ'C)5!P5O(Q;U9LN0#
M<E9!4Z9P$AC ./MY7O)Z0MD>X9+A8NZXHVOSZCN.I-'I\JFG)UJTY;91K]!Y
M<;=9HM5%TG7W9DXR*:+<U(MG;Q0R+ M1@-GVUN#J96:D>6L1&W[$T;7BQZK<
M&BK$L*RJ2,:#-1J'-&2YKD"G\$0X=K1/>);+<:0N%XFJVZJU/<=B"BQZ</BY
M.#N\FE5ZCE*G5AH4L70WS6YR$9"2$;')MXIX$FV<)(-W*3H[[ =9:R+AK3]R
M-?R'@.^,4QY:,@UFJI(72E"9N8AR=T-LFTF%X+!R%$D%%@ W(.H0_P"#NM\,
M2SQQ3]N]XD]K^-X!5T=9A6H?"[YU5K>1BERS))*6')S><E5Q  /RW@)F[290
M#">];-V&Z#G[<-N)B9&_L)7+-7A+Y6L3U).R3$33X''M8L+20@(V:<1$4E(/
MY@S897NMXHV36(V2*4QJQ/X.P_.5HS=-H:O3&-*7)P9FJ2(MTFQHE["KL!;I
MH#R"DYOD@3M '#M:R-OWV5XEKN!<DX16CK7F#&F-6)('%^0\82$HUAK',PU
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M*<HBJD<.(" ZCK'5L"X7K5AB' .XF>K^+:/#3,6Z*4Q2N8Z4CH)L^9."E.(
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M[0KYD&.R9'1R2SAW"X]STUH$>O>ET$RF \/7K=C2'9.S!Q.@66*L( @FNHG
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MM%KG8L3IVW,BA,[<L&R48H8R9@=L4FEDAU'! (<QB%+)13A+@8"FXI"/#DB
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M1=U9LE7!!L<A%6Z-NR#-R<DFDIQ423<E(8QA+Q')?T?W+YN278]VG]P#9O\
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M$&KINUE9/=/,8CF5F_=+NF98POF"+GHPOY .;=2M2IESH;QP"BW)YME-.S_
M,;AR  PR:F$K7DC=Y?B,W01%7QGCZV4*K>&4R'[C:V;(.7H&FMXZ'<' O./8
M:/L*B13<2MU# ) ONY#)D6:9RMFRS04'5L?4:.E))G"1K9!A5,>XRH4(07\L
M_*P8H-FB"9 4=R3Y11<X'<N%!-A_!&0&;=AF>W2$[FW.C%JLV<)163,BDC0/
M63N6:KEH[>4>F0D-!.ET55D'#J,451.*1R:EZ%1$(MON4PM*.LJ[=9214;,T
MI:QMHU1G9\6OY5R9%*.A\HP1"M2JJ*HMF\RUC73@X(-E &K9BH;68Q7N)VY7
MR4C9JGW>%DH]1%^Q%[6[UC7(M7<*1DD>'G(U9W%RK,QV[@$E3"DHBL5-4D,I
MN1L%TV<Y6[C:HV&K7.EW;)="<30II]U_$W(F+JM93NH/EF,)%YV,KZH<D2BF
M/P#*/Y6GYYN&XFU(LSKQ]"PUB/(I)*06,!BM4E+/DRO8[H+%-18/RO*E3+HI
M@)N9,(D*>)R;D*#9X\Q=CEG,5G ^$X*1>3,?1:_.223R4E)F7<)MOC/D2U]Q
M,B2TFDU9(KD8-446R*2!2C9MW>XNIO*KN@W0U]A%0=,G&BK*QXBP"F]8S\76
M[ P722=0]PR//,&LQ+L%>*K)JQBT%B(/$GB)?\3]QOT@;=_MOI&ML&Y1]77%
MP9;>MP^%<XO*DTDDX9U:&N)LDUJ^N*ZVEUF<BC%.)M& %L1R=NN5 RH'%,X%
MY(_\NR__ .\?7?Z'M?\ +LO_ /O'UW^A[4C';=]@E+IEC.W,6+MN9,WS>1XA
MNY413Y*CR@4N@XP=+IMEN7VBV,O/%Y(CS?;**F:-VF69C)5I;MUXVKQ'--H6
MCX_@5E4U1KM I<2FV@:O%G,BF*YD4NZGZJ8+O%G#@3*FQ][R#>ICYY5<0T=Q
M%7G:YBFXQQ$)G+-P;JG=US,%D@'@@]A\=U%R@E(0";M%-6P/NYWR8>#44CR/
M8WS?V9OW/-ONMUWWOW'V,8N_ W[_ *@8]^W'%VMM7T_X;^T6N=F^;W=I-#?6
M+9KD6:?VW(E4JD<J[<[8+C-O#O)M%]#L&_\ J.$9N4=&5B'Z10:01U1C'(-T
MRQZKQSD_:W?DXZ.L7<#?).*+8V7G\494C(TZYV#.Y5<KMDJ$A&"Z5[BE8]PQ
MF&(+*IH.B(KN$EHN/W9[;,X8/N9DT4)&9Q4K6<S8V.N0QTW$B9:2E<>WJ';N
M"E(J1HG%2QT>69,5U>0"JOA#]N^4.Z_!_=O@+^KYEOPKW3W-S_@GGOBWX$\(
M<[^1Y7=G<O.=OGN;^'J9@MCFV7)>3[RJW<,XN_;@E(7&^-XA\9,QFTVWJ%1G
M[==KQ'HFY)3,G#FJK',)AYX"E#G);.>XZ]6#+N7[JXCZ_$-T&($8P\6#M1*N
M4#'E/AD",("OL7+XQ6D>Q0 R[E=1=45G;A=96-W^;S*N6.W.W"LJ(8.Q#,-
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MMB<R+XF&\J;8LZ5'NHZ</(GM]LQA<5V8'*4CF<JEFJ+^NQ"QRFY0I-;#)@
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M\W4:ZW"9DVZ[=JJL9(95",F;'F7(S$IE$^=!M6:[$0%%>&(B)^V-J3#G *
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MOAQX#I:1Q5D_'V2638B9W;BBW&OVLC+G>T0K[P'(/3,51, @)%@(<# (" "
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M>,VYU"@<.( 81#B&E9.AW2IW:-04!)>0J-CA[(Q15$RA035=PSQZ@FH)D3@
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M[B*:SSAN>FU2R)-BQR\VU*8'!DC&%8.0!@ W#V]Z!ZO<X_T7:]O>@>KW./\
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MLC[1,R0N::53;4:DV6>A(2W0;>*M)8B-G31"K>X5ZNOEE@B9=LMRTDCI<E4
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MJ#LU;!JZ24*=!10.(@"R.Y[96I/=QHG&-5L&<T8@'YB$%=L$V3"*[P6::@F
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MM]]G%5$44H:EYQQC:9955QSG,))QT':'SPZB_,GY!0((FY \./ >S[NS]?\
M<?\ -W#VM\'W?\>_:*O^ 6M.<\89;V(RS=N6 7RA2$9HSAXFDLT0+%*3A7PK
M.D5R'3+S?*.4Y1* @(:270537073(LBLB<JB2R2A0.FJDH03$434(8!*8!$!
M >(?@O)RQ3$7 0L<F5:0F)J0:1<6Q2,H1(JKR0?+(-&R9E5"E QSE 3& /QB
M&G<ACB_TG(#"/63;OWU)M4%:V;)PJ4YDD';F"?OT6RRA4S"4IS%,(%'@':'L
M&44,4A"%,<YSF I"$* F,8QC" %*4 XB(]H TM!7'=YM?J4VWYSGX:S9^Q1
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MR&V7)7AUFY5(9*7Q/EM]B.?E&S<!Y@EBA[!,52.*KQ.<O,!(R"'(,("H(&,
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M_NV,KK&WK C>.N&/;5.TNTL&\EF6FL9%!E8*V_C99JB_8KG16*FL4JJ1S$,
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M$:X;/$R$3<%*&MR*"&1KVB@CGO,*2**5NL":222>0[$1-)),D@!$TTR  %*
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M@U6-)'3%ZL[ON(MJF['<*TE%G#Y_<\<8-S!EEM(N.>*F[>.[%6*O/I.UNZ%
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M>[J;F2B&; )%#G'#QJLRU-X=W$T>+7GDHN2+B_,D7&,R9/P[9W#=4&%AIU@
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M#M <H_"!)!!)-!!!,B***)"II(I)E B:229 *1--,A0 I0    X!V-\7W/\
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M#.Q8H=6&[O4TC<>69:KM  . AQ[8%/8-K6Y'#N<V;='GY%ECZ\0DS8X(@B0
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M#=93Y:[XP9[=LD9";PT-;[-2GA;37+/CN,B7HS%3DXF4,B@SL+HID15YHXG
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M;K.'O!K7/IF43-(0.*<!Q%1.BD1=0%46=MM^2KN5PHX:@42JGA4@14$0%-4
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MKK% 3&$"E >(CP[$/8(A?NF*G8N/F8QSR#)]T1\HT1>LE^;.!3DYULN4W 0
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MY_MH^Q>E:W5P4FF5&2A=R.<HF01(HFL1)]'9.M#-VF59(QDE2D71, &*(E,
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M?O\ J!CW[<<7:VU?3_AO[1:YV-D&\",9&48.8W(&VR[R I&*1F[8ND\H8M9
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M#(;F>!UX*EMZV7I"E=T<YS0UE/%>!HIT+'ED*7N7XY1DMQY F+S_ #G;Y7$
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M2_O 9V_GR+ULTWL1,8LY@I&JV;:[?)@G'F(B3@IB8RMBI@L''MFGV]GN!R"
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MW)9[+(7JLM49(ACB*J;15^BF8>!5#=OA5+C5<H$NV$I^:\&H)-'$R]QE.O2
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M":OL214W-\P=2&@\$XW>*II\#\LH/R"?E!P,3DCRI#'.7,GP>+\'RG LK@S
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MGH#K8_\ =_R%]HJ&O>)_K_MP^;N8>S:O>A[1:8M9D7D*W>;OL6UEFJXL+5S
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MRB9,PD,15(XE,4PQE8N5SQ/NEK\6FBT;J;A*"Z?W!-@F8XF3-?,;6''-CF9
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M((" @(#HB21")IID*1-,A0(0A" !2$(0H 4I"E#@ !V@#43].=#^;UYUBO\
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MEL4$4R0KQU3P[2*9+*D!9,RQ49J8ME\9H&4;@8I1,P4 AQ P@8 $AF-QP7A
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M;R<?!(2K<_\ W;HH=K^Z6/;GNCQ]^T_#5MD*[*V&G?&N[TKP@_JDXQLD O\
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M@$.0(AR6DC'.VLA'R#5N]8/V3A)TR>LG21%VKMHZ0.H@Y:N4%"G34(8Q#D,
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M&IV Z ++U*[Q1%5:W9&H '.@#1T<R+HB8E,X8+N$.4!53:WG;(LML)%C%7V
ML==-"B N"4_,5?=,$$99J)"CST+;X>+!HJLF!B+ 5@X*8$2',;=+^LV*OYJO
M6HOZ#:%\X+QJH_JQ ?S4TTQ^\SG_ /\ C>3^SC7[LU-^U/,VL2?1E0_FK%?X
MW2LZA[Q':-#HPBS]M)Q-RS92J#;V[F,461>M242\R==NSETDLW.4$TH\YSF
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M$RX[K\RV[CEX*BU*&E6G/(..Y9*,@(]D^;=T-55VJ_,.D#%Y:9SIFX<2F$!
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M$3<@K>Z!7[B[0<L8=(S!)-@YF#(IB4>)DR )NV(Z]A_;_P"L+(O\1KV']O\
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ME$4N;<E7.5W/8[OK1RH"IT3D+S"0"5,Y!-Q4*HE$8]R+-V[9SDJ96091K/<
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MHZ!M"+,YAXL*C;",M(.2H2S!8PM8$3ED6HMT4WR+LJB9BG(<I3D.0P&(<A@
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M^O\ 3OG%'=G<]N<<-V[U7!6"\F9-BHQT<$V\U8JK4Y22J\ HH/:)X?L:+5D
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M[3S]F\1%M''"2B,.5^0B9O,-J=I%-P)%RL>#2L 13@+CP\J9(# V6$FV;:C
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M,7?@;]_U Q[]N.+M;:OI_P -_:+7.Q@+>%6(LSR0VL9*EJ=D!5LF4JC7&&>
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M3DVE2=&P(WCKACW">2KI5I!Q&X9IC"1096"MUF2B72S!\@=%8J:QC)*D,0P
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MEJCB_(]CJ$!(VZ1SKN/@G]C>1L0];-EYAW#5M@U47,43F19I$$>!"\/^8UO
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M,/Y%6S89L4N;B \/RCI3M '^7CQ:J9B9X W+UHZB)96/M^-$<<V8S5,H<[X
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MN04106D@Y9N"R0=C>;N$3D"QDQC7;KD^3ISLX@4G[196LO:YC1J8PF*)"O\
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M!^2 Q=933EQ6&/:[X<MH58%4T2$+ FPWMX=. ;F2(4ZR/QG<R(B903'!03%
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M(0,OP,#?NRA2LBB"@E."8J<H2F .2.MH^V!@_,K&X8P;9LL3+5 1(@E:<X7
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M>741,L5HV05!L5S$--HSC&LF=NL@QMN,\S9KA9Z*,MR>+ELRFK]8JA(.$Q*
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MS\"X95RK<*_C_'&/Z_)6JZ72U23>(K];K\0W.ZD)24D'1R(H-T$2=H.V8YA
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MES*;*6VNT24U#NSR^);(_>$:5Q]*'A5A?6;&TPV<P,B=4R;ET+))^9%)%\@
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ME3Q>ZI+C<2T6$RB@"R3E+;(6A$I0 I!.@)P$3&, 6.XV:06EK);9Z7LUAE7
M@+B2G)Z0<2LM(+B   K/'[I10W_PQAUL@JCEB9I.7S&2^=["JJ4Z;IZ[SS89
MC*L,H\3,1+FUF%/M$8Q*7D%$J30@&Y1^4<V^'[W^Y;[9[KK8S_:9_<\W!=C;
MZ^.V<$9.=A&-6C=X9%0K5=TRW#;GUGC9%P)015<-$7Z!U2%$3)E63$P !R\=
M>[Z<L'";I!/!B,>=1(1$I7L3;;1%2+<>(!^49R#-5(__ &'(/9VMQ9'"9I!G
MLSB)!TT 1YU%G)9NS&W8.#APX FZ7B7)2]O\:)NQL&1>-G#18^.+N[(DY140
M4.U?YFR4^8N2D5*0QF[UBY361. <E1)0IRB)3 (W7Z ,$_S%)]G?!]W_ ![]
MHJ^K#3;C P]JJ-M@Y:LVFL6&-:3$!8ZY/,'$5.0,Y$2"+AA*P\Q&.U6[ELNF
M=%=%0Q#E$IA ;1FSW6#R)MM$DS+R[W:;>;.E#72J.SF,JY98DR%:7:4!:ZZ;
ME"*$=8'T?(,B$Y!'LB8Y2)KUW*FRO=+2)1%8R!"S>"<E),'QB@8>=B)E*N+0
M\VU,!#<E9FX71-R1X&'@.HZ$Q'LMS@RB7SAHFOD'*5+E\/8QC6SH$U5'Z][R
M4UK4'(ILF:I7"K>.4?/Q1,3FVZAE$BGV:X$>7I')VX7(6*;WE_/]VB32+6G"
M\EK>RJU-J- AY%DR<HU&IH521*F_=@$E+.W3APNDT1%JS;ZVS8N?(K-WN-MO
MN&:"\0<%*1P@ZIV.:W77"*Y")($(LFK'"4P F0 , \"A^+LFB+M4JS<8DY5B
M&B[3 Q5@CC$<)\TN4S*6:NVPE72'DG#D\#%[0\0UFO=UM/P]2=O>Y7 %%LV7
MYN,Q17X^FT#--$HT0XL5ZKUBH4"1A5V%V;UN/>2$7+QS)%_(2"?<CT7)7"2K
M76\C9/+S"CNK+U>L[GJ#"+.PY,%,14S%8NRF_8,S")U$[&VL%2*X.7@1(T<G
MQ^$MQT:-GX>+G(\RB:QF$Q'M)-D95(1%)4S5ZBN@*B8CQ*;D\0_R:>,Y_:[M
MUG&DB83R#68PGC23;OSF6!P)GB#VLKI.C"N4#B)P,/+#C^/MZAJ50:K6Z/3J
MXS+'5ZI5"#C*U68*/(<ZA&,- PK5E%Q;,BBAC D@D0@"81X=L>QL[W95R'9L
M+!G"AY(Q3DMXS(W:FEI/"SVERE'FI1(IR+2,P[KN1W4>+H2',5E#-4#G B:!
M>Q[OBP2QUCNH_ S&B)&75!8X1F+;+8\90I"G*1, 13AJB@5,O#B1,"E$1$.(
M_P!W]W;]'^X[YQX@UG"J9IQ5C?+]6C]C&2["PK64*-6+_ ,9]IGW;+&M9QG#
M6R+EHYM,-HZ6=-TW)$RK$1<JD P%4. ^P[L__P!VC"_0K7L.[/\ _=HPOT*T
MG.4+:?MII$VD9,Z4Q4<$XNK4HF=$PG1,G(0U69.R&2./$H@?B4>V'X%LW1;5
M[Q![<=TUKY^5OL)/Q3EUA'-5E$@\;'8TX%!:?QU>)8X@:2FH]K*-Y$Y.><1I
MGBSAZI++9&V<9,NE1BN4L.1<%,29QI:\<4>2,NX7QP:=GJW'@<! WAJ/BUB<
M $R92F()G<MA7,.9]OUV8/!0D7F-;Y=<7V)!XR.*9VDH:MRD*_%1 Y1(=%?C
M_E*8O#B&HF)S%9Z/O&QVS411>0F9J\T@\@)Q::92F0A,L4%K!3 RBBA.5W;8
M&=D-\(X"F/$@DEKEA924HV5*$G&IYBP)<G#5:Z8]<RIW2,;*,I)F1&-N='FE
MF*P,9=F5/E<GFW;=DY$6X;7X)-0H1LCO1@I9VB*:8G.^A<'9J9QZA5A+SI"I
M(3[H!* @4XG 1 1*7@J^>)F.XK6U;-<U%&*;D@B_7FL=UQ10X<!Y91BY]R3A
MVNV8!_R</P-]*D6HU5;%?;>6ZIF?-\T$BTVG8(:RZ9^:X%[J1ED5R+\?A<^4
M_*^%QUCU5T@Z10>9VSRXC5'"2J:3ID6TMFBB[$ZA0(NU+(M7"0F3XD!=-0O'
ME%, ;'OI_P B?9TWUNN^Y^Y^VC%O9]UW_;9_X1]>\2^C_;C\X\O]BR[6-I5-
MK.?MUM9,:.R)/VUU)EPQ@^84;H.4X&;;P+J-FLDWI!%8 >13&0C&L4<X%<O3
M.DEV!7\C=]^6>*FS?<^D%;PC:#8!K39@O\#P6$9AI&DC(LR(!S0F?*.W"Q./
M/**&,<QD'\1B#?5NE\+*)KIRR-'SUF1HZ%1VX,5ZO,'C;"S*W(\YXYW"JH)I
MF!0QC!P,(.+7DK#\/M4QA%1<E.S-PSO98AC8PBX9DI(R+>&Q56'D_D-><.U2
M$&J,FSAV2ZP@4[Q(H'.3L9#V\;@*-$Y&Q%E*!4KUQJ<P54J#QJ#A!\P?L7C9
M1%]#ST#+,V[^-D&JB3R/?MD7*"B:R1#A.W'W?-[K^YG%ZRCI[%XMR'.P&-L[
M5U$5 ,A"I3<PI$8LR"FW0 QAD#/:XX4-P3+'F'\H95GN;VOYRPBF18J",SD'
M'%G@ZK(G.KS"9H2Y+1XU.>147_)E49/7"9CAR0,(APU&!M]WIYZIL)#F2&/H
M\M='F0<8H D % @8MR06W8[$IB !3?\ JSB)0 ./:#A5\<^\LP_5Y*F2+QG$
MO=Q^!XF4A[%54EU2HC8;]B!9W-Q]NCT%%N=?+5M:+=-FB0]RQ+]P)4CU+)6.
M+1"W6@7RNQ%MIMNKCY&3@K)6IYBC)0\S$OVYCHNF,@Q<$43, ]L#=O@/$-;4
M?O?M_L8RCK/GW ,I_O%;5>PGF>L6G^KSN]AX-O")97CH%.>J63H>);@C!0&8
M*L@YC'LFXB$$BM(^>9.4Y)@S$$EDY!NW:-4)-Q*;6Y[.]+CRN%4L@[8G(YGB
M7S9J8XKN0J$(V;99BD4D"@J8\A76A.081*8W(4Y#AW4K1EW;[E.O+ W=.:Y-
MW+%%_@W"9@5*@X6C',#8HU9,W P%,)# /;X:BV%DS=%[J*&R4;$<4[<Q )W2
M56:%4'NTS?*4*XK>6#2CAN82I+2$S)-T5"E.+90.6122H#.!>8&W55*#4G[3
M@FQS24^TL-=9&9-Y"YXKN2;")2MU?9.WR9'C1=HREHXQ^)VZK8"/%/\ '??O
M^H&/?MQQ=K"E&LS91Y7+IEO&]3L#1%PNS5=0EBN,-#RK9)VU.DY:J+L'BA2J
M)F*<@CRBB @ Z]G+('^\1F_IOKV<L@?[Q&;^F^G+=';[DA@LNW612?--PN93
MNF2BJ9B$=MB/K<]8G<-C& Y 6162$Q0Y9#%XE'(NX/W<N0LJ2]IQG7YF\V';
MIE>0AKE\;ZO M7<K/,\4VZ&K]=G6EHC(AL91E$R:4LI+J$%%-VDL=(BE$SO@
MB]SV-LK8VGFEBJ-NKKLS5\P?-3<%6SE(>4UE865:F.U?L'1%F4@R65;N$E$5
M#D-MCW7,&C.-6SAA^HW.PP\<H9:/@+NJP+'9!K;%=0YU5V=;O,?(L$CG$%#D
M;@)@*81*'O"J=',_"#]+;!DB[,V)682"SIQBZ,#)R2+1ISJ1UI YZ>'<W(Y2
MI5^09,BAP*0S&4CG"C20C7C9^P=HB *M7C-8CAJX2$0$ 4173*8O:'MAK%68
MJT=-6N98QO1LEP"B*I5TE(2]UB+M,4=)<GP5DSL95,2G#M&#M_@[K4'3Y-K/
M9B4QGA&GME.YO_6LK<LC5N1L;$G=)%0YQ'&U=G78<@AE/]6^"*8_E28*PA%H
M.',GF3,>,<51S9H0ZCIP^R'=H2HM$&R:9B*'<*N)<I2 40$3"  /8]UW_;9_
MX1]3. -UE/EKOC!GMVR1D)O#0UOLU*>%M-<L^.XR)>C,5.3B90R*#.PNBF1%
M7FCB<!,41*7A[.60/]XC-_3?7LY9 _WB,W]-]'81.),R49T?E\F;JV?L@.Y-
M+EI'3+R$KJ]N$,/-',!R\IH;X10X\2\2C5,^X3R'9LT[2[K9DJ0ZD[HQBT<F
M8CN;QHY>P4/>G==8Q5>LL#:VS!SW#,LV,:0CM$S1PU1.=HJ\P9$,[A)--OFY
M#)5(PIG^C.WZH5!]$7V:0J-;R,\8*G.U9SV+)Z<1E$WZ*?=G@Y)XS*84G:J9
M]&34*4Y#E,0Y#E Q#D, E,4Q3 (&*8!X" ]H0UGC#==B316(KX^2SM@=,C4&
MC!'%>4'TF_;5Z*2(DDD$;CZWL9>M(B'*$R<,4YAY1AU@EW9Y<TODO;BM([7,
MANEU3*O'2F+&,2;'<H[.NJL]>.I'$$Y7Q=NUA$SN2(Z.(B;E<-U.Z-61:Q]A
MQUBF=;XV!T'.$?Y>N!4J7B:/[F+Q5<HKY!L$<9P! $4VA%53<")F,&U[;J^8
M+350L>2F-VS&HX2[K0#$./#'O63"R2ZZA4T36*O0JT4@JJ)@,_D4"\E0QP3/
MK:C][]O]C&4=9\^X!E/]XK:K_A##WT)I?/JW?]$^ ?IKQ7\^H+_I)]Y9]_\
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MFMIC=['>$*WAJ1N&X2RG%'GBQW[*:G*2E(D3%$2E)S65G=?(4XC\ Z@&#B(
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MB)N290ULF<XX?B*J1FC(GLTGDNEL*^6/<)E6;OC3+J:2CBLUTC@8BHJ<@Q1
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M@8 'B'8W7[9'3%&0>9@P;?JS5TETTE2-<@)0KB7QM+%(N4Z8K060(R,>IB/
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M%?Z:O\5KY6Q7^FK_ !6OE;%?Z:O\5KY6Q7^FK_%:^5L5_IJ_Q6OE;%?Z:O\
M%:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^FK_%:^5L5_IJ_P 5KY6Q7^FK_%:^5L5_
MIJ_Q6OE;%?Z:O\5KY6Q7^FK_ !6OE;%?Z:O\5KY6Q7^FK_%:^5L5_IJ_Q6OE
M;%?Z:O\ %:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^FK_%:^5L5_IJ_P 5KY6Q7^FK
M_%:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^FK_ !6OE;%?Z:O\5KY6Q7^FK_%:^5L5
M_IJ_Q6OE;%?Z:O\ %:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^FK_%:^5L5_IJ_P 5
MKY6Q7^FK_%:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^FK_ !6OE;%?Z:O\5KY6Q7^F
MK_%:^5L5_IJ_Q6OE;%?Z:O\ %:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^FK_%:^5L
M5_IJ_P 5KY6Q7^FK_%:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^FK_ !6OE;%?Z:O\
M5KY6Q7^FK_%:^5L5_IJ_Q6OE;%?Z:O\ %:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^
MFK_%:^5L5_IJ_P 5KY6Q7^FK_%:^5L5_IJ_Q6OE;%?Z:O\5KY6Q7^FK_ !6O
ME;%?Z:O\5I)!&U1:BJRA$DDRG5Y1U%# 0A"_DOQF,( '_4'>W[-.4,=XAHL;
MXQNF4+K6J!4X_P" =3_7;':Y.)AVOY-,QORBQ?@E$?Q .C1MCW\XZDG!%N8%
M3'M&S1EM@)_RWPBRN*<9W2+.C^0-^4*L*?;+\+X9.4C'P&_:A1[A=UW&12\X
M[SGC!B57D%4Y:TGDO%M2C6[7DG#\NHJ5'E<2\OB @ W3;_FG%.;ZB0R":MEQ
M+D&J9#@VZSE,RB+=W)U*6EFC1T<B9AYI4Q% Y)@$H" \/[BJNNJF@@@F=999
M8Y4TD4DRB=1550XE(FFF0HB8PB   <1U[2^W_P!<N.ND?8:2V1[[2\?Q;]X$
M<QDKO:8.J1[V0%%5R#%H\GGS!NY>"W0.IS1#&/R"&-PX (Z<06.<O8OO\VTC
MU99U#4F_U2U2K:*0<M&:\FXCX*6?NT8]%V_02.L8@)E463*(\HY0'4A6;?G;
M#=4LD2HFC*5^R9/I,%-QJJR"3I)*0B92<:OV:BK9<BA2J)E$R9RF#M" Z8VF
MDV:OW"L2G=7@RQU:9CK! R/<3QQ'/>X9>)<NX]WW)(-%4%>;4-S:R1R&X&*(
M!^&TB<CY9QGC^4?LPD6,;=[Y5JI(/8\5E6P/FC.>E6#ARS%P@=/G2%,3ED,7
MCQ 0T^?8VR%1\A,8MPFTDGE'MD#;&L<Z63YY)L^<0+]^BT<*HARRD4$IC%[8
M!P_NAI*?F(N#CRJ)HF?S$@TC&1551$$DC.GJR" **"' I>5Q'_)KK+Q_Z95S
MSEKK+Q_Z95SSEKK+Q_Z95SSEI.,@KM49J26*H=&/B;)#2+Y4B*9E5C)M&;U9
M<Y4DBB8P@40*4!$>U_>M@P)N0W>T3&F7ZHSA'UEH[JO9%L<G HV.):3T(26<
M4ZF6&,8O)"$?MW96ZBY7 -W"2AB 50@FN<5L_P Y-<WK8\8QTA=GD!0LI0T%
M6TIAPHVB&LE9;=1Z]7DY:5.W6.V8@Z,]<(MUU4TC)(+')^&C*[G=RN$<$(/$
M17C&F3\DU2I34X0!. EKE=E9-"P618.;./-L&SA3DD,;D\DIA!2+D-]L*X<I
MEY1E8'!.Z*U1PASBB?!.7J^$9B)5-RDA'@5<1Y(@;_-,418P]!]X!@9G)294
MQ8-<G2D_@TSI58$Q09IJ9N@,>(^$G!U2D3:B8'*BH\V4@G^#IA.5^5C9R$E6
MJ3Z+F(=\UDXN29."@=!XPD&2J[1XU6(/$BB9S$,'; 1_O15!?<E@-!=!0Z*R
M*V8<>)JHJIF$BB2J9[$4Z:B9RB!BB " AP'39\Q<MWK%ZW1=LWC19-RU=M7*
M95F[ELX1,=%=NNB<#D.01*8H@("(#_T)8>^A-+Y]6[_%'*_ZFPO\]F_Q6AO_
M &K'?_+:/_4&LNU'9NWJ^7MXC-,T=>[=*B68Q9MT<KIB*D?,-&BY O66&J1@
M$(4JJ;"(4.4\DHJJDI&*NLH;F<SY&SID.4=. ;2=UG'DN2,"162,>'J%>1YJ
M J,*=5,A48R(:,V*0%*5-$H   VLF-M@FXA>!?-P>1\M=*BGBAC*,S%3.D\B
M7&5WU*)*LW!%0%)5OSJ:H<1()@ >#J;NWN^MQB\6Q;E=O7-!J2.7.Y&H\X*C
MERAB:0NSE!NU(D8ZYS$ K=,.6J)"?"TE=,29"RC@/+M.?.H_P_2;%9L<WF!>
M-U3-Y*(>N(IU%2[8ICD,B[9+_DU"\I)9,Q1,4:7LQ]Y#)UN&RY:7$=6,-;G6
MC5A5X#)]G=J(,8FA98@H]LTKU7OD\[."<9,,"-(J5<J$9JM6KH4E7W]PR7]'
M]R^;DEV=J/WOV_V,91UGS[@&4_WBMJO8W[_2!C[[$,7ZV,_VF?WP]P7]PVH_
M<_;?;1E+6^'Z?\=_9TX_NET^\!@G^?)34;7ZY$2D_/3#Q".B(2$CW<K+RL@Z
M4!)LQC8UBDN\?/'"I@*FDD0QSF'@ ".O9JS_ .IO(O1S7LU9_P#4WD7HYHC/
M(- NM%=J&*0C6Y56=K#DYCHE<$*1";8,53&,@<#@ !Q$@@/XAXZB93!NZ+(D
MC4(YPU.]PWE:=E\I89FF+<YA6C%Z+:I%VWKR;],XD6>0*T1*<@"\AT02$$KR
M^5B-1QWGG&)H:$W X55?C('J,U+H.S0UJJK]4J3B;QS=/!CH\:X4(5RV7;.&
M;@!40!9?^\<F[GK?X-EK@W1+2L'T%^Y.W/DK-%C9/S5"LAS/!<(E@DQ<R\NH
M02G1AHUV=/BL"9#S\)$RDQ/6O)-TDLJ[G-P]BCUY*N8TA+3..I&QW:R<TJP:
MN)22=*+-X&"06;GD'12MT.8:HKKMJ)M?VYUOP-2Z>W.[F)^0(R5N&1KG($1^
M,60[]+LVC,)NV6%=$G+4Y!$6K5)!FU319MFZ"7X5CV&["IR+;;@V$>BWSUGT
M&S*;3PJ,RP3>-L>8V:N>Z8EUE@\:Z26E)-TBY;5U%8K9!,\J952)?)P4+G+=
M5N O[IU,R9(F.O>:\MW!TF"97DJ^*S1LEMFSH$,0%5U.<!,G#E& .&F\U%[
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M<!_R:^1>X#U[3GFO7R+W >O:<\UZ^1>X#U[3GFO5ER1[M[,^3+'D"KQ;^;'
M.?']2G R FQ;+.E(/'V1JQ6J.2O61<B ),&DRR>-7KE0"K2#,GP]15A@)*R4
M#(N/;0TE8B5CUY"N6VFW&K2A'3)ZT<)"TE8.P0$RQ*<A@%-=LX2_]$Q>U@3<
MK:CLPRHI'RN-\V(,&Z+-K^UC'+XT!8I=!DV$6T>WN;%-G8$6R? C5"6(D !R
M. :0:XR>0\AN\W ISM4P/#OB-Y!.CL&31-&UYMG(APBX9O8^B^$6Z<8T=E,W
MD9MR@4Z3AHW?$*XD)!Q>,QYJS'>!5775&8NN0\D9#NLP!0  *#^<LMHLLX_
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M-RD@#B9 1Y(B7_-,8!BF><[+2]Y&-47#)*3KV5:U"U._-XA$R8.DJUE+'<3
MR"<PX3*/!W/L;(4IC"(I#VN"&=]O4E)1[V$?-ZWE7%=J*U;WO$]U49E>> [
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M_A'U8_N@9E^>V(?P-Y&-+<T3>5ZZ[7\ZP$BF=(BID"O<9V4K:0:@?AS<A%/
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M#@3-F/\ *DO5X1VT8R\_'TZ?9S#F*C7CX#,VSQXDV$B9U0$A3#Q'M:]A[/\
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M5A.UF-EI))!,B\A'H,Y$Y4R?ZP'(+PCHK=OLSQCDM I46KZXX'N]CQ/,)))
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M"N2HQ*>Q7M_:2)5'L95YBCORG@;]DI*-<(#-J3+=['Q<@!FC%$1;#(.QI3S
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MS8@G-RTV[=-+DD!,$RZWQF,4IA3-MF.F)B@(D..\#;^F)B"(<2F$AS%XAV^
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M<F1K=WR]-T2KV6/_ !AST>Z<D$Q3% 1,40!LI?IO:YA!B;X;TMTRQ.VF902
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MB_!N/@6. <V@U<Y<CZ\BX65$J3=LHHL<P%((]G-NY3(ZQ4J5@[&-QR7/)=T
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MG,)SG.(F,<QA$3&,81$3&,(\1$>V(ZVT?=_PU]G5<U@/[_\ BS]W7=5JQ_=
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M;5]/^&_M%KGX.^/'C-HU8-*'O!W,4QJQ8JK+LF3>KYHNL&@T9K./RZS5NDQ
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M]N3RGEF>?XKMF+#U:Y5.I0D0G'VR8JTPXE2O(14[P7C12K)D(00Y!BJF$>V
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MV:2#H/@.5FZ)$CB(\"\1U4C6@BR=E-68$UA3<"U%P2<&*:C+$7%D8[(5BO\
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MZYZS*!T@UU7USUF4#I!KJOKGK,H'2#75?7/690.D&NJ^N>LR@=(-=5]<]9E
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MM;AN[M&0,D;8L)WF[V1TT8M8QHYG[79Z1*3TPX;1K%!NF=PX4,1!$B8"!"%
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MZ3V$9+)UQSA&WMU!P-+G3V%E5H3&;J ;N27*M61-L6.7FW1BBW*D8PK#RQ,
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M@]V<_BF+PU(2^1+_ $8U)A[8[NC)!*EOVC-*1+./8&N+J*2 .>49/N8 3X<
M,;L6_-F>LB5?%>*J'%JR]JNMOD21T1&-$^TFB3M*.Y*4?KB5%FQ:)KO7SDY$
M&Z2JQR$-+U#W>&VBNSE>C'3IFWS3N=4L!DK,1-06X/Z]ANBSM8E(>-/S8KM'
M,G8Q=+IJD[HC6IR'2-X2\-;;.X^[.Z?B_P#L.)X(YGE\OP=SWQK\/=Q\GX/*
M[N[HY/\ \5X]O4+!;Z]I5+GJJY<(MIG(^U^4FZQ9(1F'$HR9,69,L5JB;:\.
M %YU).SP28")CIAPY*.J_N!VMY/@\I8SGU%&)I&,[H9RU<GVK=JYDJE<J[(I
M-9NIVR)2>HF<,'R"*P)*IK$ Z"J2I_[Q:RF7I);(F<K=&K/L6[;:1*QR>0;>
MB"J[1&QV)RY!TWQ[CDD@W415FWR"O/'1738-G[E!1N6<91N=9;:WB=\L[2B\
M6;9GTACE1M$KB"16M@R@P<%RG:G3ED0I'@*2K>-<&,H*;%NFH*0.+!<K+8+;
M/._Y5-V:9D9Z7<\3J*CW1)2KEV\6_**F-\(X_",(_C$=,YZL3DQ7)R/4YYA,
MP,F]AY5BJ'XE6<C'KMWC90/_ ,HARCJ+"H[I[AF6B,%$@=8IW+O)'-U,?L4$
MS)HQ;23M,B;(=0CT.4!B)U^=B0Y10 W*)Q((XS=Q7[ ]WE?@U9:PX-GYE*4B
MKM&QB)#S%LPS:E$&!K7#LRCSSR+<(-YF+3Y9C).6B)GY_P"[V6E6G>OX+LU/
ML$S5K%&?U;]V[WP=.U^1<Q,NQ[LCL"NX]WW)(-%$^=05514Y/*(<Q1 1H^4*
M#+>'J+DBGUF_4N<[ADHOPS4[A"LK#7);P9,LXZ8CO",/(HK<P[;H.4>7R%4R
M' Q0_N<!DW;=F'(6$,A.-T6*JNO<\9V>3J=C5KDK4,HO)*$/*1*[=T:-?.HM
MLHJERN0<Z!!$/@AJI8KW$;PMPF:,;N\*9DFW5'R/DZS6JLKR\-#1ZT5)*Q,J
M^<-#O(]50QD5!+RB"(B']QDX64WO=RR</(/(N1;?U:MWJ_<[^/<J-':'/-\
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M=FJZ-8^*B(J]3S&-C6+9*3*DW9L6:!$DDR@!2$* !V@UM!NMPFY*RVVW[7<
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MWF^TSF3LT9CMBDK,/SIN'2[E_(KD:0U7J\,ASQ8NOPK7F(Z'B69 ;LF:*+9
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MI>_.E4!,0%T6%*;/USDY0<LJ0EXAQUOA^]_N6^V>ZZV,_P!IG]SS<%V,!_<
MQ9^\5NJ['N]OH B/Y]GNSM1^Y^V^VC*78V$?J!D+[<<H_@[/NY.Z/B7_ %IY
M7P_R>Y^Y?C1^R6X?%#GN5_K7='@GPYS7(_)\GG.7V^;['N]:]CMK&MXFQ[6L
M394G%8TJ'![?<PU5AE#(CI\L@HL+B2+=;8^16$YA.F*0)"! 3!,FM^5(QPSC
MX^KN,D4[( L8M-%%@ULV8,08YRY>T$$&ZBB#?F[S>)$#)EY()GXEY!.'(+L
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MNCN7NMKW1S?-\\ERN676TC]F>#\?YE_K&_MZ\-_'JPV.!^+?[(/V+^#?!?@
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MPICG&.2I_)6,5,6RL5E).U*0["'4M5>M@R$>%3L-<>A) ]KB2?Y151+FE#_
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MDJJ;FD&RV27+&OO\;O) _P (A)YDG$H_]V:6.J8A3E43,4Y#E*<AR& Q#D,
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M0E*KCJJTNR8\VQ$L$8\C'U]MMX;)1%URC72NTT3.J77*2J^@T'A"G;23R9<
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MG%#'YEEAM/D%X$*4#\0+Q$3G_#Q;M7QE8WU:MN]*U6V+O$G$.G#62_85BYA
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M''66Z'4LDT6<2(*19:I7:"8V.OOQ1/\ E&ZCF+D4C'2-P.D<1*8 , AJM??
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MU^UU69204!K.U>;!J[C9!ORCM).,<J)CRT5NWC'++1B\9X[W8[=ZY:G4*F_
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MA#$EN-4,88_[IXG\!S=YAD!M]^L35("<^ZC7D1&H+BJBD5\F5-VI)URD[?\
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MYNX>[$)BM!IW=,MMA+O*=7:IH<^]=6O!5FD,U5Z-C0 ASDD)R3H*;!,2\GE
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M%*XM9FRSC$M_H:TZW>K5-B=(DB+LK,R:@M@2%PXYW(L+LNPG^QF,RQ(5N4R
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MBJY5*K$M(*NP,8@)C"C'Q$0P1;HDXCR4TP#CV=W%!I<>UBJ'>;- YTI\:R;
MR9QS3--9BKY9(MDQ3*#9C&P]^E9AFS21$4B,VZ0%!/\ [HE&J\R^6D76W'-V
M7<#-W+DJPN"1**M=S!!L3KK$*#A&*A\P(-$!()B)-D$T0$!3$I:U]\##?S'S
M!JE?0!G;^8HSL;COU V[_8=1];B-U[F*1/DC-&>G>*FDRJ@<RS7%^(JI5I2.
M81[APW3,W+*WF\RYWQ6YCHN.X&?.&%1 ")=C=N:#0[E1MD9@FYR#4H%!%.;F
M<"8W3F%T0 .5_P"LW[([Q7E"81<.%!#@7DE#&K1XOSS>#SAGJ*BD^:13[E8+
M7$)M1#EI)D.ORI.8<J\I03G#G.2 \@I2EUDK]?[C\XI'6VC[O^&OLZKFMRNY
M1VU1?DP-@G*N6T(Q<3 E+OZ#2)JRQ<*(E,0W*FI*.2:E^$7X2P=L/Q@N^DWT
ME<\G9=OJKJ0DWQCNYBUWN_6$RSM\\.DF91S)3M@EC**"4@F.JJ/ .(\-8,VO
M8Q8-V-+PCC>MT2-,@@D@>8?1C(I[%:I$J*:1%IRY65=Y+2"W)**[YZLJ(<3C
MV=U]4J$.W@Z-D^8K6X"HQ[1)%LT0)F.N1]IN:3)FWX(,(]ME%6>1;()E(FDV
M2(4A2E "AC"M2;U:0?[><O9BP6HY<KD<. 8MYIAEF!9',5111-&)KF6F;1!-
M0"&3;()E*'-@01V%Y_B(UT\HF(<C9VQK='K9L*Z<1+YN@L53=-=/U$U.6R8N
M0PK)-^=,F*(N%44Q4(HHD15YE2\5.6N^",N4T<6YKA*V5H>W1$$:<C9Z$OE/
M;O7#)G)SU1E& \6"[A!%\P=N4@436%!5.&=;;]W&&;O.3:*"B&.I&V,J5EIJ
MJN)D^Y'^*;L:OW]NL1<AD^6$>9!0Q>*2BA!*8VL@;AL\[0F]VR_E*82L%\MC
M;.6Y2F)STRE',8KPB:MT/,E7J<<X69QR7/"T8-P75 RR@&544.;'NW[!=4^(
MV(L55]&K4*I>';+9O ,$@NX<I,?#UPF+!9I3D+NE#<Z]>N%AY7 3\   W[_J
M!CW[<<7:]WM]X"'_ )CGNQ[RS[@&\C]W7(VMCWWO]M/VSTKL>Z[_ +;/_"/K
M*&>+?%(R_P#5;P3(3E$(X0.JE$Y,RC.-*/%V 3&;JM!6840MD11(<Q%07=$6
M2XB@(E['NW<AH(<FQVBI[I:9*N>!?RL)0YC DY (<0#E#W.^R/)F[8\ YWM?
MY>/O'X1-?DQDA3]K\J\;<TB///X>:SLTCE^>,F+A/N=O..B\DIRD/SO$P&$I
M!+K+V=[UGK?>2[9KRA?\MW$D3E' Q8HEJR1:Y:XV$L868VT3,N6/++S*P(@Z
M>.W()\.=65/RCFQ1@Z@HNF]$PSC6BXHI3=\=LJ]0J6.ZO%U"N(O%&31@S4=)
M0\.B50R*""0G 1*F0O H.7SYRW9,63=9V\>.UDVS5HU;)F6<.7+A8Q$4&Z")
M!.<YQ I2@(B( &MS9[CN)PW8<E3^&\ET2@86J^0ZE:LEW:]VVLSM/@(=&D04
MN^L3:#2L3HI):26;D9Q;9-4ZQP,4J9]M7T_X;^T6N=C ?W_\6?NZ[JM6/[H&
M9?GMB'\'<;](&W?[;Z1KW:?W_P#9O^\5CG\'W>L:1RB9^TQKN">N695"BX09
MR%HQ<@Q<JI<>41%TM&."IF'M&,B< _S1U>G;-#GF\'LPS!*RJG.HI]RL%LEX
M.A$U^0JH0Z_*DYALER4P.<.<Y0AR"F,76Y7Z?\R?:+8];'?N?[:/L7I6MA>?
MXB-=/*)B'(V=L:W1ZV;"NG$2^;H+%4W373]1-3ELF+D,*R3?G3)BB+A5%,5"
M**)$5>94O%3EKO@C+E-'%N:X2ME:'MT1!&G(V>A+Y3V[UPR9R<]491@/%@NX
M01?,';E(%$UA053AG6V_=QAF[SDVB@HACJ1MC*E9::JKB9/N1_BF[&K]_;K$
M7(9/EA'F04,7BDHH02F-K(&X;/.T)O=LOY2F$K!?+8VSEN4IB<],I1S&*\(F
MK=#S)5ZG'.%F<<ESPM&#<%U0,LH!E5%#FQ[M^P75/B-B+%5?1JU"J7AVRV;P
M#!(+N'*3'P]<)BP6:4Y"[I0W.O7KA8>5P$_   -N6T2.D'!:5@G"ZF59Q@DL
M9)L\R7F:>D&!A?M2#R'BD!1*)&&9*J<3(>%W9$P("B@J;N][EGA4W]@H#>H;
M?<2R3EL"R$*ZMS1]<<MOV1UT#)H3AH=E7&:2Z!RKI,7SQ(_Y-UP-V,AY4\$-
MW=ZVH9 QWF"IR)$D2RJ,'/VJ*Q9D*)1>'Y)R0Z];O'A5XARP(NI"-S\#*(I!
MK9V\(]6;0>59ZXX+M#1)=-N278Y2HUA@ZVR<&543(HBUR(6$? GVS'4:%*4!
M.)0[&6MWN:\U;SX?)N9)"N2%EBJ!D?"\?38WXJTNMT*&95YC;-OMSL#./;5^
MJM"%3<2;KD& 0()$P(F3$>T7"#JU/\889B9N+K4C>'T))6^4/9+;8+O/2MC?
MUROU6#=RTI9+.\<+*-HYHF8RG^9QXB.K=D//&Z/"M39U"%D)A2J(Y&I\ID>R
MK,6*4@G 4G'K&:4M5MLTDBY1[F9,VRBAP6(<W(2XJ!DC(I(\L02_7VX74D40
MX*$C"VFPR,X6/*< *!RL@?<V @  (%UMH^[_ (:^SJN:P!F.M1KJ4K."]QJ!
M<B"T;"J%?@,G5&4K$-:9%QSA2M8E*Y,HZ)$>283O)EL4.';XU?<PYJ;R]8ZG
MJ?/X?S34XA5JA9)3%EPE:Y.2;FJ+OE$6 62O66H14JU17410>BQ%HHL@5<5T
MH=W@+=SB.0L\NFV ,67FRL<99>9O5B$%:./C:^*P-FE%&2YN94<QJ+Z/.IPY
MIPH4Q#&U;MR6YK:BWR1FN^MZVVM]V1S1N(HJDZG4*S$4VNF=P..,MU"L%<1M
M8@&3,%4V1%5$FQ.<,<P<=4;;1MHHW[-<)8U^,WQ*I7QFN-Q\"_'&XV&_V/\
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MWT<QL\,\K\ZW38V>]3D.H60AY!9 PJ-CF*4XB42F !#5U^@#!/\ ,4GJR_?
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M8 *H9%0"B(D-PUL'(LDHB<V/+XL!%2&3,*3C-F3ET%0*< $4UT%"G(;\1B&
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MRJ,GKA,QPY(&$0X:C V^[T\]4V$AS)#'T>6NCS(.,4 2 "@0,6Y(+;L=B4Q
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M]EB&^DN.%[4X;V5SM=2S\%(6N[6(B%7:$XMB@O@%2U-X%XP,H5P(NR-%6XF
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M^/6VC[O^&OLZKFKSAK,-,@\A8OR56Y.HWBEV-KW7#V"ORR!F[QDZ(4Z:Z"@
M(*(N$3I.6JY"+(J)JID.6>OONV<BP.9\=OW3M\QP/EZPQE&RU5"J\I5""KF0
MY3N+'5_C4E"F*FYEG%:=()F234[L.55T9RGN8VGYUPZP:F$AK/;,>6!.BN1
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MKDW<L47^#<)F!4J#A:,<P-BC5DS<# 4PD, ]OAJ+863-T7NHH;)1L1Q3MS$
MG=)59H50>[3-\I0KBMY8-*.&YA*DM(3,DW14*4XME Y9%)*@,X%Y@;=54H-2
M?M.";'-)3[2PUUD9DWD+GBNY)L(E*W5]D[?)D>-%VC*6CC'XG;JM@(\4_P
M[E_N_P"9?LZL?8V._<_VT?8O2M>\)^@"7_GV!U[N7[X&#OGQ%=GWA/T 2_\
M/L#KW<OWP,'?/B*[&Q[Z?\B?9TWUNN^Y^Y^VC%O8GVCQ?GF\'MPP;%12?-(I
M]RL%F]FFU$.6DF0Z_*DYARKRE!.<.<Y(#R"E*6VRVR3$V]/(%=82D='7N2VK
MT/.5KA64T#1=S$,;:\Q)%/V+:4!BNJHV2>&*KS1S&(')$1U[-'O?O4UO/Z.:
M]FCWOWJ:WG]'-2<%.[5O>W34)-1[R)F(>6P=O&D8J6BI%LHSD(R3CWE76:/X
M]^T6.DLBJ0Z:J9Q*8!*(AK;=<7?N[M^=::5//>'K,ZL<AM$W QL?7V\#D.NR
MBTV^D7N/$F<>SBDVHKJKK&*DD1,3&$"@(]AGDI6=>;?]UM<@TX*#SE5X)I.Q
M]OAF)3^":SEZFJ.XGXY1<5RS$8OF[UA+,"&*0%UVJ968RCN(P"UW/4A@5PLA
M=-L4ZGD-R[02,<R208SD&U=S >2.W*!C)-H!TB!QY":RH\!%-";B,M[?LK5Q
M3GD496/N.*<A02H'$G.IINTH&R1:@*)B'* "#Q+P_&&HMHWW,2FX:CL%&W=-
M W1M%,Q-)!NV4$Q6PWV3>,<PQR?,',F4K2QH) 42\2&YM/DOL2S]5+M_W=5F
M!<V"4Q&]G@GJQD&NQ8-$I>V8FM#AG%N9,K!5R"SZ#=(%DXYN85"'?-D5W:>K
MK] &"?YBD]67[X&9/F/A_L;4?N?MOMHREK?#]/\ CO[.G'8R5^O]Q^<4CK;1
M]W_#7V=5SLY*_7^X_.*1UMH^[_AK[.JYJS;F=R5@>1U4B7C2OUBKP"#=_=LD
MWF52<K0E&H\0Y=,D9"<D$62ZZAU5D6K)DV7=.%4T$5#A+QV$;TGLLPXHX<$A
MJ9A4[57(J[$P"FU7M6;).+)<5IA$AC\30):\S$3ARFYSID4!\Q1MF]S=[(.E
ME&,DS3GL[Y^>.'"Z#PZK1\W*ZMBZRRS:5<"9-0!,9-RH(AP4-QCVM8V&YFIC
M1ZLD1:6S:TA<#L8QNH1%51[(-LNR].F11;(K 8Z:#1=R8Q3)II'5*)-;>J;N
M!R!CVW9)SE0;)D"1KN-/#4E7:$SA9UI"-(5>V3C*#6LDTN9=07?,1R#-LHGR
M45W9# J'O$_U_P!N'S=S#V/>$_> F/YC@=;"/U R%]N.4?\  >'OH32^?5N_
MZ)\ _37BOY]07_23[RS[_P#O(_>*R-KW:?W_ /9O^\5CGL>[L_7_ ''_ #=P
M]V/=[?0!$?S[/:SM,LV)H^!W#4K%NX*!1$AP(J-BK04.W/DCF(4%2R.2,<S:
MYA 3 510Q>/$H@'O<-M!9<S&5WCX&PW6Z,@N=4S=U.P&88ZG7^+:$XBFW=3&
M#\L65=42@ K%C$P/Q*F7DXYQ/4T>Z+5D^^5#'E9;\A17G[!=;!'UN&1YM$IE
M5.=D9-,O)* F'CP ..J%C"IM^XZKCBEU:A5EIR4R]RU^GP;&O0S?DHD32+S$
M=')EX%*4H<.T !VM;X?O?[EOMGNNMC/]IG]SS<%V-A^?TD5%8NUXSRUAZ0<$
M(N*4>_Q]::Y=8A%RH*@MDU)=ODU\9 I2%.<&*PF$P%*!=1&VWPXS/E+9Y?+M
M4+#75GA5)Q3'N3;A9,I8^MYFQE#*^ W3VRR\&V,  !#P)R" !R!-V,P2..YQ
MG:*#M]J%.VRUNR1KPKZ,F7>.W$_/WU6,73.JV5CX[*=WG6*2J!C(.2-0<$$2
MJ@(ZV&XGF$5&L_5]K&&E;,S5(LFI'VNQTN*M5JC3%<**K?\ JZQ3;E !'D<0
M3X@FF @F5YG+=#M5JF6\K/X.%K;NXR]MR=#O%H2NHJ-X9@9E5;O Q)4V**IB
ME,#<%#<?A&,.O8(H'K"SC_2CKV"*!ZPLX_THZN-OV@[=*YA.R9 @V%;N$I"6
M6_SJLW"1C\THQCUTKC;;&V03;OS"H!D2)J"/:$PAVM9B>RQ7 ,+#B# $Q6!6
M46.F:#0QQ&0#@S0J@<A)O\98.1 2I_ %4#F'X0FU6+*=L9X2O6&%G#M"* B9
MT6)DFS\S8JPD4!(RX-^2!A*8"B/'@/XM4[(U*EFL]3;_ %6O76I3C%5-=E-5
MFU1#.=@99FLD8Z2S61BGZ2R9BF$IB' 0$0[&(\?0#UN_F,/[2Z1#7<$'*2IX
MBR7#(.2KLR@7C8@"=J\3ITQ%2'PQXG0DTA H!P,;56S"2EEOF3-M?N[:QDA]
MC^<EY*&5MMHP]MRCK-,U5W,HQ,U*,Y*8=UU9J546BRG=*A>64.(B'_+MQ_\
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MA^!4MNF,9]G9,=;(ZO9:%,R\<OW3'O,[WJ6C'V7V;%RDJ9LX;U1E58&#7X$
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M$PB.JU]\##?S'S!JE?0!G;^8HSL;COU V[_8=1]4O[P&=OY\B^SN._4#;O\
M8=1]4O[P&=OY\B^QFNI6!HHPGJMEO(]<FV*Q#IJLI>$N,S&2314BI$U"*-GC
M4Y# 8I3 )>V #VM;='MIWEX4PW<Z[A?'%5O>,LMW%G1[C4+A5*A%P%DA3LK"
ME%C/,VLK&+ U?L06:O6XIJD$.7R A;- /FLU6[1"QT["2;?BHREH.;8HR$:^
M0YPI14:OV#DBA>44.)#AQ#60*7&5YPUVX9BF)_*&V2QH(JFACT.6DQ=R&.NZ
M^:*B2P8FDI (EP@)A6.Q!D\,!2/$PU2?=_>\!R&SQ8IB[FZSMSW VQ1T2@O\
M>K+'4B<790L D<-J,\H9U3MX>:>F;PAX,$6;A1FJQ34D N57S[A6R5 6JCX+
M5 Y3HTQ6Q9(MBO%G@3D?.N(L6J3,X*F4YWD%3$#"/)'CJUPN$<J8[W7[JGL7
M(1]"QEBFS,KS1ZQ8U$%4&L]F"^U-V[KD#!U]Z8BKJ&0?C8'XE!!-%NF=1ZVA
M,;T\)+)^X_=3EJ<G['9)7G#$7L%OEY&W9&R9<GC-NIX.KL"W6?S4NY(D((-$
M%1(F8P$3'!.U3&8F7IN#,<P%%82BK-"/>6628H"XLURE&34ZC9O-7:T.GDN^
M*0QB=V/5. B';UMF]X558=9[53U7^J]F!VR0XDK\K%S=GR!B.<DDFZ G,C8T
M;'88Y9\N8")*1\>VY7*61+K)FUS=G)3$#MASC;(V_5S),>PD9YCAG+"40UK4
MW)V2N0[-]-O*?D"O146W>.V*3AQ&N8=L86ZB"[E=LVL^%MTFWO*D$[;]TDD:
M'F+']G31(',<\D^2B9]TXC7C11R1-PW<$27;JFYM4A#\2ZD[!N"W=X3JKV/9
MNG:%%AKK$7?*4T+4I^+:!QC3',[=Y-15<H(\X5D#9)4Y0553*/*#*&ZAK69"
ME4)W'U['N(:A,N&[J=@L84=JLT@SV%5F=5D2P6.3>/IEZW04609.9([9)9=-
M$JZF._VD0CJN9$W,7JS;G+!7Y-FHTF8"$N\+5JMCN+DDW!2.FZSO'5'BY8S5
M0I#-%Y15(Y"J@IQW_P 9"-%'KQKB2$L:R*1#G,2(I^3*);; [$$R',";"!A'
M*YQX<DI$Q$P@ "(;/]RN4DY(V-L1YNJ5CO:\.V6?2<;4EEE8>?G&<<W27=2B
MT!&R:CT&B)16=@WYE/@<Y1"BT'#F]_;UD&_9,DF4-1J%7[Y'KWFP2T@111M&
MMZ>L"%C;/A32,8Z2[9(Z12B*@% !U[RS[@&\C]W7(VMCWWO]M/VSTKL>Z[_M
ML_\ "/KWB7T?[<?G'E_L^Z[_ +;/_"/KWB7T?[<?G'E_6]G 5)9.I6[W3!5G
MD*/"L2**/;#=:$HRR-4:RS33XF.ZLMBJ39@F'XA.X#CVN.L!;E:O&MY6R8!S
M'CS+,? R)CH,YMS0+7&6)6NR*A4SK-F<XC''9KG('.IIK&,3@< $*U?,&[B,
M<M;++Q+9Y9,+7NW5RGYIH$J+4RTG"6B@2\HWEU"Q;A!=(LFP*\AGP('5:.UT
M0Y>I"P[@MX>W_'2,:GSBD&ZR- 3UZ? '-"9."QO5'4[D&R."$6*8R4?&.E"D
M-RA*!>WJ#V);$Z)D9IMRF;M"&FW*L/(&RMN@N$9)D/3*^QHD&=^]B\?,9TB,
M@RBEP<2<I)(LW+A)F=J1N.#;C9'I8ZNU/,.,[-/R!TU%2L(6!NL)*2KTR2)%
M%E"M6+50XE(4QA O  $=,(S$N=<.Y/DY2LJ72-C,?9,I=RDGU/25A6ZUJ:Q]
M>FI%XO74'%CCDSO2D%N11^W*8X&63 V _O\ ^+/W==U6K']T#,OSVQ#^#N-^
MD#;O]M](ULZW!Y 2F%J'@G=/M\S+=D:\R0D9]6HXPRW4;M9$H./=/(YL_F%(
M:#6!LBHX0(JL)2F4( B8/DUO ]3='_I@U\FMX'J;H_\ 3!J1# VV3=)ERWHM
MS&C&M^1QIAVD/')D4SHIN+/'73*=H:ID5,8JH_%X_ 2? Y8#Q"*L.?9V+JV+
MJ6\=N<78"Q^#^/QI1E'2(M%9M=%\[=R=OO#UEQ3<3,DJJL4JBJ3--FU4%L%7
MW<;CZ&^C]D6&K$UGHQM:8IRWCMR^0:_(+#'TJN(/$"M[#C6M3D=RK2]#G&;@
MR/@@G.JJO19=C<K]/^9/M%L>MCOW/]M'V+TK6V;WA55AUGM5/5?ZKV8';)#B
M2ORL7-V?(&(YR22;H"<R-C1L=ACEGRY@(DI'Q[;E<I9$NLF;7-V<E,0.V'.-
MLC;]7,DQ["1GF.&<L)1#6M3<G9*Y#LWTV\I^0*]%1;=X[8I.'$:YAVQA;J(+
MN5VS:SX6W2;>\J03MOW221H>8L?V=-$@<QSR3Y*)GW3B->-%')$W#=P1)=NJ
M;FU2$/Q+J3L&X+=WA.JO8]FZ=H46&NL1=\I30M2GXMH'&-,<SMWDU%5R@CSA
M60-DE3E!55,H\H,H;J&M9D*50G<?7L>XAJ$RX;NIV"QA1VJS2#/8569U61+!
M8Y-X^F7K=!19!DYDCMDEETT2KJ8[_:1".JYD3<Q>K-N<L%?DV:C29@(2[PM6
MJV.XN23<%(Z;K.\=4>+EC-5"D,T7E%4CD*J"G&!SKA>MK6/<)LU=6>[1M=BV
MZB\Y?L+V5E'#E:IQ#1LD*TO8H,U>CIZ-0,8QS)1SYLU3.Y?$(>@;I:-&J6FO
M-V;^B9CQR#X8Y+)>'[.YCEK15RO@ Q6,PR?13*7B'!RG10F8QH=9-5 %45(:
MW8"W2XK>RLFS:KR6+KM:X*@9DJCQ=-/GXNR8TM$BPL22C-V<S?NUHF\B7:J9
MA:.W*?!07UOS_NPP'B^(8,SO@0L63:L-BE$B 8W,UNG1\B^M]LD#E(82-8MB
M\=* 4>2F/ >%)Q?@EA8*WL]P)*3<E3?C&BK&V#,&19 '$0ZRS/09C@,##LJY
M_J5<CG!?"#1L\?+NC$5?"S9W?WH&9*^M$+9$K,MB3:Y#3##FWKBE.)5@OD;,
M3=-P05&C6PR$*E PBY>;669H2I^!FKMLHKF?"[IYX.:Y=Q/D7&#F0^&/<"%^
MI\Q5%GG!/\H/<J<L)_@_"^#VNWJU4*WQ;ZGY.Q!?IJJ66'>HE)(UF\T.P.(J
M6CW*"Y#$[JB)V+.0Q3%$HF3[8"&J)*&S/C7$.Y486+C\I;>,AVV%I5NC;PBB
MW:S;C'K*RR+,V0Z+)21P7CGT4H\.DV<HHOBMGO.-R/;/G3=?M[Q;$L6:CXWQ
MORU28R4>I)IJJ@C"0!YDT]89!P5 X(-6#9RZ<&*)4DSF[6KML9]W"6V/L>Y.
M36IN8MQTE$S-5D;_ $]ZJ1O(XYQ!4WR3&V-:_=DS=Q2\E+-F;I['J+L$F'-.
M1<C/5&VP<M6;559J4KEFK<_'NHF=K]@@WR\9,P<U%/TD'T9+1,BU40<MUB$5
M163,0Y0, AK:''XWW!8;N$Y<,#XO85RK0F2*@]M\G+0&+FC^QP2-32ES6$+!
M66E<D3R3 6P.X\(YUSZ:?<ZO(VV;]*5#K237"+Z:PAFQ1JASSB+I.091C,XP
MM#HR:!3-H&#O24E%N5%%3!W;9&12$* JF')&,MR!IXNU+<>:LJ6>SP;)[/.\
M.Y$JWA!I"9$^+,<W=RDU696(EE6,\A'I*2(I(,W""3@S3N99I9,&[K]O.4HM
MXU*[ :;EVC2\BR3,1)0R,Q"(S?AN!?( L0%FSUNW<(&,!5"%-VM25CW#;O<#
MX\3C6XN35U;($)8;_(E!N1T"<!C6J.)W(%C<';JD.";"-<'Y)RCPX& 1E,ZT
MNN3%2POCRCQ&&,)0UBYE.R/J/79VR6)Q<;0R:*K,HZP7&QVEZ[,U346%DQ[E
M:G56.W%4\KF;(L(Z@+=O'R4?+<!&R#-1C)(X:K\$RJN+W3]NN0J_)LJZ<Q.L
M5/\ NUXF7:*D#@<3&D5,307AS<GMCF'^8\.1+<G*D[K%A%]Q9/Q9&F!-8YI"
MYUIJB[CD"% SR<AH]N)TTU3G#%>ZO&++NRPXSG'<=<*)+.'44POE$F$U(:^X
M\GCD2558>&8A10J"YT%ACI))N[!%11N4@UZT8>W*8YK=TE&L>$WA#*UJK^.L
MRU2;>$1!>#=4VQR3-Q9"M'BH(!(P9Y.)<*" (N3B/ '=NSENFP#BV!9M3.Q<
MW+*]*B'3U,O.@5&'BEICPO//ESHG*BV9(.'"YRB5,AC=K54VP;5O#S7:#B2W
M+7&1NTVR?5^5SYD9HR>PL-9"5M^FVEH+'M4C)%YX(:R":#]ZN^.Z>-D%$6R2
M-B]Z7EJOK1M(I,;:\7;6$9-AR%K9=IUJYK64LHQ1W)2*%@:?7'#NLM'*)5$7
MS^4DD@434C%"*9>P9<P4-3\T8OO^)[85%-%54:UD6J2U/G022<D4;J*#%S"O
M)*H4Q!'M& 0XZM^,K0+RAY^VK9G[E2E6 *D-&77'%D;RM7N=;<.D4Q>0\BJQ
M9R\0[Y'-NV2Z"Y.)%"B-,-D#-N,]LFYDL7&QV1<)9DN$3C]!:W B1!X[Q7;;
M<YB:YD*MS;U)59@W9NU)EL@(%>-$3<DRAK9,YQP_$54C-&1/9I/)=+85\L>X
M3*LW?&F74TE'%9KI' Q%14Y!BB @(@.LW;*MFF5JSN.S5N&IM@Q#=[OC22+8
M<2XNQE;4'$!D-PK?H\BU;O5FM575>1+!E"NW2#8KT[UTX3!%!J]VLTJ&A'4A
M1<2Y&K&X;,\OW&HXAX/&F'+#$VYVUFUB%,5LC>+"RCZVW$>V+N73'M%*8Q?\
M [E_N_YE^SJQ]C8[]S_;1]B]*U[PGZ )?^?8'7NY?O@8.^?$5V?>$_0!+_S[
M Z]W+]\#!WSXBNQLZNC=J92 KNYV=K<L[ J@@VE;=BNQ24&B<2IBD4KIM3'X
M\3&*/%,  ![?"_VO=79W6/\ %F:<"SF*4<D$AYB?B:9;4[M2;I!+VF-KS"4G
M$J[,MZRZ9&=MFSCN1XLV,L0C45W"$YCC:IN<QUG&[5JJN;M8(&CJS+QQ#U9K
M+P\$M+OW#J(9L6Z(RT\U1(0RH*JF4$2$,5-023<-BR'\+;E-O$PYS+@J.1,4
MCRYKM8M:/OF*6ZJIP1*XO]9^%'E-R 4GHV.(HJD@98^L8[G\8,U&M^P[:'C2
MRT:P@]BF=MK3LCB R!C2VMC(]V,&\]#K.6:AC(F<1SL$W*9 7;I\*]8*CN;Q
MKA_(L@UCTK!@W/MQK>*<E5ZPNR) O!QK:VR47$9!11<J@1-]7G,DU4 Q0,*2
MHF1([M>8=Z^V6FQ;1J9X5JKF*DS-EDT2<[Q)7J97)>8N%G=#S)^2A',72QN0
M;@0>2/"I;?-M\?8JYLYPY:G5K:3%D05B;'G;(R3%Y!Q]^E*XJ4KFKU&MQ$D]
M0@8YR/=ZA7Z[M\1%91%FQL/O4,Q5]Q%5Z)A[1B[:<QDVQT7$_+SB+BNY5R^R
M*JDFJG#Q,(9S5HQ<ASI/E9"7 Q2]R(G4RKA2[HJ.*9F#&]YQ;;FZ(@55>L9
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M%5UG;:X2>4>7O[Z:&:3F*;52L43(V9MS!DS+"<P' 0+R0$>QLJ_JL26'X_\
MJ_\ ]8[X]_M7N4W4>>_:K^P;XL> ? U0M?A#F_V;2/=7.=S\URD>3R^6;D;M
M+#NCD\,R##-E5Q%#4X,576=MKA)Y1Y>_OIH9I.8IM5*Q1,C9FW,&3,L)S <!
M O) 1U=-W?NV#T^%O^0)1_:<M[8K1+-JC 6NYRSEV_GKMB.X2:Q*Y6YBS23@
M%WT%+'817=*B[EN_;@8C(75;L'NX=YDA(-%#I*N*)M^R/E*!.9/D\H6MJQE
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MNO5VO1<?!P$!!Q[2)A8.%B6B+"*AX>*8(MV,;%QK%NFBW;HID212(4A"@4
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M*%-\'L6ZQ,<\;"$F4_9Y^:9I.\H;ADW2365E7;YNFY(CM;71(X(BN ' ASE
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M4#_=WP=T'U29V34*M)351K<M(+$331(J^D89D\=J%12*5)(IUUC"!2@!2@/
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ML<Y>QS3J9)4JZQK&'DGT"]D\L4"OOG#=C8(V7AW!G$/+N4!!=LJ4"JB( !@
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MBFV.55I*JAJ8CK-*SE VK863B9K/&1X9!$)R06ESNAK6+:"L^;N8_P".EO\
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MF+B398^R/1[N\C6BB:+J0:U.SQ<\X8MEE@%%)P[18"F0Q_@E,8!'M:]A[/\
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MFJ^>',4@=HH#PUMH^[_AK[.JYKW=GZ_[C_F[A[67\U65DSD9#;MMSF9"AIN
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M")2O(G<!B64CG <! ><:2#-)4G_PY U[O<Q#&((Y^BB")3"41(I SZ:A1$!
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M:/N_X:^SJN:]W9^O^X_YNX>UO@^[_CW[15^SN._4#;O]AU'U2_O 9V_GR+_
MQI]']-^;D;K=&A+)/$)1#<7FU&21D2+)R",@GDNS$>)/DW(%<)O$W!3 J50
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M$^3;I/9^8DYIXDT(HFU2=2KU=\X3;$6576(W(LN($ YSF H!Q,(]O6VC[O\
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M98,C,8+(!8]-02K V85U=5R0HI&6:&-SA9"]6*.G,W[H]R=TC82MTNDQ2P(
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M'_&R7_\ DN(_G)M_?T1_\ER_\Y.?^OYE3Z1[Q\YY3^_<P_0FK\^JC_C9+_\
MR7$?SDV_OZ(_^2Y?^<G/_7\RI](]X^<\I_?N8?H35^?51_"L=UN4[$U:H4^!
MF+3:K//OVT5!5RMU^/<2TY.S4F\419QT3$1;15PY75.5-%%,QS"!0$=/MKGN
MIG%XQ9B*4LA:!4+_ ([K<F[W/;B9I^Y\%MG5-(DQ=V3&4'.2!R> V,,V;VI4
MH$6<NT#N#1K5ID[<!>L;T*PS+?PRBUW>[B<A6[(ROA'FE.7)I46GYQ=Q$HZ2
M,519!^Y;NTA 2+D35**8/L_XNR9D0F*L;\[,6J[;1<WVN\X^K\-$%*4\Q?\
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M F%VL/.6VNMG[-!]$OLCS,Q+PU9Q^QDVKI%=%%TY5EUVJI'"#!=$0.*32?\
M=NVN,I@N *M/P^Z:(G+.FTXDXK)5%[@.O12SC@)OR0S9"\0#\IV^U).]L^09
M!ED>LQ:<O><$9*CFU4S!3XTR[9H>7<02$C+0]EK:;QZBB>5A'\G'HK+I)+JH
MKJ%2UAW)&2,.WC,3+,5XGJ1&QM(GH&"=0SJ"@23RSY\M/$.BNW71/S92I_"
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M,2Q,NB19R59=NDJX##FP:AQ-11463:*9,S18;#8Y%(#E!N]<(U:F5B,A5%"
M(G;%._ @B  N;AQ&NX@W4XOF-EMVM<@TA:W>I2[,\CX)D)=VHFU9M;)>/B]2
MYS'*DH\6*5):0BUX=L7B9W)H% #&*HF8IR'*4Y#D,!B'(8 ,4Q3%$0,4P#Q
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M8^?RM;(\%W#).P.(]_)Q,/4::$@U52-*RSMJBL=!9-F5VX2,AHC*9]W'<V%
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MV(H<RH<G@+ZH8TK6Y#<BC&O%6KF\XVH=9K6/W7,&526-#/\ *%UI5LE."Y
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M9BF Y.(" @/#6\&40*X&O,]J\8PE#E<%*U+,R66Z<X@2K->= RS@[&*D124
MA@2*50!,7G  V _N 8L_>*W5:QBFF4I"$Q[2R$(0H%(0A:W&E*4I2@ %*4 X
M  =H [.'DHX7 -'N^O$[6=YE#G4QBB8/W)O40=J<V?N9OX<:,^!^).*O()Q^
M'R38<7AB-2R,CE[/[VV&;JF454L!,D2D>V.^(90X(.@JS",*!"@0!0*F;AQ,
M)AU[MN*5[E/9E+#NHD&'% BCUO!(QN &TMP<\@5&C5W(+LN*8F*5P= ! #"B
M/)]W@WGBN"/E-M%'?H Y<%<J##2I7<I7#%4*JL!6YZ\\:F13X@**0E()2B7D
MA83&*4PI[0LRG3$Q0$2'&Z8C3$Q!$.)3"0YB\0[? 1#_ "]CW7?]MG_A'TJO
M$G63=']S?,LE3() L<8R1V]OH^:(8ADU !%2&=+E4/PXIIB8P"40Y0>\RE%R
MMQL+.'VA,(LYG!BNBPTD]W+N)XJ+7G0*LW.^BHX55!(84C%3 #%YP0-K&C26
M.U\*OMZV)@JZ2R1EG RK?%&>%GJS3D)G[F,E =V%.L82$ BG-\KE*D*;##V!
M%P$XSPGON=0PM$.Z702S?<3N@5CA;-N;6[H< \(3D$Y!N6;@' >/#6Y1X[(U
M/966RFT!!\ZJ;NI**=9QP<G8%FK;G.:,4%R,$U%N0)TP4 A3%*J<#Z]XDYL?
M<O@]7:]D:.;]V($<I>'9=@G$U;D)J$.4KKXS/6?,*<.*2_(. @)0$/>92:Y'
M 5]Y,;0F$6<S@IFIIF.9;EW$Z1%KSHF1<$92L<*J@D*"I3)@!C<V(%BOH_VK
M_P#QTVMR_P!W_,OV=6/6ZQ02E$Y=GKLA3B4.64A\TXJ,<I3<.(%.*91$/Q")
M0_[ [&Q_[O\ D+[14-6Q>).LFZ/[J[##)4R"0+'&,D<.XZCYHAB&34 $5(9T
MN50_#BFF)C )1#E![R.32*W&PKV?:RPD#@X,=T6&:16?'$04[453%;-SOGKX
M2J%(45C%,!C&YHH$UMKCW)VH6EUOAI[V&3.D87IJ^PP+N 0LIVZX)B1-JG(R
M,2"Q!, G.9(0 >2(EV$?J!D+[<<H_P!_2_\ \EQ'\Y-O[^B/_DN7_G)S_<-L
MGZ_[R_W7MRFO>$_0!+_S[ Z]XR^(V;D>N;OMG:.'A44RNEVK*!S8LS;+. *"
MRK=HL_7.D0PB5,RR@E !.;CJ*^C_ &K_ /QTW9W+_=_S+]G5CUN0M#M'GI.M
M[+[.PB.<3;*(M?C%FK"O=[U+G4#N$) K>'!!-1)1/@@X7(8# I\'4@ZEDFJC
M^&W-80DJP=PL*2J$XJC<XAPJQ("J?=+H:W*R!!)P/P0.H?D_ Y17))('@,T-
MUF:DJ^+E$Z:)H@8'&ZRPQQSD*5PS\/+/@,<HF*#@%2\>)1 $$7C9N[1)O']Y
M([(DY1373(Z88NW8OF+DI%2G*5PR?-DUD3@'*353*<H@8H"&H^#!!&;5J&W;
M -3I\.X;]UMUVK^8N=P3B%VBZAD7*+ZRV]X)D_@$.5<0$.(F,/L6#_NXT;IC
MKV+!_P!W&C=,=;=M^NY?9+DZC.+1NZK65,Z7A"I0=>ID*PM$P+7(5A-%LY]W
MX,8GBY%TLH"?+Y)SF, #^+6 _O\ ^+/W==U6L/RL>CS;NZY@S_9IT_-MB=T2
MK7(TC3D5N4@W155Y,)4F:?*6,JH'(Y('!,"$)K$[J)2:IOYG8UB62LYVZPJJ
MKSB6:-Q<0W5?$%53N9T%;BH\@$X$XH$3/R?A\HS_ '4[K[-)5FH4"BU1Q9$2
ML =WBTW:781[*.I%7KCA:.4EKU9K OW.BU44;HHF%1=VJV:(.'",UC[W8>RV
M-80C9TIX'AZSB2][H,UIQ"ZJR$?.7%W"\S1:XU<(M3N%"> A;,1!0IWSA-$5
MA\%S5PR#M]J$RGW*XL,\XVO;:6U<:2 K(<KFZ#!L<Y HB!5#\\U9/'K?@4>4
M43(\K"&!L@V1G<;[A+=GN;Q'=[?'.I-]'VJWXVIV<*;9;(Q?3:#69>,YR9AE
MG22KM)-TH14#*E*H)@#WEGW -Y'[NN1M>\,?';-SOFV-]O;1N\,BF9T@U>V?
M*BSQLBX$HK)-W:S! ZI"B!5#()B8!$A>&E-MN'\?L]PV[H(>+F[+7I*;6A,8
MX9C9UHA*00Y&DHPJT[-6R=B'*+QK ,.Y5 CW";IR]:E5:INFMMVR;=;-1:;9
MRI2%;M>.MGU7A<>/6#I6,%NI6KWN?8W>NS$:)0'@MX1=_DG*IS*<"$,BYW4>
M]JSB^6Q70<A4:+J^$++E6EV.76NEV[KKL;9F=!P>U>XCBEHJ'3<%6>NGQ)-(
MKHR::0BNY$ME^^!F3YCX?UL>^G_(GV=-];"/U R%]N.4=>[M^C_<=\X\0:@;
M3!N3,YNM>X;B[!#NR"8#M92&]WRA(Q[DHD,0X&0=MB& 0$!XAVA#6_:UN")C
M987#>'*]$J"=$%2P=GNUMDK"0B9BBN9-1_48L3"4P$*)2@8!$2<-;\ GQ1!B
M%:PR9#GSJD)X:)N2PT>M@4R1BF%8;$5KS8#\$RG) P"41#6\\BX.OB^7<K53
M1@G((,O#!\71 3@-U.3P,Z!D2.YX.(\DG-#P#CVZHQ?-F[UB]]YO[OQH\9NT
M4W+5VU<RVVM%PV<MUBG17;KHG$AR' 2F*(@(" ]C<;](&W?[;Z1K/GW_ /*?
M[NNU7LV0+RL5\G&^])W9F9'74(4".,2VC,QL>(E,YYXO*CW5,C$TRAP,(I%*
MGR1Y/#L2J=(YP:A^P_<:D<8_G5F7Q-+*5PT(*ZJW+5"/&1)&\V<X\H5>; 1$
M1[?NN_[;/_"/KW<Z+-LW:(GVD8;=G2;(IH)G=/ZFQ?/G)B)%(4SAZ^<J++'$
M.4HJH8YA$QA$>QDOZ/[E\W)+64)601YQW2MD&7+-!'YML?N>5=9@V]TY9;E+
MMUE4N5"6UXGRD3)*#R^2)Q3$Y#ZS2ZEDFJC^&RUM_DJP=PL*2J$XKDZ'B'"K
M$@*I]TNAK<K($$G _! ZA^3\#E%S"62!X#-'?7EA* %RD=-$8@<'[;%EACSG
M(4J[/P\J] QRB8H. 5+QY11 $OO?^\O^R/=OK(>Z/<?9UJUC+';%NHY2C&J<
MG:;5/RCE-A7*328-1RS\.VZSRBQ&[1 RR#=,!.X=+-V:#ARE-8^]V'LMC6$(
MV=*>!X>LXDO>Z#-:<0NJLA'SEQ=PO,T6N-7"+4[A0G@(6S$04*=\X31%8?!<
MU<,@[?:A,I]RN+#/.-KVVEM7&D@*R'*YN@P;'.0*(@50_/-63QZWX%'E%$R/
M*PA@;(-D9W&^X2W9[F\1W>WQSJ3?1]JM^-J=G"FV6R,7TV@UF7C.<F899TDJ
M[23=*$5 RI2J"8 ]XU]T#.'S)E->\^?';-SOFS?9@T;O#(IF=(-7JFZU9XV1
M<"45DF[M9@@=4A1 JAD$Q, B0O#5<^Z!AKY[9>UN7^[_ )E^SJQZW3OCMFYW
MK;9O)-&[PR*9G2#5[FS$2SQLBX$HK)-W:S! ZI"B!5#(IB8!$A>&MC_W?\A?
M:*AJYS\$X[DE6_N=(]FU=AS@*M/#.TF-A5W38Z2B9TGC=M('.@<!_)K%*;@/
M#@.YJ2]TM@Q',3^=:X>99W>#C2!R$XJS-HKDY?&[9)6:F(DT,C85E)PQRI<X
M#HT>03\.9)Q]BP?]W&C=,=3>V;<KL4L,SC">L%8L[I"K81I]7G6\S49,DK$.
MF,TTMBRS;@L4R:H<D0414.4>''B'O!:=N6Q1<,$96I\QO)R3CBN7%NG'S(U0
M-J>.Y2"LK<8N16.+-6]Q4NFFH15)4%&IP#DB4##O'LSA%N:RQ&U^"@HEP84>
MZDH.Q97K,A8440,7GQ;KOZO%F5Y(@3E)I\H!'D<-8V?R16X241O4Q,XKJJBQ
M45_"#K%6=F#Q!L'**=USL,X<G.B'* 2I<X(?D@,6E_> SM_/D7_UH\J?2/>/
MG/*?W[F'Z$U?GU4?PKIC#'[!JYW"8CFFN;-OG/JMF8S5TK4;)1TWCQ:0<G;I
M(-<CTZ5?1Z ++HLTYGP>Y<&!-KQ#)^T;>;"W:N[8\AWY=2YH.JY,GNNV3.D,
M+>H6&T2E'%L2Q.8*38PZ$=:XM)LK+M3Q35PT0.L@X:/6-WP?N?P/E&LOVY7*
M4C3\I4V6.V >2!V\M'I2X2<'(-SG BS5ZB@Y04^ HF4W:U:I!+,F.\];B!BY
M)KCK;SB>YPETL<C:P;B2,-D=_6'DHSQ?3V[Q4BCQW*'0=K-2*@P;O'!01U/^
M\5W(LWT_B'#>;G6XO+=XEF:Z$%DO<4]G%;S0<75<CKGFCUC!651I,RK!(%V4
M;7V+=@N5$LBQ!3-&.L:P#BTY@Q),5O<5B6MLD.ZI&?LV,TY9K8X&';% 5W5@
MGL766PLHU!$!5<R#A%$H#S@@.0/=U;K,E5_$K>8R(]R=MOO=^D6]?I;J5L\>
MP87[$DU:)%1K#520/)P:,O!B_.DA(NW\@V[H*Y[@;.7>5LF94QWC_&+&/+*N
MLA7*YUVMTM&-.F"R;T;-+R+2',W63$!3,"P@IQ#D\1$-8UPWM'"8GL3)*5/;
MGAJSKQ#UHW)C>NRLM;<OY^FH9=%)[%UMLYEYF5*9R0CU6 C6)54DG1NY22N-
M:8P+%4_'F$7U&JD60W*)&UJI4-6 @F!3<"\HK.+CTDP'@'$"ZSY]P#*?[Q6U
M7L4K_P#"?^[V_GO;3V/=V_1_N.^<>(->[3^X!LW_ '=<<Z/N^A(]U,_L4WBY
M8F[%!,%$T9"Q4"=NETIV3*U'+KK(-V\E8\=V.48MU%3 DFLX*8X"0# ,/F7;
M1FN@Y8HDM$MY==Y6Y]BK+5HJR!5UHR[UM95*P4B>C@$2NF$JV:.FQP$#D#_*
M?W:&VW)%=RA=[];JI9-S%@H\NPL=1I%,H<PVME<QFYL,4NXC'=ZG;[$QDB\:
MMUE3Q32)%)V4BCQ,I:._R1"NJ_DS='=IO<I88&39K,IFN5FU0E<K.,X.22<<
ME=%9Q0ZFSF3(*$35:KS*J*A04(;5*_\ PG_N]OY[VTZW"X,Q]&>&,P5YG"YE
MPQ&$2!=S,9"Q8_\ #Q*M&I#R0&8OE2&6K[(PG3(F[E4SJ&YLIP'*'NV]V5^A
M<,NY+)TGDK;_ &W)<@C5*PK9)V/C('(N&9Z=G%F$949XLK7&\G"HOA1+(/7L
MBUYTKON)LY<9-RAE3'..<<-6H/7%^O-VK=4IB+,R0KD<GLT[),84$3HE$Q3<
M]P,'XN.J!M-]RKG*W4W%,U)0&%Z3*1-(ICQMEFXA*RLE?<Y2@W>E6&<KF-:_
M#G,8BB@-^:@8522622,X.BE5:].V60NDW UN#A9BXRS9DSE;9*Q<8U8R%EDV
M<:DA'-)"==H'=+)MR$1345$I"@4 #4E>LX7*OXGIE?WO^\'JUAM%_D4*Q!U^
M?N=8W-XZK4=/2,J9LVA5).[61C&@=T9)-)PX+SIB% Q@W*[>JUD*DVZIYOQ3
MD?#2URJ$]#72(J5LLE250A9@[B!>OV8S5-E)2.ETVQS<L!31,8@D.'*W+;*=
M^JJF#J5EV4C,89$L-M!1O 8CSMA^7L:%'G[)(+ ",9C>XQ-LDV:TXB0S%0KN
M)?KJDBTE':"F3VF1Z&ZQHE'^%E<AM[?7UJ,G%<E,_A-2VIR)H D?R%2CSPN
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M !9)$G3U>)1/R 4G+Q332\"P 3I%!Y*)"<P$ P#ECW>F[/(,/A^N9!R)^U#
MM[O[I. IT?DB2BXJIY!Q=;++)F294YQ8&M;C'T*9^9K''?-Y!N=<CUVS1=+Y
M5O.3\>T[&+9CX37R):+G78&CI1PH*NBOC6N3D6L'W*=N@<Y3\_R3%*(@(@ Z
MP_MWV4"^O&-H T+MPP7/C'/48NQ*+S#^T9BSN[8'0+(QE&8$%PY4<J@4PUFM
MHO3IHG4.B3%&$:*W,SI&',:T7%5.:'Y/+:U7'M7BZC7FYN0 $Y2$1$(E'@'#
MB':U8_N@9E^>V(>Q[KO^VS_PCZVHX%LJO,5S-WNY*QB*?7YDKGF83).%U:;*
MJ]SG,0J_-L9I0>0(@!N'#B''69<*[U(2<IN/)Y26VX[C3-(F4DEJ),5^QMI?
M'N9HR)002D[13V:G*736:(KJ/:O/JOF*+I3N9)4,L-][.T\^-1CPDS7<VX/%
M*5=2:"0IA%Q)*VHB#9P03 0Z"@E7(K^3,0#_  =8YP9M5DI*U;6-L"T]/O\
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M<1N3R'"XYQE1XUP\>2$FY1\*3TD5!56.J=/AA53?6FY6!9+F(^-:%.X<K#P
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MMI-4CK?C+),TY4.N]LEYQ8M+54P7*26$!<2T3+1AG:AU'#U!ZY.*NBH73?\
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M02! 0$#<H!+IIO7A-VE5Q+%MJ[B:#''TKB*7MS\Y\:'$R[D+$TO\ W LOQ^
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M:^1]?\FMOX&OD?7_ ":V_@:^1]?\FMOX&OD?7_)K;^!KY'U_R:V_@:^1]?\
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9L':T>L[8(*G1,<4S*(IF$.40HA_^*T7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>imux-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:imux="http://imux.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="imux-20201231.xsd" xlink:type="simple"/>
    <context id="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4062cfe935644e299fdecc0eb484705d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i113e2604b2a24be8a887c8a8b2cea29b_I20210219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-02-19</instant>
        </period>
    </context>
    <context id="iec7edf46a34f43399671610813b08a6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2aee3b3e8a14fea819077a54d4f286d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifedde0176e664cb6aff9c43204468770_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i98b37649abfa476e8663e7096706f97e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6865d74fb3c44e108442faced8021edf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7671da9018c545b3817f9563d19e0261_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if37994c8a1974311901413ff52b1e230_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i440b26b7a65b40cba6e77e9d545181b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if188cbbb4056418e817200cb3a88ab28_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4298d26d7d8640bb99d1f84822b95179_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b9a7fc5636d462982c27ea109928534_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24ec86347b48487488f1c2b7053d37cc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if52f51af4dd14483aa5dd285b20cb6c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreClosingFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11abdac7c3c743d3a599ef1d1fe7969d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreClosingFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5fc3a70ddcc2416da33598ca112c4ec6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreClosingFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic942c4f9cf4f4506ac6fc6619d7741a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:ExecutiveBonusAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8be2e94565534b38a1b810c6d9c76e40_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:ExecutiveBonusAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id653ff8493bb4f28b484c985e561ac7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:ExecutiveBonusAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2df4d80998e4e6fbb1105df3cc50d87_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie42c6f1afb234a33ac5df351a682ac65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f2bc238cf84494f92f2d022a107611a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:A4SCSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i482400df09b44e2ba6f90598101aea5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6691293a863540519bd390ff32edae71_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibee2b8da709d477caa8f18d809bc9f32_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ce55168c27842fcba430142ef8577a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78983d83235a444bb1184ca248359fe6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i41cf71437d1148fd87ec313c6ab59abc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i378b311e84c3477d87b10194049b52c6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if5a2646a9310481db842eb9736d24b75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22d73ebb34f94a97a65d4cc981b33181_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide45a6f10a8143968b9977470c96fcf0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic26eab55dd1c4325a2bf6fcd5b7880f5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b2a4218e23645fe8a43795e53bd917d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90db4b0e7fa9494cb6a2c2d5438fde97_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd95d995b8c1481499d8fe54a95ec8a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i263afee333724006aaeff1f3dcee49a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45563a45c561425c82c1d8ae4a882b06_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacb99b20fe3f4285812691db62887373_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i714a7516a3074b3b819b97a2f9753718_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0d89043cac44e13a241896366e02310_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic64924c0859a41d59136ed99d077e63b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc4d7683bd124ea18385d5d19135a5c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e16527720b5489a87c3709cb393b31c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9c5353dcba14224be159080140a4539_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c794d23984e413d94b0ee6303307fe7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6174bd787b0d4b3e9f91e9b34de11988_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e803724dcf84ceba79eba0078a118c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:PreClosingFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5f2a878d5224327b9c3906b7957b0e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98ef75f825ff45d4ba01031c2df25949_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic948d92ac1714503a6fd146abfa629ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3268a88a2d6d4e30b39a112e210ac828_D20190412-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ea2ecf153a24b4f9905b7b614e7adf6_I20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-11</instant>
        </period>
    </context>
    <context id="i6b85b15cda004eb0acf9c15243874440_D20190412-20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="i72933fde204541c88561a57e1bfee92c_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i8dbfed922e6b4c3db53e3607146b69ef_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i2d8389cccd92494f9385f182bf002a92_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i025ac79fc8a04af682b83198235a9390_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i6af0ec8f1a5c4c69afa77ae4992a4b27_D20190411-20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-04-11</endDate>
        </period>
    </context>
    <context id="ia8b8f818b75b45b29b714b36192e1bd5_D20190412-20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="idee3e91a49e343c1a30694c684b021f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c360cf3166a497fb3d4cf65ac71195d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74aac56ff24b4f3ca37eebd86a9d4423_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedcfc4dd48ac4131bacce1f46671b617_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie37f05a546ec4332b17b507cececa315_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a4868f4553f43c3bcb215ef4452c84d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i143eb8d6d87d45839179cc8aefbf2bd9_D20190412-20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="iaa7215f1ac4e44d195ec898605132171_D20190412-20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="i25a3ae5995884982bf7fb0499c7d2af8_I20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-11</instant>
        </period>
    </context>
    <context id="i291065e6920c4b3690091eb4f57fd587_D20190412-20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="id235fedbb81d4e0c9ede860eafed7c3d_I20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-11</instant>
        </period>
    </context>
    <context id="ie48d0609d585480ab6c4bfe322a0961d_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i19a1cf43d9744216bb5785e547d4a706_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic61d4640357d4308b1168153fff8bcd2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">imux:ImmunicInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib1424157daa84861a0f78d13c01de311_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i16a9132f0eeb46a4b87b6f6be10c44a4_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib628ae02a7aa42c28a8f9aec169f0c34_D20190528-20190528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="iaeb39dad72584b63ab750036af27e280_I20190528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="i3f08f68c8dad42d6bad9ef5236f6e645_D20190528-20190528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="ifd46d22b09cb441787f0d5370dea6303_I20190528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-28</instant>
        </period>
    </context>
    <context id="ib70b7b4cf5694c7a8586dce401819182_D20190528-20190528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="ia6683c08bed64561b5b0505930b9950c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imux:ClinicalDevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b5901cce52944f6baa8aaf2af6e02ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">imux:SuppliesAndWorkingCellBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i780e082104054e5f93c97de39af38fdf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5086e5f37b694c38bf5cab8772addc83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib203b4c845154f8f8ad1c43f6b7e19c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">imux:ELADRelatedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67800579096d4497ad722732c4249a21_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="i79f881980aec452681faf1a0f7dd4395_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="ie337d38b905741b0be8509a5988751e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1f631b15ff24c389fa32b2b1b7ee96e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6873df0f6d9c43829d62758343daf989_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a8dd00728074e99b84c1dca45194253_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a0a829483c0417eba5fa667a551ed28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8e15b766485e4b65beeb7634f309978f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b12db73e4fa4be7ae419856ea963c2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i222effbc88ad4922acfd743d8d31835e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie581a8ba756a444ba46878adb72aeb7f_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ib42baf0370ea48d7a0e0cc425578b84c_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i1c8556577d1b4e5f865b603839247770_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2019EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="if19cb443fde445938a82a57f80350118_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:July2019EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21e80fc4dc65422fb46f2324ebab4469_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:December2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9121799d001479e948d946e83f048f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d04edecca964096b86caf4fc622d519_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieddd58f3d1014eb8926a60bb85a16000_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="iaed6b68efee3460089ffa2c5e40b8094_I20200423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:April2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-23</instant>
        </period>
    </context>
    <context id="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-10</startDate>
            <endDate>2020-06-10</endDate>
        </period>
    </context>
    <context id="ic7ade7fa5ecd45d28246214c1fb60452_I20200610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:June2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-10</instant>
        </period>
    </context>
    <context id="i61f483edcdbf4d8bbd4fcfedfede902b_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="iaf950f67a01b415ab0151c454064f1cb_I20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-04</instant>
        </period>
    </context>
    <context id="ib39d17f19add4e67851d0c580a248614_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">imux:August2020EquityIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i15c150f722064296929dd00a3a6f971d_I20190327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2019-03-27</instant>
        </period>
    </context>
    <context id="i5a7d12cd12ee4917abc990f2310687c0_I20190327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-27</instant>
        </period>
    </context>
    <context id="ib3fe40add06a4c1e9d53068bac00bb0f_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i5b71f1d3cd7c4b9b9c8ee7ebac91ffec_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8f592217ac8841e7a80512fd12ad30e0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">imux:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4c982f0f472740879b53dcb38a14a979_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib9c91096020641aa94b1d1135b433890_I20190925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-25</instant>
        </period>
    </context>
    <context id="i8a2c83765c344137b31b8874c897fac3_I20190925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2019-09-25</instant>
        </period>
    </context>
    <context id="ib87a8c7a070d48d7a85d8cbb57c3b164_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fe3c6f83fe24a859c84ef448153d453_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ca14bfd5d1a46d6abbbe154703eaed5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idde26f9196c647299fc79cdab514e92c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d1d01b5e1504c569debfc0effaa9d69_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPSBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id98ccd8847d942049dcebd55acab88b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i884fec6fb3674d73b8111a30c60f263f_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i3d10718e641e49e498dc108252d3c28e_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="icf1e238f2761438b9315ac40fda6d259_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90330a9e562f4e60896ceea327263918_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia083d8fbd94c4989a08ae4001339a6f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9edfadac1b9748399350f656eaeb7769_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia26faf7d6c8d4e9d8a5282e0a5e8930d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e3be07c1751461587012f74b2b0f7a0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsImmunicAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsImmunicAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifdf95cecb7c14be781cbd9b72385544b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsImmunicAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic83994845a8140129953443b3610acec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9fcfd27c68040008f2db78d30da709f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82708f17c53b4c37b78d4fe97415cb49_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9204320c663f4b3084ac9313177a458b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8030a5507c8490583fc32147238685d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf66576a68e1467aaeb276eb0a1d220d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:VSOPAndVSOPSBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i630a7b979f974930b0bba2578eadd634_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd8ece903fa44ea2a909aa615b1a5ba0_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:ExecutiveBonusAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i1b19f4b3636941f2900ae6ec1f44f9d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9cf29fd89a5442609bee7357c0b527ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i78fd0b65f75d4e63a2e869c2631bf0ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58388d7d9c6a4379884d6768a332b251_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic803cd5d0c184b89902cb243dfeb5916_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7cdba0abab7408cbfbfdb0c19a562a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">imux:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9010bd0189fc4f5baf921a2f5f4333bd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0d4812e273894e708953a3a86ae37e95_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib314b2e7a1bb4652a04c736a3427cd77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6283c69a3a9a4598bf3bc29177b58dd2_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">imux:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d0f6cb2694343c6b174f7126d1b497c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">imux:EmployeeStockOptionsVitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibabb7926e0324b259339a9246df9291b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">imux:VitalTherapiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i831a36d6192c47e5b5bf54b78aaeba94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2528cb0a73b4870ae39bb50b3b9d6d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifc75b1a787fb4655b51ea8fab14201f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice52c31a25f74dc481dd7ac060b4aa62_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:FederalMinistryOfFinanceGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2658237935944ab880c53895d440839_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">imux:ForeignExcludingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iadfaa4f5c09647ca9cde1fa1c8cd3403_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">imux:ForeignExcludingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia7147fc86cd64277aadeebf96a225804_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25a9ed10cb1c434e881185327a3fab3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">imux:TaxYearsPriorTo2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42d3b597607a4a96ad990267323ffb6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">imux:TaxYearsPost2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5c7b6124efd40999803947e39ba5996_I20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">imux:EuropeanInvestmentBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-19</instant>
        </period>
    </context>
    <context id="id3797128a5a3499face40e421c2bb72f_I20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-10-19</instant>
        </period>
    </context>
    <context id="i56a7a2ec7a864425ad54d86b2456da61_D20201019-20201019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2020-10-19</startDate>
            <endDate>2020-10-19</endDate>
        </period>
    </context>
    <context id="i04d94aba3d11445ea650849b72cf2899_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i7dd92710d99b48ba8db45f94ef6715f4_D20201015-20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="i9ede6cd330124ec6a00d9b69f6869d26_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibe8c1c50bbcc47cd82232e72f9c1d366_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i35dad35cf93d448a8881d824be1e6f81_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb99bde8e3a84965bc53a2495c5be965_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i49383c3200664df28115e65f5e1bf1a7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0ccd299d58334dac9edfb2ac321eecfe_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6a7188adef1744a990c1f5be2b5baaec_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="lease">
        <measure>imux:lease</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="tranche">
        <measure>imux:tranche</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV80L2ZyYWc6OTY1NTI2M2I2MWE0NDliM2IwZTA0ZTcxMTNhYTU2YzEvdGFibGU6OGM1ZGRmZjBjMGM3NDAxOGI2MDgxMDRkMTY2MWYwZmYvdGFibGVyYW5nZTo4YzVkZGZmMGMwYzc0MDE4YjYwODEwNGQxNjYxZjBmZl8zLTEtMS0xLTA_1f78d415-fcfc-4937-8d69-d5b8b9846bad">0001280776</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV80L2ZyYWc6OTY1NTI2M2I2MWE0NDliM2IwZTA0ZTcxMTNhYTU2YzEvdGFibGU6OGM1ZGRmZjBjMGM3NDAxOGI2MDgxMDRkMTY2MWYwZmYvdGFibGVyYW5nZTo4YzVkZGZmMGMwYzc0MDE4YjYwODEwNGQxNjYxZjBmZl80LTEtMS0xLTA_9d8fcc5b-4212-40c2-a04b-301c6b240280">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV80L2ZyYWc6OTY1NTI2M2I2MWE0NDliM2IwZTA0ZTcxMTNhYTU2YzEvdGFibGU6OGM1ZGRmZjBjMGM3NDAxOGI2MDgxMDRkMTY2MWYwZmYvdGFibGVyYW5nZTo4YzVkZGZmMGMwYzc0MDE4YjYwODEwNGQxNjYxZjBmZl81LTEtMS0xLTA_b10d5060-2517-440a-95f3-7dd8cff77471">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV80L2ZyYWc6OTY1NTI2M2I2MWE0NDliM2IwZTA0ZTcxMTNhYTU2YzEvdGFibGU6OGM1ZGRmZjBjMGM3NDAxOGI2MDgxMDRkMTY2MWYwZmYvdGFibGVyYW5nZTo4YzVkZGZmMGMwYzc0MDE4YjYwODEwNGQxNjYxZjBmZl82LTEtMS0xLTA_bb172b63-3e33-40f3-bbc8-a43d965244c0">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ia8b8f818b75b45b29b714b36192e1bd5_D20190412-20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzYvZnJhZzo5ODdmNDc2ZTRmMTc0ZmYzODI0ZWM0NmFiNTA0ZjZmNC90ZXh0cmVnaW9uOjk4N2Y0NzZlNGYxNzRmZjM4MjRlYzQ2YWI1MDRmNmY0XzI5_f5453273-e5ef-4111-a9b3-49bce8f1c983"
      unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE2NDkyNjc0NDgzOTA_02686f89-0de8-4c0b-a81a-71f470466ead">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9edfadac1b9748399350f656eaeb7769_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE3Mjg_67b7eb76-947a-407e-81f5-65bf99e5e7da">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDky_4e82e96f-b3aa-4369-9b63-3350736b28e2">10-K</dei:DocumentType>
    <dei:DocumentType
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDk5_4a156479-675d-4ec6-9823-9785199c7456">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6NDU4MzNlMGQ2ODFjNGRiMzk3OWYzMzkxN2I1ZTY0NTYvdGFibGVyYW5nZTo0NTgzM2UwZDY4MWM0ZGIzOTc5ZjMzOTE3YjVlNjQ1Nl8wLTAtMS0xLTA_07436ec9-dd64-470f-806f-929abac4ceab">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8xMzE_4bfdfbe1-b2e9-4e85-8a6a-a3fba69a64c3">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8xMzE_343e85b5-71c9-4bd6-9160-3bc054c83ddd">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6MzNlZWY5NGVjM2U5NDFiZjgyOGJlNWVjOWZmYTIxOGQvdGFibGVyYW5nZTozM2VlZjk0ZWMzZTk0MWJmODI4YmU1ZWM5ZmZhMjE4ZF8wLTAtMS0xLTA_13e580a5-51aa-4e4d-8307-06c6ed13a2b2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDkz_5f07ce3f-57b3-4707-a488-472993a5b060">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDgz_d59194f6-d6f2-48e7-a5c1-8a0677f6bdf3">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8wLTAtMS0xLTA_dbb12f50-c492-4ca3-a40d-e0086915cd84">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8wLTItMS0xLTA_9df8d266-66c8-40d0-8977-924cf581ea2d">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8yLTAtMS0xLTA_350b5f24-95b2-4e50-9528-2228a71d5064">1200 Avenue of the Americas,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8yLTEtMS0xLTA_3ba40da7-41f4-47d6-9e78-a92286f90068">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8zLTAtMS0xLTA_c37009ef-6a3a-4d8d-bdc7-32f50d892770">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8zLTEtMS0xLTA_e4e07ac4-4774-4db7-b3cf-12624e22b079">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6YTY0ZWNlYzhjYjZiNDA2NWFjYjg0ZDcwNDM1ZWM4OGYvdGFibGVyYW5nZTphNjRlY2VjOGNiNmI0MDY1YWNiODRkNzA0MzVlYzg4Zl8zLTItMS0xLTA_096a9a1d-1c3f-4e1a-a4b3-bcd5d6fbceb4">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDg4_5cac90cb-fb37-4e8e-8216-3b1cd241207f">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNzQ4Nzc5MDcyMDA5_7337440f-1598-4630-a8d5-14838cc49c88">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6ZDAwMDEwNjg2ZjI2NDZlOTg5MmI3MGFiYjEyZDAzOTcvdGFibGVyYW5nZTpkMDAwMTA2ODZmMjY0NmU5ODkyYjcwYWJiMTJkMDM5N18xLTAtMS0xLTA_5ba74b32-2d2e-440e-8ea1-89124014fc21">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6ZDAwMDEwNjg2ZjI2NDZlOTg5MmI3MGFiYjEyZDAzOTcvdGFibGVyYW5nZTpkMDAwMTA2ODZmMjY0NmU5ODkyYjcwYWJiMTJkMDM5N18xLTEtMS0xLTA_beb8392f-1637-4b29-a756-09ea5a237fa6">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6ZDAwMDEwNjg2ZjI2NDZlOTg5MmI3MGFiYjEyZDAzOTcvdGFibGVyYW5nZTpkMDAwMTA2ODZmMjY0NmU5ODkyYjcwYWJiMTJkMDM5N18xLTItMS0xLTA_351effa7-44f0-4fbf-9630-e453072413ec">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDg0_b8a37541-44ec-44f6-bcf2-2bde0eaec06e">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDg5_f1bdb3ad-33d4-4c68-bb6c-b3f2ff651369">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8xMTMy_9e711402-34c0-4fba-bb06-8d9d7ba6cf51">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8xNDY5_61719b75-c2fe-4495-ad23-87fd09edcb3b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6NGVhMzU4Yzg0NmZhNDIzYzk5ZjBlMjk0MWMxOTBiNDQvdGFibGVyYW5nZTo0ZWEzNThjODQ2ZmE0MjNjOTlmMGUyOTQxYzE5MGI0NF8wLTItMS0xLTA_71f0820d-1f2d-4e2b-9b72-e31bae01789a">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6NGVhMzU4Yzg0NmZhNDIzYzk5ZjBlMjk0MWMxOTBiNDQvdGFibGVyYW5nZTo0ZWEzNThjODQ2ZmE0MjNjOTlmMGUyOTQxYzE5MGI0NF8xLTMtMS0xLTA_2209576b-692d-41bb-baf3-327a214e0c92">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGFibGU6NGVhMzU4Yzg0NmZhNDIzYzk5ZjBlMjk0MWMxOTBiNDQvdGFibGVyYW5nZTo0ZWEzNThjODQ2ZmE0MjNjOTlmMGUyOTQxYzE5MGI0NF8yLTMtMS0xLTA_ed51f1dc-f4b2-4a72-99ad-18ecc7dc1267">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNzQ4Nzc5MDcyODk2_2a7d1cc6-6161-4436-8e8c-735b7ae5c113">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNDk4_2e02da71-2da0-4908-92b7-03e073536d6b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i4062cfe935644e299fdecc0eb484705d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yMzk0_7f692c26-96cd-4746-af41-3acfb0d553fa"
      unitRef="usd">181400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i113e2604b2a24be8a887c8a8b2cea29b_I20210219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNzQ4Nzc5MDcyMDEx_95851384-9d19-4be8-b065-f826510b9059"
      unitRef="shares">21168240</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xL2ZyYWc6Mzk5MmVkM2E1N2UzNDM1Yzk1ZGRhZWM3ZWQyY2I2MTAvdGV4dHJlZ2lvbjozOTkyZWQzYTU3ZTM0MzVjOTVkZGFlYzdlZDJjYjYxMF8yNzQ4Nzc5MDcyODk3_b2f6d4bf-fcba-4490-b76d-954f55d8c9ba">Certain portions of the registrant&#x2019;s definitive Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzQtMS0xLTEtMA_73b21b38-a776-4786-8b76-b7d61949a02b"
      unitRef="usd">127452000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzQtMy0xLTEtMA_a9df473e-83e9-425e-b2c8-cd1e04b50f88"
      unitRef="usd">29369000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzUtMS0xLTEtMA_f1e18d5f-f096-4bf8-8b70-7b4ed3a69a53"
      unitRef="usd">6293000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzUtMy0xLTEtMA_d56660c4-5459-4096-80f1-95baa2f6da1b"
      unitRef="usd">2861000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzYtMS0xLTEtMA_988642d6-84d0-45da-98cb-4557057ce597"
      unitRef="usd">133745000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzYtMy0xLTEtMA_cddcf713-4d66-4978-8eb6-65074c78e020"
      unitRef="usd">32230000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzctMS0xLTEtMA_d59e86d4-da93-4b40-92d8-72714605dec1"
      unitRef="usd">203000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzctMy0xLTEtMA_089ae93f-2ff0-4813-b509-997a63dcf717"
      unitRef="usd">80000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzgtMS0xLTEtMA_f89b1d37-0627-41ce-9aab-4e89ec797641"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzgtMy0xLTEtMA_b0c18cdd-326a-4c9f-b5b5-64c49d99f13f"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzktMS0xLTEtMA_0d31503e-8afb-445b-9368-c6d58cecc9a8"
      unitRef="usd">901000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzktMy0xLTEtMA_840ec890-b9d0-4114-808d-13513a0e1715"
      unitRef="usd">633000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzEwLTEtMS0xLTA_540219ad-4809-4fa1-86a3-9428d484ab3c"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzEwLTMtMS0xLTA_d1bf6a6b-e276-4984-ae4d-492a18a9c772"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzExLTEtMS0xLTA_38aa25f4-d633-4454-b0ba-f3536b8a79bc"
      unitRef="usd">167861000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzExLTMtMS0xLTA_1fdf1a6d-44ac-43a9-a48b-0828be809a4f"
      unitRef="usd">65955000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE0LTEtMS0xLTA_752321ff-45af-4c02-84de-19453377e3c9"
      unitRef="usd">3700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE0LTMtMS0xLTA_de601750-74d6-49af-8300-f26cab06ce31"
      unitRef="usd">2423000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE1LTEtMS0xLTA_e6820193-6c66-4378-a1c2-9a0c81697e39"
      unitRef="usd">4318000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE1LTMtMS0xLTA_144c6d31-4f03-47d5-8ae7-3f483c366d93"
      unitRef="usd">3298000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE2LTEtMS0xLTA_e9d99ef6-0e2f-4b50-aaaf-570d2fff03b5"
      unitRef="usd">379000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE2LTMtMS0xLTA_47b231ec-007f-426a-8c39-48af69835ec3"
      unitRef="usd">1351000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE3LTEtMS0xLTA_a809978a-75e9-44a3-9c9e-9515bbf15998"
      unitRef="usd">8397000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE3LTMtMS0xLTA_d7e55b17-6fb2-4bf7-ad10-36d3a2c24d6f"
      unitRef="usd">7072000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE5LTEtMS0xLTA_462eaf49-718a-4f81-822b-5243f9cf13f7"
      unitRef="usd">679000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzE5LTMtMS0xLTA_3d937533-a10a-4cbb-9805-d409f4a6e883"
      unitRef="usd">520000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIwLTEtMS0xLTA_a533ab2d-e140-48dc-862a-51a04af895e3"
      unitRef="usd">679000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIwLTMtMS0xLTA_fc1d546c-052b-4180-8d7e-e005038fcf9c"
      unitRef="usd">520000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIxLTEtMS0xLTA_ead94357-8477-40d6-8f6c-b7345dc40eeb"
      unitRef="usd">9076000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIxLTMtMS0xLTA_70a41245-67cc-423e-ac22-615f89c12dde"
      unitRef="usd">7592000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIyLTEtMS0xLTA_fd981853-334a-4c55-aec5-6879cd30a16e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzIyLTMtMS0xLTA_d7bb33b3-834e-47ac-a226-3c57323e09d7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTc0_13780025-c183-403e-b14e-5faeb24196e7"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTc0_6e38d85a-2399-467d-b48b-7d2e21f73736"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTg3_11b9bded-c495-4352-9f65-9f47a42d90f5"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTg3_fda3ea2d-9702-485f-a69d-ac2390ea47c2"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTky_1981cd51-9569-473e-878c-78d475d74482"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTky_69668e5d-73e2-4dc4-94f5-474d2c987616"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTky_a85b4112-828b-40d2-a7b2-5e54dd3859b5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MzBiODA0ODAxZGM0MzY5OWVkODRhNDRjYWYyZWIyYl8yNzQ4Nzc5MDY5NTky_eeb3322f-059a-40e0-98c5-b2dd79be1ca7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTEtMS0xLTA_41d49051-6f4a-4e78-b57b-5a3ee0371a33"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI2LTMtMS0xLTA_a2c042a1-ae31-486c-ac12-f2cbd3c86e06"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjE3_3fc69153-3fa9-4f1b-9288-02874750ed58"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjE3_bebbb066-f6f3-46f5-b94a-6e672f379d85"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjMx_838a8073-05ba-4541-96d5-b114a47cea93"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjMx_bbde9585-0eee-4d60-b4a7-650409a4ca81"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjQ0_5727a808-d86c-48fe-b87a-7080f393d0e9"
      unitRef="shares">21168240</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjQ0_8db82f7f-62d4-4487-ac2d-f507ed674044"
      unitRef="shares">21168240</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjU3_4250f5a8-6137-4310-a5be-45d23ed089a8"
      unitRef="shares">10744806</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NmRiNDg1NzBmOGQ0NjJkODNiYTU4Y2ZlNDhhNTkwOV8yNzQ4Nzc5MDY5NjU3_8f1abaa6-5228-424d-a3f0-7593cb445843"
      unitRef="shares">10744806</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTEtMS0xLTA_91c7c521-4fed-46a9-ad9a-b0f7c226e35e"
      unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI3LTMtMS0xLTA_e40b5c62-955c-463c-84d6-d1922684687c"
      unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI4LTEtMS0xLTA_6d7ae77b-54d8-4494-b0f1-fe07f1333eef"
      unitRef="usd">266823000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI4LTMtMS0xLTA_7dc23769-f06a-4b36-98d1-4e7317efeb2a"
      unitRef="usd">119646000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI5LTEtMS0xLTA_8244193a-2601-450d-a3c8-278662ccd4d0"
      unitRef="usd">-4112000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzI5LTMtMS0xLTA_94f25fe4-3519-4591-a13e-fd980a8c5dc8"
      unitRef="usd">-1373000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMwLTEtMS0xLTA_f709d97d-48f6-466f-b771-33df672ff2c8"
      unitRef="usd">-103928000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMwLTMtMS0xLTA_ceaa2b0b-c2cc-49d9-b85d-eb25b9ab9eb1"
      unitRef="usd">-59911000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMxLTEtMS0xLTA_edcc58f1-ee66-4cbd-9754-37469dbde14e"
      unitRef="usd">158785000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMxLTMtMS0xLTA_08776007-5cf4-4296-a0e5-9a9f2f72f068"
      unitRef="usd">58363000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMyLTEtMS0xLTA_2f75d91f-a47c-47a1-b11b-6e825d647357"
      unitRef="usd">167861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTIvZnJhZzpmNjY1YWUzYjA4Y2U0MWM5OTJjYjVhNDJjNzg4NzhkNi90YWJsZTo4YzU1YWYyMDQyMjI0NjExODNmMDI2ZDMzNTg1MWU2MC90YWJsZXJhbmdlOjhjNTVhZjIwNDIyMjQ2MTE4M2YwMjZkMzM1ODUxZTYwXzMyLTMtMS0xLTA_84203928-353f-4ea5-9abb-e6ad28a87010"
      unitRef="usd">65955000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzMtMS0xLTEtMA_52718cb0-7c2d-4ad3-9aa5-9ebce23f638c"
      unitRef="usd">38637000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzMtMy0xLTEtMA_1f81636e-adb8-451b-afb8-168b35b53c94"
      unitRef="usd">22512000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzQtMS0xLTEtMA_22d6722c-95b3-4bcc-9dc8-8d808085f583"
      unitRef="usd">10334000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzQtMy0xLTEtMA_666c1376-4a5f-4b03-bd35-8e437bd3d01e"
      unitRef="usd">14520000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzUtMS0xLTEtMA_978ac801-2b8f-4142-9a9b-c52462eda8d1"
      unitRef="usd">48971000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzUtMy0xLTEtMA_2c3d51fa-c6de-4d5f-994b-465eb485ef6f"
      unitRef="usd">37032000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzYtMS0xLTEtMA_65ab3678-2e5b-4a3c-895e-e99f92227dff"
      unitRef="usd">-48971000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzYtMy0xLTEtMA_d04472de-5bc6-4d1f-8a78-e982443e0fac"
      unitRef="usd">-37032000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzgtMS0xLTEtMA_212fa854-92a9-4df2-bef5-c62887df79c6"
      unitRef="usd">58000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzgtMy0xLTEtMA_c87a3ca9-0af8-4ab5-a0c0-d591cc7f2aed"
      unitRef="usd">107000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzktMS0xLTEtMA_2ebaab90-9080-4444-89e1-ce2be9446108"
      unitRef="usd">4896000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzktMy0xLTEtMA_191bda6c-1fd3-41d7-8cf7-3ba2f468d5d0"
      unitRef="usd">1992000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzEwLTEtMS0xLTA_2ef26e3b-d313-4af5-adf8-c14742c3d186"
      unitRef="usd">4954000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzEwLTMtMS0xLTA_22bfc9e3-98f0-4442-9939-33d9e4c92576"
      unitRef="usd">2099000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzExLTEtMS0xLTA_c09e80fb-5410-4f81-860a-2695511d5324"
      unitRef="usd">-44017000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzExLTMtMS0xLTA_7d35542d-9344-499d-81ff-0aef4523ba8b"
      unitRef="usd">-34933000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzEzLTEtMS0xLTA_1b0eba70-5999-4e99-b22e-ebb755663a17"
      unitRef="usdPerShare">-2.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzEzLTMtMS0xLTA_8f821b5e-d0e3-4d98-a311-865d0c3b1b64"
      unitRef="usdPerShare">-4.52</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzE1LTEtMS0xLTA_cd9e9291-34f9-43c0-84b9-b66d382f8b9a"
      unitRef="shares">15663826</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMTgvZnJhZzpiMDU3NDM4MTcyZDk0ZjBkODI3MjZiNDJmZjZiOThiZS90YWJsZTpmZTU5ZWFiZDk2MmQ0YTM5YjFhMmNhYjhlM2YxOGE4ZC90YWJsZXJhbmdlOmZlNTllYWJkOTYyZDRhMzliMWEyY2FiOGUzZjE4YThkXzE1LTMtMS0xLTA_d7abdafe-6cba-4a3b-b2d8-51c51ae557ce"
      unitRef="shares">7722269</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzItMS0xLTEtMA_c09e80fb-5410-4f81-860a-2695511d5324"
      unitRef="usd">-44017000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzItMy0xLTEtMA_7d35542d-9344-499d-81ff-0aef4523ba8b"
      unitRef="usd">-34933000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzQtMS0xLTEtMA_2f9fb478-4bee-43ca-8ea5-86d55e57d90e"
      unitRef="usd">-2739000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzQtMy0xLTEtMA_c35990bc-7347-4b05-96ed-87d236d29f39"
      unitRef="usd">-554000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzUtMS0xLTEtMA_9decc73f-e29c-44a0-bd44-d32d0a45ecd9"
      unitRef="usd">-46756000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjEvZnJhZzozNmI4ZWIxN2Y1OTA0ZWIxYmUwNTMxNjcyMTI0YTU5YS90YWJsZTo4YjZlZDJjNjNhNDc0ZWViOTZkNTU0MDhlMzc1NmNjYi90YWJsZXJhbmdlOjhiNmVkMmM2M2E0NzRlZWI5NmQ1NTQwOGUzNzU2Y2NiXzUtMy0xLTEtMA_201db8c8-b72a-4801-92d9-43980b24175f"
      unitRef="usd">-35487000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ifedde0176e664cb6aff9c43204468770_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMS0xLTEtMA_69da2ff9-59d4-459e-b1aa-af97c20541a1"
      unitRef="shares">299456</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifedde0176e664cb6aff9c43204468770_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMy0xLTEtMA_61ffbb30-3adc-48d2-ad9a-073361560787"
      unitRef="usd">34313000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i98b37649abfa476e8663e7096706f97e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtNS0xLTEtMA_1eebe7c6-1331-4f27-b57b-3f07b4ec8ff6"
      unitRef="shares">13541</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i98b37649abfa476e8663e7096706f97e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtNy0xLTEtMA_bae38239-9711-4a2c-9987-fc2128d926af"
      unitRef="usd">2879000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i6865d74fb3c44e108442faced8021edf_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTAtMS0xLTA_d4d5440f-825d-44a5-9e01-b44cdb333dc5"
      unitRef="shares">846953</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6865d74fb3c44e108442faced8021edf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTItMS0xLTA_786ad5e1-cc94-4782-82c5-1310ffc31534"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7671da9018c545b3817f9563d19e0261_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTQtMS0xLTA_84af03ee-84cf-44a6-ac31-93c2dca4d5b9"
      unitRef="usd">56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if37994c8a1974311901413ff52b1e230_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTYtMS0xLTA_371185b5-8f18-4ef1-b107-7068e8c9a968"
      unitRef="usd">-819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i440b26b7a65b40cba6e77e9d545181b2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMTgtMS0xLTA_ca90c895-cd1e-4221-aaa8-2d49371c6f55"
      unitRef="usd">-24978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzYtMjAtMS0xLTA_68edeac7-b252-41fa-8d4e-a2abdd81c75a"
      unitRef="usd">-25741000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if188cbbb4056418e817200cb3a88ab28_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzctMTgtMS0xLTA_125121db-d970-4560-a17f-ee6043efc40b"
      unitRef="usd">-34933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzctMjAtMS0xLTA_a87137ed-01c1-4ded-9882-d1fc9bcb0a50"
      unitRef="usd">-34933000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4298d26d7d8640bb99d1f84822b95179_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzgtMTYtMS0xLTA_4ec1742a-9f70-4a2d-a3be-b141a1ecae03"
      unitRef="usd">-554000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzgtMjAtMS0xLTA_043a4552-ac88-42c2-9c50-b954ce05b367"
      unitRef="usd">-554000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4b9a7fc5636d462982c27ea109928534_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzktMTQtMS0xLTA_88ec25a2-403e-4117-8b46-82deb443c789"
      unitRef="usd">529000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzktMjAtMS0xLTA_7ddf1075-0f6e-41a5-b9c2-bfc203725365"
      unitRef="usd">529000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i24ec86347b48487488f1c2b7053d37cc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTEtMS0xLTA_aa3cc6b4-4d26-42c7-93ee-58f374650ff7"
      unitRef="shares">299456</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i24ec86347b48487488f1c2b7053d37cc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTMtMS0xLTA_3f61ce7a-325a-4460-bd1f-926b0a68232b"
      unitRef="usd">-34313000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="if52f51af4dd14483aa5dd285b20cb6c6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTUtMS0xLTA_c968b49d-767c-484f-af91-5295ecab441e"
      unitRef="shares">13541</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if52f51af4dd14483aa5dd285b20cb6c6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTctMS0xLTA_9fbacb22-d8c3-4357-8935-1ab510f6e2a8"
      unitRef="usd">-2879000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTEwLTEtMS0w_0bf924c5-108e-4567-87b2-765a7d0bfd85"
      unitRef="shares">5302029</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTEyLTEtMS0w_704d983f-fef8-4ddb-8701-245d54a3e2e5"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4b9a7fc5636d462982c27ea109928534_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTE0LTEtMS0w_9d56f3db-c376-4de8-933d-9564de98d9a0"
      unitRef="usd">37192000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEwLTIwLTEtMS0w_6263251a-2020-4f87-b693-140750ff2508"
      unitRef="usd">37193000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzExLTAtMS0xLTAvdGV4dHJlZ2lvbjoyNmY4MTcxNzg0YzI0MmFkOTU3ZjdiMzk3YTBjNmQxMF84OQ_0aedd507-a0b4-4f05-9a1e-fac5d429df1f"
      unitRef="usd">61000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i11abdac7c3c743d3a599ef1d1fe7969d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzExLTEwLTEtMS0w_7247186d-0a0b-4304-b2dd-aa7c279fa58a"
      unitRef="shares">2197742</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5fc3a70ddcc2416da33598ca112c4ec6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzExLTE0LTEtMS0w_0d4e455b-02c0-48fd-946b-6f091171058d"
      unitRef="usd">29935000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzExLTIwLTEtMS0w_2b8103d9-7e78-4001-9f19-e107b46acbf8"
      unitRef="usd">29935000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic942c4f9cf4f4506ac6fc6619d7741a1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEyLTEwLTEtMS0w_e3036ed0-2d11-4044-a7f1-1b9cc549c994"
      unitRef="shares">460336</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8be2e94565534b38a1b810c6d9c76e40_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEyLTE0LTEtMS0w_0ba794bb-3db7-4c0c-991c-e4d7f7eca093"
      unitRef="usd">6014000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id653ff8493bb4f28b484c985e561ac7d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEyLTIwLTEtMS0w_776c4ec0-e739-44a0-a398-8426806fb155"
      unitRef="usd">6014000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if2df4d80998e4e6fbb1105df3cc50d87_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEzLTEwLTEtMS0w_e846c858-426f-4086-80b0-5f94901f4bcc"
      unitRef="shares">120070</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie42c6f1afb234a33ac5df351a682ac65_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEzLTE0LTEtMS0w_5a4c6ca4-b66a-4b09-9a79-e7a632be03da"
      unitRef="usd">1540000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0f2bc238cf84494f92f2d022a107611a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzEzLTIwLTEtMS0w_1d8072a4-3250-42fd-8885-203a04cfb4b2"
      unitRef="usd">1540000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE0LTEwLTEtMS0w_9fc4b55d-b488-4f2f-9c9c-db8d990908e5"
      unitRef="shares">1059269</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i4b9a7fc5636d462982c27ea109928534_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE0LTE0LTEtMS0w_8d6071d5-aa64-4458-9ce3-cff1a6c70621"
      unitRef="usd">39400000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE0LTIwLTEtMS0w_92174abc-3bd2-481a-b47b-c76f88d20d9f"
      unitRef="usd">39400000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic510b294a54c489bb49b657cdc5713c9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE1LTEwLTEtMS0w_56604cb7-250c-4a1e-9f5b-f88ece7782b6"
      unitRef="shares">127500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE1LTIwLTEtMS0w_cfc1abcf-8527-466f-bb8a-ae73a4fb176a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpiNzVmZGEzYTM0ZDY0NTU5YTExZjE1MDMxNjQ5ZjE1YV82MA_c1bc88fb-5008-4cf7-9a4f-7377832af64c"
      unitRef="usd">377000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i482400df09b44e2ba6f90598101aea5d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE2LTEwLTEtMS0w_b2423402-1342-4285-a7e1-f5a6c032ac6c"
      unitRef="shares">630907</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6691293a863540519bd390ff32edae71_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE2LTE0LTEtMS0w_f76424c0-aaa8-4c29-8f3a-43125ce0e973"
      unitRef="usd">4980000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE2LTIwLTEtMS0w_f30c93a6-79f0-40af-ae02-3bcc343054b7"
      unitRef="usd">4980000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="ibee2b8da709d477caa8f18d809bc9f32_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTEtMS0xLTA_3ccf3be9-fee7-4b16-b8da-722883f5e9f7"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibee2b8da709d477caa8f18d809bc9f32_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTMtMS0xLTA_5fb31133-d144-4736-b41c-73e85b2ad62e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i8ce55168c27842fcba430142ef8577a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTUtMS0xLTA_f66a9b57-0de6-406f-9b78-c4dbb3f6f666"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8ce55168c27842fcba430142ef8577a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTctMS0xLTA_de57bac0-fa47-4317-94c6-946d2c8dd55d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i78983d83235a444bb1184ca248359fe6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTEwLTEtMS0w_9443e043-113b-439d-bb18-9d204e103279"
      unitRef="shares">10744806</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i78983d83235a444bb1184ca248359fe6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTEyLTEtMS0w_5db69043-74e5-4b7f-b051-b5de5e7498e3"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41cf71437d1148fd87ec313c6ab59abc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTE0LTEtMS0w_774320e2-08df-4be9-a39e-66bbaa5485cd"
      unitRef="usd">119646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i378b311e84c3477d87b10194049b52c6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTE2LTEtMS0w_15bbc1b1-46d6-4018-8485-af6150cc8e7b"
      unitRef="usd">-1373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if5a2646a9310481db842eb9736d24b75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTE4LTEtMS0w_075961d2-4afe-4f7e-a84f-a0d5440dfcb8"
      unitRef="usd">-59911000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE3LTIwLTEtMS0w_1b6f7088-e060-40a4-a3dc-808a34d1e8f4"
      unitRef="usd">58363000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i22d73ebb34f94a97a65d4cc981b33181_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE4LTE4LTEtMS0yMDg0_4bc8874b-724c-49e6-a237-60cbf4f8c0a6"
      unitRef="usd">-44017000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE4LTIwLTEtMS02Mjc_2207dcd9-b1ce-4e3f-a510-71d6a7999ed5"
      unitRef="usd">-44017000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide45a6f10a8143968b9977470c96fcf0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE5LTE2LTEtMS0yMDgw_26c44488-f418-4303-b309-8fb1997a6c2d"
      unitRef="usd">-2739000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzE5LTIwLTEtMS02Mjc_4930ce83-578e-47c3-9996-06cff2288ff7"
      unitRef="usd">-2739000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic26eab55dd1c4325a2bf6fcd5b7880f5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIwLTE0LTEtMS02MTU_e55bc043-9916-4557-8bd4-814fb0409c8e"
      unitRef="usd">2747000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIwLTIwLTEtMS02Mjc_dd46bc1d-5dad-4d58-9c6c-997ff2c7ca26"
      unitRef="usd">2747000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIxLTAtMS0xLTUyOC90ZXh0cmVnaW9uOjFiOTI5MjMyNWY4NjRjMzhhNWQzYTFlMGJlMTk5MTQ1XzI3NDg3NzkwNjk1MzQ_5889432e-8326-4808-a59e-34ff322a11b8"
      unitRef="usd">339000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6b2a4218e23645fe8a43795e53bd917d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIxLTEwLTEtMS02MDc_9a2f4edb-b957-4408-b1c2-cc6b5817aa64"
      unitRef="shares">733728</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i90db4b0e7fa9494cb6a2c2d5438fde97_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIxLTE0LTEtMS02MTU_63c7c57d-426c-47f9-9fc0-fde4a407af54"
      unitRef="usd">10925000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIxLTIwLTEtMS02Mjc_85785846-78c8-450f-927d-6bcf2b3bbdc6"
      unitRef="usd">10925000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIyLTAtMS0xLTUyOC90ZXh0cmVnaW9uOmRlZTA4OWFkMjRkMTRiNDZhOWFmYzdlM2I4Njg1MDAzXzI3NDg3NzkwNjk1NDg_26c231e2-4c3a-4735-977e-c4e727247c90"
      unitRef="usd">1082000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifd95d995b8c1481499d8fe54a95ec8a4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIyLTEwLTEtMS02MDc_90d8fce6-65f6-47d8-8bc6-ffdd91badc98"
      unitRef="shares">1764706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i263afee333724006aaeff1f3dcee49a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIyLTE0LTEtMS02MTU_fbc6103b-21d4-452b-bed6-eaa962b052ec"
      unitRef="usd">13918000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIyLTIwLTEtMS02Mjc_1216f58b-2da2-4c88-ac22-e355782002cb"
      unitRef="usd">13918000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIzLTAtMS0xLTUyOC90ZXh0cmVnaW9uOjZkM2FkOWVhNjhmODQ3M2VhNDRkZDI0NjgxNzIyOWI3XzI3NDg3NzkwNjk1MzY_2bd8e781-90d3-4b69-854e-ad72e0c5b681"
      unitRef="usd">1752000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i45563a45c561425c82c1d8ae4a882b06_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIzLTEwLTEtMS02MDc_d0984180-be8c-48f4-97a4-9a91b4a7a259"
      unitRef="shares">2175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iacb99b20fe3f4285812691db62887373_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIzLTE0LTEtMS02MTU_001cbc19-125d-45e2-8daa-b585bf4d935d"
      unitRef="usd">23048000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzIzLTIwLTEtMS02Mjc_8ed37efb-3a81-4aad-8ea5-64934d2e2379"
      unitRef="usd">23048000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTAtMS0xLTUyOC90ZXh0cmVnaW9uOmQwYjE4MDdjOGYyMzRkMTM4YzcxYTc0YjE4MTU3N2M1XzI3NDg3NzkwNjk1Mzg_e72b1050-e9e0-420b-bd2d-3c596f5d8b2a"
      unitRef="usd">6960000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i714a7516a3074b3b819b97a2f9753718_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTEwLTEtMS02MDc_f0f53175-5126-4560-8675-4ee454ebec57"
      unitRef="shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i714a7516a3074b3b819b97a2f9753718_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTEyLTEtMS02MTE_5857bbcb-f2c1-4f85-9042-158c0135b6df"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib0d89043cac44e13a241896366e02310_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTE0LTEtMS02MTU_fc252cb6-7fc2-40ae-97ef-94c4594bedfa"
      unitRef="usd">96539000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI0LTIwLTEtMS02Mjc_d9e9e8ed-6609-4f9c-b07b-f38f03faeb79"
      unitRef="usd">96540000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="ic64924c0859a41d59136ed99d077e63b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTEtMS0xLTU5MQ_0588d962-634a-4a66-95d1-972049c30e21"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic64924c0859a41d59136ed99d077e63b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTMtMS0xLTU5NQ_5e824d77-5723-4b6f-9403-e9f4cdc9f36c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ibc4d7683bd124ea18385d5d19135a5c7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTUtMS0xLTU5OQ_f7b581fc-68de-41ba-890e-84421efb961f"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibc4d7683bd124ea18385d5d19135a5c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTctMS0xLTYwMw_133245cd-fed7-4087-9683-0152c4acf6f3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i9e16527720b5489a87c3709cb393b31c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTEwLTEtMS02MDc_93797e34-1f48-4b8e-892c-2eaf70b0be94"
      unitRef="shares">21168240</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9e16527720b5489a87c3709cb393b31c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTEyLTEtMS02MTE_4141d337-f0fe-4846-adba-a92270a8d02d"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if9c5353dcba14224be159080140a4539_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTE0LTEtMS02MTU_a085378a-509f-4ad1-b691-b4986f911c56"
      unitRef="usd">266823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c794d23984e413d94b0ee6303307fe7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTE2LTEtMS02MTk_89b48484-f5c9-47f0-ae32-a85302bb2982"
      unitRef="usd">-4112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6174bd787b0d4b3e9f91e9b34de11988_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTE4LTEtMS02MjM_a3518b35-ca75-4220-b803-07031b3a1baf"
      unitRef="usd">-103928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjQvZnJhZzphMTk1ZjU1Y2E5ZmY0YjY5ODM0M2MwOWNiOTIxYWUwYS90YWJsZTphZDAxZDVmOTI1NmU0NWRiOTMxNTM1MzA5ZmM4ZTIwMi90YWJsZXJhbmdlOmFkMDFkNWY5MjU2ZTQ1ZGI5MzE1MzUzMDlmYzhlMjAyXzI1LTIwLTEtMS02Mjc_4c9e2614-a701-42bd-9930-431d93ff36bc"
      unitRef="usd">158785000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMtMS0xLTEtMA_3cd67c10-9b06-4d63-b395-62a68f02be4e"
      unitRef="usd">-44017000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMtMy0xLTEtMA_318e7ba0-d57e-4c9c-8147-d515a519d18b"
      unitRef="usd">-34933000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzUtMS0xLTEtMA_a2c82722-22a0-46be-acf3-3e707ae35d3a"
      unitRef="usd">39000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzUtMy0xLTEtMA_96a21022-dde7-484a-9e32-ba6083d223f9"
      unitRef="usd">50000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzYtMS0xLTEtMA_51db75ae-a901-40ea-97a2-7cc71a40b83a"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzYtMy0xLTEtMA_bd800e20-997a-43fd-9975-d5a96599c670"
      unitRef="usd">329000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzctMS0xLTEtMA_432c399b-5a94-4aa1-8843-ea17ac9c894b"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzctMy0xLTEtMA_e7cb8485-03d9-44ae-a1be-b48c11349f67"
      unitRef="usd">26000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzgtMS0xLTEtMA_607a4518-0985-4740-bef2-2a903b51d12d"
      unitRef="usd">2747000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzgtMy0xLTEtMA_7058c91b-7447-460c-822f-42a71e685d03"
      unitRef="usd">6512000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzktMS0xLTEtMjg2NA_937609f0-35f0-49b2-9338-46fa430c60f9"
      unitRef="usd">2528000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzktMy0xLTEtMjg2OA_12e70c57-f142-4861-9af8-503c46f6682a"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzktMS0xLTEtMA_89581fc3-7525-4a76-844e-cc6e42784e29"
      unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzktMy0xLTEtMA_16b57026-e8cf-4b93-a6b8-925e58b94cde"
      unitRef="usd">1540000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzExLTEtMS0xLTA_3ef430f8-47b7-41cc-bd1b-8f5eaf2a8925"
      unitRef="usd">2779000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzExLTMtMS0xLTA_dfe2abaa-0596-4442-9836-793486c21d54"
      unitRef="usd">2224000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzEyLTEtMS0xLTA_ac9205b6-f073-4714-b72f-d3d21b390066"
      unitRef="usd">1000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzEyLTMtMS0xLTA_245ef039-53d1-4f56-9a20-b6a35cf17985"
      unitRef="usd">-462000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzEzLTEtMS0xLTA_4d57a3cb-7d02-456c-a9fe-d6f838de604f"
      unitRef="usd">-1255000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzEzLTMtMS0xLTA_d7c9b84b-2ed2-4e71-9b64-6e597ccafd25"
      unitRef="usd">1102000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE0LTEtMS0xLTA_25534838-4a8b-4026-b62f-e0fc547ec303"
      unitRef="usd">669000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE0LTMtMS0xLTA_f40bfabf-0204-4e8c-87bd-73b3f0aa8653"
      unitRef="usd">225000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE1LTEtMS0xLTA_50c466a4-9255-47d5-be7b-f84e1e8f66ad"
      unitRef="usd">-46124000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE1LTMtMS0xLTA_9824a416-76ea-4716-a3cd-e7552ae73ccf"
      unitRef="usd">-28545000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE3LTEtMS0xLTA_e4be72b3-d0f7-47ab-88e7-6f3f386b56a8"
      unitRef="usd">146000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE3LTMtMS0xLTA_a47becb0-7fea-43cc-8323-46746e0caf25"
      unitRef="usd">55000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE4LTEtMS0xLTA_299cb8d8-02fd-453a-a128-0dd99ceb43a3"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE4LTMtMS0xLTA_a9be0787-b449-4bd9-9929-15c1b3a8e7d2"
      unitRef="usd">75000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE5LTEtMS0xLTA_f4065e57-31b7-4c06-9e39-0b708c6c2c46"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzE5LTMtMS0xLTA_c40bd62a-529d-4114-a53c-4f91b0e99408"
      unitRef="usd">2475000</us-gaap:ProceedsFromSaleOfOtherPropertyPlantAndEquipment>
    <imux:CashAcquiredInConnectionWithReverseAcquisition
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIwLTEtMS0xLTA_352e7371-94f5-4023-8be7-a94b29a91384"
      unitRef="usd">0</imux:CashAcquiredInConnectionWithReverseAcquisition>
    <imux:CashAcquiredInConnectionWithReverseAcquisition
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIwLTMtMS0xLTA_5faf936e-fcae-42c7-9a88-a239f8725738"
      unitRef="usd">8151000</imux:CashAcquiredInConnectionWithReverseAcquisition>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIxLTEtMS0xLTA_742d886a-c23f-4d88-b647-51057f71c9b8"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIxLTMtMS0xLTA_fcb796ab-899c-48c5-8cbf-c559ab726eff"
      unitRef="usd">40000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIyLTEtMS0xLTA_4a87c24c-b0c2-4a03-bed0-c8ca7fb441a4"
      unitRef="usd">-146000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzIyLTMtMS0xLTA_aa69b739-e82f-4053-9017-4a217f1948e1"
      unitRef="usd">10536000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI0LTEtMS0xLTA_a394522d-81e7-49e4-8efb-60cca011ed80"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI0LTMtMS0xLTA_80cc7ef3-9d62-4001-b78b-b2ab380dbd21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i3e803724dcf84ceba79eba0078a118c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI1LTAtMS0xLTAvdGV4dHJlZ2lvbjoxODZmYjc5MTg4ZGQ0MmZjYjM4ZTZlZjczNjEwN2Q2OF85NA_af9fe9b0-e4fc-4e34-80c6-ec2436500de5"
      unitRef="usd">61000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3e803724dcf84ceba79eba0078a118c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI1LTEtMS0xLTA_e588be7f-601d-40f5-9dd8-501086dbcd04"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI1LTMtMS0xLTA_b014d04a-25c0-4c41-9500-2e8785db57c0"
      unitRef="usd">29965000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkNmMxOWEwZTVlZTg0M2UxYjY1YjQzNDE0MjE3NTg3Nl8yNzQ4Nzc5MDY5NTc4_30e1fa0f-1d4f-4da4-9b0c-a2a1452fcafb"
      unitRef="usd">339000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkNmMxOWEwZTVlZTg0M2UxYjY1YjQzNDE0MjE3NTg3Nl8yNzQ4Nzc5MDY5NTg1_49b2eb5a-8cec-4446-8b68-b233b13f5657"
      unitRef="usd">161000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i19507d0d1abc4c65964f5b4d5f53de3f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI2LTEtMS0xLTA_51493e9e-0fea-45a3-b9d1-8fb7d12b21c9"
      unitRef="usd">10925000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i54a1a034f6604c3db6d375fa706b8929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI2LTMtMS0xLTA_06d1c64d-403e-4ee3-9266-e46d27015c59"
      unitRef="usd">5200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTAtMS0xLTIzOTYvdGV4dHJlZ2lvbjpmMmQ1MWIyOTA0YmU0ODM3OTQ1ZDk1ZDY3OGU3N2E4NV8yNzQ4Nzc5MDY5NTQx_2b6bf0fb-b18a-4e57-a660-0b5f7afc1b20"
      unitRef="usd">1082000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1832c2b608ad4c3594743c1bfda4cccf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTEtMS0xLTI0MTI_7e6422d0-e7ac-4649-af8b-59aa75cfbf37"
      unitRef="usd">13918000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia5f2a878d5224327b9c3906b7957b0e5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTMtMS0xLTI0MTY_d8133f8f-1b6a-4052-82c3-fd651f60ed06"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTAtMS0xLTI0MDIvdGV4dHJlZ2lvbjphNzI2NmRmZmFhOTM0NTRlOTBlZDY0NzcwN2M4YmI1MV8yNzQ4Nzc5MDY5NTI5_42f50fda-599c-45cc-9699-d001c847783d"
      unitRef="usd">1752000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2528cdd1555942d1a0cda9a163677ca8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTEtMS0xLTI0MTI_d8e8fb6a-c7eb-4a0c-b7a4-e0e926ee15d6"
      unitRef="usd">23048000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i98ef75f825ff45d4ba01031c2df25949_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTMtMS0xLTI0MTY_9e5d419f-e3c8-429c-9cd4-4ebc95dae5e6"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTAtMS0xLTI0MDcvdGV4dHJlZ2lvbjoxOTMxN2M3ODRjODM0ODQyOTExYzE0Nzg2MjRlOTQwMV8yNzQ4Nzc5MDY5NTMx_f618e98b-ae7e-4e08-82cc-f4acb874ff8d"
      unitRef="usd">6960000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i377dbdee22a64d8eb77133ea5f9356a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTEtMS0xLTI0MTI_172fb251-f5ca-4042-8e57-9be396182138"
      unitRef="usd">96540000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic948d92ac1714503a6fd146abfa629ce_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTMtMS0xLTI0MTY_275afa87-76ef-47f2-a908-dc4ffc24db89"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTEtMS0xLTA_106a828e-4966-4b4d-b50b-945559f4f959"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI3LTMtMS0xLTA_a456cd65-5d8a-4fd3-8b0f-81649e4ea22d"
      unitRef="usd">270000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTEtMS0xLTA_b027b8ff-7bb6-46a0-bf28-155a0571cf1f"
      unitRef="usd">144431000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI4LTMtMS0xLTA_4e0de02e-360a-476f-9924-5f6d9617021b"
      unitRef="usd">34895000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTEtMS0xLTA_b29f8624-23ec-4856-904a-c557beb41fed"
      unitRef="usd">-78000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzI5LTMtMS0xLTA_f96ed6d3-27bd-4400-bfbf-1262464a2880"
      unitRef="usd">-589000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMwLTEtMS0xLTA_d0c6ceca-e072-45fb-a01d-3fd0147055c0"
      unitRef="usd">98083000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMwLTMtMS0xLTA_363571f2-a7eb-44c6-a4ac-538f2a3ce6dd"
      unitRef="usd">16297000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMxLTEtMS0xLTA_4cef5a82-9a97-4025-a7d2-d2630aee5bea"
      unitRef="usd">29369000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMxLTMtMS0xLTA_f1bc8f39-8375-45d5-8f0e-d7c5f4dc0336"
      unitRef="usd">13072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMyLTEtMS0xLTA_73f974ee-194d-4db6-aab1-f9ea875752e9"
      unitRef="usd">127452000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzMyLTMtMS0xLTA_d095757c-a458-4e65-981b-7582705307c0"
      unitRef="usd">29369000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <imux:DeferredStockIssuanceCostsIncludedInLiabilities
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM2LTEtMS0xLTA_f001b553-f62f-4b10-a475-f301944a2bf6"
      unitRef="usd">0</imux:DeferredStockIssuanceCostsIncludedInLiabilities>
    <imux:DeferredStockIssuanceCostsIncludedInLiabilities
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM2LTMtMS0xLTA_947cca7e-cd90-481c-adc9-4d40a307ebdd"
      unitRef="usd">20000</imux:DeferredStockIssuanceCostsIncludedInLiabilities>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM3LTEtMS0xLTA_d7677a7a-8327-4e34-a0df-8610c94d8adb"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM3LTMtMS0xLTA_2e66ce03-7356-4ebe-9b80-4c16bcd5490f"
      unitRef="usd">37193000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM4LTEtMS0xLTA_e12b8e05-f034-44f7-9653-e77166508cc7"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM4LTMtMS0xLTA_bd11c628-3d05-4e64-821c-aa89038160e2"
      unitRef="usd">39400000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <imux:OfferingCostsIncludedInAccruedExpenses
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzQzLTEtMS0xLTI4ODg_f36d7ea8-a73c-4a16-9867-d449ce4588fb"
      unitRef="usd">114000</imux:OfferingCostsIncludedInAccruedExpenses>
    <imux:OfferingCostsIncludedInAccruedExpenses
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzQzLTMtMS0xLTI4ODQ_3a658296-42ac-40ac-8e34-b4828d39eb39"
      unitRef="usd">0</imux:OfferingCostsIncludedInAccruedExpenses>
    <imux:PropertyPlantAndEquipmentIncludedInAccountsPayable
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM5LTEtMS0xLTA_da378363-584c-4e84-a5fb-65e141618b60"
      unitRef="usd">0</imux:PropertyPlantAndEquipmentIncludedInAccountsPayable>
    <imux:PropertyPlantAndEquipmentIncludedInAccountsPayable
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMjcvZnJhZzo5YjI4YTA0ZWY4NmQ0YTNiYWMzNmRlMzE5ZTZhOTBlNi90YWJsZToyZmQ5M2U1ZjIyZDQ0Mzg3YWE5YzU0N2QyODEwNmU3My90YWJsZXJhbmdlOjJmZDkzZTVmMjJkNDQzODdhYTljNTQ3ZDI4MTA2ZTczXzM5LTMtMS0xLTA_8b2415d4-dd9c-4139-93ce-047b39355246"
      unitRef="usd">19000</imux:PropertyPlantAndEquipmentIncludedInAccountsPayable>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzg0MjY_ca7c2554-4644-4254-8df4-37653b12fa46">Description of Business and Basis of Financial Statements&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Immunic, Inc. ("Immunic" or the "Company") a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis ("RRMS"), ulcerative colitis ("UC"), Crohn&#x2019;s disease ("CD") and psoriasis. Immunic is headquartered in New York with its main operations in Gr&#xe4;felfing, Germany. Immunic currently has 28 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Immunic is currently pursuing three development programs, all orally available small molecule inhibitors in the clinical development phase. These include the IMU-838 program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase (&#x201c;DHODH&#x201d;); the IMU-935 program, which is focused on an inverse agonist of ROR&#x3b3;t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (&#x201c;ROR&#x3b3;&#x201d;), and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function. These product candidates are being developed to address diseases such as RRMS, UC, CD, and psoriasis. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#x201c;PSC&#x201d;), and Guillain-Barr&#xe9; syndrome (&#x201c;GBS&#x201d;). Immunic is also investigating IMU-838 as a potential treatment option for coronavirus disease 2019 (&#x201c;COVID-19&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $103.9&#160;million as of December&#160;31, 2020 and approximately $59.9&#160;million as of December&#160;31, 2019. Substantially all of Immunic&#x2019;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through December&#160;31, 2020, Immunic has raised net cash of approximately $216.8 million from private and public offerings of preferred and common stock. As of December&#160;31, 2020, Immunic had cash and cash equivalents of approximately $127.5&#160;million. With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying audited consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 12, 2019, pursuant to the terms of the Agreement, dated as of January 6, 2019, between Vital Therapies, Inc., a Delaware corporation (&#x201c;Vital&#x201d;), Immunic AG, and the shareholders of Immunic AG party thereto (the &#x201c;Agreement&#x201d;), the holders of Immunic AG ordinary shares exchanged all of their outstanding shares for shares of Vital common stock, resulting in Immunic AG becoming a wholly-owned subsidiary of Vital (the &#x201c;Transaction&#x201d;). Immediately following the Transaction, Vital Therapies, Inc. changed its name to &#x201c;Immunic, Inc.&#x201d; and its ticker symbol to &#x201c;IMUX&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the closing of the Transaction, (i) each Immunic AG preferred share was converted into one Immunic AG ordinary share, and (ii) each Immunic AG ordinary share was converted into the right to receive 17.17 shares of Vital&#x2019;s common stock, after giving effect to the Reverse Stock Split (as defined below). The exchange ratio was determined through arm&#x2019;s-length negotiations between Vital and Immunic AG. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate consideration issuable in the Transaction, after giving effect to the Reverse Stock Split, was 8,927,130 shares of Vital&#x2019;s common stock. Following the Transaction and after giving effect to the Reverse Stock Split, the former shareholders of Immunic AG owned approximately 88.25% of the fully diluted common stock of the Company, and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shareholders of Vital immediately prior to the Transaction owned 1,059,269 shares (plus 127,500 restricted stock units (&#x201c;RSUs&#x201d;) all of which have been issued to date to former Vital officers) of the common stock of the Company or approximately 11.75%. The issuance of shares of Vital&#x2019;s common stock in the Transaction was registered with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on a Registration Statement on Form S-4 (Registration No. 333-229510).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the closing of the Transaction, Immunic AG issued, in a private placement transaction (the &#x201c;Financing&#x201d;), an aggregate of 2,197,742 ordinary shares to certain of its shareholders for aggregate consideration of &#x20ac;26.7 million (approximately $29.9 million), pursuant to the terms of the Investment and Subscription Agreement, dated as of January 6, 2019, between Immunic and the shareholders and investors party thereto (the &#x201c;Subscription Agreement&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Transaction has been accounted for as a reverse acquisition under the acquisition method of accounting. Because Immunic AG&#x2019;s pre-Transaction owners held an 88.25% economic and voting interest in the combined company immediately following the closing of the Transaction, Immunic AG is considered to be the acquirer of Vital for accounting purposes. Additionally, Immunic AG is considered to be the predecessor for reporting purposes and the financial results of Immunic AG are reported in the historical comparable periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 12, 2019, immediately following the closing of the Transaction, the Company effected a 40-for-1 reverse stock split of its common stock (the &#x201c;Reverse Stock Split&#x201d;). Accordingly, all references to share and per share amounts in the accompanying audited consolidated financial statements and notes have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. No fractional shares were issued in connection with the Reverse Stock Split. Unless otherwise noted, all references to common stock share and per share amounts have also been adjusted to reflect the exchange ratio of 17.17.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Research GmbH (which both began operations in 2016), Immunic Australia Pty Ltd. (which began operations in 2018) and Vital Therapies (Beijing) Company Limited (&#x201c;VTL China&#x201d;), acquired through the Transaction (which began operations in 2005). VTL China was sold in September 2019 in connection with the sale of certain of Vital's clinical development-related intellectual property rights (the "ELAD Assets"). All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. Certain prior period amounts have been reclassified to conform to the current basis of presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzE4NTY_5b732074-5ec9-4be5-bbe2-c874d6a5d86c"
      unitRef="usd">-103900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzE4ODY_2e517015-ac3b-466c-ab01-b90d5160948d"
      unitRef="usd">-59900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i3268a88a2d6d4e30b39a112e210ac828_D20190412-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzEwOTk1MTE2NDcwMDI_0958fbc8-5a83-41cf-a0fa-799b12f7158e"
      unitRef="usd">216800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzMwNDE_dc4c063c-3064-427a-a76a-3384a7b21d98"
      unitRef="usd">127500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio
      contextRef="i9ea2ecf153a24b4f9905b7b614e7adf6_I20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzQ4NzU_2e668d8c-f258-421a-b6a6-dbc1b0d1a147"
      unitRef="number">17.17</imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i6b85b15cda004eb0acf9c15243874440_D20190412-20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzUxODU_bf5b4275-0dbf-4482-adab-0a8db869d82e"
      unitRef="shares">8927130</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i72933fde204541c88561a57e1bfee92c_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzUzNTY_b6809656-d6a4-4101-abf1-8894ae0c0a30"
      unitRef="number">0.8825</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <imux:BusinessCombinationSharesOwnedPriorToTransaction
      contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzU0ODI_485e5cda-0c93-4256-b699-f533bab1d2e7"
      unitRef="shares">1059269</imux:BusinessCombinationSharesOwnedPriorToTransaction>
    <imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction
      contextRef="i2d8389cccd92494f9385f182bf002a92_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzU0OTg_672dc242-0a91-4551-a16f-701a98ef4b50"
      unitRef="shares">127500</imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i025ac79fc8a04af682b83198235a9390_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzU2NDk_f6561678-918d-4341-954a-f97cd2244302"
      unitRef="number">0.1175</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6af0ec8f1a5c4c69afa77ae4992a4b27_D20190411-20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzU5OTk_7c0fa65c-07b6-459f-8ffe-c0fe1005b7e3"
      unitRef="shares">2197742</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i6af0ec8f1a5c4c69afa77ae4992a4b27_D20190411-20190411"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzYwODA_3618f571-d05a-42ae-a717-5591b5ac2ca7"
      unitRef="eur">26700000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="i6af0ec8f1a5c4c69afa77ae4992a4b27_D20190411-20190411"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzYwOTg_e37b83ff-df68-413f-8cdf-c31beabc646f"
      unitRef="usd">29900000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i72933fde204541c88561a57e1bfee92c_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzY0NTg_35680399-1b17-4141-83ba-0eeceee55f85"
      unitRef="number">0.8825</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio
      contextRef="i9ea2ecf153a24b4f9905b7b614e7adf6_I20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzMvZnJhZzozNTY1MTQzM2ViYzM0ODYxYTdhNmZlZTM2MDc3NTViZS90ZXh0cmVnaW9uOjM1NjUxNDMzZWJjMzQ4NjFhN2E2ZmVlMzYwNzc1NWJlXzc0NTg_d11dfdc6-f9a7-4bc6-b4d5-ec64e5f8d749"
      unitRef="number">17.17</imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDk4_62fdd44e-136c-473a-a3db-b1bad4b955f9">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, clinical trial expenses, share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. During the twelve months ended December&#160;31, 2020 and 2019, Immunic AG and Immunic Research GmbH&#x2019;s operations were located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income. The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years. Depreciation and amortization expense was $39,000 and $50,000 for the years ended December&#160;31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform a quantitative test that compares the fair value to its carrying value to determine the amount of any impairment. Impairment testing for goodwill is done at the reporting unit level. The Company has determined that it operates in a single operating segment and has a single reporting unit. The Company has determined there was no goodwill impairment as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, IMU-838, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on IMU-838, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  IMU-935 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in September 2019. IMU-856 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in August 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for diseases such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no more research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. The short-term leases are deemed immaterial and have not been included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2020, and December&#160;31, 2019, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU 2017-04, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;." This guidance eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit&#x2019;s fair value. The Company adopted this ASU, as required, in the quarter ended March 31, 2020 on a prospective basis. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-13, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement - Disclosure Framework&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-13.") ASU 2018-13 modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty, and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments must be applied retrospectively to all periods presented upon their effective date. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-18"). ASU 2018-18, clarifies that elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The Company does not have any agreements that meet the definition of a collaboration arrangement at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDk3_1f981e37-c8be-4ebb-9959-af8642b367c4">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, clinical trial expenses, share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDkz_bcc313a0-e3e4-402f-9e44-cf6aa5e1fbe4">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. During the twelve months ended December&#160;31, 2020 and 2019, Immunic AG and Immunic Research GmbH&#x2019;s operations were located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income. The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDY3_ce9e5ac2-f3fb-4af7-9586-de9e91828342">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <imux:CashEquivalentsInvestmentsMaturityPeriod
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIyODE_1647820e-6637-4781-91a8-5af03278be97">P3M</imux:CashEquivalentsInvestmentsMaturityPeriod>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDcy_e94b52cd-911b-4378-968f-1fd4c32741b6">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDk1_b0d071b4-486f-4efa-adec-24aab148c0e5">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idee3e91a49e343c1a30694c684b021f4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ1MDg_8cf3c298-9e1c-4824-82de-b811012e5690">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7c360cf3166a497fb3d4cf65ac71195d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ1MTQ_55781c58-9487-4ced-8cd1-7f5b3a00b022">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationAndAmortization
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ1NjA_904637a6-8cd4-4e3a-be8f-8f67cc9a85e0"
      unitRef="usd">39000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ1Njc_d451bf94-989e-42a4-b351-1d76b843e30a"
      unitRef="usd">50000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNTA1_6a33e798-cbb5-4356-85ea-c13f9842a0a5">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ5NjE_7f5ce372-9daf-4642-98af-0fedd151d0e6"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzQ5NjE_ab78d2a8-0c3d-442b-9a22-e5cc92109b85"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDcz_669436bb-f971-49b4-b498-2bd4c4878e28">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. &lt;/span&gt;&lt;/div&gt;The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform a quantitative test that compares the fair value to its carrying value to determine the amount of any impairment. Impairment testing for goodwill is done at the reporting unit level. The Company has determined that it operates in a single operating segment and has a single reporting unit.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzcwNDQ_54ec11b0-b4fb-4772-9fc0-ad3623eaa2b3"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDc5_4273b38b-94c3-45f9-b38e-3ad79abfcbd8">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, IMU-838, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on IMU-838, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  IMU-935 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in September 2019. IMU-856 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in August 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNTAx_47fde00a-86dc-4e76-b64c-d7e3b229b796">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, IMU-838, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on IMU-838, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  IMU-935 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in September 2019. IMU-856 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in August 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNTA3_67992f57-c68a-4bd0-b579-6945c32a31e5">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for diseases such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no more research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNTA4_9bcba400-35db-4a85-939e-8522347aae4e">General and Administrative ExpensesGeneral and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDg2_ed881c74-e4ac-4af5-9e95-2a9a091c9d0d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDky_54830713-8033-4b47-94b5-7c143f4f664d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. The short-term leases are deemed immaterial and have not been included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i74aac56ff24b4f3ca37eebd86a9d4423_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzEwOTk1MTE2NzAyOTE_0abb61ab-0a9d-4383-a1ef-7a0c6528dce1">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iedcfc4dd48ac4131bacce1f46671b617_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzEwOTk1MTE2NzAzMDU_e2885a39-d8a4-449e-a3ec-3033813e5e0b">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <imux:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzEwOTk1MTE2NzA0NzA_b2e1734a-324e-494a-8160-53ac843c17f8"
      unitRef="lease">2</imux:LesseeOperatingLeasesNumberOfExistingLeases>
    <imux:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzEwOTk1MTE2NzA3MzA_b2e1734a-324e-494a-8160-53ac843c17f8"
      unitRef="lease">2</imux:LesseeOperatingLeasesNumberOfExistingLeases>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDgw_0bb1417c-6071-4513-b958-96a2e650c91a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDgx_ec55027b-c94a-4644-b271-58c8705cf4c6">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the &lt;/span&gt;&lt;/div&gt;differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2020, and December&#160;31, 2019, the Company maintained a full valuation allowance against the balance of deferred tax assets.It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDY1_dca4f7c5-6cfb-4dfa-a0f2-e3bb58b59617">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDY2_c77e4c17-fb85-4375-a71d-48683373ffcb">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie37f05a546ec4332b17b507cececa315_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90YWJsZToyYzEzMzliM2FiNmE0YTg0YWU2M2FhMmRlNWE2YWQ4OC90YWJsZXJhbmdlOjJjMTMzOWIzYWI2YTRhODRhZTYzYWEyZGU1YTZhZDg4XzItMS0xLTEtMA_8ffa09ba-9dfc-4089-a7ed-49ac49516eee"
      unitRef="shares">1117160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a4868f4553f43c3bcb215ef4452c84d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90YWJsZToyYzEzMzliM2FiNmE0YTg0YWU2M2FhMmRlNWE2YWQ4OC90YWJsZXJhbmdlOjJjMTMzOWIzYWI2YTRhODRhZTYzYWEyZGU1YTZhZDg4XzItMy0xLTEtMA_9cba8668-8f55-412b-b02b-7c4d5e3ab02d"
      unitRef="shares">471048</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xMzkvZnJhZzo0ZGZjOTdmNmQxMWE0YjdmYjc3NzE1NGYzZmZlMDAwZS90ZXh0cmVnaW9uOjRkZmM5N2Y2ZDExYTRiN2ZiNzc3MTU0ZjNmZmUwMDBlXzIzNDg3_735e98f6-4d89-43fe-8ac7-34835f3f8a59">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU 2017-04, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;." This guidance eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit&#x2019;s fair value. The Company adopted this ASU, as required, in the quarter ended March 31, 2020 on a prospective basis. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-13, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement - Disclosure Framework&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-13.") ASU 2018-13 modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty, and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments must be applied retrospectively to all periods presented upon their effective date. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-18"). ASU 2018-18, clarifies that elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The Company does not have any agreements that meet the definition of a collaboration arrangement at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzM4MTM_da8fcd24-4e60-4e3a-adbe-fd0c0fc06b03">Accounting for the Transaction &lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the exchange ratio of 17.17 shares of Vital common stock for each share of Immunic AG, immediately following the Transaction, former Vital stockholders owned approximately 11.75% of the capital stock of the combined organization on a fully diluted basis, and former Immunic AG stockholders owned approximately 88.25% of the capital stock of the combined organization on a fully diluted basis. At the closing of the Transaction, all shares of Immunic AG common stock then outstanding were exchanged for Vital common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, pursuant to the terms of the Agreement, the Company, for accounting purposes, assumed all outstanding stock options to purchase 16,987 shares of Vital common stock and 127,500 RSUs at the closing of the Transaction, after giving effect to the Reverse Stock Split. Since the exercise prices of the outstanding options to purchase common stock were less than the trading price on the day of the consummation of the Transaction, they were not included in the formula below in calculating the purchase price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tangible and intangible assets and liabilities of Vital acquired in the Transaction are recorded based on their fair values as of the completion of the Transaction, with the excess of the purchase consideration over the fair value of net assets assigned to and recorded as goodwill. The following summarizes the purchase price paid in the Transaction (amounts in thousands except share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares owned by Vital stockholders (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fully-diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multiplied by the fair value per share of Vital common stock (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The number of shares of 1,059,269 represents the historical 42,369,694 shares of Vital common stock outstanding immediately prior to the closing of the Transaction, adjusted for the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The number of RSUs of 127,500 represents the historical 5,100,000 Vital RSUs of which all have been issued to date to Vital former officers in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Based on the last reported sale price of Vital common stock on the Nasdaq Global Market on April 12, 2019, the closing of the Transaction, adjusted for the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies and working cell banks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development (&#x201c;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable, accrued expenses and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of IPR&amp;amp;D was estimated based on the sales price of the ELAD Assets (including the present value of the promissory note issued by the ELAD buyer) less the fair value of the ELAD Assets. See Note 4 below for a description of the ELAD Assets transaction.The goodwill of $32.97 million is not tax deductible. Goodwill is mainly attributable to the enhanced value of the combined company, as reflected in the increase in market value of the Vital common shares following the announcement of the Transaction with Immunic AG. The Company incurred costs directly related to the Transaction of approximately $10.0 million for the year ended December 31, 2019, which were expensed as incurred ($7.5&#160;million of such costs were non-cash charges related to the 4SC settlement share issuances and the Immunic exit bonus shares as described below in Note 6 and Note 9, respectively).</us-gaap:BusinessCombinationDisclosureTextBlock>
    <imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio
      contextRef="i9ea2ecf153a24b4f9905b7b614e7adf6_I20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3Xzcx_f724044a-9e68-4ab2-b893-21b5ef4220e0"
      unitRef="number">17.17</imux:BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i025ac79fc8a04af682b83198235a9390_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzIxOA_e2780f79-9b2e-47d5-abdf-16d1bb1caf16"
      unitRef="number">0.1175</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i72933fde204541c88561a57e1bfee92c_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzM1Mg_ae65d6e0-2fe1-484a-bfd0-ab3fb1182af5"
      unitRef="number">0.8825</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed
      contextRef="i143eb8d6d87d45839179cc8aefbf2bd9_D20190412-20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzcwMQ_06f73416-41ae-4e16-b212-5132d0013f32"
      unitRef="shares">16987</imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed>
    <imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed
      contextRef="iaa7215f1ac4e44d195ec898605132171_D20190412-20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzI3NDg3NzkwNzMyNjU_b34a5a34-6b81-4105-9e1b-0727f83515f7"
      unitRef="shares">127500</imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzM4MTQ_312f9693-26ed-4494-9797-e34c00e7c6bc">The following summarizes the purchase price paid in the Transaction (amounts in thousands except share and per share amounts):&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares owned by Vital stockholders (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fully-diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,186,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multiplied by the fair value per share of Vital common stock (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The number of shares of 1,059,269 represents the historical 42,369,694 shares of Vital common stock outstanding immediately prior to the closing of the Transaction, adjusted for the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The number of RSUs of 127,500 represents the historical 5,100,000 Vital RSUs of which all have been issued to date to Vital former officers in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Based on the last reported sale price of Vital common stock on the Nasdaq Global Market on April 12, 2019, the closing of the Transaction, adjusted for the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies and working cell banks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development (&#x201c;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable, accrued expenses and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzAtMS0xLTEtMA_e53392b7-4661-4fb7-9b1e-54240123bbb7"
      unitRef="shares">1059269</us-gaap:CommonStockSharesOutstanding>
    <imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction
      contextRef="i2d8389cccd92494f9385f182bf002a92_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzEtMS0xLTEtMA_f43a82a7-325a-4a3f-a859-203458ba1801"
      unitRef="shares">127500</imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction>
    <imux:BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares
      contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzItMS0xLTEtMA_35ca1288-ef0d-4225-8bd0-d320a9f973f1"
      unitRef="shares">1186769</imux:BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzMtMS0xLTEtMA_b378313b-6f8a-4024-a520-8349573756bd"
      unitRef="usdPerShare">33.20</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6b85b15cda004eb0acf9c15243874440_D20190412-20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTowNWU0OGM2Y2YwYTM0NmUwYTU1N2RmNWViNWRlMGQyMy90YWJsZXJhbmdlOjA1ZTQ4YzZjZjBhMzQ2ZTBhNTU3ZGY1ZWI1ZGUwZDIzXzQtMS0xLTEtMA_e7c36adf-772a-4416-8f9a-76f9e4279955"
      unitRef="usd">39400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8dbfed922e6b4c3db53e3607146b69ef_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzE1MTI_91c750fc-da56-49b1-979a-5e72ce0ba746"
      unitRef="shares">1059269</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i25a3ae5995884982bf7fb0499c7d2af8_I20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzE1NDE_0cca16c7-f52a-49aa-962e-7f43eb7cc9ea"
      unitRef="shares">42369694</us-gaap:CommonStockSharesOutstanding>
    <imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed
      contextRef="i291065e6920c4b3690091eb4f57fd587_D20190412-20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzE2OTg_911f7209-4a01-4794-a3e4-41f50addd8a0"
      unitRef="shares">127500</imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed>
    <imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction
      contextRef="id235fedbb81d4e0c9ede860eafed7c3d_I20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzE3Mjc_87b85f88-c37e-4743-b7fd-62952dace76f"
      unitRef="shares">5100000</imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzEtMS0xLTEtMA_d7491ee3-a880-4dda-851f-b87c40ae8c7f"
      unitRef="usd">8151000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzItMS0xLTEtMA_c9cecf58-c44d-4ba5-8cc6-d940ec1dea67"
      unitRef="usd">307000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzMtMS0xLTEtMA_fbbf42f0-e1c4-42ea-bb50-3996f06c519a"
      unitRef="usd">1000000</imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzQtMS0xLTEtMA_70d395f2-0483-4383-b126-e710e1b20657"
      unitRef="usd">306000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzUtMS0xLTEtMA_a3518dfc-ce76-4ebf-a4bf-966fd51e5c68"
      unitRef="usd">30000</imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzYtMS0xLTEtMA_7942d1e5-52a7-484a-8a26-78a1563faae6"
      unitRef="usd">764000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzctMS0xLTEtMA_f094bdcc-7273-4d33-bce6-1cdfdc793c77"
      unitRef="usd">4128000</imux:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:Goodwill
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzgtMS0xLTEtMA_bdfb6cca-403c-46d1-997d-7cb9dc08498b"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90YWJsZTo1OWEzYWI1YzI1M2Y0NWIzOTdkOTViY2FiMDUxYzZlZi90YWJsZXJhbmdlOjU5YTNhYjVjMjUzZjQ1YjM5N2Q5NWJjYWIwNTFjNmVmXzktMS0xLTEtMA_b5d4e105-5db5-42fc-afa1-36ec15ceac13"
      unitRef="usd">39400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ie48d0609d585480ab6c4bfe322a0961d_I20190412"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzIzNDE_febd44c7-aa1b-46aa-a510-96186d37d05e"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
      contextRef="i19a1cf43d9744216bb5785e547d4a706_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzI2NjE_4d48e3d3-0f5b-43f6-a2bd-67bd9dc0a641"
      unitRef="usd">10000000.0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <imux:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges
      contextRef="ic61d4640357d4308b1168153fff8bcd2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDUvZnJhZzpjM2NiZWMxYjRkN2Q0NDhlODM4N2FkNGQxNzRkMGJhNy90ZXh0cmVnaW9uOmMzY2JlYzFiNGQ3ZDQ0OGU4Mzg3YWQ0ZDE3NGQwYmE3XzI3NDg3NzkwNzQ0ODU_8a8f4ae5-3a63-416e-80bc-b1da4c7f28fe"
      unitRef="usd">7500000</imux:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzIwMDM_fedc6122-8c3d-4e60-8ceb-b1c91fe394a5">ELAD Sales Agreement&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Vital entered into an asset purchase agreement (the &#x201c;Vital APA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) to sell certain of Vital&#x2019;s clinical development-related assets and related intellectual property rights to RH Cell Therapeutics (the &#x201c;Purchaser&#x201d;) for approximately $2.5 million. The assets sold were clinical development equipment, supplies, intellectual property and working cell banks in addition to the equity interest in VTL China (collectively the &#x201c;ELAD Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Purchaser deposited $1.1 million into escrow and paid the Company $50,000 prior to the Transaction. The Vital APA was amended and restated on May 28, 2019, to allow for two closings. In the first closing which occurred on May 28, 2019, the $1.1 million was released from escrow to the Company. In addition, the Purchaser executed a promissory note with a face amount of $1.325 million, which accrues simple interest of 10% per annum. The fair value of the promissory note was estimated to be $920,000. Therefore, the fair value of the ELAD Assets was based on the cash in escrow, the $50,000 deposit and the fair value of the promissory note. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the ELAD Assets was included in the purchase accounting allocation as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies and working cell banks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In process research &amp;amp; development (&#x201c;IPR&amp;amp;D&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first closing, the Company transferred title of the clinical development equipment and supplies to the Purchaser. Also, the fair value of the promissory note was recorded as a note receivable and the fair value of the IPR&amp;amp;D and working cell banks assets were removed from the Company&#x2019;s audited consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promissory note was paid in full upon the second closing on September 4, 2019, at which time the Company transferred title to the intellectual property and working cell banks as well as its equity interest in VTL China. The difference of $405,000 between the $1.325 million face value of the promissory note collected and the fair value of $920,000 was recorded as other income in the accompanying consolidated statements of operations for the year ended December 31, 2019.  The Purchaser is not a related party.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ib1424157daa84861a0f78d13c01de311_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzI3Mw_73278212-b4d8-44d4-9aec-df983d68d595"
      unitRef="usd">2500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <imux:DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit
      contextRef="i16a9132f0eeb46a4b87b6f6be10c44a4_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzQ5MQ_91f5de94-9c16-47c9-b2ae-877a7c009d22"
      unitRef="usd">1100000</imux:DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit>
    <imux:DisposalGroupIncludingDiscontinuedOperationCashConsideration
      contextRef="i16a9132f0eeb46a4b87b6f6be10c44a4_D20190301-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzUyNw_a884450c-9e1e-44cb-ba48-2ff2be99fe35"
      unitRef="usd">50000</imux:DisposalGroupIncludingDiscontinuedOperationCashConsideration>
    <imux:DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow
      contextRef="ib628ae02a7aa42c28a8f9aec169f0c34_D20190528-20190528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzY5Ng_613c851a-e0d2-41ec-87cf-8352fcbcbe52"
      unitRef="usd">1100000</imux:DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow>
    <us-gaap:ReceivableWithImputedInterestFaceAmount
      contextRef="iaeb39dad72584b63ab750036af27e280_I20190528"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzgxNg_6a18b95d-9c4c-4640-8fc7-3eb3b59eb5e2"
      unitRef="usd">1325000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate
      contextRef="i3f08f68c8dad42d6bad9ef5236f6e645_D20190528-20190528"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5Xzg1Mw_199614cb-d7de-4de8-9c4f-a20b5b44b237"
      unitRef="number">0.10</us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ifd46d22b09cb441787f0d5370dea6303_I20190528"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzkyNQ_c88cc33d-b4b3-4e05-8ede-f80f035e2910"
      unitRef="usd">920000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <imux:DisposalGroupIncludingDiscontinuedOperationCashConsideration
      contextRef="ib70b7b4cf5694c7a8586dce401819182_D20190528-20190528"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzI3NDg3NzkwNzE1OTU_c8c76553-7e7c-4cac-8d18-9c5cdf9cd31d"
      unitRef="usd">50000</imux:DisposalGroupIncludingDiscontinuedOperationCashConsideration>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzIwMDQ_c50065a2-37da-4b9c-8bf0-58f37b383d49">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the ELAD Assets was included in the purchase accounting allocation as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.152%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies and working cell banks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In process research &amp;amp; development (&#x201c;IPR&amp;amp;D&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="ia6683c08bed64561b5b0505930b9950c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90YWJsZTo3ZWQ0MTRkMDRhOTk0ZWQ0YWI5ZTZhOGVlM2U4MDE1My90YWJsZXJhbmdlOjdlZDQxNGQwNGE5OTRlZDRhYjllNmE4ZWUzZTgwMTUzXzAtMS0xLTEtMA_f4e23951-5891-4ee8-8ecc-52a9761e0e58"
      unitRef="usd">306000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i8b5901cce52944f6baa8aaf2af6e02ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90YWJsZTo3ZWQ0MTRkMDRhOTk0ZWQ0YWI5ZTZhOGVlM2U4MDE1My90YWJsZXJhbmdlOjdlZDQxNGQwNGE5OTRlZDRhYjllNmE4ZWUzZTgwMTUzXzEtMS0xLTEtMA_28a04b38-e272-4d1a-82fc-a5ded5c703e6"
      unitRef="usd">1000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i780e082104054e5f93c97de39af38fdf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90YWJsZTo3ZWQ0MTRkMDRhOTk0ZWQ0YWI5ZTZhOGVlM2U4MDE1My90YWJsZXJhbmdlOjdlZDQxNGQwNGE5OTRlZDRhYjllNmE4ZWUzZTgwMTUzXzItMS0xLTEtMA_8a1ad30f-5208-4411-b801-ef7c1539a7d7"
      unitRef="usd">764000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i5086e5f37b694c38bf5cab8772addc83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90YWJsZTo3ZWQ0MTRkMDRhOTk0ZWQ0YWI5ZTZhOGVlM2U4MDE1My90YWJsZXJhbmdlOjdlZDQxNGQwNGE5OTRlZDRhYjllNmE4ZWUzZTgwMTUzXzMtMS0xLTEtMA_4cc7145c-163d-4f25-b93d-19d4de0dc48e"
      unitRef="usd">2070000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="ib203b4c845154f8f8ad1c43f6b7e19c2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzE3NjI_98433325-4497-4bce-a5eb-06227a6dea49"
      unitRef="usd">405000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:ReceivableWithImputedInterestFaceAmount
      contextRef="iaeb39dad72584b63ab750036af27e280_I20190528"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzE4MjI_6a18b95d-9c4c-4640-8fc7-3eb3b59eb5e2"
      unitRef="usd">1325000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ifd46d22b09cb441787f0d5370dea6303_I20190528"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNDgvZnJhZzo5YWI4MmM3ODEwOTI0YTUwYTA0MDRlODUzZWM2ZmQzOS90ZXh0cmVnaW9uOjlhYjgyYzc4MTA5MjRhNTBhMDQwNGU4NTNlYzZmZDM5XzE4NDg_c88cc33d-b4b3-4e05-8ede-f80f035e2910"
      unitRef="usd">920000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90ZXh0cmVnaW9uOjYwZjg4OGI5ZjM3MjQ5YzE4ODQzYTNiYTA2ZTA2MzM3XzQ5OA_1114635b-2fdc-4143-8c6c-67f712d0ef37">Balance Sheet Details&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid Expense and Other Current Assets consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist  of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Deferred income represents cash reimbursement on invoices received from third party billings, prior to the related services being performed.</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90ZXh0cmVnaW9uOjYwZjg4OGI5ZjM3MjQ5YzE4ODQzYTNiYTA2ZTA2MzM3XzUwNw_f40e4f22-32ce-40bf-b51a-13c01eef1355">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid Expense and Other Current Assets consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <imux:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzItMS0xLTEtMA_d3976518-dcee-4867-8fd7-726787220206"
      unitRef="usd">3416000</imux:PrepaidClinicalAndRelatedCostsCurrent>
    <imux:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzItMy0xLTEtMA_5f6e01e7-1250-4542-a40f-4f1ee30154e1"
      unitRef="usd">1307000</imux:PrepaidClinicalAndRelatedCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzMtMS0xLTEtMA_ac4aa80f-ebe2-4e85-a78b-55f9581b62cb"
      unitRef="usd">295000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzMtMy0xLTEtMA_ee460591-3c52-493c-8165-32ed8a5ab3c2"
      unitRef="usd">408000</us-gaap:ValueAddedTaxReceivableCurrent>
    <imux:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzQtMS0xLTEtMA_1ca972a4-aa1b-4753-a1fd-baea43a543ec"
      unitRef="usd">1348000</imux:ResearchAndDevelopmentTaxIncentiveCurrent>
    <imux:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzQtMy0xLTEtMA_2976115d-97f1-4f43-bdda-b14d1603e98e"
      unitRef="usd">350000</imux:ResearchAndDevelopmentTaxIncentiveCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzUtMS0xLTEtMA_00153ec2-c78b-4ccc-9f28-0bc5666e4eba"
      unitRef="usd">1234000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzUtMy0xLTEtMA_83289fb6-5e55-47a6-9b3f-4eba2bc28e06"
      unitRef="usd">796000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzYtMS0xLTEtMA_377c16df-0322-4c4e-ad2d-7d285815ad20"
      unitRef="usd">6293000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZToxMjBiZjRiOTJlNGE0N2UwYWNjYmRjOWEwMDAzY2U0ZS90YWJsZXJhbmdlOjEyMGJmNGI5MmU0YTQ3ZTBhY2NiZGM5YTAwMDNjZTRlXzYtMy0xLTEtMA_f729bdb2-f94c-4b61-b1d6-39db6eba1764"
      unitRef="usd">2861000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90ZXh0cmVnaW9uOjYwZjg4OGI5ZjM3MjQ5YzE4ODQzYTNiYTA2ZTA2MzM3XzUwOA_e318a316-e877-461a-973a-2502ff696ccf">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <imux:ClinicalCostsPayableCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzItMS0xLTEtMA_6e753a80-2dc1-412c-bee8-c4f437ced3d0"
      unitRef="usd">3408000</imux:ClinicalCostsPayableCurrent>
    <imux:ClinicalCostsPayableCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzItMy0xLTEtMA_dd00d4e6-b462-4173-a3b2-5f4eccec0477"
      unitRef="usd">1981000</imux:ClinicalCostsPayableCurrent>
    <imux:LegalAndAuditCostsPayableCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzMtMS0xLTEtMA_59307645-cbd7-4603-8166-bf5318fd665b"
      unitRef="usd">139000</imux:LegalAndAuditCostsPayableCurrent>
    <imux:LegalAndAuditCostsPayableCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzMtMy0xLTEtMA_6e4baed8-98db-4972-b725-de419d4f1c5e"
      unitRef="usd">226000</imux:LegalAndAuditCostsPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzQtMS0xLTEtMA_5e910613-3264-45c1-9e6b-ce4a0866026d"
      unitRef="usd">153000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzQtMy0xLTEtMA_ac07b33d-d400-42ef-9b41-984adf6f557b"
      unitRef="usd">216000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzUtMS0xLTEtMA_8c655f5d-6832-4e1d-8bfe-152ad950c991"
      unitRef="usd">3700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTpmOTExNTE3MzE4Y2Q0Y2Y3YWY1YjIwM2UwODc5OTM2My90YWJsZXJhbmdlOmY5MTE1MTczMThjZDRjZjdhZjViMjAzZTA4Nzk5MzYzXzUtMy0xLTEtMA_194e8e6c-e1da-45aa-a122-623273724d56"
      unitRef="usd">2423000</us-gaap:AccountsPayableCurrent>
    <imux:AccruedClinicalCostsCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzItMS0xLTEtMA_a50fb894-ba8e-4402-b090-371b39f1c55b"
      unitRef="usd">3301000</imux:AccruedClinicalCostsCurrent>
    <imux:AccruedClinicalCostsCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzItMy0xLTEtMA_b384c841-b9f3-45b2-88d6-ced989eed2bd"
      unitRef="usd">2863000</imux:AccruedClinicalCostsCurrent>
    <imux:AccruedLegalAndAuditCostsCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzMtMS0xLTEtMA_595252b4-7ec8-42d9-a844-9533f7842a0e"
      unitRef="usd">114000</imux:AccruedLegalAndAuditCostsCurrent>
    <imux:AccruedLegalAndAuditCostsCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzMtMy0xLTEtMA_c258deba-eb4c-4c7f-b17e-ce30350fabd8"
      unitRef="usd">211000</imux:AccruedLegalAndAuditCostsCurrent>
    <imux:AccruedCompensationCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzQtMS0xLTEtMTEwMw_6ec303c3-e904-46bb-ac62-fb144166245c"
      unitRef="usd">658000</imux:AccruedCompensationCurrent>
    <imux:AccruedCompensationCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzQtMy0xLTEtMTEwMw_760f1cc2-c231-4c5c-8fdf-47e69c96582c"
      unitRef="usd">0</imux:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzQtMS0xLTEtMA_5fb83e0c-4685-4261-9485-b5049061fc35"
      unitRef="usd">245000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzQtMy0xLTEtMA_b3b7703c-a510-41a5-87fe-5583edf19573"
      unitRef="usd">224000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzUtMS0xLTEtMA_bb47997d-5658-4ce2-b991-975057692eb6"
      unitRef="usd">4318000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplN2Q1MTU5ZTgxZWQ0MzBmYTUzNmE2MDg0YmVhZjZkNy90YWJsZXJhbmdlOmU3ZDUxNTllODFlZDQzMGZhNTM2YTYwODRiZWFmNmQ3XzUtMy0xLTEtMA_cfec01da-c1ca-4abf-a6e1-215d752b2746"
      unitRef="usd">3298000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90ZXh0cmVnaW9uOjYwZjg4OGI5ZjM3MjQ5YzE4ODQzYTNiYTA2ZTA2MzM3XzUwOQ_98f72048-4137-43da-bc6b-dd544f0bc596">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist  of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzItMS0xLTEtMA_67473a33-bb39-4fde-aa03-6ac0ce7ee307"
      unitRef="usd">0</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzItMy0xLTEtMA_0ed316e4-dbc3-4971-95ac-e44d28d29753"
      unitRef="usd">1008000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzMtMS0xLTEtMA_f7665167-1aa5-4a78-ad6f-0a1517a4b46a"
      unitRef="usd">379000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzMtMy0xLTEtMA_bf8d1794-ddd4-4bf6-b4a8-3209c3a53e13"
      unitRef="usd">343000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzQtMS0xLTEtMA_3d07ec29-0ccd-4e58-8931-741ad32d27f6"
      unitRef="usd">379000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTEvZnJhZzo2MGY4ODhiOWYzNzI0OWMxODg0M2EzYmEwNmUwNjMzNy90YWJsZTplZjVmNWZiZDU0OGQ0NDc0OTMxMTdmZjQ0NjFkMDJlOS90YWJsZXJhbmdlOmVmNWY1ZmJkNTQ4ZDQ0NzQ5MzExN2ZmNDQ2MWQwMmU5XzQtMy0xLTEtMA_b388e7a1-33c1-4cc8-acf0-d548892fa18c"
      unitRef="usd">1351000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzQxMDk_87fe52b5-05a1-4b17-92fd-73fd7803c8a8">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and June 30, 2025 for the Gr&#xe4;felfing, Germany office.  The Company formerly leased office space in Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE2NDkyNjc0NDgzOTA_02686f89-0de8-4c0b-a81a-71f470466ead"&gt;five&lt;/span&gt; year lease for its new facility in Gr&#xe4;felfing, Germany. Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease.  There were net additions to right of use assets of $427,000 as a result of signing the Gr&#xe4;felfing lease and shortening the term of the Martinsried lease during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Immunic&#x2019;s operating lease costs and variable lease costs were $354,000 and $135,000 for the years ended December&#160;31, 2020 and 2019, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Maturities of the operating lease obligation are as follows as of December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company has non-cancelable contractual obligations under certain agreements related to its development programs IMU-838, IMU-935 and IMU-856 totaling approximately $1.2 million, all of which is expected to be paid in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016 the Company entered into a purchase agreement (the &#x201c;Agreement&#x201d;) with 4SC AG whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#x2019;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the issuance of these shares on April 12, 2019. No royalties are payable as of December&#160;31, 2020 or 2019 as sales have not commenced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daiichi Sankyo Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE2NDkyNjc0NDg4NjE_873f4cd0-a656-438c-a832-8c0cb7f8cafc"
      unitRef="usd">427000</imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <imux:OperatingAndVariableLeasesCost
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE4OTM_3622af73-fd27-4db5-8450-d65fe53982fb"
      unitRef="usd">354000</imux:OperatingAndVariableLeasesCost>
    <imux:OperatingAndVariableLeasesCost
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE5MDA_5b4851fc-a649-4fed-9670-0f1f8a0da9a8"
      unitRef="usd">135000</imux:OperatingAndVariableLeasesCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzQxMDY_41b76e1d-6c1e-451c-b4b0-d9209e668edc">Maturities of the operating lease obligation are as follows as of December&#160;31, 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzAtMi0xLTEtMA_9f702d87-4f26-49bc-898c-1f188b3cb8a3"
      unitRef="usd">348000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzEtMi0xLTEtMA_01bcb31e-d129-4dd9-aaea-122ec57b9cbc"
      unitRef="usd">348000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzItMi0xLTEtMA_4adc301d-034b-491d-bbee-a4a7a307551c"
      unitRef="usd">198000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzMtMi0xLTEtMA_b7bb4acd-fecf-45eb-8c45-bd92e085dc7a"
      unitRef="usd">124000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzQtMi0xLTEtMA_2e6a70f0-34b2-4a4b-9c90-104d53dcba3e"
      unitRef="usd">62000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzUtMi0xLTEtMA_21dcb49b-712c-4fdd-af95-ca6c9693f6e1"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzYtMi0xLTEtMA_e8013c16-5bf0-43ef-81ae-17b75bffd7a1"
      unitRef="usd">1080000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzctMi0xLTEtMA_b7bf23ab-2870-4899-a55d-30395effa06c"
      unitRef="usd">107000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90YWJsZTpmZGY3YmI0MjBhZTY0ZmQ5OGQ4ZmFmZDIzZjIwNzU2MS90YWJsZXJhbmdlOmZkZjdiYjQyMGFlNjRmZDk4ZDhmYWZkMjNmMjA3NTYxXzgtMi0xLTEtMA_31c69a73-35e0-437d-9d57-766fc27427e0"
      unitRef="usd">973000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractualObligation
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzIzOTQ_c299ac5c-0677-4f9a-a21d-0fa650b2da3b"
      unitRef="usd">1200000</us-gaap:ContractualObligation>
    <imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
      contextRef="i67800579096d4497ad722732c4249a21_D20160501-20160531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzMwNDE_6c71296c-ad56-4313-b7e7-b219f5fa8315"
      unitRef="number">0.044</imux:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales>
    <us-gaap:CommonStockSharesIssued
      contextRef="i79f881980aec452681faf1a0f7dd4395_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzMyNTk_06e7dba4-041c-491a-ac89-60fe16a3f467"
      unitRef="shares">120070</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i79f881980aec452681faf1a0f7dd4395_I20190412"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzM0MDA_4a8004ae-607a-492e-84f8-7ef9bc2c6ae5"
      unitRef="usd">1500000</us-gaap:CommonStockValue>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90ZXh0cmVnaW9uOjVhZTcyYzczMGI5MTRkMDI4ZTViNjliMGMzNTc2ZTI4XzExMDA_342978c9-6a0b-4207-a0be-dc19ab2e7ccb">Fair Value&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90ZXh0cmVnaW9uOjVhZTcyYzczMGI5MTRkMDI4ZTViNjliMGMzNTc2ZTI4XzEwOTY_d1fa381d-09b4-4803-a2c1-088b10930867">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie337d38b905741b0be8509a5988751e0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzQtMS0xLTEtMTkxNw_686c2eb3-3835-4e92-aa1a-4409c69bc66b"
      unitRef="usd">39615000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib1f631b15ff24c389fa32b2b1b7ee96e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzQtMy0xLTEtMTkxNw_ae3a7ecd-3235-4f91-b3fe-d04ab3c503ad"
      unitRef="usd">39615000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6873df0f6d9c43829d62758343daf989_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzQtNS0xLTEtMTkxNw_0c02e81e-9d89-4ec7-8754-152806595bc4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0a8dd00728074e99b84c1dca45194253_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzQtNy0xLTEtMTkxNw_a0c536c5-1b07-4df5-91ba-ec8e42b4bbfe"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7a0a829483c0417eba5fa667a551ed28_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzgtMS0xLTEtMTExNQ_eecf93fe-ec29-4c8d-8318-41f03840c521"
      unitRef="usd">4491000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e15b766485e4b65beeb7634f309978f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzgtMy0xLTEtMTExNQ_c8858f99-e294-451a-b89b-67dcc201f42e"
      unitRef="usd">4491000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b12db73e4fa4be7ae419856ea963c2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzgtNS0xLTEtMTExNQ_bcb77002-6854-48e1-bea9-f8756a7867de"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i222effbc88ad4922acfd743d8d31835e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTcvZnJhZzo1YWU3MmM3MzBiOTE0ZDAyOGU1YjY5YjBjMzU3NmUyOC90YWJsZToyNDJhNGM5YWIwYTE0YjRkOTcyMzJjMjBhNDM0M2M3Ny90YWJsZXJhbmdlOjI0MmE0YzlhYjBhMTRiNGQ5NzIzMmMyMGE0MzQzYzc3XzgtNy0xLTEtMTExNQ_5235382f-c6a1-4953-b32c-2ac2e4002023"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzQxNDA_3db58fc9-2877-4f78-b153-d664131ebd0e">Common Stock and Preferred Stock (Converted into Common Stock)&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, Vital filed a shelf registration statement on Form S-3, (the &#x201c;2018 Shelf Registration Statement&#x201d;), which became effective in June 2018. The 2018 Shelf Registration Statement permits the offering, issuance and sale of up to $200.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $40.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("July 2019 ATM") with SVB Leerink LLC (&#x201c;SVB Leerink&#x201d;) as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The July 2019 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the July 2019 ATM or (ii) termination of the July 2019 ATM as otherwise permitted thereby. The July 2019 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, $23.3&#160;million in capacity remains under the July 2019 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed another Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, $50.0&#160;million in capacity remains under the December 2020 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, the Company raised gross proceeds of $11.3&#160;million pursuant to the July 2019 ATM through the sale of 733,728 shares of common stock at a weighted average price of $15.42 per share. The net proceeds from the July 2019 ATM were  $11.0&#160;million after deducting underwriter commissions of $339,356. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2019, the Company raised gross proceeds of $5.4&#160;million pursuant to the July 2019 ATM through the sale of 630,907 shares of common stock at a weighted average price of $8.49 per share. The net proceeds from the July 2019 ATM were  $4.9&#160;million after deducting underwriter commissions of $161,000 and estimated offering expenses of $305,000. As of December&#160;31, 2019, there was $34.6 million available under the July 2019 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Public Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;April 2020 Registered Direct Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 23, 2020, the Company entered into an engagement letter with ROTH Capital Partners, LLC ("RCP") relating to the Company&#x2019;s registered direct offering of common stock to select institutional investors. Pursuant to this agreement, the Company agreed to pay RCP a cash fee of 6.5% of the gross proceeds from the offering raised from investors and to reimburse RCP for certain costs incurred in connection therewith.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, on April 23, 2020, the Company and the investors entered into a securities purchase agreement relating to the issuance and sale of an aggregate of 1,764,706 shares of common stock. The purchase price per share was $8.50 for aggregate gross proceeds to the Company of approximately $15.0&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds to the Company from this offering, after deducting the Company&#x2019;s offering expenses, were approximately $13.9&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;June 2020 Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 10, 2020, the Company entered into a placement agency agreement with RCP and Ladenburg Thalmann &amp;amp; Co. Inc. relating to the Company&#x2019;s public offering of 2,175,000 shares of common stock. Pursuant to this agreement, the Company agreed to pay the placement agents a cash fee of 6.5% of the gross proceeds from the offering raised from investors and to reimburse the placement agents for certain costs incurred in connection therewith.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, on June 10, 2020, the Company and certain institutional investors entered into securities purchase agreements relating to the issuance and sale of an aggregate of 2,175,000 shares of the Company&#x2019;s common stock. The purchase price per share in the Offering was $11.40 for aggregate gross proceeds to the Company of approximately $25.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The net proceeds to the Company from this offering, after deducting the Company&#x2019;s offering expenses, were approximately $23.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%;text-decoration:underline"&gt;August 2020 Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into an underwriting agreement with SVB Leerink LLC, as representative of the several underwriters in connection with the Company&#x2019;s public offering of 5,000,000 shares of common stock, at a public offering price of $18.00 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 750,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions, which was exercised in full on August 6, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, the Company closed the Offering. The net proceeds to the Company from the Offering, after giving effect to the exercise in full by the Underwriters of their option to purchase the Option Shares, was approximately $96.5&#160;million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Subscription Not Yet Issued&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18.9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%"&gt;On March 27, 2019, stockholders of the Company resolved to increase the Company&#x2019;s share capital by an additional 156,920 ordinary shares, par value &#x20ac;1.00 per share, of which 27,176 shares related to bonuses for executive officers of the Company. Under German law a capital increase is valid as soon as the consummation of the capital increase has been officially registered with the commercial register, which occurred on April 3, 2019. Therefore, the capital increase became effective subsequent to March 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic AG, a non-public company as of December 31, 2018, had authorized 846,953 shares of common stock, par value &#x20ac;1.00 per share, which were issued in March 2016 for approximately $56,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December&#160;31, 2020, no cash dividends had been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception (2016) through 2018, Immunic AG issued 13,541 Series A-1 Convertible and 299,456 Series A-2 Convertible preferred shares, par value &#x20ac;1.00 per share, to investors as part of its growth financing plan in the total amount of &#x20ac;31.7 million (approximately $37.2 million). Series A-1 Convertible and Series A-2 Convertible preferred shares were converted into Immunic AG&#x2019;s ordinary shares immediately prior to the Transaction and were then exchanged for Immunic (former Vital) common shares at the consummation of the Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20,000,000 shares of $0.0001 par value preferred stock, rights and preferences to be set by the board of directors. No preferred shares were outstanding as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issued warrants to purchase common stock in connection with financing activities and for consulting services in 2011. Warrants for 6,015 shares of common stock at an exercise price of $3,719.60 expired on September 25, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance as of December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
      contextRef="ie581a8ba756a444ba46878adb72aeb7f_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2Mjg_2f45debf-eaba-480f-a196-248790c4ca93"
      unitRef="usd">200000000.0</imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration>
    <imux:MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders
      contextRef="ib42baf0370ea48d7a0e0cc425578b84c_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2NDQ_99a7e8df-ebd3-4481-adee-931752811cee"
      unitRef="shares">250000000.0</imux:MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders>
    <imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
      contextRef="i1c8556577d1b4e5f865b603839247770_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2NjA_84fb6949-819d-4414-925d-3b5e8e226dfa"
      unitRef="usd">40000000.0</imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration>
    <imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
      contextRef="if19cb443fde445938a82a57f80350118_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2NzU_e4dcac59-c2f8-4cb7-88e4-f02c7d9cbfb5"
      unitRef="usd">23300000</imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement>
    <imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
      contextRef="i21e80fc4dc65422fb46f2324ebab4469_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg2OTA_5458f762-b284-417f-b1c1-71df3c179455"
      unitRef="usd">50000000.0</imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration>
    <imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
      contextRef="i21e80fc4dc65422fb46f2324ebab4469_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3NDg3NzkwODg3MDU_ffe7c219-63a8-4a22-a198-872060e9c1ab"
      unitRef="usd">50000000.0</imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement>
    <imux:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzE4NTQ_3c2daa60-2373-40d2-a99e-817ecc8004a8"
      unitRef="number">0.030</imux:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzIwODU_5cf6d048-0ff1-4e0d-9b53-146ab45a88c5"
      unitRef="usd">11300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzIxMjg_1f7abadc-4164-4dc2-8f67-e0eea60d40c1"
      unitRef="shares">733728</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ia9121799d001479e948d946e83f048f8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzE2NDkyNjc0NTM0NDI_bbe72db1-961f-4877-8ad6-120156fdbecd"
      unitRef="usdPerShare">15.42</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzE2NDkyNjc0NTM0NDc_fe249615-a7c6-4fce-aab5-69a485fcd8f8"
      unitRef="usd">11000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="i79e38e78333f494499b926c7f9a48cd1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzIyODE_0003d5a5-5583-4067-b726-43c64ec54ebe"
      unitRef="usd">339356</us-gaap:PaymentsForCommissions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzMzNjA_075306be-c9cb-4f34-86da-22a401a7704e"
      unitRef="usd">5400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM0MDQ_c2b77475-63a7-428a-99db-3d4ac82738b2"
      unitRef="shares">630907</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ieddd58f3d1014eb8926a60bb85a16000_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM0NjI_0a92f482-c6e2-40ad-870c-ffd8a6b9df73"
      unitRef="usdPerShare">8.49</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM1MTM_fdc5d2b3-6b8e-4c81-b1ac-fa32e9050632"
      unitRef="usd">4900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM1NjA_e161fa78-bae1-41b8-a4b4-7881f92698fb"
      unitRef="usd">161000</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1d04edecca964096b86caf4fc622d519_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM1OTk_11b4c4b8-321e-4ff8-8fef-c8b75d61476b"
      unitRef="usd">305000</us-gaap:PaymentsOfStockIssuanceCosts>
    <imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzM2MjI_aff990be-9d5c-4e9f-bc6a-1bfb9c2926b4"
      unitRef="usd">34600000</imux:MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement>
    <imux:EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
      contextRef="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQwMTA_70762fe7-900b-4e22-84d1-cf1828d17cac"
      unitRef="number">0.065</imux:EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQzMDk_e7b062d1-2e4a-4b93-b38d-917fadb38771"
      unitRef="shares">1764706</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iaed6b68efee3460089ffa2c5e40b8094_I20200423"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQzNzA_19c2fa0b-c532-48c1-8a08-90457f17d1dd"
      unitRef="usdPerShare">8.50</us-gaap:SaleOfStockPricePerShare>
    <imux:ProceedsFromIssuanceOfCommonStockGross
      contextRef="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQ0MzU_e2ac4771-6d51-4e30-b27f-06ee43a58ab3"
      unitRef="usd">15000000.0</imux:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQ1NjM_759cab3d-88f5-4a0f-adac-6d22488f71e0"
      unitRef="usd">13900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQ3NzI_c0a1cbf7-e706-4e17-bb77-79be9e8ee197"
      unitRef="shares">2175000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <imux:PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
      contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzQ4ODk_e82fd4bf-a90d-490e-b65a-8f4f80c2b5c4"
      unitRef="number">0.065</imux:PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzUyMjI_d45c8e3a-9de0-49cc-b8cb-bec526dd4ffe"
      unitRef="shares">2175000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic7ade7fa5ecd45d28246214c1fb60452_I20200610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzUzMTM_1de6a95b-e1e7-41e2-a41f-40d4d9d95b2a"
      unitRef="usdPerShare">11.40</us-gaap:SaleOfStockPricePerShare>
    <imux:ProceedsFromIssuanceOfCommonStockGross
      contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzUzNzg_aba46557-3586-4806-8cc1-cade98da69a2"
      unitRef="usd">25000000.0</imux:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU1MDU_23ad8ed2-6eec-4dd3-b22f-aa8b0143f1a9"
      unitRef="usd">23000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i61f483edcdbf4d8bbd4fcfedfede902b_D20200804-20200804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU3MjI_2e460511-bb93-40b1-bc36-690ce90fa35d"
      unitRef="shares">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iaf950f67a01b415ab0151c454064f1cb_I20200804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU3ODA_420cc360-4f6d-4abf-9daa-ce222f4342e2"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <imux:SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock
      contextRef="i61f483edcdbf4d8bbd4fcfedfede902b_D20200804-20200804"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU5MDY_48e44b57-b9b4-4622-aea9-9973df5c3147">P30D</imux:SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock>
    <imux:SaleOfStockNumberOfAdditionalSharesAuthorized
      contextRef="i61f483edcdbf4d8bbd4fcfedfede902b_D20200804-20200804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzU5NDM_979a4df4-29ac-4c74-a59e-a2ef01eda132"
      unitRef="shares">750000</imux:SaleOfStockNumberOfAdditionalSharesAuthorized>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib39d17f19add4e67851d0c580a248614_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzYzMjY_ab4f142c-6d23-4871-9b4f-a6abfedf6937"
      unitRef="usd">96500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i15c150f722064296929dd00a3a6f971d_I20190327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzY1OTk_222409c1-86e2-41aa-a3e1-c6f544fb3403"
      unitRef="shares">156920</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i15c150f722064296929dd00a3a6f971d_I20190327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzY2MzA_279dd9da-9a5a-4ae4-a326-292271d30ebb"
      unitRef="eurPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5a7d12cd12ee4917abc990f2310687c0_I20190327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzEwOTk1MTE2MzY2NTQ_595b0b7a-7db1-42a0-929e-b490c180b5d7"
      unitRef="shares">27176</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI0NTQ_4337dac7-24b8-4e1f-a68f-8b8f06131fe8"
      unitRef="shares">846953</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0e761ae9b79f4eb893c8044e6566ecbd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI0OTE_702cb439-e04e-4cc8-8615-c891420b41f2"
      unitRef="eurPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue
      contextRef="ib3fe40add06a4c1e9d53068bac00bb0f_I20160331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI1NTU_aea53c0c-696d-4134-adec-4d38dc77ad34"
      unitRef="usd">56000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI2ODY_9e8e1441-91eb-4dac-a0af-4ed46e48178f"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI3MjY_a0c218ed-78ed-4c0d-89d5-df7110bfe48e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI5ODY_1a2633ad-5544-4684-9f01-588e32e8b144"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzI5ODY_746e9aa3-08ce-4939-9619-ac838bde1235"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5b71f1d3cd7c4b9b9c8ee7ebac91ffec_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMwNjU_6855d3fa-4673-4226-b300-5222401cc73b"
      unitRef="shares">13541</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8f592217ac8841e7a80512fd12ad30e0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMwOTU_b2e3fdba-85b7-4713-9228-65d7da3441c2"
      unitRef="shares">299456</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5b71f1d3cd7c4b9b9c8ee7ebac91ffec_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMxNDk_06f922e8-e998-4aad-bc7a-91d2f2122d3e"
      unitRef="eurPerShare">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue
      contextRef="i4c982f0f472740879b53dcb38a14a979_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMyMzY_e6385e99-9e42-4063-b3dd-97a14cc8eee6"
      unitRef="eur">31700000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i4c982f0f472740879b53dcb38a14a979_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzMyNTQ_f3e737be-d465-46c6-9a53-e17e51af5775"
      unitRef="usd">37200000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzM2NTM_bc490dd0-f548-4600-aec0-040ad3218671"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzM2NjY_661a5172-46f1-48cf-b013-1457e05b831b"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzM3NTY_c02acf8b-a935-433d-8b26-a4024315db0f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib9c91096020641aa94b1d1135b433890_I20190925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzM5NjE_a50b6e1a-521d-4f69-ad73-73caf73e2933"
      unitRef="shares">6015</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8a2c83765c344137b31b8874c897fac3_I20190925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzQwMTE_d0e64b2a-0eb2-4ab6-9a7e-62ab0b724dd8"
      unitRef="usdPerShare">3719.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90ZXh0cmVnaW9uOjJhYzE2YzQ5NzliOTQzMjZhMmEyN2FmYmU4YTIwOTdkXzQxNDE_5c280000-67e1-4f42-87a5-63d065e1f4eb">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance as of December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib87a8c7a070d48d7a85d8cbb57c3b164_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzItMS0xLTEtMA_8120d617-564c-4e0e-be49-1d471191a4d7"
      unitRef="shares">1117160</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7fe3c6f83fe24a859c84ef448153d453_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzQtMS0xLTEtMA_2051c334-c0bb-4873-bd1d-867c4a2cdc28"
      unitRef="shares">43311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2ca14bfd5d1a46d6abbbe154703eaed5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzUtMS0xLTEtMA_3407918e-11f2-4f97-bf02-a84c7c83c1f6"
      unitRef="shares">46250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="idde26f9196c647299fc79cdab514e92c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzYtMS0xLTEtMA_06ad3cbc-52b5-4da3-b429-51b15f577336"
      unitRef="shares">831474</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjAvZnJhZzoyYWMxNmM0OTc5Yjk0MzI2YTJhMjdhZmJlOGEyMDk3ZC90YWJsZTo2NDJkMDA2NTQ5MTg0ZTRhOTdiZTg2MGNiMmNlMTJkNi90YWJsZXJhbmdlOjY0MmQwMDY1NDkxODRlNGE5N2JlODYwY2IyY2UxMmQ2XzctMS0xLTEtMA_e1d8994d-5283-4e58-a53d-561cf68a315f"
      unitRef="shares">2038195</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzQ0_617f0aae-7829-437e-8198-4974dd7d2272">Stock Compensation Plans&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under German law, (i) a company&#x2019;s management board consists of employee members and is responsible for overseeing its daily business, and (ii) a company&#x2019;s supervisory board supervises the management board and serves a role equivalent to the board of directors of an American corporation. Under two stock option programs, the Company granted stock options to the members of the Immunic AG supervisory board (the &#x201c;Supervisory Board&#x201d;) and to key employees in 2018 and in 2019 prior to the Transaction. The programs were intended to incentivize the beneficiaries to dedicate their working capabilities in the best manner possible to the benefit of the Company. The stock options vest if and when an exit event occurs. An exit event is defined as a direct initial public offering has taken place, or an indirect initial public offering has taken place, or a trade sale has been consummated, or a disposal of the Company&#x2019;s assets has been consummated, or another financially equivalent realization event has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the stock option program for the members of the Supervisory Board (the &#x201c;VSOP SB&#x201d;), the Company granted stock options of the Company to members of the Company&#x2019;s Supervisory Board for the time period of their service as members of the Supervisory Board. The shareholders&#x2019; approved the VSOP SB with a total of 31,593 stock options, corresponding to approximately 0.5% of the Company&#x2019;s issued share capital at the time of the decision. Under the stock option program for key employees (the &#x201c;VSOP&#x201d;), the Company granted stock options of the Company to certain key employees. With the approval of the Supervisory Board, Immunic AG&#x2019;s management board determined how many stock options were granted and how they were allocated to the respective beneficiaries up to a total of 31,593.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further terms and conditions of both programs, the VSOP SB and the VSOP, were substantially similar. The following information is therefore shown aggregated for both programs. The Company accounts for both programs as cash-settled options and classifies their fair value as a liability upon vesting. Vesting of options granted under the VSOP SB and VSOP was contingent upon an exit event. Upon consummation of the Transaction, which occurred on April 12, 2019, all of the awards vested and were settled for cash of $508,000 based on their fair value. As a result, the Company recorded $508,000 in compensation expense related to these stock options in the twelve months ended December 31, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company&#x2019;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#x2019;s common stock are available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#x2019;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased by 448,634 shares effective April 1, 2020. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE3Mjg_67b7eb76-947a-407e-81f5-65bf99e5e7da"&gt;three&lt;/span&gt; or four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Movements during the year&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the number and weighted average exercise prices of, and movements in, stock options for the VSOP SB and VSOP during the year ended December 31, 2019.  There were no awards granted or outstanding after the awards settled in 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unvested Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled in cash during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recognized during the year ended December 31, 2020. There was $508,000 of expense recognized in 2019 upon the vesting of the awards as a result of closing the Transaction.  There were no cancellations or modifications to the awards in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity since January 1, 2019 under the 2019 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,894,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,894,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s stock for purposes of determining the exercise price of options granted under the VSOP for the year ended December 31, 2019 was $12.87, which was determined based on prices negotiated with investors participating in the Financing as noted above. The fair value of the zero-cost VSOP SB and the VSOP options was equal to the fair value of the underlying stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of comparable companies that are publicly &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected  term of options is estimated considering the vesting period at the grant date, the life of the  option and the average length of time similar grants have remained outstanding in the past.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December&#160;31, 2020 and 2019 was $9.50 and $8.28, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.526%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Early Exit Bonus Share Agreement (Anti-Dilution Adjustment) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with an Early Exit Bonus Share Agreement (Anti-Dilution Adjustment) between the shareholders of Immunic AG dated August 2017, each of the four members of the Management Board of Immunic AG, through a limited liability company controlled by the respective board member, received new shares in Immunic AG as a form of anti-dilution protection. The AG shares were subscribed by the Management Board members at a price corresponding to their nominal value in the course of the Additional Financing of Immunic AG, which was carried out in March 2019. As part of the closing of the share exchange with Vital, Therapies, Inc., now Immunic, Inc., in April 2019, the AG shares were exchanged for 460,336 restricted shares in with Vital, Therapies, Inc., now Immunic, Inc., which were issued to the members of the management Board. Upon consummation of the Transaction, compensation cost of &#x20ac;5.3&#160;million (approximately $6.0 million) was recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;br/&gt; Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 there was $7.0&#160;million  in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.72 years.  General and administrative expenses for the year ended December 31, 2019 include $6.0&#160;million of stock compensation expense related to the  Early Exit Bonus Share Agreement disclosed above.  Research and development expense for the year ended December 31, 2019 includes $1.5 million of stock compensation expense as a result of the settlement of Tranche IV with 4SC AG as explained in Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Equity Incentive Plans Assumed from Vital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the Transaction with Vital on April 12, 2019, Vital&#x2019;s 2012 Stock Option Plan (the &#x201c;2012 Plan&#x201d;), Vital&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) and Vital&#x2019;s 2017 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There remain 43,311 shares available for grant under the 2014 Plan as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, Vital&#x2019;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#x2019;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recorded for the plans assumed from Vital during the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity since January 1, 2019 under the plans assumed from Vital:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed in the Transaction with Vital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In an effort to maximize the cash on Vital&#x2019;s balance sheet for the Transaction, Vital restructured existing change of control and severance agreements with certain of its executive officers in January 2019. At the same time, Vital canceled options granted to such officers and granted them a total of 127,500 RSUs. The primary effect of the amendments and the RSU grants was to substitute stock awards for cash payments owed upon a change of control. &lt;/span&gt;&lt;/div&gt;The RSUs vested in full upon consummation of the Transaction. As of December 31, 2019, all RSUs were settled.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <imux:ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans
      contextRef="i6d1d01b5e1504c569debfc0effaa9d69_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEzODI_a7467c20-8ede-4363-88a2-5eebbe9b95f1"
      unitRef="shares">31593</imux:ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans>
    <imux:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital
      contextRef="i6d1d01b5e1504c569debfc0effaa9d69_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzE0MzE_bc0f7a3b-3892-45da-912d-e2e8e1adae61"
      unitRef="number">0.005</imux:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital>
    <imux:ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans
      contextRef="i6d1d01b5e1504c569debfc0effaa9d69_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzE4NTI_a7467c20-8ede-4363-88a2-5eebbe9b95f1"
      unitRef="shares">31593</imux:ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id98ccd8847d942049dcebd55acab88b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzIzNzA_37f3ee51-d583-43ec-b271-6d13a34f654f"
      unitRef="usd">508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id98ccd8847d942049dcebd55acab88b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzI0MzQ_37f3ee51-d583-43ec-b271-6d13a34f654f"
      unitRef="usd">508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i884fec6fb3674d73b8111a30c60f263f_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDA2NDc_283a2c4a-07e3-4875-a0c2-7d7a7f1a3a63"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
      contextRef="i3d10718e641e49e498dc108252d3c28e_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDA4MjQ_1045c287-bba5-4be7-9681-ce65f4b23aac"
      unitRef="number">0.04</imux:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i3d10718e641e49e498dc108252d3c28e_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDA5MTU_e479b580-157c-49b3-9810-6d12595b7856"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="icf1e238f2761438b9315ac40fda6d259_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDEwNTY_0bc650af-dc32-44a5-9ebe-9a03ebaa6775"
      unitRef="shares">448634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i90330a9e562f4e60896ceea327263918_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE1MTY_13ac078d-fc9b-46c6-8117-af76952e4664">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia083d8fbd94c4989a08ae4001339a6f9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE1ODY_0f80f497-d7fa-4de6-8e5c-77b027430b55">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia26faf7d6c8d4e9d8a5282e0a5e8930d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE3MzU_5d89fd47-affd-4d89-8ee5-21463dbd8122">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzQ2_511db112-1e17-4a2c-9df0-a0ef4e59b614">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the number and weighted average exercise prices of, and movements in, stock options for the VSOP SB and VSOP during the year ended December 31, 2019.  There were no awards granted or outstanding after the awards settled in 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unvested Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settled in cash during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recognized during the year ended December 31, 2020. There was $508,000 of expense recognized in 2019 upon the vesting of the awards as a result of closing the Transaction.  There were no cancellations or modifications to the awards in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity since January 1, 2019 under the 2019 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,894,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,894,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7e3be07c1751461587012f74b2b0f7a0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzItNS0xLTEtMA_e85d2524-c1e4-4c67-b48f-d0e92c8a2da6"
      unitRef="shares">6937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7e3be07c1751461587012f74b2b0f7a0_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzItNy0xLTEtMA_9f78cc31-2cbe-4aac-ad40-8ed7f851f733"
      unitRef="usdPerShare">12.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzMtNS0xLTEtMA_7b8fcb61-9779-410a-8f3c-361ecb096f68"
      unitRef="shares">32177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzMtNy0xLTEtMA_697da609-3d6c-4cb9-892a-987a5d02d6b2"
      unitRef="usdPerShare">12.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzQtNS0xLTEtMA_f28c60c9-5c30-4854-a4ac-a68f0c415276"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzQtNy0xLTEtNzk1_9b167b08-4f9a-4b58-a1f6-1e10f920053d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <imux:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod
      contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzUtNS0xLTEtMA_a1858cab-d4f7-4f70-a83d-a80fe9e65fe3"
      unitRef="shares">39114</imux:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod>
    <imux:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice
      contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzUtNy0xLTEtNzg1_2454e32c-2535-4a4c-81e2-75a8b3e8b03a"
      unitRef="usdPerShare">12.87</imux:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="iaae3ab8518064bc4958adc8323d8343d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzYtNS0xLTEtMA_6a5033f9-417d-497c-aa73-f87c7534ab91"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifdf95cecb7c14be781cbd9b72385544b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzctNS0xLTEtMA_3c581c30-142e-4c27-a241-352af7a43e92"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifdf95cecb7c14be781cbd9b72385544b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzctNy0xLTEtMA_0b9ebafb-d983-4ee2-8acd-83463bd4cd49"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ifdf95cecb7c14be781cbd9b72385544b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphNWE3Y2QxZWUxZTI0ZjhhOTQ5OWUxMDRlNjEwMGZiNC90YWJsZXJhbmdlOmE1YTdjZDFlZTFlMjRmOGE5NDk5ZTEwNGU2MTAwZmI0XzgtNS0xLTEtMA_45dfe409-3f97-4f11-a1c0-3f385d3b8d97"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic83994845a8140129953443b3610acec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzQxMDQ_9be46de6-3d86-4433-ab93-dcf447ab51cb"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id98ccd8847d942049dcebd55acab88b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzQxODE_125cf697-8f74-4498-92fb-af9974d87457"
      unitRef="usd">508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic9fcfd27c68040008f2db78d30da709f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEtMS0xLTEtMA_733c7d8f-c54d-438b-9dd2-7e63da32f117"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic9fcfd27c68040008f2db78d30da709f_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEtMy0xLTEtMA_61ab822a-5f24-4f20-a9d4-8942be651a05"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzItMS0xLTEtMA_e39ceb4a-a6ae-4aff-b8d9-b5189c28c0a1"
      unitRef="shares">456645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzItMy0xLTEtMA_8b12cb48-8f7a-4b60-a1ae-aa430fb10ccb"
      unitRef="usdPerShare">12.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzMtMS0xLTEtMA_dc8e7b84-acad-42d0-84cd-10665bfbe592"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzMtMy0xLTEtMA_9bab5622-d4cf-4bbd-86fa-7582d932d3d0"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzQtMS0xLTEtMA_4bd40755-afb3-4d38-b54c-c37a36dbbf55"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzQtMy0xLTEtMA_0f4c403d-667b-424a-abe7-806e9e8ad54c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzUtMS0xLTEtMA_b689e5e9-0253-4cd2-b12f-9cd903421531"
      unitRef="shares">456645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzUtMy0xLTEtMA_5c029a30-38a2-4587-807d-51e5b6c3f7dd"
      unitRef="usdPerShare">12.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzUtNS0xLTEtMA_6df0d855-1968-4a88-934f-5e63682dc0b3">P9Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzUtNy0xLTEtMA_a472f0ff-cc85-4df6-b071-552779198298"
      unitRef="usd">114399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzYtMS0xLTEtMA_7dfc8dba-5969-4971-b6eb-501eab6b73d7"
      unitRef="shares">456645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzYtMy0xLTEtMA_e3f66665-2980-4751-895a-857c3429d4ff"
      unitRef="usdPerShare">12.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzYtNS0xLTEtMA_c694b3de-c9ee-433f-8224-8195ec290b01">P9Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzYtNy0xLTEtMA_63a19f90-11dd-48bd-a1cb-4cf513f064e1"
      unitRef="usd">114399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzctMS0xLTEtMA_f4ec42e1-c139-48bb-9f08-fee6f68408cd"
      unitRef="shares">31956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzctMy0xLTEtMA_5e86d28c-a92e-4473-b77e-e6f9b9063dda"
      unitRef="usdPerShare">13.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ib3c004b15ce84c9d8146c72e2cd7bdb6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzctNS0xLTEtMA_53f70c5d-550f-466d-ae4a-762f871759d2">P9Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzctNy0xLTEtMA_d3d9e656-575c-47ea-aa95-39aa9dee253b"
      unitRef="usd">3382</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEwLTEtMS0xLTgwMw_28e4b498-e2cc-4352-9f7c-3af72dec40c5"
      unitRef="shares">456645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i82708f17c53b4c37b78d4fe97415cb49_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEwLTMtMS0xLTgwMw_c9ff209f-28af-4750-a302-fb263d9406a4"
      unitRef="usdPerShare">12.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzExLTEtMS0xLTgwMw_62ba576e-6dae-446e-8c0a-7347a872c79a"
      unitRef="shares">744406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzExLTMtMS0xLTgwMw_5399d1c2-bc28-4a1b-886f-b3570315f81f"
      unitRef="usdPerShare">13.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEyLTEtMS0xLTgwMw_e5b26402-1991-46b1-954c-8e9b862a786c"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEyLTMtMS0xLTgwMw_87dc5483-f5fc-48e2-945a-507c64994443"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEzLTEtMS0xLTgwMw_abcd9c0b-9c70-49d2-8115-c21307519473"
      unitRef="shares">83891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzEzLTMtMS0xLTgwMw_4198394f-bbd7-467c-ba62-66ece2dac5f7"
      unitRef="usdPerShare">13.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE0LTEtMS0xLTgwMw_4ad16b47-8498-4b36-8d4a-fa4a3868f131"
      unitRef="shares">1117160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE0LTMtMS0xLTgwMw_c716afff-e5b5-4335-8502-4a3eecd3bca5"
      unitRef="usdPerShare">12.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE0LTUtMS0xLTgwMw_2bb3cfca-86d2-4aff-abaf-dbbee37cdec7">P9Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE0LTctMS0xLTgwMw_515c5b41-bb2d-4f80-81cf-8566cf0eb0b4"
      unitRef="usd">2894754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE1LTEtMS0xLTgwMw_225102e6-977a-4a28-a44e-63b5ae3be19c"
      unitRef="shares">1117160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE1LTMtMS0xLTgwMw_165b112e-4654-4955-9ccf-bcdd611f464c"
      unitRef="usdPerShare">12.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE1LTUtMS0xLTgwMw_8f3954da-7aea-41dd-865e-0ca75f27238d">P9Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE1LTctMS0xLTgwMw_d5a79631-15a2-4c80-bd0b-011f278e0378"
      unitRef="usd">2894754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE2LTEtMS0xLTgwMw_dc47e691-4eab-4f14-ad94-1c9d41724c23"
      unitRef="shares">263507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE2LTMtMS0xLTgwMw_0d8f87c9-5ac7-4ee0-8603-7440a86a2bb7"
      unitRef="usdPerShare">13.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9204320c663f4b3084ac9313177a458b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE2LTUtMS0xLTgwMw_9ba77602-c128-4842-bb6e-386561ff1a81">P8Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i436c280218e64d5eb8ea1ce5e4aa90d4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTozZjY2MDg4MTVkOWQ0OTBiYmFlMjRmYTVmMWM3OTJmYy90YWJsZXJhbmdlOjNmNjYwODgxNWQ5ZDQ5MGJiYWUyNGZhNWYxYzc5MmZjXzE2LTctMS0xLTgwMw_96108346-0e32-4524-a0f1-5f34e06dc8b3"
      unitRef="usd">661952</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice
      contextRef="ib8030a5507c8490583fc32147238685d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzQ1MTY_555e2f8a-ceca-43f2-a609-9c3f36d6d5d2"
      unitRef="usdPerShare">12.87</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="idf66576a68e1467aaeb276eb0a1d220d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzQ1MTY_7dec6908-2f1d-418c-a1a5-ef8caee9713e"
      unitRef="usdPerShare">12.87</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzYxNDc_8a53dfc4-23e8-4cdf-a47e-5b5019c3277f"
      unitRef="usdPerShare">9.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE5Mjg_9b3b00ed-98c7-4704-859c-831bdef7c9b6"
      unitRef="usdPerShare">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzUw_18659ced-e64f-4ec9-a32f-b4bd411a7160">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.526%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzEtMS0xLTEtMA_68b79f75-3a6a-46e6-b706-ce5db54e88d3"
      unitRef="number">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzEtMi0xLTEtODUw_4f8daa87-216f-4f29-a1d3-b62d0a12c74f"
      unitRef="number">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzItMS0xLTEtMA_e4125276-aa71-4aff-a1de-49a4ab159606"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzItMi0xLTEtODUw_83a2e17f-d68e-433c-bbf6-4fb8ef732415"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzMtMS0xLTEtMA_69bd7abf-6680-413e-8850-ddef89eff016"
      unitRef="number">0.885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzMtMi0xLTEtODUw_9395a5d9-6b4c-4e2f-8ff7-704ab49c20e8"
      unitRef="number">0.753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i630a7b979f974930b0bba2578eadd634_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzQtMS0xLTEtMA_6ab0ae58-aae2-4278-af2e-30469c7c4b5b">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib1aed6e2f0c346149edb7135c81e41f7_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTpkMmUyODk4YjRmZWY0Y2VkOGFkYWM1Mjc5YjIxYjE0Ny90YWJsZXJhbmdlOmQyZTI4OThiNGZlZjRjZWQ4YWRhYzUyNzliMjFiMTQ3XzQtMi0xLTEtODUw_fa9eaaaa-6c60-4e84-b65c-edd685af30d8">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icd8ece903fa44ea2a909aa615b1a5ba0_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzcxMjU_772ef6df-10db-4fc0-8e2a-ae5f95e39f68"
      unitRef="shares">460336</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd8ece903fa44ea2a909aa615b1a5ba0_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzczMTQ_7e0bf5ac-a310-4d34-9e70-e0aeebc7ba64"
      unitRef="eur">5300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd8ece903fa44ea2a909aa615b1a5ba0_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzczMzI_015b718f-4633-4adf-8a0b-d554d89c9812"
      unitRef="usd">6000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzQ3_cc01d212-1ba6-4265-bc8c-874e3f46a681">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;br/&gt; Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i1b19f4b3636941f2900ae6ec1f44f9d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzItMS0xLTEtMA_4945cec5-ca18-4432-812c-5a0f53eb8d77"
      unitRef="usd">731000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9cf29fd89a5442609bee7357c0b527ac_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzItMy0xLTEtMA_c3e62991-9196-48e4-879d-f744d92b14cb"
      unitRef="usd">1824000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i78fd0b65f75d4e63a2e869c2631bf0ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzMtMS0xLTEtMA_69540739-89b5-4460-949d-e35573d3d11a"
      unitRef="usd">2016000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i58388d7d9c6a4379884d6768a332b251_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzMtMy0xLTEtMA_f202cbd0-f19a-45bd-8afa-81ed54520cbe"
      unitRef="usd">6736000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic803cd5d0c184b89902cb243dfeb5916_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzQtMS0xLTEtMA_a330ef44-5a61-461d-9bb5-6811d8912bd5"
      unitRef="usd">2747000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia7cdba0abab7408cbfbfdb0c19a562a0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTphZTI4MjE2ZTdkNjA0MWIxOGEwMWNkYjcwMzBhMjY5MS90YWJsZXJhbmdlOmFlMjgyMTZlN2Q2MDQxYjE4YTAxY2RiNzAzMGEyNjkxXzQtMy0xLTEtMA_8925d09c-3a19-4beb-9f79-8b929e26156c"
      unitRef="usd">8560000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0Xzc1ODQ_8199e45f-4566-4ea4-9b34-098a7d7c8ec8"
      unitRef="usd">7000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDIwMjY_3568ed2c-95a8-4ece-a18c-a16e3ed0b6ef">P2Y8M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9010bd0189fc4f5baf921a2f5f4333bd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDIxMjk_e282d593-9a73-4aa2-af72-ec6202c48d5c"
      unitRef="usd">6000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0d4812e273894e708953a3a86ae37e95_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDIzMDM_3211fbf1-b34d-4160-b8a4-3aa23e9e9bad"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib314b2e7a1bb4652a04c736a3427cd77_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDU3MzY_cda2ba46-879f-4f5f-8ca7-d8ede9ff4ea7"
      unitRef="shares">43311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6283c69a3a9a4598bf3bc29177b58dd2_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDU5NDk_879aebb5-cf54-4b19-a9f9-5a40be7f85e4"
      unitRef="shares">46250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMzQ4_9e1982a5-0b67-41fc-9358-38dead0fd030">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity since January 1, 2019 under the plans assumed from Vital:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed in the Transaction with Vital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9d0f6cb2694343c6b174f7126d1b497c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEtMS0xLTEtMA_b301732a-9e0d-4980-935e-b7a6c35c464f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9d0f6cb2694343c6b174f7126d1b497c_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEtMy0xLTEtMA_deb47b96-dd96-4125-86db-59cf42a52168"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzItMS0xLTEtMA_497eb85a-1278-4088-a6b2-4d01bf3779c3"
      unitRef="shares">17117</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzItMy0xLTEtMA_91f59286-2634-40b1-9315-15731990d711"
      unitRef="usdPerShare">306.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzMtMS0xLTEtMA_8b13365d-18fc-4318-a8da-2e79c46aba32"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzMtMy0xLTEtMA_05cb218a-8f2f-44c4-a846-b8b24511aff5"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzQtMS0xLTEtMA_92b34536-8d7a-4b22-b56b-87b01804ed49"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzQtMy0xLTEtMA_354d346d-de73-496f-b2b7-14e69a8dd14c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzUtMS0xLTEtMA_3376b65d-1d86-431a-8bed-d4a45362e78a"
      unitRef="shares">2714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzUtMy0xLTEtMA_34edcb4d-4141-49a5-b54b-e66f1f5986a6"
      unitRef="usdPerShare">312.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzYtMS0xLTEtMA_0a932752-d28f-4075-bbcf-d3511c6e4abb"
      unitRef="shares">14403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzYtMy0xLTEtMA_c709fee9-627e-4bf6-ba43-0780a3a2d1ac"
      unitRef="usdPerShare">306.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzYtNS0xLTEtMA_7f36b8d1-8ec7-4b71-bf51-aaf5f3c75294">P2Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzYtNy0xLTEtMA_dbc3d2cc-f979-4b15-a720-1d4b1dfae9da"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzctMS0xLTEtMA_e9dee496-2299-490c-85f4-5610b09a19e3"
      unitRef="shares">14403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzctMy0xLTEtMA_6ba7340d-b8a1-4f48-acce-8f985d1b6d9f"
      unitRef="usdPerShare">306.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzctNS0xLTEtMA_0757d9f1-d7d5-4da8-ba8e-8b73fcda40da">P2Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzctNy0xLTEtMA_4f380eed-11ab-4eb8-9b00-f87102b3e24c"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzgtMS0xLTEtMA_83e4ca95-eba0-4728-99e3-75f239c692a7"
      unitRef="shares">14403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzgtMy0xLTEtMA_bee4c968-3fad-46fd-8e42-960b9392800f"
      unitRef="usdPerShare">306.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ib1566a91625a4890b0f3bed135fdad9d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzgtNS0xLTEtMA_620986e7-4a71-49c0-9716-54de7682f5d4">P2Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzgtNy0xLTEtMA_65c8adf4-dbff-4d64-900c-3f2ff4b0e05e"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzExLTEtMS0xLTEwNjA_da0f69cd-47ce-4c1e-ad92-dd7201d82186"
      unitRef="shares">14403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic92c1bfcfde34cb6bb090f5450ff896b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzExLTMtMS0xLTEwNjA_d95eba32-8708-4f6c-90ec-ab57a3c1c73e"
      unitRef="usdPerShare">306.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEyLTEtMS0xLTEwNjA_27681a7d-2591-423f-b518-f18c45461103"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEyLTMtMS0xLTEwNjA_ca1c5f11-e2db-4fe7-b4f5-52ffac98b5e9"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEzLTEtMS0xLTEwNjA_874be2b2-dc93-44e8-ad3e-5cbce8e0a079"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzEzLTMtMS0xLTEwNjA_6c62a045-7a15-4cf9-9046-23b0205db797"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE0LTEtMS0xLTEwNjA_e90ec0ef-5199-4ea2-9365-d666134d437f"
      unitRef="shares">14403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE0LTMtMS0xLTEwNjA_45b8b483-1a28-43a5-aa7b-9b61a7077974"
      unitRef="usdPerShare">306.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE1LTEtMS0xLTEwNjA_9de6882a-471f-4526-9da6-1d0c6a3ec753"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE1LTMtMS0xLTEwNjA_ddb13fb7-6791-407d-ac73-32b28b18c53c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE2LTEtMS0xLTEwNjA_73a45a9b-d67d-49ef-84c8-b4ff9853af1e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE2LTMtMS0xLTEwNjA_bd534f73-ef64-4d4c-96ef-4e6df5406dfa"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE2LTUtMS0xLTEwNjA_5ee03de5-817f-4084-8a36-f8d676bfbd15">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE2LTctMS0xLTEwNjA_b6d1eff1-a5ee-47ce-945b-44c14f950730"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE3LTEtMS0xLTEwNjA_82185629-046e-4b6b-8290-e7213e350823"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE3LTMtMS0xLTEwNjA_b13c3ff2-507f-4af2-9c7a-37cc8724b203"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE3LTUtMS0xLTEwNjA_5e50bb4d-4806-474d-a2bf-89aaa773cd60">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE3LTctMS0xLTEwNjA_6b734c8e-f4be-4af0-92c7-51a52ff97d13"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE4LTEtMS0xLTEwNjA_ddb44e3b-742c-44d2-a5c8-cfce071b23f0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE4LTMtMS0xLTEwNjA_141fa570-70dd-49a6-ac0c-dea2ec117ffe"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i67f3e841772742a2a623c89ae15880f7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE4LTUtMS0xLTEwNjA_7bff2f71-ddcf-4b1a-8cc7-ba0d4b7d13f5">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9ee32b23c5624dc9a4ac2d4c34e398ea_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90YWJsZTo5ZTQ1N2JiY2EwOWI0ZmViYWNjNzYwYTE5OTFhOGQ5Yi90YWJsZXJhbmdlOjllNDU3YmJjYTA5YjRmZWJhY2M3NjBhMTk5MWE4ZDliXzE4LTctMS0xLTEwNjA_3969eeee-7b43-4e45-93d0-6b83cd9cd8bb"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibabb7926e0324b259339a9246df9291b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzExMTEz_d5ca433a-c323-4705-a8c1-06578dbc0391"
      unitRef="shares">127500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzUwNjY_c78f42ba-f2d9-4169-a6a8-5b50eb062e16">Income Taxes &lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rate reconciliation consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax effect of rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is no current or deferred income tax expense in the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $6.8&#160;million and $23.7&#160;million for the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, Immunic had available NOLs of approximately $75.7&#160;million in Germany and Australia. These NOLs do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. federal NOL carryforwards of $15.6&#160;million were generated prior to 2018 and expire over 20 years beginning in 2023. The $67.1&#160;million of post 2017 federal NOL carryforwards do not expire. Section 382 of the Internal Revenue Code of 1986, as amended, subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined thereunder. The Company may have undergone such an ownership change and therefore may be limited in the amount of net operating losses available for utilization in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any uncertain tax positions for the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are no uncertain tax positions that would impact the effective tax rate if recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2019 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzUwNjc_4166ddda-f9ca-45d0-a6b0-c64fe0415952">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzEtMC0xLTEtMzkwOA_2802cc48-aa7e-4e00-9a3e-b16ca4e64a66"
      xsi:nil="true"/>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i831a36d6192c47e5b5bf54b78aaeba94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzItMS0xLTEtMA_9d26fec6-f4b2-4a95-8e04-98b9072a3cc0"
      unitRef="usd">-8681000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ie2528cb0a73b4870ae39bb50b3b9d6d1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzItMy0xLTEtMA_17e34d88-3439-4e32-b1e7-265ad57aa806"
      unitRef="usd">-20258000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ifc75b1a787fb4655b51ea8fab14201f2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzMtMS0xLTEtMA_5448698c-ebc0-44a6-a2b1-5c5ff3d3729b"
      unitRef="usd">-33617000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ice52c31a25f74dc481dd7ac060b4aa62_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzMtMy0xLTEtMA_750c0cba-5c36-4fb5-8af7-3d841877d520"
      unitRef="usd">-23674000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if2658237935944ab880c53895d440839_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzQtMS0xLTEtMA_2f776c26-927b-4c54-ab33-44cf8ebbda48"
      unitRef="usd">-1719000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="iadfaa4f5c09647ca9cde1fa1c8cd3403_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzQtMy0xLTEtMA_a8a4502a-a679-4d53-845b-9fbad991ea04"
      unitRef="usd">-827000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzUtMS0xLTEtMA_7f0cb02e-9ea9-49a8-a2e3-07549b63d23c"
      unitRef="usd">-44017000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTpjODAwZjQxMjBmOTA0ZDVhYTFiZWVkZmMyYTAzNmJkMC90YWJsZXJhbmdlOmM4MDBmNDEyMGY5MDRkNWFhMWJlZWRmYzJhMDM2YmQwXzUtMy0xLTEtMA_d8d6ae69-5571-4fd3-a00a-741fc163d31c"
      unitRef="usd">-44759000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzUwNTc_236a216c-6b20-49ed-8178-aab3291cfa15">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rate reconciliation consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax effect of rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzItMS0xLTEtMA_ba7a9e76-f987-49d0-b150-fd2d3e64c810"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzItMy0xLTEtMA_c53bff78-66fa-4f00-9251-e8ed60d58c7f"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzMtMS0xLTEtMA_c8e60a8d-d44b-417a-ae06-ff60d33e44be"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzMtMy0xLTEtMA_010f0085-4f51-4810-868f-78e205ddfc7f"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzQtMS0xLTEtMA_147ccd23-5a6e-40af-8fbc-cee617319abd"
      unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzQtMy0xLTEtMA_0f4eacfa-6498-41a6-84a7-8613669841a2"
      unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzUtMS0xLTEtMA_29700a15-8f5c-4616-8d59-35ea58eeee71"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzUtMy0xLTEtMA_efc5f2b9-114d-4703-b601-66fb15093333"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzctMS0xLTEtMzAxOQ_d34fac34-65b2-4ffd-a81a-8a2af3419ea4"
      unitRef="number">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzctMy0xLTEtMzAxOQ_6ddb92cd-0054-4a81-a090-761c81654598"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzYtMS0xLTEtMA_69437007-1d02-42b8-a1a5-72e0ee691e65"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzYtMy0xLTEtMA_e11ebd0e-b1dd-4788-ab63-097a0f8fe950"
      unitRef="number">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzctMS0xLTEtMA_5c92df99-2167-42ac-bf85-0f7bcf68a381"
      unitRef="number">-0.203</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzctMy0xLTEtMA_bb475357-cfe0-4e10-b9e0-4d9129e3c2c6"
      unitRef="number">-0.202</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzgtMS0xLTEtMA_a0019133-a6d2-4980-aba5-f134e8909ba7"
      unitRef="number">-0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTo3ODUyNjVlZWEyMjg0MDY5ODQ3OWEyMWIwODNiZGJmOC90YWJsZXJhbmdlOjc4NTI2NWVlYTIyODQwNjk4NDc5YTIxYjA4M2JkYmY4XzgtMy0xLTEtMA_9a507dea-a2a9-4dbb-9260-9afc56109846"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzUwNzY_8ed332c5-b701-4c59-b0e5-c967f44bdd1c">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzQtMS0xLTEtMA_d7e37754-63ea-4f59-8df8-c34fd4241462"
      unitRef="usd">17369000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzQtMy0xLTEtMA_fc292f21-f7cc-40fe-a000-c8cc88a2e1eb"
      unitRef="usd">16357000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzUtMS0xLTEtMA_9f5cf20c-37cd-4f18-8b11-40efe1484dcb"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzUtMy0xLTEtMA_addcf0b2-a4bb-4f38-bd02-21d74f7016d6"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzYtMS0xLTEtMA_ed6c82a9-b7e4-4c0f-a116-ceb94f70bb28"
      unitRef="usd">125000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzYtMy0xLTEtMA_917dbfd3-af72-4f41-ba1d-bfbbf5d85a64"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzctMS0xLTEtMA_b5f215e4-9386-4285-8ecc-7bb32cf4641d"
      unitRef="usd">18998000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzctMy0xLTEtMA_871f6fd1-bf89-4f11-a16e-8c161a669a2c"
      unitRef="usd">12237000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzgtMS0xLTEtMA_f0ddfc71-8252-4ffb-a2bd-d0523abc0cc0"
      unitRef="usd">30000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzgtMy0xLTEtMA_79a3230c-ef83-4ace-aba5-daee90f8512a"
      unitRef="usd">72000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzktMS0xLTEtMA_07ae1cf0-0e71-4bda-ba40-0e4326dcd9fe"
      unitRef="usd">36522000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzktMy0xLTEtMA_6bd7504c-86b1-4522-a46f-12972543f907"
      unitRef="usd">28666000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzExLTEtMS0xLTMwMzU_f56adb2b-96eb-40dd-aff1-14a5fa97a193"
      unitRef="usd">5000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzExLTMtMS0xLTMwMzU_7dfd4daa-f1b6-401b-9235-67c838de9ef2"
      unitRef="usd">311000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEyLTEtMS0xLTMwMzU_ae5563f2-5561-4b00-8d87-4112453f3b0d"
      unitRef="usd">5000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEyLTMtMS0xLTMwMzU_c0127cb6-e8ad-4e5d-8eed-78172df66751"
      unitRef="usd">311000</us-gaap:DeferredIncomeTaxLiabilities>
    <imux:DeferredTaxAssetsAndLiabilitiesGross
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEzLTEtMS0xLTMwMzU_8d470286-41c9-4e71-9b0a-97b5d00692e1"
      unitRef="usd">36517000</imux:DeferredTaxAssetsAndLiabilitiesGross>
    <imux:DeferredTaxAssetsAndLiabilitiesGross
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEzLTMtMS0xLTMwMzU_8e4d0282-0af7-438a-9acc-722775445489"
      unitRef="usd">28355000</imux:DeferredTaxAssetsAndLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEwLTEtMS0xLTA_2ed45efe-1254-46c4-be04-0c9e01d59b50"
      unitRef="usd">36517000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzEwLTMtMS0xLTA_d173f0e7-137c-4e14-9ca4-ab80044da8d4"
      unitRef="usd">28355000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iec7edf46a34f43399671610813b08a6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzExLTEtMS0xLTA_932b7620-922c-4fba-9c39-580f59f86025"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ib2aee3b3e8a14fea819077a54d4f286d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90YWJsZTplZTM3OGI5Y2I0Yjk0NjUxOWM2Y2NkZDhjMTNhYTIwMC90YWJsZXJhbmdlOmVlMzc4YjljYjRiOTQ2NTE5YzZjY2RkOGMxM2FhMjAwXzExLTMtMS0xLTA_c391d16f-1106-4628-b32e-8fe2b59e7753"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODM5ODk_2f509739-5956-42aa-b7cd-a2d84bc601fb"
      unitRef="usd">6800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODQwMDM_a18c714a-2163-4efb-a2ed-1bba652a78b2"
      unitRef="usd">23700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia7147fc86cd64277aadeebf96a225804_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODQwMTg_097e6f4f-d064-4ecc-9329-1d590a7f6523"
      unitRef="usd">75700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i25a9ed10cb1c434e881185327a3fab3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODQwNjM_dc3a6127-bcd8-4f15-80f5-a53066af949c"
      unitRef="usd">15600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i42d3b597607a4a96ad990267323ffb6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjYvZnJhZzoyYWM5NzdlZTBjMjc0Nzc3ODkxNDlhZWE5ZGYyYzNlNy90ZXh0cmVnaW9uOjJhYzk3N2VlMGMyNzQ3Nzc4OTE0OWFlYTlkZjJjM2U3XzI3NDg3NzkwODQwNDc_e67dfbdb-8ce7-4c0a-95e6-065ad43ca357"
      unitRef="usd">67100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8zMjk4NTM0ODg1NDI1_a48e7879-c3bf-46ef-897c-7ddbfd28023e">EIB LoanOn October 19, 2020, Immunic, Inc. (the &#x201c;Company&#x201d;) and Immunic AG, its wholly-owned subsidiary, entered into a Finance Contract (the &#x201c;Loan Agreement&#x201d;) with the European Investment Bank (&#x201c;EIB&#x201d;), pursuant to which EIB agreed to provide Immunic AG with a term loan in an aggregate amount of up to &#x20ac;24.5&#160;million to support the development of Immunic&#x2019;s lead asset, IMU-838, in moderate coronavirus disease 2019 (&#x201c;COVID-19&#x201d;), to be made available to be drawn in three tranches, &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with the second and third tranches subject to the completion of certain pre-defined milestones. The Company has the right to defer payment of principal and interest on the first and second tranches until five years after the respective borrowing dates, at which point such tranches must be repaid in full. The third tranche is repayable in annual installments commencing one year after its respective borrowing date and must be repaid in full no later than five years after such date. Any outstanding borrowings under the Loan Agreement will accrue interest as provided in the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From January 1, 2021 until December 31, 2030, the Company and Immunic AG are also obligated to pay EIB a very low single digit percentage of their revenue, as set forth in the Loan Agreement, subject to certain conditions and limitations tied to the total amount drawn under the Loan Agreement and subject to a cap of &#x20ac;8.6&#160;million if only the first tranche is drawn and subject to a cap of &#x20ac;30&#160;million if the full loan amount is drawn. The Loan Agreement also includes certain prepayment penalties that may be triggered by certain prepayments prior to the maturity date.  As of December 31, 2020, nothing was drawn down under this loan agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will guarantee Immunic AG&#x2019;s obligations to EIB pursuant to a Guarantee Agreement to be executed by the Company, Immunic AG and EIB (the &#x201c;Guarantee Agreement&#x201d;, and together with the Loan Agreement, the &#x201c;Agreements&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic5c7b6124efd40999803947e39ba5996_I20201019"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNDU1_9fe62b42-3c0a-4048-9196-fb3de515f9d6"
      unitRef="eur">24500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <imux:LineOfCreditFacilityNumberOfTranches
      contextRef="id3797128a5a3499face40e421c2bb72f_I20201019"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNDY5_112b916d-5a16-4791-b6cc-e1b6861ae7fa"
      unitRef="tranche">3</imux:LineOfCreditFacilityNumberOfTranches>
    <imux:LineOfCreditFacilityTranchePaymentDeferralTerm
      contextRef="i56a7a2ec7a864425ad54d86b2456da61_D20201019-20201019"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNDc5_7d926b30-7565-4d1c-8e10-c6c51c977926">P5Y</imux:LineOfCreditFacilityTranchePaymentDeferralTerm>
    <imux:LineOfCreditFacilityTranchePaymentDeferralTerm
      contextRef="i56a7a2ec7a864425ad54d86b2456da61_D20201019-20201019"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNDk0_f975c074-691d-4d9b-a984-01abcfe12fcd">P5Y</imux:LineOfCreditFacilityTranchePaymentDeferralTerm>
    <imux:LineOfCreditFacilityRevenueShareCapFirstTranche
      contextRef="ic5c7b6124efd40999803947e39ba5996_I20201019"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNTEw_966e65b9-3b47-47e2-884b-921c171ea0c8"
      unitRef="eur">8600000</imux:LineOfCreditFacilityRevenueShareCapFirstTranche>
    <imux:LineOfCreditFacilityRevenueShareCapFullyDrawn
      contextRef="ic5c7b6124efd40999803947e39ba5996_I20201019"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjM0L2ZyYWc6MzI4ZjM2NWVmNTc5NGIyOWI3YTI3MWQ1YTU4ZTgzNGYvdGV4dHJlZ2lvbjozMjhmMzY1ZWY1Nzk0YjI5YjdhMjcxZDVhNThlODM0Zl8yNzQ4Nzc5MDcxNTI0_386e6fae-2538-440e-aed4-56c44728f07e"
      unitRef="eur">30000000</imux:LineOfCreditFacilityRevenueShareCapFullyDrawn>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjQyL2ZyYWc6ODg5OGFiYTU3MDUyNDhhM2FhMGEyMGM4ZWU5ZmNiYmEvdGV4dHJlZ2lvbjo4ODk4YWJhNTcwNTI0OGEzYWEwYTIwYzhlZTlmY2JiYV8yNzQ4Nzc5MDcxNTA2_7a0410b0-2c26-4f7b-b810-07e2d1b8efc8">Related Party Transactions&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, on April 15, 2020, the compensation committee of the Company&#x2019;s Board independently reviewed and approved entering into an employment agreement with the Company&#x2019;s current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#x201c;Executive Chairman Agreement&#x201d;) and pursuant to such approval, on April 17, 2020, the Company and Mr. Nash entered into the Executive Chairman Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Executive Chairman Agreement, Mr. Nash serves as the Executive Chairman of the Board as long as he is a member of the Board, or until termination of the Executive Chairman Agreement (as described below) or upon his earlier death, incapacity, removal, or resignation. Pursuant to the Executive Chairman Agreement, Mr. Nash is entitled to receive: (i) a monthly base salary of $25,417 (it being agreed that such fee is inclusive of any fees associated with Mr. Nash&#x2019;s services as both a director of the Company and in the capacity of Executive Chairman), (ii) employee benefits including, health insurance, dental insurance, basic life and accidental death and dismemberment insurance, long and short term disability insurance and participation in the Company&#x2019;s 401(k) Plan, and (iii) reimbursements for pre-approved reasonable business-related expenses incurred in good faith in the performance of the Mr. Nash&#x2019;s duties for the Company. The Executive Chairman Agreement establishes an &#x201c;at will&#x201d; employment relationship pursuant to which Mr. Nash serves as Executive Chairman. The Executive Chairman Agreement contemplated a term that ended on October 15, 2020 and was subsequently extend.  On October 15, 2020, the Company and Mr. Nash entered into an addendum to the Executive Chairman Agreement, pursuant to which the term of the agreement was extended to April 15, 2021. The Company made a one-time award to Mr. Nash of 120,000 stock options, which vest monthly starting on November 15, 2020. All other terms of the employment agreement remained the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <imux:SalaryCostsMonthlyBaseSalary
      contextRef="i04d94aba3d11445ea650849b72cf2899_D20200417-20200417"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjQyL2ZyYWc6ODg5OGFiYTU3MDUyNDhhM2FhMGEyMGM4ZWU5ZmNiYmEvdGV4dHJlZ2lvbjo4ODk4YWJhNTcwNTI0OGEzYWEwYTIwYzhlZTlmY2JiYV8xNjQ5MjY3NDQyNTMy_509ed528-cb26-4186-9904-cadd370109de"
      unitRef="usd">25417</imux:SalaryCostsMonthlyBaseSalary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7dd92710d99b48ba8db45f94ef6715f4_D20201015-20201015"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjQyL2ZyYWc6ODg5OGFiYTU3MDUyNDhhM2FhMGEyMGM4ZWU5ZmNiYmEvdGV4dHJlZ2lvbjo4ODk4YWJhNTcwNTI0OGEzYWEwYTIwYzhlZTlmY2JiYV8xNjQ5MjY3NDQzNTkx_41df52cb-d5bc-4097-ae6f-af7fd2161358"
      unitRef="shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90ZXh0cmVnaW9uOmU0Mzc4MTJhYmVkOTQ0ZWFiOGFkYTA2NDliN2FmMmUwXzUzOA_93ef7ee3-1bcf-4601-b9bb-e0af3fb84169">Selected Quarterly Data (unaudited)&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Quarters Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per share (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per share (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share calculations will not necessarily equal the annual per share calculation.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90ZXh0cmVnaW9uOmU0Mzc4MTJhYmVkOTQ0ZWFiOGFkYTA2NDliN2FmMmUwXzU0NA_a274dd7c-8497-48bc-bd1d-40d81e7a8430">Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share data):&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Quarters Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September&#160;30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&#160;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per share (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per share (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share calculations will not necessarily equal the annual per share calculation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:OperatingExpenses
      contextRef="i9ede6cd330124ec6a00d9b69f6869d26_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtMS0xLTEtMA_1e9d019f-4569-4e5c-91df-028e8fd7dcd2"
      unitRef="usd">9014000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibe8c1c50bbcc47cd82232e72f9c1d366_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtMy0xLTEtMA_f8e47176-b0de-401f-aaef-d380bf4dfbd4"
      unitRef="usd">12222000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i35dad35cf93d448a8881d824be1e6f81_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtNS0xLTEtMA_baa38431-5e33-4b51-85d3-2909bb2cdf15"
      unitRef="usd">13545000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtNy0xLTEtMA_89f56309-8503-48da-95ed-6ec9c4cbb41c"
      unitRef="usd">14190000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzMtOS0xLTEtMA_4d3f3e9f-3924-4cf2-9ad8-c981a1302673"
      unitRef="usd">48971000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="i9ede6cd330124ec6a00d9b69f6869d26_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtMS0xLTEtMA_900032d9-a462-45c6-8890-ee80f2c4895a"
      unitRef="usd">-8487000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe8c1c50bbcc47cd82232e72f9c1d366_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtMy0xLTEtMA_bf4b6cb3-4857-4b1d-b315-aa731e57fce3"
      unitRef="usd">-11458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i35dad35cf93d448a8881d824be1e6f81_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtNS0xLTEtMA_b8814354-0e45-44a0-9adf-b6de5f161cc4"
      unitRef="usd">-12913000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtNy0xLTEtMA_da445772-8b62-4a95-895d-217e8fae21a2"
      unitRef="usd">-11159000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzQtOS0xLTEtMA_431f1474-0a2b-4934-afba-57a8612d03e1"
      unitRef="usd">-44017000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i9ede6cd330124ec6a00d9b69f6869d26_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtMS0xLTEtMA_387ce40c-ecfc-433e-b2bc-7778590dcb1c"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ibe8c1c50bbcc47cd82232e72f9c1d366_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtMy0xLTEtMA_be13ebe6-36dd-4768-82e2-a3ca326e3950"
      unitRef="usdPerShare">-0.90</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i35dad35cf93d448a8881d824be1e6f81_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtNS0xLTEtMA_b33c447e-445b-4af1-bb56-0def56dc0c51"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtNy0xLTEtMA_e1d6daa3-d381-4dc2-9308-44321b99e3f1"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzUtOS0xLTEtMA_1b0eba70-5999-4e99-b22e-ebb755663a17"
      unitRef="usdPerShare">-2.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:OperatingExpenses
      contextRef="ibb99bde8e3a84965bc53a2495c5be965_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctMS0xLTEtMA_bc77bade-ac72-421f-b7cb-c116144ae676"
      unitRef="usd">4662000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i49383c3200664df28115e65f5e1bf1a7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctMy0xLTEtMA_f154c766-7f6b-4052-a1ea-d7f5cc72a672"
      unitRef="usd">15007000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0ccd299d58334dac9edfb2ac321eecfe_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctNS0xLTEtMA_bbbf22da-3908-4abb-96d6-b8c45cbe06a9"
      unitRef="usd">9177000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6a7188adef1744a990c1f5be2b5baaec_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctNy0xLTEtMA_c0e9d057-c7d2-4167-8f18-09b1b69adb8d"
      unitRef="usd">8186000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzctOS0xLTEtMA_e2872fea-4dd9-4563-9dc6-c91065aad531"
      unitRef="usd">37032000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="ibb99bde8e3a84965bc53a2495c5be965_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtMS0xLTEtMA_10d679a5-bdc4-4094-9361-1158d2ff586a"
      unitRef="usd">-4313000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i49383c3200664df28115e65f5e1bf1a7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtMy0xLTEtMA_de3ce41a-7e40-4428-8bf2-0f594a1be326"
      unitRef="usd">-14714000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0ccd299d58334dac9edfb2ac321eecfe_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtNS0xLTEtMA_f773acfa-aaf6-46e3-bfe9-5f58b56242a0"
      unitRef="usd">-8215000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6a7188adef1744a990c1f5be2b5baaec_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtNy0xLTEtMA_664e3366-3359-4c8b-b71b-24a2f5fb2a17"
      unitRef="usd">-7691000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzgtOS0xLTEtMA_14bb91ae-24e0-4dd3-b970-33128f273971"
      unitRef="usd">-34933000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ibb99bde8e3a84965bc53a2495c5be965_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktMS0xLTEtMA_53216505-bcd2-466a-88da-e9f7ab10de23"
      unitRef="usdPerShare">-5.09</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i49383c3200664df28115e65f5e1bf1a7_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktMy0xLTEtMA_1de111ee-5d92-48ca-a6bb-54be9046af8c"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0ccd299d58334dac9edfb2ac321eecfe_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktNS0xLTEtMA_1757fd92-5227-43d5-83da-d04107b8ff8e"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i6a7188adef1744a990c1f5be2b5baaec_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktNy0xLTEtMA_21b294aa-2ad8-43e6-8d52-eb33aad1731d"
      unitRef="usdPerShare">-0.75</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic0b11e8678424f3ba323d448f9faee53_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjkvZnJhZzplNDM3ODEyYWJlZDk0NGVhYjhhZGEwNjQ5YjdhZjJlMC90YWJsZTpiNjFiNzY1YzIwOTQ0MjhkYjIwNDUyNmJkNzg4NjIxYi90YWJsZXJhbmdlOmI2MWI3NjVjMjA5NDQyOGRiMjA0NTI2YmQ3ODg2MjFiXzktOS0xLTEtMA_8f821b5e-d0e3-4d98-a311-865d0c3b1b64"
      unitRef="usdPerShare">-4.52</us-gaap:EarningsPerShareBasicAndDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011799658312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain portions of the registrant&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011812474040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 127,452<span></span>
</td>
<td class="nump">$ 29,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">6,293<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">133,745<span></span>
</td>
<td class="nump">32,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,970<span></span>
</td>
<td class="nump">32,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">167,861<span></span>
</td>
<td class="nump">65,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">2,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,318<span></span>
</td>
<td class="nump">3,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,397<span></span>
</td>
<td class="nump">7,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,076<span></span>
</td>
<td class="nump">7,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December&#160;31, 2020 and 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December&#160;31, 2020 and 2019</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">266,823<span></span>
</td>
<td class="nump">119,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,112)<span></span>
</td>
<td class="num">(1,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(103,928)<span></span>
</td>
<td class="num">(59,911)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">158,785<span></span>
</td>
<td class="nump">58,363<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 167,861<span></span>
</td>
<td class="nump">$ 65,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011816410536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 12, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 27, 2019 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">21,168,240<span></span>
</td>
<td class="nump">10,744,806<span></span>
</td>
<td class="nump">120,070<span></span>
</td>
<td class="nump">156,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">21,168,240<span></span>
</td>
<td class="nump">10,744,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011798866200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 38,637<span></span>
</td>
<td class="nump">$ 22,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,334<span></span>
</td>
<td class="nump">14,520<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">48,971<span></span>
</td>
<td class="nump">37,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(48,971)<span></span>
</td>
<td class="num">(37,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">4,954<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,017)<span></span>
</td>
<td class="num">$ (34,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (usd per share)</a></td>
<td class="num">$ (2.81)<span></span>
</td>
<td class="num">$ (4.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">15,663,826<span></span>
</td>
<td class="nump">7,722,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011802766008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,017)<span></span>
</td>
<td class="num">$ (34,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation, net of tax</a></td>
<td class="num">(2,739)<span></span>
</td>
<td class="num">(554)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (46,756)<span></span>
</td>
<td class="num">$ (35,487)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011723968488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Series A-2 Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series A-1 Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Pre-Closing Financing</div></th>
<th class="th">
<div>Pre-Closing Financing </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Pre-Closing Financing </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>4SC Settlement Agreement</div></th>
<th class="th">
<div>4SC Settlement Agreement </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>4SC Settlement Agreement </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Public Offering</div></th>
<th class="th">
<div>Public Offering </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Public Offering </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>April 2020 Equity Issuances</div></th>
<th class="th">
<div>April 2020 Equity Issuances </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>April 2020 Equity Issuances </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>June 2020 Equity Issuances</div></th>
<th class="th">
<div>June 2020 Equity Issuances </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>June 2020 Equity Issuances </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>August 2020 Equity Issuances</div></th>
<th class="th">
<div>August 2020 Equity Issuances </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>August 2020 Equity Issuances </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>Executive Bonus Agreement</div></th>
<th class="th">
<div>Executive Bonus Agreement </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Executive Bonus Agreement </div>
<div>Additional Paid-In Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,456<span></span>
</td>
<td class="nump">13,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (25,741)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">$ (819)<span></span>
</td>
<td class="num">$ (24,978)<span></span>
</td>
<td class="nump">$ 34,313<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock-based compensation</a></td>
<td class="nump">529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A Preferred Stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,302,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(299,456)<span></span>
</td>
<td class="num">(13,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A Preferred Stock to common stock</a></td>
<td class="nump">37,193<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">37,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34,313)<span></span>
</td>
<td class="num">$ (2,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,197,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,935<span></span>
</td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="nump">$ 4,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Exchange of common stock in connection with Transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Exchange of common stock in connection with Transaction</a></td>
<td class="nump">39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,744,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">58,363<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">119,646<span></span>
</td>
<td class="num">(1,373)<span></span>
</td>
<td class="num">(59,911)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(2,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock-based compensation</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,764,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,925<span></span>
</td>
<td class="nump">$ 13,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,918<span></span>
</td>
<td class="nump">$ 23,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,048<span></span>
</td>
<td class="nump">$ 96,540<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 96,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 158,785<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 266,823<span></span>
</td>
<td class="num">$ (4,112)<span></span>
</td>
<td class="num">$ (103,928)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011816802792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember', window );">Pre-Closing Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember', window );">April 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember', window );">June 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">1,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember', window );">August 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 6,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011806770552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (44,017)<span></span>
</td>
<td class="num">$ (34,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of ELAD Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="nump">6,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized foreign currency gain</a></td>
<td class="num">(2,528)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Contingent payment settled in common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,779)<span></span>
</td>
<td class="num">(2,224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other current liabilities</a></td>
<td class="num">(1,255)<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46,124)<span></span>
</td>
<td class="num">(28,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash distribution in connection with ELAD Assets sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment', window );">Proceeds from sale of ELAD assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_CashAcquiredInConnectionWithReverseAcquisition', window );">Cash acquired in connection with the Transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(146)<span></span>
</td>
<td class="nump">10,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">144,431<span></span>
</td>
<td class="nump">34,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(589)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">98,083<span></span>
</td>
<td class="nump">16,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">29,369<span></span>
</td>
<td class="nump">13,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">127,452<span></span>
</td>
<td class="nump">29,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_DeferredStockIssuanceCostsIncludedInLiabilities', window );">Stock issuance and deferred financing costs included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of net assets acquired in the Transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_OfferingCostsIncludedInAccruedExpenses', window );">Offering costs in accrued expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable', window );">Purchases of property and equipment included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember', window );">Pre-Closing Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">10,925<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember', window );">April 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">13,918<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember', window );">June 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">23,048<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember', window );">August 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 96,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_CashAcquiredInConnectionWithReverseAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Acquired In Connection With Reverse Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_CashAcquiredInConnectionWithReverseAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_DeferredStockIssuanceCostsIncludedInLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Stock Issuance Costs Included In Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_DeferredStockIssuanceCostsIncludedInLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_OfferingCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Included In Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_OfferingCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_PropertyPlantAndEquipmentIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, And Equipment Included In Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_PropertyPlantAndEquipmentIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011802596952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember', window );">Pre-Closing Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember', window );">April 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember', window );">June 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">1,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember', window );">August 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 6,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PreClosingFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796102328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Financial Statements</a></td>
<td class="text">Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic, Inc. ("Immunic" or the "Company") a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis ("RRMS"), ulcerative colitis ("UC"), Crohn&#8217;s disease ("CD") and psoriasis. Immunic is headquartered in New York with its main operations in Gr&#228;felfing, Germany. Immunic currently has 28 employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Immunic is currently pursuing three development programs, all orally available small molecule inhibitors in the clinical development phase. These include the IMU-838 program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of ROR&#947;t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (&#8220;ROR&#947;&#8221;), and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function. These product candidates are being developed to address diseases such as RRMS, UC, CD, and psoriasis. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), and Guillain-Barr&#233; syndrome (&#8220;GBS&#8221;). Immunic is also investigating IMU-838 as a potential treatment option for coronavirus disease 2019 (&#8220;COVID-19&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. Immunic has never been profitable and has incurred operating losses in each year since inception (2016). Immunic has an accumulated deficit of approximately $103.9&#160;million as of December&#160;31, 2020 and approximately $59.9&#160;million as of December&#160;31, 2019. Substantially all of Immunic&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31, 2020, Immunic has raised net cash of approximately $216.8 million from private and public offerings of preferred and common stock. As of December&#160;31, 2020, Immunic had cash and cash equivalents of approximately $127.5&#160;million. With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying audited consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Acquisition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2019, pursuant to the terms of the Agreement, dated as of January 6, 2019, between Vital Therapies, Inc., a Delaware corporation (&#8220;Vital&#8221;), Immunic AG, and the shareholders of Immunic AG party thereto (the &#8220;Agreement&#8221;), the holders of Immunic AG ordinary shares exchanged all of their outstanding shares for shares of Vital common stock, resulting in Immunic AG becoming a wholly-owned subsidiary of Vital (the &#8220;Transaction&#8221;). Immediately following the Transaction, Vital Therapies, Inc. changed its name to &#8220;Immunic, Inc.&#8221; and its ticker symbol to &#8220;IMUX&#8221;.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Transaction, (i) each Immunic AG preferred share was converted into one Immunic AG ordinary share, and (ii) each Immunic AG ordinary share was converted into the right to receive 17.17 shares of Vital&#8217;s common stock, after giving effect to the Reverse Stock Split (as defined below). The exchange ratio was determined through arm&#8217;s-length negotiations between Vital and Immunic AG. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration issuable in the Transaction, after giving effect to the Reverse Stock Split, was 8,927,130 shares of Vital&#8217;s common stock. Following the Transaction and after giving effect to the Reverse Stock Split, the former shareholders of Immunic AG owned approximately 88.25% of the fully diluted common stock of the Company, and the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders of Vital immediately prior to the Transaction owned 1,059,269 shares (plus 127,500 restricted stock units (&#8220;RSUs&#8221;) all of which have been issued to date to former Vital officers) of the common stock of the Company or approximately 11.75%. The issuance of shares of Vital&#8217;s common stock in the Transaction was registered with the Securities and Exchange Commission (&#8220;SEC&#8221;) on a Registration Statement on Form S-4 (Registration No. 333-229510).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Transaction, Immunic AG issued, in a private placement transaction (the &#8220;Financing&#8221;), an aggregate of 2,197,742 ordinary shares to certain of its shareholders for aggregate consideration of &#8364;26.7 million (approximately $29.9 million), pursuant to the terms of the Investment and Subscription Agreement, dated as of January 6, 2019, between Immunic and the shareholders and investors party thereto (the &#8220;Subscription Agreement&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transaction has been accounted for as a reverse acquisition under the acquisition method of accounting. Because Immunic AG&#8217;s pre-Transaction owners held an 88.25% economic and voting interest in the combined company immediately following the closing of the Transaction, Immunic AG is considered to be the acquirer of Vital for accounting purposes. Additionally, Immunic AG is considered to be the predecessor for reporting purposes and the financial results of Immunic AG are reported in the historical comparable periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2019, immediately following the closing of the Transaction, the Company effected a 40-for-1 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;). Accordingly, all references to share and per share amounts in the accompanying audited consolidated financial statements and notes have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. No fractional shares were issued in connection with the Reverse Stock Split. Unless otherwise noted, all references to common stock share and per share amounts have also been adjusted to reflect the exchange ratio of 17.17.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Research GmbH (which both began operations in 2016), Immunic Australia Pty Ltd. (which began operations in 2018) and Vital Therapies (Beijing) Company Limited (&#8220;VTL China&#8221;), acquired through the Transaction (which began operations in 2005). VTL China was sold in September 2019 in connection with the sale of certain of Vital's clinical development-related intellectual property rights (the "ELAD Assets"). All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. Certain prior period amounts have been reclassified to conform to the current basis of presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796440344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, clinical trial expenses, share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. During the twelve months ended December&#160;31, 2020 and 2019, Immunic AG and Immunic Research GmbH&#8217;s operations were located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income. The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years. Depreciation and amortization expense was $39,000 and $50,000 for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform a quantitative test that compares the fair value to its carrying value to determine the amount of any impairment. Impairment testing for goodwill is done at the reporting unit level. The Company has determined that it operates in a single operating segment and has a single reporting unit. The Company has determined there was no goodwill impairment as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, IMU-838, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on IMU-838, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  IMU-935 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in September 2019. IMU-856 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in August 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for diseases such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no more research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. The short-term leases are deemed immaterial and have not been included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2020, and December&#160;31, 2019, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU 2017-04, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." This guidance eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit&#8217;s fair value. The Company adopted this ASU, as required, in the quarter ended March 31, 2020 on a prospective basis. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement - Disclosure Framework&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-13.") ASU 2018-13 modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty, and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments must be applied retrospectively to all periods presented upon their effective date. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-18"). ASU 2018-18, clarifies that elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The Company does not have any agreements that meet the definition of a collaboration arrangement at this time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796125768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting for the Transaction<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Accounting for the Transaction</a></td>
<td class="text">Accounting for the Transaction <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the exchange ratio of 17.17 shares of Vital common stock for each share of Immunic AG, immediately following the Transaction, former Vital stockholders owned approximately 11.75% of the capital stock of the combined organization on a fully diluted basis, and former Immunic AG stockholders owned approximately 88.25% of the capital stock of the combined organization on a fully diluted basis. At the closing of the Transaction, all shares of Immunic AG common stock then outstanding were exchanged for Vital common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the terms of the Agreement, the Company, for accounting purposes, assumed all outstanding stock options to purchase 16,987 shares of Vital common stock and 127,500 RSUs at the closing of the Transaction, after giving effect to the Reverse Stock Split. Since the exercise prices of the outstanding options to purchase common stock were less than the trading price on the day of the consummation of the Transaction, they were not included in the formula below in calculating the purchase price.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tangible and intangible assets and liabilities of Vital acquired in the Transaction are recorded based on their fair values as of the completion of the Transaction, with the excess of the purchase consideration over the fair value of net assets assigned to and recorded as goodwill. The following summarizes the purchase price paid in the Transaction (amounts in thousands except share and per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares owned by Vital stockholders (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fully-diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Vital common stock (3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The number of shares of 1,059,269 represents the historical 42,369,694 shares of Vital common stock outstanding immediately prior to the closing of the Transaction, adjusted for the Reverse Stock Split.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The number of RSUs of 127,500 represents the historical 5,100,000 Vital RSUs of which all have been issued to date to Vital former officers in 2019.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on the last reported sale price of Vital common stock on the Nasdaq Global Market on April 12, 2019, the closing of the Transaction, adjusted for the Reverse Stock Split.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and working cell banks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (&#8220;IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair value of IPR&amp;D was estimated based on the sales price of the ELAD Assets (including the present value of the promissory note issued by the ELAD buyer) less the fair value of the ELAD Assets. See Note 4 below for a description of the ELAD Assets transaction.The goodwill of $32.97 million is not tax deductible. Goodwill is mainly attributable to the enhanced value of the combined company, as reflected in the increase in market value of the Vital common shares following the announcement of the Transaction with Immunic AG. The Company incurred costs directly related to the Transaction of approximately $10.0 million for the year ended December 31, 2019, which were expensed as incurred ($7.5&#160;million of such costs were non-cash charges related to the 4SC settlement share issuances and the Immunic exit bonus shares as described below in Note 6 and Note 9, respectively).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796435944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ELAD Sales Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">ELAD Sales Agreement</a></td>
<td class="text">ELAD Sales Agreement<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Vital entered into an asset purchase agreement (the &#8220;Vital APA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to sell certain of Vital&#8217;s clinical development-related assets and related intellectual property rights to RH Cell Therapeutics (the &#8220;Purchaser&#8221;) for approximately $2.5 million. The assets sold were clinical development equipment, supplies, intellectual property and working cell banks in addition to the equity interest in VTL China (collectively the &#8220;ELAD Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Purchaser deposited $1.1 million into escrow and paid the Company $50,000 prior to the Transaction. The Vital APA was amended and restated on May 28, 2019, to allow for two closings. In the first closing which occurred on May 28, 2019, the $1.1 million was released from escrow to the Company. In addition, the Purchaser executed a promissory note with a face amount of $1.325 million, which accrues simple interest of 10% per annum. The fair value of the promissory note was estimated to be $920,000. Therefore, the fair value of the ELAD Assets was based on the cash in escrow, the $50,000 deposit and the fair value of the promissory note. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the ELAD Assets was included in the purchase accounting allocation as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:87.152%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and working cell banks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In process research &amp; development (&#8220;IPR&amp;D&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first closing, the Company transferred title of the clinical development equipment and supplies to the Purchaser. Also, the fair value of the promissory note was recorded as a note receivable and the fair value of the IPR&amp;D and working cell banks assets were removed from the Company&#8217;s audited consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promissory note was paid in full upon the second closing on September 4, 2019, at which time the Company transferred title to the intellectual property and working cell banks as well as its equity interest in VTL China. The difference of $405,000 between the $1.325 million face value of the promissory note collected and the fair value of $920,000 was recorded as other income in the accompanying consolidated statements of operations for the year ended December 31, 2019.  The Purchaser is not a related party.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796136136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid Expense and Other Current Assets consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist  of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Deferred income represents cash reimbursement on invoices received from third party billings, prior to the related services being performed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796424856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and June 30, 2025 for the Gr&#228;felfing, Germany office.  The Company formerly leased office space in Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNTQvZnJhZzpiMjc4ZWMxNDUwNzI0N2ZiYmNhZTEyZDY2NGMzYTE3Ni90ZXh0cmVnaW9uOmIyNzhlYzE0NTA3MjQ3ZmJiY2FlMTJkNjY0YzNhMTc2XzE2NDkyNjc0NDgzOTA_02686f89-0de8-4c0b-a81a-71f470466ead">five</span> year lease for its new facility in Gr&#228;felfing, Germany. Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease.  There were net additions to right of use assets of $427,000 as a result of signing the Gr&#228;felfing lease and shortening the term of the Martinsried lease during the year ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $354,000 and $135,000 for the years ended December&#160;31, 2020 and 2019, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Maturities of the operating lease obligation are as follows as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has non-cancelable contractual obligations under certain agreements related to its development programs IMU-838, IMU-935 and IMU-856 totaling approximately $1.2 million, all of which is expected to be paid in 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016 the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC AG whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#8217;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the issuance of these shares on April 12, 2019. No royalties are payable as of December&#160;31, 2020 or 2019 as sales have not commenced.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796174072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div>The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796416056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock and Preferred Stock (Converted into Common Stock)</a></td>
<td class="text">Common Stock and Preferred Stock (Converted into Common Stock)<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, Vital filed a shelf registration statement on Form S-3, (the &#8220;2018 Shelf Registration Statement&#8221;), which became effective in June 2018. The 2018 Shelf Registration Statement permits the offering, issuance and sale of up to $200.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $40.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("July 2019 ATM") with SVB Leerink LLC (&#8220;SVB Leerink&#8221;) as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The July 2019 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the July 2019 ATM or (ii) termination of the July 2019 ATM as otherwise permitted thereby. The July 2019 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $23.3&#160;million in capacity remains under the July 2019 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed another Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $50.0&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, the Company raised gross proceeds of $11.3&#160;million pursuant to the July 2019 ATM through the sale of 733,728 shares of common stock at a weighted average price of $15.42 per share. The net proceeds from the July 2019 ATM were  $11.0&#160;million after deducting underwriter commissions of $339,356. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, the Company raised gross proceeds of $5.4&#160;million pursuant to the July 2019 ATM through the sale of 630,907 shares of common stock at a weighted average price of $8.49 per share. The net proceeds from the July 2019 ATM were  $4.9&#160;million after deducting underwriter commissions of $161,000 and estimated offering expenses of $305,000. As of December&#160;31, 2019, there was $34.6 million available under the July 2019 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">April 2020 Registered Direct Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, the Company entered into an engagement letter with ROTH Capital Partners, LLC ("RCP") relating to the Company&#8217;s registered direct offering of common stock to select institutional investors. Pursuant to this agreement, the Company agreed to pay RCP a cash fee of 6.5% of the gross proceeds from the offering raised from investors and to reimburse RCP for certain costs incurred in connection therewith.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on April 23, 2020, the Company and the investors entered into a securities purchase agreement relating to the issuance and sale of an aggregate of 1,764,706 shares of common stock. The purchase price per share was $8.50 for aggregate gross proceeds to the Company of approximately $15.0&#160;million.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to the Company from this offering, after deducting the Company&#8217;s offering expenses, were approximately $13.9&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">June 2020 Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2020, the Company entered into a placement agency agreement with RCP and Ladenburg Thalmann &amp; Co. Inc. relating to the Company&#8217;s public offering of 2,175,000 shares of common stock. Pursuant to this agreement, the Company agreed to pay the placement agents a cash fee of 6.5% of the gross proceeds from the offering raised from investors and to reimburse the placement agents for certain costs incurred in connection therewith.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, on June 10, 2020, the Company and certain institutional investors entered into securities purchase agreements relating to the issuance and sale of an aggregate of 2,175,000 shares of the Company&#8217;s common stock. The purchase price per share in the Offering was $11.40 for aggregate gross proceeds to the Company of approximately $25.0&#160;million. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The net proceeds to the Company from this offering, after deducting the Company&#8217;s offering expenses, were approximately $23.0&#160;million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%;text-decoration:underline">August 2020 Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into an underwriting agreement with SVB Leerink LLC, as representative of the several underwriters in connection with the Company&#8217;s public offering of 5,000,000 shares of common stock, at a public offering price of $18.00 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 750,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions, which was exercised in full on August 6, 2020.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company closed the Offering. The net proceeds to the Company from the Offering, after giving effect to the exercise in full by the Underwriters of their option to purchase the Option Shares, was approximately $96.5&#160;million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.  </span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Subscription Not Yet Issued</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">On March 27, 2019, stockholders of the Company resolved to increase the Company&#8217;s share capital by an additional 156,920 ordinary shares, par value &#8364;1.00 per share, of which 27,176 shares related to bonuses for executive officers of the Company. Under German law a capital increase is valid as soon as the consummation of the capital increase has been officially registered with the commercial register, which occurred on April 3, 2019. Therefore, the capital increase became effective subsequent to March 31, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic AG, a non-public company as of December 31, 2018, had authorized 846,953 shares of common stock, par value &#8364;1.00 per share, which were issued in March 2016 for approximately $56,000. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through December&#160;31, 2020, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception (2016) through 2018, Immunic AG issued 13,541 Series A-1 Convertible and 299,456 Series A-2 Convertible preferred shares, par value &#8364;1.00 per share, to investors as part of its growth financing plan in the total amount of &#8364;31.7 million (approximately $37.2 million). Series A-1 Convertible and Series A-2 Convertible preferred shares were converted into Immunic AG&#8217;s ordinary shares immediately prior to the Transaction and were then exchanged for Immunic (former Vital) common shares at the consummation of the Transaction.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20,000,000 shares of $0.0001 par value preferred stock, rights and preferences to be set by the board of directors. No preferred shares were outstanding as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued warrants to purchase common stock in connection with financing activities and for consulting services in 2011. Warrants for 6,015 shares of common stock at an exercise price of $3,719.60 expired on September 25, 2019.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance as of December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011797801256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Compensation Plans</a></td>
<td class="text">Stock Compensation Plans<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, (i) a company&#8217;s management board consists of employee members and is responsible for overseeing its daily business, and (ii) a company&#8217;s supervisory board supervises the management board and serves a role equivalent to the board of directors of an American corporation. Under two stock option programs, the Company granted stock options to the members of the Immunic AG supervisory board (the &#8220;Supervisory Board&#8221;) and to key employees in 2018 and in 2019 prior to the Transaction. The programs were intended to incentivize the beneficiaries to dedicate their working capabilities in the best manner possible to the benefit of the Company. The stock options vest if and when an exit event occurs. An exit event is defined as a direct initial public offering has taken place, or an indirect initial public offering has taken place, or a trade sale has been consummated, or a disposal of the Company&#8217;s assets has been consummated, or another financially equivalent realization event has occurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the stock option program for the members of the Supervisory Board (the &#8220;VSOP SB&#8221;), the Company granted stock options of the Company to members of the Company&#8217;s Supervisory Board for the time period of their service as members of the Supervisory Board. The shareholders&#8217; approved the VSOP SB with a total of 31,593 stock options, corresponding to approximately 0.5% of the Company&#8217;s issued share capital at the time of the decision. Under the stock option program for key employees (the &#8220;VSOP&#8221;), the Company granted stock options of the Company to certain key employees. With the approval of the Supervisory Board, Immunic AG&#8217;s management board determined how many stock options were granted and how they were allocated to the respective beneficiaries up to a total of 31,593.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further terms and conditions of both programs, the VSOP SB and the VSOP, were substantially similar. The following information is therefore shown aggregated for both programs. The Company accounts for both programs as cash-settled options and classifies their fair value as a liability upon vesting. Vesting of options granted under the VSOP SB and VSOP was contingent upon an exit event. Upon consummation of the Transaction, which occurred on April 12, 2019, all of the awards vested and were settled for cash of $508,000 based on their fair value. As a result, the Company recorded $508,000 in compensation expense related to these stock options in the twelve months ended December 31, 2019.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#8217;s common stock are available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased by 448,634 shares effective April 1, 2020. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjBkOGQ2MjQyMzhjOTQ2OGJhMTQ3NDlmYjQ5YjdjYTY5L3NlYzowZDhkNjI0MjM4Yzk0NjhiYTE0NzQ5ZmI0OWI3Y2E2OV8xNjMvZnJhZzpiMTYxYWIyMGIwYjI0MzdlODM4ODhmZThjMzhmZDhiNC90ZXh0cmVnaW9uOmIxNjFhYjIwYjBiMjQzN2U4Mzg4OGZlOGMzOGZkOGI0XzEwOTk1MTE2NDE3Mjg_67b7eb76-947a-407e-81f5-65bf99e5e7da">three</span> or four years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the number and weighted average exercise prices of, and movements in, stock options for the VSOP SB and VSOP during the year ended December 31, 2019.  There were no awards granted or outstanding after the awards settled in 2019:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"><tr><td style="width:1.0%"/><td style="width:75.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unvested Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled in cash during the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired during the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recognized during the year ended December 31, 2020. There was $508,000 of expense recognized in 2019 upon the vesting of the awards as a result of closing the Transaction.  There were no cancellations or modifications to the awards in 2019. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity since January 1, 2019 under the 2019 Plan:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,645&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,956&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,645&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,894,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,894,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,507&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s stock for purposes of determining the exercise price of options granted under the VSOP for the year ended December 31, 2019 was $12.87, which was determined based on prices negotiated with investors participating in the Financing as noted above. The fair value of the zero-cost VSOP SB and the VSOP options was equal to the fair value of the underlying stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of comparable companies that are publicly </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected  term of options is estimated considering the vesting period at the grant date, the life of the  option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the years ended December&#160;31, 2020 and 2019 was $9.50 and $8.28, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.526%"><tr><td style="width:1.0%"/><td style="width:57.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exit Bonus Share Agreement (Anti-Dilution Adjustment) </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with an Early Exit Bonus Share Agreement (Anti-Dilution Adjustment) between the shareholders of Immunic AG dated August 2017, each of the four members of the Management Board of Immunic AG, through a limited liability company controlled by the respective board member, received new shares in Immunic AG as a form of anti-dilution protection. The AG shares were subscribed by the Management Board members at a price corresponding to their nominal value in the course of the Additional Financing of Immunic AG, which was carried out in March 2019. As part of the closing of the share exchange with Vital, Therapies, Inc., now Immunic, Inc., in April 2019, the AG shares were exchanged for 460,336 restricted shares in with Vital, Therapies, Inc., now Immunic, Inc., which were issued to the members of the management Board. Upon consummation of the Transaction, compensation cost of &#8364;5.3&#160;million (approximately $6.0 million) was recognized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/> Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 there was $7.0&#160;million  in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.72 years.  General and administrative expenses for the year ended December 31, 2019 include $6.0&#160;million of stock compensation expense related to the  Early Exit Bonus Share Agreement disclosed above.  Research and development expense for the year ended December 31, 2019 includes $1.5 million of stock compensation expense as a result of the settlement of Tranche IV with 4SC AG as explained in Note 6.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the years ended December 31, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity since January 1, 2019 under the plans assumed from Vital:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed in the Transaction with Vital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to maximize the cash on Vital&#8217;s balance sheet for the Transaction, Vital restructured existing change of control and severance agreements with certain of its executive officers in January 2019. At the same time, Vital canceled options granted to such officers and granted them a total of 127,500 RSUs. The primary effect of the amendments and the RSU grants was to substitute stock awards for cash payments owed upon a change of control. </span></div>The RSUs vested in full upon consummation of the Transaction. As of December 31, 2019, all RSUs were settled.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796177288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,681)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,017)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,759)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate reconciliation consists of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As tax laws and rates change, deferred tax assets and liabilities are adjusted through income tax expense. There is no current or deferred income tax expense in the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's net deferred tax assets are shown below. A valuation allowance has been established as realization of such net deferred tax assets has not met the more likely-than-not threshold requirement. If the Company's judgment changes and it is determined that the Company will be able to realize these net deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on the net deferred tax assets will be accounted for as a reduction to income tax expense.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses each year since inception due to its history as a development stage company with no realized revenues from its planned principal operations. These cumulative operating losses provide significant negative evidence in the determination of whether or not the Company will be able to realize deferred tax assets such as net operating losses and other favorable temporary differences. There can be no assurance that it will ever generate taxable income. As a result, the Company has maintained a full valuation allowance against the entire balance of its net deferred tax assets since the date of inception. The valuation allowance has increased by $6.8&#160;million and $23.7&#160;million for the years ended December 31, 2020 and 2019, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, Immunic had available NOLs of approximately $75.7&#160;million in Germany and Australia. These NOLs do not expire.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal NOL carryforwards of $15.6&#160;million were generated prior to 2018 and expire over 20 years beginning in 2023. The $67.1&#160;million of post 2017 federal NOL carryforwards do not expire. Section 382 of the Internal Revenue Code of 1986, as amended, subject the future utilization of net operating losses, to an annual limitation in the event of certain ownership changes, as defined thereunder. The Company may have undergone such an ownership change and therefore may be limited in the amount of net operating losses available for utilization in the future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any uncertain tax positions for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the full valuation allowance that the Company has on its net deferred tax asset balance, there are no uncertain tax positions that would impact the effective tax rate if recognized.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2019 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div>Immunic, Inc. recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. There were no such interest or penalties for any of the years presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796383768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EIB Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">EIB Loan</a></td>
<td class="text">EIB LoanOn October 19, 2020, Immunic, Inc. (the &#8220;Company&#8221;) and Immunic AG, its wholly-owned subsidiary, entered into a Finance Contract (the &#8220;Loan Agreement&#8221;) with the European Investment Bank (&#8220;EIB&#8221;), pursuant to which EIB agreed to provide Immunic AG with a term loan in an aggregate amount of up to &#8364;24.5&#160;million to support the development of Immunic&#8217;s lead asset, IMU-838, in moderate coronavirus disease 2019 (&#8220;COVID-19&#8221;), to be made available to be drawn in three tranches, <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the second and third tranches subject to the completion of certain pre-defined milestones. The Company has the right to defer payment of principal and interest on the first and second tranches until five years after the respective borrowing dates, at which point such tranches must be repaid in full. The third tranche is repayable in annual installments commencing one year after its respective borrowing date and must be repaid in full no later than five years after such date. Any outstanding borrowings under the Loan Agreement will accrue interest as provided in the Loan Agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2021 until December 31, 2030, the Company and Immunic AG are also obligated to pay EIB a very low single digit percentage of their revenue, as set forth in the Loan Agreement, subject to certain conditions and limitations tied to the total amount drawn under the Loan Agreement and subject to a cap of &#8364;8.6&#160;million if only the first tranche is drawn and subject to a cap of &#8364;30&#160;million if the full loan amount is drawn. The Loan Agreement also includes certain prepayment penalties that may be triggered by certain prepayments prior to the maturity date.  As of December 31, 2020, nothing was drawn down under this loan agreement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will guarantee Immunic AG&#8217;s obligations to EIB pursuant to a Guarantee Agreement to be executed by the Company, Immunic AG and EIB (the &#8220;Guarantee Agreement&#8221;, and together with the Loan Agreement, the &#8220;Agreements&#8221;).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796428440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on April 15, 2020, the compensation committee of the Company&#8217;s Board independently reviewed and approved entering into an employment agreement with the Company&#8217;s current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Mr. Nash entered into the Executive Chairman Agreement.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Executive Chairman Agreement, Mr. Nash serves as the Executive Chairman of the Board as long as he is a member of the Board, or until termination of the Executive Chairman Agreement (as described below) or upon his earlier death, incapacity, removal, or resignation. Pursuant to the Executive Chairman Agreement, Mr. Nash is entitled to receive: (i) a monthly base salary of $25,417 (it being agreed that such fee is inclusive of any fees associated with Mr. Nash&#8217;s services as both a director of the Company and in the capacity of Executive Chairman), (ii) employee benefits including, health insurance, dental insurance, basic life and accidental death and dismemberment insurance, long and short term disability insurance and participation in the Company&#8217;s 401(k) Plan, and (iii) reimbursements for pre-approved reasonable business-related expenses incurred in good faith in the performance of the Mr. Nash&#8217;s duties for the Company. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Mr. Nash serves as Executive Chairman. The Executive Chairman Agreement contemplated a term that ended on October 15, 2020 and was subsequently extend.  On October 15, 2020, the Company and Mr. Nash entered into an addendum to the Executive Chairman Agreement, pursuant to which the term of the agreement was extended to April 15, 2021. The Company made a one-time award to Mr. Nash of 120,000 stock options, which vest monthly starting on November 15, 2020. All other terms of the employment agreement remained the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011797787720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Data (unaudited)</a></td>
<td class="text">Selected Quarterly Data (unaudited)<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share data):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Quarters Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,933)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share calculations will not necessarily equal the annual per share calculation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011798909176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, clinical trial expenses, share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. During the twelve months ended December&#160;31, 2020 and 2019, Immunic AG and Immunic Research GmbH&#8217;s operations were located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div>Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income. The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></div>Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets which range from three years to thirteen years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. </span></div>The Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then the Company would perform a quantitative test that compares the fair value to its carrying value to determine the amount of any impairment. Impairment testing for goodwill is done at the reporting unit level. The Company has determined that it operates in a single operating segment and has a single reporting unit.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, IMU-838, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on IMU-838, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  IMU-935 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in September 2019. IMU-856 is currently being tested in a Phase 1 clinical trial in healthy volunteers, which was initiated in August 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for diseases such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no more research and development reimbursements expected under this agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text">General and Administrative ExpensesGeneral and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. The short-term leases are deemed immaterial and have not been included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the </span></div>differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized. As of December&#160;31, 2020, and December&#160;31, 2019, the Company maintained a full valuation allowance against the balance of deferred tax assets.It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU 2017-04, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." This guidance eliminates Step 2 from the goodwill impairment test, instead requiring an entity to recognize a goodwill impairment charge for the amount by which the goodwill carrying amount exceeds the reporting unit&#8217;s fair value. The Company adopted this ASU, as required, in the quarter ended March 31, 2020 on a prospective basis. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement - Disclosure Framework&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-13.") ASU 2018-13 modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty, and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments must be applied retrospectively to all periods presented upon their effective date. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-18"). ASU 2018-18, clarifies that elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606. The Company adopted this ASU, as required, in the quarter ended March 31, 2020. The Company does not have any agreements that meet the definition of a collaboration arrangement at this time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011797759512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011797549944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting for the Transaction (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following summarizes the purchase price paid in the Transaction (amounts in thousands except share and per share amounts):<div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares owned by Vital stockholders (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fully-diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,186,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Vital common stock (3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The number of shares of 1,059,269 represents the historical 42,369,694 shares of Vital common stock outstanding immediately prior to the closing of the Transaction, adjusted for the Reverse Stock Split.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The number of RSUs of 127,500 represents the historical 5,100,000 Vital RSUs of which all have been issued to date to Vital former officers in 2019.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on the last reported sale price of Vital common stock on the Nasdaq Global Market on April 12, 2019, the closing of the Transaction, adjusted for the Reverse Stock Split.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and working cell banks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (&#8220;IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011797759512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ELAD Sales Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Estimated Fair Value of ELAD Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the ELAD Assets was included in the purchase accounting allocation as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:87.152%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies and working cell banks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In process research &amp; development (&#8220;IPR&amp;D&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011816607208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid Expense and Other Current Assets consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist  of (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796170376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Obligations</a></td>
<td class="text">Maturities of the operating lease obligation are as follows as of December&#160;31, 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011797755336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011797658360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance as of December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796271912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the number and weighted average exercise prices of, and movements in, stock options for the VSOP SB and VSOP during the year ended December 31, 2019.  There were no awards granted or outstanding after the awards settled in 2019:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.058%"><tr><td style="width:1.0%"/><td style="width:75.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unvested Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settled in cash during the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired during the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recognized during the year ended December 31, 2020. There was $508,000 of expense recognized in 2019 upon the vesting of the awards as a result of closing the Transaction.  There were no cancellations or modifications to the awards in 2019. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity since January 1, 2019 under the 2019 Plan:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,645&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,956&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,645&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,894,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,894,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,507&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used</a></td>
<td class="text">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.526%"><tr><td style="width:1.0%"/><td style="width:57.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying audited consolidated statements of operations is as follows (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year<br/> Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsVitalTherapiesInc.Member', window );">Employee Stock Options, Vital Therapies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity since January 1, 2019 under the plans assumed from Vital:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed in the Transaction with Vital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsVitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsVitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011798169656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Net Loss before Income Tax Based on Jurisdictions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income tax was subject to tax in the following jurisdictions for the following periods (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,681)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,258)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,017)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,759)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate reconciliation consists of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect of rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total deferred tax liability    </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796428440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summarized Quarterly Information</a></td>
<td class="text">Summarized quarterly data for 2020 and 2019 are as follows (in thousands, except per share data):<div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Quarters Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,933)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per share calculations will not necessarily equal the annual per share calculation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011803489240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements - Additional Details (Detail)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 12, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 11, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 11, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,928<span></span>
</td>
<td class="nump">$ 59,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,452<span></span>
</td>
<td class="nump">$ 29,369<span></span>
</td>
<td class="nump">$ 13,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_ImmunicAGMember', window );">Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of shares owned</a></td>
<td class="nump">88.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member', window );">Vital Therapies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of shares owned</a></td>
<td class="nump">11.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=imux_VitalTherapiesInc.Member', window );">Vital Therapies, Inc. | Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.17<span></span>
</td>
<td class="nump">17.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=imux_ImmunicAGMember', window );">Immunic AG | Vital Therapies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate consideration issuable (in shares)</a></td>
<td class="nump">8,927,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_BusinessCombinationSharesOwnedPriorToTransaction', window );">Shares owned prior to transaction (in shares)</a></td>
<td class="nump">1,059,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=imux_ImmunicAGMember', window );">Immunic AG | Restricted stock units | Vital Therapies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction', window );">RSUs owned prior to transaction (in shares)</a></td>
<td class="nump">127,500<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issues in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,197,742<span></span>
</td>
<td class="nump">2,197,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate consideration from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="nump">&#8364; 26.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Equity Interests Issued Or Issuable, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_BusinessCombinationSharesOwnedPriorToTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Shares Owned Prior To Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_BusinessCombinationSharesOwnedPriorToTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Awards Owned Prior To Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_ImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_ImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_VitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imux_VitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imux_VitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imux_ImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imux_ImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011799778920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_CashEquivalentsInvestmentsMaturityPeriod', window );">Cash equivalents, highly-liquid investments maturity (or less)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_LesseeOperatingLeasesNumberOfExistingLeases', window );">Number of existing operating leases | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_CashEquivalentsInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents Investments Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_CashEquivalentsInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LesseeOperatingLeasesNumberOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Of Existing Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LesseeOperatingLeasesNumberOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011802663960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,117,160<span></span>
</td>
<td class="nump">471,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011803493640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting for the Transaction - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 12, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 11, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,970<span></span>
</td>
<td class="nump">$ 32,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=imux_ImmunicInc.Member', window );">Immunic, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Incurred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges', window );">Incurred costs, non-cash charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_ImmunicAGMember', window );">Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of shares owned</a></td>
<td class="nump">88.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_ImmunicAGMember', window );">Immunic AG | Vital Therapies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member', window );">Vital Therapies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of shares owned</a></td>
<td class="nump">11.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member', window );">Vital Therapies, Inc. | Immunic, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 32,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed', window );">Outstanding shares to purchase (in shares) | shares</a></td>
<td class="nump">16,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Vital Therapies, Inc. | Immunic, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed', window );">Outstanding shares to purchase (in shares) | shares</a></td>
<td class="nump">127,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Equity Interests Issued Or Issuable, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed, Non-Cash Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Awards Assumed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imux_ImmunicInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imux_ImmunicInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_ImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_ImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=imux_VitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=imux_VitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_VitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011800309080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounting for the Transaction - Preliminary Estimate of Purchase Price (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 11, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares owned by Vital stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="nump">10,744,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member', window );">Vital Therapies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares owned by Vital stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,369,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member', window );">Vital Therapies, Inc. | Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares owned by Vital stockholders (in shares)</a></td>
<td class="nump">1,059,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares', window );">Total fully-diluted shares (in shares)</a></td>
<td class="nump">1,186,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Multiplied by the fair value per share of Vital common stock (in USD per share)</a></td>
<td class="nump">$ 33.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Estimated purchase price</a></td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Vital Therapies, Inc. | Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction', window );">RSUs owned prior to transaction (in shares)</a></td>
<td class="nump">127,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed', window );">Outstanding shares to purchase (in shares)</a></td>
<td class="nump">127,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Estimate Of Purchase Price, Fully Diluted Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Awards Owned Prior To Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Awards Assumed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_VitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imux_ImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imux_ImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011812499064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounting for the Transaction - Assets Acquired and Liabilities Assumed (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 32,970<span></span>
</td>
<td class="nump">$ 32,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member', window );">Vital Therapies, Inc. | Immunic, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks', window );">Supplies and working cell banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Clinical development equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment', window );">Other property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">In-process research and development (&#8220;IPR&amp;D&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable, Accrued Expenses, And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Property And Equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Supplies And Working Cell Banks</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_VitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=imux_ImmunicInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=imux_ImmunicInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011812499400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ELAD Sales Agreement - Additional Information (Detail) - ELAD-Related Assets - Disposal Group, Disposed of by Sale, Not Discontinued Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow', window );">Amount released from escrow</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Fair value of promissory note</a></td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=imux_ELADRelatedAssetsMember', window );">Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestFaceAmount', window );">Face amount of receivable</a></td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate', window );">Effective interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member', window );">Vital Therapies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration', window );">Cash consideration</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Cash Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Amount Released From Escrow</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Escrow Deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The principal amount of the receivable or note before consideration of the discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=imux_ELADRelatedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=imux_ELADRelatedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_VitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011800263384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ELAD Sales Agreement - Estimated Fair Value of ELAD Assets (Detail) - ELAD-Related Assets - Disposal Group, Disposed of by Sale, Not Discontinued Operations<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Estimated fair value of ELAD Assets</a></td>
<td class="nump">$ 2,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imux_ClinicalDevelopmentEquipmentMember', window );">Clinical development equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Estimated fair value of ELAD Assets</a></td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imux_SuppliesAndWorkingCellBanksMember', window );">Supplies and working cell banks</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Estimated fair value of ELAD Assets</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research &amp; development (&#8220;IPR&amp;D&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Estimated fair value of ELAD Assets</a></td>
<td class="nump">$ 764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=imux_ELADRelatedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=imux_ELADRelatedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imux_ClinicalDevelopmentEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imux_ClinicalDevelopmentEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=imux_SuppliesAndWorkingCellBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=imux_SuppliesAndWorkingCellBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011800230680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_PrepaidClinicalAndRelatedCostsCurrent', window );">Prepaid clinical and related costs</a></td>
<td class="nump">$ 3,416<span></span>
</td>
<td class="nump">$ 1,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ResearchAndDevelopmentTaxIncentiveCurrent', window );">Australian research and development tax incentive</a></td>
<td class="nump">1,348<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 6,293<span></span>
</td>
<td class="nump">$ 2,861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_PrepaidClinicalAndRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical And Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_PrepaidClinicalAndRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ResearchAndDevelopmentTaxIncentiveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Incentive, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ResearchAndDevelopmentTaxIncentiveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011800317000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ClinicalCostsPayableCurrent', window );">Clinical costs</a></td>
<td class="nump">$ 3,408<span></span>
</td>
<td class="nump">$ 1,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_LegalAndAuditCostsPayableCurrent', window );">Legal and audit costs</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 2,423<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ClinicalCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ClinicalCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LegalAndAuditCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal And Audit Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LegalAndAuditCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011800024808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_AccruedClinicalCostsCurrent', window );">Accrued clinical and related costs</a></td>
<td class="nump">$ 3,301<span></span>
</td>
<td class="nump">$ 2,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_AccruedLegalAndAuditCostsCurrent', window );">Accrued legal and audit costs</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 4,318<span></span>
</td>
<td class="nump">$ 3,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AccruedLegalAndAuditCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal And Audit Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AccruedLegalAndAuditCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011800285592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 1,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011800027832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
<th class="th"><div>Mar. 27, 2019</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Increase in operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_OperatingAndVariableLeasesCost', window );">Operating and variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales', window );">Asset purchase agreement, royalties as percent of aggregated net sales</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="nump">10,744,806<span></span>
</td>
<td class="nump">120,070<span></span>
</td>
<td class="nump">156,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_OperatingAndVariableLeasesCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Variable Leases, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_OperatingAndVariableLeasesCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011800052888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest portion</a></td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease obligation</a></td>
<td class="nump">$ 973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011802756520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - Money Market Funds - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 39,615<span></span>
</td>
<td class="nump">$ 4,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">39,615<span></span>
</td>
<td class="nump">4,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011799763096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) - Shelf Registration Statement (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders', window );">Maximum common stock shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement', window );">Maximum aggregate offering price under ATM agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Commission, percent of gross proceeds from sale of common stock</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2019EquityIssuancesMember', window );">July 2019 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement', window );">Maximum aggregate offering price under ATM agreement</a></td>
<td class="nump">$ 23,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_December2020EquityIssuancesMember', window );">December 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement', window );">Maximum aggregate offering price under ATM agreement</a></td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_AtTheMarketSalesAgreementMember', window );">At-The-Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">733,728<span></span>
</td>
<td class="nump">630,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance of stock (in USD per share)</a></td>
<td class="nump">$ 15.42<span></span>
</td>
<td class="nump">$ 8.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Underwriter commissions</a></td>
<td class="nump">$ 339,356<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Estimated offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price of Securities Under Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Of Common Stock That Can Be Issued Under At-The-Market Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_July2019EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_July2019EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_December2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_December2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011816432440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) - Registered Direct Offering (Details) - April 2020 Equity Issuances - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Cash fee, percent of gross proceeds</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issues in private placement transaction (in shares)</a></td>
<td class="nump">1,764,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="nump">$ 13,918<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Engagement Letter Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_April2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011816198760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) - Public Equity Offering (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Aug. 04, 2020</div></th>
<th class="th"><div>Jun. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember', window );">June 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issues in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Cash fee, percent of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,048<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember', window );">August 2020 Equity Issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issues in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 96,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock', window );">Exercisable period on additional issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_SaleOfStockNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Placement Agency Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Exercisable Period On Additional Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_SaleOfStockNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Additional Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_SaleOfStockNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_June2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=imux_August2020EquityIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011799916680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) - Stock Subscription Not Yet Issued (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 12, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 27, 2019 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">21,168,240<span></span>
</td>
<td class="nump">10,744,806<span></span>
</td>
<td class="nump">120,070<span></span>
</td>
<td class="nump">156,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011902726952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) - Common Stock (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 12, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued | $</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock cash dividends paid (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011723937752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) - Preferred Stock (Detail)<br> &#8364; / shares in Units, $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued (in shares) | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_ImmunicAGMember', window );">Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,200<span></span>
</td>
<td class="nump">&#8364; 31.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_ImmunicAGMember', window );">Immunic AG | Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,541<span></span>
</td>
<td class="nump">13,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=imux_ImmunicAGMember', window );">Immunic AG | Series A-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,456<span></span>
</td>
<td class="nump">299,456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_ImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_ImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imux_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imux_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=imux_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=imux_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011812462008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) - Stock Warrants (Detail)<br></strong></div></th>
<th class="th">
<div>Sep. 25, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="nump">$ 3,719.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding and exercisable (in shares) | shares</a></td>
<td class="nump">6,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011806887848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock and Preferred Stock (Converted into Common Stock) - Shares Reserved for Future Issuance (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,038,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,117,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">831,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsforFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsforFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011724095464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation Plans - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation cost will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_VSOPSBMember', window );">VSOP SB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans', window );">Shares authorized for grant under stock option programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital', window );">Percent of Company's total issued shared capital available for grant under stock option programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_VSOPAndVSOPSBMember', window );">VSOP And VSOP SB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.87<span></span>
</td>
<td class="nump">$ 12.87<span></span>
</td>
<td class="nump">$ 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember', window );">2019 Omnibus Equity Incentive Plan, Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent', window );">Additional shares authorized, percent</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_ExecutiveBonusAgreementMember', window );">Executive Bonus Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">&#8364; 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,336<span></span>
</td>
<td class="nump">460,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_IncentiveEmployeeStockOptionMember', window );">Incentive Employee Stock Option | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_NonStatutoryEmployeeStockOptionMember', window );">Non-Statutory Employee Stock Option | Minimum | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_NonStatutoryEmployeeStockOptionMember', window );">Non-Statutory Employee Stock Option | Maximum | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Vital Therapies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs to be granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation, Number Of Shares Authorized Under Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation, Shares Authorized Under Stock Option Plans, Percent Of Total Issued Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_VSOPSBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_VSOPSBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_VSOPAndVSOPSBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_VSOPAndVSOPSBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_ExecutiveBonusAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_ExecutiveBonusAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_IncentiveEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_IncentiveEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_NonStatutoryEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_NonStatutoryEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=imux_VitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=imux_VitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011794927688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation Plans - Summary of Stock Option Activity (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsVitalTherapiesInc.Member', window );">Employee Stock Options, Vital Therapies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">14,403<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease', window );">Assumed in the Transaction with Vital (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (shares)</a></td>
<td class="num">(14,403)<span></span>
</td>
<td class="num">(2,714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning balance (in USD per share)</a></td>
<td class="nump">$ 306.01<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Assumed in the Transaction with Vital (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in USD per share)</a></td>
<td class="nump">306.01<span></span>
</td>
<td class="nump">312.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending balance (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">306.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted-Average Exercise Price (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">306.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted-Average Exercise Price (usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 306.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual term (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , weighted-average remaining contractual term (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted-average remaining contractual term (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , aggregate intrinsic value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">456,645<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">744,406<span></span>
</td>
<td class="nump">456,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (shares)</a></td>
<td class="num">(83,891)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">1,117,160<span></span>
</td>
<td class="nump">456,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (shares)</a></td>
<td class="nump">1,117,160<span></span>
</td>
<td class="nump">456,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, (shares)</a></td>
<td class="nump">263,507<span></span>
</td>
<td class="nump">31,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning balance (in USD per share)</a></td>
<td class="nump">$ 12.57<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">13.24<span></span>
</td>
<td class="nump">12.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in USD per share)</a></td>
<td class="nump">13.32<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending balance (in USD per share)</a></td>
<td class="nump">12.96<span></span>
</td>
<td class="nump">12.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted-Average Exercise Price (usd per share)</a></td>
<td class="nump">12.96<span></span>
</td>
<td class="nump">12.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted-Average Exercise Price (usd per share)</a></td>
<td class="nump">$ 13.04<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual term (in years)</a></td>
<td class="text">9 years 2 months 26 days<span></span>
</td>
<td class="text">9 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , weighted-average remaining contractual term (in years)</a></td>
<td class="text">9 years 2 months 26 days<span></span>
</td>
<td class="text">9 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted-average remaining contractual term (in years)</a></td>
<td class="text">8 years 11 months 1 day<span></span>
</td>
<td class="text">9 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 2,894,754<span></span>
</td>
<td class="nump">$ 114,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , aggregate intrinsic value</a></td>
<td class="nump">2,894,754<span></span>
</td>
<td class="nump">114,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 661,952<span></span>
</td>
<td class="nump">$ 3,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=imux_VSOPAndVSOPSBMember', window );">VSOP And VSOP SB | Employee Stock Options, Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod', window );">Settled in cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning balance (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice', window );">Settled in cash in period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending balance (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period, Weighted-Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) of non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsVitalTherapiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsVitalTherapiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_VSOPAndVSOPSBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_VSOPAndVSOPSBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=imux_EmployeeStockOptionsImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011802483304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail) - 2019 Omnibus Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">88.50%<span></span>
</td>
<td class="nump">75.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=imux_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011802708360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,747<span></span>
</td>
<td class="nump">$ 6,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=imux_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="nump">8,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=imux_EmployeeMember', window );">Employee | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=imux_EmployeeMember', window );">Employee | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,016<span></span>
</td>
<td class="nump">$ 6,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=imux_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=imux_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011802700776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income tax</a></td>
<td class="num">$ (44,017)<span></span>
</td>
<td class="num">$ (44,759)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income tax</a></td>
<td class="num">(8,681)<span></span>
</td>
<td class="num">(20,258)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income tax</a></td>
<td class="num">(33,617)<span></span>
</td>
<td class="num">(23,674)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before income tax</a></td>
<td class="num">$ (1,719)<span></span>
</td>
<td class="num">$ (827)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_FederalMinistryOfFinanceGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_FederalMinistryOfFinanceGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=imux_ForeignExcludingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=imux_ForeignExcludingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011796412392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Rate Reconciliation (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax (net of federal benefit)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock options</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax effect of rate change</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.30%)<span></span>
</td>
<td class="num">(20.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011806512040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,369<span></span>
</td>
<td class="nump">$ 16,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Federal and state tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforwards</a></td>
<td class="nump">18,998<span></span>
</td>
<td class="nump">12,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">36,522<span></span>
</td>
<td class="nump">28,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_DeferredTaxAssetsAndLiabilitiesGross', window );">Net deferred tax assets</a></td>
<td class="nump">36,517<span></span>
</td>
<td class="nump">28,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(36,517)<span></span>
</td>
<td class="num">(28,355)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets, valuation allowance total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_DeferredTaxAssetsAndLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets and Liabilities, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_DeferredTaxAssetsAndLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011799918200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">75.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=imux_TaxYearsPriorTo2018Member', window );">Prior to 2018 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">15.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=imux_TaxYearsPost2017Member', window );">Post 2017 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 67.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=imux_TaxYearsPriorTo2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=imux_TaxYearsPriorTo2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=imux_TaxYearsPost2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=imux_TaxYearsPost2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011802518040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EIB Loan (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 19, 2020 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_LineOfCreditFacilityNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_LineOfCreditFacilityTranchePaymentDeferralTerm', window );">Tranche payment deferral term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | EIB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan, maximum borrowing capacity</a></td>
<td class="nump">&#8364; 24,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_LineOfCreditFacilityRevenueShareCapFirstTranche', window );">Term loan, revenue share cap, first tranche</a></td>
<td class="nump">8,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn', window );">Term loan, revenue share cap, full loan amount drawn</a></td>
<td class="nump">&#8364; 30,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LineOfCreditFacilityNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LineOfCreditFacilityNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LineOfCreditFacilityRevenueShareCapFirstTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Revenue Share Cap, First Tranche</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LineOfCreditFacilityRevenueShareCapFirstTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LineOfCreditFacilityRevenueShareCapFullyDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Revenue Share Cap, Fully Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LineOfCreditFacilityRevenueShareCapFullyDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_LineOfCreditFacilityTranchePaymentDeferralTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Tranche Payment Deferral, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_LineOfCreditFacilityTranchePaymentDeferralTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=imux_EuropeanInvestmentBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=imux_EuropeanInvestmentBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011797861704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - Board of Directors Chairman - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 15, 2020</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_imux_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_imux_SalaryCostsMonthlyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Salary Costs, Monthly Base Salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">imux_SalaryCostsMonthlyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>imux_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140011799894200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (unaudited) - Summarized Quarterly Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 14,190<span></span>
</td>
<td class="nump">$ 13,545<span></span>
</td>
<td class="nump">$ 12,222<span></span>
</td>
<td class="nump">$ 9,014<span></span>
</td>
<td class="nump">$ 8,186<span></span>
</td>
<td class="nump">$ 9,177<span></span>
</td>
<td class="nump">$ 15,007<span></span>
</td>
<td class="nump">$ 4,662<span></span>
</td>
<td class="nump">$ 48,971<span></span>
</td>
<td class="nump">$ 37,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,159)<span></span>
</td>
<td class="num">$ (12,913)<span></span>
</td>
<td class="num">$ (11,458)<span></span>
</td>
<td class="num">$ (8,487)<span></span>
</td>
<td class="num">$ (7,691)<span></span>
</td>
<td class="num">$ (8,215)<span></span>
</td>
<td class="num">$ (14,714)<span></span>
</td>
<td class="num">$ (4,313)<span></span>
</td>
<td class="num">$ (44,017)<span></span>
</td>
<td class="num">$ (34,933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (usd per share)</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (5.09)<span></span>
</td>
<td class="num">$ (2.81)<span></span>
</td>
<td class="num">$ (4.52)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MOU@56G&8%PYW_8"QJN2<XH(\!DIA3BOBJUH>.$#3VJ.5IE-<C(N @@!5&G2
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M<(1[ .XOE;*[$_>"\DO1Q7]02P,$%     @ B3I:4I.80H]'!0  #14  !@
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M?<F<R1-[UB;!>&H[K,B"3$P</$@#]FL# )0-\S-K%^)H2H0X'0.TK6#QI1,
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M^QX/@;;5];S0"G:!XP8@;"'=/;V'!I@?])PCZ]^VWDX7UN6UN*!I*_D6%6E
M'I2D-&%NG9;TZ1E>X4N:2<3( JA6IPN[ER@/I.5 \;PX0,VY@N-8<9G (9X(
M#8#G"\[5ZT"?R>J_!</_4$L#!!0    ( (DZ6E)W-R*PG0,  'D+   8
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULC99=CYLX%(;_BH5ZT4J=@ V!,$HB
M=6;VH])V=S33;J\]X22@ L[:3C+]]WML"$G!H+D)'SGG]?/:Q^8L3T+^4#F
M)J]56:N5EVN]O_5]M<FAXFHF]E#C/ULA*Z[Q4>Y\M9? ,YM4E3X+@MBO>%%[
MZZ5]]RC72W'095'#HR3J4%5<_KR#4IQ6'O7.+YZ*7:[-"W^]W/,=/(/^MG^4
M^.1W*EE10:T*41,)VY7WB=[>T\@DV(A_"SBIJWMBK+P(\<,\?,Y67F"(H(2-
M-A(<+T>XA[(T2LCQ7ROJ=6.:Q.O[L_KOUCR:>>$*[D7YO<ATOO(6'LE@RP^E
M?A*G/Z$U-#=Z&U$J^TM.36P2>61S4%I4;3(25$7=7/EK.Q%7"30>26!M NLG
MC(T0M@FA-=J065L/7//U4HH3D28:U<R-G1N;C6Z*VBSCLY;X;X%Y>GTO:B7*
M(N,:,O*L\8)KI!416_+/'B0W<ZW(#?GV_$#>O_M WI&B)E]S<5"\SM32U\A@
ME/Q-.]Y=,QX;&8\R\D74.E?DMSJ#[%<!'^$[!^SLX(Y-*C[ 9D9"^I&P@ 4.
MH/LWI]-T B?L)C2T>N&(7CMK]8[ *^XU!>IV0C7J5".K&HVH/H$"+C<YP5G'
M*CWB]MN;A7(M0*.46"6SBX_K<!&'R=(_7L_*,(JQ.65=U"^8\PYS/HGY!]3H
MOK24/,-R+90VLW$$%VBC%5\AT" ,HQZH(RJ:FY5V@<8=:#P)^E5HQ!2#M7)A
MQ@. :)$FM(<YC J3(!R9SZ3#3"8Q_Q)*D:T4U1D5-Z,+,1D,?N-B=(1-0"XZ
MR,5TQ>L<)!X+&U'!5*VGG5XZ:?ISK4&"TJVDRV\Z,#)?]+P.0VB0N(W2X')8
M!I-HUU8_DAJ<^Z_5Z!5,W.-S1-$T'5D*>G6<T[<4]A6G$Y$.$=-Y?^<YHEB0
MIB.([(+()A'_QN:DQ,)V@K'!L70310'MGUZNN#!*PW $[G)ZT_!-< 3W&U$Y
ME[C.V"84F^;D+<J#^5"^/ZCL$O'!Z:09QRSS!9'-%OT]Z8R+9O.Q2KA\,>CT
M)^.[[6 @N^%'/#IV0+ 8*FR<+#)^X ]::?2$IY_387&.=+N+AM4[C^-PP09U
M/HQ,$L98W*\C_ZJ)J4#N;&^GD/I0ZZ8;Z-YV_>,GVS7UWM^9OM(V1Q>9IBG]
MPN6NP':FA"U*!K,$ORVRZ?.:!RWVME5Z$1H;+WN;8V\,T@3@_ULA]/G!#-!U
MV^O_ 5!+ P04    " ").EI2K%F9KJ@"  #;!@  &    'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;(U574_;,!3]*U;$PR8!^4X I9%HV30DV!"%[6':@YO<
M-A&.W=EN"_]^UTZ:E2ZM]A)_Y)YSSSV.;[*-D"^J M#DM6%<C9Q*Z^65ZZJB
M@H:J<[$$CF_F0C94XU(N7+640$L+:I@;>%[B-K3F3I[9O0>99V*E6<WA01*U
M:AHJW\; Q&;D^,YVX[%>5-ILN'FVI N8@GY>/DA<N3U+63? 52TXD3 ?.=?^
MU20U\3;@>PT;M3,GII*9$"]F<5N.',\( @:%-@P4AS5,@#%#A#)^=YQ.G](
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M?[_G7)0OV??GZW\I._H/4$L#!!0    ( (DZ6E(@_Y#JP0(  &8(   8
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULI99K3]LP%(;_BA4A#:1!+FW3%J61
M: &-26@5'=MG-SE)+!R[V Z%?S_;2=,";334+_4E?M]S'J?V2;3FXDD6  J]
MEI3)B5,HM;IT79D44&)YP5? ]).,BQ(K/12Y*U<"<&I%)74#SPO=$A/FQ)&=
MFXLXXI6BA,%<(%F5)19O4Z!\/7%\9S/Q0/)"F0DWCE8XAP6HQ]5<Z)';NJ2D
M!"8)9TA -G&N_,N9'QB!7?&'P%KN])%!67+^9 9WZ<3Q3$9 (5'& NOF!69
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M[$ <6N0DAMQ9$ER<56VQ]HG*,\H(Z&P%IGWEOA/5IC09U;:W$X8A]6*SF_1
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MY@?60#WKEPBFW"]LJKG]H0=)J;0H:K')H*"\>I*7>B%V!&%\0!#5@NBCH'M
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M(:9O\4"0+CRG5=_0X0/?PR[G:?$>;1WHAOH ^OUS5\Z3T.Z/0^[@"G%4(YR
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M,RF:XC.IT:N@E;)B6N;JU8VNMU4\U4T^_6A.0FR@4'W"2!0PDC["20^D4I?
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MF<.'SFWIE^66K@-&TY\;\)BFQ1?@^Y4##"4?<('X4X//_P502P,$%     @
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M6$,?H)618STY"BWTE2SKDV>>7[?E^/'Z)GR\ZKO.T>%4W!FND#V1#I.C9*/
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M)UHQ32;8\L\P&.9$VP2RM)"Z=.UA+9K=ZZD.1]QV:NR[U2XC^K8L%S';.P^
M>^C3(!$_V @.(;0M]DFL54%\WY[)NN,B)NGK/1TED?,#: X!7:+-+.D@L3'%
M)K0'&ODQDF+L6X6MN^R'4SCAGLZ*^!\^]^5IU/O8!Q)8\2=-XFUT\_#=KWO:
M?36]#A\+]^+AD^M[:5<8Y6%*CJ7CX=EB$$(0;[RI^=/ATGAO2KY<*XPEE@3P
M/C<X [8WM$'W+?GJOU!+ P04    " ").EI22LG)7UH#  "?!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6RE56UOU#@0_BNC<$(@K3:;[+:T97>E
MOH! NDH5W'$?$!^<9+(Q=>S@<9KN_?H;.]E<$*4@^!([MN>99SS/>-:=L;=4
M(3JXKY6F350YUYS%,>45UH+FID'-.Z6QM7#\:W<Q-19%$8QJ%:>+Q7%<"ZFC
M[3JLW=CMVK1.28TW%JBM:V'W%ZA,MXF2Z+#P3NXJYQ?B[;H1.WR/[N_FQO)?
M/*(4LD9-TFBP6&ZB\^3L8N7/AP,?)'8TF8./)#/FUO^\+3;1PA-"A;GS"(*'
M.[Q$I3P0T_@R8$:C2V\XG1_07X?8.99,$%X:]8\L7+6)3B(HL!2M<N],]P:'
M>(X\7FX4A2]T_=GE*H*\)6?JP9@9U%+WH[@?[F%B<++XCD$Z&*2!=^\HL+P2
M3FS7UG1@_6E&\Y,0:K!F<E+[I+QWEG<EV[GM:R$M?!"JQ77L&,^OQOE@>]';
MIM^Q35*X-MI5!*]T@<77 #$3&=FD!S87Z:.(5YC/89G,(%VDBT?PEF-TRX"W
M_&%T<"4I5X9:BP0?SS-RE@7QZ1$?J]''*OA8_=(-/FKK*^Z,&I'C)N*2(K1W
M&$U)_U4AE$9QY4B]@])OW(6-2J(5-J_VX$2F$(*U=B!U7Z=!\!D7(:#(*Q;,
M9V,A%PYWQN[!E. 8^=+4C=#[IT].TN3%2X)2:J%S*10((G0$0A>@I,BDDD[R
MO=4H_ 46(-R4C/?%!9JWUGJ:7"22X)G4[,2TQ"#T_ PF45WW,+4GS$B<=*PS
MM&/BIV?_Q#M4D QC.HQ+..\9LOYPS^'96WZ_RI9=P1^P/)T=)T?320@Q?3F9
M_32=Y/1WZ:QFJ]-D,GY+AM-L$3K_T098F9I*M 09N@Y1'[S.1K><S(/G(55%
M&^[>I[5!*PU['C2!Q1SX 7LPX_4W?&?059(5(YB+U+EJ"Y]NE@+D;,O'^9)8
M/KF@*L@C3/!+*UD*O$=>#-Y3;C09)0N67,&*4"PLA/!,S5@J0LE_>7W'36-0
MF>$PZ&NO+"#)]#D*KVMVC_ ,[[D;$3Y_T TY'NJ>10G<MVPH!)K#0V4>3Q[-
M&NTNM 9BQ%:[_OT<5\?N<]X_NO\?[UO7M; ['XG"DDT7\Q='$=B^'?0_SC3A
M"<Z,XP<]3"ONH&C] =XOC7&''^]@[,G;_P!02P,$%     @ B3I:4F14F +2
M#   !"L  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL[5IKD]NV%?TK
M&#5-US.T5A3UV/5K9NW$B3-.O.-UDNET^@$B(0DU"=  N?+FU_=< *1(O;QQ
MTDPZ[9==D00N[NN<>P'RR4:;]W8M1,4^%KFR3P?KJBH?G9_;="T*;H>Z% I/
MEMH4O,*E69W;T@B>N4E%?CX>C6;G!9=J\.R)NW=MGCW1=95+):X-LW51<'/W
M7.1Z\W00#YH;;^5J7=&-\V=/2KX2-Z+ZL;PVN#IOI62R$,I*K9@1RZ>#J_C1
M\PF-=P-^DF)C.[\96;+0^CU=O,J>#D:DD,A%6I$$CG^WXH7(<Q($-3X$F8-V
M29K8_=U(?^ELART+;L4+G?\LLVK]=' Q8)E8\CJOWNK-MR+8,R5YJ<ZM^\LV
M?NPL&;"TMI4NPF1H4$CE__./P0^="1>C(Q/&8<+8Z>T7<EI^Q2O^[(G1&V9H
M-*31#V>JFPWEI**@W%0&3R7F5<]>Z** <VXJG;YG7&7L&EX1QH@LW#M[H=6M
M,!5N2%5IUIWPX,EY!1U(TGD:UGONUQL?62\>L^^UJM:6?:TRD?4%G$/YUH)Q
M8\'S\4F)7XETR)(X8N/1>'1"7M)Z)''RDB/ROOY0R^J._>-J82N#I/GG"9F3
M5N;$R9S\85X^N1XA^9$M>2J>#@!5*\RM&/Q&)=C-6N1+]E:L)/G%0>JFXI4
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M*N9\X\JQ5[NU$"P+I61&O&0U;55L<Y+D/A_H'@KM3:8#@H40RJL@>9[?=3<
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M)%_*?,._!;K.RS)?\\>5T8@%M #OESDR6/^%#JA_'/;\_P%02P,$%     @
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MI9=<_21:.9@=RBNY DD3_$$3&)1:R#*4J26'[5B9"CG#OB;=B+K/'S;O:/L
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M.6_"M[T'\O"%]%?I4!H;4:HECH[CV60D7/CJ&!Z\K?E+W\)Z;RM>KI6$^D2
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M &.Z'GC]EG3VV8MG=\N>E']*:9@H$3,61< OSC3TJ.)JR>ZK?%I';1T0)T(
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MG@97$%OZ4D#+"G2_,\9/&W8P?WML_P)02P,$%     @ B3I:4N^\+[#X%P
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MB8023+'K>0_ $B+>O7:4I4T*'XW;PLQ;\8F$-&$ !7GY;;$ZEWW1[8AZ%'
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M_7*RH/P99]I @K/<DY$][!0C*/; 8GEG$R]-WAER7$YM5EMKJC*,O=L^NI?
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MKLG)^6D$IALDW<;I)C1OKAV-@K"L:/:B\09T7VIZK'[C"89IOG@&4$L#!!0
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MM :]"'1X2X2%596?WRME\37@/PM\?C'M!/!\K90]+)R!XX-N^AU02P,$%
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M7J4(&Z> .S1<%!I>WO-M@?K5U#>4PWKZ:8NW;/#8!;R0P7M9F5S#ZRK#[%L
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M:*GF3=),C*S=.R"3AEX5;KBB9QPJ*T#["RG-?F()VH?A_!]02P,$%     @
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M)/!8P]&2(^#A;9VK8YE?$3P&Z 93PN.FDH],URWN"?FQET#2F-PA&KH=PG&
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ME\.@"S0+<M\"WL!*0^A=\%GXAS?R/,6JF:A[X<^&P3M2""*517$U&(-MC[Z
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M@3M+(7.J<2I7KBHET-2*<NX&GA>Y.66%,QK8M9D<#42E.2M@)HFJ\IS*OP_
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MN@',<<$*81_4YA.6!;5<O%0)XW]A4^Z- D@+8U56BBF#C,OMD[V61NP(DOB
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M3]N+>"SS_VAK^KH=%&52\<2 @4'"TN*7O)A$U  X; %X!N#M X(6@&\ _K&
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M..#GCVM*8&AT!_B^Y%SM7K2#\J)I_ ]02P,$%     @ B3I:4J5!=?SY @
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M8 1IJH1D&;^,IE5/J8C-]T?UJ5Z[7,L"<QC1]!M9BO7 ZEEH"0DN4W%+MQ_
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M8BT#A860+*W H""E6?F+GZH\- "N?P#@5 "G+\"M &X+X-@' *,*,&H#1@<
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M+KN(H\L&IQQ8M?)-Q4Q9;%'\ZQ*;0M!N Z[/E;+;@>M3ZC9S]!=02P,$%
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MN5M??(UV__+"("O5MXC\)/N+=H6L,4*+;2*BH!@L$01>F/^Z+X4C]@80JV,
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M:7NV6] 4!"U0!$3[$5#O7@YM<@=AU#+L.N*F',6.Q3H *YZATX]JZ%#%"71
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MR/\_19%XNTDG* _P7_X'4$L#!!0    ( (DZ6E+OO1JG) ,  (H(   9
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;)5676_B.A#]*Z-(*^U*M^0#*.T*
MD("V]U;:WJ)6W7U8W0>3#&#5L5/;E.;?W[$3LG05HNX+V,Z<XSDSDYF,]TH_
MFRVBA;=<2#,)MM867\/0I%O,F>FI B4]62N=,TM;O0E-H9%E'I2+,(FB\S!G
M7 ;3L3];ZNE8[:S@$I<:S"[/F2[G*-1^$L3!X>"!;[;6'833<<$V^(CVJ5AJ
MVH4-2\9SE(8K"1K7DV 6?UV,G+TW^,YQ;X[6X)2LE'IVF]ML$D3.(1286L?
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M6_I80.T,Z/E:*7O8N N:SX_I_U!+ P04    " ").EI2GJ$]M1@#  "@"@
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MG:X]CPZ>+R(GXPKB/AJ$GU$41$&#0\MWP\.)PYU!'<B!Y1MT!A*MB(PIEX4
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M!FD,\/U2"/TR,*U8VWK/_P!02P,$%     @ B3I:4C(>JE_C @  ' D  !D
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M!Q?(_&^O<XHYEHBVH77MG_-5?C6Q^T/^'\S5:V6?^"#D<'+^C*X!.7?(\25
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ B3I:4J*"Y(P$!0  F"P
M  \   !X;"]W;W)K8F]O:RYX;6S%FEM/XS@4@/^*U2?V@6USY2**!!1VD=!,
MER)>1R9Q6PO'KFP'AOGU:Z=3.&';HWTY]*F-TSI??/N.+V>OQCX_&?/,?C9*
MN_%@Z?WJ=#ATU5(TW/UI5D*'.W-C&^[#I5T,W<H*7KNE$+Y1PW0T*H<-EWIP
M?K;):VJ'\,)X47EI=$B,"8]2O+J/^_&2O4@GGZ22_FT\Z+XK,6"-U+*1OT0]
M'HP&S"W-Z]_&RE]&>ZYFE35*C0?)^L:CL%Y6_TF>1<@'_N2Z%,^?[GD &0_*
M4<AP+JWSW2^Z_'E@?!'AQ^NKUIL;J;RP$^[%7]:T*ZD7,9OP%D/P&ETY;#[7
MA7AJ_T\QFOE<5F)BJK81VJ_+T0H5 ;5;RI4;,,T;,1Y<F1=AV90O1'RI\)3;
M>OV"/I"!XK*G,MRPMW7'2,FCG5&R#D^OV2577%>"=>7H &"* *9[ V0'4PX@
M,P0R^T+(682(?W#,S-GWE;  ,D<@\[U!7IEF!2 +!++8&^3,FPI E@ADN4?(
M'RF /$(@C_97W=PM >0Q GF\1\A>29X@D">TD!/A*BM7,3V"7;9.:N$<XSJ.
M2'"<3$;82#ZBQ9RU3</M6]<*Y4++\#>N/;NH*M-J+R$F*AQBXVQX](*%_S._
M%.S!<NUX%U9 2LPZ";%VKN\N)FS&E7#L8F%%URPA&R:;A-@V/0NRB?!<JEXK
MQ"23D%NF::1?]^+804(/CW4M="5%#Q*33$)LF1LN+7ODJNU%89A1$G*E-$T8
M7J+CGKMRFUHQ%]9VPV+/>PGFE(18*FN^&"Z(T&.[$7$:&F.O8C&=),0^N=65
M:<* PG_V&QMFCX18']>WE^S.<#BTI9@G4F)/W,?$T*ZFW/HW./;V(GY,$2FQ
M(F9"A4EF0/RG#8S"JC<6)FZ<';2:MS4T68K.3(@=@0JW%[RDF"Y28EW@F!G$
MQ,21$HL#CPL8Q,34D1*K8UM@P X>>*!P?T!(S"8IL4VV1@A;*3&9I.0S%"14
M8 <0$W-*2NR4CV!A:PEB:DF)U8)&#;T1*,.,DU'/3'9$#;_+$V)BVLF(M0.#
MAVU5G6&RR:AE@SFQ7]7H0ABQ;-"Y<A\3DTU&+!O<B3G$Q&23$<L&QRP@)J:;
MC%@WJ+K[E8[Y)B/V#8X) Z$,\TU&[!L<L]<V,?=DU-.:;8'0(;NH:_EI(2?'
MW),3NV<'YK7S,F0&W9-C[LF)W;,]8CMDLY!WW2J(B5DH)[80BMGKZ3EFH7P?
M*V3OF+"GY^B&#+&%<$S8TW/,0CGYG@P6IQ]"3,Q"^1<LH>W$[+=-S$(YL87
M=.*]>XMH^!NI0VN F)B%<O*=&6QJT>M"F(7RO<Z 8!<J, L5Q!;",6$@5V 6
M*LA/ V"8)<3$+%20GPG ,(\@)F:A@OQ4 (9Y##$Q"Q5?L&.S&_,$8J(' [[
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( (DZ6E+.( U5[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( (DZ6E*97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ B3I:
M4NGK?YYE!@  -1H  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( (DZ6E*3F$*/1P4   T5   8
M      " @:@.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" ").EI2/718+4(#   B#   &               @($E%   >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ B3I:4G<W(K"= P  >0L  !@
M             ("!G1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( (DZ6E*L69FNJ (  -L&   8              " @7 ;  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " ").EI2KZNZ8(,'  !>
M)@  &               @(%.'@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ B3I:4B#_D.K! @  9@@  !@              ("!!R8
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( (DZ6E(J8A21
MOP<  ,DC   8              " @?XH  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " ").EI23+"\J;P"  !<"   &
M@('S,   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ B3I:
M4D/<6&_3#0  GR0  !D              ("!Y3,  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " ").EI2CF6#MG,:  !V4   &0
M        @('O00  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( (DZ6E)8)8E._P4  "$/   9              " @9E<  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ B3I:4AVJ]')P!0  50T
M !D              ("!SV(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " ").EI2LM^5KFL#   P"   &0              @(%V:
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( (DZ6E(\V8BZ
MA D  %<6   9              " @1AL  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ B3I:4DK)R5]: P  GP<  !D
M ("!TW4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " ")
M.EI29%28 M(,   $*P  &0              @(%D>0  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( (DZ6E(^;N*2N1$  "@V   9
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M970R,BYX;6Q02P$"% ,4    " ").EI2[[POL/@7  #62@  &0
M    @($,L   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M (DZ6E)6+)@JO (  -D%   9              " @3O(  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ B3I:4G I$:F'!   W D  !D
M             ("!+LL  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " ").EI2*$RZP;X"  "B!0  &0              @('LSP  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( (DZ6E)%'*!GI ,
M %@)   9              " @>'2  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ B3I:4H=X0K^B @  J@4  !D              ("!
MO-8  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ").EI2
M'H7)8=4"  "(!@  &0              @(&5V0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( (DZ6E+-J!2VO@(  !H&   9
M      " @:'<  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ B3I:4GPA&]BR!@  0A4  !D              ("!EM\  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " ").EI2O"1=OD4$   D"@
M&0              @(%_Y@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( (DZ6E*Y)^CO?P,  *L'   9              " @?OJ  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ B3I:4H?#QB2W
M!   T!(  !D              ("!L>X  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " ").EI2!GRC5(D#  #I"P  &0
M@(&?\P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (DZ
M6E)O(!WBQP(  &L&   9              " @5_W  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ B3I:4G6GS@/1 P  M@\  !D
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M=#0Q+GAM;%!+ 0(4 Q0    ( (DZ6E*NN?7^W (  %8'   9
M  " @1L- 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MB3I:4N0HONB, @  <@8  !D              ("!+A ! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " ").EI2] 0RYZX"   S!P  &0
M            @('Q$@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( (DZ6E(UEDH); (  -@%   9              " @=85 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ B3I:4H&/>$RH P
MF L  !D              ("!>1@! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " ").EI2/Y"H"LD"  #6!P  &0              @(%8
M' $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (DZ6E(;
M8 CPI@(  $D(   9              " @5@? 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ B3I:4M>B47*A!   =!(  !D
M     ("!-2(! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (DZ6E*&>-WVDP,  $T.   9              "
M@> T 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ B3I:
M4G>VFIM2 @  ; 4  !D              ("!JC@! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " ").EI28I8]+>8"  !R"@  &0
M        @($S.P$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( (DZ6E),@!W>,0<  $PE   9              " @5 ^ 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ B3I:4NGD*'[O!P  S"\
M !D              ("!N$4! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " ").EI2[[T:IR0#  "*"   &0              @('>30$
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( (DZ6E*>H3VU
M& ,  * *   9              " @3E1 0!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ B3I:4OS$4J'R @  @PD  !D
M ("!B%0! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " ")
M.EI2]BJ9SQ0#  "["@  &0              @(&Q5P$ >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( (DZ6E)SWNRA8 ,  (8+   9
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M970V-RYX;6Q02P$"% ,4    " ").EI2.("O*8<"  ! #P  #0
M    @ 'Z:@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (DZ6E*7BKL<P
M !,"   +              "  :QM 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M (DZ6E*B@N2,! 4  )@L   /              "  95N 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " ").EI2R%S!4B "  #0)P  &@
M@ '&<P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ")
M.EI2XB$R0O$!   9)P  $P              @ $>=@$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     2P!+ (04  ! > $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>196</ContextCount>
  <ElementCount>376</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>66</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1008009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Basis of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements</Role>
      <ShortName>Description of Business and Basis of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Accounting for the Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/AccountingfortheTransaction</Role>
      <ShortName>Accounting for the Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - ELAD Sales Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ELADSalesAgreement</Role>
      <ShortName>ELAD Sales Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - Stock Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockCompensationPlans</Role>
      <ShortName>Stock Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2146110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152111 - Disclosure - EIB Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/EIBLoan</Role>
      <ShortName>EIB Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2154112 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2156113 - Disclosure - Selected Quarterly Data (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SelectedQuarterlyDataunaudited</Role>
      <ShortName>Selected Quarterly Data (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://imux.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Accounting for the Transaction (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/AccountingfortheTransactionTables</Role>
      <ShortName>Accounting for the Transaction (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/AccountingfortheTransaction</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - ELAD Sales Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ELADSalesAgreementTables</Role>
      <ShortName>ELAD Sales Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/ELADSalesAgreement</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/BalanceSheetDetails</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/CommitmentsandContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/FairValue</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Stock Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockCompensationPlansTables</Role>
      <ShortName>Stock Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/StockCompensationPlans</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2347309 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2357310 - Disclosure - Selected Quarterly Data (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SelectedQuarterlyDataunauditedTables</Role>
      <ShortName>Selected Quarterly Data (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://imux.com/role/SelectedQuarterlyDataunaudited</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business and Basis of Financial Statements - Additional Details (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail</Role>
      <ShortName>Description of Business and Basis of Financial Statements - Additional Details (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Accounting for the Transaction - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail</Role>
      <ShortName>Accounting for the Transaction - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Accounting for the Transaction - Preliminary Estimate of Purchase Price (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail</Role>
      <ShortName>Accounting for the Transaction - Preliminary Estimate of Purchase Price (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Accounting for the Transaction - Assets Acquired and Liabilities Assumed (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail</Role>
      <ShortName>Accounting for the Transaction - Assets Acquired and Liabilities Assumed (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - ELAD Sales Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail</Role>
      <ShortName>ELAD Sales Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - ELAD Sales Agreement - Estimated Fair Value of ELAD Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail</Role>
      <ShortName>ELAD Sales Agreement - Estimated Fair Value of ELAD Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Shelf Registration Statement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) - Shelf Registration Statement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Registered Direct Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) - Registered Direct Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Public Equity Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) - Public Equity Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Stock Subscription Not Yet Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) - Stock Subscription Not Yet Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) - Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Preferred Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) - Preferred Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Stock Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) - Stock Warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Shares Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail</Role>
      <ShortName>Common Stock and Preferred Stock (Converted into Common Stock) - Shares Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Stock Compensation Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockCompensationPlansAdditionalInformationDetail</Role>
      <ShortName>Stock Compensation Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Stock Compensation Plans - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail</Role>
      <ShortName>Stock Compensation Plans - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Stock Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail</Role>
      <ShortName>Stock Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Stock Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail</Role>
      <ShortName>Stock Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail</Role>
      <ShortName>Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - EIB Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/EIBLoanDetails</Role>
      <ShortName>EIB Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/EIBLoan</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="imux-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Selected Quarterly Data (unaudited) - Summarized Quarterly Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail</Role>
      <ShortName>Selected Quarterly Data (unaudited) - Summarized Quarterly Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://imux.com/role/SelectedQuarterlyDataunauditedTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="imux-20201231.htm">imux-20201231.htm</File>
    <File>exhibit231.htm</File>
    <File>exhibit42.htm</File>
    <File>imux-123120xexhibit211.htm</File>
    <File>imux-123120xexhibit311.htm</File>
    <File>imux-123120xexhibit312.htm</File>
    <File>imux-123120xexhibit321.htm</File>
    <File>imux-123120xexhibit322.htm</File>
    <File>imux-20201231.xsd</File>
    <File>imux-20201231_cal.xml</File>
    <File>imux-20201231_def.xml</File>
    <File>imux-20201231_lab.xml</File>
    <File>imux-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>imux-20201231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "imux-20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 196,
   "dts": {
    "calculationLink": {
     "local": [
      "imux-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "imux-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "imux-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "imux-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imux-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "imux-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 493,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 7
   },
   "keyCustom": 49,
   "keyStandard": 327,
   "memberCustom": 35,
   "memberStandard": 29,
   "nsprefix": "imux",
   "nsuri": "http://imux.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://imux.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Basis of Financial Statements",
     "role": "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements",
     "shortName": "Description of Business and Basis of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Accounting for the Transaction",
     "role": "http://imux.com/role/AccountingfortheTransaction",
     "shortName": "Accounting for the Transaction",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - ELAD Sales Agreement",
     "role": "http://imux.com/role/ELADSalesAgreement",
     "shortName": "ELAD Sales Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Balance Sheet Details",
     "role": "http://imux.com/role/BalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Commitments and Contingencies",
     "role": "http://imux.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - Fair Value",
     "role": "http://imux.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - Stock Compensation Plans",
     "role": "http://imux.com/role/StockCompensationPlans",
     "shortName": "Stock Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146110 - Disclosure - Income Taxes",
     "role": "http://imux.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://imux.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152111 - Disclosure - EIB Loan",
     "role": "http://imux.com/role/EIBLoan",
     "shortName": "EIB Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154112 - Disclosure - Related Party Transactions",
     "role": "http://imux.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156113 - Disclosure - Selected Quarterly Data (unaudited)",
     "role": "http://imux.com/role/SelectedQuarterlyDataunaudited",
     "shortName": "Selected Quarterly Data (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Accounting for the Transaction (Tables)",
     "role": "http://imux.com/role/AccountingfortheTransactionTables",
     "shortName": "Accounting for the Transaction (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - ELAD Sales Agreement (Tables)",
     "role": "http://imux.com/role/ELADSalesAgreementTables",
     "shortName": "ELAD Sales Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://imux.com/role/BalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://imux.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Fair Value (Tables)",
     "role": "http://imux.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) (Tables)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Stock Compensation Plans (Tables)",
     "role": "http://imux.com/role/StockCompensationPlansTables",
     "shortName": "Stock Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347309 - Disclosure - Income Taxes (Tables)",
     "role": "http://imux.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357310 - Disclosure - Selected Quarterly Data (unaudited) (Tables)",
     "role": "http://imux.com/role/SelectedQuarterlyDataunauditedTables",
     "shortName": "Selected Quarterly Data (unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business and Basis of Financial Statements - Additional Details (Detail)",
     "role": "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail",
     "shortName": "Description of Business and Basis of Financial Statements - Additional Details (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i3268a88a2d6d4e30b39a112e210ac828_D20190412-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imux:CashEquivalentsInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "imux:CashEquivalentsInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ie37f05a546ec4332b17b507cececa315_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)",
     "role": "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ie37f05a546ec4332b17b507cececa315_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Accounting for the Transaction - Additional Information (Detail)",
     "role": "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
     "shortName": "Accounting for the Transaction - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i19a1cf43d9744216bb5785e547d4a706_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Accounting for the Transaction - Preliminary Estimate of Purchase Price (Detail)",
     "role": "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
     "shortName": "Accounting for the Transaction - Preliminary Estimate of Purchase Price (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i25a3ae5995884982bf7fb0499c7d2af8_I20190411",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Accounting for the Transaction - Assets Acquired and Liabilities Assumed (Detail)",
     "role": "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
     "shortName": "Accounting for the Transaction - Assets Acquired and Liabilities Assumed (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ie48d0609d585480ab6c4bfe322a0961d_I20190412",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://imux.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ib1424157daa84861a0f78d13c01de311_I20190331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - ELAD Sales Agreement - Additional Information (Detail)",
     "role": "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
     "shortName": "ELAD Sales Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ib1424157daa84861a0f78d13c01de311_I20190331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i5086e5f37b694c38bf5cab8772addc83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - ELAD Sales Agreement - Estimated Fair Value of ELAD Assets (Detail)",
     "role": "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail",
     "shortName": "ELAD Sales Agreement - Estimated Fair Value of ELAD Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i5086e5f37b694c38bf5cab8772addc83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "role": "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail",
     "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "role": "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "role": "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "role": "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "imux:IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Detail)",
     "role": "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail",
     "shortName": "Commitments and Contingencies - Future Minimum Annual Obligations Under All Non-Cancellable Operating Lease Commitments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ie337d38b905741b0be8509a5988751e0_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ie337d38b905741b0be8509a5988751e0_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ie581a8ba756a444ba46878adb72aeb7f_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Shelf Registration Statement (Detail)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) - Shelf Registration Statement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ie581a8ba756a444ba46878adb72aeb7f_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "imux:MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "imux:EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Registered Direct Offering (Details)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) - Registered Direct Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i8c33807a7afd46868d0752d5c12ed414_D20200423-20200423",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "imux:EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Public Equity Offering (Details)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) - Public Equity Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i79fdb57b7ec04328a6d934397d2118cf_D20200610-20200610",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Stock Subscription Not Yet Issued (Details)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) - Stock Subscription Not Yet Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i5a7d12cd12ee4917abc990f2310687c0_I20190327",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Common Stock (Detail)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) - Common Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareCashPaid",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Preferred Stock (Detail)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) - Preferred Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i4c982f0f472740879b53dcb38a14a979_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i8a2c83765c344137b31b8874c897fac3_I20190925",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Stock Warrants (Detail)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) - Stock Warrants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i8a2c83765c344137b31b8874c897fac3_I20190925",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - Common Stock and Preferred Stock (Converted into Common Stock) - Shares Reserved for Future Issuance (Detail)",
     "role": "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
     "shortName": "Common Stock and Preferred Stock (Converted into Common Stock) - Shares Reserved for Future Issuance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "imux:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Stock Compensation Plans - Additional Information (Detail)",
     "role": "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
     "shortName": "Stock Compensation Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ic92c1bfcfde34cb6bb090f5450ff896b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Stock Compensation Plans - Summary of Stock Option Activity (Detail)",
     "role": "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail",
     "shortName": "Stock Compensation Plans - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i9d0f6cb2694343c6b174f7126d1b497c_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i630a7b979f974930b0bba2578eadd634_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Stock Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "role": "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
     "shortName": "Stock Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i630a7b979f974930b0bba2578eadd634_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i6865d74fb3c44e108442faced8021edf_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i6865d74fb3c44e108442faced8021edf_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Stock Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Detail)",
     "role": "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail",
     "shortName": "Stock Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "ic803cd5d0c184b89902cb243dfeb5916_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Detail)",
     "role": "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail",
     "shortName": "Income Taxes - Net Loss before Income Tax Based on Jurisdictions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Detail)",
     "role": "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail",
     "shortName": "Income Taxes - Income Tax Rate Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Detail)",
     "role": "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iec7edf46a34f43399671610813b08a6d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://imux.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "id3797128a5a3499face40e421c2bb72f_I20201019",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "imux:LineOfCreditFacilityNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - EIB Loan (Details)",
     "role": "http://imux.com/role/EIBLoanDetails",
     "shortName": "EIB Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "id3797128a5a3499face40e421c2bb72f_I20201019",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "imux:LineOfCreditFacilityNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranche",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i04d94aba3d11445ea650849b72cf2899_D20200417-20200417",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "imux:SalaryCostsMonthlyBaseSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i04d94aba3d11445ea650849b72cf2899_D20200417-20200417",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "imux:SalaryCostsMonthlyBaseSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Selected Quarterly Data (unaudited) - Summarized Quarterly Information (Detail)",
     "role": "http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail",
     "shortName": "Selected Quarterly Data (unaudited) - Summarized Quarterly Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i912471f54a6f477ba3fb8f7000a67e94_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i915c7c67b28a433fb898ee3efd75d7a1_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://imux.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "iaa38d193c88845d7a0895d6237dc7547_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i3e803724dcf84ceba79eba0078a118c9_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imux-20201231.htm",
      "contextRef": "i3e803724dcf84ceba79eba0078a118c9_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 66,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail",
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail",
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://imux.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "imux_A2017InducementEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Inducement Equity Incentive Plan [Member]",
        "label": "2017 Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2017 Inducement Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017InducementEquityIncentivePlanMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_A2019OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Omnibus Equity Incentive Plan [Member]",
        "label": "2019 Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "A2019OmnibusEquityIncentivePlanMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_A4SCSettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4SC Settlement Agreement [Member]",
        "label": "4SC Settlement Agreement [Member]",
        "terseLabel": "4SC Settlement Agreement"
       }
      }
     },
     "localname": "A4SCSettlementAgreementMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_AccruedClinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Costs, Current",
        "label": "Accrued Clinical Costs, Current",
        "terseLabel": "Accrued clinical and related costs"
       }
      }
     },
     "localname": "AccruedClinicalCostsCurrent",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_AccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Compensation, Current",
        "label": "Accrued Compensation, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationCurrent",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_AccruedLegalAndAuditCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal And Audit Costs, Current",
        "label": "Accrued Legal And Audit Costs, Current",
        "terseLabel": "Accrued legal and audit costs"
       }
      }
     },
     "localname": "AccruedLegalAndAuditCostsCurrent",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_April2020EquityIssuancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April 2020 Equity Issuances",
        "label": "April 2020 Equity Issuances [Member]",
        "terseLabel": "April 2020 Equity Issuances"
       }
      }
     },
     "localname": "April2020EquityIssuancesMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales",
        "label": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales",
        "terseLabel": "Asset purchase agreement, royalties as percent of aggregated net sales"
       }
      }
     },
     "localname": "AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Sales Agreement [Member]",
        "label": "At-The-Market Sales Agreement [Member]",
        "terseLabel": "At-The-Market Sales Agreement"
       }
      }
     },
     "localname": "AtTheMarketSalesAgreementMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_August2020EquityIssuancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 2020 Equity Issuances",
        "label": "August 2020 Equity Issuances [Member]",
        "terseLabel": "August 2020 Equity Issuances"
       }
      }
     },
     "localname": "August2020EquityIssuancesMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Equity Interests Issued Or Issuable, Exchange Ratio",
        "label": "Business Acquisition, Equity Interests Issued Or Issuable, Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableExchangeRatio",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Estimate Of Purchase Price, Fully Diluted Shares",
        "label": "Business Combination, Estimate Of Purchase Price, Fully Diluted Shares",
        "totalLabel": "Total fully-diluted shares (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable, Accrued Expenses, And Other Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable, Accrued Expenses, And Other Liabilities",
        "negatedLabel": "Accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Property And Equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Property And Equipment",
        "terseLabel": "Other property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsOtherPropertyAndEquipment",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Supplies And Working Cell Banks",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Supplies And Working Cell Banks",
        "terseLabel": "Supplies and working cell banks"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsSuppliesAndWorkingCellBanks",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed, Non-Cash Charges",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed, Non-Cash Charges",
        "terseLabel": "Incurred costs, non-cash charges"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_BusinessCombinationSharesOwnedPriorToTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Shares Owned Prior To Transaction",
        "label": "Business Combination, Shares Owned Prior To Transaction",
        "terseLabel": "Shares owned prior to transaction (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationSharesOwnedPriorToTransaction",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imux_CashAcquiredInConnectionWithReverseAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Acquired In Connection With Reverse Acquisition",
        "label": "Cash Acquired In Connection With Reverse Acquisition",
        "terseLabel": "Cash acquired in connection with the Transaction"
       }
      }
     },
     "localname": "CashAcquiredInConnectionWithReverseAcquisition",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_CashEquivalentsInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents Investments Maturity Period",
        "label": "Cash Equivalents Investments Maturity Period",
        "terseLabel": "Cash equivalents, highly-liquid investments maturity (or less)"
       }
      }
     },
     "localname": "CashEquivalentsInvestmentsMaturityPeriod",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "imux_ClinicalCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Costs Payable, Current",
        "label": "Clinical Costs Payable, Current",
        "terseLabel": "Clinical costs"
       }
      }
     },
     "localname": "ClinicalCostsPayableCurrent",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_ClinicalDevelopmentEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Development Equipment [Member]",
        "label": "Clinical Development Equipment [Member]",
        "terseLabel": "Clinical development equipment"
       }
      }
     },
     "localname": "ClinicalDevelopmentEquipmentMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_December2020EquityIssuancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2020 Equity Issuances",
        "label": "December 2020 Equity Issuances [Member]",
        "terseLabel": "December 2020 Equity Issuances"
       }
      }
     },
     "localname": "December2020EquityIssuancesMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_DeferredStockIssuanceCostsIncludedInLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Stock Issuance Costs Included In Liabilities",
        "label": "Deferred Stock Issuance Costs Included In Liabilities",
        "terseLabel": "Stock issuance and deferred financing costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredStockIssuanceCostsIncludedInLiabilities",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_DeferredTaxAssetsAndLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets and Liabilities, Gross",
        "label": "Deferred Tax Assets and Liabilities, Gross",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsAndLiabilitiesGross",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_DisposalGroupIncludingDiscontinuedOperationCashConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Cash Consideration",
        "label": "Disposal Group, Including Discontinued Operation, Cash Consideration",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashConsideration",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Amount Released From Escrow",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Amount Released From Escrow",
        "terseLabel": "Amount released from escrow"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationAmountReleasedFromEscrow",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Escrow Deposit",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Escrow Deposit",
        "terseLabel": "Escrow deposit"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationEscrowDeposit",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_ELADRelatedAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ELAD-Related Assets [Member]",
        "label": "ELAD-Related Assets [Member]",
        "terseLabel": "ELAD-Related Assets"
       }
      }
     },
     "localname": "ELADRelatedAssetsMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_EmployeeStockOptionsImmunicAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Immunic AG [Member]",
        "label": "Employee Stock Options, Immunic AG [Member]",
        "terseLabel": "Employee Stock Options, Immunic AG"
       }
      }
     },
     "localname": "EmployeeStockOptionsImmunicAGMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_EmployeeStockOptionsVitalTherapiesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Vital Therapies Inc. [Member]",
        "label": "Employee Stock Options, Vital Therapies Inc. [Member]",
        "terseLabel": "Employee Stock Options, Vital Therapies Inc."
       }
      }
     },
     "localname": "EmployeeStockOptionsVitalTherapiesInc.Member",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail",
      "http://imux.com/role/StockCompensationPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_EmployeeStockOptionsforFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options for Future Grant [Member]",
        "label": "Employee Stock Options for Future Grant [Member]",
        "terseLabel": "Common stock options available for future grant:"
       }
      }
     },
     "localname": "EmployeeStockOptionsforFutureGrantMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Engagement Letter Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "label": "Engagement Letter Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "terseLabel": "Cash fee, percent of gross proceeds"
       }
      }
     },
     "localname": "EngagementLetterAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_EuropeanInvestmentBankLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Investment Bank Loan",
        "label": "European Investment Bank Loan [Member]",
        "terseLabel": "EIB Loan"
       }
      }
     },
     "localname": "EuropeanInvestmentBankLoanMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ExecutiveBonusAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Bonus Agreement [Member]",
        "label": "Executive Bonus Agreement [Member]",
        "terseLabel": "Executive Bonus Agreement"
       }
      }
     },
     "localname": "ExecutiveBonusAgreementMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ForeignExcludingGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign, Excluding Germany",
        "label": "Foreign, Excluding Germany [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignExcludingGermanyMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ImmunicAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunic AG [Member]",
        "label": "Immunic AG [Member]",
        "terseLabel": "Immunic AG"
       }
      }
     },
     "localname": "ImmunicAGMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ImmunicInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunic, Inc. [Member]",
        "label": "Immunic, Inc. [Member]",
        "terseLabel": "Immunic, Inc."
       }
      }
     },
     "localname": "ImmunicInc.Member",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_IncentiveEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Employee Stock Option [Member]",
        "label": "Incentive Employee Stock Option [Member]",
        "terseLabel": "Incentive Employee Stock Option"
       }
      }
     },
     "localname": "IncentiveEmployeeStockOptionMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Increase in operating lease, right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_July2019EquityIssuancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 2019 Equity Issuances",
        "label": "July 2019 Equity Issuances [Member]",
        "terseLabel": "July 2019 Equity Issuances"
       }
      }
     },
     "localname": "July2019EquityIssuancesMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_June2020EquityIssuancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2020 Equity Issuances",
        "label": "June 2020 Equity Issuances [Member]",
        "terseLabel": "June 2020 Equity Issuances"
       }
      }
     },
     "localname": "June2020EquityIssuancesMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_LegalAndAuditCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal And Audit Costs Payable, Current",
        "label": "Legal And Audit Costs Payable, Current",
        "terseLabel": "Legal and audit costs"
       }
      }
     },
     "localname": "LegalAndAuditCostsPayableCurrent",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_LesseeOperatingLeasesNumberOfExistingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Leases, Number Of Existing Leases",
        "label": "Lessee, Operating Leases, Number Of Existing Leases",
        "terseLabel": "Number of existing operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesNumberOfExistingLeases",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "imux_LineOfCreditFacilityNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number of Tranches",
        "label": "Line of Credit Facility, Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "LineOfCreditFacilityNumberOfTranches",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "imux_LineOfCreditFacilityRevenueShareCapFirstTranche": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Revenue Share Cap, First Tranche",
        "label": "Line of Credit Facility, Revenue Share Cap, First Tranche",
        "terseLabel": "Term loan, revenue share cap, first tranche"
       }
      }
     },
     "localname": "LineOfCreditFacilityRevenueShareCapFirstTranche",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_LineOfCreditFacilityRevenueShareCapFullyDrawn": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Revenue Share Cap, Fully Drawn",
        "label": "Line of Credit Facility, Revenue Share Cap, Fully Drawn",
        "terseLabel": "Term loan, revenue share cap, full loan amount drawn"
       }
      }
     },
     "localname": "LineOfCreditFacilityRevenueShareCapFullyDrawn",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_LineOfCreditFacilityTranchePaymentDeferralTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Tranche Payment Deferral, Term",
        "label": "Line of Credit Facility, Tranche Payment Deferral, Term",
        "terseLabel": "Tranche payment deferral term"
       }
      }
     },
     "localname": "LineOfCreditFacilityTranchePaymentDeferralTerm",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "imux_MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Aggregate Offering Price of Securities Under Shelf Registration",
        "label": "Maximum Aggregate Offering Price of Securities Under Shelf Registration",
        "terseLabel": "Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount Of Common Stock That Can Be Issued Under At-The-Market Sales Agreement",
        "label": "Maximum Amount Of Common Stock That Can Be Issued Under At-The-Market Sales Agreement",
        "terseLabel": "Maximum aggregate offering price under ATM agreement"
       }
      }
     },
     "localname": "MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders",
        "label": "Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders",
        "terseLabel": "Maximum common stock shares authorized (in shares)"
       }
      }
     },
     "localname": "MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imux_NonStatutoryEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Statutory Employee Stock Option [Member]",
        "label": "Non-Statutory Employee Stock Option [Member]",
        "terseLabel": "Non-Statutory Employee Stock Option"
       }
      }
     },
     "localname": "NonStatutoryEmployeeStockOptionMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_OfferingCostsIncludedInAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Costs Included In Accrued Expenses",
        "label": "Offering Costs Included In Accrued Expenses",
        "terseLabel": "Offering costs in accrued expenses"
       }
      }
     },
     "localname": "OfferingCostsIncludedInAccruedExpenses",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_OperatingAndVariableLeasesCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Variable Leases, Cost",
        "label": "Operating And Variable Leases, Cost",
        "terseLabel": "Operating and variable lease cost"
       }
      }
     },
     "localname": "OperatingAndVariableLeasesCost",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Agency Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "label": "Placement Agency Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "terseLabel": "Cash fee, percent of gross proceeds"
       }
      }
     },
     "localname": "PlacementAgencyAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_PreClosingFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Closing Financing",
        "label": "Pre-Closing Financing [Member]",
        "terseLabel": "Pre-Closing Financing"
       }
      }
     },
     "localname": "PreClosingFinancingMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_PrepaidClinicalAndRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical And Related Costs, Current",
        "label": "Prepaid Clinical And Related Costs, Current",
        "terseLabel": "Prepaid clinical and related costs"
       }
      }
     },
     "localname": "PrepaidClinicalAndRelatedCostsCurrent",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Common Stock, Gross",
        "label": "Proceeds from Issuance of Common Stock, Gross",
        "terseLabel": "Proceeds from issuance of common stock, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_PropertyPlantAndEquipmentIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant, And Equipment Included In Accounts Payable",
        "label": "Property, Plant, And Equipment Included In Accounts Payable",
        "terseLabel": "Purchases of property and equipment included in accounts payable"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentIncludedInAccountsPayable",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ResearchAndDevelopmentTaxIncentiveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Incentive, Current",
        "label": "Research And Development Tax Incentive, Current",
        "terseLabel": "Australian research and development tax incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveCurrent",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_SalaryCostsMonthlyBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salary Costs, Monthly Base Salary",
        "label": "Salary Costs, Monthly Base Salary",
        "terseLabel": "Monthly base salary"
       }
      }
     },
     "localname": "SalaryCostsMonthlyBaseSalary",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "imux_SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Exercisable Period On Additional Issuance Of Common Stock",
        "label": "Sale Of Stock, Exercisable Period On Additional Issuance Of Common Stock",
        "terseLabel": "Exercisable period on additional issuance of common stock"
       }
      }
     },
     "localname": "SaleOfStockExercisablePeriodOnAdditionalIssuanceOfCommonStock",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "imux_SaleOfStockNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Number of Additional Shares Authorized",
        "label": "Sale of Stock, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "imux_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "imux_SeriesA1ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 Convertible Preferred Stock [Member]",
        "label": "Series A-1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_SeriesA2ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Convertible Preferred Stock [Member]",
        "label": "Series A-2 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2ConvertiblePreferredStockMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "terseLabel": "Additional shares authorized, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail": {
       "order": 2.0,
       "parentTag": "imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Awards Owned Prior To Transaction",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Awards Owned Prior To Transaction",
        "terseLabel": "RSUs owned prior to transaction (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOwnedPriorToTransaction",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imux_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Awards Assumed",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Awards Assumed",
        "terseLabel": "Outstanding shares to purchase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityAwardsAssumed",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imux_ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation, Number Of Shares Authorized Under Stock Option Plans",
        "label": "Share-Based Compensation, Number Of Shares Authorized Under Stock Option Plans",
        "terseLabel": "Shares authorized for grant under stock option programs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationNumberOfSharesAuthorizedUnderStockOptionPlans",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imux_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Percent Of Total Issued Capital",
        "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Percent Of Total Issued Capital",
        "terseLabel": "Percent of Company's total issued shared capital available for grant under stock option programs"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansPercentOfTotalIssuedCapital",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period",
        "negatedLabel": "Settled in cash (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriod",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "imux_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period, Weighted-Average Exercise Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Settled in Period, Weighted-Average Exercise Price",
        "terseLabel": "Settled in cash in period (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsSettledinPeriodWeightedAverageExercisePrice",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "imux_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "terseLabel": "Commission, percent of gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "imux_SuppliesAndWorkingCellBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplies And Working Cell Banks [Member]",
        "label": "Supplies And Working Cell Banks [Member]",
        "terseLabel": "Supplies and working cell banks"
       }
      }
     },
     "localname": "SuppliesAndWorkingCellBanksMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TaxYearsPost2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Years Post 2017",
        "label": "Tax Years Post 2017 [Member]",
        "terseLabel": "Post 2017"
       }
      }
     },
     "localname": "TaxYearsPost2017Member",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TaxYearsPriorTo2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Years Prior to 2018",
        "label": "Tax Years Prior to 2018 [Member]",
        "terseLabel": "Prior to 2018"
       }
      }
     },
     "localname": "TaxYearsPriorTo2018Member",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_TwoThousandNineteenOmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_VSOPAndVSOPSBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VSOP And VSOP SB [Member]",
        "label": "VSOP And VSOP SB [Member]",
        "terseLabel": "VSOP And VSOP SB"
       }
      }
     },
     "localname": "VSOPAndVSOPSBMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_VSOPSBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VSOP SB [Member]",
        "label": "VSOP SB [Member]",
        "terseLabel": "VSOP SB"
       }
      }
     },
     "localname": "VSOPSBMember",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "imux_VitalTherapiesInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vital Therapies, Inc. [Member]",
        "label": "Vital Therapies, Inc. [Member]",
        "terseLabel": "Vital Therapies, Inc."
       }
      }
     },
     "localname": "VitalTherapiesInc.Member",
     "nsuri": "http://imux.com/20201231",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail",
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r68",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officers"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r218",
      "r220",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r218",
      "r220",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r208",
      "r218",
      "r220",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r208",
      "r218",
      "r220",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r163",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails",
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails",
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r24",
      "r54"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r71",
      "r72",
      "r73",
      "r376",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r118",
      "r119",
      "r120",
      "r307",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r42",
      "r254"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r198",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r222",
      "r248",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r155",
      "r157",
      "r161",
      "r167",
      "r304",
      "r308",
      "r320",
      "r362",
      "r375"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r67",
      "r112",
      "r167",
      "r304",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.",
        "label": "Assets, Fair Value Adjustment",
        "terseLabel": "Fair value adjustment"
       }
      }
     },
     "localname": "AssetsFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r223",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail",
      "http://imux.com/role/StockCompensationPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r217",
      "r219",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Aggregate consideration issuable (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of shares owned"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Multiplied by the fair value per share of Vital common stock (in USD per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r296",
      "r297",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Estimated purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Accounting for the Transaction"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransaction"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "In-process research and development (\u201cIPR&amp;D\u201d)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Clinical development equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed",
        "terseLabel": "Incurred costs"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r16",
      "r117",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r17",
      "r50",
      "r103"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r104",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r97",
      "r103",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r97",
      "r325"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r110",
      "r112",
      "r130",
      "r131",
      "r132",
      "r134",
      "r136",
      "r142",
      "r143",
      "r144",
      "r167",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price (usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of warrants outstanding and exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r60",
      "r190",
      "r368",
      "r380"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock cash dividends paid (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, cash dividends declared (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r198"
     ],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail": {
       "order": 1.0,
       "parentTag": "imux_BusinessCombinationEstimateOfPurchasePriceFullyDilutedShares",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Number of shares owned by Vital stockholders (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December\u00a031, 2020 and 2019",
        "verboseLabel": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockCommonStockDetail",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r77",
      "r79",
      "r80",
      "r85",
      "r371",
      "r383"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "EIB Loan"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r363",
      "r365",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r59",
      "r115",
      "r199",
      "r202",
      "r203",
      "r204",
      "r334",
      "r335",
      "r336",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).",
        "label": "Deferred Credits and Other Liabilities, Current",
        "terseLabel": "Deferred income"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r36",
      "r37",
      "r269",
      "r364",
      "r373"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "imux_DeferredTaxAssetsAndLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "imux_DeferredTaxAssetsAndLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets, valuation allowance total"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Foreign net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r275",
      "r277",
      "r278"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Federal and state tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r101",
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r101",
      "r154"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r176",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r9",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Estimated fair value of ELAD Assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r15",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "ELAD Sales Agreement"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share (usd per share)",
        "verboseLabel": "Net loss per share, basic and diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations",
      "http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax effect of rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r262",
      "r284"
     ],
     "calculation": {
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax (net of federal benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which compensation cost will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r122",
      "r127",
      "r129",
      "r141",
      "r168",
      "r198",
      "r205",
      "r251",
      "r252",
      "r253",
      "r281",
      "r282",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r311",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r310",
      "r311",
      "r313",
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r209",
      "r210",
      "r215",
      "r216",
      "r311",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r209",
      "r210",
      "r215",
      "r216",
      "r311",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r311",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r315",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r109",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalMinistryOfFinanceGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Germany.",
        "label": "Federal Ministry of Finance, Germany [Member]",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "FederalMinistryOfFinanceGermanyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized foreign currency gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Presentation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "Gain on sale of ELAD Assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r169",
      "r171",
      "r361"
     ],
     "calculation": {
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r109",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r101",
      "r170",
      "r172",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r175",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In process research &amp; development (\u201cIPR&amp;D\u201d)"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "terseLabel": "Net loss before income tax"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r10",
      "r12",
      "r13",
      "r14",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail",
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r265",
      "r266",
      "r268",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r263",
      "r267",
      "r274",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r109",
      "r260",
      "r261",
      "r267",
      "r268",
      "r273",
      "r279",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesNetLossbeforeIncomeTaxBasedonJurisdictionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r89",
      "r153"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Contingent payment settled in common stock"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest portion"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r56",
      "r112",
      "r158",
      "r167",
      "r305",
      "r308",
      "r309",
      "r320"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r47",
      "r112",
      "r167",
      "r320",
      "r366",
      "r378"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r112",
      "r167",
      "r305",
      "r308",
      "r309",
      "r320"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r34",
      "r35",
      "r112",
      "r167",
      "r305",
      "r308",
      "r309",
      "r320"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Term loan, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r59",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/EIBLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r97",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r14",
      "r75",
      "r78",
      "r83",
      "r102",
      "r112",
      "r121",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r133",
      "r155",
      "r156",
      "r159",
      "r160",
      "r162",
      "r167",
      "r320",
      "r369",
      "r381"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://imux.com/role/ConsolidatedStatementsofOperations",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "terseLabel": "Fair value of net assets acquired in the Transaction"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r41",
      "r164",
      "r165",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Fair value of promissory note"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Notes Receivable"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations",
      "http://imux.com/role/SelectedQuarterlyDataunauditedSummarizedQuarterlyInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r155",
      "r156",
      "r159",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommitmentsandContingenciesFutureMinimumAnnualObligationsUnderAllNonCancellableOperatingLeaseCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r57"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r302",
      "r303",
      "r306"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r76",
      "r79",
      "r82",
      "r84",
      "r198",
      "r326",
      "r331",
      "r332",
      "r370",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Foreign exchange translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r23",
      "r57"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r57",
      "r192"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Underwriter commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs",
        "verboseLabel": "Estimated offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Cash distribution in connection with ELAD Assets sale"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r223",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December\u00a031, 2020 and 2019",
        "verboseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r20",
      "r48",
      "r49"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other current assets and prepaid expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail",
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for the sale of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Proceeds from Sale of Other Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of ELAD assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r52",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r30",
      "r31",
      "r179",
      "r379"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r109",
      "r179",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r30",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementEstimatedFairValueofELADAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Data (unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SelectedQuarterlyDataunaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.",
        "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ReceivableWithImputedInterestFaceAmount": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The principal amount of the receivable or note before consideration of the discount or premium.",
        "label": "Receivable with Imputed Interest, Face Amount",
        "terseLabel": "Face amount of receivable"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r259",
      "r410"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r109",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r205",
      "r254",
      "r377",
      "r389",
      "r391"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r122",
      "r127",
      "r129",
      "r168",
      "r251",
      "r252",
      "r253",
      "r281",
      "r282",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Aggregate consideration from private placement"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issues in private placement transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionAssetsAcquiredandLiabilitiesAssumedDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r10",
      "r12",
      "r13",
      "r14",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Estimated Fair Value of ELAD Assets"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ELADSalesAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r222",
      "r247",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r222",
      "r247",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Net Loss before Income Tax Based on Jurisdictions"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r52",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Summarized Quarterly Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SelectedQuarterlyDataunauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r113",
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r223",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail",
      "http://imux.com/role/StockCompensationPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r227",
      "r236",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r61",
      "r110",
      "r142",
      "r143",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockSubscriptionNotYetIssuedDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/StockCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs to be granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail",
      "http://imux.com/role/StockCompensationPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Other Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted-Average Exercise Price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited and expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r229",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "terseLabel": "Assumed in the Transaction with Vital (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending balance (in USD per share)",
        "periodStartLabel": "Outstanding, Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest , aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, Weighted-Average Exercise Price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r221",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/AccountingfortheTransactionAdditionalInformationDetail",
      "http://imux.com/role/AccountingfortheTransactionPreliminaryEstimateofPurchasePriceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockSharesReservedforFutureIssuanceDetail",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail",
      "http://imux.com/role/StockCompensationPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r109",
      "r223",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r242",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail",
      "http://imux.com/role/StockCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) of non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)",
        "terseLabel": "Assumed in the Transaction with Vital (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest , weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Issuance of stock (in USD per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r110",
      "r112",
      "r130",
      "r131",
      "r132",
      "r134",
      "r136",
      "r142",
      "r143",
      "r144",
      "r167",
      "r198",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPreferredStockDetail",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r64",
      "r118",
      "r119",
      "r120",
      "r122",
      "r127",
      "r129",
      "r141",
      "r168",
      "r198",
      "r205",
      "r251",
      "r252",
      "r253",
      "r281",
      "r282",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r141",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r39",
      "r40",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Exchange of common stock in connection with Transaction (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r63",
      "r198",
      "r199",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "negatedLabel": "Conversion of Series A Preferred Stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r39",
      "r40",
      "r198",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/StockCompensationPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r198",
      "r205",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/StockCompensationPlansSummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r64",
      "r198",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Exchange of common stock in connection with Transaction"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r64",
      "r198",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A Preferred Stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r39",
      "r40",
      "r198",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r198",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r45",
      "r46",
      "r112",
      "r166",
      "r167",
      "r320"
     ],
     "calculation": {
      "http://imux.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r205",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock and Preferred Stock (Converted into Common Stock)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockPublicEquityOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockRegisteredDirectOfferingDetails",
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockShelfRegistrationStatementDetail",
      "http://imux.com/role/ConsolidatedStatementsofCashFlows",
      "http://imux.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://imux.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://imux.com/role/DescriptionofBusinessandBasisofFinancialStatementsAdditionalDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r2",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increase"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/CommonStockandPreferredStockConvertedintoCommonStockStockWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://imux.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r412": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r414": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r415": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r416": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r417": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r418": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r419": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001280776-21-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001280776-21-000009-xbrl.zip
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MWL]4/B-0OL__E@?]JR(O_@M02P,$%     @ B3I:4E<V'GM8 P  > T  !H
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M4[_-WG&')0*)?,8>"C/54HQD,Z)E(TS"8,;"@ 4Q(%<%X\6,586WE83"X,5
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MZ>WXF0L,3MO?SP/X 3*20Y4#+ +??=U03:+BE%=N^R[$B8D$Z/5,D65-93$
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M2R\1$($H)*7X\_DY>MXG>4=JY4U>.=/9":9\ ]]4"P+_B,!HDL#:J^@<MRW
M8=)BR!'0D\RV*,).6,(0T'7I95K_J9'V/8Q?^ 5Q;T1</$E<BY'G2* 6X<E@
M8LBT-(^T);U7+D8IF<1++]_L/"!I5X"NOJ9MQ^PMR/DC<I)SY+18$BMHBP9*
M05:!DM8Z,&P9]5IPPI@#68VF4X5K*/JF-"Z90]F@ES?T[ VZ-I1+%VBLK(H*
M*RNY9=P2,(8QLU1@30*VGB<:8XT8(,;HCZ7,!Y=WX=G_7%IOOQF1?&CLOMCJ
M%^[K?M$![5^M@>'1/VT7_5!_NW78R?M@A0S]AP_)7@.629(/ Z#I\LC)QK>=
MH]W>7_N[WPJ^N>J[[55'=K<_=#>V'0+:?MM<74>[GS=0N_LF;R=^.=CMME]K
MM/OO?>2ZGWKFLQYL'GQE;;(#X^]VVF]W3MK?$M]LL(V##S"?O\G.YW4,/--M
M=W?0O[^M\R^1,T[!2VD%'F*+88Q;1EL@N;8NJ(B=5A2T[C(B?$3H$66_*[O!
MR> C$X:RR"C56D@L,%*86J2,\%_6+XKLB'[O0E6%L'D82B!/;^]= #-_.Y3=
MS9CLQ_3L*=.IO?WWD$Z'^<:!8T"3D_;JQ^/VMW74)KOY3K>]O[N]=KJ[ND/:
M;X&JVVNTG5^@4W?]M/UM'YX-S]A>H3!7NMO]*]\A;SH;VW_!7';0SK<VS-F1
M?W];(^W5KZ?M P=XL?=M$^03$:%$5+J%?/(Y';(MH[!I21R91$R(D(RE]_Q6
M>*N!8L8;AZV63 '-*$?@V<)8P8+!I;^#MV/AVS=E> 44\Z^+[F'H5;5+M%*"
MA[07$A:_.CV[Y+TY35^M')O2U__Z%*I$\D8+XVF3^6#CC,S;.R<@.J<;;]>/
M=]+]WWQG<W6#;:[N=W>W]P_@^5T8.[\DCMUU&.?-/MP#][T"=OG[6YM\9!O?
M]MCFV]T.0/LW^"^\QSJ(X]KQYO97O+&=R+T&++'W14@K8>U%2S-I (9E:"D<
M>4MP&[4&D97> )GI93(_/^_WE"&&,H C6%WAKB5G^D55>^O "%D=6WC1!R?M
MGTM5WCWL).^Q_FZ_K/EDTC-;/JF T?Y\?GZ,YOEG#QW.H2H&9?VI=EM?#)FO
M(?//*/O10*%VOT:?<I\^QSR463VA<*7__GK]?\][$Q=O?CGZZOSHAS5SCCZ!
M=UWV5TT_O!PYSPB/[CO[;3Q-?W8I*#2*SQ[1_#+Z/'K(\W,+-1HG:=1ZT0;U
MVC=?=@$G!R7XS4V<X\7'K=71[:.?1I_3_5?2@"%!7 P@]X*Q0+2.H&D="I8I
M0!4^!&TD*)J!I6]"&_WAP@MP(\8##7^YY6I6"9BJ2PLZ)&;]XZU7%&,:B  O
MAQC";%!&*>G@WY:X8,#8J5<4PS]ZME84IT@?UC^WHN=6X!:&P$RMP 4)_845
M -J'0"T%ZF,6 ^AI#5,TG'D6B6I6 .N96P&L?V4%)C$*]'FM],>OY_,CF-;D
MI;7>,OVB_$DXNW1_^G(U](INWKMJV)L*];DAGI^?_8]D'XPRC(,24C'"(K6&
M$NH94U%'8 A.AZY-H]%FA@$F-1JPP$TUVD5NN9U&.[=N,8#9@K 400CFK# Q
M:L<H08P))26JY44]Q'(-WSKL)3.U^>CA82?@1KJ\OQ&2/YOY''YMTE%G+BB\
M>KKG=<=4U6:LG<^5DQR42S*>7FS!8H1JA32N:#^WG?"^-I;*X.MKFZ'_?'[E
M$W]F(HTCG&SRH@<?JV8RH\MN]?#G%U;E=J"B[@Q6M;)4"J:-C88!LR@A:) (
M] L24<OP:-@$+]CD%]@$_&3P)EBTU(%-"X8'8R0:%[P"*P<LDSEBD^]3![[O
M%KUY(HT$4] ;T(#*<<8M55A&S04%-S @(O"C(<V*]WF*@YC.>Y/[]=YK<YCW
M36=.R!2IU)J!UX*U9!0GDX5A&B,G%@="YTD?_X!,S@VZ@TXJ'-GL[X<R75>&
M_33:45CON:(;YH1DC"%+A)5&<,N0LT8$*8/V(&9 *4L>#<D^A+[)>\&OF;*7
M]_:J.:$/"E)@$[25.K)@50I[@7D;!!<B..L?CCY3 Q6LE+,6N),+AE4 ["<(
M.)4:I8PE:@K.T=RSZO1=-T:T\D1XZ94 "+):>QP54X18S;'4CX^J4]$9,T!H
MJXV,#HPUX9D JA-'9# 8:4T4I^P1$OJA;+CI$Y>PX)2@3*:XOY),I3PPL1)Q
MZJET;AZ)NXC$S AS@=L0.3:1>8\94]08[CU@AB6@_843CX^YGDS\9OK,Y3@&
MQT<SPYEC2MM47"^X=-YQB:E[A/;'O49]ID]0C;F33DCP" RC-(*KI$*@(7J9
M:@3P/!%T8*O<YZ8\W3*=<!DM0#I?=XH*7(,W><_T'/SQ&"F*L;'> %&IDPSL
M"<.U#A&#GQ"D%MK/$T7O6D07O'0[7N+142.1]\X1AH4WE'*MG,&8.+!AY\J6
MN'.*+AR@GS<C- ,&BMI%%AE'PC@1G1!8>RD9GB^M,S6,>M\QO;;IA@DF7CL)
M;M#/C\*KHC>H5O;*4$_M,;*0LH$$S;C@G#)+E<%68>2$UTZ*P- <L="=$7*!
M2#_-3EYP&J-BFH)/$XE*D1FG%0]<8#"FYLEJ>MJX$(F/S"NDP8]A041K,4;<
M1^H<1U[).2+D[)J_*VSK]5;H]SOU]!XU/P6P5$3$)EI"&=B_QB5FXM@(1<!L
MX8^/GWX.]1>\]1-9ZDBL2_TJ0/$P#?8P ?1"A!B,I  _?IYX:T'5L=/,##:(
MLB@$8HYZ*SR5/((?+:S29*YBI#]RF@<61MB,$5;G<49 F"(,(1^1MFG'CC4B
M:L0UN!K8!,/GR2Z<77/B\;.1$, :FAHE*&>(8VT]U2A&2H(W03["@,>4K8C'
MSU(V !PI#VI%>R:E,T9%K)+G8YT&QGJX74^_S$F+VH%F3>]H:]CY.)D+G&.A
M'$G;I**SAE&$&0E1<2G-XV&3)U,%<"]L(I56U"M**#>,L10U4<P9PA3E.@8Q
M1VPR&[LX[HXT#+LH,:/28\Q4]$H&1S%UPEBNC76/AC33V,5Q=V2B4EF:]J."
MSP?Z&,ADP9S3##%M.7&/1X*FO8OC[D@6N2&"":,I1DQA;T%#!JLE%9XP*_FC
M(=F#[N*X._H0XB4-UE(6-3,Z[;;QS#GPOBVE6.$IM"R9>T)-I:'*^51;8-R(
MB)%1H-6T4%;KU+X..2VBB^CQ477J>QBF0VA'1  ;A7N/4WL! %L;@<*>6ZD4
MBOP1$GH:"?/I$!=KCJ1''H,%RIS@6K#(+?,\<NH#C?-$W!F*)4V'F,(2PPA6
M@5#!> RI%EAJ'CBU7N.F^F%>B+F(<D^-C33REED49#2:Z;JU#''$<T;!;0UZ
M&BWF9A+P%RQU<S6C*+"0%4@9,/TIUTPRZK"-WH GX!Z3FEDY+/-.>HF&Y=:K
M:I!.%GB4/D#TFGNMN54.@^?-=.I='C@X>3PXT#[S1-:953A/B:&(H":&0"F5
M*6$OC DQXDB]"X%IL_ U%LSU"\S%B7+@Q7(.^H> RX.<-]I@045*O*IY8JX?
MD/6O02\\$:HRS@$T&'=<8$:X4\1AKTQ@1BEBD9@GJLZL#GI"_&2<U=H2% .-
MC"BN,!$:>RN(4I)*.D_\="]4G0T-.)>\1:7TUH= B!',JW1< *8T&!Y3+_'Y
M,F]^9%@,]@95_XE@AL3,2(Z%H4@R2ZW"VFII2-224XD?DV7QLW2=GA*<2XZR
MR"N-&'6F;L=*#6%8:;!414# /7.579L3CGI">L@)I@ES2'%M&/9<8RJ"U]H#
M[8.@]N$.&_AE4WE1=-JLZ;V<R."8ET)1ZS%AP6!%%??<8V 7;KB3CX9-GF#1
MZ1VRB0Y8<"(E098SI8V2CDJDG:6:6HK='+')3!2=WB%IHG:<<NI=.D:;I*-U
M,-=((<R089SJ1T.:*12=WB&9A).:>4*U8H%AZG5*OX(B1A0<BACF"6AGL(3J
M?DB&P=/S4DFPU,'E"SIJ'+2ES >,M5*/AF0/671ZA_2A0:&41/)I5[8+UD@-
M_T)(*H.Q<E<>TCBKA)JU+F93"LSR2,"V4)Z#(J-$6NVH1L)*S4$(PURU<)C)
MK-R46E>J$"6/BO 8&0<L-4!"L!J)CX1K]ICVV4\EBS*UUG#*:V(<EIAQ1(V(
M'C.1#J$21+OPB*@ZI4CW=.A*B4B'<QKBA6>!(O#Q4AO)0# R3HW/HVC.(7\8
MM?H3Z\9@/>Y=>8V/=AP>Z#[Z_OS9BH?PYVB &Q^7JH,AP47,4US8LJ@UXE9:
M@5F0QL?A)C6@PLP)E0_YBW=ASW36ZOE,B-%ZMPOOZU;>_FK(I2K[X*D/8+G*
M0R#MZ84F:I^27[@-O@=XB*$"GV/YGK=1)6Z[$X_#*FXQ=QZL6!8LR!MX]YB#
M+:0D8^-6B8WH-7_,&O5'D/IJ -9JJ*H5!XA9U8[[?7#"]<SV$$SPDZ!S\=)?
M24L236GT8',PSK!3*G5!Y#)@&T/0Q(UA8N88Y==AXBZDEMR!U"H/BPV6$ G"
MUFVD. U4(+"*A!4ZQ-FEP9,2UGNA/?&**NV< _K7C>&HXA$K8B-"Q&@R^[1?
M.3:EWSX]#!=C0E6_S%U_F*?X"'9*]6'KXUTE2Q8<]],'YA%NG-31*8.8B0)X
M35&L5>H'HJE&L\MQCY 8PD04G(J@<]/>2FVBD=($IL$O9I;(L<&&6[-JKM_
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MSB'"P.>6\UEV6@RR)B%4Y]L..\:E:_P@O>XP&EF,[KU^_LO92J=JRD^N>T-
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M-C[^>WCM?,K_CXK]SNUP2Y!7[X$Q36.@T&R32)7+XQU4Y@P9&M^O)LWDM]T
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M#_UA\%3A\37W=T/H#TW3T/.'15Z''4?WI9)46V<MR[ WZ P=V4.8XA&,,JI
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M\F,IO[0$C8@GRJ0U'A7WGJW9%0HLKS-C%:Q9VKC6\U<R>[.Q.HW9D+0S['
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ME=Q>A8K3C/EDTV9!OO8:?Y=K%[32AR#@2^9TO\4F&S%!B[!GZ=4E9;@IS76
M/R;I1NSEMBJ44.)#/<\OTK7XB#F15^J"7/G>J,O;>Z.^]ECHX?Y8Z%W@6=_N
M5=5#QGQ4M2CF5',D *<5]^5WX/_=-W)UZ7SPU#5;")'K\W1;)9?\;7STHLY_
MK\J4]\'SG&*GIFI3.HJKEIOWY2*H<K<H(N+II!D?J7\VQI(YICL&*:&]=9?
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M<2ZE#MB=$ =^-SQ?DJX /.1;!J&DP0)Z\W2/70F6W8//#;OR.;%O\ R%:\]
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M] :I!]E=^ZEA:^U)&#R#FLN0#WSDPCX>?U>-7*1[K@=/J'=^2[I=(.5-:QP
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MX)ML2GB1:U7)11"CA):F/L9Q>IGI:@P[I+HJU9) 14#$]*$4_D"J#'%KWD#
MSU?=T5[D'D@$30S#?9V5N<56,;%Y(P&5DU73='V@"A9L4>]A\T5Z!PSG^;6W
MQ7=89<SVA$2^L;?BX*2+>S+8Y""*WH3%-2)N;0YW<:X"P;+QG(= J]?(*4A"
M0-/O:4#*&&)!1:$PM 9W?K>[2E"C8 @/B%+4&R.)>O:U3W&\PT'"&NY86TNW
M!#R_.%.X]>(&[V^6S]A54\ NRS=*5<?Y%G?[G=WK/+S7PHX[,#ORC^^0>PC/
MB7<)/;AD8Z<-8I0\AXLB%G5%R[_@%HXJ9&'VIR#Z$=5#!JUI<C5^E:0+"D2:
M-O"J0HE)B#@THM,(5NR+@%4^],/6Y"FJX\_G;EXL*OY)96<C'<AP_ZFG[SC-
M6>5G)P1WAQ;EA#M27)DYC(M,Y2@03I]]<:2]]]B;8*>-C[X<\,TGFJ(>R7/@
MR>H91S8D,#N.X%FJIA+@JQB%D(JWT)EOM;7/X2B%*U=\*%J^!;G<RVJZY=QS
M&Q-]L@XKV[+6H7V-A!T09=BI55K7="P;_+='VOY'B!F_RM/FC<^O#*2(U8J@
M]O_)BG^FY>\PGZ_F=$$R=QP)" ,RK79AC_<4_O1F1 VH,;D'V';]%20*W(VX
MES)<6-JIK$8T;RK 6O#UDY#A@4Z:&) _"+-#TI=H1I\6Y?'1^.'.8H:45J1J
M8=U5;1P[WOEE(;'GL\=/\*ZXG1PISH@BF;TWS5/(PADX-R4O*?J3>@NR;<.&
MI?'HW?R3=VE/)\8@'5PDMW<LP5B??@/YEG+V';VYRR=_$(2QAX+WC_'M?M0T
MVB=FWCWK,N^>RB+\T;E?WR<7V)GC?5I /^7@4^8W^5-:I'1Z5HT&N0#*7S.]
M":V$5<Y=Z!$WB$"T(H])CI? Y_*.8%*8-%2P,(..9SJ?UC0KOU=(1+M /8C3
MPZ455N9%[)%\[46JV6GT')AY\C=PRS*236' &YS2 00S<ND(#NR2T'$QU#L)
M&Q'"W OO$)<Z:#42U<+S++%4%1UJ.X65[JFG/SKU]$N-8+#\*<89<UBP%G$3
MCG:LERIJS:+]\%H^I^F"*7>.\1\NLP*>C"SZ_W4^.DXF6E3G3S6J^F(WCI91
MA[I6@"G]1ANEB-'($!_:93'O%\>_NSA^#8)59Q]5&G&/F;R83/Z>9[<8QAX1
ML5G([F'(7!(_0B8ME2(5,  #NT&H#V@GJ[*&=M=,:BI8M+3K3<Z'KV=;O1#
M,6=9<1F^NS?&@SAB=Z))0>PZBZRO4T?*?!$SMMA19E98?N\0C3J=N=H+YW0+
M)(D]#++8*N@9^%AA@B?>]RAL\GKD.B4G:GPHICIP)3OMW[WYOW\[#K(RHQ#-
M#\:"] 8W1H*>!]@3BXI\N^Z(R*D<[=6IRE3;U Q=Y]*TK#>3=)%7?XH%.,=N
M?G<:LY\;::OU]\/3$6S8-?1]:,7JH@(B03*<?_FO\?GII[)<!CM2_"+J\-PR
M3Z_#::=>U.EU>C^O?VA>4>,ME05/J@]DTC#!\TUABSY4O@I\/5.\<G)_AB,P
M'.H=CT5OK1K8\7";GL1WKY2VR7WZ[@A,O%>OZU*0.9(W3G?7"GP#Z^,G8=/5
MKY?<-D9#+M*)OB&356,Y YP2K)#PMH1ZHC(":W\3^3O+;0.Z)]0O0"GR@B*>
MI2%A@T2-/S%$BK':0."E+T0 2&K;Q$,WI5A<GY-!(V8:K"1(?8+RP<5LE<.)
MUP<P8> ?GUR8,/# Y1(?8P$VT#/,VPT=:7_YK^.SXQ]JLI^_EUF^RMLV ]7R
M+'F>S?+?\Y+9$]X&<L./YQ?U<W]=+3EP(4+8N/8\P5TP!.]/BOQ.TE[R? XN
M+WYY\O+JZ7!\+XCBJ$[\G&B"I0D4T ="LJ8XR8%T'TJ1)N:V'!B28:A(AH+%
M'YCQP5F'-/$<>X:XZ:)EF*=C(#9#;N#TRW4S*CRR\VLAM VOJCU:_8\%MSOL
MZ29X8LXRA CP3UDY)+.6A=561J V/2"!%P[CYE:6!JN-G@2_LHEP5Y*!="4J
MK,!JE')TJ\;HC/1F0Y<7,D8@ ;<YG.MV*"V6_A-D9"IDIH3K6*A0."_@JKA9
M*?RA@G7IHZ.\/KSML%"*(CQ)F-B3TV;/.I0W6,-L;<T0/GOQQ.FND\=?:(=9
MERC! $68%[+('ZHA0U__" HR)Z?C1P^.[X()OAV<X(R'P]UH>ZPD-Z/^ IMW
M-A\(\6H<V^">&I]JNS9C+V.YU'ZMQGT4=_A'QCTQ@^22+ELKQ#MNE!DE3YES
M48EW@PT5LO#*UP=N9W)P5$I)GS'A$?^DVUSHV&BF=9:5QM0BY#@.Q4=QR4)[
MG??%N7DKA?[T;8;FX\U,^IFS-3?.ABW;P=";>*93( -+7JUIJW^%L9"^:MTN
M\E4(TE6T0OAK11'/IT0=T7TZ[W7 \#/ Y>CM2:[&7X$3T]=DPO 5BE:*=CEE
MP HCU8W%#19A>K<AJD*]0.^W%4\EYGX^/@T;LL"&KT&+V&P[T^35NTTH9XAP
MQMGR0Y+.48ZBJTS)0<</@6?6ERA8%<[R>8)51SDKS%K" ^V*#<Q<^O+OSYX,
MQX_H9C29JWPZT/8V^4GLOW:3D<.\JE#D5Y0RVBX&VK$DJ]PVE!)4UY](_$?0
MZY\2.K^LFC5<7M&0QXD>&$?9G])82#9NGCET3_@"FW6&*0<\C+DOPBH7FU#7
M\"I_Q5O@G*[G] XOES==#D'/M+:_(UZYZ$.-,<=^9RZ%T++UKQ]Q%'HFQ.#R
MQ_MIV.^P6?'-CNQY+>A@XC=H4'>O!C<S!VK >?AEO+6G0H_@-4WK;$C^F6/
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M,T 4F:B>T7D"DUG5FN[8I46.-* CL)>VFT%\2JQ5ZB(\CP<!U/0ATSOXBET
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M1]LM?F9L7&$-M22;G'8]?@'U.C;P,!-Q/9QZA_#$#S?K_J>.'W97+N#'4?M
M^&%R"7SVE_]J#98N72%GH[M2^/88V7)\LBNC&#:C_[%DE^0> &DH,M6JY@$V
M66M).9Y*&9;/4%H64FF8N6U2,C@LI<<7&70G2>?'3ZR?I ='7^:N?7]\J)S6
M06EL>+4F$UC!=AG>)[D-/WK)W7>IYTY^V61%2^,& 8HM[4A0\55D-@U_2L[
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MIFU#(JL5@)@VI<M5Q'@F 7^.3<UE#ZJ2(;ED=S;8HVUPR(B)RV HW;$7FK<
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MHDVTRKH$]\8-4@,EF")F&RR*3L?E\;=X]2<NYWL#T+GO&PXP]=IE*[V7X55
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M@[^<Z3'@'P_42?"4%6)%>Y.$"6B[U,TV3\,Y&V=F2%DRA,2L#LF=9O[@)CT
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M?PSGD1*OIH47%H,F'U) ;FVWW>(/N:5(08!C,K@R>=ZD/_>?0;BE(&JX0\<
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M-&[CFD;K0[+<OHC?%!14M T<9"N7/Z.C!FGIGN1ZU_(-V Q85< DY8!(,Z3
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M<B+>2VS&EW\<;,;'XY_\&JJ*&F2]:N*QASZTQ:]DVI\[E[2@O7KVZ_/0@Y;
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MM-XEK!3MF9B]I8*1CPRH+JG\F#8?IB_!J6L^>F0[\%'+<D&T6PZ:N6F'5'W
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MLW*AR^,)C6 +ZPS"T*>A?+UG"QKU.XI3I/-D^"L]$O1,X1:-'J[T?/%#?46
MT4QZ,_IR52>>QRX$F4)IYZC<%N54T\9QHM&OG]9 4G!=;-#$>4AN<QYA[3%3
M@U66[VK@AF18A9JZ"AV6I\@#]:S!C_RUM:.4.[+"[_*U=R8+I,:B:RI^(I'S
M._<& ?1(:*@/K2TS;/C-M4<5EX;E-3T^^#I+IJF2WK&YZ&V+WE]\K$7OCT8*
M)^U%@&#6Y+J5?)R)'$2GBCNIH9#9HZN+)@TAA6;PH<L5?]RZB!&VB!$R;V(7
M3NRG=HR?J=@$LJ?[[I#\PJE"UEL+&F(WPN>G,/614]8;APM*;Y%G@R/L%&3=
M!P\EQ [8S_P]D+Z7QUXPA/0WY8-#<\.:HUI@.2W95O_8,#G'7K(NKIR[J;J%
MPM\MFXX6'ZX(^,G?=5LE[DF;]B A?2RY$;_!6*T/P'Y6T@LX_EB#,J#=D9*0
MM)3XV^S]S@T:NT,9!DU\A6K#NFA]U!7[2B>:&&PT-"AG9FE"4_PY_WZN1]Z7
MU@^2<LPV67-&=BB!&9-&/)=G;@!MZTM&T47ATRS=X8J$(7L>=T]_]I0KC%[>
MOE[5@-V<//,I"=U *AG?F191KYS+?9ZQAIP41S@"Z5K75Y_$/*4)E4I<[!!(
MT"@2G!PAL=:0]OZZZ+RJ]W$Z 0JG#$+>R2=7>5.IUA+C#^Q#R;T"@W%.BC9D
MH^)#2JIT6>:K-][@_:[)4KTP;NKOFN9[>DU^WGGR!T3P  =,=71\+AQX(X+7
MN8MTG\IB076V3W[^[N7K3S[+.$IO+IUW\2FW+Z#XR\]XA,(Z+/-"V1$'KXIE
MMO,[FN<X48/Q;KM;.]F#NG+&I<RN7X1TY*N9B,)GDND>J5M??\4LMKEC[[6A
M4LE?C4&U_AV'W3BLI>?DZS*0P<NLTAUEVZ4P:#(H69+,P7=LG3RV5@;7*=Z-
M#BOOZF CB12>9M628]''/3[BSZ80 #*!-T1_+3G\7S?Y5940JB0RX6HE++_^
MK7I,-4S4'HW$BF7:Y6A"(R'>L/520WB3G0HAI1MOXD&$@X6LG\(?Y <Z.TS5
MN189N.32WCV%"X3PF*X@/XT]ZY-8I7!Y"H/);0G23#0@0X>7D@WIZ/<TRB3Y
MMG45]]R;/XLF>Y1DVO@MEVI6"61GHFM3%]&X MH]E22\I4,7TDL#04I)0Y@J
M 6,+PL&A;CIB)_\NL6@@#,_W8KQ/>JQ/>Z4!LE?IR4L)']0*C(]J>I6SL+^5
M-;MHT_Y[&?-8Y+M=V1_IKPFO%2S&TM)/?B28GH+UF]9&2+;<=U.:AK? "-L-
M/B&6Y#_>@5]23E)<^5K@\%@D=AU,< [(PLU/=F.KIET*&PD2:E0.2.9'G;;9
M:KP Y@"2IVTAIZN$N EW8BW^+SO.R3"K;1;GB7EPN)8::%29TTU%W[V1WQ8M
MIU>E_AH,ACD6_$0_Z[0/4D"*G)X/$?$4Z<1)_6E.#S//3C]2J[U#+) $UHOD
M;,IVW+]+TFG 5_1J-0*Q0$?PT3A%^E3JERR/_!L9*V5$UU E_O!&4<:T_9H7
M_"M;1)?^R@!*7+K%27S8C<Z\V6B/&6U9G+3U>ZJC2=X)#KP!?L5LP_<$JOL'
M\U22H7@58'6??/^/5Q3VHY[EMPXSSR*)X"<K;]8H!<*($6E/76G $G 7?DH5
MA5QOQJM-RLD*^<W+"!Q1W"QI:1>(0?PF>S7&N6_D2KR5.:,][A_I=^\I^-LF
M4O0YJ:'4/HY)_U:P36H*$$T0EK?8H>IE(^P-AU F99)6Q1*.U_;-F?2+VA1+
MDN*+YAA!:<R"0$"Z=/E:<E+1Y?,/CO:(*/G@#=%%L2RT9NT71+A3360\Y6%,
MD2!846\UDGX'7E6JBAD!+&U"_)>O+R2_UX/2^N42E@9NY+TY70JC><K]B,T
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M7[:7UG D[TAUH94DZ2;L (W_HCYM<<D]QVQOF.(Z,'0S4$45AA-,@:O6^[H
M*]1KEH&(-Y1.=1^-EQW7EI8!76$5C(;'/038L\ R/E V7.?'LT-]YO]'I)FY
M"06ZS#(:_&M\6[>X_X6B->AO% C39TCPBL)ROUAPOA#KCPVJ(AX8'64U)Z]-
MC'S=F$$+#?C!B _?4P5-->.SH<3KQ:CUN#W:YX]J]F]Y/ ?&/TV*TXJ!?[]0
MZ5Z"J$S1D)XOOG7< 74P<I.T5_*F+-PPDJ9"/14=5:BH,,"M2]Q&J*)#KQW<
MSX$,8L@R$8B&A6<;U-_'? >Z(4Z@37Y9J\X6/ZI?:27%+F,]>9HX''KQ]\+1
MNQD=Z/7K9M*[2];1+^GZV0])>QF+X-?5\2:5CPEF+6&=3Y=<;^UB09SQ\_?Q
M@HM7H^(QO(;:@.8:6X4T4F@0I#21PM HJVR20<')(@$HE"_:/1E8OWHE:MLV
MI 6T#NM]:J"8V'? ?G:^>&(9%E)4 RISE5&' ,7).BG?M^ZPS%=O\-:R^?KT
M*P&JJ16OZ#J:DAR_M'^C35%2=.9GAHX1H*;E7;G%U>Y5-2OZ,@-6VER-A5M<
MW\9K< (28ZS\,2G"1J$=<*3--YOH\[5-OB,"X>>+9Y1N#BJWL;U>J59;( :%
M^I\.;BY^VJ2W/'?O 6E=A^\--@.S(;?!_AWI'_KFI-%K@V.AB6:=M-/)NAN*
M:@V$OR, <X O(#NBOI*CT@@R=K07=!F@Z#<0\K *=EE?]CMJVVV0AN1]9^".
MXN^4^14L/U(?W.#5QB!E\IFC88%/X^^<(PG150?:\J. *6:BE T4JTU4&5&J
MOH@K8@<2VW "DBI%AJB))8_+7)UNU1U&>.6,(,J$7-9@(0V'+@A%#3EY1U/1
M_E/**M&BHF]2FJX #IE&<,\\\KR#-M[OT[T0"N0V5O1VQ3]["V$PL'K?3'.[
MC< K#!F9HE"@CTZ^3DD 2@TUKR9&;;SP/0I+TJ23X*66#KDIR&]1->?WG!*1
M4+;H'5+7Y4RF,R/K&F^C66^_O<\H?<5XQ!"19+8 &I<5XQ+I5\6.X@K &LD2
MTC_TQY(Y$'C)FBB]UK8SYN9X$ M.21\D06XD9&'HF*+WER-&XWM->(33J-\;
M(./%8-'$. @D74 1?>GZFXA;ZNS:1#G4_-)D.4V\/:#CB2Q6: *'F,+M"6>$
M-]JBQDJG65MWS4I]J&A7P,T3#K6;G?JO+B@<>X1+\7]_/M3^1AV26PU;9N$[
M>9X/O)3[[E^_D&9;@L@AP,FXI!T([,SD]'C/HCOY5S(ANMIUU+5.'PGLHL5
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M\^F,<P>6Y4N6SFOVB?S'M,>+2 IA&7?C#UTC/;5IZXE2)K>IA(]0>&D_NXH
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M2;W7820=HOYW= ' H@&**G?2IF8;K<=\9 "4EJ00GH]F$.,(1DADT,/E:F*
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M<V!W2G]DK[?PN K-M2T!P<&\MNR.TX-Y]ZKT"X#Z=7L#$-\9<$W*H(2>$-A
MO'*8:ZQ'FZ5S3>SC'G+)X!'2'\]F*G''=0>+^Q]$3P9V1HR#;+Z-=UF8(JMH
M2Y=3!ERW8=[RL%.'0"M\<R+[GAB-\\5S)#US@LZ//(@A(0L@'/5\&.?/H#FL
M<^ZON:JC'"L96@(PGH'>F"4]+OR3GAWJ,_K?(7QN$Q&JU9%MQ1N"PF$ E.4N
M;G]*AW:$#6;#HEYL^',E(Q AF74C1+S4RXG6N^_U/:BZ#1N@ALA?F&":P]89
MDG-F*)%_'AJ@==ZLQ?HB6!RW4()XXM\&<R)-0JW36;9>P*A5F\OJMJS^Z&,M
MJT^6BMZWL=&E&,]Q7>&#/)L:[6M\V#S==\-5/5OX%R-IF&S2'5M)\.X(&+YB
M1Q/>**/#8X7-#_!%L2PLDC$&+/U3]FTBEQ%H* /)TZN'6L^-(Y,?-7D'/;'4
M>XBU("92Y6M1'QKH,$/+C*I,41(C/$T< HZL)5VWH_\\6U)_)''L4)K2FP-W
M.)2*+(6.$ H1J\9I8W-=G7$;@*"VZ3^Y/715-_NZ47X0QI<:/AF4-#>N:3BQ
MVKI5UZ.<Z67A]+0U*EFM<V^ &\BAR6%+V/P,(O[&'<&BNA:<!,%'^JF69Z<H
MDFN"P,?[#7W("59R+W;GVY%$##0%$Q(DV847Q5Y U=Z+\4[U*A?*)77.T2N@
M*[=N9*WY!9G+PC,Y<R)I/70T?WZ0_%:B3R*O3_A0_(0H7K[/CY+=&%:2T6+@
MO<,KL+&E35K4?.-#+(IKA>**_Y4)%HG2UA!G]0]P]J98O5GFJS?>,VORCBNT
M^1+[G]U/]EELWX!_+E8S;/S\^$=EG#@/5-+XXN/!2^JH1LN$WRU-D;3,F*$=
MLX1ICP/!:@R7&EDA[3F[%XO]Y%'T0[)(R8UOTBCX[9<6'(@] 3DHC5'L*)_:
MU&7@MZ:6K)U?#NO8ZY1D1:0@W)>8C"T_-@DVJ0D]I#,;V;TIW]3'L7F%/:.W
M=)=-G:_+H]V,O=TWO4W,N<UH:TI$Q68K*3"X-84\BR>TQ?]'MC@FN).HS7[K
M.3;Z4PY.GO@#YM-/GC]]\LEG6<Q[T0!!OP8_U%0WNCTBDZ$=?][,UIPJEU@Z
M[:V/'I%K0!&2V>>T74 Z$Z?7#N&,L&3&4DF]P_A$0^M)RQ9MD_8QC9HU R&2
MZ%M'U^",P%7!?_WU_/7YHHT[3M-Y:1$]\(P-NODLWB%40L-BXEMG?(/D^GVC
M&_%.XY@:6U7:.W&.N!"$EU2![)'NF1N9U8\;_O@Q=]O\<NT^UU"B'6MWRB01
MV7*EG!*__N.2ES59?>9Y;X$4XV;=FLIU^"_.X IXCX\<KM3[Q>.TN77*"R&0
M0=Y>"-[@C?]3QAPQ?F4[AMA>Y<TZ0.GXF"''FYM*<B9A]/?LE%Q>.X&[9D5]
MFZ2+G'.3$?G4S-=LCRDET]@"'>C#%(&;^7,0Q+I^FBX+RH1%6Z.VP50!,MZ?
M-5/D"E=3)HZ\3@VL!+9A>AHQXZ0V4;Y$KE=X_/D?Q9HDC^. @C\6(522ZI.C
M! ,H!=KJB"FFL2*J1V<2P\S>BQL9JIX6"X9B5O>[V^UCO=)$LVC\O,B;)1UK
M_OD/CIECE%V;QI<<  IT.>95.A -E/AHZMTAN2P]%S4/58O*'R;U%3,<: 7-
M7'IHQ+W'X6_"2L:,\CT&^NQUC12(<']IM!L>9"&=N_(8?K3(S%Y*\9V^?5G4
M98"ETDN,[S>M^S+Z0GJ9W.]^5@#HY_$('#X"'-%U,K(ZR*Y3 E0N'^8?EEX4
MR>V9NW2'*_K[GNK3^0I\E0#XV$@\CB=J&@$OS;33V#X)VRQVGLH QY1!*"DT
ML<.7_DLNT813;4=%,) YY5O7C(7(3_Y_]MZVR8WCR!K]*PC'<V]($2!7I-=>
M^RIB(RA*6LNQMA@B??VY!VC,M ATP]V-&<&__JD\^5)9U=48#,6Q1 \^[%J<
M&32JZR4K7TZ>0WH7:UQ<K^GUR0.I=JRB3;]_V\&]>*M7[2NYMMG3Y1O,KE1W
MV^)6&\)81JFM29(YO@0=]\&=]\$E&$0Z?;+TITTN_*1F9-]E80E\>'>'+9/W
MT1C0EG[HR3$<\B<S;'WBE$7>C6B4<& ,97E5A[NX$ U=+N)'O8B_3=8-L#;M
M-_ A='0D^0^#M:S1^JCF*O/N.7WT^M52I&+C4^,S;$^DGV-'F_\D;)1AW-97
M86OP5?B/0[,8JYT ULDWN"8/>G27*G.R4">@;+>R Q%]!K(&]/?P$GHP7 MG
M&>K#^&7-UWS9-<[?NW@?.CIOF5(<(W7:M7Y>.G4H6+]'>""_-Z5/F-';K@G#
M0YZP&H2FKEW5F&S'Z<,L;$>LW7'^;9[3NCEU^F:8U3R7B,I9?_*#!D(J*O$=
M,J;1I2.C)S7JOD8%M]I!78I!4-9#:^8BF)?_\^+%\O>__QV-^/^\_.WRM[]]
M0=Z?WYZP@CHE\^BD)UF ^NVOM0#UZ[;9O^;>,0J>BF:8D6-\V-CN#I[Q2DPE
M5*80/IFE/%(D4+:3T-5B+K\ZUF?,+*K%Y-]Y@QGKXD0;/N\I1A](!D66F1V;
M&V1/Z=]<(8+KFX4Y_/&[2I2#V,2L04I$WRZ$?4/)L,Y;BLO>_#E[4]>:,[O!
M9U8=P#==/WK:TE<K(![U1Z^XJO;BCW_\_>*SW_SINS>O7OWF<]O(ISP([(VY
M+$"(E2B&D^N]&D>$3GS#\^]JPKD-JYMP?[#P@B8TCWZ_"E&KU[#A!-Z2\F*[
MNF):I](-CGBW';C&*B<D8:#9-0.7^)1N46YI_FTX& 0.N6L!CUER?]U:L@M(
MXZZ/2B+5=UO+$,P/'K7>JE]OA?05QX^ROHO/ZN?7SRD6"G[#BK^_N0U7Z^?+
M^0D.H?@__[F5C,HPAF]U08C45LJCB _IKH+?((2N55SLI,2*!(I_*TKJM))P
MGAL=K0>S9B_5+[+&S=N:*ZA[6D%@>OH0%'&Q%,:E,G532K0DKAC UJ9\FOEE
M@W2CM+5K1@'G>KUMA!0)ZZ@.(/S4Z7H-RV*<MZUT [N/["J07ERLVL>W:K!%
M8+S3V%XRX6;B8N'P7;VZ:<-8KSE9\TW8!>%XK[ K7RM42SXG%N_E%U_\,;+5
MFK*[ZQ_BA#J'4IZEDVA-:!?7:PMY?#1R4ZRMR8D$:1I_K?N[U;8&3"S<O6R2
M(LL?PSR#]=HS0BV64JR+0G+R+$2OJ=9Z&5MSX?F'[Z5&RABS46,(TW2SHDZA
M'@N09T\O?%7?5-L-VX+DY8]+)>O""+G.N@D3& Q=1*2@_K%,:[HRI&$0(_.0
MD5W.V^-Z$=^'6W[QALWD$&\.WF)K=Q&^L5*8_/7B[8'*=RVR<DO&L!A&_*U8
MYM]_\<5+O0'?2)'LC62(I29<RO%]1G\O4-?"[P7J^OG]I]HR)%7;'B#JHU1P
M$T9$S5:G.5%M!5G*G17^XZHA^T.&1@)K 6.#VD7=I;U.*?V%O G.P4:>BO2[
M8G;-L?8U1TG(4F,DK$TW0 @LM1KDMO141>6IP'W.B' *BVM"YMZ0NE:PJ).B
M/]F;9D?#IQH$;[_P-I3ZE\+AV[^]>?/]#^_P1F^,?)Y,+1-$PCND!:M_"GM;
ML[+#BCHHPCO&V69$,C?\$;X7F7IJ)!3:2Q"C)',VG:QDEB2,.NXYBS%7SG^^
M^#8VU(&H=10-@:77V+*&TQK_Y+*2]&/F9I)IPMDPZHB7I>&B3F_+@S)08752
MBN>YP/-B!A_%#$K!"PVQ59CJ[II BM/2..=?M2*GOW<8*?[K/*7K:;RI,L-:
MV:Q'W7M<0@Z/D&>$#=-M;S-7H^2Q2O,MCGD+%*/F&\&ZD6-/EDFU!@%(^,D
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M(02C@S<J[W%ZTA?!Y(2#0@%%G.-(,<4FOK HA,=&^#']!@+@41C#W5[5B#\
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M=" DCD5&&<?8&^%JS,WB8JJ,4T/L'/Q=WY0M-$"3%KY(41F?=_(L]CH$R"&
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M#100$MR?LY-^$S>6L4YSR/<V! 4W:'4#%FG-* O!N?IT.!X:IA4X7I^$Z?S
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M"JZMR>S91'!@GOR%'^?8:<PG:QRGKZ2E<5DUV#UY'V,?H:0&PWD3 UVHXB@
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MN!LC$/!*>RU/%!I\K>66DT#95XC+4O)35/ ;-?9P,2ZMB@FV/JU9W'>WBQ=
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MXR8160A>^@$.7D_O-*C B/8VE?R&.*HRP(?RUGU3C^C@=EH-4-$F+T,4%X2
MH48+C=IQVK>;ZK;KU>N4R;ELTW^%U5B!#X][9;JQ/GEMS][59Z1ZFDUV2],
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M+,\7?\\J8Q/(F>J;QJ^)W)GV??%5Q^->WC/?_ZX;1'85<TT8,QIY[]N.=%K
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M4CSNZY@@Y%SBL.KVUD82 ;+ T#+BU?**"0Z-80ZH-TG#1^DCG.\DY-*ZT;*
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MC\A23Y1WH%FUC,,T]<1<UPC8"WS27'4!>>#2>#[[T45/4M],)HG>N>[[AN7
M"V.:#N/J,"9L&;+G*5:ZJZOWX%0".U!I6[]3J3Q=(X6L"%'V.83<IR<R);DI
M9,I+QDC>4@M+?:F$EC7L7KG6+_8Q3$'$G0BAUI<D>]<^A>O_=-^*HI2X%P6+
M9'V*]?H#.A7ON4?4;&;G%XXQZK?#<1CI2R@M*.F,B=4'S3_7.-)$XIEE5XM
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MENR[_+'X[D+=C&$$S_@9.X[RTR0.X_K:R3)^!VP%M9@=PFH3MF NP3D;4T&
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MBJM ,;B! 4*W[[:0;"WF$C2G=\'OTBP=61(A<4^>#@U^&.HUD[-ZG$*[I8)
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MF+L[[.HJ4OHQ-S[J459<<2NOPAI)S&WX\@WWG%DF!]S1'O-"L>:*X1DD6KA
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M#2P?\0,U7[H@D?1/K9=;K/=9AC?YD?F8:P1]6#QA5)(BRV_8<W1]3;0C!AO
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M>L\IY"__XRT+Q#T,\,1\ZFVP7E7MYUJ!:9%PI(<:$.:<?8;O%^2Y1?B+5<5
MI=JE:? %H6_!,3PB/!1DW"5>'C@G7)5)P02NJ2?CKZ=J,2FN XK18^$,TVC#
MN8!]33DTX2!4F+5\Q+@[V"1"D<:"6:K4#^S"2[*_DDAW#TW-99I,$]WU_6ND
MXMC[UR2(U&$PFU4X5NX<?=>E,;[&I>E:/QM25PF>&W&Z2+L0JD421>B#W7 /
M-:RA;<#5MWM<TC^QL.,2'3-<#0V,X3LOL8X=D1(LO;)!1YP'[$VP32;+<L2L
M'@4+V(4C^(\#E3\UM ?4A0Y*(AP(P;LOX/D(2Y!)169$E-^O@SA4$8QU#DKO
M<M)XW?#%Z[3ZT5T .Q\Y+[*$>U.JOV7$[G40@FH-T>'^LDATZ](;:8/:ETG?
MVB8C'?+&F-I>9-^IJR@HRM+*.+;3:<9#6'_3!)8,YEJ+$A-G%A(??!J-;A#)
MQ8!)$,)"BC*M(P3P2H%G;GAG3HYH/L&X 9]E>8_I4*,NR,SMJC:(%1E+OCM^
MHP(THSMSV'!\0B"FD4- CZ)HT\T=J30(,O$$]> 8]GPV3A.LH89#%1/R,=8I
M+XW([?Q<O=:E3[ V&EOE%8A:*& A"(6-*VUX#0TB"5X;KQ$M7,/<,S:<0?O0
M@!Z9[\:1TF0AK?85"U,7I;E%:;U[X?OIUWP_SJ*>8PY[6#31Q,@:"G+I&]"O
M6.Y[& 6N#.-H8R6()EW%CL,=!Q@W0F $4D@"W(I<!4,$Z<;[E5TS0>B);#G
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MYPT43C$KPEC9M0*SOH9#R2%.,D_<&X?S5JYZ#-Q2J0\*M7,^C4XCHYT-TW#
MZT_PC"/D5XX8=A)DJ.U[3Z[R*7$J@'Q=.<^LT)/^$[V/3*1EH8W7<W UO"NE
MA#YJ3$#T#-D/_X*P\S14#*.MT]%[LW%;WA3>PJ[ 4+US1CU>>)^P1"0*##W:
MI<$:2>)]68-;35/Y!FW5Y%"O _BDGZ^\$=R:A9O!Z-0YN)1?%4>JLK7=&[2
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M98@W])>ODBX)]9C)" 3FUX:3EO/RST(914SM)A&E0T92B\$PLIL\W<4R==Z
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M<N(J$"<Y8[,CJ$$<$*F#$.I_Z03,>N5HS5N""Y<2=956UU7P5EC2*7#"#"B
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MH0PI=O7+736BML5XAR =<R!F%H3 7*>7A. 25 QZ-V"\KK F@#=27Z<VVL0
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MLPG(&FK;?#K%G)C6B&0N40X+_7KE_G1=5^L](Z\XR6%XH^SYB]M.IXCB\:H
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MN  @>-0FKI$C?(WI\#\@K7.EJ:'>$PF Q06($4TD31#;A@ ;!D$6"N@%/=[
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M)$_UVG[MDKYF*CXD/?7<ERP#YG"<<-'5FW.Y1L1R2:6/\-5@,UNZON&]4F2
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M;39:=_RLUUG]SG6_7#?67J?1[>S+8(\;Q]W3/1EKK]'9FW5M'3=Z_>.-'GM
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M [DP5<B.BMG5ZX]VVZ7FNXLX)]8;55[ _S 40@:7N<#E="*B(95!C@@ .1:
M(NN!TMH ZJ6*(E2"4U38(DHLRQ994>?">JOK"_@/LKH^55U'7,! BZ1U#A#,
M-:!6A<@%# .<6JJ<4@&14$)U77OOP*>BEG JQ-+U_;A%]@R\B&=@T%ZP=?J7
MUUU?B&$_''9]X:S,2#,7TGP=)P;0$<1@2LC2(=(!R@Q0A$M@N6/2>FN5EAN;
M"I8I/II= Z5A!5E+GU%+1WQ 4NBM5! 8E2*'"%$@H70 $8:(AAX)Q#8V.2F3
M V_MG0/]5,EFNW4*4N6])>0QK#?*+(T+C%*DZNV6S8'*)Z#+[O<"60H>L'7"
M*,1(:0>HA K0H!&044Q 42P=E50;8C<VZ1I>%LG:N70.D+5S*=I9N]5.ATS@
MFAO@<;K/I20%VM.HK IK)+6R0N"2:>?:.P+Z&8S33_R?37*Q]*45OITV]_S7
M!EQ?+$LS ^U\0/MCG 81J35F@0(7+:GD"Z' 0*-!((QP([50)M(@Q,42\\5+
MDY_Y$V=)!K4,:J^5BYI!;6Y0&[%'%%Q \8B)>*8MH$0KH*DT $HLC8_VGJ9A
M8Y.SJF(+YYR_%*:MD6MI>E&EOQJZ:+B9.D04F:B?Q[KO#NL7[Q8]>)=4>8E$
M4;CV5:J46.+22[..<NWMCV'MI>9HH^0"3*M?@&EKV'#K4E^G J2Y[M(;J6WR
M$@;B8&]]Z&^M?,'G2=P*CAN,@F&"40B ,AW_L1"GJWT>($49(4)X8M7&)JG&
M0[Y$SKE<9RECT6O;=1F+EH-%8U$"SR$2# )!78H21$"2!$(0,+?:0&X]27=\
MJA0OG"10OD#!:E"[HC%3KI]4#BZ4A#%F9F<(>A($H7$ZY+E,)P,!W*8+ST1(
MH)'%0&EH)>(J\J%(AVB5(%FB/*6<3;B2_"'K[Y+T=\Q53*GECB!  R2 "L>
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MM4ZT$7<V-A&9)_PW<!65( HXYP;-7LZR[="/\(0)+"+^2>"2O49E\,!(H8&
M$@:BB(->K03\Y0!-N3:6=$;B( +@V%% J10IY\&!P&#<'5Q02.G&)D95Q&45
MTYD2'^;&N5=A>7DGEF@G'I(3BAD,3$O $1& $@2!9B8>Q\QAXAV42C]FP99G
M8^4#M(2[2P:DC=8<,(PEH)@ZH$F 0#!%K*&429I*F<.JH+0JX?T[T#\+!B;4
MFR\:6*W$CU_Z^+1OOGF]0&SP31166U8YHS%UG8PEY(O&LZKH* 2HD!66X=1+
MR#L0A:. =DH# X.P&'-/F(_LH415U'+!P]($_[)>+EDO1S$^3Z%AEF.@&(OF
M(B<VM2SFP"$5M5)2+H6-IUV)]/+M]/?:B@-.BZV;E4O=<*#1JEA]V>CI9F[P
M]9K-0F_%\B%*9:^UW9=)AJ'Y8(B.TP/NA/8BI011%TDW530Q P2"AR(@0DC<
MNI$><%Z5I>I7G#.$2D,2LOZ^N/Z.U1%R%A/!%0B0:T -X4!)AU*N'T'"!Q_E
M&FE$-&4Y7;AJ6/E2A5:!3%A[=7'53)D4E7:_<6C[XK+CSWRKV_CF*\UV]ZWU
M5?CE17A%-\XS_C1?-^.AJ(I>A=OC@MIK1;GYOZ*TZKZW'P[TCPQ<\P'71"L&
MB2E%BFB .8QPQ6#R]ED)L)"<8VL==3#U*$?HOF_B7HVM[)981=5^.N7(JET^
MU1YQ$A7%QX*G@#"DHFHK!#0B'J0J9U!+RYR514]2<=^B>!75?D.>C3$RXGQH
MV$;OC;DTRLH]/OF>CH-UN[K3BDO:'9/43E]0&9/FPJ3:1$.'(*!R2KB4F,,!
MY3P (P0"A+B0\F4#+C )DJK"<@%4RBZ.$NOS2Q*.K,_/H,\CCF&]UMA  RQ.
M]9.C;@,CF0/>8&:4-LH;M+')5%6A^S&45U'GM2]_V>_8T'VP"&9NX%#6P,IX
MX=+=0E89F^;#ILD^#LY:)@,"WG.>6M>EFE4LFD."<N6,\XCZR#68K K)5J6Z
M>^[DL&;1F*ST2U#Z$2&!4@@.H0#,!@HH5AQHZ!E06@4<HH4!>30PHLX3OG <
M-7=T>*XF4T7FY^P49L8Z^?U5_8U$,;CVE6GZ6RDM!G'3%O-5$>X?K[A :X/]
M+]NQ:ZOE\DFPZ$DPT<PCHCUS"@60+KVF)@DH78$U@'N)F>-4$"8B_>.B*OG"
M^7U+UZ-7]E9E1,V(NHIL.B/JTA%UQ*TEQ9 H+ %A) #J=:+5Q@#/M<-22P$1
MW-CDK*K8PO9T:0"U(-__[.GXI<,K1_&?X< O=.>TT>I_/9[$,.OCUN^\O%;B
M@E&?^8JV*<-)MZ[3):O4%2W2ZD[\<ZO2B",[[11IU9U>I1TJO3/?]4E9B_4K
MPI*AT=(MVRA<B?$/11.G=Y-7K\;68?#E%+\3+ [PLMTM4@Q_Z_BF3K>V_O6]
MX7IG0\@8^^! LG#T$6WB(*YZ#W^D+&O\'E3HG;MH8_^F 1<( YUT'%-,I%64
M2Q.Q3U 5#%5&6,W5"4+IMF;_4V>=X2PN]:D'IN/U5Z!#G.1ONOE=7W<W_CFY
M_^+FN[/V=Y>MOSB;_S:=^-$IPWW5E1535W:O5CNL[VU7*WOU[8?WW)CN\5=1
MO>F#WQ[7HL^WNI/4;/_2=W3:Y-U5F]0O>ZT^@/?.VE?Q0:Y;[?_N?UA_V>O_
M7%SS[/\8W]'_X7)XJ7/\Q8N(]+WNKS];A $V/+0.!2:/<*0X!^)Z-/5EU_\V
M_.%?KM&];.KKWQJM8E;%AZ9X/@9J(_D["DG2G(&_9?#X@5*]*Y3JSN'5?XW+
M=QSA!U^&[]"#KSWV6$3><?SPRX\]]O'7..7/,]C9UN G/JTY75?/PX#E3 1X
M.K&YG9.:94[]/?TZL[JG\,6LCKSN="N[+1=!;'@[NT)0=6*>;T:(8Y;T''RS
MW!).WJME37B6?H9KM'!C]<G?A']^P%NB&>%_7/I6UW>?UDGS*6UK5Z*W[AN[
M2_,I6HNZ8\^*,(WSWWRS?9E([B))P^OF!YPVQ;7QY&E-I$.*6"DE94YH*!6+
M5BX1S@I&Q<E..ET@@@@L'"09;K:MEML9;;7=/A"5R)]W.O3G-6H[A_&9-5H[
ML-?'.U_A<?KNG3U2.S]NU'?^O#B._]T_.&L<?Q[Z\RXOC@\.V?&7]XWX?ER[
M^ B/#FIQ/._/:A?ULZ/SLV8-'_W8_V.7'M_UYUT<-^L'S6;\V]?]@Z/X?9_.
M:C?-1NW+[O41?M_8_^/PYOA\EQX=G'W]S\W0E[?;JVV=,"R0M 8"D<J84>T(
M4#KY]+RQ'I/ B;0;FT16.1$EJG^PI R8C$UKBDT6&H2\Y$)23 ,QFF#B*)5!
M!>T](PF;D!I@TX+AAHQ-2\6FZUML0D$B3K@'VAD)*$,&Z!!_0EP:P@PC5J5B
MB[C*IMQ+S+59GE\A__ MGR((B0%J=]%H-;J]3N'J?V,7F4K*F@;RB<"T-2&=
MC$U/P::/X[P)8\<%QA8H9@B@QL:?G)5 .@GC_[+ 9+] (B&T1*4>\CVF%28:
M69V7K,XCJL$YMX@('BT@%J(Z0P*,(PQ(3XF(/SF(TC4!6F7X?DWG]:C<0D29
MJ48_.[A]SP>9+S*5GH7<.HX'.-7-0#474!V.\PXEI+8RB<7("%2(XG2KP0#+
M,.78.QW%NK%)956)9=6K+$VZ:K[.M&J,):O^PJH_XBC8$L=0T,!RE]KN1**B
M%#6 <N8-E<P''C8VB:A"LBQW2+[5M*ABID)&E=!I7PRYRWC>UQ.LJ74#KGE*
M1BR!M,Q?.^(6PD:%J3*(S05B1^/\A3-M2#Q[ /8L0I=.I;85\\ K%13&6+@0
M'N0O<]>** UU6:(_Y2TCP!*X2T: 5T& $8UQD%*!(X-AQO)(8U  4D= \"J5
MH20>!FT?I#'E0X"U+R53E&BL-(J]_[2,KUGMMM=\QML)VNVE5$K?[0U$FB-U
MST@W)P^2O=:WN.XI.:!_D@PED4^3N4Z3TXDX',)!2T:!PJF1NPL8&!]8M)&Q
ME)%,"F5Y*O51(J=]CL&5SZ.5%?5Y%'5$^ZP4T=B+.@IUD-'P,PQH:"%P3"%K
M1<#:NQ0P7SC+L*3AM7*3@G&25ZVT_-,J$:]NJ?2RALZ26.KM5GO2!,T!_Z?
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M!(F181XXZ F@3DF@"4H.!N:@)089GGP+[]@B%QZ6'YG.G#ISZ@4A[DOQBW=
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M']X[T,1:;BB@#O,4GQ) I>J03 8B*&<P!/%P!ZB<!+!ZZGZ?D2RHZPM4AWJ
MM<RN\IG!S*KRM5&ER,"1]4(#$LUZ0"F'P#@4@,+<0,TE)M@\V $J:_SJ:?ST
M7HT,!X9TH,ZA:'T0K9ES6#*#H37<\GS K[*V'XX*12HN#54.""Y2OS<:4G='
M!**%PKS5AE+D'VS]E+5]];1]RN7^Q50]G^^KH/'V5N-5B/O<8 R<M 10P@20
MBC" M&$H>2VPE@^U?EH+A<\WG)Z[=Y.-&\E@136CEDIEX@%C.!/66280L3_+
M^,_DH=10<NLA^'X"35"8IJ8O4/I46"1BB3 XD@FFA8NO.IF\G54"<14N[O,L
M,:B\+:V?$K983.7G"UMD@O ,6GU]J]4"4J<D"2#X($&DA29J=1(<98Y133SV
M4:N7U0DV:W/YM'D).3G9$BBKHL-;15>.\4"B>ELB>*HJ)($BQ '%>/Q%2:=T
MJBHDJDCAK.VKI>WYFE^64I;2*J;OY).SI"?GWLCPY9@3S)".0L00T" %,%P1
M@"@4*2B.&92#DW-9K8Y7[OZF:WQ[E72?I!&Z97U*]AE/Z*DT6I7+C@>VV>[&
MR51"HQ7?5OS4[E2L[IY5*RW?2Q]K#!]AV]U>-_WE'W-@@$+,"LN%P5)30H*1
M2GI/?'"".:'1W+;PUFTYP>Y!>RN*(HU -S_HAMMK;>O+1D\WQ\!@N #;:?!9
MS^?3\^0C'_K*O[D__J;N__YL'N/F-W/>OJY?'-':@?U1OSF%1S=QWO'9^P>'
MY/C<-6HW7\G1P>_G]8N//VKO)=W_> *U=XY! 31,*30!,J T\G'76^8H5BZ@
ML+')[UO2M]A0Z-#;R)'-F<Q92EE*64I92BLKI7SK^+DCJPAIXW1DE\0*2AS1
M3"D?D$/!"\65>[G(:IQ]\5*.H,Y/,,<BJ )3@21W $:.""B!%!CL'-!:6"Q4
MT$RFMIW1CA1501?VPI88/-92N]<.XM=22G/8]BQ8H@5TSEI,$7>:$*:DU0AA
M2_U,R7)+\>_=A]]LW\\,OZ,(&'344\8,@-A"0&5P0%%N  ]0(2009-*E^RU5
M15C&WM72ZHR]64I92B]^0B[!^YU/R%<^(<<B7=A(!(E30'@A0=P="*B %/ (
M"D.YMB;($IZ0ZWZG_<$@%ZC\WFY==2N%^Z"B3SO>YSY4.:TB2RE+*4LI2VEE
MI)1O:3W[+2U%L:5!V4 #93!2.1XLYT@Y(5)[CQQ+*#U5OYZ()7@""?<. NP0
MBE2=4J!%0  992VCRBI%-S8IAU5"[A=K61_H6$O=7CN 7TLIS>$GD<9CKRCC
MC!%JB-0H6=J6.V4%]Q1F/\D*@.]8),%HH:@Q@#@C +70 J60!9XZ$82W&BJR
ML<FK$-WOY9*5NM1*G:$W2RE+Z<4/2,<9"4%218RA <M4?LXJR3SC2%OQLURG
M?$"6X( <"R0(P5.&! 1>$ 4HU1!HHB20%',)>3"(L?(=D.O>\>R1.$+7]WK-
M(GC0?['5BQ-*OUWJZR>'%%8V IKCU%E*64I92EE**RNE?#WAN4,* ;M G81*
M24]]Y'0&(<A<(-8RZ*3((872D_:;R9""I-Q*EEH3\P HE!Q(:"!@0=$HQT"-
MM1N;",,J%+!$Z3\9X-\BP*^EE.;PF'B*+0](!X,)U82D:^:!,)2JMFO+6?:8
MK #XCD(*3%/+K:; <*X!-5 !I84"7FA.L/&0.!W!M\IHAMX54^H,O5E*64HO
M?D#"@(W%1-H@*54T*!PM%HBQ1E!PA'0^(,M_0(Z%%% T-06.!R3!#$83)3@@
MI611=D1#:H.A!I?O@%SWJPF[/^R9;IU.K;\5M;'E^VKZO=$[JQQTXO?T)9)O
M*.1H=992EE*64I;22D@IWU!X.WUDMNQ_KQK=HNYFCBC,R=GA1$1!!4L-8PX8
M*B6@ 0>@K++ &>F4@@K*HKE$%3)5Q3RWC%DQ!5\[E%]+*:U@*Y"I")R])C,C
M\"BL(!V' CD&M.844,ID1&!/@ T!:6X%Y!AM;!)5C7LGP^]J*7:&WRRE+*4W
MV_4C'Y(+'9)CH06%D:#:6$",PX!*I*/!(@RP@@<I'89.A1(>DF_VND*<DN]4
MHJ7>ZS1LS[O;/S=ZHR)(W7QE(8>OLY2RE+*4LI160DKYRL+;B3'D*PM/9.YH
M(L# .(?4&@$P@Q;0U&]+!69 I.W>>B$D-CQ=61!5MCAU+S%TK*5NKQW 9REE
M*64I92EE*:VTE%[/5WSC.VVGNV<Y_?QEF.:8C]@&B[2Q 4B&!:"<!V",U$![
M030-!@FN;Q6X1$SS11/07ZL+](<KTVS82CL$GW;_E/HVTWL]S]/HF47K0D-"
M0V%R$&>X(X(%+2 W4N&?V8ZYT?-KZC)^N-'S9:-^\_?%\1^[-T<'-7B\<P3K
M!X<LSO?'\7E\UDX<2URC]//1WQ+7MDXL,E;*8$ T*26@-@B@(@( 0:*]2; .
MG-K4#EXLL]/SR@96<_@[2RE+*4LI2VEEI93O/CQW7()*'!_C E2&4H^-YD%!
MIF0DD]IKECL]KP3#'(M+&$PQH1 #1"@&%$L&M/ (!*:YA205:(D<D1-85? ^
M3UP?Z%A+W5X[@%]+*<UAVG,>(541+3EA%#*DC",*AD"P=]J+W,5R%<!W=.<A
M"$XQM1!HK9.!CA60@6A "<+,>NB5(!N;M*IDF;(YLU)GZ,U2RE(JXP&Y!-]W
M/B!?^8 <BV4% FVD.QP(%2"@4 >@?316B+&64 (9-:)\!^3Z7'<04_7Q=]TL
M0E.Z5]GQUE\8WZD05*TDC5KD+L/ -Q/G]9!K9@TP:ZI;Q7B/C701II2C0MA(
M!P.2J62UL2JR^Y.]F;PI#T;=B^_<O^IU>[J5%C+[3.9#)3) I!25.R'6!F*\
M L%[ :A!'"39 8&QE"0PKX)8=H!]-M5XY62:9]3O:?CWFNK]C^<1X!R"*Q.F
MW>=A3P.TN;*(SMK-N*+=W?]>-7K7F6;-#6BU6T!CP1"$" $.40JH(!'0*+)
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M;Y!*GFB+W<8FK@JB%D_5SLJ=(3A+:77\PQF"GP6")]W&5!%HO22 ">D!%98
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MO(K P32S(M.+5P>,PUO V/]X$D1J&Q8LX-)Y0)'10"KH@:04(Q^,XBADP,B
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M@'$*BW5,AJ97C-VU>I/NN#@%E#E273,<X)9YM?;IT\[^VNM.,.DJ&(4;'RP
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M[W)U<="@'H;?#/)YCMLC*=VU[FAPV2! FXU1NPSQR_6(G.8Y@<T63/H],PY
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MQ(J$J4S H.669-8: F\;\!-BF1JV]B;JT#SMI#R:-VFS!S>8>5Y67Y3I2U-
M&T]KEH79X/L@<"SAOR^5+C.9-4(_*5HW2A5H2=;;]L@_^5"^!J.U2+9>7F[
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M5=D'$#0%N_KQD$9^JV!%^.7]%[B^[NWV/O[8^6<KA.O"]0%*7&S1W?>'%U\
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MGH-[F^S.;,N$M-*@UML4P]7U!BZ]JYH=UQT+NX^'Y@3<)"2D*#7?*QSJZW4
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MEM-)4W6JZF(ZX<CWM7,7<J/NB7.<Y$FIL\LI:5WU[F+T#RF5?^'#^Z,?Z@)
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M#4%.<[$RA1D_*PF$X>&Q46#?,0#U?/W'2'1=%PIW[XI)R(#O/S@WR/'?-[;
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M=CYHFK>OO?;3.O/YV\%ZI^SW-_-3_(%S(H]A:<;^_*-I-H.G-^X<&&EDJZ'
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MFYQ#2UP8;CX)T_W .3K'?=\[QNO!KF]/TS"[O"I>XP7%#%%4V;N\RG5W]3D
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M0O7G6!\]"ZP?UKAP6F_VZ7W R)\[8H )K8EVX<*EC'^=DK9K_C,D;&H'HS!
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MV><(_C[9Z7WJ[OZS%1W^\Y'OO2U_\^\_3V1/=_>^_OEUYV#G L9R<?C/=@3
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M2HA):6BHC,(D=M@L66&S>]VKOH/0:2GR#J']G-I: ;-KJ*U?B[[<FE9:;*7
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MJ8BD6H"IL%%FP2:DZ_-=9KTS6$DG4HM-0/*\<BS[W?6)JXE5?MYG-27??QL
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M5SAF'Q&"K,($A5PZ(F YI9<K(=6JS:VEMN)>;VCF"&5N>L&:O.'Q)NC5(+G
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M.Y?QNN;/W:TCW*3;E_N=[?.=SK?SG9/FY1S)QLG^^<')$=_] ![_29,UXY@
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MOJA#"D]@*51N3%J!(NNE!IF[@,RW2:L 8R) \5/D8ER!.^>0!CV L'4BR[+
M@S71*J#LWH7D=8SA^>[;5<48ZLUY_\TYM@ 4HTKG-D,B" $FN\F0MBQ'<5-2
MZZ@*\:A5ZGL?M-9QA8<B>)@^U*D)'AYA@EX-*#^",56>'Y?IQ>#.U0!^3P#?
MG[2NF)2.9#Y'F%$*UA4/R'CJD?14"44$_(+7WF7K5+/5GAX_(7_#XR;3U(A:
M(^JS2,>I$?4!$75L$N>2:NLM1;F.E>8V([%-=8:8]C8#LYC(C$=&')7-MQMZ
MJ8AZ.T:<YU#+M&2MW6;!TCYH?#(74ZDZCUI25XVB'$1L.I#Z OF_6\:VVJUA
M*]1%=KN;AX$191C)4%!2(IX1@[1D!E&!:9YG.G,N?Y%%=K-B^%:*Z=@&(^(A
MV@)(?K=N T]03$<VN+Q=06%=3%<7T]7%='4QW:K;A=2%<W4IR7-(PJH$,E6.
ME);0ZW)83SN[>]OQ'JP)ENX^_8SWZ3[;_W>?[)]\/&^"\[J[Y<3N7I/.4;AV
M]D5S;YLT]]QE<^_XY&#KR\G!B3\^./FGU3S9O 1+F>]<?A?-R_U9GNXL2,&,
MPHAZ1Q GU"$;>Z.XN(K2!<\\3N5R]\\.K<OE:HQ[V1CWT.5R-<:M$./&03GO
M,?8\9,CR+'8 EPP99BD2.0\@S YS&=ONKFNUXJ!<721WYUWY=S@J&1P2E?)B
M,[1.D%E5K5R"GS3G,;X89[S&H/MBT%2I7&P8*#,ND+,^1B<QBS4X $FY8$3E
M/LN$!0QB^AGERM1I;,_&?JAWZ0/NTHL);XA;$[Q"6GF+N)8464D%\H''GA8Y
M<2(VM*!U1MN+R&E_$Q4SJRJ3GSEGG&3RK"%E*4B9JFL301.<$888S3CBPA&D
M0V:1"]Q@E6689AX4OUA5AM4SBJ#4>W35^>OU'EWA'KV8X+' TD:>?P\KC3@-
M.=*6PT95W/@\RX60D<=B98QA=01@Y8GLM^D/=G58YE7':U<Y-:\&D1\A>7T&
MK&N<O@M.3U4#*I<)D0N/,L4BWQ#Q2-D\("*H\5I@IS6)AU5R9?VP5[%IGCC\
M4D-F#9G/_?2KALS50N;8M"6:!Q4RAP L#;B?QB!#*$49950R2;D764Q(Y_3>
M#N@S@,P%J>C/),-W^=3SF.(]:O.R7+/09Y*UG-X@5(UJ7E#6LM8;2K [)2W3
MC4S?+;OXACS@C#U$!Q#!'FBPM\N%OF62[I,:%[,9HHOUZ&*L?.O9U2]_X5YG
M-G.=!EZG@=^.I;+4XG5/E3IM\CG&VE)&1"FD4]F3K\QU;._0S^#^?1,'>T<_
M#_[]C)N7?W3V][Y=[G2V:1.^N]_Y!]S!@^\[<Z[C-W:P]0V>WV[O;KUO'VQ]
MOFQ^.#C> 3<3W@5<SB^M@W_?=W8ZG]E,:K@1.+=*<V2-"HAS3)'%&B,FB64Z
MYD+$E"6VSO"+29NL4\-KC'MQP;$:XU:-<>/PF&6*.\4)LCIGB M+D5(^0RYX
MK70(GEI?\#6LF &G3@V_MTW:KE/$'SU%O**>F,M!K;'H+E@TDR(NJ*"6(QF<
M0IQZC8SB'&G!6"X5IP:'M7>$U$RGKWB7KB1%O-ZEJ]ZE8XO!4:%\L 8%&QF>
MG,R1)3* Q< P X_)6*]BKMB]?:(Z1?P.8:I>)YXVF3C?=<;X8U@"?T[,>(TN
M=T&7B6SQO>WSYOEA%AQ B6,H:,P1SZQ%QF44Y99P3K*,<N'6WF6B[H/RBO?H
M:N()EZ'?\V9P7._<!]JY%U,[5V8X)RYV*X!U =M N-A[.D=<ADP[#5N6NGCB
MJ"BAOS^CW?MF0@:]NCW*8Y22%9RR<RR5-<K<TSZ(_9ZM8@&#XY$I@3C-"-(<
M?K("<XTSDCLFP/O@=<?55[Q-5]L-I=ZFJS8&XK&"E1)L>&0$P8@3(Y"2>4!"
MP.[U.=%"LEA'_IQ">:\^2%!W1GG L]Z:Q__1B\MJV%X!;$_5EUG+I=;2(P&N
M&OAO@2*K-9A84F A,TV#S=;>\75&5DR&6/=#J7&TQM$GJCBK<70U.#IQ1I8'
MAV.]F2/.(&YLCDP6"*)$>"FHI9)G,7.0ZM>#HZ^V"TKR$AOEKFA,;)3';(<R
MR712]SV9Z'OR^5"K7%+,P5XA3"+.8@MNEUGDO> \CXUR=?8B^YY<*7BC4L)7
M7DO(-CB]7?./)1N@9(2M_+9T@V9WJU"\[JYZ@^JL[G_R<!5Z;ZQ^JRY\JPO?
M;N6E;(4\@.+QC5;7]3JAKG*K*T >)>@WF[%1&<"5//X)_VL-!U7CSE?LMQZ<
M_-/9^?>@!3XHAG'BG2V'=_>:/YM[OG-P K^?O/_>W/JKO3O;O;,3O[=/#CI_
M?=_9^\S!;TWC:UYN_]RA!YV=+7CG?S^?-SO?Q&PS%,DE,XPA:YE&//<!&8,9
MRHS#+L@0&):KSM]X90&^&O'>#N(]0GBNAKT'@[UQN X'ST@6./+6L<AZ3I 6
MQJ' N:?*4RT%B_U1\,OI ?7J,]KN3HK^)E)D5IK)]A5FKW]18\X],6>JV"V7
M629()A$Q1B!NI$+&9SG"A@@B#;>P=FOOF*S[H;SB7;K21+9ZEZYJET[DL>7*
M$ZG!,O">(V[SV$/-*,0HUHX9P0(!RX#Q57%'UGEL=1Y;G7_Q;/!YI594C<SW
M1.:I0@#FL0R.:H2=\X@'H9#2C"#)B?&,>BKS;"7VT[-)L*@3U6J@?*Y ^0B1
ML!I#5X2A4^1/*DA#$&.Q][ESX(.Z'",ON%*:YH8H%^->3*R8X.YYIZG%WZ-T
MM[IGJ3CX960+_9^941>[@?B0>VDRHUC@3BM%2. ::VV5\U[G<P>]C7XX[8<!
MO,Z@X<S@&'YO=>Q9?Q Z,0LIWK?[H]=R,/!^<*'U [Z9]WN=QO"XU?>-4],?
M7C1@C\( CP;KC=-^J]=O#'OP<1CQIL(;_DAWL &N:IR&?D2!X#?FI[[1N#*A
MJ7Q[3C<DS/KOI[U!*W[EM_04&-?O5;I/FIV)+Y;2A\=?,18$[6QX]5?FDA.>
M:)'?HP:1TS,R^=\XXK3LV"N?44Z9<IIGR@(J2ZYSR[65SF3ZD B^5GWKN#].
MBCD*R/:#^8Y,#F_YFVF?FXO!VG]/;P&0_YG)GYVW8G;>_1_;AZ\N&.[5&^K!
M)W9QDF>VT7C@#,X_>YU.:Q@W43S%^3,)^5'H.E!E6ZV!:_<&9_UGE,KYN51F
MIZWFB>,'H,!VMD!I@3(#I=+:[^P<'^QM7QQL[=.=#\U+N _;:<VD<G8^7NQ<
M'L.SX1E[FS&5DX&2:NW3]^WF'BBKDWT,ZA'&["@HII_-K>^'L4A04"L0%J"6
MN"42@1[R2#) ,85A_HTJ3 ] B. WH^%@- DL5R3S#G.CK14<Q)S$B(W02MK9
MW,^)A4CD>5-+,:\,9G)\YR'VYN=/CU=QRR3H6N\<X8)Z(YQR!+LL,[GBG#V?
M[-1E$Z4!R$V<RL;?P0S"U<B]\)T*=#TY&PQ;^<7S4:M[H+<B4XCI7C3:\;5
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MO9.,K4NJYN2G0O+98$3TNAH%A$6G#KPF<Q1N&=SZ%$-(IA]F30=-P.'3VH.
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M0@N+K31(1MI03@U&L ,#LEQC1Q2VPL><.+E.Y-45-2E]I5 JMM<]B[9'#*6
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MO5B!NP</_Z/]%KDZ/O_<V=H^%(ZJ*#(HD[&A<,XI4M+$!O<>9R*0F+*^U@B
M J<Q8:I_%FZ1Y?,<C(:O5?W3A%SFA5R.*7ROL0]3\HV)&K_=[IT/?KMIJY;I
M9UEZX6$J[AXEIO5]Z"-X\;8Y'83?JA]^]ZW!:=M<_-;JIN&G+_V>PF" N:4Q
M!A,[3MZ*SE1,X!KVX7^^NG_Y\4;ZZ+^'?OXSE6T0=?7'>(-<^=EUMP7+**.W
MN^U_IR$7PX;WCU.96,U'>6VIF/TW>OJS0::MT5C?/CLIQ5RO6K#4C=R3\5T+
M*1E)0_GBR[U3D6SX-&\US]H7WZH@J2G>K9>GM,!B TV]Z VK:(W[?M3OG74]
M*H?M7 AY_ON2RPLR_P3$HA/E<(6!-P4=(\R 7WZ[Q>I?.1<E&B3 /!TV!KU8
M/EF]6351.$[3+??._)/R]'^SL]Y(_](-*I[S"DQX+>4R%/PM@ROGG"XW$[BQ
M0 I3S.EQ]N,MYV%))Q-TMG)@+TGLN0+#20FOG+5".F9)QE=<)U$VI2T0XDK[
MZL7[#OO__C4XV.O1G:V_OC>W-F-1MFCN'>&#O2_'8$.U#O:.://#3JO9V6DW
M]_[ZOM,JO_.?OXYMQ[=W3_9QLP-^Q-8^V=GZ_G-WZTM[Y\.VV*'PG*W]\WWZ
M\6*??OL)U]#_7'X<-K_BGW_O;0^;FX<*C!B?$8E$QF/S]=B)(G"-B.>2$$T,
MC[7?9)T0N4X6^!V+M=1=$ /??I^\01U1@M-$H_L).S-Q'-Y+6=3Z %"+5[W3
M/W:CX103X#^U3;=6"->U%,D#<UFN6!XH!VV@G>(AYUP1P3P7K%8(SU\A?)Y4
M"!0+XACCR&%K(X\90]83CU0F'3?4>?#CU]YQML[(_'';B]<&+P:K)("4/RN[
M-JT.MA;,RJN$+>H,X3;WPH.%D_G,6&L#$5QB%DSPHH:MYP];WR9ABW$L-5$!
M$9)3Q',MD<TQ149Q)YUBCN09P%:V3A>T?UX2MJZ!C@>'K1=N8NG&;J?;LF>#
MVM1:&K.\#S3+-=&9R[BD6N=.:N>-%80'35V-6<\?L_8G,0MGQC-G'1+4BDAZ
M *86IQH)8HF(6:^, 68I1M:YY*_/UGJ^0+67Z@>FTV^O.]^YCZE5AFG+4QT&
M2^)[9]&_KU[S5G'<5PMZCTS,4H/> X">FP2]0+S2FGL /<40#T(A(QC\FA&7
M9\HP@+[8W1(SM4[T5639R]IJJ]ME]P+-_TY'KY/T)!.=*!;3E5S/3IVD#WOE
M,\HI4T[S2.]%0%_HW')MI3.9/B096[LY]^/!\6!Q6H?>N+;?RCU2-:K]O=4:
MQ&8!L(%3OD9D1D_S^Z6@+/TS-CA.._X/,PC^D[E(#7F?3\)&L]SCIZWFWO[/
M_7\_7C0_?#S?C]^_A+VXU>2[6\>=@[WC$WA^!^[=VIE-V.A\A/N\/X;OP/?^
M:,%8+W?H-]Z\/.*['PX &YJ7\"^\QT?\G\OMG\W+S_@P(S+'Q@0D%1@EG,F
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MG"7NQ5R3(F;4[57N;V6JQ9J=R38-^;!$O/*Z*G>B+"Y9@GMWGF7U@=AX-=[
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M*0+_HQ)[)B3CQE&Q=MM][JJV^SC!>^E9O:F8;M$*.'?VJ3I#5E5P&[8JT=P
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M./9;20)PS&/,'1$^:NY-T(1+KVBD/B@7G*P+ZZ[4^K S2:LC,SXZ;I&5-A=
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MD$'D=K"/F*R0I!1*6JDCX5)9&QU5,CIL2: 4AQ]XN^O)NF6R% R4-%@CFDA
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M;B_Z:_^:EGH0^9G!GQVW<G0VBQZ\-SWN[3KT[ -[K8EP,; $;S1^Y&NRENE
M#/-::RZ"LE@; 4/,5/!*\)M]3=/+T4['=T_COOV^W>K[=K</1& ?KO];&\#J
MU1>.@VKAZ%X<?&Z*75@LONS_=M(\\7"\9WO;7[_#?8Z_?'XGOGPXN#BXW&WO
M7LPL'"=@5%U^9;OT4[OYH7D!]V%P+M^#>^Y]?M\^V&]__7+RQTF3?F3_N?P(
MQM7!H5<Z<>HL2C08Q(DTR$JKD7 "1X<EC426# +P((:MO.IS(9DD4ANOP!@S
MSBJA* DD*(Z3Y7ZM$6$Y/LM*VQO&S.GRL#=@W$%:;G4!%5)Y(T+>?;_IYY."
MFP G.<TM=X%HZ93PB0H;9( /?NS3G(.<_>./8QBVXUXJ7_VW"$M@'$L?_ -+
MD]_JA/?P.4#:?F;R;UL4_2$(GPPA@"@:;Q$,/091=!AYR5/$G @CZ*QHW4D%
M%F'=WP6S!- &+)5"#F#]+O1A8+\7S EHTTFF6L"@\D>PNN<U/'7;[>YY-E!.
MAKU6/[1\:2*,[)OQ]V<%!>XW?BK.[ [A44/_YU]N7;6K<:K68%FZ(XIDGZO5
MN7 4P/"T[5D__C+ZY=?0ZI^U[<4OK4[QDL5)-Z0OC=>B#5RN1U442G7]ZNN-
MXJL9CTSYG2(;QIA;O\8;Y-;O?G190C8D>=QE?_R=8+??= $?EMWKS#OBAQZ8
MUO8\7F9]+R?SS3[ JW<B]#XO5;+.UWFM:XRI>*V#:'O]QCM N'#%[\M7!9(_
M];:K,Y5S7[F_]UN_=%KM:D&96<BWHQNL#E<L'?EG)WO;6^=?3O[ZWCSY[71O
M?PM_V?YT?+#_OO7E\Z>O7TZ;%P?[6Y>[IW]\;?X^X\@_;?+F]F^GN]OO+IH?
M#D1S^^^ONY_?'S<__]'^\OGOTX-+>,?M)CTX_>O\/Y?O!LW?"R?^H'GY]7QO
MZY!J3+WG.A>%CHA'C)&Q#*P=(KWE47(+%M'L^C[#%N_0Y E_Z@-**2VVEO\P
MW?:!+WP?1_0*#1PQSS)P*Y\(_K%3M'OY9V 'L?]L3>%7;?/]P>^_V#OSM_>\
MN;XUKQFQ3 ;@J]1S%843+@GNE+8V.FOX'9L**"L/O##\]H#-A=*>_C<85EN#
M0:_EAH4]LM_]T_8 BZZV!%B]6M]CM=X9;;D/FKG>-Y4I>IDS'BCBU@BDP0)'
M1CN#%;7,>[RVJ=>EOM['X?[]:AZJ+PN>DE[CWMO#O4@%U=YAJYCC6F$;F7%.
M8,><"3*0C'O$5+A'3(U[BXA[%U>X1U1D/&B-&&>Y41>C8)Q$A:@4-@AEK<8R
M\\IU*O0; ;Z5KZ;](8+:=2[JAH:W@ESR2CABE5;)<2F W)%H=;*.< "U1&MR
MM^@@UYPD=X)S+8WV*#J/$><Y3X,Z@H07*;' %#5N;9.Q=4G42G4CK%7Z2J5]
M%-2#S49%4CQXKDD(RGHLL>/62EKSEB50Z3%O40)[[)T%'682\>3 7K-)(18T
M)UJI("C8:Q146O'54>F5=\-5P0%OK!?=@Z@),'--F3),&%C)G-;8"Y9W?3C'
MFIF:FBPZCOTU24UH4DKZW%V.*H>X%QQ9QUBN#)MT="Y8KM<VR;K*COVGFE^+
M8F'5&CVUAQN2M3P)CXWDREOC0R3)$J]]8!RSAS"36FV?4VW'],-JRP6F%EFI
M#.)!,*1S06>3G W&@+6(^=JFID\Q)Q9,:>==6^>>M3ZJF*T;TK?>K/=Y_@.T
M0F#ZF("8FAXM$,Y^G*1'*H&1AVE$)EJ3*VQH9&ED",-<&B=9H+E#)>?K>!Z>
MF_EIU(*7'ZJQM<;61[C0L",D:JDTISPQ9QEE8'7J9)*-43R(J-;8^DK8.N:P
M.5O+1FF0$(H@G@)#%F.+%"?)$\!61DIL5>(IMN=*8>L]LM!?*L_F79&MVOHV
M3K+YVP[BWQ'NZ%OM5I%,5"?9[/M#RJ2E1'HD'<6YK6G(3;YR3*YCU! /IK98
MRB2;G"3;@SEO]*8FO<B/;?4'_5%N[%7>S.LGR!BS0:5Y5'X,C#13SY%RH@A]
MEI03^3P/*^I,ELEW,G4BRXK,Y&H&Y->9#//)9%C]K<\(4V?;<%L[& ZZO8MB
M;9]3U[E'&/&+9ZO>:JIVJHK>\_0$%E5_IKGW?1CWUJ":QW]&TSAU\)6]BEZ_
M4>]3#-8N?/_Q8O?D$QB98'B>'.'F]H'8V_Z+[>6_/^^<[VWOMKY\^.-T;]9@
M/?%\=W^'[G[^!&Q]YP+..=\]^<IWM[V O[\?G&SQ)OWCZ\'I 9^)T7=661.5
M1,EH!40^8.2(P"@%&EB4W&N28SZ 0<V_=]S<3=+74*#_>8[>,#4BW1>1GN@_
MJQ%I01!I[$+S@KF4E$92)HMXROF]5! 4=0P2!Z&]2C4BW1N15C[ROD@O+4J>
M_-2)1:6Y5+$^%SLQM0;7W*HK'L'[HI2./08^BRG;ZH1_=V'(KH[+-29KW'P(
M;DX%Y'L=);8Z(%C^'.)$660C!F*7 #49B_!I+,JG+T9MX]='QCH?8.'H6(TF
MKXLF8Q8&4P3,2PL@8,"].%B!2$N=D-*18A%"*EA8C29OR)=6IA&4NV.A!8J9
M@P5:MOW&$@L6GUY5,S5UQ/;$A-7 ^#!@G$HN(%QY'RA#PLJ(.+8)Z>0\ GF6
M1#%B;*X,RN9FG2X],-;)#:M!LVI4F3NJ3-"MQ*/UR2+)C0;CS4JDN57 N0B3
MTFCXA&94836JO!FW5FY]4'7T>&,>K-L#:)^)8]V2ZW4?6-SMYGB3(1SFVC$W
M5>_TX\W]2G[O]@<U2#X,)*<2%ZA1&%LB@' )C[@D ))!&,1$M$+GWEZ*9)MT
M#I&U2X^/M7/K&8#FZ;2K!IK%!9HQ&XO)BT2=083PD+L@,>0D3*J4*0='& ;_
MK6V2C:>4+5P5H+F#B(U"F6&0XH_C[%[JR)5WU %Z3+3=*MQU97.L-^:H6R86
M^7LQ03N==QUXUACJ.))'@;@?L\7+K>][?QT&QI/UC",I<@7:E *R.O>5MM0F
MQHF)EF<@?_TZ(*\/Y+6?;C7\=#64S E*+J:@1(;@#/4!82PXX@ CR&*#D9+$
M:R(%%T;/94-T5?!DY3UT12_9VC.WL)RJF)^KCSI'.X-XVO\S]OQDCGL-A_>"
MPX-)/YPTG"F,%2(! ZNB3B-+K$"*1ARC-"1*4?OA:C_<:OKA:EB9*ZQ,>-U@
M3EW N9-7R%XW#;#B)$/8P+J1=(I&X)LC*]X>K*R\$ZNT8G(7TV^V777QM;GD
M@NWXVI&UN*1K9'UNQQ1[O<+\W.KWXZ#_:32-6Z-9K,'RT=ZMK4/A#0W)&$2)
M5,#!K$<N:8%P4LXGJ4$&2,[XOB%BI'9MU:ZM92=A-<R\A.=KZ] YK@03"OD4
M,>*18.1,_BW A)K(//5%*Z,-6L/,ZGN\KC2S2+=\="F-ERF8N7C2LM T[G>X
M=ZLSA"'=.XN] D+K#*H'0N?1)$.S.*]ZC"$K T7<: SFK!4H$<:C-M@XJ^:9
M0?6JQ2!?'WQ?P=%6 ]@";'[6N#47W!I3/F,%5B%:9&DN#QZ<0X9*C(Q-7DB"
MC>:RQJWYDL8?5[^=J"EZ:YW4S?]UO7]MWEJ+=&) 3H;]02M=+$[)U9$-UV@5
M>IVY)5R\%_O#]J"1>MW3QB">GG5[MG=QE7?JX0@7!^<Q=HIRK)F/.MMO%?59
M;6$)-FPG-,!<=& S#EJQ_!N.;?7@VG"YW)K>GH) PJ&M\BJIU0&+L545C(NG
M,7\W.+:#QGFKW1X]4C[8?B\*N79[C7%,[N35TG P[,7&1:Y(N=&X>L/\F+<]
M'1Q^&FU_F(\;]D&F&[&,X+@BV_U&_'X6RX^Z#7MVUK[(OXP>IAH^N'MQV_S+
M^7'+'\,;=/OQED',MYV\JBLKWX*^P-_P>O"L@W8,&XVM?O$<;7M>/GOY0&5@
MX3J,POW>T(8L?OFX8\""H^.).2\>H]./&XW]8[A[ ^:RTVWX82_GEY4C?4U.
M1N>,)K!\\3A5 ;3!R'HC,^3B@?)*LYYG\JQ<2]H7&W-1FH74/WHO_6N,GOHU
ME/\?&))6 FB&.899/>MV"J6KJBSGJ';;N?B_( IQ<+.0@:3TC[OG'9#<=O<<
MY/2F#8/&L<UX 6 1^QEJ6_WCK/T996!2+LNCX9[](:C+;;?*U^AT!Z"E@^+A
M3KMP[W;K*\@0 I#HH/PER'6$YVF#@L3_#EN] D0V&CNS[W,R#$?YJTJ#2FUI
M#;+4ASB(O5,8J5!BS\2))0Z!CA8*#^I:/G_,QX 6W/+DZV.(+"LBY?=NPTL#
MQF0@@>OV(FA\'X"O&OB;QK!;ZMAMPW/U:-YG&(0O$R@MC)F%JQ<8F2_0O4GC
MI]4F+W^^9'7%([Q<^?=KWL1<562,8'7E]\N#0QT#8]0+Y!2,*??"((>C0-Y(
ME3AW(1!?&@(P?S%LY7X4/$:I,,P'-1+X/[=@ AO' ]/1!)/<M4KQ/V! %7IP
MNJ$ ,G\]Z_9;64A^*27Z6ZR*HE<&R\2)%<'$XU.L RXY'-Q^RK5JOJ_$D-ZC
M1NYZ-J4D$S^/>^/"U4<1.0"%K\@F>-Y?;/O<7O37_C5=F+[503/#.#L"MR]J
MY<\9%2U500IN A?2:6Y!$(B63@F?J+!!!OA@5BR\DIH*HIQP',ZPQI%$-(U1
M&RZ]QC>V#)@JIW_C8]PI;<]3AA\&;P.7 _B(.OR*W?[U$TK;2V*>I0[_\SPL
MO=\#O9GJ[4M:A[^NO3_KA5RA$O*O47N_POSKEUJE@7U8;?[541.SU&IR2RA%
MX8_H#N$2H?_SVXK<N\'9]<NS1N.\YC56?LM_-Y=4+C=6.D>-=K??;WC;ZUV
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MA"0@EYQ+(FAA)9\;*ZD='@]OAM5YX/98;3$MYGY2-9\U5CT(JZ8JDCB1*!'
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M<X9[99[D7[2@O4#)M1B!YIV$<-:6(W2C!4P.=J)SP34)'EJ1 [IZJ6%Z!Q@
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M"I8MB+YV7'MU%C5M"6DG[&;6XB+/DG:6W+_!3$D;\WQ-&HMIF\:7/[Z%'?[
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M<U0HP85B9 =)2/&(.?1J1"0%/E<6RRP6LXS4]+67$?IY!O??]U1FV6B)</
M5E6S5FL:+<%@EE6WW79-LLJ1HG" <K0'*0VNPC%T;$28H*_D/A0K"ZN,R"PS
MM]T^L9?9#':DT!]D-WB6H?=]% 8^X>+FKXC*Z:K"6X#)++V3=OO47GI%]/^#
M8@('^2T8]97=7!VT9LF>MMMGZTGVX O+QA&+T6T0OJUN73,$9NF=M=OG-:PJ
M8$4:[4%&^1!O9!(NP6:6WGF[?;&*]/9XQET3X7$Z4=C"P64D*"-"8 9QOZ @
MAEO*($JG.,B'KDJB*V T2+7CM!TG7F53X06AB#A1/W(B2I0I&01TD":DGF:D
M"H(_B-8@B)[O:^(XN"82TT#$_VQ>XLL(F13!;<-_FU,$@,VY0 D;Z.?XCWVR
M ,_1>(SY%.(>.F1T  :0R9[GA1&3E T?P7AZE%3.>DLLYIG>=71>9T; "6(=
M+.6H48X;I<@/,IL;[<W*SDJ&G;;;*4]2>QF")T[^.DS!>0&\X'ZP*6$FN$RB
M[+9/NNN),B9R$.3\X.=^YXX-0C[63-NYVO4)F%WLJ;N.!9[UJ07:![^Z3%2J
MCLB/ A(.'D,)G84@)9A>TR"2])4\$R_B5&VM?0WE'?."R"<^95=Y]\*!;DO\
MKT2JK-Z$\.<1K&4VJ4W;9=&LCV>NWD5871]3YE7K OLHY1_E'4#0 Y1V 5&&
M"IU0X$DW$/1#9U 1] 3IKNRC>N?##;,<5LXO'#.!/86]2NU,H.8 \=PIJT-!
M[H . 3Y40'B0B,)N%SI4(S#'"Q?=LO,P2V<?8P3#**\1&*R(U6A]G;:K]P7K
M"/00 5A)^I&3@(XI S]V(R2%,5+N->+>" ORR*EGZ<$W0<*L XZK]QGKZ4"!
M-DJ):P^<D$>:_D$G9N>I$$2*GO=71#GQ,?/O*>[30,<F\"X:$W]]6V!-PZP5
M:JE0WS)HXBBEKG-T!?HH86 ?U>+FOG?]C,$3]H:<Z 1EE9 70!AC)Z?KE(VY
M0H(T%I2AV>M1MPN4EL(9XR/'[9:CUT42V,>HJ#RD:P1#]9"9+=V)J_?SJX5V
MB'Q,TDRC /\64_X'#B((1E2KV">L*E8KK&;YGKIZQ]]&OADUI,@A34]%-;IY
MXMSV4-C%$M%D'ZU*DHM S-[KS"F'H3,EI.D6WGX/O)W_6@YH=F#GW7((L5 (
M^^C!%@QJ(7/*R013_^9]0I@@:G/\ >)C?A5Q57=2QPANBHS9*EZXNI+&0M)S
M*=:8 91RH&-\S0-*F#@8RL6B2U9/XA%/U=39@#(LQFB4>Z?M.NU5Y)[20@FQ
M@WC+PN 1R6;F9L2[ *-9O([KE'9T+<6K:.73^B#>66$4S6PAI;$!,9LQF\6M
M$C6KB'O68!=3-'LH]ZMP/*92UXR!,[L*=8:+,)O"&A.H,=R%6*N<7RM@TVYU
M!M]!(/8E,M4(C&%PQ^V6UR)&X>QC.&P8Y#4R.RMB-9O)$]<IY>7,\CSD>JP$
M?1M)&,TO0&L<C7N,13AXZ =T&)\>_)WYA/>"X&O(KI1+"@(U29+3A6QX3[ @
M!>1K*\@VN#$KUJGKE-;+58H5<XD2-E',)RHPBC2G"%A%P&NKP"S*N$6:W1E:
M!\W<LB[\Z>R6;O[I'+1SE[4S2UE7J4W>T!PSGCGEG8H\4;V/(VL7#LXW-P=_
MY]UR9%[8#MC#2"\;OWS1FAVXB9-]LW4&7V#V1ZKZ0.:[-NQ)E6%R, [ZT(Z=
MK]\>8;/AO'"=4OQ?4('9M71^]BA)?,Y7/:1<(2QG]I48REA+3C+MH9%4/B)D
M^I0TC-LC)P/"N3HI"@_ -[T2+E6YL0P+#6W<<&V<1M/;;3OE3<08.C[AK86>
M44J>_9P10XK:#,!!QF9YV"_T5\1L= )=D'C)U:XG[WUT'*N(YWE$@L$3&5(A
MXTMHLA.=]NO#C=,TNHNN*C+8L+*TD.8)%9DJ''L_. HKN<:C1Z#9->7$DP\#
M  )W:UG$L V29DWJNLZFS4X+Y2RAF">4,I7JT<$H54CU,8(%L!??WO(#E,A$
MSJQ KNML.$Y1Q=Z:G?3RFH/RU/4N^O^B?G:/P==0_IO(.R&BM!A[*UID1=>L
M3B>N4ZH26=^SZ59%QO3!/& -Q;P=-,M2PH4_MQ<<E8F8=>;4[90J3-;6F1D$
MA^C'SHO,M-J>@BRD8]:1,[=3*E-9WTW-MS^HB;6;^(8YQ[7VX#9!QJPDYVZG
M5-RR(>>3\G'0$=L%,H8^/T&W^2OQ!R&/MXF4NU;[/]M<F=L0-NO1A=M9N/N_
MYO)<,892SO2!N&3O+&5N'Y4KC1A4%:%FY3' U?<;+X$RIF3=ME.N8(YE5\2$
M-*J]EX#EU4(F6&/"U'6ZY03Y,FGL8RIT\="N<U%0;81&*^EVX'_6 CR41U5)
M-K]Y1[U^T,O<GB?I*Y73=01L@=<LYZ[;*>UM&N1<O(M'MXI)HI3F0>*I9)XP
M&Q(1#G1]3#"E;*B/NT_B A^A0IO+YR_Q\*G;$:#!E] G@0QA! D?4T8*AQP+
MXA6_JEB5^#*\&4^"<$KTN9^O(2/ISW44JGFVS?H*EJFTN6+0U[@[2EWS#J%"
MCY#JDKK["3J5ZG+2+:3[A2#8RWHV=PZT. ,$2OJG +(>ZEBRV,?#_,@L5U;#
MH=^K;_SXQ4;)T1/P)?I][PUS'R)_+QPR^A_;FS&V2=JLIR=NI[1U8[*KA0H2
MW:REN9IMG/"E%Q<QKI@UE/.VC_IUQT#>Y 6_5T>TQ:;FY<2I4SX8%T,C#;Z?
MXVNW;B@#F!<+9]WRTJTXUONX0"B,87*/8E\9))(]OU3V(62_19P*G^HK=RP=
M_SJHS4;OW.V45GTS@FSEERG&- NOD2:KZN!F".^Y1<O^?,*2*#O//!K0&@O#
M6KC,XKUP.^9Y6OR)%!$T2V7/97F=Y!3AQZ)RU=KRM,-GE.E)V^T:_9QZEZ9"
ME527%+7NMV#7R-M88C$+T7&[I?VS.2$>$C39745WE_<AKKRT-FUF#!-/.D[Y
M@#U (@6Z?V-J6;TRU]JLVUVW6]KV2T=X+RM#GDB@[J1ZQ%Q."_<M5H[Z4CBS
MAKM.^4Z!!!72N(J7/N[3LFC9>!K,^,HR,N(TSY\3MUO:[EPNOTI/L5=3[9D$
MQ(.!^M\(!DIE#Z^QQ!'#$8P0\2N33V9H\[0[=<IGU%.$*,.(%$KT<X;T()QT
M)"QW.&UP&),7)V?=<J+(0E#[F-,PCW:\M:22F-G[^KN@ZU,P6]-SMUO>%K60
M=KISIG.T>;O]"<5_.7X7'_%D0J''ZDG\F[$PYET_@B<PE/I$BU(7)=H_[\;C
MB%$/5C,?OI!QG_ CA/OJ"(PG/QU)KDY3,SPFL!PK-V0T/HF>-GSO\X!^G!!.
M0U]Q]NG(C^*S-$=(1("5RDC]^I6'T>334=P<Y#<^0E(W9R%CT?BC'XXQ97?P
M0F$Y.E[*?&F!WIM9H ,=]?WHO#\#'(BL0W; U7VD3$BL[I>.7_7C^Z"@[Z1/
MI67'XR?CD(&*\JE%S]5EJ@_Q]LK72$GC89#'%7&Q5"^2HU!/B*5#4!/+QN4=
M/Q&:D$6G05+_)IB+1R#(7\).VSDWZZP!H''=_>/YX?'YTLS_;)O&6=8:<3F_
MF]=3M9U#W?1RFC=YQ%-]4;3:08NWT1[>&#R.13'S=9MEVKDE<C6F]#:T^)&3
M*_!ME V3H^QL:-8" T#S*I'LJSX,9@[EQ56:M_/UHSHD>R'O\C((U;GR98)?
M"^FVQD2F)"R&!7RWXAZ\"Y6W6.7GY32UL$H7H8/+'9,=\':TF#))AH1;J7'H
M$>*+6QZ.4U',",SL?6W!ZTCS1SK@+_A=W=B3RB5A7-N EQ&65YA=DN<P\'59
MS/(#SV#"2 #AW%"#)A^N7SIHVR7:L%U4S@Y",%N_6&K:N"V$1<LD%#C0"./O
MWJF#I+"4T9<^11##QS<VA4Q]19WZR8_>6%WU^P3XE"-3$^)&>#Q\6QZY;IS0
MKLZR]//3H.E]\'T*>?K1@(?9;R_=1NE'%&$=JE5NZ?"MA[3A6?(<32:!NIV1
M^=]"_AWD?@5S^1*S[\(\9RP &Y]!BSS?$WDEH-)Z^*_PY)9R(1,O6,N#&O&L
MOLKS-)$?L,R[>2?<HT)Q^:CY>BA^B&Z1![59]JV"=4O+P!1HJPN1I:M;Z+VG
MOQ*U\<5(-<G-SSN8=),8N\5H@@?ARB-<D_C?.S9[$^(3'8[DP^!W072>9.D0
MU<:SJUXG^>C"%81(U,,!6,QD0^<J%%(DUW@;(ELKZ!U-+"UPCK'>UEV]UT?4
ML&=-+]K08DH_6WS'YCX+L+2_MN"[JO1I3;TYBIAOU7C(4"<6QF(T$P]O), N
M(]U5"2>JF!HF*V-FA-G5J$F[ES20SSXX]A1.<1!_ES/QO ^#WA#>#G'\,77]
M@;+E([$6TH9=_ )CG)]IN/.A+1U0Q9_%]TQG/GYD6%74\0P_@)D=][>ZET)'
MBO'%3W=,W2&F?(F^I.>!ZV@<.G#S#BH(0>>3&KG*05X9[W:\\40E;K<8X,=]
MC#< $A79?$B_D$C3FV,S)CKY:E25=3?"[*IU7]%\]!:9C[E/>LT%:[WD<V\%
MN$T;M4UQM:O"2N/%XD'5I)*@]ZM=J&D$;3S^O&%#'%N+>R+!LF:1@4J94"&
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MEH?(J@$;#Y_U9:@"QGZ,/__T7U!+ P04    " ").EI2W1II5/ A  !M9 $
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M&#T6 ]4PNF3Q3=YD^\WX* $/HF/:JP D,QO+-8J>^'+N&"+58$I:GFVR7=^
MESXE5/Y J']H5#V$FT&3%U9Q3TI]472#)!!/I20Z!,&RI!##*4WXO6[&<8O?
MWY(D-ZYI'JAL%%"$BT=-$2E]"1^30<_0V^Q]HCXWJ>)\+V5]B@(:8>JNY>WC
MM55]W>A-?@YAOB;LV60V+W71<!P7+\WZC#-@PI@BA%3N-8R<<VPKM2DW> =-
M>[KF#[)65!TYE5349-=M$\H8C$[G90GK[725'KL$=HJ61ZUQPG*L %N;LE!F
MB,L:8U7GJ!1-ZK3M26>?7.H'-DHU-'G:ZC7K4\+-3HO?TD/3(\]-SH8_AUF<
M#C\5,B?YZ6(V',-LYL?IJ9\-L?,5Q/SH&T6'B/& 7HX1Y;%,G5*<9REU.Y%^
M]+Q<9SZ:+7^=1LJW=7Y:X>\D@L-U\KY8V>GE)+\??AP/,XZ>\7R57H^V\RV.
MN>X^Q ,$OF/+QTCS$.);BZJ]R$XHNH<1X8=RJ*.A %?MMQ??-D9:"^^;O7@Y
MSI/IQ>J4^Z%F\_A.VXMY9Y9;R_Y]/(>T&,$DOYU@3W,TY*/+Y\/1HI2Y?@]Q
M,5W=:C%?+E]!&HZ??9/))'?/0D*7MF3E?H)I=T:XM?;:DMU>_R<4^^$(^D8V
M0A0=U8TL[$,T>U=SQTA\9S*;2.)PRW]_HXVD4M?&W]%19<-^8$^-I'@"$WY'
M[QBZCX87Z'M/+W^9S8?8>[$EBVD\]S.,ZX?Q"!-<H]M&0C^,[2/+B75YJ.O(
MY]GD(F#_A9@U!6^N4_!BL;;E&/@7JUS.9THO V,$I.-$ZJ"(\RD0GKBGTB>?
MV6ZYPL=0<73ZV+?5[&6#;Q;SV1PC0534@#'%J+;(811 I R^7 "'K[RSC&:?
ME6]RD.HNHOJP#W%:['QW%6,ME=7)L-]>/N:LU/OXV"T=/+W\]LAJ8?SLBY^F
M[L?LS9<QOCT=3J8?)ALV89"2B4P)0Y2QF4BF';%4"A)!F:!,UCB*=AI=;>CK
M0\+1P\"P+TIOLEA]EVO0)?FN3RW@<-LX2(V?+2X@M?&"=NZWE4]T&..5RGUN
MP?<[B!,,P_X'TLM4PJP\]%=)V&LRUW>UGVTC%P.L 6?1>\8E :-+"31PQ F$
MFDLY@_&)6=DDI[$1/\?Z 0>2M96<52+*9NI)B+F<&BX79@I*I.6FG!G7Q"1K
M(U4YL= DH:DM6WWP1?HT3FYZ*CT"5;6=]*H\+6]]73YYUXW) R=1\MHQPB 5
MM\[B1!VR)TQI&<N-)Q&:7 ?S(-SVP;?ZRPRK)A#LY6B[_?B?0^JE!TDDT')W
M0C$D5AE"K7% 0Y1<B;Z/KJ..?IXJ1^;//IKJ0*R7H^?F:<?.-'PX]^.U<@;4
M!<X<!F_%(A#)4[F[W%D25722"TJU;E*-]:1<]BF=_<\^FNI"KLYJ5TW^;I2/
M7)4 7-]QO)Y^-^NU!:MHLD(2XP$U8Q4GSLJN#I-.3@9T>-VA2\ZG8Z-7I\?[
M-(@>7C5[(:Q>1<#U>&:,<<.M)$)V)U18($X)CY)3,8+./K4Y ;*/===_8>M^
MD*(>U/!N7:Z\%O2\7WSZ-!IVH^'WR?2/X?CC,QB-GOKQ'[,B*QP!0A&194F>
M3I&X,BXR19_-!!7%S;L)ZMK;HZCO4XGF/H'YQX!3ST?-M4)?UR.=1&VV9=\Q
ME!E$4[0*40%),1KNC8S:/_"8N97V/E6B_NN,F#I0:K(=^,NKL^>EL-WL[.,4
MNGW-0S;WMK1RS%;=?40=GIKT?<N')\+=VE9=UNNFO7W??N5LM_TZJ"NJ$^2V
M?=_I.A<AO?##Z7_XT0(FN3RU'/HU!;E33W4ENC]SAXOVJ1^5HW[OSP'FJQ,X
MA\AM6S/'".5>LJIR?+@YNKVQRMS7-4A;.MC(,K^V75..;RTO<MZ<7 \?8;6Z
MKBS?X]FOE)ARUV;9BH9!S")RQA2)KASTY=*3$*PC1@*& 3)8$VZLU]4Z1GTO
M;4>%%:OVG^&'Y9QK5W5D5 QA=\1]S3VG($I=,Z)+8IGD.1&;LD-ZE7":*Y0,
MWRD2V*F[/B5CU,;&-4>\OO#KQ)KO8 ;81LG2> Z?833YM'30OK[$(3PN9V#6
MM&G+2_49A&T(CLB<&0E.6L*9XC9IR,G8G8"Q<Y=]2BEH"HXV2JBVTKN%U429
MC591PK36&)"*$HOJ2!@S#D-4P76;2QSO,XD/NU/>"B25%%$-$)W7C)$)),3H
M.X@P_%P<J#5-BCOGA7*$A1"0)I=($ I(Y$BHR$RZU.1&\[O)ZM,F<&N@5%10
MDR6:.UW$&_M?C9SA[;TT\WMW8*J2BWNCI[7.I?5.V$Q)5+:4XV>:N$@%X98[
M&T'RI)L4!]I.SG'70ZR<J,YUNL$F\SH$)14!6BY'4\X1:R&1"(DJCVZ4]70G
M+^6.3OKDM%;0]O5+'BK)MHYW^@H^=K[RV2(-Y]M(\L@**]??.&G$\BX\STN)
MQ*29Q'\"F-Q)W??UU"=?M+;.JTJYFI-Q@\O-98(!*H\QZBFQ"FF1SD1B<^*$
MZT"-Y4B/;A*BWT%3G_S0B@"IK8T'<2<V\V?:N1-;>FGI3MS'5#UWXL8=MU?3
M@02@B0%.!Q'0067HH&H1B!"N'.40$G23PUBW4E0GSKV=WQ2T,0EC*]75#<6!
MY'*.Q"G\Q$66:6QRG.-NLGKFC%3 RO:HMXI:ZG@E*UJNN4I7\7A421N&%A!=
M(B*I!1+ 9&(X^D>!6IUN5K2_Q2&YHY.>^2(555Y5O%65_;V/=!6G!R&8=9DD
M5X[8Z"B(]<:1#$QD1X.1-^^"N5OCM_;4,P^CD=KK"+KN0-\X+?_-YPG("/=$
M:U8*-41/'( B7 7E<D(W2^\6>-S>1Y\6K!H.\R.%>WJ'<M/WW1!((\?R[MZ:
M.9A[,%G)T;R9U7ZUY>%0V\QK$FRY'X0Z!%@*EB2MC? 0<<9OM]70R,E\OQBG
MZ>469DT,TFH-Q'2W3UBJB6=2$N:]@)QI\+3)H<8[J>J3BUD#)5L=S"HJJ;;X
M\7Q5#OP9_C^<;SOT<65_.4;TOFP.L'+B@RI!O-.".!>XTXX:)9O<M+PSA7WR
M5EN@IXVJ&E5UO[@8SKO*T'Z,,V]7.@;&AU8<OJNYX^JU[TCFX2E:=W1Q>+K:
M_8TVDDK=]+4[.JJ<6'M@3XVD>()4VSMZ?[&8+Z;P*\:\%XN+L_%XX4=OPFCX
ML:-B]AOV-ST;C5ZCDUR<MM&H6X5=7Z?VJMQJM=%X$Y6TH+"1*IL+LY+/^PIF
M,[C1\WKBN%S?1_-\ 8,(-B2;.=&&X01E8BZ)888P!M%*RUF,35(J=B7P6']G
MUWY>H^ _?('19_@5]7T^&WA@22ME,4!TB4@P&"IZYU PWEAAE6+0Y/#IH03W
MR9=N@KZ;[M%)-%O-[]Z5VO\"/_WP93)(D*5-TI!82NO([ SQLCB.E <34PI"
M-+GY;4\Z^^2#]PIUA^CQ8<"&Z($!R!!"8IP8I)-([2T)7I64/V=%MIIEVV1Y
M8&]*^[16W3_ [:W+!X'<B\EB.C"@<A81"!40EUF(/@I-L@)A3 Y@<Y,:D/L2
MVJ?%\MX!;F]-/@S>AI]Q5-@4BLW%45&* WF;B%<4B(&00 C%F&V25+ OH7N6
MP_F+X6U?39X<;V=Y#M,K4AV%K,NMCL$Q=#6%E^ATEJUEYE.VBED0#PJZ:]3V
MJ=Q-KY!WN$Y/O=C:8'EB<"-AOX^K/4CCC[/><U.@IU[Q$>@,2I,\2=P8Q&^@
MQ$GK2<:XV.<@57C8A8VFEAHU-IQU":<EQS'BHV<7Y:\!MU2!$0RMA[&EGJTD
MP>I(E/-)1JH3]:</@&ZC]H=<Z]D'=WM9ZBHZK7>F<3N1.&W$8"&@@\RR)C+P
MA#-&#B1;%JU0.LJ;Q<,J;<!OI^>'7+@Y!D(U]-)D.K^J%G+(//OMR\=,@+>0
M</AVU%6#A^]YWFRB"G]U]S.OFOV6W71U5?+RR.7U<E>_(O(6I0C6_%N%F%(U
M:S&=(BZ[RY8/WU]K1TP5R;<5T7$;IZOKLY"2M]-5SD7W!GJ"GV$Z+Q=SSB<;
M#Q[J$._=S[%.[7&,G5:HQV5''-C;J05</Y]B7PK>G\,HOX./P]E\VC%[=:?[
M<5O[U>DXM6KV$\QIE;8D"_"QY\,IQ/F;C%]">WA$Y:\69)Q:97N)Y;0:>[L(
MHV$LM2OGEP^DK;M(.+6F=A;'B8UA]V,19G$Z_%0D\'HR_R^8OYS-%NM;[$ZF
MKIUH.;E1W%M IU7@QLO33E_?=WQJU=S#^HG-W;6G3JN*K7V?W,#=*X 'L&R_
M^W(#Z[%)FS6Z?A"[=1?[IW:ZR_VZI1C;]#.D/)DNMQ6*&2W;!J?VO'<AYO3N
M]]XB.ER':P-Z=3ZPW-!UT$Q_2TO'2&\7XFJS?GCP?6=[]<50-X#>WD?ELPC[
M=U)?;"<X@;"]X_=E"V!Z.<G=QV\Z'_(LSH>?,1"H+=(=^JHOV7T9K"W@=^6*
M]=DD=UO1HTN,J[I+%3XM]Z=GQ<X^??_KDJYR[SL^\.LDP6@^0>I@>C$<PT:Y
M\@TF9O\JDR>D^>075,GD$KJ:RJ\G8UC_65M_#\]*?7@\/$]MA_?5JG[W>?"S
MZ^?N5V6$T.1TGY]]\=,T^W9/2'4+4(6<!D:BOI@.U^3+,;Z$#_[K81/^YM>/
MD=2M9%3A['"'YOM&*G%9UW79:/@US%]-9K-0\ -7[S\M()N,_\]B.IRE8>QL
MQN'C[9CN*LGO.#:K2/KJY3L_AS(^QW$X&A[I'^[5?B59[LE(I12U7W*&XAK!
MM>Z7^78+G/E6*1JHP4&RR>:@RMW(H(G,.A"GG2< 0!WWS#C9)%MF=Q*/S1/:
MWM-U79S-7P#Z#7Y4]J(6V-[EM8<'V*K.PF?BM7!$2B6(E6!)$M(ZF;TPKDG2
M6@7:^Y3"U@B7-S.03JWQ:BEMNQ#>[9:6:^:PM=&&I1FPS(Q.F1*5E2Z7,F<2
M"@-"9YJT2]*Y)L4-CR&Z3\EQ/0)G%1V?%)48#^&TM<#'T/=:>=G=2N/3FRYX
M*0@W8-0R[JTBP8J2"Y@T\9EWU8DIC\9E+_5#874_5OIT3+)'"&Z(AY/BNBL$
M=/76^.-+5,#L+4S+I2X# 5;F$".),0LB70C$LB1)-N!%C%8DU>30T;&$]^FD
M98\P6TW7)T7HL_.R\O5RO"YBA0\M\SW+4M92JZ/1Y$O9VQED(YR6WA(I'"S+
M_[O(&:')<"=DTC8VJ316F8\^G=SL$7Y;(>&D<'XQF:+:QM>>>#XLF4SE&BT_
M&IC,&06(Q*1R?Y;TAH0H@0CTUJDSTD06'@K#]Q'?IX.?/0)N59T_B/']9>SC
M?'E54PD> Y(KF ?BO30H-2:)-XJ3Y"&*S+51ILGE%H>3O LRS5\/F17TV^0H
MTT9,^)VUOW[.H\IRZ6Y]5%HR/8"A(Y=-NV+6WW5[=JW;?TTGL]G !*MXEI$$
M%GBY?P45#]ZA-=(8O@"708C[Y+IS;[4JT%[)=J.# 1=*6)LEB2%'C+B,)19B
M)CGBJ!"6*^::Q"YW$;7G4B5I8H7:@.&VDK-'ZZ9ZO>(KEI=,0C1)2<&),8PB
M+9")1S)(RMIXZ9UA2K;$R75R^K!>>%J '*&.ZM#8"E;00@;K&<E9=<6U<YD5
M,Y')FN %S_[F=7VG-B1'C86-5M].)^AYS"]+IL$<]5U.6737_ XL!\U41ADH
MC9QG84D(TI8STPP$> VF26W//>GLTU90-4S=,7"JZZZUL8U4!EWB',HENK,0
M _'.>B*XY#QQ+U5L4HMR%V-;@<EOE0&P]6=^.KW,DVF7@G-MPP.]>BUCC(R
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MM\627[Y'/>P)_U0/-EJRV-@WN(X7N;>UQ A45D84<H:57%V(&>;K260 GLA
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M5.4>\^" FM)'^$/;!O\U7L+D]X\XAT]CK/TY_G*YWT7D(:&03*9 ^YWUA@7
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M>X!6D^6<(Q,A8PK&@<ZFT_(U)*H3T*_#,M4@M>@J@6&$(B;-:RP+>,NTQ\Q
M$!A)!F8,4?E&K0>O )R <NPDTP8I09M:E>,GF,,2)U_>89I]F([_&_,-Z_-&
M;OB+\:)>@9S3 GE#0,]GB^7+/ZO.D^J*:- )&A['[&I<:F:Q=A>@!=05;;+3
MN>GNUFA<)Z2)QZ0! ^8YW;(H&XWM-_H6%A^OLOMRTDH'*9G.O&9T\<"\-X7I
M:'R1$0J6TLL?V OL$U#E(^=ZP&RLK>LZVAK!J,$S9UT@T"1;"%G5H$APW!2K
M3).ZJ4^R:_ NRVE39HXF&.%6!>.<1-9!\^H'R1K9X<B8T<A(>+$H^IFU373K
M:5;([\7W@Q7R^\C]J107[S*F[Q7R^U?([Z4K^Z@RO@W13T6):_$/4ZU=-([V
M#S2<@5:)98B*DSF,;KU?W+>FO+TJY!^=[O;AMX'.OCS[-)E]0;Q[?0T0K(FY
M,&5L)E_+UN[0/C.A"W<>0@FFR17-O8A.I#)^+\)G+=AJ<%_Q<,E^)\@."5B8
M7)4GR<8SFFQD$IE0N (;D^F2^M=;E;Z%1@N[J--PK U<I'V]9KGQH@1%ZNQ5
M%$R'A"RHJ%G6T?N<N2_A6VZTL(T;L*N8![P;N%-$NPN.DVVTT(N$^^KS;R/!
MEHT6ZA:4N*(%*@O#M"B&079D@#DK>03EC=V0-7>$3/9HM# (D7T$U[K1@I=<
M<^4+ U'/*46A929#8M9[K846F./:-G[TC19ZB?>A1@M]9+.W1@N*UX0Z+YA3
MM9"+I7TA1! L"^5CL,&E%#H1=H2-%K9F;A!I#5PI8V/O6P/%)DD;>I$YU5ZH
MF0'$Q%!YI94K0ILN-^2GWV1\&_-G$*D/>(?>KTUN%Y#?>I/Q7D1NU3IZ&Q:&
MKH_4&:PHT9+Y 0RD :8-?>5C(NRY8,$42^3#54]Z6DW&VVM*'^$/;<7=N]\%
MB^AHW"RO\E-,42QZVOD@ZI*R\MXZ^42L@X9L=#(=^HAR/]'"%X?=02N)7#&"
M%ZIB"P9)(Y-*YR@U64BZ276">_"<M$$Q)!<-2C1O@G41A?SU$JT#P):WI8\B
M/,S5YR!\=M"1W<EH<#OT.%!/.V<403,,T=4DQ\BB*9PA>DM+8"X._ EIRR-W
MC8=1ECX<-#HCNK$72N-=M#*QH@6-U99:F\4D)B1JQZU&>D*?4Z)#V!.-9+_A
M &E+P1TL7_CM'"?CL_$4YE]>+I;C,UC6<F^7AM?;^3CM4.5OB->VR<S<;M3K
M:9HQ9)KN$35HS9V(R7):!++3+H#AZJ$TS<X &N9L%FF#51X9A]K2O19+B#Y:
M)FWBWF:$XN.>EOJOH';=X)[/SLYFT]7MY^KF=?'F?+E8PC03"2/PL61?"@N2
M&Z8=(AGTRK!DHXN"S$#GFI3Z>PC44:R!V^G$^L8VF.R'/D_?.M_J(M/JS1]3
M^O%\/)O_/KLQA4<E&2.#T$R@$;15\,( 2F!&!QZCX$EXW6EC;(/O!#3K6-@;
MVLC:D(YPM0N\N;T+_')^57(5\\6D&@65([?<DUD!F>DB!8MD2Y!'RX4!IT3I
M:(_M@N)4E&MO3#1(O=P@D16P%=Q1L%PDSRUSN4BF44G"A202%VD9QEQ"FZ2.
M!U&=@-H,+_W]9&X^GY'+FU=M@V;3U4)8<#['+$8"@)>4D0E=#SN3E^2GU!8S
MTI7BM98!FF3N]@%Y@HHS.#=#)T@.FJ8NO<FHD79:#TC;+?U##K5D4LIDR%]2
M.MBVQM+Q%Q38OXFT*U/'D+VH%) ;7AR+(M N#$XP'^JI'#B38HW84DU.+)]D
M]N(N"U=39HXS>S'8%!V7CCD?%-.UKGGT3C.GR'<%Y93O%++SC60O]N+[P>S%
M/G)_*HE?7<;T/7NQ?_9B+UW91P;8-D0_%25&;FD,/+"D/$ULY04#%4P].DG>
M:)1<-VD5_G24MU?VXM'I;A]^&^CLPPE,!BQ7PMH:S668EMJS: PRS)%'C2&;
MTB1U]EM(.^M%?*^TLSZL#7CRORF#PZ,IVB=@47(R4&KK11!:TG031D$1@G[^
M#:>=;6._[2KFEFEG77"<;-I9+Q+NRU;:1H(MT\X@NJ(C;9 @:4'1#B0#!Y'9
M4GR2(F<K-R0>'R&3/=+.!B&RC^#V%K"<5>0*!6<"/%D_F9:UD.I&(16-34NN
M;+<:R8</6-Y-X)UBDOM(:X\QR5;8D)PNS(2HF8ZR,(\QLT0CY:GHK$.3H(JG
M'I.\RV')$%PTO'6Z/[JN"\#O,<G;\=D[S'0;,@X2D^R2,<:1@PP8/=/U.BSX
M4J-M52JH>,S>G9"V;!F3W%99^G#0.F\]:NN5M(9EFVBD@1;14!U,)&=2)B!L
MJ5O@U<'RUAO)_:&$]CY".U@T\K/% J_+Z<,TOQY#'$_&J]Y>%_>3;7K#='YO
MHTXQVXU[/2!9E)#!B%S0:S(@@HTEQN0=%UE$>+!Q4G<$#2.2,V321IY8R;D6
MO3+5:,9:^\@C</ RB":GRRTCDC>$>UP7''Z5:UOU,JX6X6T&GFUBH!89IE_4
M6_O/,*DG?2, S+XVS371N-KL3K#H?1VDCSD!!-*(/07O##BLHUB)M]/+#N$^
MA^*_H5<XR.C.Y_-Z4KWZY-LY?H)QOJRP39]_0^O5_.)W(TP^(Z[J[SARKK51
MS,LH6>+2NI"#++9IMZF]CO;[7-BCMNPATKO+B#?NO[=&_/[\TZ=)_=TT_W,V
M_Q=MZ<]Q,OD9IO]:C!)-?<]=#15TM0L16!8R6N9*CD6#"5QWJ^MT"/0GH.Y/
M@_F&$>E#S.^W\]DGG"^_U'O*Y>6F]ZG>9(Z<+=+88)@!QZNCJUA,Y.T6Q))1
M@':RJ978='0GH/['JPT#GGFVG>.K[>MJS+>&RS/W4=)P7>*TF7%>6##&,#0J
M!2U5$JY;";C]8S\!U7X*K#<L-C+$3'XU7<+TP_CKAU>#_OTC3*^[GBDEHC."
MV6"1:0#)HJ%_B#"O!%@>L6GFTEY&>0*3X?BU8\#TA%UF_L:17I[%+=["E]5?
MI#0_QRL/9G'EPMSXNWH!'+2 S%2T9-PYE1D@PJI2A8BZ!%#=ZGL==!@GH/B'
M%V(O7;@["^Q@73]Y-ARCR>1;U^ 4S+7[J+!,60N<HTYAO2+M27?]W&49W4JF
M=[EU!]KLK^!O5/#?<#D*N20>M*T1#F2H&P4,( -3$BSYK+[PHSJI?FP\)Z1Y
MQ\#X747V>\\DY"$5B-JPS$$QK5QBT6?!$D=K@A3"8/J>23B PC5EYM"9A)MB
M.*5P0G//6>0A,AV59]X'S@+H[ 5@MILB6+Z9P/->]#X0>-Y'S"W#E+O@.-G
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M?;(!=).HT'L1?=>R^[1L&!(;Q-2W%^!%; <&7:1WR+A39/IZ\N&\BY%I9XV
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MA#^-)*!>['1) NHCV@,D :'@:E54 7PME4OZSF+6GOY)V2:C<@A-"OE_XTE
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M(!OSYFYT&5EV\]KKU?3&[C32W&H1 )G5B@Q%)PV+7M-&8@JO9=#!\B9EDOJ
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M?:MBZP[3<-C3AZO+2YA=3\N=.QVW(]7[GOG4X5V]CW[:E[_U"5"@/+>%7)>
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MYQ4S.."TB/CU-B8E%\6AA,P,@JZE!IJ!L\A,E#$XYQ1@F_!V7QST"'BXN&@
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MTH+2EMVAG3V9J:5TLDPRDTDRF4EFDHA>)[-DF\E,)I-EHF!9+B)4EH(@B("
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M6 7UR0+EJRU'QA ';;2S7H?TDG6Q:R-M ?50<L19;BKC#9K=)%J4C1RJ(CE
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ME:0IPZ0PAMNE#IPS)US1+(?E[< F.'. ;P[8!&>ZEM\DL G.E(J\26 3G%G
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M#@BI0) \@B:'A/&)?+(V2R2F^I:I#M:!\R(TJ^N<FILE!'B ? _2(YK'$Z0
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M&Y]N$8RQ*%G.,KH337. #WA\%&9$,%1^AFC7+=FHV'1>(P*XU.A5^5+5+_5
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M-3L=#32Y9N;'3Q_R&>Q?X*=/.>*>P_YPT$TYA?[>]]=_Z:(-SQUZUG.+G_K
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M%)4N@R(2/FNU J:")^D_TL%EWF,^EI<*8H/QP@:XHG&<V7ZY6Z!D#U&G\-M
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M[#-9V5EY ZV=/^#KR!H/IE!S!IBB5K"=#MY4\.PY]OW-2S07N9SSH@T7Y9$
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MB\)+@6J]MD"]GI),;G,9/40YJS0Y-?' \"'_YN'5]T!*/D6>$G:S;8+2DN@
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M57*C=]WG=JKEHR>0 YF%VBWMGP]=1J.7M"^O MMK(CK4(O=-/>J^FP;O :
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MK6Y;JF#7-_;1+CZ&VZ9Z*:_,?$C!80X=@-^?95-TNJZA?;GY@P(00!Q  P.
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MW_H)G!4,0$,R07%&I#,4?BRBYNWRN@(\)$;]@IR,:YA2A(?7Y8FC$XSB1^S
MT5%$2(:'P\<;L4B(YK1?@7KB<ILH& HDG=9<ETIB@C1'3@=Y1H$V#6Z3D$FX
M#K4XS05S6#?#://:$,-B1@^J'X$_?]>C9Z6W[<C!UCO9WG5RV:![#::DL^FO
MFE*S 8F87H"MEN2^)DJT&[IHF/VKYD&.O<^X;ORIR<)9/;:!$Y0M](P$D+9G
MR7.WGV86:"6:;D/"IX(5Z%'ANL2N^M8 8E>M+WIX< \(:02]<_@I/.FJ" 7Y
MO-/>SWL*00;S^4;/Q(PEM&I3B&%;ESP$5UW@%"0,<Z2;(.KGT,LXV\N02-\*
M"*$&T#8RU?:X!%%=\_Z=<(@69^Z,59_:(>4\QS@^W%JGE# /?1'*]D.J?MJ@
MF]_VAW.>9[S@3=$<0,(@,C4,TQ(6I'P7RC+XLT>/A;?$%FE(L):Z"RO!DJ']
MY=/'Z>>^/\GO>"Q=_RD+6_H@P3,<"C\,BN2+,DL7S8X&=Z/,48HW:ELJXJ5N
MD'46 )-)QU.&X2N5A3]VP.G+H)XC+XO\KCGDC9L.02G\1T&!-#W*N;OD[HL]
M1<&N/2[N6>X23$.)QB;H:3R@&L\T"G]!.TY0*\U_6&P'@QEH2% K^VQ$-RG;
M^K#^$XJG69I.B*%NG! T)#=J9#3!.SF7& KQO2(P&JW'#R_0FEX@ZSSA['@)
MZ=G<ET"EO?$:['2YIJL_\84VCKUM$F/BZ_3]-Z^6A31</_)U1K01=$OQ;PY>
MXW)W".,_^*"^/7</V^>%BV,R:TM]WPRD^HH_W]9/<1>Q,HH$N5:%WD0NLXMG
M0W.5C/AV/]FQ'4\!B]-3&5KS?1.YR9Z5K<<KU2/$A/884_KO!&BTM8U)3D.=
MAR#SAP%KNOV$1:-V(Q%56LMEY"WI$6*\2?U=@0!G:B T*XTP3EC!S1#US-TH
M/D"NLOOCX)-C@/8;O0?O4&,H7[3X/2()HZ&Y( Q2' [^6;RYWZ]G^PUP#V(9
MQH8G8/?_%+G[K\%*[]FY/72/S/V7#P7AMP([R1D%W"!;Y3>V>C@+=_> //A7
M,7\ ^'%@SH_'O4/=\?KK1^?_>(!0$\X0,X"*":'29Q+^-@FO!FMB:G>W]\1%
M(\SQ"Z",,>N'=]HAR'QEXTF^]9__!/@;[TV;@LVLWK6+'UZ0_?%02DC::IS+
M.;>JOE_]%>3? 1XV1L_'*@.D7#(^%5-BMEIJ,L?KJU"484M0!WTPPWFWOZ#^
M4#^RD9## ,WQ-8]K"M0(BA"9*)>W2$E&NS>M/\ ='$?*)@A A&<A\>Z)N&%X
MDX-?[2.<ITUL_0,4A0-]>(;-8/'YNJ9ON-,["" +5XQX,_AF4??"1=FVJL9M
M) D?TCT?E,%9MQ L5FG\K4OBUP7Q/6U35:P7L-*-@RY%V.&4)"W+_'%4Z/0Z
MA #QHT'A0OAHLR;/H/N]S_ACIYYV$GW4MW9 #7V;/+\+R;N\UZ6,$'+32E]G
M>+K<6\;%#>"@<8!4<Y]%=J08(O^@,I?]5M!-+Q6_Z;4(O,]75)=8L:A.M"A$
M3[5V8W/)9QZ(DJ'M?E&^[0B2&FEZ@HI^R=$(GB5JOW5Y_+I >D^-0U8-YT5,
M)SR?.? )JB1.B1<^0KXZ6?@E)0P;6 BV(<(L1R/&S%QK6.VX&D#JW6+Q5*ON
MRF@C@!,L<-U2'"SIO>!B$ PF6!0V?4NB, ?,FM@,0W>+^.11D^FTY=J-.2E*
M]GF?-X"_<CMJI%I)6YISC8?0ZII#-44WN0?S>-@_X;<N@E\9Q/=T/(TLP?I6
M$+4'E\4[]4(QA+VYW2P'H_BPT-C <3A7TQ/?NS#6??(,)FNK!X@4,:R\TV[C
M^.$-=<!33D; P!ZJ'6*<_%'+L^DE#"=U/\,/&@HFL !(K-8*[L3;X5.4+KIQ
M?-K#HK :&FQJ;CJ[^UBH*>BLO_6%_\KXYJC /_@Q^X<)F_GWPB:P6#;=GW;)
M@&^'#'3I>%*UKC-WZ]8U7%4K2UV((YR*CB!_5K*B#!R#+L\6(RY(SM7]C ]@
MV2EYZ1]1Q-'C,A6>61"%2J8BI2JFB'7?#DR->DA]H<'9J..%+*)O2O;>D\<#
M, DNOW4)_+JXL<-8BLV81&\*"Z$S)#R3G5YR"EHCS=/J8<\M@?,U:GY0.BK9
MHX"BKR1*$&\>P-HK8>52<(OUV^L)</G1V1&[:N/HYG 3BG[F5._+(&C=Q;I[
MJS24*C3T44&X&,.[T:T6I5()._#'7!8AZ3>COD=P]ZCK:&=8N'N>C*\]<;F=
M,/NMB^'7!=AS"&T.=KD(=6>Q(^S^=,:-] %^'Q:*J,4NZ!,(50$#'*6GKF1-
M3O/RQ1^]/D9BXF$LW(-^I P :]-2]4UQ 1 )OJYBX-.*E^:O$E]82SHH3FX9
M$ LF)."*)H"8Z=/'(LF/?K>0 =$I5DED_6;N1'(1IS7.6K:TO)!AJT#/2.VW
MOGH00  !!!!   $$$$   0000  !!!#^"P'UR<GI$#-P[;?.QV\#3/OS]3[R
MN^?5,)#F5^6 @,2I7_K-'Q-0=K9?Y=O6CEQNR=?$OAGK_:O?.$N_$<"W&YR9
M\+M^*5(H"""   ((((   @@@@/"+8)A\J[N[<'+^%\F+@D_:;$" S]:?;[GY
M/K8OYT-G;92^+C^)\#FION!FSQW7_Y-)@*U,M9*V1Y]\M[X";$VC#7O:WAG_
MOS6O_VF@KDYB*C@SK%#^I5G<7^-5O%_&\J*B\9],@\4&J^D=IA[?=X&Y=_T5
M7];Y8O:X_#OS^A_'OZ/A+%9!(C9>"#+])0DH!_UQI"VY:\-_:U[_TX"T/6D;
M3>QE]%/Z203&!!_QB50,*F\/P'Z_)VV/>O&1=$3UG>KQ1 \N /!17H<# ,B%
M'U[Z[G4C<?Z&G\?\ 6\S?XS__B3,ZB\BV*\CQ<1?BBZ_  "]W0,4WQU\7^ZY
MJ,Q:B=G8W(^92!1(^B$&!81U7S'^S][(^[WA']]]F92K6F-B^]3U-'S$9!P=
M!@=*G=W!:\*V*%#\$:7$]_B2!]-K_8K\1=O9B&<4'GRUH'23.#SV*0W=$NUX
MYJ'01X"?5+3'T)R>/9[>TWF0Z"-H.XN5UZ%*-9PV&N[(\&%#<HQ;&<D6SS+B
ML$/0%,%/L3&OZ"U5U9(% JS\FO="\5)OZ ,KCK_D]05ST%L6N-+4K+^(;%KS
M@E5: E<: 9#\GAE+)O#:PO"D<V=4B _Z<3'BS!\'&)(TRBJMA SP(6/X<'7H
M6)0^7 ^NE8]:.R *O(_GDC,_D)[JUR;@0'*/?[T/XHV -_Z>VZO% #%2%B<7
MEJFLHLWTP@>E;/=/FH3%.K J ]3Y!!:IFFF9B3-X][4U9OB;7MV/>/FF79/A
MR<Z@E:@R,8-P,)D.=G@^XW!P2%_C?ZH._Q7\0\,"J>FQZ4T*\')-YW7E5<J(
MX>7(*(44SDA??NJ/[&?58R?H'S(J'=6OEK9O_YF62^B0"ES$C>D5#Q=;R F>
M-5Y(A@5/DQ F. DB?PI$+R^V9F+(2%L.O)+4@P&"KK4AX=:/8PQ]IOW"O::#
M[KU'E<'\X.*2:5!JX?(TM51PM '4:C1MU+(T4=3NY(]%OEL:XI=JW\O3+,.?
MURJC!FOU$"U4%L&'YZMP-LP]6$<VM2"$8IS>H/LJ-'W\ TO9V7J<KJT?\*1:
MPY?-A$B1AG"%"_:ITH0CR:E]:30)_11H^KAKLQ^Z#T3H0^HOE_=2O'(Y7.ST
M;7ON:7OF __Q+;_Z7OI#$4B?F(@P A+=>]K<>B]U./4'-3KU#G0Z]2.TG53<
MTR7LJ%D73G%AA.PB?FFYP-\4_]B$4ON2-@E'$6F_&WB9[O7X3$@^3(<&"+AM
M_]2?R>QTI/6SN"14BM&%2)#J<>+F4SE*&(L/6AUP%C$:Q3Y!9_BT, 6,D3@\
MSA>1"'A+?<:2-+ATA"4MMS;8Y0']B.DI(2TK :3P^X<KKA[\?>;$+_1*>>!E
M70E[R!_OB9#[S77A!^6K2F=B$[M_MT#$/W9EFA]TW[U9JB>,0,V>8[SL]1LR
MS64\2Y?W%^_.]^:' D<\L#S36B1+Y:;R6QT-VM +DEP;>/)10-7"LTL2PT5D
M7^YE%X1:S[,'>-C-KM325)7X6,A7D+*\64F=EV&<HVFI;GW='3"\G4-Q4V]*
M!Z63QX_3F&*XD9AH[E,UT]10U] T4[N1,ND4RV$MW3/]H$P31R1H-Z\S]Q^K
MRG\!.HF&CGJ7BU$MC3^)$)-1#1&&]^QF ?>>^#"BR< 72II6C\M+7F4H0B9E
M&/,F:LMY9FJ_T^H3CO!W]3% ?"$U5_=>IO@RPZ'5:T7&,P+/!B\& M[7,SH7
M+38Z*6+BIO[38*@Z9Q/].*#3Q]< GDUIO!Z\2MJID&];,[4 711A<#2?J9W(
M/"6BAFLSWI/@<HC<-(";1C#7%8^ZAB8=G8Y2_WU@'KCG[10)4!,2PW\1,2^^
M:2]0;SM4 X#C<'$U5>+N"A?VB('UK0CC?>*UU\H7Q(Z)CYZ,?,14FS6_X_4J
MTHLJC23*AI"&5QDRNH7"'^YQ'(RZ(#8"I#DV38OV(\?HI9B2L'=X)!GOL\>5
M$(,>.;D1EP@M,#]LPYQ2. K=LST+%"@:X+S7UH(E<,T<%O.*S(U_(8L'"'A<
M!$/6_2WGN4^A:9\1H8D*Q$/G=L2CLD$DNOS'ZO3_#C"Q#B! $!.U?8_C)QFT
MZ"#"CMW+XP\N )>FCVV&D3*L[W*\'RV7=J@23\A5YF5KID +Z%.-XUGN2LYY
M& GA(@5BN9=E4^,*"NBQ..06J;]L=2=%4L=_$"55_ZG1@S+@C$Q%UK(P^,(%
MR0)KJ:R#&O?F-T]<!=["NZ,DB,J'G18G<9<ASQ'KR@F[<C9IW@\EX<1^L.J"
MW('WW5*@_[#N[R5X!#WHQ=_+KC)TL3B+P"; R8HD)#)5Q-@W_^ 5C^)&W,N%
M#03P5'; $'#:$.[C)@? DKC(;!6,T_-A([,1WQ.6I\=A0K+%Q:CVEG+]LJ3S
M@D:X\%5_FL36\AX_(^[P1I#M62@J*7=PI!B1J9Q[,O149G.$)B-_X;Z4:[^6
M21<G4CS^GGMQ$4X1"AGQCLQPN*MMA]1_K@[_+0 G^RQ!\3,)^U(73M#B^QYF
MN/);YMZY%9+J(<("E_+=C[ZR-M!W7=5^-_)RY&OI! *<<]=OR<U]^$[[=E5M
M"(Z !A*'[U,'6UW1]4Q4^[4NYS\,.'36H.^__QZ<&5=U,FZ^,5\XO_WV)^R/
MP%RQC=[X]3(( @@@@  """#\5P(X 7@ =@\ !@$  @[7@3>?D 3"XE')E)SJ
M[BW0/HA/\4 41$$41/^;*9O3"_:Q0"!@# @08"<' B;/9]@PV6$Q\&$1O: _
MN\\WF<XSF,8QB(($( %( !* !+^J8![*RROP^DSGJ9PH80M#YM.%."D?,]#N
MW]_U73!S$"7W;MEGJ,=':5[X&J>*^&<6D? AO_*%;_FPT&RFSE"$(1?P!Q<@
MO/*&;_ZPP&WVDB$8@S\ !R3XKQ8\=F*C=%;LN>PZV&=3P>]J/GN72(ZXO.!0
M*Q;I_2<6X3WSHWRF3M'\]L-G>,]7CWE!%$3_D_03O.NK^[P/_."?O:3@5ONO
MI*[/:E_>C&X]%';/ ]<@18" /2>5!.?)ZZ#?K4!1\T2 *-VN-9@)M(&V/_&&
MB[%*"!5Z<<U]!02\= ("@MF=VQ,;EL1F#_!WSQ!/+[U!JE]2X6PPL'1D7N]S
M?*E24>Q+JV-2L;.L/5JW71\\'$I?S13J$XU,B"=G!8E!XC^(F.#)9PC;\R2#
MA@WV)*1'5Q?''&/.P\X<1"@7IQOO\X& K&L7:?+3W1%P92! X@J0I;H[FP-9
M<YUZ#B;>,-L@#6-SQ7=T+]FYP2D+[=8Q0W " 4Y7XK2SQYC]#SVNKWZ6\OA*
MR QOV 8JV# 5>)8FE'@[;'+0<RXL)D\.J\<N(#%(_$<1J]HFJ,8K.^]TA2TX
MR\E,%6@A(1;[>(_S<&^EI%A+2# 39,6'28MV$N&#%'\B1=P!9VH7(^;8Y*TI
M!0(0"537V O*;VSI-9YX0[^SJM&-+;T43G9.NJZ?N+&E7Z-O;.GK*\>R&UNZ
M3^5Q[79^<6M+%[0>74$=G]Q:Z>9.E'.XS>U;*PT$>(>1'_W]M'5=,P7Z+:\U
M$+DHO9.CFON[U76U*6FHG\6@^HD\;L7S!"G^1 HD_:-$44+5JXEI3+XE'Y)0
MXE+O\ GNSNV76M;!5#7\T<IIPOF#>+)ZB" %2 %2W"JHE]66M%5_Z/EF.>\"
M =^ZON#B0,#L];>^+V0R$-#P0]\7A@L(</ZA\XOF=0T$_-"OIH6[&7/^V+'6
MQ[P  G[L60^SGP(!?_<$!".B'Y/.,%H)M36>EE#ZR$>UD'2K1VA3"E$_2X_V
MD^P&*4 *D.)&H4/;?5:[2@L$U)#1V2I5)*0SV7%8'KFLKX,-#8)GID&)\<,F
M!#UGQ0*)0>(_BM@<HX)\L>MZ+(+=H NS;#EPXJ!MVU;CI+;H0D7NJH#$":3X
MIE O.*@M((^XPKYST8\;@ #T@VTM(,#WG//.4:,Z7],O3W0! 2A'[G?>F@H(
MN#3I*HN\)E^'_N:R;X[^.AMI0'ZI.HCXS6_?'+[?0#:J^K4A#>_.>4<" 8M.
MRA\;]IWY1>X\.#D0T'I9(^^\<!T4<]=/4 4"_,^LBX& EK^5%4.E,=(E2954
M<E9>%3N_VF-4VPVJPV&MU:RN/HG(!) 8)/Z#B!GAJ+OVEBOK)5H. LC#S!Q2
M?9<Q5 D6SOA0.AG^V$(D=U.>+N?=IRSN/C:T!^=,^4R@[<^TL4R(YAPX-/PT
M6_>&?>/'V;J/-W[GVTR@B-RMQ_DV%1A3=.MKODT%TFK<>)EO4X'Z;5=\/TP%
MC@2>!_XT%9B+>8SY]Q,_J$Q;M].IZ4B>7NK?.="UL:5AKHUY/B,"NXOG91/*
M!5+\B10/DV5$SSIU@ #KBJ !)"V)+FMO(6;N]/@4R=X!0AW=L))20?D)7))M
MA(@_O$)$:F.0;_D<8^J(L6K-PJ)_936YIX\K-L&+GA76V.Z/+&Y/"Y5[^\VZ
M=#Y*O))=5C&XZ8]^,RP$9,['JN&V!9<FWPS*95(5$##B)+/2L-]P9Z<.7%>!
M )DSV9B;7NY_)HT)Y$R)(U;6*)K*;C0E;1@R:LA(5#<AOT_IK6J#BQ1Z9G]T
MA6EVKB6K1+L52]R&+>/P@47VTJI41V]F:+P8/E."Z!]:W,>6'L:W! 3LC!Z@
MO?R8PVC\>S(@(,5OI6 ,R^9>.C/Y;?I3N@KQ?/U')[^]70 I?GL%$MI6K+#>
M+A!0(E;KX,#"0MFDX=X&'8"(@<<@;!HU#Z(@"J(@^E]-YS'8V-A'#]FOG(]"
M#X" JX:\Q?GYQ7E7Q/MX#X2?1&%3<*JY?X(&41 %41#];Z9B#][N[0,!AX$.
M8<F\*RP)O](@)E$"28N\RWG]D9ASOW.WI>H&>\R24D%P;W>UOJ#E<-AZ-N&0
MI%1&6J:(@&A,2#PM+M/_0YQV&G[ 2!BYN9, !"0! 5%K#</.M$.8IYB'^LX7
M@6/3K$# :R" <L YZ]H@@WV'?648"#C%+*BVOW:[UDBYG;P9$W:><N[)OAF$
MLZM:GEY!7;;Q7*>>Y4<! 95 0*P4$##E5+^^>PYW%N![Q7>H3 D$F $!=)DW
MZBO'H=DCS,/G*.>!*]4:UXO71F(WRO.+S(8U]A4F\F/,'LNVJ[;+B<3KQ>-3
M?)50-DFI7ZF;_B@EGF_LZ>EWN0 "TO!#5\^F&J(W$:5&\3(_BHC)Q204T;*J
MZ]LU#Q][9_]_Q"R[[+TK+'U P$N4NVAIX-]'2P.]M RB( JB?R3*IL*&.>8&
M!$P" 0(,-T,$Y[SYQ8/]-OB 5QB\#'YFSQ8HFS4^@"B(@BB(_C=3/C\5-C;,
MB^4XB@4&G<?S<=2>IKVHGW_SW4M8S/>?]QB<H. :Y[]BL(-[S8%$(!%(]+]$
MOZ>(AO\9P>]I=N5?I$_97KS '#VX'3ICLH.OSCE<PB6^/]QC<X+J:SS["A*!
M1']&T;/?2Z!L$/WCTP!RN&?.)_.*'Z[$K@ CSF>)D5E P''B($RS4^:UBW[#
M95_7L/-YWSKD KL4$,!!JWJML[S!?J5SY&:&F0T$)*$5  '4!\>8UR7GKRL#
MAX& ?AA9("#ZS"X0")"_PIKBVW!>@\P% KHOZ_B @(_70<:OCMF/P&6 @!4G
ME50@8-29GQ[^//$<+ <(.&0GEP "-MG3T'\I-Q"7$F6._*DG16+,<IGQ'Z5Z
M1PE7#9X>EOG83K2P;*LG6(,4( 5(<:,@\E;JZEFY0C.VHYDZTJM:&[(8R%A-
M%>GCC4WPIV?]<XH[I3H/66)L@(!W297"GQ.7AON4XE]4,;&:6]HMK1UW#&R&
MIH[A\^6+!H+$(/$?1/P@SNPL:VS#]9L;)_ :,!F!N'.J$G ILSF/[AQN"B9/
M@S3*G3?F9O-URB*[==7W/C@B7XDKW?IQB"?GI.=)W[S\0^PCQ>/7W_H 3[G6
M*GZ><B/A^N6\X)I//V@#;7_FC><RD#F<S_E4JW/?4"@4-< HMBA6>TM[O :U
MW+@51$#D+T1@ZAR./?:Z?N?&ZEX*?W#4NW*\'3U]C7YR/G1^<6=U]ZFPCS./
M3^^L[H(FUZ;8YLZ=U6UN]QI-')N^L>= @'<P7!Y[0<V-00<"$%]B*CBKVMQ8
M]&L\;K;2OY>VC7^/D+R!H7=!*_?8XDN#_6#:K^TQEYHB3E1X#:B(JGX@Q9](
M@4BG5B'9R7>];;P6CZ3B(7/^(7LEA<@VRR=!_V5F#(B "(C\'\DR*^6A#@+<
M#QUN7>>C@O_$[KV/4T,\$6;!./?;0^YI"H!1X;A$(W (>V/A<0<AON2'!BE
M"I#B5A%ICE&;HWH;9T[I7G)BQW!^11XL: -M?^(-NH^]CZO/SJ_Q&/7]!C7X
ML#945C><1-2+5 I67K4_H_C^Y^@5AVOG(X]O4UZHL]?.R\,%UY]_/P+3:&?V
M7L($+R966$L[C+4CQH$UB]3^5;[DWD"N^!<@,4C\!Q'C*S4D+O9=3T:Q&W5C
MEJ_ 35I ;5>YG4Q]NC!6NZJ@< (IOBG>DQW4SI(G @$S!#HR_M@B9U=#PK#K
M&5"60^#5>N^G:1IW8M1L1"B8,Z*>@Q1_(H7YAH)9SQD0\.,D(6ZB%!#PPRRA
M$%OFC[.$$8YB/\X2DIPG_C0#*7_,_M,,9,F&\X\SD!TZ-]H?IR!#^K+_0?(S
M!YSI6?J0<K*+),3[$4A?NQY>:GDX434UH+Y5]2LL: 4I_D0*Z$E3I71!J.MM
M$_G<CA2;OA5;,&H6E^@$#N$^+#R=($3J=NCHI?O=!_>T_^@**2%S,3G;J[?"
M\7_B+4BF=#8:\P>C0D#==R+66;Q[ 7=G6*[%=1*W$L.U9D\P[VS+95(?^S@[
M45?#%ON=>3E[G>!<["03Z?S%Z<Z$';BQ  &:E[ED0$#A-TNV#&E[W7'V1AD(
M>/N#/>M\?'@5>O"QYOKS#T8M#'7U G]9WN;*ZY<S4>$SBX1D5]F!Z$W%O2 <
MS!"*(XKS)R7&1M&J8OC*M3FB,S+X)D2A%>$"DYUIV\N2U@?9S+;2\7\VQ=(:
M6F+'"A!P:F#7HR*"6._\^[ Q(,5OJQ"P#^32K@4"_H5>T[^I4P:R62#RCXD@
M3&Q!"-$B$+ UM L'AXGX.UC)'$1!%$1!]-]%7U!\_>JL @<$F%SAW!BZX^L*
MK\# ]SZOGO(2^$D\2Z'D5O_0 @^B( JB(/K?3 .?U3HX7R[NZ'5BLP32_DKC
MFC#UVAB"."#@.JBLX2+SLLO&4>QR3%[8=ES:K2#G\Z^P-?E''9;(0VWN5  !
MED! M/'NS<@F9IC]V.0L>_6\XO<GS]*&O:<CN>3='/W2#(\_3B $'T'SWTJH
M,[YFI=&VK93!72E>Z]M>Y]W&P*/M-*\]#1T<GO\UMLZ#N()72T# V9.&NSAX
M8#_&P=M@BHE+71J/-,;3FO2.ME[05JZ,!A$0 1$0 1$0 1$0^?\2*2%U:@41
M("#/S*3D9@B_G7UJ=:7UGC #>6E3T+-53_Q+#Q$Z:CJ7!DV6H78XC-]@<E&,
M-!TU2 52@50@%4@%4H%4(-7O0?7,C\*=%5J<_;H!YO@4MUY1G;UO)<]RZ"Q7
MF>9:?TP$H6<'CE>"JIQLR<!IJCC]>MLZ?LCF_ML*^!3Z!&78](] 0+9UIG5:
M89>-,ZU!1JSESM92_IIO@8S#,BL7>Z3_DG\92J/C*:=5XJBBDML[(P08N3Q-
MW)PFN<I^SSFCQC&D"I$67=9)6<\LXL2^LMK=F(RLAN]/SQY3-B3VHZ B8QO=
MKX:^!PC ,[+LTFC'RV:^?KLY8G+5=#WI]V(Z=Y;^\$VUWN5(?LQM7KP]3U8K
M"*,57UD\;S!FE';^7#695#"N 7Z;+-V2"D^O\H'?\_*-FO+4_.*V27]CI4MC
M[RN8SE,JRX@Z?>>NU@.>P/B%SDLCFRN3FPP,?F*^.<4P)OV)<NMIL$6$6^K/
MLI9:4:0D%!)=R#K;+=$W?+#N5V]"3DY9#7:E6+[4H_..MBOBE!$(8-I @<C(
M<^EPCIOK5 HPC6$_B6^)M#9_X\L#!'R?6CI]X91!:#3%]H*P8\MPB%YW0FIH
M9,54]R5IB=E3/EN8WJ?IJ==&;2;KQO9:(L3;^Y7: FQ?[<CCHB=[CTZ.JAHB
MKW;F[4N-J88P?U8B'R).;5"(HR>I3H79-B0'=O*LI RT@( >A?6,*=]%9O2Z
MT<3#I\L\]#RZ^,JUQSXX97#A]6P->]%ESU<^0JC$I?M4:U:*8TZ<OKOH0&"F
M5U9/#SD;E:LQ"5XF]&;*\!F):Z#L-H]K_8*>)U.!KC4[;8-M/Y&.*=V0704W
M3C .<U*\1'C6(S=]]* VN'1G(K NC*5OTT3W H*N\N(I>C2ID!F?E:7E0M.I
M1SB!<Z)TO5!<="8:X73M@.CVHK]&($S2 ><KPRYW1NY='N:*B(C2LIX0Q5CG
M#FM,RTEQUFWG2A.<4U-"139ENLJ,5\5EDTGOI?F0ALGR7!EJ*\L+E)V*G;>)
MKY&N66-% A*%^ HT[,L)R,E-M)+S%<;R@8 KF"]^/0-UUGI)/$O^=1\>MH_E
M@5TYQCKM8([;M%R1PJ-K*V%WXMO=9$<%S2+9P():I^5+KJA^!3V?_>;DY.[F
MM99*DKC>Z<N:Z=XO/?D\E>I71<H^'TG2MS&O,NW[)MK=)[6N&3? ;W+N._G:
M*D\UELYYVJ<T8^30"@BHRQ6[R  "HJNH=JASWU)'+QU828G&;N*]$VV".,YD
M@LQE2"46_,28:ST_HYI0;:%U?6S79WVN$)F5ZY-XDV"H+\UT  ])MEY,B%\B
MGJ"^JQ_!&^7* GS+1\[*OA/M7]:/I:ZU%Q7[1F7Q+25M:6928J4C,JORGG,B
M0]4.AAO(LBZ=S<A2+COK3R_NXM#,EKE>1%P+8)95BT1OQ'4&5*ME['(:ZH6$
MZL:W?*B;Q@@?.Q4H9;8BH#.9VEK+US"#WU2"3I[LH#*;G!Y:5YKLF!D]GX^B
M,]IN'^&BU1-[7< 6ECMW9@PY3-H=4)FW2]V >L!3M_SI  E1O(Z9PMYP]ZRV
M+*17]HO +HJDC_$17FLT(9WWE)SO]$"'LK-E+%>%I)OV56^OSPH]/)E\9<[T
MZ$"6S//=KJDF#8%=BW=QB6R]%<&*^^9Q^#FX]_(&7EU-&\_*H3=HVI=.?IZT
M1I&9DFLU,A$7._U$[M"\[6:"I&/,62<Q$M:")3+=>HR<'SL<AO>5-C \46'E
M[*/VID/D\0]MUK=UQH.R))W^<D:AO7 &.YZN_&&MB9VT;8X'^LS7T@-J>T,5
MZ"!EP>"O2H(;'\O'O"<VZ[;%5E8_0)Z&XT=D[>2:9J2;/Z_5;C<I"V>J7);"
MF;R]S'Y%=_BN>M*VF[OD,I$,"#@U5.Q('BZS/J7W[NV!W]Y[&(A/6;Y]3CII
MT>L\;VX_74BL</;HQ5<(S)CH=OH*U@05]6&;+.JR%_KO&=PIA])W._9?(:\;
M,0>2UW88%XYV$1HK5F@U&(5]5D6@--,>LLSK_F"4-^U!76=;(#V"_^EL:B!"
M4<7%E'F6\/J-"?E-/5W66WW<U3 .]QLOJ^8]V!M,!@)8F(S>T\"M'(P*F<TD
M5[.W\N^=%N .ATOQ[%K:7/HMC-5$RXFTZP?V*BY<1\2*7874HT!4V^.7LSZL
MV74.0!VNL%=</ZA:Z:G+ \_!\X??*>-;B$+QKV\2TQ&,O"F!X/VIJTS%LG*2
MBQE9-KL4K5S#JZZ2\)YW?.A,<MNG1:^&T_GX3&YJ-6QCB/Y*:^RMM^6,\(1X
M2_FX?6*_;S3S </<P5PEVZ:B:?&$:_7,UC8>HJ6._7EJ1W=>E:.0W30DY>A.
M0'DJHYE0O!:!1,0D*AN.^K0LIL9DQ/:X*3[/58,M?LU[$]5"SH.3:P'C9TTB
MB41QG6XU7_YQ T>8M]'30/Z<-I:W._1EI;3\%"6Z4W@<<L_>@>'<-2%+$\G2
M/8"!I9(,O@9R^F-K>AY]=4VOG6&PB8MLU0NGR=CWI ,6\D7.@=I#&IF# S]<
MT!1S1C]S0.W"SJ0OO#U/%9&.W:%*=HY0ZHQWQ(1YF%1%+6.VWW'UKFTT#ZLF
MW'&6D@06V95UV$&_;N2AK0%NI<HQJ=FH.N.JPO2X#_>Z36FJ=/-AY\R7LUH\
MHT![?4))$07%'D.X9'S&>I/P)4;9Q9J$Z1[1](\5MSE3BS%Q-$.8L?4PCBTG
M'D[XA/%"$Q/F)SM'EWB!"PM=ERH:C_6. (5F1-DQ$8DQA-KRT-*FOJZN_CH_
MKQ+77R$W/O^TAMG6_2S31$=8G^D]P/1#;A9_'W/O094SX=5.?X401_:FT4[O
M4&)4)O,L1EA%@KI]'JG/7F:"6/RRQ0OQO9D+>;5UXJ"9;1[!U=J,DXHQ*)9)
MFZJTT(X26L=MJCEHKZ8%&_>WY?5!9(JSFW!,>ORW]WK8@)_Q<85!?**@]F#V
M9>Z>2=PELN1)X/50W>JVY@3ZU@0I?XSH(L+JP422CIC"^$9<!V*E=S40,#.2
M>36D+'GE9SULFF4_/6W8ZC!24=X_E/.^G#'M^6RJIMFGY4^F1J/E*UI6,E9U
M\Z/">- GIQ7,I*MR*ULUFLS0?80]![5  !$S?M"XW"#_"GUE)H+ ;FA=WO%G
M"F/[Z2&]CR.A4\^3E%AIORJ)[OG1C0U"=-E?O5T5(7R^8X(8$D/I/U.^;5&R
M+CPAPQ[N!#-%!JM;I((P*V+39U=@ALX[>/(ULN8DR*N>]Z@V30;<2:F\I&#(
MG>K0>:9 ?F?6Q*2AP'-'T1G'5Z96)* SKBLF/;]E6],P-GL]AZC(D;DGYH!>
MIIV^LG9'Q<:P;LCO-1 PA@DEN3-I@<,?MW(RK!T79V$_,:OD< !??T]V57C[
MROH$Q8(1OVEE\@/IKF%T=6+=?K.PMK3HJ8Y>N[ \Y*Z!.:/W5(P%?M;2ZD^&
M2ELQ.E$:*>-4UK9/)%AD=P.%F+K\:L?HPI+]U9YRBUD4W85&+&F4@AF%6,_L
MEAFN0<''TC);%BDCQZM<F\#:H"&GT4>5C#'/4R=-Q[NXN_5]JV _[\1,C<%+
M;E=)6#C,TO8=*MZX<-7#20&CF2%5XB73BL=FA';B6:0C#=0538>UZ82J^&4'
M,K*3^HL!R%^,E=.9:,+7*R Z=,048^@M'P7DH;RV-C]S:#*A&-1>4WXZI=2Y
MT#6<JI$Y\OJ+XY!BS *1<@41F4GL2M6U@3Y47?YB3>SPFX&*YJ:W%+'=J,^3
MR&C-"*FN*A ._#L#Z8RG\.J2GK^O>C0SDE-%=)Q4^53/=TI]'C&2K.MY+ET"
M+-,6.5@_5>EHCXV4;!;3@4L!0N<G! 49R)6\PDP9'(?'0^>Q077;DH$YO%\;
MTE.ZY^-YF@U4[$VNEM./E'8$F#(R8<!&<C_Z=[S4;R&J2Z5'=\ANJ4+]7&+5
MY3MI^K2.5&KT&$95/S8:_XA*OX8H&Y?"T/-"WEK5 +(CL*'$6FLC5\_5CVZ3
M9AI^2CS?+*8ZXZVLY(B($-=PC3V9,UTU(EA-S5GDI(P+T4,[][*LC\63< 'S
MAR/LACQ;"!/&MJ_BI:CS\E&@"Q0@NBI>T".UC"F8#4Q*G!;[<+PV@C$?XPS=
M_FQ,["M1NK*+:8N3NA%LN>F-]Z9>.Z!HM !.WHJW?R2^>4P&=E:Q9^AIF8S
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M&M47]-+$-T0[FRJWUUV D*[G'7652Z*KJJ?V'=]9].JP$+9!DQV7D+%BH"#
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M+)N0=[[)KJ4/XORJ1H,NU>\'/T#O<,1\I1CFW\6ZG,]LEPX8.<1$0_K8LEB
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M/>2)*BSM8B.$WX$0=9FN=9*=\\J_2UO=-5<49Q+[%^/_ L-6SJRR5OW]M,G
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MA](*%#8$4%%9DF7-2K,.??R?$B8JI;.D-K=Y,G;^<)&2Q!9&Q;W=YA$;RN4
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M4^L5D;,V[")AOB![T%2&FX=&S=&MR:3HR,$4KV>D%R@W]^3G1?[O69%5'H:
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MSRJ.36O09X[.T* N6N.RMLER,U]'^6Y].RM:QW&^/S7[$XZY)S5'T#, OD
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M5JS7!K("T1P;"1!;>\RZNV4'2+@8,R+DDS_^RB)@T=M\BG]8UP@D+#0<+-I
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M ?;.:J;$%T$#-.<ECSO X Y#^-<Q:8TY_N#%#)C( \Z30<R[V5/LGOM*&VC
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M]N@8E\=&IE=C<G:?+S:'\@>=_>K\F-Z#K^A.9<!Q9V66.V5-M4L1,]HTQ8Q
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MQS\@9/583JW-"6FFMUA,VDAI<<E"\HIS8LJJ_"$=3]*JU>Y<_I-8VZX4"<H
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M]\+K%P[>(EB)S.7>N;YL7\RSNRD8UB)R<^F#Z/DKV!QGU@M>XB0T2X8#1)+
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M&A?YS5MV#-MY]-*PI%FOVR_0XE2_-^1/$QWSXUW0JYEUKC.J[;C<'E93U8Z
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M;SFOE >1%8UG,_8#;['U)EGK^MO7'/'Z*:)<D"(E.VO9F?]AC7_&U;%Y8D=
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M>O(4P;LB$S*>N*,\I7]&F,VY31-R^>; YBUEQ<-!P:#@#7FV:JPG32CQ OQ
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MKYQNZZD\GV_SHV@QS+(^U.<VW^,FY\6+QKX&1X)#ZW)[T#SK2JF$B2+>_-W
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MKZRXT0&^1Z4FCE7\ZS^U>3B7=R?/W@;$F_"(3B:J&#@2?[.FVSR/H\*KN+D
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MA4#-FJM])]LV,T<T_ -KM2<6+?HJ\)Z^.;$=??'^:]C"C<@:S:4.]^0*;1H
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MIE'M@MD66[QEKN_:N'FF ! BKVH4!3Y*BI$](#.?73Y" [@%KB7+RG06S-S
M&FQ[+-:6X_P!J7FIFK&=AD#CTPB;'+>M:H;G_:4Y_?#HJD@-5W1K/V0&<C!3
MHZ"++3O=:W16?NH<!W!UPT2BM3Z@/LKJ!:)G^<)0 @X9?_WU+*X^23>?<1"*
M'N;"5NK."ND9OKP ^=6(T:DNXC#$%5(0SM9\";4EE>NN7?TDIS)+><0-;%[-
M\_9&3,UI1DW?&.B-+UW]-JUO[N40QP$7<6+]DZ-1EL.GMXNU+"2=?]I0-S5
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M8^@%#2 M&->:Q5)*X2#Y?5UW^8B1<\L4=/4G#EP7DAY<46TNT<>!/4:M<I:
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M;J*(8IE(.I_V-EBJE,6B)W9'=8.6)T(&6$-D]UK;_KC;Y=!E648]&0\]M\#
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MR;A<P[#CDR9,7 ^/]NV[Y!V_MI?9P$.AY5 \VBHCQ<(C/P;L+MJM_<.:-N$
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MI!1PO7?:J.>$6Q$36WDOODN.J1F]-Z+>?QK56/KR&^Y%YXX&S76?A^A/%-$
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M0.IDNN*RQRW"&$;1_2=B![EO^A.]0"_0"_0"O4 O_&L+"3<%[Q.Y621F=6J
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M#N#;:7GCIG@BZ,ZX#!=#@\1=!'/(6-(E[4=OW-M?\#6.RT[?.F'S";'*3[^
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MW"%[ HISX%_@9;A^*9*7R\20HAK!\?2*:=G]QB8Z\0<0RA$LC(=L$I]F*]$
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M/R$'VJF]$'?%E.9NY\+NLGE,5'D;H;AT)QRR:!U2$2=IC]181# A)A  ^L:
M7!MV[M.;XT244)CUQ)_1W@G@-U&.GZ*]T9^ XM4/!L-&!475TYVV% ""8&_3
MWIUC>&R27[G6:Z,C0_KXR02?&:-Z%1FM$]@N]C_*D:DIY#-U9, **3>4<TGA
MOVJ([SE_RB+18VV^Z=I B^]2?=$)V4F>H%Q)E7'7GO1L$"1W7HA/C[V(JZ]O
M=OR,:$D'2_*&O>,P%7_]*/Z+_F'3@>4S>6>MWN%YHX&I:^][8)UAK;(8_''H
M3^P'Q6X(AX ^):'W=W6-L2YU;')6@GFX4CI Q?L)(&2^^3ZQV[]*FW,W:+UK
MG)\:/RY*U:'M)(5O,SI=@;B0%MPG_Z%#'V./)5=M/12 ]*/$5C*H\JB#P@7.
MM:D2\VI6K-_T:RNKL?51V_"3\&Q4AWL-J7P@U^12SGHL1-D;H24)CG#51S)Y
M)NRX#HT^--M>NZ&)=A-W2MDMBEAM%Q5M!V-4B'+"R=C&K6G1C.H=OF,C#>//
M8:GHCC-"03)WEF<Y/!4CJ>/%N'W<6GGFK<QZ$D-C'= Z!"@;C)4'@_R^S0SJ
MDTQYZ-QU&^G6_/D$<'LE=?D$N#W->K:=&QCFFN)ZN<)N-NQ]U\;7$CFQY(CS
M6?FK0P #XI(R\QQU).5JK/65?*0OA HHN/$E&8?=\NV%GGY:VHN<8>6!P09O
M;D%^CGMK"3L6!L8QSN\O R\&(K0X4MGF=?8QT_]E-:B(:]7&GV[G/V1I%./J
M1J6MAQG9XM&Q:K&HZN;99PNCOZDY.70I\N=*4MST""#<F'E%,M4+@JU1LZ;\
M4[X\CH%/ (5D8P?==WMV$?A<*]-YT;%A!,ZE7+;4&?P( H="^OR<(9'#UQVV
MJ3_Y<GX*95.#;:%P<F-.0CPM6#HK,I:KD A3'Q"-3T+Z+^HW/@0+:U]1?K9Q
M9?%]%+_Q-CMQXV/>@(8%90F?<8_2?03\F*)?VK'[%^0*-3UM;1&QGW"KQD1K
M=C'[L54&E1#?/%9&^7CI!GW&.:O#$D/6DC#LGU?8.K:!(K8%X?7Z0LCM/0*!
M>DJIL.CEZ$/[0]K7J3@?"CPH"/S>LN[XK@E,7[I[7F^OJ/ESS#X!DF;>LAZ5
MR_W%&=P?K0ZN3O-]*TR%K_\(3._#6EM8<UT^=O-_13HUZQ&4)MG9N.$*5Q\M
MGX%W[8L7UN%NE)"K^.2%9?GSXF'K#$Z%NJ;S/++3& CV6LM ,L]NF73?[7/=
M8QFUBI5NYYG+A4@3\[<1I9<(%OK'I>L=I75NLQ5;D*'"C:N6JBU*WCV+;TWY
MN-:+-=S^_0E@-G;U=DI_PU::O]NY&>+URMTZ5$3?(*RO0^LD':16$>^$32J5
MWDW,V-MG%[1NGS/-5_=2='C!SS=H2=2_=UQ$BY,ZJE"7-7?4Q-4]E08_],!Y
M?LHHPYKOU/YG-(K$6B*KD0$^SL:9:.#;_2=UQ_%MK<HHQQZN>,&@13Q/NY&_
MK<Z-+8Q/!2#":H=-K@Z^26EN ?9O$3>)P2=YU'B9GV&DNZ2G7%)$_NP6_<#!
MM_UME_<O;1';.:X(A:^I2(\-US,ZKE^_[H2> %3IQD65,YAQ![1_MT@2=Y=5
MRWZU%K")<NU&X\=0&"MA4-KD2!1G5]YG!A^JY+P,,O5I%(7'V#&D+*$?>C2,
M\1_,F4=S[0@K1B9$['_E2,,P"1W8II:]<B5MTK<O3IW@3,(H!6!.FN1)DJ5+
M"/5=0^)AO,KEC5,(3MI!HE)*^GOG#-]I^E8L 6.>T]*3#P(9[RBEK8488D?=
M%CYEJ/F;K<X:[="SI@=B1MS)Z6DL<&"M;18XE9\>V]RYK>CK]J7<60M$^8RT
M<KG"L#6(39Y/$>4S<&P5A,9ZX>%&>&#"[G>E",/RVKS:9+$7DGT.X]RD^5]8
MYO*17;M,O1;7R)9%0''?4[[14+F2D&BYQ7\-$?9E(SJTG6=CS(8Q<F35WWR\
MCDGL^F&\W9;@H:HR^';33X9HMRD7G=HBEWYI>'!3]IPTD0/3*;\QY0!588=C
MP6H)Z_X\)!\?EO##I4EVK&=D*<Z.;3=-\^\K<'48*N_JCH8D%]B(V:BU4=T'
M8],^C]4'D+@;NK;9U'3L/BI+JO??0+X?37BWP+F!G\$&OY"+D=T,/LGJ9*L(
M8O/=$D8R91()@E:=XO-X<Z/6^^A#$=.N=6_P'#)W][GU\FQ6K.>[2^Q=J=IU
M$;WDUHA](5U-%/0X.C+!3Q5%9E]GT? ^Y9N0R"KX7T:[(Z'?"?CCQ3U5)Z[M
MG;Q;>X&: 4W^Z8G%'],R(<'<DVS400.+0"6D"MMZYU*(!_*[UCV7>@?S 16N
M1@12&:?XN16R?,Q+G6<F$=HRK@F&_832'(Q[T_%LK:_RX/.!]MEFJ5APJ983
MV2I40OO4YO88&[Q&9_DDM53ZS%YJE+]!)Z0:SX*E.]*G$6V@ONZC/D61O+UC
M>P:G!O1E*O-.Y:I(@N 3@%5Z.K"7'(GL;=OC'<H+.8-B[R:12O)(@^!:7VV(
M2IO\[QW4Q#4F[U?IVDA!NGVQM@(MTZ4X9MW#Z=-$2E='L(<8("W,_)T^;SQ5
M7D:<6XM90I)0BF"YLV2LRC_F1>7V$3Z8@J6LY5OF<G'IUFT<"I1@_:QT3$:_
MX"@;"5?<'\V/(\D"?E $,;'>EFGGK T;UT)>N:$0KU!_? [7APTQ!J/1F!#%
M;6[( %/A<\N>"GAK2O8A->.!G]/KF%;MC9^7PM^@^4WOS^M*Z%X##:=-DZO#
MBV!#SX?ZRY&)[Q8%!]SLB@W.WFRNZQV!,$I2KE1GR5Z/WW;H,Y/'.]D3:S02
M):L:V)+):/+T2QQS=,Q[&BYSL475Q*Z7%)5?P:?')%3_?"OL*!4@F\\IQJ$^
M4V23[HOG]1^(N6<D(LCLB)-TBJHV%?O4W&OS['EJ1F?SN)%"XR]#W(2!/7M.
MYPS[$9<W,G!@QEITVP4DUJ;BSX/!(9UGX[Y Z<>*;R!S&>R; %6EEJ^OE>:M
M6/%AD\:&<TEF'/T2M3BVH]$A0X:Z>F3"H&F]^!I#AP>[4=,,5_I['XS4R^<-
MC#3@#'Y?+E;-!<NO!CUO[*TM"J"\V,7TQP5[%S)L8[O9#9<^?1=YIV9'I$D,
M,Z*N9>5RH:I[5(:"^<L\2VJWSFSC6!E8!='\H^2$E9?W ](A S[^U4'Y5D!X
M=M/I#P$V.H*4-7"S-.E'2Y0@ R>OQ2B5P40>]EG1!L]AD0:'PZDQG>T<RUG7
M[6^%D1_6M%^,EJ[_YE_%RC:$G&3S/WLC"J3;1OPA(%]-LJSKJ\*LP8F /Z!W
MM5_FA"/R0@35,X0U@]/U)/DO(GNBFIX U1#O[[__G<6[L1#4OLNM:1U$HG&7
MBR)H=:K2JA>F%KN/_N:C\3^I"-?PB.8:M15?KY"J*OZL6&1+CH'['#;RD6Y?
MURZWRBJ&H23>O=LI%QT&-YA4BT*"QV+=OB\T7)FXN-K-3$Q@24*MS2*8,9\Q
MM)J+:WJ84J%OD%1YI$EOK+J+WQ9JCK2(A$T@%OE.25+I)J44V3"PB2]BX,(>
M!VD8V^2B##:C[F1?#-A7U=[4VX.3E"J1/%,;R!BJJZ-[%G7P"O^>1R6Y6#/%
MH5KSHDXTJO-M;C;QH.SBT:5[*%>UX'?!I(OGXL4!JC9C*&$0_GGZJN67! C[
M*D^A6G=U<?NHZGA>C,"U.%PMRF?)98VNL&\QM\)V>>K +-NJ=1K"\8P+T>-K
M4* Z:V0P+\+8C&[@XE0@Z8<&*L>:V,^]ZV(IGIPWEP(B*.ZPV+X:N'AH^3N(
M)!G/BP"IER=L@EDI@Y>ODDO)R*1J&:4;?KAYK&9J./C4<:H,0P2OHPZI&=AV
M9"FJ9^+6'PU&FZ\SC:_?6Y8"\V:#[79^I+ +H"=*I/AD?I#,_95]D/&LCDA]
M _+D&6&>.<V*2JFAU*+1$W3V>'&0!W)!K>NJ#S8;$=J"_A) +,E.WRX'O/H]
M-&+^JSH[O&'X>Z,%2_JP7PVDXC?BU+$*.C(V4NY:,Q_)6^S'$;U%$[H]"NYP
MN&,,CV>)5Z[O:GM;M% %@WOL342HA?F<?F/+,/9>A*&U*'4A13:T SB\_P[_
MD=52<]A*JVU-Z?QQ0L/J9C:2-#H# G9KE^/-2O=E\/@G0.0BY#%8-.<?QD</
M3U! >3[D$#-.I]6J-6>>-5M1X^6&X[BDOQ(I!#,&AHQ$CIQ2@@A6A</(,49:
M 6_0914.?R)T7#SY,C@^:UB=#%J7JM6_DL+LVJ^G,2F];V[P+]A-*=S-)N'Q
M5]H)1H!;N EV*R$?\S+MF_K7;MP2DXIW1WXV@^'?J[1%C?W'/RAK5?E,2.GR
M2!M^S16%&+Y;Z9 Z/V%[UNZ2PF8[20XZU%!V?2"K3^K8N_5,3#%6%:4@(R[=
M8G42=I],PCTKY[")O=IZIN,Y58$3N.;>15C2KUP"UXO/GO2/]%GB>GRDI'SS
MLD;/.7VX@1.+-M@^9D*>#!,_+'@OF$S<E4%^=7)(C2:TNH"S<<%-Y>" @ED/
MD2IQ;&H[,84QT6>,]%?%\MS4Y2U^N]:VYF:PQE='M(!J0PD\0/XHV%9DBVUH
M0)OMS MV>9#?,>T4:7\ZW7*0C$5)L4W0_W5<*X.7[$-,'?@*2;P+I\7RHN%S
M;HIOP/+4!V=(_Y^E4(*>1+]<W\G,[9Q#K@("I:W.R;^+)[>TNGLHTCG!BQ/&
MH,19WRQ3,3LHHS%8?6HINS;&CC.5*MY!A9P#5Q@C'% <YG&V7.25'M3&Y##?
M:/:[0R/* J7\J1/BZUU%P/Y=^;LK?T?J>7X(QGY\K.U^\/[>!8#GV)4!//TM
M(-D_PY/[-&M',Y98#+7,YQP8N(X+'ZO_0)"5.D9*8G[)GR5A]R9S1LAUE$=A
MC[+ 2__6.)A^(]OFV5!++SU=KU)84JV)VF6&?5KEY+/EBK&N9V)D8B4:13&Q
M/[??A9>1\D2G<]X4!JUQ&8[[T,;*"YV5-A:Z52@K"RS^'!M<K%8;MV/OY8\$
MNW'J#,BEX=^TO*DI;#2[60C WH4 A>"C4N>'D@;&#SX$M97X/S+?S<H&@X)E
MK3%63UI[S]9$![XMY("W#HW^BE.=W.L#I6PMGDF6VMQ9M^>E..>&<85>:J8T
MRU(90)CEW @I!_Z*OF6@RLP-59\-8?#ZF@VO<5,_5I+AX?(U^L%B>#*U++"5
M#6$?:ZXEX/$X9224:SW(6%6=_?XZ0X'&U69A$I1DJ!E\P>Y[AJ!L? XCVSJ/
M7[%\ FQY,[W9^#N+D" #CX\UF[)9'>>Y.=2TR4R08D*="\4)$EUU4@1UI3NV
MZTWZ3OSK11SSM$>A%)*N24*S5ZHO/C_FRFJ):'>.3MV;MKW;)D23[TDTM?"K
MO">>I?$4J3%6%Z4B?%: C,:SD7#[^P.:-TK5S8V'(\FK7?/%BDY2(OUTN .J
MCDM22FC_?%YQ*CZ.%D:,F6,/.(W^3TJ9^R)])YEK.(!DX#-MR/^M#5KCGQ"+
MYU2*BJ^#5H]/H#$AH].*<GD+<081O-^EWF>)I5#JVD8[O?\T<E/.FV7%OBZT
M4&LY[5../".V/%T 6OY^1KVTS2DHM/DC*_,==6I6>* >PG^1%PE1XNA57G%;
M<Q4_!^'XC9NW<7\KHV0EZ!@HE9;F3*4#VD01J\4C@BVPAO"2G'LB][KE6Q+&
MC0WXZ?_R3(CHSE(%S%?&C7- 12=T1U_W&>UE4%")L>_1*TSTFJG$KW3LQGP9
M>>7K</QWYZ_;UMGP>F^R)-G-#]^3AO:S0<&F&H@10^UV0FR58.A<5B.=2:WJ
M64:E;HX4>&9[5< #>)F484.ZH8B]X ,F5J);>][H(E9EF&SL8>4R??_.9$J]
MC4I*0K0[(.E8:+F_&J8^+D7^E56?#JJ&CQE8RE ):G8MZTW@C1?*46V?)-/.
M9"WS8#,=E?DR6;",AFD N9PK"!24@_$O0U]2^'1)CB['% WCGM4A3?Z0(*U'
M45&2;%='\$\DM%,JPT6X !C]**1C4U>:0@I)CMV$.WME)RDZ2]CD@S@V-)=Z
M:UFIT>%&/!O:HV]OJFI:<37B(G=H/-[HV!D=S:.4+4JY4TUB.F;$#K0'7PTQ
M_49P3C&/F81HX/ ]^UV%YZB6&B1.O*>.M9HF8IT%X.%P,]QY'D#B\ 0P0A[W
M7.-UN'XS,S=@<P/54(X@SW!0U$2%:0+NK#/Y@AIQIG@0O93 A:;P_K4#S<;H
MI ,*T1'7<92U;\G:],B%O'59W+2*5][7Y#.:*LKT]Y8= :7']#*T1Q)4.PV4
M29-D0R$,(1"H_P<='O.R,YDE"A(LIW7<E7-5U\;^I9!#2S:'RU9!U/=]:\L!
M];E#TJC$E$^ZU'U;WIG[:A;&TVY<#!]<OW8P5\6"M(C%9ENK>H;5I4;]%A^+
M2C8ZK5E]]?1FH8FJ)T@Q+=^O&SPYSU/A=OC*:@8^ALT3$A8QEO?VI>/9P^NT
MP^3&$JB*Y.XZFYQ=>-'D)1>D@+#50D.#ZLCI' =)ND].UGF/]:^1;S+4L$7/
MF\O,I#O.:9)2L:(,KN;TZ<CB;)A(01I<"3!"*RQ\6JQ4[@+=K]+AOB :XFUG
M!W=CP77$[.Q%PR&9OW&UJ4?2/MLEC-'$@4**5S<IVRU50ZC;65 #/H6L3V^=
MO,H[*6,:SWY&K0Y]_<-1L'C?%G3=:E%R"8_SY7D63C?:'BTR1J:XEQX%D'3!
M@S$5Z+9V95YDI/[!"\AU\&@U<YH]3SG4Y9V3I'&4MB&.84$5WWS;!X-XSOFB
M,"0=\>KM*$%J2I0CTM.6O/A*P<AA4#SKOQHO%9WDB*7?/D?);_L]\4V([AJO
M5#<_.PE+]*9]=@5L(:I^?\7M--IO)SJ:, .Y)L-3H5S2D6(4":$TI3OY[-;"
M0V;LQ<GPOFNW.T9(=9_=PR4US>/9]HUS=6H$#%KP.AF%,0I0(L"&V?_P6",N
M6-Y:%'%2T]S*Z[(N'7M-:H;(")SN\*UYDS-%)_$%NX:$KX^X?( &AR2DA&^9
MFZNW='_3NNDVUW\RGDZOL2%7S,V7)'^15 EJ795LU 2F@AM](T?P-[M]ECFE
M1H/\C@5/HP3[SCRGU09N1BC70J^)3/6RJZN$5JH,G>GI=6^@43[7G\7.\XB+
M;2'L(YO'(%OZ>PMRW-OTR^?CI*D\9:L**=0!+MWK3F\DU1T(6,^K?Y!2L<%T
M2E^18M%B16\++CK<M#FT#R093 C/:?T?877P=7EK5SD8QY,MW7DE/B-0TJC4
M$/\S5*5#%2 <Q>$9.>,!8=ZEVS-KNUC:;HJ[$4,M'3D]*H]DKN=*;SGYK:>\
MO"X7ZH#XP:2?4QTPQMHRJT.X7]R][+A5&'PCWWAK8_/%ZT]S4-QL%]TMK873
M-T0'<V7\V>TDCK^%."HS,"#3>>'6Z]I7Q\M\O+LD4#Y1CY=VI744'^NN_!D'
MV\3^M!:H5,)G2^IDI8UH2BG5UH+;^>?U]N+E(-6BFH;MG,<,!.&A[AY:2(B*
M"0E&Y94M*@[_:C7.W_V^<XQN3+Y4+WT"L!0M*BY _1^?14VE&&,8<YTM6O*1
MEM^!>8/QVJI:UQH6UR\_L.66;#YPN7O;=:ZBTE*TBZI\)]\J6SSO4N.(/I7&
M$[K4(\8OC,K%7N/1O5,5JC8-''J7+;AQ)E-T.*EUB=O@XJ2)ENKTQT0P&KK1
M\:J9*EW1\)0N<'L/*:MVL\/QFPSKC'K4?M+0N0*? &V!> F>/7\[TO:7<LH[
M1Q&&?@N.R/T/W]'8MF4U>"&(W!4>ZQ1=VEE\5D]>/T;IH,BY+M3$J=7IG&Z5
M^FP]6K# 3!1\T<EM#*QY4]*,^-$_P]_N@N+,RO&BP"6FH(3\@SIG'7M]&F8-
M$BPD-9YA.^TX%I +X.=:'^4S@'(T?)>OJW?";H2J1,$I:\@Y=8*MJ?3P0R.
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M IE9SAGJ!%2IQO;)5$@)_)YZTQIRWE8=$S2ZQ9]UET*X+":XC#2MSN670Y9
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M(.]-QT %YS:C7^3_LQMO#O3T3\Z;9D@WD:\.90@:J@6:00U6U5IH&O2D#9:
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M0+S9W8%/0<IO0 V9:,#5$V&]A^0IXD>/VJ^\XS29K+!3Z(X21P9P^&5EXGK
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M'FWA/4.,I295##Y"%6>\RK=JU&-GJ&TT^<9@Z,.6_L;"JLYX6 &P :-%??P
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MYW6#I<''8##X.D+,)YQ Y>#?ZCB]S;##CL#OS@'B'VZ:;)ID_#B&< 5V3[K
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MO7>_'3.SC=&LT?R\P2L+QN"EX.!+I//8.3H-F$<10D)/$#;T>W*=!'9>VH0
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MZ=;33MA\?>XIQ^:5;30L/M\J!-%&P5[+8/T+Z=#EFZ:?8)-*(Y!95E=&N6)
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M(5AJ27J?L]\N/J\9.3(B6"LH?4BJOWR^/B%XOMG*56&A7=J;HJ&0".,WV-G
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MNI:C%FZU\ZR_\QC-HE<V+)HC2\+%JZM;U)<?C6Y -N8-!.9V<I>JD_%S T@
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M2')RK-99):#L3EM9B2R^865W[^P/&+<(HT5%I0U5RS,1-\E):$K\TPHR*5
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MS"/TR^OVXO:7QL[_/.7YYT5&[_AB"WXYYY)T@\O CS?"<SE!9&C)_/5;*?B
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M8Z?Z;6=V4X.Z#I[ YD%!:E:5M4D=U$I.-:C1;T"?+$FM+9U#X(K.X=5TN^\
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M6?"L-^FQVU-H<8T.;C%F =;4%W/7 >$ZQ.IZRIK'@D<I;0=R3NFF''H_+E^
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M_KO>="E3;\V\ZN+1R:)=/26@\\6F4Q2LL=V9WVZJU 9T<+EW$JB1<VNR+L[
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M#,+L6K2DL](-ROQYJH034CBRU3B<DQ9T6XP)50S9*-FTJ#?'UX\_?P[ZW!*
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M09VVQSQ+Y4R.7:+G?<=G9%J%2!I'*FO<=>"'V^L]^M$@J4#7\'1A*BB,-X$
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MR(UF:O8-7Y3WB:E6.$TLHU+&TUV&^=E02(-EI;>1J"8W0IUW@D)$JKP@DEG
M24M_63*O4U7F?2YZRW!2-L^'YGL-=!=XN_JC #,66*+-=%*QO*(\+I(N,"9$
M4#6NB(.-H?S!O&;+/H656</0\V:5B;(SNG3. +PL),S?+\';IT,M"H23=^#C
MQ38(?-J#J<T4[Z<^GAK0H=(,H#:@GM.'E#2KB[J7P9VQ*N!:9 HG5?^57\7
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M"0F#O\@QE2X5N<Z$-,0P+M;A_UC;;JFQ:=C<[G\U9MG4'=YO[MEN13+O?RZ
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MW8BH ^D+VA$6[C!FUQ$AOA(?/$IAUML8 =L%@;QVN?P >0:IHB> W28_B_V
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M3FH 1-,X:U--+;OZH*O1\XU%I3W$0PX8ZI^1!DMBWK%1JPG9RP?)/SO]C(/
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M<\LH VBRBHP$=%;:JEUT#%C(PJ 8J]BZTJ#A:]")= BO%^I:<;E<O5SY'6>
M\W:\]-M IDT1Y<@GU<D1+>X!H%R?>$O"ZA. IW>/.$2\06R/1L?3]ODGZ9T>
M[7>VYS(%_G753:>9F![G#9L;'>8U$=1<7FNOY3NDD,7DY['4]P6]@XRUG5F-
M05R.)4$'C/D)P=5:!&*FAK'7RF3-KQ58;.^W6%]R8:4AV*)IZ46Q'84.KV8\
MLX09TTBUIV_:AIG$-V.U-T=HY\^^G$]J FXD&O&7-CL#;R=\5 V$#=9&$Q?5
M_I,MF\7F/[<C6!&24!?&HN]#AG"U0F)B  [V3D)G;0TF62Z#7: *7YQ8$%/R
M%@N;YZ0U]]0Z\] PP8T\_C)^5M8(A"@NI=B($A627K16R'TV-;W+S[%<\ZEA
M3$E(:9J(+3O$"I!?" +*GKX63&GP6D7GF[0D,SRPBZ@>H=@E05AFW!_L/9<;
M!@^AX)L1$&,]%)6"..\0J_F'->_-/!5D7>D(591$]A"LVMG6B(WN#']TMIAS
M%7& R,^6"*>1)CQ:4%Z46XZ(\IJPV@(;)?,:1.H7J(N#Q"]]F#==]NS%3<B>
MC/*V_A7>K.;@Z(PQTVR>[D\2U>ICXWJO66D2!%#5B@(7Y694ELZT8\'N0P9Q
M!QGO(D6L8L@Z/T$U#W=VCXFY/#^;!E^G>#(Q%N%1] .3Q4F1P.=W1KV_,$P?
M%"J"^1D>7\[W7FE*WOSJ77_8_1#\L!-T9D!M>B39^SCU!/"K]5R^]@GJ/9;<
M.Z8]W/3S;4A@-%\;GF!S^=6W>4"H74Y:0[]152L72<AO.6P%C$.?CQ!VUI:K
MN%? 'WJH'[BE0#Q8DFD-0I@V^Q3.3D]K]5+3 CM'0TC)XO-H9%_<XFHN>LTT
M[^JGY?3R[O1T\N2%)Q\P,Z<<>^IAQ51:WS"QR _UQY[ZD8CX=!N+45,^SDEV
M[FUV4[PX1HF3]*M;\)'8^"9%2#?3O%Y0^3"S]J[%AF=D0%(#3+Z6J'E/.6%2
M;LO3J5\K.[[L[$,Y>E3\W=S<PN E\TM^/I9+.8-1^>'1-DW?9]4P)K@<WR2]
M!N'"$F9 CYNN6K<+G$P:B<)/HS/MY+\FR/1%?64!_NH+$'G%5-;K90KC[E'.
MGJE>CH >E/I?,N:-&_*0_7U8ILVH]Z1^;>K,OIU- 0S[@]?X:X2(-_WMJ%#.
MZPFH;%ZJ!KXX0(Q _2.^?ZO2-L6^6I256PY(7>4B_)#0@4U6-$$EB^=,[F?B
M^W*9]*_0!4MF0"E#0*$VBJI5\V=.I07.89<YE7+88"H,6_+C5FV(+;./C\PN
M6%A\76@@1<<3C1>[6)FL%(*?^X):W/&;VLFBR%4GEL3.G*K4T<4S]!"P1-M;
M[F;/"2,75TUAGZ%M0Z4Q0?&2"!4>(,]NLP $%[*?G-GLFO3*N,Y[*56E-W+P
M%-8$K65X_:8+MUL!*FY&>[VU;<4+4F9YL9ZR,YA:F%,@[E[E/SWD?4#R[?@_
MB<0LQ-5&:5<K_BN16(R'@'=4V^-_)1)+]RMM5(R5"AZCJCB*VXCS< L<OHJ.
MT?NYUI1JF?9Z0S0O<#-&7F *=[@TXETW78?&KMS%)T1^C_+4S&?H@16-K@-/
M6%5]V,\4:UVY74WF5(U"KP5E&9R88D>"/F9>[)"0,_SA$YN-PSMQDW<+1#(R
M13F^QBNE-F$:5XO/*D<&%?NKE%@9T*<*WGG-VSY.-^$#N7Z3<FD(<WJ5FBB9
M7;Q2&Z-TO.0JAB.,STU&!OU;QMB:?G7JS+ >GH-AB1!7<L@07F4TVY9DO.+'
MKVNMST>LX]79Q95W,F1$'0P";>Q)IHLBJ:->?L!1(2WB1T6@J)]+0)-)\;S4
M<\,G<+K*ID$OR-W("64;DQ$W"'9$OU''$E"$R9'2C)25Z6B^J56P-#'/7^DR
M [:'<I%.:&"3XC4UD72"S:7<1K-DH_HR 7F41K:V5#%GS6@XQ&F;TV:]J)7&
MHH:T&@YH/%"*&L_W#T2OS&IMN(TX1IL@"+)87/:UP"_1U!:P-%R/FER(E8K?
M @-ACHM-D=X?41*!4W:, RJCZ7Y7_>VT*#>]:%S6AR:N'LK3G>!Q]0&*5P-]
MXQ&E$B-;#PYQ>+_=1'+[TB,#*'59WPOJ#($=/LGC:P32H_SG%-T4;\3ZZZX'
M).O:OH,Q_1ZRG@ Z3X"_)GNT(M[D'GIS\&#S6?#F94<V>.\><J8B_&$7UG%-
M%2CB3BL9'=DDM.*IJ]0O/%YWL)VKT]I-OEKF2'PN2 DD[;A=NAQ-U<2GAIC2
M(*=<PLL(^"*B#'(5";9D3M^/&*6L3P=-W5P^;[ QDA&8S$FM;5O=TF6K\7GI
M0"V@U&DW396I'&>@B%-:29XIP^..LFEQJ/E3; KYXM!U)I7S7"C7V.ZP0MA:
M$J]O6"F3^>[X:%A_]8*.9E*)@GBOH#ILY D@4DIT=9EBVV:2)^D\F_U>IIT\
M&?@X=;XG=HIVY^D0[;T#R6^0*>[(. WWP[+=!3.F,D^YZRBQT%,;D:>L[GT'
M+Z($O^W:C])C]:L^$%3SL'5 PXC3BW01J.4O'PF*-_R:J!JJLX63XQD3G"^Z
M?N3I1?UA*N<8LRCBQX6W7WQ5,NLQWRG12<-K7G]FDE6+[?25'M@D"F.E%!I%
M0=%1L/OTK2? ^JZ-=OQ4SYD"076;Y$Q$&J=J!9G\I!F3[8RPY+.F%590YUZM
M6V17!12K4)2L$B[.N._Y;)3O@!<Y.H+UZ1)$_CQDN.BJ%(1O/2XV>Y>_&/C2
MI/6L*6"S!L@H/ 9#B*]ECE<"\33HCK. 96E'R5[&WDE.L*N[5@3B@6*,:LH6
M(_4K^ +<D,6G[3H5)X#O^<)9,1HU)%L*<R%68NV8QF4"[:/7+QJNS3_,>?G7
MZ=2%C5]U?4A2CS84OO^93)&-$SI:J[%"A\LO!$[)ZYBO.^G")G.TP2OY(M"O
M5WA5R=PYJ Z*G![[N@(%]88&^R(5M*CBO<.K]X;_IS<P5_J*</I!0G&'1&-0
M^%QEFB40R[&#3(]H,9NCE,]?DSK2"$]%YVI.&G(QX6JPI[KGQI;"]'RF.KM:
M@UV-.O+>=#H@AL9Y1(Q$5%AR\'A_ZZ7-%*AKNR5)LG$??%6G(_VIC=J<[+XK
M96\VV#NNV&F0=_-'K>J /&$>K$[5XX#^X#.MH5.,J69-IEK.'MZ&"?BK.)W\
M:'O<:+T?;U>?)SG=7G"8*Q\$.?4,&#*?F8Q8%C!($HS P_<\FNHMD&W0;:$9
M/(X4_ICT"EJ&M<6=GT8%ZPJP&4&.C26]%BD]<*;L1R3#]T.;"8I?3,T>A[:T
M$.G:9 6E^FA1#;2+U\ >/^PG -P@"[9FWZ(PUW3Y:CW:TMRNK$;P+H"EUN56
MIL&@0$V)4SPP7RP-$IUF ,Z14[6.-^=#QP,P'-%(/0%\ VF^O M0U)!<_X;E
M16<Z.__BVK=_'6O6FK5)"&\\ 44ND=<W\)F6!9EE>5XJ#3%WPL+HG/'JGG&%
M2'B?""413%4+'BDNS[KQK-W*HL4Z4[KJP@?=7]"S>+A#?YQ@NHZB/O#$+3F9
M^P:X[TG.;A6PQHX[UH>I#>7JCP1CO&&WO)LW8'$4KI:;8_^SLXW&5HQ+DQ^'
M 54"\OO $Y"%0;)1B:F:&#&Y5?F1AZY93MV>4]ZXB50C=(UTL0L_5?GA=4G;
MCZ)',P0[8B\D):VKQ]4DC[NAK>>[^YF2 O+28'?52#8[9%UW]SSWU8$L4F7Y
MJI411ZERUJBYAIAJUCG2NM;[%8@F;CC,T .1?UX*[DD+]3=.34=K[N:>V(1<
M"09^@E=#<1QU?J?C"1;$>_X,+)&O?:4Y1!J:'R$>JA.=#\LF]5+7RMXT!_!)
MR>)JUJY%%HO7(<\WA*N6*<M">&L$363TZWF_G->E^BRFIV56\_1O17+$9E<3
M**9KH@!HIWIY]VJ.S"BV_N")Q1Y$;FUSK9+U8E%\2S7UGAM59&/[CM@'<>>5
M8KD?(6*+8TF@,@1S'=OK&7"+[S7.IJ+F)F/[]M#="BZV4JMB ]5WT<.VFI?E
MCI797"L+"0Y8S]HU<'M>"TI)D6:,FYX^G^7BK/7%E9UMRG\$5<)'^/!QR9)B
MEDJTM<$L])[&F2B39[2*K.FNW*6,OK(=V=>'BVJ#PI/-MBKV9S41\9C*?]=X
M,TO3,Q;S+6V2/G.Z(5'; YJ3:X^DM4;M] UB]O6LZ8STKP1*%?89;H)%P1'.
MD\.O6W+96-")*89V\D=X^ZS>^-<S1$?# Y"$-LAZ5'@Z.@B).]9*&9@13=N;
MY;,E(9=H]_+#8@&\$FZI^\4Q+ 1'Y_PSJ =ZKB[X:;#]0X6I@R>7,VD>4"P%
MHOV.E!O8= 0LAVJ+.@*H,U/'"_A#U65)!'T*XC4JQV7FG5-G#V@$%D%O2HK>
M]]@7I>B4*VNE>*F M 'I?4!T$:=5T=#'XQNQPC]7B87!W9_Q?[SZ5%))=WP2
MWO6BE%9LAF+ HTO\!$+*V=ZC$(=EO,7!I/Y.265>/,<_/)_DI<#N*U9ZE$ZY
M79)9/K'EU2#AS_.D[GG^3N^13':5Y/9M+#IAM:DZ^>&6G8O<3=@E"("C@>,Y
M1U[:K?7-"S;8WAQX4NV117PR%UGM&F,OGI2P^ZVTNNX[[#G-;1R_J=>F$9?N
M-'KUJ!(J+DU:%CO!FY7E]DO(V.5]\)W[8_.'%C?\[2Z)NX$G0/.;7]=GBIU!
MD/[)&]:.5Y((V%U>WO[MUD5^O7-^3CY*UV2W;H\59H#/."5.#Y<0RTA+EG7+
M$M?-,9CYQ^3\@28X2A[3!TL>#*HL]1#!@8.T8H(P%O'Y/728K"SJVI2R?[]I
M[V%J3+6B 5_FR4TVM:155Z5)$X5D#[#P1A/2BJ[B;UU8KXG1ZD[XI;Y:\<]/
MBH37-Z?F>7!R+>AQ?Z=?;8Q-4!UKI?>T!^5:#";A@R0W R5^LV3-U/@^2-5\
MJYP_V;.6'/Z3]8A@?0+0Z-WU]C2?/ %ZDC8X&9W6*Z[_2HG>$]+$ -KCF:6'
MT?OUP?5XN>H(CTW5P?9)R;Q?Q\#SVU%5UX6FYH_YY6!KAKS6,5Y^M90=G! B
MJ4)&!!K K<01_ 8!.HKB17*#>75%@$6T6WK4.TN[KA9$%!64HJF6L%"Y8@TT
M6$=:6MUO4Z//G)3=KK0!X0=AT/CP79OFWZ6N- 9*9<0$^JF:O.W"J>@0=/Q8
M@QPI@AT/W >%CG%EL>?E,)9.#&!,.FER3G[0!I@[5<:#75KQ30$A^(P GV4Q
M:)!P1B<E:<B@@<,*D^@9(*QAY8N;]H)" Q3E*"PQ.9;]KZ_J%VKC?R@/]ISJ
M]^&E0Z*1!9T951\&?/H< I+\8-<MIGGWH>W.'F&2$!%4:/VR'5ARP^TA3V5B
M[S^UNN>X0=,L8GLX62II??I%"!@9Z#KEI8HO3SE.-2DNMA,>I@[:-2ZNZL3%
M=71,^?3-3\<E]PE FK/:(!'9=HOCW*AQ,,6W]?+;Z*@I3#XJ]Y%HGY/;4PS\
M.<:"FJ6_1#^-J;E$#+K9;L%G,D)AVM^*C"I]^U,7ELDVYD_D8N]/E&)#0>L:
ME^)RU662"Z0%%A\1N"*D!]U)4H+FD9'*>4+=F82.!4\ K!WV/R07V6<:L]H,
M1#\46&9PO>%YX7UK](LN+'U0D-,S80=X!,.M/)YFO!%"]#70]6NWVX !)G77
M<R0^,]5BN9L^PH]Q&B9HZLAS:>!&&Q>ZV>Q#_ *>G23N-;_XTV6F8C%S],;G
M0:Q=G!^8EM: \R+)?7XR04WQ(S-D9MS)OT,@H[':@U9S*4L87\5&#6SUO,RR
MD\R[O5V0:>_8=T67I]2B<42DIH52[-U7Y3C9XII+RA9VJM$64J.4^^:V!-4N
M0$=MGN'"=$-!TU0MH\J&+*-!LT18IT!+;D*\(I'F1P$2QP6*WTH_MDIL#_C\
M<-)+015FH9-E:& +SH0:5A=BGN4"K>*RE[3/=1_@388>,_LKFCQ$[HW)']M$
MUM1\N _&#%BFJ*K=$]ZN?\7)(0%*+#[W]LO0\MEOG\!H=M;V?%;+*?J..EX[
M*GFT]*U5;=.(/S6\SIUK7C1\FL<6>?H$V'#R-]B(9BMED;5*6-Z>#.9=&&O)
MB&BW#7#Q)50PV,Q@#^F'J'(O*)<7 \PY4C:M2(;90U0]LT<ADZR0:9 5<(3P
M/PE:"/GB&8?D BQ%VX_7?&&Z47<6I28T5EWJ A43=?KYDUG9NII$B[[:5U$_
MXWMHA>O!.=*%-VQ'.TP[&3JQG^QU<5/FNJQUY^BVKD<2! +E[X"V\5\V+DSU
M.A$K[+J)]7K=!;"WRJCI>&@02JXPN(=H;/X 2/BA1M_YF8ECY=" M:IDLC&?
M"M_4";$QWH/H_>#-3@94R%.3F)"(-U6>%?T-*\GF#RQ>KPB?K [1^9)R/,X5
M>(G1&#>!N[7&1\N PYJWINHA?MGY=7J<J\YKS6VDB&*7#Z7K8^3Y4F%T&Z0S
M79A4MT=9K;HSN.!]-K*>#^^&G'<TT=B167C!.B/7["Q:J!I$K:?Q/*J./H'U
MJ+VPSIVSO3>#L#SF1A52Y1[2Y))F(5'[7=EG&1Z+)J[VW3K&EN86JHR.67\^
M?C*6*Q/V,D1K<Z?%N7+G&:_14M!"<]&_'%$92\CK$@&50Z<<1CNCX.E6XSLT
M"WH4T@J?[-O9Y(A;>*0 1[&-088%-DC!^'[VY!S-2 U>D4R+A/=ZEJRLFINH
M.<7S']4::',ZSN_*!<=PI IEJ3=B'V)[M[;OHM#NG@!;,^M+WH:-#U_X7\XX
MRRXO/P'6GP ,[XJ+&OP^'#PB7[GNT8[0-[@F*G(K?AR +5'F.C1"/Y.5?M?S
MC?+>TY86*)U2F=<;RZ":<#6ORB!4'? @%&8#@%UE5N_KG9/?3Y"*P%T*<[3.
M4)R3U$%DYG/.4R0;M&E0S9)^/P^T_%\<VL0M&"A'3P!WI-M7S/7'M9]4RS-7
M.0\SPA@/<^AW[8WWVY5ME&2D- /'>/$T%[(2N@E-DJ&#+;$ U\H<^PR7A5B#
MT3H]-I0"^:%:=?'0A:)%]?3W54>2;F-+Y1<"2"S,M*78[F=9X3I#4(@-W*OX
M@WZ>G+@W.RB'7$M(L)VI3&UPQ#%"T,J%VFR@(S2=6O?($+%0F?P!^ W-AAA*
M[L,5R;(J<^>2B4'($'^EJ[P]"+<FYA!//=7"OU.O7O].RA&A2[MN&M,T7"D/
M1]>O5IQL?OME5R>TKX]IT_P(OUZOH&3;4'U.V(J&ZMRT\()ZI.C-("7(HIBS
M4Z$H^:Q'QG[^X,>R'E\JS@]=YP\ML"J@*-:/4F[U/]Q_=/&"TQI=9B>P*CT3
MB[AUXG9![D?(LNEBK_=#^IP^V(-8;%$<=<B2(70\4]$UVOU:N+"00N/<^ES3
M+Q<$G%E(=\132X"SMMVC_3[>,R B'BO:L(TM1MB&+5;D#.5>/.MW,.RVD_GA
M,K[QZ@<3N#00GZ7M-;)Z?]AG[&U^6.J%^TZ$GX$>,:F1EOI*.!B0'*'&2/+0
MR!OMI#<YVL;NO,O@,M;Q^V;ZG7A98(/A]W%CB53\KU:CS=$ET"P7YN^B?U"F
M<VQPIG FQK;HS9\ )+[4OT/;@]O^*+1IAH.MG6+C/7*NW=KNWR2#J)0^1WMS
M*HUU)N:\:1UIRXPWJ4TWBO["CT_$&/6+I0N3EX:?9!?EA1U7Z.,996_YGRO8
M&-T)8=X?MRKT,^9PC[6 9HIR<8'( ,:F,>_,>O\F)BW5); .WOUDCSTVI;1R
MRZ1GJ(;L@SDV<'ETK>YXV]-UI8Y?%D,#R4W+_-O:$Y*A4EWK>/NJ].=D7H^G
M8XIS;+J]K%@PQ4T9G^%G ^LE>8I*SORCL(FFR7;SI,3I[,D:3OJ-TNZY$F"4
M8Y%")30R<J \)/W\^>J%A7F<G&$]I@G+LY;P5EWFDOT#77N_"8RW/LQ?7Q:7
M%^X9,# 3<U-<=B:&C]VRX&L;D"I9@&+S\5#I&9:_"5_9/LP(W=4MO3M!OHNW
M/.G[UOL+4^+.8WAU36_ND?I.OMX'^#EPMYN%*Z_V:'O4B66E1J$N#3P-['1O
MC($__R(7YIF_A<$N)2<'$.2'\W%72R>.G)H4W>NR-HQ6_XP(,FL>BHOIY#IQ
ML;5*/G=4S3^H,) ?Q^9S5R%!(E[0CL%VTT8/6H>I_0O'!2PR?%\XQ[YC,(L.
MVHSIPG4A(^V*?Y,,!J=,9,R6S'G-EF!6J.E-KX9'17H2&"1T-R(?I>SAC"]3
MA$4.8<HVZRB "53]L1V+Z&U&E<U1$B(NW'IX<GI<ISL36HS>XK(08C&44\!J
M@-"D=G,8A!(.(V2BB'#X43Q)69AKPTZT _M/GBD P-'X=SR72<G./G:EO7-L
M.\:,7K3E81EDM80[QI3CA'1\("X4Q3U-:;D30VM+[@.]>%I&P@MAL)W'B#"4
M"6B!O-6POA4E4TXT=R?G(E5>$MTJ"8QQK;9-#?.ICA/:QRWQ+F@155]H<+D3
M0M))+(]XM0K%="I,=&L.N6)_>E._^(I?<'&LV*F&!E>16?E369XG2UKEX+,-
MF?KEPMPR37Z2'8@*#!B%1K##BP*WS"ZFM\S&BL'VB1!,?4PZ-A-FZJ9FF_;G
M1S5E ;^R6U58.Q^1RG(HN" 1,S#Z+#^8/A%9K]RB:M-?ZVSD.S>'3\KH\[,\
M#(.7$)P>"?@_%KFNZ"?YF>RJK81%N;1YKA.+E QI>7]@M -C.H5U#)_[6JIX
MB!ACJ7C1;O)#/=G4H L=@Y+K*/;7[0W]EP+MK:6;GM.2M8T,2^_,56AI!G^(
M?S"+L$UN .WQIIP_3]FJ5"AH>MVADM9ITF[\'EK?*AS+S$?@K:M5D_SK68>T
M\OV[=Y'LB(VW%9:N,80ZB< #&T1:6S7]6;?WUV&QIL&M$@JGWX9UW +7];.^
M@HE@)DK$P)%4/I2(";>G82)]?7I36XYNM'KE.S&'NC;^:-?)G?,38.!5;; 7
MWL3%&L$COLI#<,?]5LI2]]H/5,;;JX#[%]&?([[>7KH^ 2I) RZI"NXGHV]Z
MM?X*=KDGP';U$\#W.O/=$^ ZY6[8VB6@Y?$)<"?\L-4X8[6^\N<)T/$$R.L(
M:#PF6!?#%.^-7U/J=GE<8-+I\!4><MJ>C).R;-K\,'!\LLJ<(1?#>N0K&H:R
MQGO@ZOS^LV:DFV3_CDGWBHZ:^ANO0-]:D8]:% 4, ,Z(C5U'FW=\;-D]B7I_
M93X]P>JJZ_*RV!X3OZMOHPTD_8M9V,0"KXG ET&J6]0/P^=D@8.T/_D@051G
MTF/".]-HC2J@0_@?VH:<D@N;D#B":$O]?#1RUIQ0=J9Y4"S7B+I*\DIL*D0N
M+F=62]A^N^[TX>2:^VK&>W$DN&7FV+^#9P3M+L1R9H/3VR3)M_T+NN+%X;6=
MHZ3GU3<7RM>-'Y/F\2*OMM.#L?#V[,F2Z 3[C+)"#7>P0<4)EE6=,B76%>AW
MN]@YB##[C;30)/I\)6DMU6>CZ<QL!Q9S-UM:@N<B^Z[+$Z@FC#D\R!G.3FI,
M'8;&N@$>EUS9&87Q5^_,N(JM]4LU?<#<Z^3I:1'3[]RRN"S],?E)% VHJF3C
M<N/<UW=T#J,HARF> '@K%<5F FR"*;%Y+5]HNQUW&41=C6KE5;QQW2%MV7Z9
M2:01@],O;T>.0+.DI%S<07&R[]WPC[['Y(S%0<3#(3AD5OE*IL:A4EA_W^Y7
MOU/>>OD,4G5EG[D6?"Q6(Y3W(2TW:$OY#[+L##Y!7>"UL[?EF3\XVF9!N]&<
MZ3;M;X2U<TW)^+QE&,HP##>=SPB7#V@A[1HB,J-V%&SKIV-Y.X@/'%^0%$'V
MJ*"L'4II'>*7C*RGM$O'47X!+6 >*%<>-^+X-.KO91>Z\V<>;M-3LRU,- %(
M^96*0R=IOFI]T"+K7*RG'K636+9UKM$0_4%#U%TWHLL71&XP9T5]*^O18HD#
M]@Q=W2VW? +\.'A[F5NBF%2K@W@GR2]@/\4,I-'/YTMEOP7]L*$&Y<9QY9)0
M'5:'CG\?TX@4B4DOUISE;4$O=8"]VN#758D;\VZJ1S8[C%KGC%+B9KG"QJ*.
M/Z#."&3X A?&!U-KLA6528)!]%3E5G^8PBFK"GJ.RK,28,YII&L=7._.'0^"
MQ_8J*[UPW<$+?UI'^&PZJEF4YRZ3P0Z5L4-W:GVMF4DTX[L2_5MO<\LMX7&<
ME-A_]@F<!",M2W,KU%\U&BHCX\K\6= -6S6E\3'H3JCVU]&>!UY-K%[G*_2/
MY&JS'[WV$3Q"SFNKM9/F#6GSKIN*/F)XL</AQ?N$J?,-GDP6I#3-SBQLIV^,
M[!N55?U8:>V4(]L&TR'#>'&*I,C)7Z*@RBWI(/$)I3^/AC9&&>Y-(>SEZV'Y
M10QRZJ;#4=N.&79H>E7]$P;.::D<%WRG7WA5@2JJ*I_UI?S+/6:/= RTW6^8
MZ!/;"3M)<R:4U([)A59J!3EN,AQP?*#C#@UHVQROK<>P3+XNK'K:CT7ML.'$
MZPZQ86T]#RAL>T=K:_V^_X[X+>(T7)!0DU5X34'AG?G8(I,J$@/%S@[!.2.F
MF&HCID#+*A+-M?'[S:':$X"<)@[J\CS-7%A)[] S.:;3B-X:S/&=+4=8E=A$
MBY!66D<GH6\$< 1(<M*O8?ILN<%])3/RVVEP;!'.UJR_KXL8,KZ(XLXP"D.T
MVS>?J49)#O"IH$I\'OGERXB!16>7M[:W=I'H%E7W6@0VS3'(">=+*+ZEPV(Y
MRG[6UG@^O8F];D.$[QY;"3*+0*E%BRAK<PC;++X@<Q[V:U)Q%;T-]F1X3I?L
MIB'(FEIKU"E'77\NT=.9J00/1 .&8!YA7_'2?7L"D 4==U<O)!V'Y@0%6-)8
M(-<2^9A?\JI83RZ_YWJ'XYN7'YX4GR1!MN9"J9M(K^3[3!R+=(!Q3+)OA\WB
MWIQJL).5Z?OJ*YIWT?87+7[+J^*'OP\,,IN;A]Y#+W;M8N23W<.&]A ZC]A9
M;1*?[. ;@OT4)V"&]ZQL_+!I-R$Q+MR/'%_T#;/Y9422T2' "OK76E$:T*-T
MK9>L9XGMPM;C^H;144M]5^)F.$2K"9+F[U7\.7_;K-P-[[QY)4/3E+)?7:[3
MSS,;J@WK)7!R733[-?-@+>G6AI>$@31K<_OK2X8E5WY[2SP!O'W?'%:P^_D.
M/ &H(<!$EP^>UY*T6OF?T:<I9OZ4!NN]7%Z4;##M$;Y[^]!P;WUZ&7]*^^S4
M[=",_(:N$P*\EES'[YP6?^_<N^_#'X7_!#AQOG=\B-_#RX*_$@@V-D.YMWXH
M6&>IIJ4]9;W4SSZ5C!)_L4XSL>[:_2%_[W;77[S9_/G"L25TU_5;)_"E[(1(
MKTNZKTL#Q'3^U[Y:P^J&=-_%CT7&D5Y=K<"$]_J[KU]0#H6@]'\=:];\*;34
M^M"^A:M4"6OBT7HE-7D]QY(61HF%J]:_ZB&A6>%-+XV1%\]9]":K+RXF'=\V
M$FF[?+64[5#P)?O3:ZK'+^Y3.P2B4<>A,D&&<QF.B L<;%SV>"I;WG2I7TEL
M>(I7:IU(6GEKQ_P UAQA-#,MA[\V\^]@X6+CA9W9B_F,S+[1/-^5QQG+6.<%
M1X->YW07\5LZ>?0J4?O>N94Z64FNVEV+(\EM!R.KG<O:K3K??B\ ?[02MY*@
M?*$T>N'2+X-']F9"W5!=H6^&Z4=86O98Y>VX$"[!T-OUJEN =T("K_H7OCHO
M(&YMSO@\K.P/0B>82\.)T=PWX^"T07LG/XQ%AK+HUGI[-!6DIB",W)N[NLYP
ME'>'@UU/?R?<X9O@CNTQ "5!BWED)K7C2D+L\45&&>DP'@BSDHYB3"T^=*WN
M89X%&I: (U;^K<F2BQ,2]'&R8#*ORHN!(#4UH7W!J,LGUS8STN>AF!4J@(SS
M3D</?L;?FL$?SA<QE!<<7X<ZEL,TCEW/'Y-C7(?/S";B*@3Q1R$.R4;1A(B<
ML86XSM".0BPANIW=FIU&JP2$.""K@WJ:D=/LW8EPU+"N>&CC%Q=F.?00&39Y
M/^S8>)05Y.)>6PUK.UN\8#ZWA@$JF.<AA:LU[K51X#!/"R5D*-Y:7?2])4;N
MN-)K):8B8XI1Y15_BPDT;*3/2E>LJAL[S+/SV;%2)37YBDV=QG.^A_)H^'9N
MBR\CGTEMAXK5=N1;!R@AIR>+#E2ISX-O$F-A0LR5F$G7XQ73Z-EGDM;U.C>\
M12$)M.H\VP1J^G56L#:QUDRF6@WV'ALDF/Y(9ZU-'IH.LLVMOOM\U6N07*_8
M95 :9($\R+E6T9]E18]_?/GBBQW'\>9J]BXX ?K.QL1&FP_#1XD"/S%*U>9J
MWL=DWI>./"'\1C9,@1A'/VRG+;4?676VB;:.? +8BU1*?.8C+7@"'!EV97C\
M&G)AR&QKN[)(&T/-5H&K?_M^F&+^@7*QF'6?IO;K_(*U-D,DICJ>92G)_5W;
M?8[!A'[F[R':I;H%7T4H&IL4FT1T=J)/F@%\(9?2$Y>(4(M[=5P1PIX""U-)
M'\+[WWWJ#1[S-<-;?_94Y[,#):M[G$2CQL;=@QKK>8-.&^UP#P8:&MVJ:R-O
M(LJ<+%4*MF*.8N0Q,*US1/-YDPN_FTA;J4U^>[QG#A,,W[(SCA>#R(7)YI>/
MJK110JK>)A?W-$(>'5V>0703^#-5FWESJLBZZWLF*(EQVQ&B$&ZY!V="8Z"T
M<,A@W:+,D$'IR!F2'4090L<*P5'HCFZP5W$A]LB4IQSMM[JODB3E3&H@GL%?
M[R*@V'[9[H)%^5+DZ-=FG/ZMWP_6DP4^;=NX#'05FH29HZ#.%BY6M]"^G&9Z
MRXXXN?6MWR.F0:\*7IW3M-2F"6''"<W0LBSC%Q'12JN*H[768IV\W,!+5V>%
M3_HYT7S3&/5FSOCX9L7M^M>6=GQC)E=,BONTRIQ 8Z0FJZA7JN,4ADF/0;<.
MF0F$Y*JN;>KSEJI]7 D9/>S"J=YP7.OYK&B$,C*_(&@WL6J6.5E)6IZ2D>ST
M**DO\FV5"NNK96&[[&('=W].,)3KZU7'I#\E_W-UYW,LD+'#5,(S2O./AF6K
M+%NB'? :4KV#,W=O]/PP'&WF4?Y]8#AT.+L^E*AT_?.E9Z;+<Q3LOFJ6=5K_
MN31 QSOZ2Z_<9OM8J,_MUKBP:VY-=:YM=L5=S]4L>0 \SN][C>I*9S09=L<S
M F'1&%]K?,HRE:4ZN7 _R[ IXW'];;H"-,!+X(HTW^OO3,Q7"\"9]XX-(92;
MC\:*#*@@J-'%5[*E.>3$'),5A\3:-*#2U7D\A.09.<[G=V6:1]Z1Z8ZKBO1'
M<"W' H<8QQRYN/&J!)@)? W++=FSKUQ46;]FC&3 B@#0DQ[V4NSH#:?4+L>S
MW3!1U4G(S1VSZ(#"CTY?[4\+3%^=)#6;P<HPX)1I879M[%@7)K2IBNL=I3R>
M%D$DW[1G-JX,02$+7[P5-HJ*!CZ(<16P\.&9<QYU\_JB;$W/.QQSQ+F/38U1
M4,1[ZT+Z[ZT.OV6%%\4[\L@=*E,//FJQL&NRT>3'M8RF8P5COU^LQ(NWP1!1
M:2/+#.J+A(0HH6Z=)?,0C8+E\0$27P'B<G*2Y-B_F_?0UE[!JIE*@G$P'(5.
MHAL2O[(**$I,V3C8=<U3539B6V%1K89 U4;O^U#1NY;!CI8I.>PI+LS@5]_
M$*ME:]$YC/B5XC9]9L;U[MA/&@,&?4)<M6_S6_"]5!Z:28T+8R_#S\TN/1X;
M>]N<0RV+;\BO>N_H;]HW<7]Y/I*<9AUVL_E9==U..V7O45T$0HR_]TXMZO7W
MSM_]Z0J:Y/V38[:M>!GZ4'_CF=<%K:8%G+(>OJ;P$TX:,?UQ7'_P]UCRF+J0
M?)%IPIGOJQD@^);]KH*/Q% <36<?K*[9+.R,GV14".TN*RI=IT\9LU-'<BWR
MB,#+?1.3.2*(E?A739<^NH)*,BQ47FGS-[A.K."L><6;RF[?&W[<-@RDFH&
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MO#@_  .#KY-ABCWO.+;1DBT?3/<1;L4-V5;6N:Q?59F0XQP+#U7S@WG*P/X
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ML5%E1-P%(Z/@;3$7FJRI]  "[B"\]9[<JYUU3O?Z9B-LO1(WDR%#,^\D0FM
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M!U26$0.G*H;B22-%P<D PQ!E#7R(,LH0JH@4Q0P08T4^<;/DH%YE@\C4WWY
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M5U9NJ2>LT#_KTKS_?):8C_,5\OC5?5[[8N?L&^OV2ZC^!MYVSCEI5MWD3^
M^79? "CP*#?Q12:BDMLA[]\E?:1%)S^[#E8=Y&Z8Q-'!?-BFF^1WNNM5X:M)
M =40DU#[3+(HY1]I,KW=I^LCR/#$P$:_MI&VV#\JDOQL]E &STCD#AT/,!L^
M8%[<M5A\KJ6T\_*ARYB97M2%3X2#;?T!;=.B-$/NHXRAW:SRT+&L^1;3$C%Q
MU-1DTE#"EQ.;D,2^N8<!5@ %Q _>[P#M#S]TR@CF9)C!#=1TI9M/A6<A1W2)
MM7G/HC>*(?OGM"$$PMSPH(X_*HBLH2Q9D\B.)[A\T;0'WH1 7&7.&)O0VK^
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M_1T38.5K]8TUEG%IG ;>KH?NQ;%ZPW%,2LJ4JSV[-X$@K.$9VHBU[\W5*1U
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MC2OWY8I6P[6 LQJQ:,OQ[+4-J][/M=ZGU30"^0KN"B/FC0/CQ="52>492'L
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MW7_$*12/@HEB1RERJ5@&$;5US<EV8S9 <1685>#QA(F8/KBFA6_YE4,>JDC
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M_?V%*9GF.HNG,)\M@W"7UXL7'0,M]LPA84\V7>\<'Q*A*5XNK<"DXA >E4B
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MCLKXC@UO_>5CO9B+L[WEP@>ZU)W?QO7BT,AUH!/<NJ5!C52S_DVT87;^<)(
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M#%;,;TD_!I#CD+$-3$QP=#/?QQ/N7DX"XZ$Q')5(39Z7J4!74(Z@HNJ23BC
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M+AM3C="CQ7&@H&7KGQ/?GP,OBTXF=8.[0[[3RY^,F#G^HMWO6(KPD7B#,"'
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M*.D'9'X&V=R^5MY@W4?NVUUUE;G?G<DGER^<WM94\5BT'748-LX'>7="2U?
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M.UIO]-4F[1L+#^_(_@P3C&#7P0G13%^3G:5OJ^GE?)I X%K-TS $1()94X2
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M]*3<S6)4-B)03FKE8C@:(HY#:(ZQ*':HZ]7@;N@%7CY4'/I(=+#N*:L9Z22
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M6^09<'K'_,\'T.2)/_#[P^3 Q-E&E-??)BC?]>]FHQ5+4?658[82<BA,0Z&
MB_C/" :%2MR]HZ9^%PDI9B?@U8?_A1L2^_K MC3FG\IEZ5/<CQ82%RUY7567
M<>![%,%,/3HSAS_K9O,*;^R:QN3RE+)%A@;C0#NTWYV/^=#R!N(_L>;=>M0=
M:90EE=MG6I#"E;H"_H%30T=#QFL3YJV&=%9*(8%H^22]&HH(/<#+P4V"+[==
MB9VY06/=K_7:M/3FLUQ,H6.>:?WDA2A<::8-3&J?2%5DG"P[IWH3F6UI\T8E
M66YF?.@ED"&(+0P:[,^?4(K86GA?V<:X&I^V6[1K0E+56K4UD:'OIM8X-O/B
MLGNBA#+<RQ3T!855&$ON;T3_S7<HL-E8R<^!Q*TS4BDJBI.#*.V"'1U48A(9
M-<FEFRYQ1*B]XSM<_ PH 'YA5$:C/P<>M,&<^M+B,P>G<3+M2\$0E6)_AB"L
M\Q[F*I([42& 5#@(TS[,2-4^5VSU5=9E@N9.U6S"A&(143^W@WFF(9&FLCI,
M')M0P\HLED,F**5Y"\H!;N"0SO0YX'95%F5,&,CL4A" Y*8.;D86#A^BT*,-
M8K;\6S%]V[^-6%V]+\8..UZE^\\:(*=MDI\H?$^/:/]S-9EIA*9UK.7N])&"
MX*#F5B2%+&I@'W;G,;EFCH]Z,(+@L$XS@+%O85T;1MV4YGG1]*@4%U4X!4CV
MOB'0KL]UXBV[OMUC*6\9NQ&/!S5!1SL_+)1Z9)R5=PFA'XK[4!FZ^V)_1 &4
M(-\=\YP[B?&@T<QQ7NXFVN0=2[@9H>^Q9L#;;./NNKLI?\&F"(72UPH%:6NJ
M]3BEDKGL-P+>SN2\F-F6J<K2IK<\SR1?T%HM(!;D<O3)'V6J]UB48%0T4^V
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M\Q"BA_%14!,PFR_]_A$79RNJ/M$,4JU2%RVG $&J,<)I99N8(@ 43TZKWRD
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M^M)C+LFL?FU8UU20&2[TTE0RR[7'^>*0/A<;'_W$S] 4DZ",U) D01E8\<U
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M7X??3L)HHD:O1536;SWK<!L]@:JXLTUTZZ1.@YNT<T8>[2W1">:P$!>A? 0
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MHNN.Q*08+#*EV* $TT0UXQ46<6 8J7YH8C%#U"?.N<A7*FY\*2X#;J*)8H!
MN5D(64^9*PE644)T_<D^YSA?@MK^[)<<IAAG5$"55-$'!WLGMU8>1S)VUF<
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M@WA*.ZN*H1OXRK/LPMUJC=&1AHO &D5:O\CR_V#OK;[:8+^MT02' D6"6X
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M2)9$V\Z %3<-QFVM\I;4!4571([?8U["K:E[;LJ+US')7:@T]C$[\I3S*E=
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M/EF_S9S;@R\/:)_]3Q%]<8+;O,:M)L]"AZGBRX[ W[[KG2IHJ$T56!ZDX0[
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MA\]L1L0^$D\/GA=.[A!\[^EC5BI@^WRY92<0BCBTA86]:^:A2,!"A5,GG<*
MU'G83.XFC\O<6OMG.2/Y _A\U@MRU_6EUS(&5MO; K:,-KH)=>]#M(9F2G,=
M?A\<U.(2(-A;\<!F^72N3UC7FN3ZV.5SP?[70NSZRYS6JS+BYG56-T\_P03>
MUX*C1S1H*:4$388UNFP8[5YKX^$RHTIUEE]X/Q'5@R@/3.DE*$T_)04(W&/Y
M$PP&9R0AX2VT-*\X:=4;W.S(P4=VD^M^_5O%3'OF-M2CBEFMUD+\ME+ 5MTF
M1\$1X8?Z;BF98B)6@SKE2J<B>V$.K4]&%MFNV7BS[U$;A\A[Y<!K%\8Z%*52
MP?82H'(=)JLL&E(M5"XSC<DXZ2F)'!(V<D4-EO2-1QG2:ER1.U99XJ6])DNW
MN1[V)7E<:8&"N5[+<.DSMC;#.H5:".?,FCJ,93-''?L]DYXN+6F^KQ\-6;--
MY?.!.WUF94Z,FH61+@N4N_1N$#10,".C@A2E+.B:V[^AK'8A<UPDZR<%YZI/
M_<'G8#_&?2!?CU]."M"V.H@$D9XZ[Z\,?L9JDJ_0)&ZD?X6T_\R=KS$\+,CZ
MU3*)YM"#Y?J-)?J1EX<96O^ELQ;?BBP'4) G9 )(JL)<_Z.%66O P8-^-37
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M*Q@9ZHS"=MU1UFOY3Q&8<>$*NHL(@1EJ-_U$8+ED[6RZ+R5 6Z.([=< Y_L
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MD<*2Z]RT]<G-2LY7L'@65P0O<GN'KH29CF&:](Q],0.TIP;Y#?B:6LQ8F'=
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M7#NI9#76_; P6)3BKZ)-A(4O!9123[*:MW(B3XT]5^G/ML:2LE*P I24E
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M7?30%PQ^Y^$=[F6TH!,UL 4?,'$,K4_,%XP'\HZP]DICGI<2UF7[G?F8-KO
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M<"+<L+.F=#(JH$K*-K4>LT*(;S;?U:[TC56'T$+LV;.+2MEN-3E)T]5!KI/
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MG:-RR9^V-\DUV\QMS;IR8_8$<'U_J[*8?!::$QQHQ=P__KKAACE?5^HF\"T
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MFPZ#3W&N.=Z*2YPF."M^"MX7(<.B!%8V1[+Z9_=AL+/'"07+C,]>$"%M^9X
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MR?2_JJ/U%PRYB;%,HSNFG6$CKD1F]B]C%!2'9F7=P_^JXP?TZ[942U^SB">
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M)E><] \@DO:].$4<3^'Q#R."V$2LM[]0EY_/:S,O9:H!'YV9.WZT6B_.;<E
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M'C*_5+=@V$GXZ-.^OE.Q]MP*GJE73KHP$Y6P:;;@0W;CN71QP;Y&^0JW,.^
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M4QTQ=8$46=RJ+G)H5]QS(MI0B<!(U3A)KH^5 EV,;S8L3[XS7SF]>13!)<)
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M4/]M))PE8M(,TV8?7U?\F:=@1H2+FRF=#@:)[75RL2'/RYFYYG./64Y1*.9
M5ZJC\_B+S*&?=;]WS^8L5$N'BOIYT9-+<EAI3!;5&$\PO9>=E(L+VL)<8K6E
M7>-I\X=K>VVB,SH\"2$@$OEB,3S^%AN$SQ2=TW8)C(>#?058DE([H=]*N"<8
MR*QQ?W2"6@*18J-&.M3@.&5,)TQG\"A)U9B&_FFRI @],C%=I#C%@)V^6K7Q
M&SNB<8\[KV&T8H]5UZ@=,K68T^'=ENX[Y^9-[:&G/(M*;E %^Y ;(X/%89GY
M<:&3<D_15-1!3=(P,95KH7MHMN3..X#%3?#YGYW[IXF[OG< J07=INA74J^F
M%/$OEN9LSOY^O>K^=2WS:"90*0L7\&G/GL(_/.$;_6PFTJ.C3E$F5'/R"N(I
MQ-9F<=+'0W&A"OHJT>-HY]]S5 YGU74 ;CI6%$MOFG@X3A$1_11)MR#MV7!>
M0A ETSTX;<_(J:EF>DIFCMX<.B,)C@O59_ FV#*/)II+O_[#$:X:&EP\\558
M\,:KW"J<?XTZKH%40PYCFS.>^7C/7!^PM37)=/.>%Q_ $D.1&@L6G_!T9*JL
ML#)WV]V'-%RXEO&+&KR%? ON.;@G!'<@Y=6?Q<-+1X63.5!)$(8\V@F?&J<R
MHM@HF](W\)BRO/PB]E8V/27]FBQ-+0'*Q\ZJK/[PDU].G\I6O7).X#0C[?I[
MI9T#;,%>>6YS=/HW I_5O:(7W:[6K]29 P\#WV9QR0G@+@6O\0EVWJ::,84S
M6U5I3X6'C2^F'+1,;+8ZKW>?;75CO>:] L$Y#)[?)TN=*><"=/WE@,:[/3=3
M\-W<Z-*%D@JK0+3L&4P037+YI#!4S<S"<T#B$)\Q)W\V_[^69 +B&WA_<0I:
MA/;\XO(/:[OZS O1+5+W!)))G57"%46>=D@30_AO8GRD&')C6(/JP$2 S53\
M\X56T TH3CB0^CN#(H]AO_IFP)*V[B,,<*%:J67WUWR[KH:=>RP=^R2DZ*60
MJ3K..UJ(->5C?,.R8]E6W<^K[BMM0>T<A-:8VHC&0XU89U,GHG*=-L&K2WTT
M4K#2N++ ^7_]?'4C\EI@=GK3'-Y!6,[W;<FOIB/UT1^ZE7)JY52-U%!^T1.Z
M=49_&0,XZ23ZLP8OK;RGU/.-PJ7Y1,>D%["-O](:\V_(4 ["='KD1GE,^T2N
MS8Z%[5ELJ*36<G'Z- 3S/N*^5\\L6[]"]<,5CCZS+/=\4S9-Y=,Z?P,O.)X*
M=TS:P;O#,^&OU $%??_(AJ*8== $@H3@!=WE6U!,74H1/?&OAO%5SG,;7FH#
M)SI6M#DK*AN3NA[/J:X)Z;G98B706Q>G:WNT%OQF6R95 +@C&EY_P3BT< )C
M$UK/RX\<D5H>#[B4&T62L96MDX]<F?T!RX/XA]KB]<WO  1K(9]0/1DY9#9'
M"5/*EER+7FQAX\N:HALR<6BFL\'#K"A.G[3R9S5D@>^VRSKK1#[N &'=MCV9
M@0K65V5]-P8%4RB$50.8-*6-(MR2%6IZDK?_%3+,KW+!"]9^"H!.U1Y'UF"_
M^.]C+HED[-]\>Q8'?"?T3= Z;$Z2ZBQ;^ZA3J$Q<HUY'Y;UAWX<HJ-FL8A0^
M\2!8'?8P=I7(>&+ZJ4C4YFK;?%J>)H2KMP2*T9Z$3!HW,W3%*3/@"R62'#1%
M*@^2,(U)$#H%ONCI, MEZT$.HW4_V O7<X!B_-I_*RO.I/3I\09Y?U;OUZRY
MUKY.8*!NV%FD,FO#Z],@'KT#U(7\]V>3E<=)JQ%R.A&QSBXVV29=2?9G*@&<
MQLQ.I9,]*69"?(:':9B\! 0=A6-DZB[5S?/>W8;>LO0!]U5YRN<9%R%DO^G'
MVWM.YIV]W(/:%OB+:_>#%X2.VUTIXE1Y6TM1.>(/547D(.L,Y:\TL/BOI9?U
M/TN=A9%X1[!GQKK["V>;#CDO9,!/IU$C60 0NE0M"XBX WR5&1PZ$'G)EN98
M!Q%S>9>/1L]IT3Q6V;5WW<.X16<CS=2$5@"E9$Q[@!ME_/7%0#:G+P^%37NR
M_+F]FO5SGQ^2H'\L&!E+ZXPFYJ::@4Q-1\8T#.";NW< $I3S*7?CXAJY5$#4
M50(#?%N2MU5KBU,QFU8V\@[PC5B_(7BCPZE]?U6!9]]+KT34S7EF1_?[%SFO
M^V[9>:^]VURZV7BH41H\=*4&3WC[E'Z7C"0P+YZ9UZYK,7D(B#T87''97A<[
MV.UO$/L"(_F5/&_VR@.2FV-/&Z![;R*2J&<!_;<(=G/8V %1JF*(D/=J@*8>
MCKV=+3@VX?GM[_:]\E_"OX1_"?\2_B7\2_B7\"_A_XR@&S#O+!XM[(I+_U.:
MF_4<JS,+)S3%SPK,4]>Z*54,WLU_*MC[5\%.+OLB<6"WX]_AO\/_;PS-(7WA
MYZLZ= NCPKG"8L9,M@A2)%G1EA'5'4 P(J%5;B!X%=Z+/*2$MFG'XH!U?_27
M_!#?)\T%I4@6-BSATGR3@QNSDSW]L[GT6&8&G)$CU/R2M/.Y#TU1QE1[*D8A
M4_)/]J7#NWA<A:63E0826*$=KG8'*,A$O5#5$O > R6CN3X#?Q2;KD9/F)7S
M"9"=7@ZPCM+IT,TFL%8ELAH,J$-31>X=+ZNJ,6&C!.]3<K?UKT_@+-L7Y#$6
M%]+WAXQ/;*I+UA/B/)[9!-MU4TMPXZE69I5ZT-')1BGO$)'H/NES@S?_=,\G
M)H$$OY&>IYUUX@Q;I/$NBJLBMZZHEYQU_ @:"YWC.MA0X-*V]Z)!)9E&5Q3X
M/=:HW;.!/4\V,&\(J=+E$:847!CF->.2#\]>T9&PJ=18%^#5V!7@E1<N+RB7
MPV]S&S6CYY7Q0-6N)4Y,.?:9R'!PZ)8;O'.JK']L-*W7GA_=@'EH2T\=S$:#
M&9(8FI2KJE]#1$5]<\BP]VE<5I^BX2+3A#AEB"*D#8D+%#?B)46?->GIR(#C
MHQOLRZSSWAE*^E-)Y$_M_3H,T7?3$^PI=TGRHW."%*N1)IE_/.\N+B-RCTP=
MTJ=#Y*NU&T=Z,"XK=L2W'4/DA8Y&7+R)4^U7&B/I=%U5WU.DCA@GE,(5PS3\
M9Z,B'S,".24L?[U<>67M)0W32$L5LR]]GS8IJZ%5F\K+!BM5B!-)3LVK;T'F
M$_)Z)\_O",D%;%"!IVP&=GM=X+\TND=:FA?.3*^[U_FL9O#YHU@GH(-/1E!A
MC.(,UZC!0['H6MX2K01UM9;7ORCCFZ4?S2Q8OS)(&\L76?98ATK6!BWT!WLQ
M*$2PT[?30\\E29=<U_M@'])JY(ETTM2GOK&A3F/D?%*I=IX3/1O@2M)/$^I*
M#+S.$WY9*Z^JP"JC^3@8;[Q/<RPM*PEI6B7OJB\S7$(PSLD?,;A>?)_)4=?
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MRD30T>U?D<]ROB,)]/2B]#5OHG$Y93%#JT'1XBS<JHCM/NR1&#4SLP8Z?3G
M:LDB*<I[4I*III2!.'YW%$O9%1\(^4PVL9Y@K.>53X 1*A#-\LG)3='CJ-\S
MFS:?*6R>]OO9L6RSP_I)570=0'UR&N],/ZG&)Y[_U1@UQ]OA6:)B;.CO%&AQ
M:&2<D(<MTUQKDHZ_GXZCT^KQO&VCP\^HI(Y0 'HH>G4LV)XAKX+3+*<I[@"L
MCY.U&#2KMV0?2E:%A=A1?^@PU=_P9NH#JJ UY![][RV(^*'6X>G.%N.8]3#,
MHJ4C&:@Q)&>"[EKK84W(I!"?]M=W#:=Y_;X8*O''V*(7++33M,"DWT/^:TO,
MQ@M7MY_&3L<9,FEMNOON -9<-@&V:UP;U:PEAK),LH+O_ PW(W_SPQ+EM%&:
M<*?R,F=K[LO'FH^.!+S/$_?AVG6AWAM=II.U&7%@.J[8RGOWJ);;-#=O]9T:
M4[P^2RH0=O5QD,N0MU!^UE.#CNX\IPNJA]:';+;2HJ]E)XG\2'H=.(?6>,WH
M,^3H=%3O(3GM[RU)W494A>^DG'S]EA;]C9U(I+ZVN<7RB^A6+.3]8ZM!8GDW
MZ+BK.QTV)MH?5[V98P*(1-SOG3=><'6N&_^:ZM%T$I_NN^&/BW)[\P7(3W%=
M73X0U";RW).LYN+^E  5+I6=(^HK=5HL3&JU"[OWE]2IG  OQZYQK]]U$/'=
M%1PV_NDCT$3I;ZY(&0; SE4? 7L>*)C"/+NZ_D#S(AZ1'1N7_L8&!_BE.C+)
M@ZUL)A[2BPR)+ ( (\Y'_B/D-ZK^"=3JP%?ZE @B&9 :1(A21KB+U2W=S:8R
MP[V\?ZV8QVUDO@9 ]:RV-1CZDJ 520+(FXW <'(K+*XO!^4Y0=@W/5!YS&][
M#$PWM_N29M/$K+]QY;]SL3Z JV*A9@QX?(,4IA/I#?^1S;P&6E.R<QP8I8V"
M"Q$G^"],A['*R;/M$]<5CH=NCX2&1G(<M_&K9M,J!41>B[-S<C5YO!SXO3=A
MR[/<_G[S-F"W,?UX[:GO7Y3_LO;/]\]GU!0<>FTSK!)4-,4&K"=_Y*^B^(QF
M+&?F:[1&QV;E7YVK%W(&4YA^DLB&,(VLW6/['^]E%L@ZV7TH5?<NT7I@4@PO
M@R&UOTR>KZ_[]!/N=&4JHP535WI3ZX!84PTY0G5 A77"R77!RTP+_S]VZZ=+
MQ[80G-"$;SJ$KDA,--H4 ?I&9EJ38_T@LLL;W5A@DW$NP?HV!K5C87DEWU&D
MHXMUMK9S*]P5S3INP#IK8;_0):"^O;=,>!LV!5++W&!=C9W@2O%]1@1XUAK%
M:(;:PH[8^DY9'CY0O26.J+!9VK]^?^!=PK)K27.!"N\8Q,KZZ:7\Q^+UG_#]
M$[VSXY0(?*\_R7!T'4RB<[?8J:*8FG=(\T?1JEI1>IZ9&Q[GN]+B-CJ5<O4K
M)CD#]:&1R/-?KZSS4)(12;W1#0ZY%7< &,0@#WZO/N6^WVI0(;6*::D<H.I)
MCI&^%$*#@@\O8*KI/]+2FYGLT*14^:U'_G/9S%!AUD=VG!= ^+-B\Q,]/NGS
M1$E%6^DCIH1[UZX@"DX\0G;V^3\1/Z=2>K3^KP*9;J%BNJSR8@/E;*Z^9\27
M83S$&;2HHTJ**/6D&N23((F,/*=\T?\^DEOIK=O X-6++_KB;\V__HZ*N'S0
M\MV5Y\:N+>(DY^U-M]*.4^Y<4??SG\=QQ7W/3EU8>T(.,:]A([EB#. EV^%C
M5H/ (O5Q"00"D=*_Z;W[":(M&ILL4@(M12+>O^U9=W->P!=T8B)KST)6X=T!
M"I0EZ-X1 NZ/_/)3%1P0@CQ^VT-J[H,J5\N/ $M%6VDWS=%+^%4%R<1XVNFD
M.-(6[!@*YNVXW;>E5['K[X N@EEY#;6-^^T"6959I^CP+VJN'OO[X:7NR&9M
MXF[$0WDZJ#P]Z."]!?#%R7EMN_+)!09JH]^42S3?#SO\>C7'+2NHN&8S5.VI
M0<]\5A)J2YW]4V6 2!S7M'%CNE_QC)^.8Y8R'911.1ZO$!& -KJQ9TNZ[3B>
M@Q3[RCL6OI$+Y&PS?"9Q_T1BUFIPK:"3GH;0N58:N)?E\2UQ:$I](M7+_#=A
M27N<@N!V?;S2DY:'.BX/,(N^*Q?H,P;;5@,:NB5?+F+'>,,*N3!^[@1_(-Z#
MM=ECYOH-B]74^TL"/H?MW*#VU$DC[1H+3/.,]F8TYV=B/A4]B !>YE87D)?S
MG"L8=0R%EK@(6II[-*Z"6Q.J7=8%[(;K'L>T-8ZA\XR#6>2RBU?V6(32\+3@
M-]%&LJ\,KQE#0]RC.WN^WN<12K9=.V1E$XCSJZLIB LL) 91N_(7HN=\@/0$
M\07/9AC($&\SWO*T#$244[R\Y$K\^?;Q'>#ZR:_@M28G_\WJ?Z8V8-EQN-*3
MJZ\GAQ-;G[D</YQ9HE^\S!&3ZY)OO9T=?NQQK(D(G*6##6.G@G3MC./!,R,)
ML5J(8WL,RM:-C)'-KC!;8U%^0C@DK(K_H7N404F2O4:=*4F&RQW@84):A2
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MW@&:!999$6,>=W"47R?8+;+-=%+I4+!&1R\N-/"#=9U'QGZ[9RS'B;>D3TY
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MNW,_LVO4%#?]E=+4E%Q8\<&X%09241N3U")UF*78:->+8B\(BO(J-_"8]IK
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M;ZY2,]YC;,G&<TA)H"4Q02,"TT,QQ?]'D.YC1.N[AQ-HW@>C*_J-1\!MTWY
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MX!MUA"(O_-?K@X4O5RD,R%\,+^IM@K=37M3O,VAIPQ!W!)F-'Z?%0::\Z(3
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MVPZ;WU98OU<_0:UB^PMT.?^0A"_,Y.2PB?QQ</=OF.^6+?&:S@PYI#1G0C?
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M7_R,*SQ:#;W(^;*9D?J SSA*HTQL6RN>*U*TZ\)W.X7]T(YJ7W/# 2Z,YTX
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M4'#':JTJ7X/0BX-&^X\JB^(53+M&N^V4,#<,Y&BQ)ZV!A;UE >?\B,R!2<]
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MZ'U927=GMILRJ_(?E,117B#]8]--R6O#F7IE?PV9X3NDQ_0I0 . )*,@1MY
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M_4JAO.$2]D92G ]DD9JQ,5I2%BOZV>SAS8+'$4LLJSBU9A03UF&VFU+(W5^
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MK(!<_-7K.8'FU&[X;C 6SU\ .*#PE[I:<:S: WR.;%SXT^BQE$4;5(31HJ<
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M?&>HW_7S6*GJY?OX!+""D1$(GYV;G9'4(_*<$A6!: Y&W([5(-=D*0DLVAT
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M7DGU+HHT3Z$\T_E.FK1&L9#/JTQ3GJ$BGIC440-0FCLWH -; ./8D[E.W:M
MY;I>RE.</K/VIS+YH;*,7<K&"QVX#OL.J2W:5PV4V#DB1@WT-/]0_(]-"43"
MYH<H^?/5YZ-.L3_K:7\!)YUO+["Y)-)8S+O@:(?T&O:I@ZP57E9\9F\.5B2&
M3N[Y@YB2:WK[42]8/>:TQX"V61#M,:PN?1^L/*YI7U'/KA+_IN=_-'"R=*"
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M@O )N;:%!Y)]:H63QCI6=L1NO036'*U8<MO)^?B<^IW5=;=+G=H>URH^M$*
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MDZQ%6CRYW[7!Q %;?=E;DH,!#9-JDP/S2W(A/T$8KIN+1APE.F.\,61,TM5
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M].:)>F43;."VVXX#&*D^)K;6FRLY.N(0Z(C3O7[94DE/$+X/ZP,7$<H^V<@
M2/QLOOC#K[K]5"Q8#?_U<HK[FL[.Y%J=$1^<BK@L;K2F3##WG>:H*<5K#CQ&
M(XJLH#:7DLE<X.K6^RQ)LI^?@U>U?ROT1FS!+FS3NQ?I1.W,1FC?I*8=:(XI
M<%RX&:^2/:]>-9N4,+Z(NT@-?-/G5X_?7JM+::Z'8AC]])EFZPG@]P2PO[5V
M*/&)[?CT/.MY(#[H>=X1.CBW\Q/[;DY073;G'%Z7[#?I'M*#85DU9F0#-N?$
MN\OS90$[[<:#,R,"97AS>0/\B[KQV8,%  *7[@(:G')A#$O=A/P4YD*+S_(9
M_3WJQ4C'#]$L.-)URTQP^^I!S&H=A<L5] 1@%NA<V\6^_(XX)'U0:>+-[3;,
M][FB&R^0J8;=E 3F2QWR!8E5#4T2GO,;U2'JS;S)/[X[^U3I+'A8:+O5&+/?
MH2>C#X0(N_]Q+ 8\ 2+2^YX FAM/@$*G887/[%Y#BQ*M/2W?OSZ[?06&M%D+
M+65>D1%XTWOA@"#-?K&15N\T^-1NR"<+)1=$M#ELI8D-,()0K!O+?PD$?*=S
MY,MSU>R2"-M*#?9M<XZ%6U>:?Z%SZ?8JZK7_-@O::\P[KRM< NH6):!A$']N
MITP&:Q$BXGQUM2-4NI7*)V]N5:([9'B+.@U,9M.,C\#H14XB4*8%547 :VQ+
M4B]9LH_^NF+%0.I(O<G R7,& Z8*-=Q%&S&FBF#2]H6'T[15)5CZ3H?4S8)1
MPN49Y+5[8:68I[*%D@9?5\-DK-R/E(I09RIZ5BH"#U@S]' )/$'.8+W%= W&
MF^(%&Q9JM$E)/ &Z=:9'.3?L:"A\\Y#2>+N)9,(]T9/?+ES .:1[DZ2= G9,
M<A5P .9\U2US._@ZP]V@)((U_)GE=)"8DRT:DTK:6U7YMTQ5Y2D&Y'#HG3JO
MJB(F0)7EAII_T K8_+/M6AK_<C4>6E"WL?N6PU;$:U^ E(06-"'%DNARRJ?B
M5O_.^@GPB7;.29:/7\/SJR^_I /A">?4A*C?_4^'W$4W(C:=R"!D_0BQ79_@
MB*MJ=$X%DXZJZ>NF378<DCVYW,XUPF %%=&@^D86 =\#+>I>D%@JO.*;>=]8
MCJ%7?)L]R]%W[!@.8 Y+OHME1DX.A*_8;)K,.*+D"P,=]91]2='ZCN3DO T'
M'T?L\NY94"U$LZHN)G)YBOV:-<DPWV3&&(O'Q'1[=Z>Q1T*0@Q+(H5_6)MU:
M:&).?I-2>&"U=NZRMN/7JS*)H('9L$]S;7S)\76==DC3$.XZ].MW7*+:X-<9
M]3IPLJ_DH/\.XCH66LK>453N ^\KTPUDCV8R84D,;@]IW&?<322)#X$/SZ3[
MOO]:(]M+LR/A*$_AGY@XMHS<GY>(A::A*_S^8,4RGU?F0T[%I+>OKQC.]-45
M(@EN(P&^V67?E@4P!089Y)78'L7Z9S*A%QL?E10,MHXC.K^JL!2,*!<[XO!B
M:L ,&20]<(1I,@' #R)1F0>D/*_7FR<DH\(Z G[Z%TW(OK;_@8.M>)@ZN&$Q
MM5-(BVO/."(:LH$09:J(4,22=*) 2T$W6.>2ZVA3>X0,9E?[<\8W9GE5:N#N
M-ECG"XT@PA8^1#$C\CN7*M>%DD&U@MQ<1S3%&$E!(G^PWDOH;#\7/9 =%^JH
MJ/23_EN[F?9MY3II&2WH3\'GZ#MA(LFXM E\<;PI]DF N",G1Z;C_)89K0^@
M[GWVK1L#$M/,B$P*RAHFUR5_FBZ ?"NRN2/R\[>U]15_,Y*O?U?["L'6*^[$
M4UMTHO",X8+OW,Z?)KOWICW.UDS2,^L-W\18C0P<H) 5?RTZUMTL'F]K<-7R
MA#)LE*8?3\J%.9/1OM^V^1 8%$$TJZJV;Q'':&,'8]@#E>5N;^,%G_GN,]R/
MWFAD3P%J'-_LJO&_.O?+ Z.^?\U(HM88-N:72V"J46D:$ABI<@^2NALKA@1%
M)108;4EK"&<Z"&^73%#]]6?;+XAR1CS>$'P<LA)*_V##\(Z1@B-[3E +@OJ:
M[Z-"6^_OXI^P#TUN3M.1"-ZZN*(C_Y#LN%GJ4+&AEF$YL7J&89*A&"5W*RHM
M-XO"9/K8YY65N7_PZ38O\@EPFWV/A'IZ@/#E4X,R!#\A_E@66)-S$&A-'=WG
MYK-CG#1R-8SLC?CF<<TF<4L*2EPN:<,4P11"W>,.E#64LUT.-5P\N%D' T1#
M-5PL2;Z\<8G D$3OJ*37^39?BQ[C^X3,-)R=NL=/6Y):E.?L49W%W"96E%$-
M<KE%YGQ$5. 'C6+]> 6.K3>:/X69MS"H7UU;-JP-Z/UX G@Q2_H3MXG[$2N-
M624<?,?FV;Q^(R:2W$N;3'7BUUPDUU##.MM=TF3OW,00]4!ET6<,? (H6/(:
M^O7B/-N_X#:<GCH\;UY[OGD>(.?-0)O2:8<R_G2N5K'S1Z@+V5RTKF='G:*;
MS\K4&U9L>\1H#__\7> 3SOVAY]IO];6':0FT/W?T@7^R.QH([J<>/Z?^.]1Q
M1VAK^9]8QSO*_Z]99[>&\FB06^D2R;(D7H'[KZ)MM7?*&_6K'@[T6=R;^MSN
M)GP'4[B\(:&@;+JFE%E3 U;684"XQ>UKJ#322KHD9Z.&*;XX["(Y>Z9DEJ^:
M63.WP*J>K\V^:BS>5T.9A1/#?RL4[_IX^@_6YZ$S;/E[7^1&;,<:!X.JF;LA
M6<XWR"PAI"^M,"$L+LTJUH&VEM=*).)3"NG?\AI)O#IT3-%#(J!TE_CR.]X6
M3A[+PVBM@.EM@A>OF#5;!7YI;F&<PTBV<C+8:9$,(<C<;@9XA9_4H(8OWU:
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M:!D])IE74%W<S^Q+'>0;$.N5)EP54XI6T>:3EPEO_7KO*6ND;?O<^W#;TJR
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M+1"/'T6?SWNHK-_"<^^LR7P_MUS-%<CR51N9\[[U/E,OB'J'=@^_'M><Q(U
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MM\@9^Q?4ZF![%D[R-)S]?;]YLE ,BO'""?_<C9!/ZV9/1%QY3]1YAO-MD-5
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M3)D1^P69+GW+JKW0L]F<HAFZH@=Z&3D[B!65(HJEWA!<S8H+R8IC5:QBQ0=
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MN@3O5_;QX2_T6P8WWYB%+623>I7>I)%+,MCQ\US$(O]:Z<KZXYBL.HRM4VK
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M6A!+8E2=N9")FO_U\]^-XHJ8JHHUZZ\./&&\(XNGTC 9XD>I=PR3B@<SY23
MY#;,^Q@.;&/U;P'3TR=NE%$.!4E)E)BJ %"%$^^D'_Q0FA";==(6@Q+YMU9!
M"I.0DE[B!@F:GC=-RQS)9%J6=&]ZB'!)L^\VBM=-&!HN/<\HI-1/V]]?Y^NK
M@!0HQC$!%%+UBD;N$4P@=9@2BNRY]5>.[#9R =#NZ;N ,UZB!E3-AX.N7972
M7H9>S P[%KXR'![?])T?FA*B_5N(2Z$5W_&3(O&L7[]7[)K'IS^Y8B.8GO6%
M?C?FW!$8MDD+)PL0O%OPRN0O?OZ+YC^]-#U?ZOWROJ3N_25[,)&V(6Z[F#C
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MU>Y6U!CZA,8)/=V<*=-<S \ADY?=7AW)W4*P.Z6#<?O_84'+W!2A%G4KVPI
M]:+*E::FZ=L)#FR[6*@X?C0.M?^7.01C[>BW1=R"Z3:JW$YA5F^4F(E.5&DR
MAEX5EZ1*.)Y(?$M[^U>O<32 %B;LR\/[$]VN4+EQV)BZ76^^$^@J"=E/-ECR
M$WLR8MV8@W.1.^X]Z!7#$2_JOX\CZB^FK(HE8>7X3V1(Y]W0$;4GN#>K*@M]
M#IR6->^.+U\W.A'869IO(ASJ;)=YSV)GMH^+ >!'L/S7F/O\-^)5YAWS32:9
MUZ>4QY1W^P?F<G8#S.F)]7XQ!8V;NUR+>&*=N2?W=^021M?$\]\LG'D9+LS
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M4(]P&/66*2"_YA/[Q]R,RRJ8E70@N5ZF#*=]AT:HRL*DR5.W#D$:EN"!$SZ
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M( XZ"[[!NQJG^08GH-<T CDE&1JTXF2+/PFK14S"@1.(;-RSP0P_8=<<CC>
M*38,A*K<U"9[QO>;P>*=EV'UJ,U)1+GS=^MIN?H/HF6^$\CI%@$NU-8<AD3!
M&_QJT>20OP",27)4GD#J=+=9B1"O18&!ZYX?W>UX!2!&\/X/FL'%S4L"AUV7
M,%>BL/(P94Y!9=91CB<K>]/MFUCS:,V>NS"GITUA0L?'9M%TC,!02>N[$D?;
M:;)>/!028^)SM-<)L_'A#0%L[X0'UB_B1DWW_F@E6(0]%P*OY68Y4>%><AE]
M@C<M&\Q&O"I77U/7H_SP$3Y;PV$OM9,Y=#XO-O!SPP)?ESL9V$8B5D;U+=45
M6D'L\XQ80BAR.OM%*4?]/+7G;PM,CM2:%C)TMK9<KBHF32.X:7SJO?F95%^/
M:/"O[U1Z9@43JB-CFFQKTCP\8E!L#80+I0&5";NV:HPRUK=JT5>G;8_/Q)Q3
MI(@NZ!H979=@K;-W HG:&R<]8;U$@BL(-?.650-^OEH?%IZB)#;^:1#2@^ 1
MYH?KF34?"+)JD=QQU<^GX0/6!2;+>,#KU+#XD%(#Y?SP# &(87@E1MKN,=M-
MDA=U=HB=N^O,,04\==9*(X>''VY4K>.VO"'.O6\(+21TCM&N4$$"@$F["@RL
M8KZA'F$+Q*^.)!+XGXE/@CO;V1?JY(%M$+H;^O>">YA4L87_4"3/E'CLP\,K
M.J]/K[+Z_$+9U>I@B><=55&NS_ J?E+TBOO%$2GWP^DO@;D.\O)4YP_6*7PF
MA>6EHF:+X*T=!;M7[W!8EG@H""F>5IE)*IA%8'N.B@/%8H4VM:8ZO+---:BT
MU9?URTVB 8!7N+=7EX#"S.*Q58-9]'2#^"*QD1<Q+4/IL($%6%O4L^/";F2)
M&QQ -+.E2576[5 <"Z V M2AY<U SM<MWUV++W%'&RYP"'@*YN?\-78WJ"W$
M\"L+5CV<JM-[R1Z*\H*A3/\:'B1UF;'ZS.'8_4V!^1<)=S=+KW69;KC S:_&
M.Z_ILI?J"YO:-ZNF0(=\,E&@K\4^L:_\K4>).*[;G_9W':3$41$MZPZ*0G^F
ME3P5B;\]CZ8R'7@0^VWT_,UQ6.!+Y!O>AX,0_Z<P;O>HE,3U]]]"O\CFK42@
M/,/Y#UL_G+:B6CG"?U#*NW)^ .O7Q]HJOZ_O?YXLU?=UL\9_FK[XU^2?:06I
MJU.$7?1][V^VQ[I[F9%7 &/#LV]3%RJO7I?NS=\!H][<I&^T^?P.ZD.R<A_,
M?-*K&0\"3FV<FGZA&F'VJ;2F8R9H**T0G63Q6=;06:AR[K5ME :[4,'S-H7/
M E[NPQ%)O@<>B&QWUZGU%^8*U41+3+V"D1;#YI<0''U"XY FUP#* G4-<4
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MXQLWBQB6GNS2#OE&=2HE3)_^JM,VR9M7W-NIPCE;I=)EKB')6 7S>M5*K2Y
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M"K>#'U*<H)T!YG:6'2_;H<0=>;M^ZJ[L< A953]SGN '1K948"YW<5>R6UN
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MG&<*6IAFZ5V?6'6 ER)=7VQ4%(?=99OP\NN'4T*".TIDA:%JG^X8 V<27(
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M1=<F@R0[JL)_NVQ[8G^(E@$,(D!,6S9_MS>-B?J'2A/>*R;@>>I7[V)-?!"
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M4<&=7D'6)0-MWF-# HYZ'_7L"L_'<WEKC1)Z\\874#7S.NHR:9J/QPO 8?W
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M<^S1;O=@._"WY3[4-W%L0Y:O^J]Z>)T=6/F+@(=B+BAH6,>Y(=M",:NT=T"
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MEJN*C(S[FW*V$CF>W?T[NR-'86#\Q\^V7(OZ=Q0TYOY3!?N%SNM56B4\V);
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M$5=-8^] HJ4KE)+]:@RSJ[491ZO#)<#!A<<'-S(\U__H>T1W6N?C@.UI=UH
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M(E$FO=&'>9SA"7 X<8#,Q%T/SV5&/J=%8%SDQ]$,-401T:X_L]SAA8?)Z1-
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M_]D 53+<#F!H^$_),C&FHD45%=O+P'D^FU,<3- ^*OAWJ'.CI2TIHKB:+]/
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MP\ ZR U*O#Z^^@57U\@JQ8/PG_=N6L;SP#FK]KG7%YOY[[_^R&+<U)\ UXR
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M*!'IS%^<(9\*X1[=2U^7^W&NR6V%PQ+\'V<I\/;T4A<PCS'W57]J^N'9<L?
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MATZ'""XA,GE'#O81_D\J0;NF>*:Z0-9CR:\ NI56\W<_%- O(8W.=?\ IR^
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MO>Y,2_5*&59K"CHL>#@1=_3;]&98U4]]1?([9_GFTXD&LR41YQ?'):M:*?H
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MG4VD.BGG_$#%GF M!F+:I*GI((EH7IM,W?M?5#HMC-SMN(M,]>2,(D@C?(G
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MR72I1F< +ZHK:0&'D+'&?I-]<LDMPZ^P6'_%6(6:WDCKBQ!C39>'@H!P0JK
MHZ@9].T0,Z!O6IHX%/R3.92!*UTF5F*NHEA&0L*?B2:\A"I:0@;E!>"O^5][
MP=,!-E.?+XZ;_SD]<YHV"SXS I7QNAK94[@V<31+,C,7!"PE FD);CDQK.MW
M,ADJAV#T=UDA*:S6R>'I03B_JIG1R_12&I:MOE:S @ E[WH8#Z'BQ#X_FGHK
MG=Z?069H.L_ZE'P,OD&OCZU!CC$8^K?V/RLTI 4_<+6S&]=5)1%D:(_C( @
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M\IX^KZQ._'0BJ>H#-VL7K[M164GY$L><IRX\*G.JT;<R_MN82)*M^60WIL(
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MT^KVM;JNUMR5?C&:8I,07A6SO"(QE@KU..UPZ. :]+UX]IWJ]OBMI)EB5GD
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MS?M6=FJ0Z6SS/&G9P=&&H:<H/A/VQY@K;!'P?$#8J&DZ*A6I9XVH[Y#2T27
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MX*7IF]WJ\OK;]<TRS-0^GX]03HUZ[=ZHU_K2MX"=L-70#,>%D=]+^M2 >T=
M(;/=[;:8[WT<-7RE\33H9"MNSD:M0GT\(QS2TT1(RSJ(T0T*@X=-DCF\#;2<
M@C\'E(6E?FO1?'X>;N#UDP3 ]YYI@@5=2W'/^D%:W'?=<ZEAZF7/^Z\I_<),
MO<Z][U]:I3Q<J%E;U-)CG*>C0&,(:E$[3D>!I>=;= MY+@5&&07<!T!;H=\W
MZ! 2/*(*-:0O./OZ+R0YPY]RKUNG;5I#)GIS$-I++TU?KWW;UYQ2QP\_3BS[
MRCYL/6TQAFX)KO@H&I'\J<O/BNY,GX;'+F_>RV7@FYLW%]B%5#%?I%% PBLN
MV1L-.?F2(2"WK-QM'S]HR\CG*2\1WS"'>@8E*Y<[G'ZYV7LCI#SFKK)9I:_C
M?-YO[AM1NCP':BX6+SK6$WCF"30M&7WC%ZL?BJWF+?CY'Y;W/ZS?(5L[[W;_
M88G_J;3^;KS-FOQ>T7IL*11N_[[?XB('X"?*F=ZUTT,*X 2.IW8;VBX$]$Z,
MO[Z!-E$Y<X<G&KB\-@?D3#*,N]OYQ=6!TPP![D\"R7GG^)Y^R%KUKD$R2]6P
MN2^$Y8?%3PNF!&'V!@((962K^[.[3L:] :?]+UD]%()I*@0M0(%C0';&D_2%
M/6^VY;TXEDUG1>B 12W4;:-/F<IS=.6DO-N ;H8[/W3AXK@J,LLA>\GY02\&
M$S;#<5"!:R_Y26@+E>S5;X,0E,D&_BY,;YXQPZ*EX-Q>A^WP/O#PMEEW]%O9
MK,B/3^KI:]:*SWY# #(A2-O5.ZE98?-&&>@&4X/[E[IOO2T7A90!"9-F8?!
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M71CZ1]A]>-#KA(11U5>LNR=I7$!E4%[7J<T2!7P9E-0LO; Z=W_6K6X+-BV
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M_1F]&]DKD2_CY6#A])?^D"KTCV.3$\113NV^FS-&U!S[C$7/]F:W@_Q;_I0
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M*9&L?3(NSBM"4XKZ?._:'WX+SL2@T1TA 5#B8=/.(0MH(K;EQ?)GGR $'G6
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MXWQ<J_#,"'9CRG^S4_TAK-L41,8\%&"L9?;WQF&F^X52:L >++1_"!E1[#Y
M:2,::.0!&/H0&&J?C3K-L1ZU,?>2 (UR.!3ZO<@((RVBGNG"E]"4FWI#(0Q)
MH-:W? "D^?CF8IH9'Z4E#&W:LPE8NY2M0IVJ)M?M2/E7J; MYA,23?B?R')
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MQ)GH3+1+5,KPQ*WTO/0_ %!+ P04    " ").EI2K7&_/P3G  !UV@D %0
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M"G;W-S2N'F8P#=X%;?8Z[S9K%6&AC+[;Y;K(I8E'?\>+#9\G413X*"(PB(2
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MC=<K\51>_D95&E$2SL"2&_),/[YZ%&,--<?L<G3(4XD*5P)*8>N<-P<5-OM
M<5)K\^2 +U-ULT_WL_4W>V\:QB*=?+-.#:^SP9'S,.%)G(48)@(E$+$ 0Y*0
M%/H^XIRD.$XI&6#.&(HQ4=MF%Q[\M T/YJW,9NQC.B]Z?.0"YG$8:B\)=Z^V
M7V],MCW6&@B=31XS%6%49AN(SR'7#7V,VQB<#_S'^LMWOOC&?UTMUP_EG-(T
M%"AC,$L228,DRV":2=]99&DF&.=",*W.Y=<*,C7+2[ZYOIL8G*,IT&.\,8!U
M3'VFD3A5#,[=\@5"<,Z!^!)1.$>R3#(0YQQB0V-QSCYOY#R6IM_XW69=KN6"
M+$7^L*D[OT4H" G%D(=9 !%%'&8AY]!'+*(X2#!/\;S.WOB\QL5:CSZMRVGR
M^1]*Z]!-VXDY Z_X?;Y46PN X$55Z%QENU1=84=+=SD[S8AG0O TAA%/0[D^
MI@G$+/0A5?V!B!>&'$7--+]=LC_,)+>RCC3%;ZO_3G%^]1;?%YTQQZNRA<2F
M1DOY0W?2:TTGD.!T:1(FD>5T5L@_1JK3)8RMY3M='&B8@=!6PY32D'Q9":/J
M&MTO5:?96Z9.-$6N EF:8@"J3*;T[J0+U_'NY-\VCU+<\YM.*HPO3E0'*'6&
MAM(4DC -8.I[Q$MYF&*]P)11I9Z::_9:/C>G>+$7R#)P=VJ<:==;9"8WF8X7
MGFVMX8[",[!3&71U;NO5M5I7NV,=O4&C^-$VVLS5/MJHTV5SB1I'\%&7K5'G
MXG I&W=PM_N#5?:+_,+G49!DE'L!C*-$0)20&*;"CR&*XXP'"16(.$G/:P68
MVJ(COR7D9C]P"[G=?< A0$YQ_T_I,/X&X"%Z+['QMY5ADAM^AP@-W>@[>LZU
M9;7>X;Q0M49;NMVCV5^E&!M)OG>*HC=%(263'D9>5K5ROO ?ZU<2BW_,:<"1
M8#B$A#/)?I0SB-,PAA[F/$V3@&*S.M%6I9L:-7;[1]2=='-IG-_L6CAUS;16
M18#70&%1%2"6MR[!5F50Z3RTHI>-Z=?<%'JI276](=2=S^T4S2[.Z/$<-H7$
M@-(25&HZJ2EF$7XWA<=L"/A"U<DL8GN^A)G-008D%IWHA*+L[O7S[5+R)R_7
MI>KX*24HJLZ?<MBW/VA5YOJ3LO;G-$(IICB"3%4S0T%&81IE/O03$3&!XC")
ML7:ZT97"3&UQ:(4#5?-O@S28:R>EG\/'AGJLK92.*C-0*P.VVH!:'7!7@%8A
M>5$[09]&GB"#[*41)VJDG";W$V:6[60)X=X<J&O'&"\SRA(:>_E2MIXYL)'.
MX]-B]<SY9UY\RRD_??KR8;7\)@7A=4VYLLHH[_Y=];O^L%K_)U_O]K?FJII)
MB#F&F>]1B+(H@%FBXB"RE&4)$W$6&6T4.9-T:BMCW?1ZLRQV&]ZT>_S:-+PU
M;+/C;)[U?*))S-Z(!^;;@_#=P>4,;/5KS\>50O*W:_#,UYT##NE2/:H<>8M]
M=ES#;[7CCC-AQ^V]XQKSHRX\S@>\PH?J'()\YD]86OU\\;P;XHO\3$I,JR/\
M&\:J91 OWN0E7:R4E]=='I6(3<->)M5YC<N'UU+7>U[._0CCC'@9)%DD%QV,
M"<Q0$D&,D2\]KX!$J58EZ?%%G]HJ=+NL>JZKM:=4S:N7JR6D4EQ :WD'. 3C
MO (&_MWD)O9%#M9WJG?/V+O*S\!.?=#1?[;7_+=:S%H,JL4.*AC ZXF_, /\
MS<F].&-[IY-Z@89YM*/.H9;_.XY$XWO+HR)]TK<>5X(K,A&ZX8OSD",JHC"#
MJCTA1+&/(*8QD68-$B+VA K#&)A)T!UGFID MH/_]Y!-,8YXS#@, H]!E*4A
M3+. 0N&32$2("$:]0<'[U^'J/OC>:KS]'J2:1Z/7@#2&^[X?JVXY1OV4XM9C
MS/<&&3]&_)2.)V.\3UXXC#H_%DU.[>?UBOZC.C"<>SSV,T0Q]$*2091D,91^
M(8,X\&D4^Q'%86"R_7ABC*FY;%L10:EDG('_T_N+YWD^D"M>U:B;_PT$WDS^
M2OT/X,WZ8554MIHZNE^N&BH >7VXL"K :C=%*B[C#:=54\I_^6<_]OX6^C.@
M7L3J;FG39&84<FK2" NC@ @$68)CB$08P"RC/@SB- WCC 9>%L^_\8*L1IJV
M[EBC35P[ 8/9^12T>OQ\)5R.&7J'T^?Z!6\"4.H#$GMDW8."3;H^-<RHA-VC
MYR%E]UTZC+2WK<*KKB//NR"KU,>">UX*&4D"B/S0D\R-,>2J" %+$A8BHXK7
MYP::&GW7<JKR'[J;)1>AU/OH;0#D^,O?83.KFP8]@Z_-?YW$D%V"Q"8-G!UK
M5"ZXI/$A(5R\?A@K?)&SGK<I$;>/3S@OU+Y6NU<GB8"$E%,8$^FNH8 RF 7R
MGTF:)9QQ'C&S^-O^X2;'$%L!P6(E)3:DB0O8ZI&%/<0<4T8K:!V>"CK86=M/
M-,/$)F=<&'%4YM#3_I _-.^ZLG)DLU-7S@5*HR3Q?8A#/X2(IRE,8Y%"7] 4
MX]BG.,I,>C\<C6#$%6.U?0"K;49-$S5B2!G'0&9$$)Q@!GDD76KD!S%,?>6G
M!0SQ#(O($V10V<U!0(Y NG?6(=0CVJN <<RM.TS>7L)D>/',0[V=%,S<#O(R
M13(/=3Q;&//HPI<I=_3V!R]H7JHHQ*9.BOSF,T$B'V9IAB 2F8 XB3#,DBSQ
M/(Z%GQB5X;4NX?3XI))3LLE6T!GXZ46JWAS/IL$N_DO-T1BG ):JWKSM3O'4
MJMZ<G80I5;TY%O(/5?7F+,:VJ]Z<'VC8.B&E>%PMJ[V^C[BX*ZI6=ZS:]OO(
MBTJ4N2<PPBE1)4&Y-*FII']"40*#)/:8\%(<$6["_!IC3HW+:Y';XY;M,4NU
M<__;YS= KM[U#KXAL>O KT?5ED%U3+X-GLWNOA18'4+5(C?YP%+HFGKM$:D!
M1#:I46?84<G. (=#^C*Y=:!'OW[@A>+&@C](>LR_\7H#\OVJ+#_P]9VH=B*+
MBC77ZR(GFW65!KJ2\BBN;#J:S[/ 2SU,$^C[/((H30*8$N1#&F ?,4EH6>0;
MN:]VY)H:L55J56DG6[VJ+<>_&OJ^EF9-TV,>?RY<^]G5-.RI!)JCD)^45G^6
M9B6O^H T)R-%;:IVM%.%4VK]P-=60XL')98QM^KC6Q)MW)T!NW@>[2=8?OS+
M[$*\6Q6"Y^LJ,G/)WOYXRJLD\F5YN_Q8!=+]G:L6(IS=?.,%ON>-=<P_%CGE
M\Y +P@*"8>JA&"+$!,0^1S#V14QI@I,T06/N6%RES=06CD:9.GR(*UV:0)9K
MS.&7?5_&V1,9[2WX ^V?=#"IBS7N4 'RE:IQF8$6&=! T^Z[2&]!@3.=+1<K
M<SRE[9GK%/I#;>58F3O;VSYVA!J0U7DG!%<%=U0VA!R,+C:,L]OE#:7%AK/M
M25<0,1+Z/(1AAE,5KB&76A%$,(U)F,8I2D*AM=0:C#FU!;&5NLZC5+2%:X$-
MCQ--8.]?L1R!Z=H5:G&L) :MR/('T A]^2QR,* &*8+V@1TIM\\&P&:9>&90
M]:;0:3YJO-PW,]WVDM8,;QU8]T4.0J6_UZDEP^_J;#;Y/U6 YAM>J$J<G[AT
M^7(JUQ#U![G*[/^B<^4\BF+&):W#+**2[8D70I(FDO(#X7D)9IF?&1T%.Y!Q
M:JM#K:+:P.&=>F@<U#^7JG1BE72OK-_J![[3Q;  C(,)U_.,7G@:':]+NQGL
MUM^J"I<JH6?5_X..[*J2?:M6_4<UN8>_>ZLQS^958-S-A-7Z+P[$'+?RBSN<
MCVJ^.!QJ@%_P&:NRG=5!4'T.?2=V"=5UVM_--NULGC$>^Q[Q8<Q\ 5$6JSVY
MA,$X#3A):9;$OGZU%J.AI[8.U!(K%L&[0@E-.EXG3\\X(VS I&@X#\Z@=KTW
MA>OBQ<WY\@[T3G6*6GRPD]\9T 9.A3/ 1_(M[ )OYF4,PJ[7V3![XG@^QR!-
M]UR/84^8Z"'0'!&,/"*DB<$8@H@&/B19XD$F$DXP%H3$6=O)?2)'/5K?[G[;
M]]$.=*I>[^V)SHO$JUZ>\HF<U4QIS1O[/.8/=-SRASQ2^=_LV.3%CD:N<7/>
MY.73JL2+7XK5YJG>HLN7]ZI@U&JYSI>J6G.=N-$4B)+#YJSYQ3R-:(1#RB'/
M?"Z7I2B%:2*]'I)%."5^C)G0RF^_6I*I.4'5Q@?M2FA@>U\U)1H^SUA .UX.
M6C5 I<<,;#4!757 5I=F_^KU2\R*@8,TUNR,Y"\YG24S]\D&LKW>U%4#C.=<
MV<!AS]>R\L!AKM>VK4[30D>]T>\*_E\;OJ3/;U:/.%_.!4+8PWX*,QXG:I6*
M84:]"&8)RX*,!)@'B<EACL:84UN/NCVN.E*#K=C@:RWX^7C:P?#K.3*6076\
M]@S$T-AO,$#%IN6O,^RHMKL!#H?6M\FM ^SG_[E9<H5BT^A$]361&I6_5M7E
MYB&*XH2%%&9QR"!B*($XH1GT">8B2'S/B[3.D2\/-37&4<+6-?7:CC^MO 8V
M5S^X&J:N-<@<\\EYM,#76EA-8M: S< 6M0;?2,;F@)?.S(34 J371NQ_PGA&
MH)8F>U:>WAU7[*#7,>JIQ_U$VFLP":),6FLX@"G&/N19$O@L$B+*,N.<ADDF
M&%22@2<EFIV\ N,@_TE&W#L)=7<;=_Y20>"7([*O"8]N'W2BK=O-C[R<!S$)
M@E"ER>,TA"A)$Y@F7@"CF,89(T&($V'RI9X99VJ?[:F^AN"KDM30>3J'J]X'
M; $MQU_S$*",O^X+,-C\U,\-->IW?T'?0Q*X=+D9(Y3%>OYJI4XFQ)N\X%1.
M3?GZ0=6[P\O6XTEXC&(4P3 .?4D*A,.4LTP%TJ(TPD&&A18I7!YJ<KR@I%61
M(%MY02NP'B]HH-M/#78Q<\T.Y^&Z[/-HTX0^)#U,(1_280GYKT.&T!AE%)+0
MU[;E"8,[!EKVJGZ&<OW>2QZZE3^6<^03+*T#:3=X@D.$8P)QS&/H,2\,.,E$
MFAFU4ST>8FK4L)40?%4R@DI(0VOA!)":EOY5\+BV^,V0,3?^SRIOU0DX'F5<
M9^"LED=.P?DKAW[?*_J/NFO!FXW*]:E#$IH(NYW5H1I:T@3)3QQR03%$H821
M".DN! QS%H8A#6(C=T%[Y*FQP3:[0BY^M%-V2P4>R0E?\JI]%_B>KQ^ZK>>N
M:'&D/4>ZC.( >>=$HQ!NFLW74F^S[MMV25W1;5*0(5IVF4EW\)$)RQ"38QXS
M?<! >J,/G&U4*/'-<IVS?+%9Y]_X9T[EH.N<E_);KI(:WTD55737IM[BOA-O
M<:%:OI5MT;!=)XN8ACS./"R)+Q*JL2^'))0_)3X+4Q$'/L)&34'LBS@UPFPU
M5(3Y<;66JU>.%XMGZ3G4NH*=LE4+\FW";ZXRUQ9TLZCC1"MG0]XB_Z)J3:E*
M0=6&:W\5OK'>"TWN?='9=DW2G8GNJM>=X%9!H%@%=%2L$A<;)7?%%<'7+U7M
M,">]5=Q-AM4UP+Z4XRX6SE ^6E7<C32P>.T"EV63QM*$T]!8D,!/$RA0(I</
M+AUGXI,(!CB,LS@@:11CHUJU1T-,C?XK";<Y5P,CE4X@J4>XU^'CF#!-H3&O
M*'M6>ZL%9(]'&;=>[%DMC\K#GK]R:)>H'[7I6AW]"!Q&F(0IQ"R2/K+'.$RC
M@,,H](G/./>R.#5K"M5Y^M2^:RE<XX(-.C[;1T[O8QZ,A^/O6!^* 1V=3JAL
MMX%3=X"1^S6=T.VX/=.IBX:VYUU1SEFI#( ZP_173!_R)2^>56J.=#N?U.;:
M/$E\[-/(ASS,*$3"BR#A",&89#$-@BQ(F=%>E^:X4_O"6[%K6[UL4J=Y*ZYI
M*U@][/68P &BCCEB'\PV#WTK=9W&>!': 1UDC8"RVU56;^B1.\T:X7'<?=;L
M]NM"=J230O)EY:1\XG1UOU39[K=,[:"('+<]Z^H-LX(S*<%[^>M\47D[\F^;
M1\Y>;XJJ8')UY<>"/^&\+=TEKZ_*,-=_FS.4><0C*4Q\&D+D^P'$A& 8^"RC
MF9^RQ#,*W7L1+:;'H96LVQJ+U7>^JJJIXTK@84%'X[X9>IP\^?EV'1+1!DQU
M % UMEH(0!>#NAEH$UQ5-$4-.CB !H@9:*!H;IB!]HUJX*ANK,OSW_2_4(.#
MLUYD0EV$?HVKR(L$EKW(7)T+6WL98<S67,;S^5LIT/KY]]5BLUSCXOE=OI K
MPSPE,6$)RB"//*82#S-(4ARK3JV,I&&4"*JU57=VA*FM5;608"LEJ,746Z'.
MX]B_>EA!QS&SFP*CS;07E=^Q8-G28,GI7^Y7WWZ6]]8,*'\X)+[SSQV%E"ZJ
MU1+&Y0NO#%NK3H_F<1!+EUT:M32(/(B2F,.4AAAZ+*0XB1GR$Z,4XOW'3^TS
M[@1E5?(-C52KL=.-*1F*B// $5TPA@>G[>GL)#"M'N%E@M+VM#L;D+9_U8!,
MW+>;8O7$\?)V^8V7ZZJN#E[^X_UJ&SR-B8>%AS'$J<<A8ED(B=IK#U%"!"$!
M#Y&6>ZHUVM2^Z;>WKX"2SB"-]"*@_5^V=9A<K]&-J& G*U#"5K -2<.]B)]!
M)JY-'$=*QNW%TU(^KBXLO2FY%Q\R7E:NKCY[B;G:-YDG^WQ2<:K5^5H<1Q%/
M$88T(C%$&>$0Q[$/19#%&0U$$(5:E0SVGCHUDJP$,SJ,W >IGQ 'JSZ"A9.7
MZYSBQ5YQ&%LGD2?UOC;=9O? T3)KCG3H)M$<_W'H"2,7O"@XJT(,ZGC6.LYU
MS@DB @<IQ"B3]DOF$9@F/H4!18Q'09BF))U_XP59Z1\KGAO,Y/7L#NET'[R6
MM>U1W=04S^N0[L'!\3V ZYXDV@#1^>%ABUY3N+JI45T+:O.T\!(8=@\(SXXV
M\IG@):V/CP$OWG%--YQM-]0O^(?JHZ V3Y<T7^1U$;8J_>1V^7:)5=.$YIHY
M]ABC@A,8AF$D_:-8P$P$ K(@#E"<):'\?_.F-T-$F9I=H,)S^+8[2J>MS9#&
M-8/F1H^*QD'<M1_6*M'VAU;H5XUH]A69@5H5%>7?*+.]=*:BJ:C5.(CKL;7?
M6&:0-"_0/^8:U$ZWB;GJB4.ZP9RLX=QV%CCL)_#;4CZV8O:ZA/-'^8*7<^+C
M0."(02\*)+]RY$L72E 89A$E&$7,C_3WGRP(-#66_7S4)$:L"G!?8.F+;)0"
M39KDJE(!/!4K^;?'<F@K&0LSJK$!-O(\N785J]+ZKXY*\&\;H=R)X^XGH-*J
M"5&O]0*58B//EDF7FG%G;:S>->/,GF%3&WM0][>ZL3#.B UP[*&RWQ;'XG.'
M.2A5P$43D]$)UJB.?W;)D"@@GL]( (,TQA").(:8,+EJXI2(+/,83XP2(;1&
MG=R"V$F'K .TVE"NC@IF+H@>^GK>AG5,'2]>9R%TFB-JA))-%T%OX%&] 2,L
M#@U_LYL'EI-?%3R_7[Y>;9;KXKDYILL2ZODD9E $6$#$.(68"PY]2E+D"Q:$
M:614/_[$(%.CGD9&PVKPI]#3XY)K,7%,'8UXU?Y"LSRNGRV6*=.!P6J!]U/C
MC%O1O4?3HQ+N?==>E5C]=ZRZ,*WOBD_Y_</Z[0]>T+RLBZ9N_U@V?RW]N1?%
MB0@(A913U>4U(3!#E, P23(/\R@F669V C-(CND=SK02M]6,-R4;7,IXV-3H
MT8QSN!WST#;?NQ%2OO.@DG(&ME-0J=&YIMQ>9#&R_RH@':2.&PKR$MGEP[ Z
MDX ^\&'6LLG*&U*N"TQUTRW['C&A[^M4!HYT#UI)'=0M[@/$<0;+;KR73C0Y
MTEPC'^3XGH$'I@>E6U[A,J<W2]94BIHG K$D2C*HPD,ABL($ILH%\%,?49R$
ML<#";,V_,.+T5G=5+&O1%LNJEO09($KH*G6,-26UKEKT+\U"C&-*>81A@%6G
MR<03$$=9!FF"!1<>"85GE%!O<0Y&J2U]A/;R:$[<3H#F ;0]6%V?,A]5"IN!
M'<J-O!9/C_6 L7I$?&'(<<^!]?0_.NS5O&UHQM[G1[Q8M(O+',5Q$A&?PBC&
M#"*.$<1I1J"7$!$B[B=Q%ICEZ^T]?VJDTB2E53*"5DC37+U]!/M9P@(NKEG!
M")(!67HG%;\Z1V__J2-GZ)U4Z3@_[_1EPVRVVR4M."[Y&U[_]W99'5(]K!;R
M&67=H.K3:K%XMRI4'^TY$5&<D32&A*G(MEC"F'I^*(T)X;/0)XQRK0][X/A3
M^_!;\<%/K0)_5D%471W^M>V@]E7I 1I%#!,!3:=)S\9P"+YC=G& N[$A,A ]
MFX:)J0BC&BH#\3DT7(8^9F"V<E5(J!IA_RB_#BF^77;*R,_#-,0A2F*8!=R'
M*(A4+G,<0Q\3+_&RB&/J&^4R&PP^-2;\W,DA*-6W^%3DWU2HZ=-"WE!EP:RM
M5. WF2 ]&G0%NV,.;.N6-6D(3>#12NPG)*BIZ,AO,>5Z &I6$[)-QA\W77L
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MPU$ZM':O>-(51NPV UYMJE1AY+?+VKZ^779X>9XQ*I>D-(6$,0P1#0*8<1;
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MHVKA)_4)XGI2E];8:!!U*J@?HDZ)Z/,0P%N5-0DY 8/5./$_$;8U3UQAO%
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MU90C')<BYP"E60P@)CG I<[+Y,K.CX4HBM)J?W;_\6-;'91T^GAO(Y\=YQ]
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M_:\O M+?\?K\[0/VN+ZHPWY7Z\N7V[O%'\4CF;];K&?KU[N?LVK*E<^;4D6
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M"+)J<^HBQ/CXK=-!'^UHV<%<"W^I&[&_63'<YPF,=7 2W<*\BC:][#K(/^Y
M/DQ;IFOP]+J?Y"+'L+M-5R!UM!=US;/<F/*C4 \5V]:INAOU-[%Z>I"Z:'%=
M*9S%E&14,( RJ@-M4JCL.674I23A,<*Q3*!5Z>#+0XZ-!6L1(S72DQWA&8!K
M1F]^(0M,9HVP>YV9M;R32$NL.:V3V1]=F>/CDYP,1AV4BLQ1."0>BSO=:.9\
M;^:FK2W7N^ $E:#@R@"#+(. Q@2#C.=I$DL&,;(Z([LPWM@(IJ^)N5L_XDN
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MW\MJ5O%9W<S2,@7AVMDSW$$8;DY";S7L5#5OI^)H8B91IU =7-2J-%!M\ZL
M#E/>W$VD&U4XOPJ_\T7.KWNL:T>N,Y6T?JN$?)E_G$DQ%;G,2\$E$(3I!C>P
M!%C&'* XTWLJ0G!JU3?"8,RQ,>P[-05/=1.6EUK&:*Z$M.VY=1EI,Z;TC%]@
M-CPHOK=?>V\2-3)''_OP=.BT98R0WS9;EX<=N,>6,0['#;;,;W6CGDW/P6TL
M2;79&"$)+/,T*T"LW%.=#T\!$@71!?APCI'Z-VC5 K!OL+&1S4[KT!UIG:/7
M>G$V8QQ?Z 6F&G?@K!G&!!&?U-([WJ"<8J+Y(9D8W>/&(F_;/H"Z&%F=ZOEQ
M1NAL/EO/1*7\HBDD25:45#F,!64 EB@&..<E2%$"(4IX3'/E.FYZW5_\%"Z,
M9\4EFU'#NH:\:W>Y5@XA:1.B=2/19H^&S.?+/^KR0;5 =N1R"7XS?O$(:F"*
MZ21MB@^V6"H1_3&+(18^R>72D(/RBZ'^AQ1C>MO5??>>GN?+5R&^BM6/&1-G
M.B[/ZWE6/SU(W:3J<3'[E^!-=;7[9;5N\PD3Q!.&B@Q@1)61 _,$X*)DRLBA
M,N$("LF-.H<&E7)LUM%>S[A6S:C5<Z\A^WX[H:VR^L:MNEU!P5IAM[31,"^'
M[:[9C:8\]%[:I;"=-ER'UWYE6[=+ZZ1F_$E'HOK/8PT*>:#F@1X%O5570?]8
M][0;##"82WZN'I<>C;M]_>GK]I+VZ[C3J<$/S_4V_U>Q7L\%GRT:H?XI9H_?
MUX+?_1 K\BC>_10K-JO$YY52<9KB.*=$,I!*F@.88 ((BAG@95QF19K"&!H5
M<AI:\-$M3XWHT6P1U>&$ZL_G9H71Q3E_^_I6_[4ITFEXTCSXJ]"_\HQY@@=<
MC';UWEV1=)?NDXN6UE[7=ZGUGT0[[TF#P23J4  M#%&'0U0#,=*WQ2;I>IQO
MS5#IV^-\>RR3PH>?PO[T\@'E&3!1?7B4]U/>;S"^HV.NOMI:(GT^L7[5XBX7
MNE=0W>^BR&E"F: @1R57#C;2.:,0 2)+D>0Q+S"W.D7H'6ULED@C8[05TJF3
M2#_ ADZJ+]@"K^_6B-G[CB9(>/4!>P<<UI<ST?W()S.ZR<&WZER\KG1,S'-"
MJ 0H20L \R(&)-6EU2!-)9=E47*CZ-@3SQX=+[326=B3!V 9. CN$(3^QKLM
M0X<*1(?OC+GEZP['0,:I.2QV]N)IQ7M-NH-;AK.Z3LNZ9QB=N<3UZ)*N/RRJ
M]:J>X)V6P8S!M! 9 C3A&8!%20$A/ <IRHL28;T58U7OXMQ 8V,F+6>T%73B
MTISY(KBF)Y+70Q;\*-()+8<#R7XH_)Y$GAEKX"/(?HV/SQXO7._(#YM@"5U2
M=NN'?1%S'8I8[S$?N6';T)Y"N3M%QDO 998"*(L<(((0X"EF19IR2A.KTOS7
MB3,ZKMG6J*JK*^_LQ[0*-4>"DU/[,>[!6%?.J2%Y#393MSW]"Q+9Y0<\KZ1X
MG43#4J<7](X(UL]3';>8B#X2;/I"+1?5C-?U>/7@3.@. Y_%ZIMZ)2M2Y]9,
M8Y:+E"8)D$0'G$$=>I9B""12-$PPC[%=L3*[X<=&LW>/CROQJ"8I8KO"1_K-
MB9Y7LQ_ZGY[GZF;[AO>6$V.X5Q4,[M!<29J8F*Y?W1[<G?3ZM"#:D=_CSI83
M;EZWNNPD&';ORPF=H\TPMZ=X"JS]=;6LJBDO<8X@PR"/$T5O<1(#7"0%D'F9
ME'&.8TS@5?&T]3!6-#9 &&W3B?-$(.V5T;(-IJ8NZ;5(!7=(3\3&UD(&C([=
M R%H4&PSTFUC8?>TO1@"NW^U'0U4J_7T[[/%[.GEJ=WN))G(19R7($\3"& N
M,D!R3 ##RLB1B!-$C7H!'#UY;#9+*YS9IWV,4__7?)7V@3_@5BZ/>\!GM>WY
M4M4].U^I^MOA%WK\T$$^RK.Z=-_A^0L<SJ?41_Q?@JRJSZO9<O5MF<8):M\O
MO0M<4%WB-.:Y^@Z5JT$E1J#(82+3.%>+LU%5L_YAQO91U@)&ZV6D1;0XLSF/
MH\$IEA=T G^T>K&MA8SV('(YWSJ/E<51EQ?,!CKU.H.=I[.OBTCT'H.=OWNX
M$[&+&NP=CEV^VK$Q;5<+X>YE_7VYFJU?=XYSTHQG.$6)HC\: UAD,2 )A(!E
M99ZQE!.2&U6;,QEL;)RX4^=E(^U5AV:]2)MY*;[P"\R:UT!GWQC6 !.O#6#[
MQANVT:N!YD<-74WN<;"H3O5KK#Z]:()ZD.]^SJKM;Z>RS*#,8@PDQR6 3):
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MU<U/@MQ0-#G]<7RRS\W=9L2[!?^@\%GH[63=_Z;ZO)S/V.L4\8Q34A8@*Z
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MW*B6US(YIA=G,VO$%WJ!OWYWX*R-#!-$?%H3O>,-:C:8:'YH'QC=<V4A[;;
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M=BE88(N8Y_H%QL,/7<[ %I<3U0VL'W%= <=-/87=+Z?,(4]BI-PW2B6 )6$
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M(80>VYK2YHSKF,'U=Q%]4[I6VE%7UNX?L_7WZ!^Z7=25H:.AWP/#3>21S>Z
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MXUW_:!WWW@TPAFL+Q/N7U4H-T3BD>HM)?38OU12)I$"T*  NB5J$6:$784@
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MP>*R+$2Y72B6/5Z]T5<.CW/,,] ]=;XOY^J.2@=QK5\W:;D09B1-!00EEP1
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MV)[E?;H>]2[OO=@A\OJKX@Y1W:7WR\4/L5KKC;//J]9'K8^BVE<W366:Y9B
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M*DQ,:<C*W9MD,*,HA5DJ%4[C5*^%B%-"2JMNQ\;Z#^OG9[9XK6H?;A4 6PU
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M3=-OLT583ZR,WJ 44)PSH#QF\"P92+6_BV48PH!E9]<>O!\0.@Z&GL;*+G!
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MZ=<PJP?MB_7+L%Q^(Q/M'V%VCA.KG.59*S+LHR(37Q##BK;U^$;+&!VL1K4
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MU&3+/$C5N&@:2/)WTA:&$D,'F/H;SHE',UK+BWPVG4\K?^IXR,OE")=5C+Y
MY-'4P5X2G,5 9E]D1G+&#6O2#?41NL8-J;?!U9"BZ !9=Y@T(04N.-H AHDZ
MQ2,GVB3*01*6*X>1F-?D=N8.)>.&S=N@YS1V=Y '\WT!5ZF&$_1!!<L\8" O
M0UE?T[]X@<PUD@M )W^;^[P=M(RK<9K:14<RO ,=\_MBOKBYBLN^Y-^K82WJ
M$EB$HA2GC60\'<=*@XP"O6:TL=K<V3U*V;@ZJ 6>AA5&!^AZ/?^*JTTEXG8Y
MF^G9],HD:SIL:W,1+BUIUDQ*U0D5( IKZ1!.SK:IM+J/H'&M[('EOF@@A [
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M.BW'6[23^VU-=I(0CD;1%UQ.%[6@=;D>Z-B[,W2=3F99/)*?@8+6X;2!0 8
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M(P^02XS6Y*BR9_O!XMBVC6,V\SP>$:?R<FPP/-96T''OC$-(I$!!9>7 N:+
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M=0=GW_U13UF\QSI3WI%V!J68@&!]@:)E$2)*Z1OMBV=QVW"0F/>^;3B$YSV
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MB!M7D?<%IT5CV7: U[^1'UDY^7:^]3=?S[_BA0 F,;LB2E# +*MM%NFG0-H
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MIWJWG*83^IH.\=A6173'K?LI*NHX2A6"]F2(A R*B0(!O8:$.F+VAC/19#!
M5Q5U4H9,1XR%2&8ZJ&#)Q_3U@B&0IH@U2T\VN87Y@2KJ#L'1R15UA\BK V/Z
M9MV--RE:)BQ8YR6HVITF.JO RBAUD)9<@3:-BIYQ1=U! G^PHNX0[G< G28%
M"\@,K95,BB0=\5 Z#D'27@VA)*<5"J::Z/P?O:+N(&P]147=(8+N .P/%\/H
M8)CDQM1$-DV6NW(0M4; '%E4Z+,N3>I 3R]G>EZ5=0>!YJ!RID,DV%DYDT-=
ME$L!HF!T -5)SH$K05N;:QD*Y_3Z )4JS[N<Z9A3^E1F]U3.%*(M*I+"#X)
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M%$J;QXVZ=SAXS[SD-80*AZ#G@6\WE/#'#A5N:G:^<U7OF+'"1N.@L#I1&ZV
M&"U"0N\IZJ$=X?$XWN>1M/--KR%4.!5.PZBA$TS]./]2]Y"-2+=L9&,X9TI
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M=7#Y@"5;KP]+5:!6[]3FKP%\9@Y$D#(+&X-436[3[$';N#FN=E@;6BT=(&V
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MS:)#+Z,4?0VG'83M"_5?^TASGA%QKV"[O%=O\:Q8I&6N2.2@G-.@,)$_P;"
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M:70R,S$N:'1M4$L! A0#%     @ B3I:4BQMAIM+$   L$0   T
M     ( !'@,  &5X:&EB:70T,BYH=&U02P$"% ,4    " ").EI25S8>>U@#
M  !X#0  &@              @ &4$P  :6UU>"TQ,C,Q,C!X97AH:6)I=#(Q
M,2YH=&U02P$"% ,4    " ").EI2.A@:&\0'  !I(0  &@
M@ $D%P  :6UU>"TQ,C,Q,C!X97AH:6)I=#,Q,2YH=&U02P$"% ,4    " ")
M.EI2Z4(4AL@'  "<(0  &@              @ $@'P  :6UU>"TQ,C,Q,C!X
M97AH:6)I=#,Q,BYH=&U02P$"% ,4    " ").EI2U:[!S*P$  ##$@  &@
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M>"TR,#(P,3(S,2YX<V102P$"% ,4    " ").EI2W1II5/ A  !M9 $ %0
M            @ &VX , :6UU>"TR,#(P,3(S,5]C86PN>&UL4$L! A0#%
M  @ B3I:4A4'F.8H=   <C0% !4              ( !V0($ &EM=7@M,C R
M,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( (DZ6E+8#AM.B5$(  EM#  4
M          "  31W! !I;75X+3(P,C Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    (
M (DZ6E*M<;\_!.<  '7:"0 5              "  >_(# !I;75X+3(P,C Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " ").EI2I "N5:"<  !V00< %0
M        @ $FL T :6UU>"TR,#(P,3(S,5]P<F4N>&UL4$L%!@     .  X
*JP,  /E,#@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
